Methods	O
for	O
direct	O
sequencing	O
and	O
mutational	O
analyses	O
were	O
described	O
.	O

Patients	O
with	O
biallelic	O
mutations	O
of	O
SLC26A4	B-GENE
tested	O
for	O
variants	O
within	O
the	O
KCNJ10	B-GENE
gene	O
The	O
evidence	O
that	O
genetic	O
factors	O
in	O
addition	O
to	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
SLC26A4	B-GENE
gene	O
contribute	O
to	O
Pendred	B-DISEASE
syndrome	I-DISEASE
and	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
EVA	I-DISEASE
has	O
originated	O
from	O
both	O
mouse	O
and	O
human	O
studies	O
.	O

Families	O
with	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
variants	O
that	O
segregated	O
with	O
disease	O
represent	O
10	O
%	O
of	O
our	O
cohort	O
.	O

For	O
those	O
patients	O
with	O
milder	O
hearing	B-DISEASE
impairments	I-DISEASE
(	O
whether	O
conductive	O
or	O
sensorineural	O
)	O
,	O
or	O
if	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
predominantly	O
sensorineural	O
,	O
then	O
hearing	O
aids	O
are	O
often	O
a	O
first	O
line	O
recommendation	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
7	O
ml	O
of	O
whole	O
blood	O
using	O
an	O
automated	O
DNA	O
extractor	O
(	O
BioRobot	O
EZ1	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

This	O
complication	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxicity	O
of	O
high	O
-	O
dose	O
etoposide	B-Chemical
therapy	O
for	O
malignant	B-DISEASE
glioma	I-DISEASE
.	O

SLC26A4	B-GENE
has	O
been	O
known	O
by	O
Everett	O
et	O
al	O
.	O

The	O
missense	O
mutation	O
replaced	O
a	O
glycine	O
with	O
an	O
arginine	O
at	O
position	O
115	O
(	O
Gly115Arg	B-VARIANT
)	O
located	O
within	O
the	O
PDZ	O
domain	O
(	O
aa107	O
-	O
174	O
)	O
.	O

If	O
the	O
patient	O
has	O
not	O
aborted	O
by	O
then	O
the	O
oxytocin	B-Chemical
should	O
be	O
discontinued	O
for	O
10	O
to	O
12	O
hours	O
in	O
order	O
to	O
perform	O
electrolyte	O
determinations	O
and	O
correct	O
any	O
electrolyte	O
imbalance	O
.	O

NCS	O
included	O
recording	O
of	O
sensory	O
nerve	O
action	O
potentials	O
(	O
SNAPs	O
)	O
from	O
median	O
,	O
radial	O
,	O
ulnar	O
,	O
and	O
sural	O
nerves	O
.	O

Subjects	O
with	O
SNHL	B-DISEASE
were	O
submitted	O
to	O
DFO	B-Chemical
reduction	O
or	O
temporary	O
withdrawal	O
.	O

Note	O
hyeprfluorescent	O
rings	O
around	O
the	O
foveas	O
in	O
the	O
younger	O
patients	O
,	O
and	O
hypofluorescent	O
areas	O
of	O
atrophy	O
that	O
encroach	O
upon	O
the	O
macula	O
in	O
the	O
33	O
year	O
-	O
old	O
patient	O
and	O
invade	O
the	O
macula	O
in	O
the	O
72	O
year	O
-	O
old	O
.	O

The	O
vertebral	O
bodies	O
are	O
mildly	O
foreshortened	O
with	O
posterior	B-DISEASE
scalloping	I-DISEASE
.	O

Other	O
manifestations	O
such	O
as	O
pyloric	B-DISEASE
stenosis	I-DISEASE
4	O
)	O
and	O
abnormalities	B-DISEASE
of	I-DISEASE
the	I-DISEASE
uterus	I-DISEASE
or	I-DISEASE
vagina	I-DISEASE
leading	O
to	O
dysmenorrhea	B-DISEASE
,	O
menorrhagia	B-DISEASE
,	O
or	O
amenorrhea	B-DISEASE
have	O
been	O
reported	O
12	O
)	O
.	O

For	O
patients	O
with	O
one	O
allelic	O
variant	O
in	O
the	O
hot	O
spot	O
regions	O
,	O
the	O
other	O
exons	O
were	O
sequenced	O
one	O
by	O
one	O
until	O
two	O
mutant	O
alleles	O
had	O
been	O
identified	O
.	O

303	O
Chinese	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
entered	O
the	O
study	O
.	O

METHODS	O
:	O
We	O
report	O
the	O
clinical	O
and	O
laboratory	O
data	O
in	O
3	O
patients	O
who	O
presented	O
with	O
severe	O
hypercalcemia	B-DISEASE
(	O
corrected	O
serum	O
calcium	B-Chemical
>	O
or	O
=	O
14	O
mg	O
/	O
dL	O
)	O
and	O
review	O
the	O
pertinent	O
literature	O
on	O
milk	B-DISEASE
-	I-DISEASE
alkali	I-DISEASE
syndrome	I-DISEASE
.	O

The	O
genotypic	O
class	O
-	O
phenotype	O
correlation	O
performed	O
in	O
previous	O
studies	O
[	O
18	O
]	O
,	O
[	O
20	O
]	O
showed	O
that	O
differences	O
in	O
ages	O
at	O
the	O
onset	O
of	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
/	O
or	O
optic	B-DISEASE
atrophy	I-DISEASE
correlated	O
with	O
genotypic	O
classifications	O
(	O
Figure	O
1	O
and	O
2	O
)	O
.	O

To	O
examine	O
if	O
overexpression	O
of	O
NARS2	B-GENE
rescued	O
the	O
respiratory	O
deficiencies	O
caused	O
by	O
the	O
NARS2	B-GENE
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
Tyr323	I-VARIANT
*	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Asn381Ser	I-VARIANT
)	O
,	O
O	B-Chemical
2	O
consumption	O
of	O
transfectants	O
and	O
their	O
parental	O
cell	O
lines	O
II	O
.	O
1	O
were	O
measured	O
by	O
using	O
a	O
Seahorse	O
XF24	B-Chemical
Analyzer	O
(	O
Fig	O
.	O

From	O
the	O
family	O
tree	O
spanning	O
five	O
generations	O
(	O
Figure	O
1	O
)	O
,	O
the	O
disease	O
was	O
shown	O
to	O
be	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
manner	O
.	O

researched	O
data	O
,	O
contributed	O
to	O
discussion	O
,	O
and	O
edited	O
the	O
manuscript	O
.	O

All	O
participants	O
provided	O
their	O
written	O
informed	O
consent	O
to	O
participate	O
in	O
this	O
study	O
.	O

All	O
the	O
patients	O
denied	O
any	O
history	O
of	O
ototoxic	O
drug	O
or	O
noise	O
exposure	O
.	O

In	O
the	O
future	O
,	O
critical	O
gene	O
mutations	O
may	O
be	O
accurately	O
and	O
quickly	O
identified	O
in	O
families	O
with	O
hereditary	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
by	O
targeted	O
genomic	O
capture	O
and	O
MPS	O
.	O

China	O
is	O
a	O
large	O
country	O
with	O
a	O
population	O
of	O
1	O
.	O
3	O
billion	O
,	O
of	O
which	O
91	O
%	O
are	O
Han	O
ethnic	O
people	O
.	O

The	O
effects	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz	O
.	O

Administration	O
of	O
DDAVP	B-Chemical
which	O
has	O
antidiuretic	O
action	O
but	O
minimal	O
vasopressor	O
effect	O
failed	O
to	O
increase	O
blood	O
pressure	O
to	O
the	O
levels	O
observed	O
after	O
administration	O
of	O
AVP	O
.	O

The	O
b	O
-	O
waves	O
are	O
within	O
the	O
lower	O
limits	O
of	O
normal	O
amplitude	O
(	O
OU	O
)	O
with	O
peak	O
times	O
that	O
are	O
delayed	O
(	O
0D	O
)	O
and	O
within	O
normal	O
limits	O
(	O
OS	O
)	O
.	O

Data	O
obtained	O
from	O
the	O
homology	O
models	O
were	O
visualized	O
using	O
Swiss	O
-	O
PdbViewer	O
4	O
.	O
1	O
.	O

C	O
.	O

Symptoms	O
such	O
as	O
euphoria	B-DISEASE
,	O
emotional	B-DISEASE
lability	I-DISEASE
and	O
puerile	O
attitude	O
noted	O
in	O
the	O
patient	O
were	O
diagnosed	O
as	O
organic	O
personality	O
syndrome	O
according	O
to	O
the	O
criteria	O
defined	O
in	O
the	O
DSM	O
-	O
III	O
-	O
R	O
.	O

Subsequent	O
HD	O
-	O
MTX	B-Chemical
therapy	O
caused	O
acute	O
renal	O
failure	O
that	O
required	O
continuous	O
hemodialysis	O
.	O

We	O
did	O
not	O
detect	O
known	O
pathogenic	O
variations	O
or	O
novel	O
mutation	O
in	O
the	O
gene	O
GJB2	B-GENE
and	O
mitochondrial	B-GENE
12S	I-GENE
rRNA	I-GENE
.	O

The	O
level	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
in	O
terms	O
of	O
PTA	O
,	O
was	O
described	O
as	O
follows	O
:	O
normal	O
hearing	O
,	O
<	O
20	O
dB	O
;	O
mild	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
21	O
-	O
40	O
dB	O
;	O
moderate	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
41	O
-	O
70	O
dB	O
;	O
severe	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
71	O
-	O
90	O
dB	O
;	O
and	O
profound	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
>	O
91	O
dB	O
.	O

Electrically	O
-	O
evoked	O
responses	O
in	O
auditory	O
nerve	O
fibres	O
(	O
electrically	O
-	O
evoked	O
compound	O
action	O
potentials	O
)	O
were	O
absent	O
in	O
all	O
but	O
one	O
(	O
Subject	O
7	O
)	O
implanted	O
OPA1	B-GENE
-	O
M	O
patient	O
.	O

Normalization	O
was	O
obtained	O
by	O
halving	O
the	O
estrogen	B-Chemical
dose	O
.	O

Electroencephalographic	O
and	O
behavioral	O
monitoring	O
revealed	O
a	O
profound	O
reduction	O
of	O
the	O
threshold	O
for	O
pilocarpine	B-Chemical
-	O
induced	O
convulsions	B-DISEASE
.	O

The	O
primers	O
used	O
in	O
this	O
step	O
are	O
modified	O
at	O
their	O
5	O
'	O
end	O
with	O
a	O
universal	O
M13	O
linker	O
sequence	O
.	O

JE	O
and	O
KG	O
designed	O
the	O
study	O
and	O
experiments	O
.	O

Together	O
with	O
type	O
IV	O
collagen	O
,	O
laminin	B-Chemical
,	O
and	O
heparin	B-Chemical
sulfate	O
proteoglycans	O
,	O
entactin	B-Chemical
is	O
a	O
major	O
component	O
of	O
basement	O
membranes	O
where	O
it	O
facilitates	O
cell	O
adhesion	O
by	O
binding	O
to	O
calcium	O
ions	O
[	O
44	O
]	O
.	O

All	O
of	O
the	O
probable	O
causative	O
mutations	O
were	O
novel	O
and	O
were	O
not	O
present	O
in	O
409	O
ethnically	O
matched	O
controls	O
(	O
Table	O
2	O
)	O
.	O

Clinical	O
diagnosis	O
and	O
evaluation	O
for	O
RP	B-DISEASE
were	O
based	O
on	O
the	O
decimal	O
best	O
-	O
corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
,	O
slit	O
-	O
lamp	O
examination	O
,	O
fundus	O
examination	O
,	O
visual	O
fields	O
determined	O
using	O
kinetic	O
perimetry	O
(	O
Goldmann	O
perimeter	O
[	O
GP	O
]	O
;	O
Haag	O
Streit	O
,	O
Bern	O
,	O
Switzerland	O
)	O
and	O
electroretinography	O
(	O
ERG	O
)	O
findings	O
.	O

This	O
variant	O
converts	O
a	O
highly	O
conserved	O
Arg	O
to	O
a	O
Trp	O
at	O
amino	O
acid	O
position	O
544	O
(	O
p	B-VARIANT
.	I-VARIANT
R544W	I-VARIANT
;	I-VARIANT
figure	O
1	O
e	O
)	O
.	O

FSGS	B-DISEASE
patients	O
were	O
included	O
to	O
serve	O
as	O
negative	O
control	O
for	O
AS	B-DISEASE
and	O
to	O
identify	O
any	O
new	O
mutations	O
in	O
FSGS	B-DISEASE
associated	O
genes	O
.	O

Selective	O
distal	O
tubular	O
epithelial	O
toxicity	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
profound	O
potassium	B-Chemical
wasting	I-DISEASE
that	O
is	O
a	O
major	O
clinical	O
side	O
effect	O
of	O
treatment	O
with	O
AmB	B-Chemical
.	O

We	O
also	O
evaluated	O
the	O
effect	O
of	O
cleavage	O
of	O
the	O
GST	O
fusion	O
tag	O
by	O
TEV	O
protease	O
on	O
ELMOD3	B-GENE
activity	O
;	O
no	O
changes	O
in	O
activity	O
in	O
the	O
Arl2	O
GAP	O
assay	O
were	O
observed	O
compared	O
to	O
un	O
-	O
cleaved	O
proteins	O
(	O
data	O
not	O
shown	O
)	O
.	O

RESULTS	O
:	O
rs6693503	B-VARIANT
was	O
associated	O
with	O
METH	B-Chemical
-	I-DISEASE
induced	I-DISEASE
psychosis	I-DISEASE
patients	O
in	O
the	O
allele	O
/	O
genotype	O
-	O
wise	O
analysis	O
.	O

In	O
order	O
to	O
compare	O
the	O
activation	O
kinetics	O
we	O
determined	O
the	O
time	O
needed	O
to	O
reach	O
the	O
half	O
-	O
maximal	O
current	O
level	O
(	O
t	O
1	O
/	O
2	O
)	O
.	O

The	O
characteristic	O
physical	O
features	O
and	O
growth	O
curve	O
of	O
the	O
patient	O
are	O
shown	O
in	O
Figure	O
1	O
.	O

After	O
48	O
h	O
,	O
about	O
80	O
%	O
of	O
the	O
cells	O
expressed	O
green	O
fluorescence	O
,	O
indicating	O
that	O
the	O
transfection	O
efficiency	O
was	O
about	O
80	O
%	O
.	O

Combined	O
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	B-DISEASE
and	O
elevates	O
plasma	O
lactate	B-Chemical
in	O
transgenic	O
AIDS	O
mice	O
.	O

Pfarr	O
et	O
al	O
.	O

To	O
identify	O
SLC26A4	B-GENE
mutations	O
,	O
a	O
DNA	O
fragment	O
containing	O
all	O
the	O
exons	O
of	O
SLC26A4	B-GENE
,	O
including	O
flanking	O
intronic	O
sequences	O
,	O
was	O
sequenced	O
as	O
described	O
elsewhere	O
.	O

Probands	O
of	O
families	O
1	O
and	O
2	O
were	O
screened	O
for	O
mutations	O
in	O
exons	O
1	O
and	O
16	O
of	O
the	O
MYH9	B-GENE
gene	O
whereas	O
probands	O
of	O
family	O
3	O
,	O
4	O
and	O
5	O
were	O
analyzed	O
first	O
for	O
the	O
"	O
hot	O
"	O
exons	O
1	O
,	O
16	O
,	O
38	O
and	O
40	O
and	O
then	O
for	O
the	O
exons	O
10	O
,	O
24	O
,	O
25	O
,	O
26	O
,	O
and	O
30	O
.	O

2006	O
,	O
2011	O
)	O
.	O

(	O
DOC	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

d	O
Siblings	O
.	O

(	O
DOC	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Headache	B-DISEASE
relief	O
at	O
2	O
h	O
was	O
75	O
.	O
9	O
%	O
for	O
rizatriptan	B-Chemical
and	O
47	O
.	O
3	O
%	O
for	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
,	O
with	O
rizatriptan	B-Chemical
being	O
superior	O
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
within	O
30	O
min	O
of	O
dosing	O
.	O

These	O
procedures	O
were	O
performed	O
at	O
the	O
Frist	O
Hospital	O
of	O
Yunnan	O
province	O
,	O
China	O
.	O

The	O
entire	O
custom	O
design	O
was	O
481	O
targets	O
with	O
a	O
total	O
size	O
of	O
132	O
.	O
763	O
Kb	O
.	O

Patients	O
U277	O
and	O
U286	O
,	O
clinically	O
classified	O
as	O
USH2	B-DISEASE
were	O
found	O
to	O
have	O
truncating	O
mutations	O
in	O
GPR98	B-GENE
.	O

Multi	O
-	O
CE	O
-	O
SSCP	O
was	O
performed	O
on	O
an	O
ABI	O
Prism	O
TM	O
3100	O
Genetic	O
Analyser	O
(	O
PE	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
California	O
,	O
USA	O
)	O
with	O
GeneScan	O
polymer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
California	O
,	O
USA	O
)	O
at	O
18	O
deg	O
C	O
and	O
30	O
deg	O
C	O
.	O

A	O
clinical	O
evaluation	O
of	O
etomidate	B-Chemical
for	O
outpatient	O
cystoscopy	O
was	O
embarked	O
upon	O
.	O

a	O
Patient	O
II	O
-	O
2	O
was	O
unable	O
to	O
walk	O
and	O
has	O
been	O
wheelchair	O
-	O
bound	O
since	O
5	O
years	O
of	O
age	O
.	O

Figure	O
4a	O
shows	O
representative	O
whole	O
-	O
cell	O
patch	O
clamp	O
recordings	O
.	O

We	O
conclude	O
that	O
125	O
mg	O
i	O
.	O
v	O
.	O
MP	B-Chemical
should	O
be	O
given	O
routinely	O
before	O
and	O
after	O
TDI	O
of	O
iron	B-Chemical
dextran	I-Chemical
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)	O
-	O
granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	B-Chemical
-	O
treated	O
rats	O
.	O

William	O
L	O
.	O

For	O
gene	O
analysis	O
of	O
COL4A5	B-GENE
,	O
the	O
entire	O
coding	O
region	O
of	O
COL4A5	B-GENE
mRNA	O
from	O
cultured	O
skin	O
fibroblast	O
was	O
analyzed	O
by	O
using	O
reverse	O
-	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
direct	O
sequencing	O
,	O
and	O
genomic	O
DNA	O
was	O
analyzed	O
by	O
using	O
PCR	O
and	O
direct	O
sequencing	O
.	O

Diameter	O
of	O
giant	O
platelets	O
,	O
defined	O
by	O
a	O
size	O
equal	O
or	O
over	O
the	O
erythrocyte	O
one	O
(	O
>	O
=	O
7	O
)	O
;	O
examples	O
:	O
7	O
.	O
24	O
,	O
8	O
.	O
36	O
.	O

We	O
investigated	O
how	O
CNVs	O
in	O
80	O
known	O
deafness	B-DISEASE
genes	O
may	O
result	O
in	O
deafness	B-DISEASE
.	O

Images	O
were	O
acquired	O
using	O
a	O
CCD	O
camera	O
and	O
analyzed	O
with	O
cellSens	O
software	O
(	O
Olympus	O
Soft	O
Imaging	O
Solutions	O
,	O
OSIS	O
)	O
.	O

The	O
USH2A	B-GENE
p	B-VARIANT
.	I-VARIANT
P1684L	I-VARIANT
mutation	O
occurs	O
at	O
an	O
evolutionarily	O
conserved	O
amino	O
acid	O
(	O
in	O
red	O
box	O
)	O
.	O

For	O
many	O
cases	O
of	O
ANSD	B-DISEASE
,	O
the	O
underlying	O
molecular	O
pathology	O
and	O
the	O
site	O
of	O
lesion	O
remain	O
unclear	O
.	O

In	O
this	O
work	O
,	O
the	O
observation	O
of	O
affected	O
features	O
,	O
combined	O
with	O
a	O
molecular	O
analysis	O
,	O
is	O
sufficient	O
to	O
perform	O
a	O
correct	O
TCS	B-DISEASE
diagnosis	O
in	O
35	O
%	O
of	O
cases	O
.	O

Mutations	O
in	O
USH2A	B-GENE
account	O
for	O
over	O
70	O
%	O
of	O
cases	O
affected	O
with	O
USH	B-DISEASE
type	I-DISEASE
2	I-DISEASE
.	O

The	O
PCR	O
product	O
was	O
purified	O
using	O
SPRI	O
beads	O
(	O
Beckman	O
Coulter	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

This	O
suggests	O
the	O
above	O
-	O
mentioned	O
variants	O
are	O
the	O
possible	O
causative	O
mutations	O
impairing	O
the	O
hearing	O
of	O
this	O
Mongolian	O
family	O
.	O

The	O
combined	O
administration	O
of	O
CSA	B-Chemical
and	O
various	O
chemotherapeutic	O
drugs	O
with	O
a	O
nephrotoxic	O
potential	O
,	O
such	O
as	O
gentamicin	B-Chemical
(	O
at	O
therapeutic	O
doses	O
)	O
,	O
amphothericin	B-Chemical
B	I-Chemical
and	O
ketoconazole	B-Chemical
,	O
which	O
are	O
frequently	O
used	O
in	O
immunosuppressed	O
patients	O
,	O
did	O
not	O
aggravate	O
the	O
CSA	B-Chemical
induced	O
toxicity	O
in	O
the	O
rat	O
model	O
.	O

Moreover	O
,	O
KF17837	B-Chemical
(	O
0	O
.	O
625	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
potentiated	O
the	O
anticataleptic	O
effects	O
of	O
a	O
subthreshold	O
dose	O
of	O
L	B-Chemical
-	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
;	O
25	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
plus	O
benserazide	B-Chemical
(	O
6	O
.	O
25	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Variants	O
in	O
SLC26A4	B-GENE
gene	O
in	O
Caucasians	O
are	O
rarely	O
overlapped	O
with	O
those	O
found	O
in	O
Asians	O
.	O

Fluorescence	O
-	O
based	O
flow	O
cytometry	O
was	O
used	O
for	O
cell	O
sorting	O
.	O

Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O

Prior	O
to	O
whole	O
-	O
exome	O
sequencing	O
,	O
the	O
frequent	O
deafness	B-DISEASE
genes	O
(	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
,	O
GJB3	B-GENE
and	O
MT	B-GENE
-	I-GENE
RNR1	I-GENE
)	O
present	O
in	O
Chinese	O
populations	O
were	O
excluded	O
as	O
the	O
causative	O
factor	O
in	O
the	O
proband	O
,	O
by	O
direct	O
PCR	O
-	O
Sanger	O
sequencing	O
.	O

These	O
findings	O
suggest	O
that	O
progression	O
of	O
diabetes	B-DISEASE
toward	O
total	B-DISEASE
insulin	I-DISEASE
deficiency	I-DISEASE
may	O
be	O
slower	O
in	O
WSD	B-DISEASE
than	O
in	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
.	O

OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	O
P450	O
isoenzyme	O
(	O
CYP	O
)	O
2D6	O
.	O

Yang	O
et	O
al	O
.	O

In	O
a	O
double	O
-	O
blind	O
6	O
-	O
week	O
trial	O
,	O
458	O
patients	O
with	O
acute	O
schizophrenia	B-DISEASE
were	O
randomly	O
assigned	O
to	O
fixed	O
-	O
dose	O
treatment	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
,	O
asenapine	B-Chemical
at	O
10	O
mg	O
BID	O
,	O
placebo	O
,	O
or	O
haloperidol	B-Chemical
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
)	O
.	O

No	O
consanguineous	O
marriage	O
was	O
identified	O
in	O
the	O
family	O
and	O
both	O
parents	O
had	O
normal	O
QT	O
intervals	O
.	O

Genotypes	O
of	O
USH2A	B-GENE
variations	O
for	O
all	O
include	O
members	O
from	O
each	O
individual	O
family	O
are	O
shown	O
with	O
the	O
specific	O
variation	O
detailed	O
under	O
the	O
family	O
pedigree	O
.	O

Seven	O
different	O
life	O
-	O
threatening	O
toxicities	O
were	O
observed	O
in	O
patients	O
while	O
receiving	O
treatment	O
.	O

In	O
addition	O
,	O
only	O
a	O
few	O
functional	O
studies	O
have	O
been	O
performed	O
on	O
the	O
previously	O
reported	O
myosin	O
mutations	O
.	O

In	O
the	O
current	O
study	O
the	O
efficacy	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
GEM	B-Chemical
and	O
VNB	B-Chemical
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC	B-DISEASE
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	O
cisplatin	B-Chemical
were	O
assessed	O
.	O

Two	O
patients	O
also	O
received	O
intravenous	O
corticosteroids	B-Chemical
.	O

From	O
the	O
analysis	O
of	O
these	O
cases	O
,	O
two	O
distinct	O
forms	O
of	O
carbamazepine	B-Chemical
-	O
associated	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
emerged	O
.	O

One	O
of	O
them	O
(	O
no	O
.	O

Five	O
patients	O
were	O
diagnosed	O
as	O
having	O
subclinical	O
heart	B-DISEASE
failure	I-DISEASE
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O

The	O
WS	B-DISEASE
is	O
caused	O
by	O
a	O
novel	O
missense	O
mutation	O
,	O
whereas	O
DMD	B-DISEASE
resulted	O
due	O
to	O
a	O
deletion	O
.	O

Out	O
of	O
the	O
fourteen	O
individuals	O
,	O
three	O
(	O
II	O
-	O
1	O
,	O
II	O
-	O
3	O
,	O
III	O
-	O
3	O
)	O
were	O
only	O
affected	O
with	O
the	O
most	O
severe	O
type	O
of	O
Hirschsprung	B-DISEASE
disease	I-DISEASE
(	O
long	O
segment	O
aganglionosis	O
;	O
L	O
-	O
HSCR	B-DISEASE
)	O
and	O
one	O
(	O
II	O
-	O
5	O
)	O
was	O
affected	O
with	O
L	O
-	O
HSCR	B-DISEASE
and	O
complete	O
heterochromia	B-DISEASE
iridum	I-DISEASE
(	O
Figure	O
1	O
)	O
.	O

The	O
missense	O
mutation	O
is	O
located	O
in	O
the	O
highly	O
conserved	O
motor	O
domain	O
of	O
the	O
myosin	B-GENE
VIIA	I-GENE
gene	O
.	O

We	O
have	O
recently	O
shown	O
that	O
estrogen	B-Chemical
negatively	O
modulates	O
the	O
hypotensive	O
effect	O
of	O
clonidine	B-Chemical
(	O
mixed	O
alpha2	O
-	O
/	O
I1	O
-	O
receptor	O
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O

The	O
effect	O
of	O
variants	O
that	O
lead	O
to	O
premature	O
stop	O
codons	O
is	O
not	O
questioned	O
;	O
however	O
,	O
it	O
is	O
complicated	O
to	O
predict	O
the	O
consequences	O
of	O
missense	O
,	O
silent	O
and	O
intronic	O
changes	O
,	O
in	O
order	O
to	O
discriminate	O
neutral	O
variants	O
from	O
those	O
with	O
pathogenic	O
effect	O
.	O

Amino	O
acids	O
conserved	O
in	O
evolution	O
are	O
marked	O
in	O
bold	O
,	O
and	O
mutations	O
are	O
marked	O
with	O
red	O
.	O

Note	O
broad	O
medially	O
deviated	O
/	O
great	B-DISEASE
toes	I-DISEASE
(	O
1D	O
-	O
5D	O
)	O
;	O
Note	O
syndactyly	B-DISEASE
in	O
Proband	O
5	O
(	O
5D	O
)	O
;	O
(	O
E	O
)	O
Patients	O
hands	O
.	O

4	O
cases	O
of	O
endometrial	B-DISEASE
carcinoma	I-DISEASE
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problems	O
of	O
inappropriate	O
and	O
unsupervised	O
unopposed	O
oestrogen	B-Chemical
therapy	O
and	O
the	O
difficulty	O
in	O
distinguishing	O
severe	O
hyperplasia	B-DISEASE
from	O
malignancy	O
.	O

Furthermore	O
,	O
most	O
disease	O
-	O
causing	O
mutations	O
are	O
located	O
in	O
highly	O
conserved	O
regions	O
,	O
which	O
exome	O
sequencing	O
is	O
expected	O
to	O
cover	O
.	O

The	O
female	O
patient	O
was	O
referred	O
to	O
us	O
for	O
genetic	O
evaluation	O
because	O
of	O
dysmorphic	O
facial	O
features	O
at	O
the	O
age	O
of	O
13	O
months	O
.	O

Male	O
rats	O
were	O
subcutaneously	O
injected	O
with	O
morphine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
,	O
and	O
Rg1	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	B-Chemical
once	O
a	O
day	O
for	O
10	O
days	O
.	O

Furthermore	O
,	O
our	O
findings	O
illustrate	O
the	O
role	O
of	O
molecular	O
diagnosis	O
in	O
accurate	O
disease	O
classification	O
.	O

USH2	B-DISEASE
is	O
characterized	O
by	O
variable	O
degrees	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
progressive	O
visual	O
troubles	O
beginning	O
in	O
adolescence	O
or	O
early	O
adulthood	O
.	O

JDS	O
looked	O
after	O
the	O
patient	O
.	O

These	O
cases	O
demonstrate	O
that	O
bromocriptine	B-Chemical
may	O
cause	O
psychosis	B-DISEASE
even	O
when	O
given	O
in	O
low	O
doses	O
.	O

The	O
main	O
clinical	O
and	O
audiological	O
findings	O
of	O
affected	O
subjects	O
are	O
shown	O
in	O
Table	O
1	O
and	O
Figure	O
1	O
-	O
b	O
.	O

The	O
differences	O
in	O
specific	O
activity	O
among	O
the	O
three	O
human	O
GST	O
-	O
ELMOD	O
preparations	O
from	O
HEK293T	O
cells	O
are	O
predicted	O
to	O
result	O
from	O
differences	O
in	O
substrate	O
specificity	O
,	O
sensitivities	O
to	O
co	O
-	O
activators	O
(	O
as	O
known	O
for	O
Arf	O
GAPs	O
)	O
,	O
or	O
both	O
.	O

Table	O
S3	O
,	O
Common	O
variants	O
with	O
ancestry	O
-	O
dependent	O
allele	O
frequencies	O
.	O

Like	O
most	O
deaf	B-DISEASE
patients	O
seeking	O
genetic	O
testing	O
and	O
counseling	O
,	O
the	O
majority	O
of	O
our	O
subjects	O
(	O
179	O
/	O
190	O
)	O
were	O
simplex	O
or	O
recessive	O
multiplex	O
probands	O
with	O
non	O
-	O
syndromic	O
,	O
prelingual	O
or	O
early	O
-	O
onset	O
,	O
severe	O
-	O
to	O
-	O
profound	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Regional	O
localization	O
of	O
the	O
antagonism	O
of	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-DISEASE
by	O
intracerebral	O
calcitonin	B-Chemical
injections	O
.	O

Air	O
conduction	O
threshold	O
testing	O
was	O
performed	O
for	O
the	O
right	O
(	O
circles	O
)	O
and	O
left	O
(	O
crosses	O
)	O
ears	O
.	O

HMM	B-Chemical
gastrointestinal	O
toxicity	O
necessitated	O
discontinuation	O
of	O
the	O
drug	O
in	O
5	O
patients	O
.	O

The	O
degree	O
of	O
these	O
seizures	B-DISEASE
increased	O
with	O
increasing	O
concentration	O
of	O
tAMCA	B-Chemical
.	O

S6	O
,	O
S6	O
segment	O
;	O
'	O
h	O
'	O
,	O
high	O
-	O
voltage	O
activated	O
;	O
'	O
l	O
'	O
,	O
low	O
-	O
voltage	O
activated	O
.	O

4a	O
)	O
.	O

In	O
approximately	O
80	O
%	O
of	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
and	O
PS	B-DISEASE
,	O
the	O
mutation	O
is	O
located	O
in	O
the	O
exon	O
8	O
and	O
10	O
of	O
FGFR2	B-GENE
,	O
which	O
encode	O
the	O
third	O
immunoglobulin	O
-	O
like	O
domain	O
of	O
the	O
protein	O
(	O
IgIII	O
)	O
,	O
but	O
mutations	O
in	O
different	O
exxons	O
have	O
also	O
been	O
identified	O
(	O
13	O
,	O
14	O
,	O
22	O
)	O
.	O

Examined	O
by	O
echocardiography	O
,	O
chest	O
roentgenography	O
,	O
and	O
/	O
or	O
electrocardiography	O
.	O

The	O
children	O
had	O
a	O
medical	O
history	O
significant	O
for	O
attention	B-DISEASE
deficit	I-DISEASE
disorder	I-DISEASE
previously	O
treated	O
with	O
methylphenidate	B-Chemical
without	O
success	O
.	O

The	O
inclusion	O
of	O
X	O
-	O
linked	O
markers	O
in	O
the	O
RD	B-DISEASE
-	O
chip	O
has	O
proved	O
to	O
be	O
extremely	O
useful	O
to	O
diagnose	O
families	O
compatible	O
with	O
both	O
autosomal	O
and	O
X	O
-	O
linked	O
inheritance	O
patterns	O
.	O

c	O
Conservation	O
of	O
the	O
amino	O
acid	O
sequence	O
in	O
the	O
p	B-VARIANT
.	I-VARIANT
T487I	I-VARIANT
mutation	O
region	O
.	O

6	O
.	O

*	O
Different	O
from	O
mammals	O
having	O
multiple	O
ferlin	O
genes	O
,	O
drosophila	B-Chemical
only	O
has	O
one	O
ferlin	O
gene	O
called	O
misfire	O
,	O
which	O
is	O
also	O
its	O
protein	O
name	O
[	O
28	O
]	O
OTOF	B-GENE
sequence	O
analysis	O
of	O
a	O
TS	B-DISEASE
-	I-DISEASE
NSRAN	I-DISEASE
family	O
at	O
mutation	O
sites	O
.	O

We	O
report	O
a	O
patient	O
in	O
whom	O
hypersensitivity	B-DISEASE
to	O
carbamazepine	B-Chemical
presented	O
with	O
generalized	O
erythroderma	B-DISEASE
,	O
a	O
severe	O
leukemoid	B-DISEASE
reaction	O
,	O
eosinophilia	B-DISEASE
,	O
hyponatremia	B-DISEASE
,	O
and	O
renal	B-DISEASE
failure	I-DISEASE
.	O

Choreatiform	O
hyperkinesias	O
are	O
known	O
to	O
be	O
occasional	O
movement	O
abnormalities	O
during	O
intoxications	O
with	O
cocaine	B-Chemical
but	O
not	O
opiates	O
.	O

(	O
A	O
)	O
At	O
P02	O
,	O
ELMOD3	B-GENE
immunoreactivity	O
(	O
green	O
)	O
was	O
found	O
in	O
the	O
stereocilia	O
of	O
outer	O
hair	O
cells	O
and	O
in	O
the	O
kinocilia	O
of	O
both	O
outer	O
and	O
inner	O
hair	O
cells	O
.	O

(	O
B	O
)	O
Pedigree	O
and	O
segregation	O
pattern	O
in	O
Family	O
DE2675	O
.	O

This	O
patient	O
survived	O
without	O
sequelae	O
due	O
to	O
the	O
aggressive	O
sedation	I-DISEASE
and	O
neuromuscular	B-DISEASE
paralysis	I-DISEASE
.	O

D	B-Chemical
-	I-Chemical
Penicillamine	I-Chemical
caused	O
nephrotic	B-DISEASE
syndrome	O
in	O
1	O
patient	O
and	O
milder	O
reversible	O
proteinuria	B-DISEASE
in	O
3	O
other	O
patients	O
;	O
none	O
developed	O
renal	B-DISEASE
insufficiency	O
.	O

Mutations	O
in	O
the	O
CDH23	B-GENE
gene	O
are	O
known	O
to	O
be	O
responsible	O
for	O
both	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
ID	I-DISEASE
(	O
USH1D	B-DISEASE
)	O
as	O
well	O
as	O
non	O
-	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
DFNB12	B-DISEASE
)	O
,	O
and	O
molecular	O
confirmation	O
of	O
CDH23	B-GENE
mutations	O
is	O
clinically	O
important	O
for	O
diagnosis	O
of	O
these	O
conditions	O
.	O

Younger	O
children	O
have	O
an	O
additional	O
risk	O
for	O
renal	B-DISEASE
complications	I-DISEASE
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
hypothesis	O
that	O
calcium	B-Chemical
channel	O
blockers	O
in	O
general	O
induce	O
cardiovascular	O
malformations	O
indicating	O
a	O
pharmacologic	O
class	O
effect	O
.	O

Superoxide	B-Chemical
dismutase	O
(	O
SOD	O
)	O
or	O
dimethylthiourea	B-Chemical
(	O
DMTU	B-Chemical
)	O
significantly	O
lessened	O
the	O
GM	B-Chemical
-	O
induced	O
decrement	O
in	O
CIn	O
.	O

Thus	O
,	O
the	O
yield	O
of	O
CNVs	O
was	O
2	O
.	O
0	O
%	O
among	O
the	O
100	O
genotype	O
-	O
negative	O
index	O
patients	O
without	O
an	O
identified	O
mutation	O
in	O
any	O
of	O
the	O
LQTS	B-DISEASE
genes	O
or	O
RYR2	B-GENE
.	O

UV2	O
variants	O
fulfilled	O
the	O
criteria	O
described	O
for	O
UV3	O
,	O
but	O
were	O
only	O
genotyped	O
in	O
96	O
CEPH	O
control	O
chromosomes	O
.	O

A	O
full	O
-	O
shaded	O
icon	O
denotes	O
ESRD	B-DISEASE
;	O
a	O
3	O
/	O
4	O
-	O
shaded	O
icon	O
denotes	O
impaired	O
renal	O
function	O
;	O
individual	O
with	O
unknown	O
phenotype	O
is	O
indicated	O
in	O
gray	O
.	O

High	O
-	O
resolution	O
temporal	O
bone	O
CT	O
was	O
available	O
for	O
all	O
144	O
recruited	O
patients	O
.	O

The	O
evolutionary	O
conservation	O
of	O
p	B-VARIANT
.	I-VARIANT
Ser16Pro	I-VARIANT
was	O
assessed	O
by	O
multiple	O
sequence	O
alignment	O
of	O
PRPS1	B-GENE
across	O
species	O
using	O
ClustalW2	O
[	O
14	O
]	O
.	O

Analyzed	O
the	O
data	O
:	O
MSim	O
EMR	O
XW	O
MSis	O
MSh	O
VHH	O
WGN	O
RH	O
SNK	O
MXG	O
TBF	O
DKW	O
VP	O
ShR	O
DCW	O
ZMA	O
TH	O
SaR	O
.	O

CNS	O
complications	O
included	O
posterior	B-DISEASE
reversible	I-DISEASE
leukoencephalopathy	I-DISEASE
syndrome	I-DISEASE
(	O
n	O
=	O
10	O
)	O
,	O
stroke	B-DISEASE
(	O
n	O
=	O
5	O
)	O
,	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
(	O
n	O
=	O
2	O
)	O
,	O
high	B-DISEASE
-	I-DISEASE
dose	I-DISEASE
methotrexate	B-Chemical
toxicity	I-DISEASE
(	O
n	O
=	O
2	O
)	O
,	O
syndrome	O
of	O
inappropriate	O
antidiuretic	I-DISEASE
hormone	I-DISEASE
secretion	I-DISEASE
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
events	O
(	O
n	O
=	O
7	O
)	O
.	O

QYZ	O
,	O
HMY	O
and	O
YS	O
conceited	O
and	O
coordinated	O
the	O
study	O
.	O

The	O
lysates	O
were	O
clarified	O
by	O
centrifugation	O
at	O
100	O
,	O
000	O
x	O
g	O
for	O
one	O
hour	O
at	O
4	O
deg	O
C	O
,	O
and	O
the	O
supernatants	O
were	O
loaded	O
onto	O
a	O
Ni	O
-	O
NTA	O
column	O
(	O
GE	O
Healthcare	O
)	O
that	O
was	O
pre	O
-	O
equilibrated	O
in	O
the	O
same	O
buffer	O
.	O

Conversely	O
,	O
dominantly	O
inherited	O
mutations	O
result	O
in	O
an	O
adult	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
mitochondrial	I-DISEASE
disease	I-DISEASE
,	O
featuring	O
PEO	B-DISEASE
and	O
ptosis	B-DISEASE
at	O
the	O
clinical	O
level	O
and	O
the	O
accumulation	B-DISEASE
of	I-DISEASE
mtDNA	I-DISEASE
multiple	I-DISEASE
deletions	I-DISEASE
in	O
muscle	O
at	O
the	O
molecular	O
level	O
[	O
1	O
,	O
4	O
,	O
8	O
]	O
.	O

All	O
patients	O
are	O
bilaterally	O
affected	O
.	O

Since	O
the	O
RP	B-DISEASE
onset	O
ages	O
for	O
the	O
two	O
patients	O
were	O
15	O
and	O
13	O
years	O
of	O
age	O
,	O
both	O
of	O
which	O
were	O
in	O
accordance	O
with	O
the	O
typical	O
clinical	O
manifestations	O
presented	O
by	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
2	I-DISEASE
,	O
we	O
therefore	O
concluded	O
that	O
the	O
two	O
patients	O
from	O
family	O
USH01	O
displayed	O
USH	B-DISEASE
type	I-DISEASE
2	I-DISEASE
phenotypes	O
.	O

There	O
were	O
3379	O
patients	O
randomly	O
assigned	O
to	O
enalapril	B-Chemical
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
974	O
days	O
and	O
3379	O
patients	O
randomly	O
assigned	O
to	O
placebo	O
with	O
a	O
mean	O
follow	O
-	O
up	O
of	O
967	O
days	O
.	O

MYO7A	B-GENE
is	O
responsible	O
for	O
DFNA11	B-DISEASE
(	O
OMIM	O
601317	O
)	O
[	O
37	O
]	O
,	O
DFNB2	B-DISEASE
(	O
OMIM	O
600060	O
)	O
[	O
38	O
]	O
,	O
and	O
Usher	B-DISEASE
syndrome	I-DISEASE
1B	I-DISEASE
(	O
OMIM	O
276900	O
)	O
[	O
39	O
]	O
.	O

Our	O
cell	O
-	O
based	O
in	O
vitro	O
functional	O
assays	O
study	O
also	O
indicated	O
that	O
c	B-VARIANT
.	I-VARIANT
109G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
homozygote	O
could	O
impair	O
connexin26	O
gap	O
junctional	O
coupling	O
and	O
should	O
be	O
assigned	O
to	O
pathogenic	O
mutation	O
(	O
unpublished	O
data	O
)	O
.	O

Maximal	O
CS	B-Chemical
-	O
mediated	O
protection	O
was	O
observed	O
in	O
experimental	O
animals	O
pretreated	O
24	O
h	O
prior	O
to	O
the	O
toxic	O
insult	O
.	O

Control	O
samples	O
were	O
incubated	O
with	O
PBS	O
instead	O
of	O
primary	O
antibody	O
,	O
followed	O
by	O
incubation	O
with	O
anti	O
-	O
mouse	O
-	O
PE	O
secondary	O
antibody	O
.	O

This	O
report	O
describes	O
sequence	O
analysis	O
of	O
nine	O
USH	B-DISEASE
genes	O
MYO7A	B-GENE
,	O
USH1C	B-GENE
,	O
CDH23	B-GENE
,	O
PCDH15	B-GENE
,	O
USH1G	B-GENE
,	O
USH2A	B-GENE
,	O
GPR98	B-GENE
,	O
WHRN	B-GENE
,	O
CLRN1	B-GENE
and	O
a	O
candidate	O
gene	O
SLC4A7	B-GENE
in	O
the	O
ethnically	O
heterogeneous	O
UK	O
population	O
.	O

The	O
experiment	O
was	O
repeated	O
three	O
times	O
.	O

Our	O
aim	O
in	O
this	O
study	O
is	O
to	O
utilize	O
next	O
generation	O
sequencing	O
to	O
assess	O
the	O
spectrum	O
of	O
ABCA4	B-GENE
mutations	O
in	O
our	O
patient	O
cohort	O
,	O
and	O
to	O
examine	O
patients	O
for	O
disease	O
causing	O
mutations	O
in	O
other	O
retinal	B-DISEASE
disease	I-DISEASE
genes	O
.	O

The	O
PCR	O
cycling	O
and	O
protocol	O
information	O
are	O
available	O
upon	O
request	O
.	O

Paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
has	O
demonstrated	O
significant	O
antineoplastic	O
activity	O
against	O
different	O
tumor	O
types	O
,	O
notably	O
ovarian	B-DISEASE
and	O
breast	B-DISEASE
carcinoma	I-DISEASE
.	O

Based	O
on	O
these	O
data	O
,	O
we	O
conclude	O
that	O
p	B-VARIANT
.	I-VARIANT
Pro404Leu	I-VARIANT
is	O
likely	O
to	O
be	O
a	O
severe	O
mutation	O
.	O

gDNA	O
libraries	O
were	O
cleaned	O
and	O
size	O
selected	O
using	O
the	O
AMPure	O
DNA	O
Purification	O
kit	O
(	O
Beckman	O
Agencourt	O
,	O
Danvers	O
,	O
MA	O
)	O
.	O

As	O
a	O
result	O
,	O
this	O
mutation	O
may	O
cause	O
NSHL	B-DISEASE
via	O
its	O
interaction	O
with	O
SIX3	B-GENE
.	O

We	O
then	O
modified	O
our	O
NGS	O
approach	O
to	O
enable	O
more	O
efficient	O
discovery	O
of	O
variants	O
associated	O
with	O
AS	B-DISEASE
or	O
a	O
subset	O
of	O
FSGS	B-DISEASE
by	O
multiplexing	O
targeted	O
exome	O
sequencing	O
of	O
19	O
genes	O
associated	O
with	O
AS	B-DISEASE
or	O
FSGS	B-DISEASE
in	O
14	O
patients	O
.	O

MJ	B-DISEASE
disappeared	O
when	O
LTG	B-Chemical
dose	O
was	O
decreased	O
by	O
25	O
to	O
50	O
%	O
.	O

Overlapping	O
audiograms	O
of	O
subjects	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
caused	O
by	O
CDH23	B-GENE
mutations	O
.	O

Thirty	O
-	O
six	O
rats	O
bearing	O
breast	O
tumors	O
induced	O
chemically	O
were	O
divided	O
into	O
4	O
groups	O
:	O
control	O
,	O
hydroxytyrosol	B-Chemical
(	O
0	O
.	O
5mg	O
/	O
kg	O
,	O
5days	O
/	O
week	O
)	O
,	O
doxorubicin	B-Chemical
(	O
1mg	O
/	O
kg	O
/	O
week	O
)	O
,	O
and	O
doxorubicin	B-Chemical
plus	O
hydroxytyrosol	B-Chemical
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
homozygosity	O
or	O
compound	O
heterozygosity	O
for	O
missense	O
mutation	O
is	O
more	O
likely	O
to	O
lead	O
to	O
a	O
"	O
mild	O
"	O
phenotype	O
whereas	O
patients	O
with	O
one	O
or	O
more	O
inactivating	O
mutations	O
would	O
have	O
a	O
more	O
severe	O
phenotype	O
.	O

The	O
total	O
number	O
of	O
Altaians	O
is	O
about	O
60	O
,	O
000	O
.	O

Our	O
previous	O
genetic	O
analysis	O
for	O
the	O
patients	O
with	O
high	O
frequency	O
involved	O
hearing	B-DISEASE
loss	I-DISEASE
successfully	O
identified	O
CDH23	B-GENE
mutations	O
[	O
18	O
]	O
.	O

It	O
indicates	O
defective	B-DISEASE
conduction	I-DISEASE
of	I-DISEASE
the	I-DISEASE
optic	I-DISEASE
nerves	I-DISEASE
.	O

These	O
findings	O
indicate	O
that	O
gabapentin	B-Chemical
has	O
a	O
measurable	O
antinociceptive	O
effect	O
and	O
a	O
stronger	O
antihyperalgesic	O
effect	O
most	O
evident	O
in	O
the	O
brain	O
areas	O
undergoing	O
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	B-Chemical
is	O
more	O
effective	O
in	O
modulating	O
nociceptive	O
transmission	O
when	O
central	B-DISEASE
sensitization	I-DISEASE
is	O
present	O
.	O

Among	O
these	O
,	O
patient	O
07	O
-	O
0430	O
-	O
01590	O
is	O
the	O
grandmother	O
of	O
07	O
-	O
0430	O
-	O
02009	O
and	O
did	O
not	O
previously	O
have	O
AS	B-DISEASE
diagnosis	O
and	O
is	O
clinically	O
phenotyped	O
as	O
FSGS	B-DISEASE
.	O

As	O
a	O
platelet	O
count	O
of	O
<	O
50	O
x	O
10	O
9	O
/	O
L	O
is	O
recommended	O
for	O
measures	O
to	O
prevent	O
bleeding	B-DISEASE
(	O
Slichter	B-Chemical
2007	O
)	O
,	O
we	O
defined	O
two	O
groups	O
of	O
patients	O
with	O
a	O
platelet	O
count	O
under	O
or	O
above	O
50	O
x	O
10	O
9	O
/	O
L	O
.	O

(	O
DOCX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Two	O
schizophrenic	B-DISEASE
patients	O
,	O
who	O
had	O
a	O
prior	O
history	O
of	O
LSD	B-Chemical
abuse	O
and	O
who	O
had	O
previously	O
developed	O
EPS	B-DISEASE
with	O
classic	O
antipsychotics	B-DISEASE
,	O
were	O
successfully	O
treated	O
with	O
risperidone	B-Chemical
.	O

Within	O
8	O
hours	O
after	O
initiation	O
of	O
therapy	O
the	O
patient	O
died	O
with	O
a	O
clinical	O
picture	O
resembling	O
massive	O
pulmonary	B-DISEASE
obstruction	I-DISEASE
due	O
to	O
choriocarcinomic	B-DISEASE
tissue	I-DISEASE
plugs	I-DISEASE
,	O
probably	O
originating	O
from	O
the	O
uterus	O
.	O

Although	O
we	O
have	O
not	O
reached	O
the	O
final	O
conclusion	O
,	O
it	O
is	O
most	O
likely	O
that	O
these	O
heterozygous	O
cases	O
are	O
also	O
related	O
to	O
CDH23	B-GENE
mutations	O
because	O
:	O
1	O
)	O
allele	O
frequencies	O
are	O
found	O
to	O
be	O
higher	O
in	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
group	O
(	O
Table	O
2	O
)	O
,	O
and	O
2	O
)	O
the	O
phenotype	O
is	O
similar	O
to	O
that	O
of	O
the	O
patients	O
with	O
two	O
mutations	O
.	O

Data	O
are	O
expressed	O
as	O
means	O
+	O
-	O
SD	O
.	O

METHODS	O
:	O
ASA	B-Chemical
was	O
administered	O
as	O
a	O
single	O
dose	O
on	O
GD	O
9	O
(	O
0	O
,	O
250	O
,	O
500	O
,	O
or	O
625	O
mg	O
/	O
kg	O
)	O
,	O
10	O
(	O
0	O
,	O
500	O
,	O
625	O
,	O
or	O
750	O
mg	O
/	O
kg	O
)	O
,	O
or	O
11	O
(	O
0	O
,	O
500	O
,	O
750	O
,	O
or	O
1000	O
mg	O
/	O
kg	O
)	O
and	O
from	O
GD	O
6	O
to	O
GD	O
17	O
(	O
0	O
,	O
50	O
,	O
125	O
,	O
or	O
250	O
mg	O
/	O
kg	O
a	O
day	O
)	O
in	O
the	O
multiple	O
dose	O
study	O
to	O
SD	O
rats	O
.	O

We	O
thank	O
Dr	O
.	O

Plasma	O
was	O
tested	O
for	O
amphetamine	B-Chemical
and	O
the	O
cocaine	B-Chemical
metabolite	O
benzoylecgonine	B-Chemical
using	O
enzyme	O
-	O
mediated	O
immunoassay	O
methodology	O
.	O

Special	O
attention	O
must	O
be	O
paid	O
to	O
cardiac	O
patients	O
who	O
are	O
often	O
exposed	O
to	O
heparin	B-Chemical
multiple	O
times	O
during	O
their	O
course	O
of	O
treatment	O
.	O

This	O
correlation	O
proves	O
true	O
in	O
the	O
majority	O
of	O
cases	O
,	O
but	O
exceptions	O
can	O
be	O
observed	O
in	O
which	O
same	O
genetic	O
constellation	O
leads	O
to	O
largely	O
divergent	O
phenotypes	O
.	O

1	O
)	O
.	O

Mutations	O
in	O
the	O
transmembrane	O
protease	O
serine	O
3	O
(	O
TMPRSS3	B-GENE
,	O
OMIM	O
605511	O
)	O
gene	O
on	O
chromosome	O
21q22	O
are	O
responsible	O
not	O
only	O
for	O
arNSHI	B-DISEASE
with	O
a	O
prelingual	O
onset	O
(	O
DFNB10	B-DISEASE
,	O
OMIM	O
605316	O
;	O
Bonne	O
-	O
Tamir	O
et	O
al	O
.	O

In	O
patient	O
5	O
,	O
a	O
known	O
mutation	O
in	O
the	O
TMC1	B-GENE
gene	O
was	O
identified	O
previously	O
,	O
and	O
this	O
patient	O
served	O
as	O
a	O
positive	O
control	O
.	O

Recently	O
,	O
whole	O
exome	O
sequencing	O
has	O
substantially	O
aided	O
the	O
detection	O
of	O
a	O
series	O
of	O
new	O
causative	O
deafness	B-DISEASE
genes	O
[	O
49	O
-	O
55	O
]	O
.	O

The	O
clinical	O
diagnosis	O
was	O
based	O
on	O
simultaneous	O
occurrence	O
of	O
bilateral	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
HL	B-DISEASE
)	O
(	O
HP	O
:	O
0000407	O
)	O
(	O
Robinson	O
et	O
al	O
.	O

The	O
device	O
revealed	O
that	O
the	O
patient	O
had	O
AF	B-DISEASE
6	O
%	O
of	O
the	O
time	O
and	O
no	O
ventricular	B-DISEASE
arrhythmias	I-DISEASE
were	O
detected	O
during	O
the	O
observation	O
period	O
.	O

Among	O
39	O
patients	O
screened	O
for	O
WFS1	B-GENE
mutations	O
,	O
34	O
mutations	O
were	O
detected	O
,	O
13	O
of	O
which	O
were	O
novel	O
(	O
Table	O
3	O
)	O
.	O

COC	B-Chemical
use	O
was	O
ascertained	O
through	O
mailed	O
questionnaires	O
.	O

A	O
total	O
of	O
100	O
(	O
0	O
.	O
9	O
%	O
)	O
patients	O
developed	O
postoperative	O
convulsive	B-DISEASE
seizures	I-DISEASE
.	O

Valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
in	O
patients	O
with	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
treated	O
with	O
pergolide	B-Chemical
.	O

Deletions	O
,	O
frameshift	O
-	O
,	O
splice	O
-	O
and	O
nonsense	O
mutations	O
were	O
considered	O
disease	O
-	O
causing	O
if	O
not	O
found	O
in	O
controls	O
.	O

PAX3	B-GENE
is	O
expressed	O
in	O
neural	O
crest	O
cells	O
including	O
the	O
spinal	O
ganglia	O
,	O
the	O
craniofacial	O
mesectoderm	O
,	O
and	O
the	O
limb	O
mesenchyme	O
during	O
embryogenesis	O
and	O
plays	O
an	O
important	O
role	O
in	O
the	O
migration	O
and	O
differentiation	O
of	O
melanocytes	O
,	O
which	O
originate	O
from	O
the	O
embryonic	O
neural	O
crest	O
[	O
17	O
,	O
28	O
]	O
.	O

Finally	O
,	O
our	O
comprehensive	O
study	O
also	O
throws	O
doubt	O
on	O
previous	O
studies	O
that	O
have	O
suggested	O
that	O
mutations	O
in	O
the	O
known	O
genes	O
are	O
not	O
the	O
major	O
cause	O
of	O
MED	B-DISEASE
[	O
Jakkula	O
et	O
al	O
.	O
,	O
2005	O
]	O
,	O
and	O
we	O
conclude	O
that	O
mutations	O
in	O
COMP	B-GENE
,	O
MATN3	B-GENE
,	O
and	O
type	B-GENE
IX	I-GENE
collagen	I-GENE
genes	O
account	O
for	O
the	O
vast	O
majority	O
of	O
classical	O
AD	B-DISEASE
-	I-DISEASE
MED	I-DISEASE
.	O

The	O
LOD	O
score	O
was	O
calculated	O
using	O
a	O
recessive	O
model	O
of	O
inheritance	O
assuming	O
a	O
fully	O
penetrant	O
disorder	O
and	O
a	O
disease	O
allele	O
frequency	O
of	O
0	O
.	O
001	O
.	O

Adzhubei	B-Chemical
and	O
S	B-Chemical
.	O

To	O
date	O
,	O
mutations	O
in	O
12	O
loci	O
and	O
ten	O
genes	O
have	O
been	O
found	O
to	O
be	O
responsible	O
for	O
USH	B-DISEASE
.	O

Fifteen	O
variants	O
were	O
considered	O
to	O
have	O
uncertain	O
pathogenicity	O
(	O
Table	O
1	O
)	O
.	O

Screening	O
of	O
the	O
delta	O
(	O
GJB6	B-GENE
-	O
D13S1830	O
)	O
and	O
mitochondrial	O
mutations	O
m	B-VARIANT
.	I-VARIANT
1555A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
m	B-VARIANT
.	I-VARIANT
7445A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
m	B-VARIANT
.	I-VARIANT
7472insC	I-VARIANT
,	O
m	B-VARIANT
.	I-VARIANT
7510T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
m	B-VARIANT
.	I-VARIANT
7511T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
was	O
negative	O
in	O
patients	O
who	O
had	O
no	O
GJB2	B-GENE
mutations	O
.	O

Two	O
of	O
the	O
mutations	O
found	O
in	O
this	O
study	O
are	O
truncating	O
:	O
the	O
p	B-VARIANT
.	I-VARIANT
Y63X	I-VARIANT
mutation	O
,	O
found	O
in	O
two	O
unrelated	O
families	O
who	O
were	O
carriers	O
of	O
Catalonian	O
origin	O
,	O
and	O
p	B-VARIANT
.	I-VARIANT
R207X	I-VARIANT
,	O
found	O
in	O
heterozygous	O
state	O
in	O
two	O
unrelated	O
families	O
who	O
were	O
carriers	O
of	O
Basque	O
origin	O
.	O

In	O
conclusion	O
,	O
where	O
succinylcholine	B-Chemical
is	O
used	O
,	O
lidocaine	B-Chemical
is	O
proven	O
to	O
be	O
the	O
useful	O
pretreatment	O
agent	O
for	O
the	O
reduction	O
of	O
postoperative	O
myalgia	B-DISEASE
.	O

XY	O
selected	O
and	O
designed	O
the	O
targets	O
capture	O
,	O
performed	O
experiments	O
,	O
analyzed	O
and	O
interpreted	O
the	O
data	O
.	O

Here	O
we	O
describe	O
clinical	O
,	O
histological	O
and	O
molecular	O
features	O
of	O
two	O
patients	O
presenting	O
with	O
mitochondrial	B-DISEASE
myopathy	I-DISEASE
associated	O
with	O
PEO	B-DISEASE
.	O

The	O
majority	O
of	O
the	O
affected	O
family	O
members	O
appeared	O
to	O
have	O
developed	O
a	O
high	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
tinnitus	I-DISEASE
at	O
the	O
onset	O
of	O
HL	B-DISEASE
.	O

To	O
predict	O
whether	O
a	O
rare	O
missense	O
variant	O
is	O
deleterious	O
,	O
we	O
used	O
the	O
combined	O
results	O
of	O
three	O
computer	O
algorithms	O
:	O
Sort	O
Intolerant	O
From	O
Tolerant	O
(	O
SIFT	O
)	O
uses	O
sequence	O
homology	O
to	O
predict	O
whether	O
a	O
change	O
is	O
tolerated	O
or	O
deleterious	O
.	O

He	O
was	O
awake	O
,	O
revealed	O
no	O
changes	O
of	O
mental	B-DISEASE
status	O
and	O
at	O
rest	O
there	O
were	O
no	O
further	O
motor	O
symptoms	O
.	O

Rhodamine	B-Chemical
phalloidin	I-Chemical
(	O
red	O
)	O
was	O
used	O
to	O
reveal	O
F	O
-	O
actin	O
and	O
highlight	O
the	O
microvilli	O
on	O
the	O
CL4	O
cell	O
surface	O
.	O

However	O
,	O
regardless	O
of	O
the	O
duration	O
of	O
recovery	O
(	O
and	O
irrespective	O
of	O
either	O
lesion	O
volume	O
,	O
amphetamine	B-Chemical
dose	O
,	O
or	O
post	O
-	O
lesion	O
motor	O
exercise	O
)	O
,	O
amphetamine	B-Chemical
-	O
induced	O
rotation	O
tended	O
to	O
become	O
gradually	O
more	O
ipsilateral	O
as	O
the	O
observation	O
session	O
progressed	O
,	O
and	O
all	O
rats	O
circled	O
ipsilaterally	O
to	O
the	O
lesion	O
in	O
response	O
to	O
further	O
amphetamine	B-Chemical
injections	O
.	O

Family	O
pedigrees	O
in	O
which	O
the	O
co	O
-	O
segregation	O
of	O
the	O
detected	O
mutations	O
was	O
performed	O
.	O

(	O
2003	O
)	O
into	O
three	O
types	O
.	O

Thirty	O
-	O
six	O
percent	O
of	O
all	O
reads	O
had	O
this	O
mutation	O
,	O
with	O
a	O
variation	O
score	O
of	O
35	O
in	O
the	O
targeted	O
sequencing	O
.	O

Variants	O
having	O
an	O
allele	O
frequency	O
<	O
8	O
%	O
were	O
removed	O
.	O

This	O
finding	O
could	O
be	O
related	O
to	O
the	O
pathologic	O
condition	O
in	O
which	O
the	O
main	O
portion	O
of	O
enlargement	O
is	O
the	O
endolymphatic	O
duct	O
rather	O
than	O
the	O
endolymphatic	O
sac	O
.	O

Since	O
the	O
initial	O
reports	O
of	O
the	O
association	O
of	O
MYH9	B-GENE
mutations	O
and	O
inherited	O
macrothrombocytopenia	B-DISEASE
,	O
a	O
large	O
number	O
of	O
isolated	O
cases	O
or	O
series	O
have	O
been	O
published	O
.	O

She	O
had	O
defects	O
in	O
the	O
supratentorial	O
brain	O
including	O
the	O
basal	O
ganglia	O
and	O
the	O
striatum	O
(	O
multicystic	B-DISEASE
encephalomalacia	I-DISEASE
)	O
due	O
to	O
severe	O
perinatal	B-DISEASE
hypoxic	I-DISEASE
-	I-DISEASE
ischemic	I-DISEASE
encephalopathy	I-DISEASE
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predisposing	O
factor	O
causing	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
.	O

Flynn	O
for	O
assistance	O
with	O
human	O
subjects	O
protocols	O
,	O
R	O
.	O

This	O
is	O
likely	O
to	O
explain	O
why	O
there	O
are	O
so	O
many	O
apparently	O
rare	O
inherited	O
candidate	O
variants	O
in	O
this	O
case	O
.	O

3	O
)	O
,	O
but	O
affect	O
targeting	O
to	O
the	O
nucleolus	O
,	O
the	O
site	O
for	O
Pol	O
I	O
transcription	O
.	O

Effect	O
of	O
adriamycin	B-Chemical
combined	O
with	O
whole	O
body	O
hyperthermia	O
on	O
tumor	O
and	O
normal	O
tissues	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
is	O
a	O
group	O
of	O
recessively	O
inherited	O
disorders	O
characterized	O
by	O
deafness	B-DISEASE
and	O
vision	B-DISEASE
loss	I-DISEASE
.	O

Molecular	O
investigations	O
and	O
MRI	O
neuroimaging	O
of	O
a	O
58	O
-	O
year	O
-	O
old	O
female	O
presenting	O
with	O
a	O
multiple	B-DISEASE
sclerosis	I-DISEASE
-	I-DISEASE
like	I-DISEASE
illness	I-DISEASE
and	O
harbouring	O
a	O
c	B-VARIANT
.	I-VARIANT
2613	I-VARIANT
+	I-VARIANT
1g	I-VARIANT
>	I-VARIANT
a	I-VARIANT
splice	O
-	O
site	O
mutation	O
within	O
intron	O
25	O
of	O
the	O
OPA1	B-GENE
gene	O
(	O
UK	O
-	O
6	O
)	O
.	O

The	O
sequence	O
variations	O
were	O
consisting	O
of	O
16	O
nucleotide	O
substitutions	O
,	O
six	O
deletions	O
,	O
one	O
insertion	O
andtwo	O
indels	O
.	O

Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
sodium	I-Chemical
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O

Mutation	O
profile	O
of	O
TECTA	B-GENE
gene	O
(	O
located	O
on	O
chr11	O
)	O
.	O

Only	O
5	O
of	O
the	O
160	O
F2	O
pituitaries	O
exhibited	O
the	O
hemorrhagic	O
phenotype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituitaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
mass	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorrhagic	O
,	O
indicating	O
that	O
the	O
hemorrhagic	B-DISEASE
phenotype	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extensive	O
growth	O
.	O

Levetiracetam	B-Chemical
as	O
an	O
adjunct	O
to	O
phenobarbital	B-Chemical
treatment	O
in	O
cats	O
with	O
suspected	O
idiopathic	O
epilepsy	B-DISEASE
.	O

In	O
total	O
,	O
37	O
genes	O
for	O
41	O
different	O
GSDs	B-DISEASE
were	O
reported	O
in	O
Chinese	O
biomedical	O
literature	O
,	O
including	O
43	O
novel	O
mutations	O
.	O

Figure	O
S3	O
.	O

No	O
change	O
in	O
protein	O
levels	O
of	O
beta	O
-	O
and	O
gamma	O
-	O
actin	O
were	O
seen	O
between	O
these	O
two	O
cell	O
lines	O
(	O
Fig	O
.	O

The	O
terminology	O
of	O
auditory	B-DISEASE
neuropathy	I-DISEASE
spectrum	I-DISEASE
disorder	I-DISEASE
(	O
ANSD	B-DISEASE
)	O
was	O
recommend	O
to	O
name	O
the	O
disease	O
in	O
2008	O
due	O
to	O
its	O
heterogeneous	O
and	O
multifaceted	O
characteristics	O
[	O
3	O
]	O
.	O

The	O
ratio	O
of	O
exon	O
8	O
of	O
DIAPH1	B-GENE
gene	O
was	O
close	O
to	O
2	O
,	O
suggesting	O
that	O
the	O
DNA	O
segment	O
containing	O
this	O
exon	O
was	O
doubled	O
compared	O
to	O
the	O
normal	O
copy	O
number	O
.	O

Table	O
S1	O
)	O
.	O

S1	O
)	O
.	O

Treacher	B-DISEASE
Collins	I-DISEASE
syndrome	I-DISEASE
(	O
TCS	B-DISEASE
;	I-DISEASE
OMIM	O
154500	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
craniofacial	B-DISEASE
disorder	I-DISEASE
(	O
1	O
:	O
50	O
.	O
000	O
)	O
characterized	O
by	O
bilateral	O
and	O
symmetrical	O
malformations	O
,	O
which	O
frequently	O
includes	O
hypoplasia	B-DISEASE
of	I-DISEASE
the	I-DISEASE
mandible	I-DISEASE
and	I-DISEASE
zygomatic	I-DISEASE
complex	I-DISEASE
,	O
down	B-DISEASE
-	I-DISEASE
slanting	I-DISEASE
palpebral	I-DISEASE
fissures	I-DISEASE
,	O
coloboma	B-DISEASE
of	I-DISEASE
the	I-DISEASE
lower	I-DISEASE
eyelid	I-DISEASE
and	O
absence	B-DISEASE
of	I-DISEASE
eyelashes	I-DISEASE
medial	O
to	O
this	O
defect	O
,	O
external	B-DISEASE
and	I-DISEASE
middle	I-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
,	O
and	O
conductive	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
[	O
1	O
]	O
.	O

There	O
is	O
evidence	O
that	O
immotiles	O
nasal	O
cilial	O
can	O
be	O
associated	O
with	O
USH1	B-DISEASE
[	O
13	O
]	O
.	O

Autoantibodies	O
against	O
pancreatic	O
beta	O
-	O
cells	O
(	O
anti	O
-	O
glutamic	B-Chemical
acid	I-Chemical
decarboxylase	I-Chemical
:	O
GADA	B-Chemical
,	O
anti	O
-	O
thyrosin	B-Chemical
phosphatase	O
-	O
like	O
protein	O
:	O
IA	O
-	O
2A	O
,	O
anti	O
-	O
insulin	O
:	O
IAA	O
)	O
were	O
detected	O
by	O
RIA	O
[	O
12	O
]	O
,	O
and	O
the	O
analysis	O
of	O
HLA	B-GENE
-	I-GENE
DQA1	I-GENE
and	O
-	B-GENE
DQB1	I-GENE
polymorphisms	O
at	O
genomic	O
levels	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
/	O
sequence	O
specific	O
primers	O
technique	O
[	O
13	O
]	O
.	O

Harry	O
H	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
changes	O
leading	O
to	O
an	O
alteration	O
of	O
myocardial	O
dynamic	O
imaging	O
with	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
are	O
not	O
the	O
initiating	O
factor	O
in	O
doxorubicin	B-Chemical
cardiotoxicity	I-DISEASE
.	O

The	O
programs	O
used	O
to	O
analyze	O
the	O
data	O
generated	O
from	O
NGS	O
followed	O
different	O
algorithms	O
.	O

Among	O
the	O
three	O
mutations	O
of	O
GJB2	B-GENE
found	O
in	O
Uyghur	O
patients	O
,	O
235delC	B-VARIANT
shows	O
the	O
highest	O
allele	O
frequency	O
,	O
and	O
35delG	B-VARIANT
follows	O
235delC	B-VARIANT
in	O
allele	O
frequency	O
.	O

Sanger	O
sequencing	O
was	O
used	O
to	O
analyze	O
variants	O
in	O
the	O
coding	O
and	O
adjacent	O
regions	O
of	O
OPA1	B-GENE
.	O

CONCLUSIONS	O
:	O
Severity	O
of	O
ifosfamide	B-Chemical
related	I-DISEASE
encephalopathy	I-DISEASE
correlates	O
with	O
EEG	O
changes	O
.	O

Aided	O
threshold	O
=	O
average	O
thresholds	O
at	O
0	O
.	O
25	O
,	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
4	O
kHz	O
as	O
measured	O
in	O
the	O
free	O
-	O
field	O
with	O
subjects	O
wearing	O
their	O
sound	O
processor	O
;	O
Acoustic	O
ABRs	O
refers	O
to	O
the	O
presence	O
of	O
acoustically	O
-	O
evoked	O
ABRs	O
in	O
the	O
implanted	O
ear	O
before	O
cochlear	O
implantation	O
.	O

PCR	O
reaction	O
conditions	O
for	O
all	O
fragments	O
were	O
:	O
95	O
deg	O
C	O
for	O
10	O
min	O
;	O
then	O
35	O
cycles	O
of	O
95	O
deg	O
C	O
for	O
30s	O
,	O
60	O
deg	O
C	O
for	O
1	O
min	O
and	O
72	O
deg	O
C	O
for	O
30s	O
,	O
followed	O
by	O
7	O
min	O
at	O
72	O
deg	O
C	O
.	O

Earlier	O
observations	O
that	O
ADR	B-Chemical
interacts	O
with	O
mitochondrial	O
cytochrome	O
c	O
oxidase	O
(	O
COX	O
)	O
and	O
suppresses	O
its	O
enzyme	O
activity	O
led	O
us	O
to	O
investigate	O
ADR	B-Chemical
'	O
s	O
action	O
on	O
the	O
cardiovascular	O
functions	O
and	O
heart	O
mitochondrial	O
morphology	O
in	O
Balb	O
-	O
c	O
mice	O
i	O
.	O
p	O
.	O
treated	O
with	O
ADR	B-Chemical
for	O
several	O
weeks	O
.	O

MG	O
,	O
SM	O
,	O
DW	O
,	O
AEA	O
,	O
LJ	O
,	O
JL	O
,	O
JAS	O
participated	O
in	O
manuscript	O
writing	O
.	O

DESIGN	O
:	O
Pooled	O
data	O
from	O
3	O
multicenter	O
,	O
double	O
-	O
masked	O
,	O
randomized	O
,	O
controlled	O
,	O
phase	O
2b	O
/	O
3	O
clinical	O
trials	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
0	O
.	O
59	O
-	O
mg	O
or	O
2	O
.	O
1	O
-	O
mg	O
FA	B-Chemical
intravitreal	O
implant	O
or	O
standard	O
therapy	O
were	O
analyzed	O
.	O

Although	O
the	O
neurochemistry	O
of	O
opiate	B-DISEASE
-	O
induced	O
rigidity	B-DISEASE
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
,	O
recent	O
work	O
suggests	O
a	O
role	O
for	O
a	O
central	O
adrenergic	O
mechanism	O
.	O

Group	O
2	O
received	O
diazepam	B-Chemical
alone	O
followed	O
by	O
vehicle	O
.	O

Click	O
here	O
for	O
file	O
Overview	O
of	O
data	O
production	O
using	O
WES	O
.	O

Mutations	O
in	O
the	O
CDH23	B-GENE
gene	O
are	O
known	O
to	O
be	O
responsible	O
for	O
both	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
ID	I-DISEASE
(	O
USH1D	B-DISEASE
)	O
and	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
DFNB12	B-DISEASE
)	O
.	O

DNA	O
samples	O
from	O
family	O
members	O
were	O
not	O
available	O
.	O

However	O
,	O
there	O
have	O
been	O
no	O
reports	O
of	O
the	O
detection	O
of	O
pathogenic	O
mutations	O
by	O
screening	O
candidate	O
hearing	B-DISEASE
loss	I-DISEASE
genes	O
in	O
small	O
families	O
without	O
using	O
linkage	O
analysis	O
.	O

Spinal	B-DISEASE
anomalies	I-DISEASE
such	O
as	O
the	O
cervical	B-DISEASE
spine	I-DISEASE
fusion	I-DISEASE
are	O
rare	O
in	O
Pfeiffer	B-DISEASE
syndrome	I-DISEASE
15	O
)	O
,	O
but	O
coccygeal	B-DISEASE
anomaly	I-DISEASE
occurred	O
in	O
one	O
other	O
case	O
in	O
Korea	O
7	O
)	O
.	O

We	O
examined	O
the	O
abundance	O
of	O
ENaC	B-GENE
subunit	O
mRNAs	O
and	O
proteins	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
induced	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
results	O
demonstrated	O
that	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
(	O
E2	B-Chemical
)	O
induces	O
neovascularization	B-DISEASE
,	O
as	O
well	O
as	O
the	O
growth	O
and	O
enlargement	O
of	O
blood	O
vessels	O
after	O
7	O
days	O
of	O
exposure	O
.	O

Structural	O
comparison	O
of	O
wild	O
-	O
type	O
versus	O
mutated	O
AIFM1	B-GENE
protein	O
showed	O
that	O
mutations	O
in	O
the	O
two	O
flavin	B-Chemical
adenine	I-Chemical
dinucleotide	I-Chemical
(	O
FAD	B-Chemical
)	O
and	O
reduced	B-Chemical
nicotinamide	B-Chemical
adenine	B-Chemical
dinucleotide	I-Chemical
(	O
NADH	O
)	O
domains	O
have	O
greater	O
impact	O
on	O
the	O
protein	O
surface	O
than	O
mutations	O
in	O
C	O
-	O
terminus	O
(	O
see	O
online	O
supplementary	O
figures	O
S6	O
and	O
S7	O
)	O
.	O

Demographic	O
,	O
survival	O
,	O
response	O
and	O
toxicity	O
data	O
were	O
recorded	O
.	O

We	O
also	O
used	O
DNA	O
from	O
50	O
Chinese	O
familial	O
patients	O
with	O
ARNSHL	B-DISEASE
and	O
208	O
ethnicity	O
-	O
matched	O
negative	O
samples	O
to	O
perform	O
extended	O
variants	O
analysis	O
.	O

Among	O
these	O
groups	O
,	O
intermediate	O
-	O
sized	O
platelets	O
were	O
the	O
most	O
abundant	O
(	O
median	O
:	O
44	O
%	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Residues	O
comprising	O
the	O
N	O
-	O
type	O
and	O
C	O
-	O
type	O
motif	O
are	O
boxed	O
and	O
the	O
consensus	O
sequence	O
of	O
each	O
motif	O
is	O
indicated	O
below	O
.	O

In	O
particular	O
,	O
the	O
most	O
common	O
classes	O
of	O
TCOF1	B-GENE
alleles	O
are	O
small	O
deletions	O
(	O
60	O
%	O
)	O
and	O
duplications	O
(	O
25	O
%	O
)	O
resulting	O
in	O
frameshifts	O
[	O
10	O
]	O
.	O

The	O
predicted	O
amino	O
acid	O
changes	O
and	O
surrounding	O
ones	O
are	O
indicated	O
above	O
the	O
sequences	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
following	O
a	O
standard	O
phenol	B-Chemical
-	O
chloroform	I-Chemical
method	O
.	O

Because	O
the	O
silent	O
mutation	O
can	O
also	O
be	O
spliced	O
normally	O
,	O
it	O
is	O
not	O
clear	O
what	O
phenotype	O
would	O
result	O
if	O
this	O
novel	O
C	O
-	O
propeptide	O
mutation	O
had	O
been	O
inherited	O
with	O
a	O
null	O
allele	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

S1	O
)	O
.	O

One	O
pair	O
of	O
specific	O
primers	O
was	O
designed	O
for	O
detecting	O
a	O
mutation	O
in	O
exon	O
32	O
(	O
Table	O
2	O
)	O
.	O

Consistent	O
with	O
our	O
previous	O
results	O
[	O
8	O
]	O
,	O
partial	O
mislocalization	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
ILDR1	B-GENE
mutant	O
in	O
this	O
study	O
led	O
to	O
the	O
incomplete	O
recruitment	O
of	O
tricellulin	B-GENE
to	O
TCs	O
in	O
LSR	B-GENE
knockdown	O
epithelial	O
cells	O
.	O

All	O
experimental	O
procedures	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
the	O
University	O
at	O
Buffalo	O
that	O
conform	O
to	O
the	O
guidelines	O
issued	O
by	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

SK	O
interpreted	O
the	O
NGS	O
data	O
and	O
confirmed	O
the	O
NGS	O
data	O
by	O
Sanger	O
sequencing	O
.	O

Shafique	O
S	I-Chemical
.	O

Since	O
such	O
features	O
are	O
occasionally	O
manifested	O
by	O
patients	O
with	O
22q11	O
.	O
2DS	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
,	O
the	O
results	O
may	O
suggest	O
the	O
relevance	O
of	O
TBX1	B-GENE
to	O
such	O
rather	O
infrequent	O
features	O
in	O
22q11	O
.	O
2DS	O
.	O

After	O
completion	O
of	O
the	O
reaction	O
,	O
the	O
mixture	O
was	O
purified	O
by	O
gel	O
filtration	O
on	O
a	O
Sephadex	O
G	O
-	O
50	O
column	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Piscataway	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

CONCLUSION	O
:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
had	O
mutations	O
in	O
BCHE	B-GENE
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	B-DISEASE
.	O

GJB2	B-GENE
was	O
screened	O
by	O
DHPLC	O
and	O
sequencing	O
analysis	O
as	O
previously	O
described	O
[	O
25	O
]	O
.	O

Availability	O
of	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	O
prolongation	O
.	O

The	O
methionine	B-Chemical
side	O
chain	O
is	O
longer	O
,	O
more	O
flexible	O
and	O
is	O
unbranched	O
compared	O
with	O
threonine	B-Chemical
(	O
Figure	O
3	O
)	O
.	O

We	O
also	O
observed	O
in	O
individual	O
patients	O
that	O
febrile	O
infections	O
and	O
general	B-DISEASE
anesthesia	I-DISEASE
may	O
induce	O
acute	B-DISEASE
neurologic	I-DISEASE
deterioration	I-DISEASE
in	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
,	O
indicating	O
that	O
these	O
conditions	O
may	O
constitute	O
an	O
additional	O
source	O
of	O
ER	O
stress	O
enhancement	O
.	O

Isoproterenol	B-Chemical
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp	O
/	O
dtmax	O
and	O
LVdp	O
/	O
dtmin	O
.	O

Myosin	B-GENE
VIIA	I-GENE
has	O
been	O
implicated	O
in	O
recessively	O
inherited	O
Usher	B-GENE
syndrome	I-GENE
type	I-GENE
1B	I-GENE
(	O
USH1B	B-DISEASE
)	O
[	O
8	O
]	O
,	O
atypical	B-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
(	O
USH3	B-DISEASE
)	O
[	O
9	O
]	O
,	O
nonsyndromic	O
recessive	O
(	O
Deafness	B-DISEASE
,	O
Neurosensory	O
,	O
Autosomal	O
Recessive	O
2	O
[	O
DFNB2	B-GENE
]	O
)	O
[	O
10	O
]	O
,	O
and	O
dominant	O
(	O
DFNA11	B-GENE
)	O
[	O
11	O
]	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
HL	B-DISEASE
)	O
.	O

The	O
arrows	O
refer	O
to	O
the	O
expected	O
effect	O
on	O
PEX1	B-GENE
expression	O
levels	O
.	O

Thiazide	B-Chemical
diuretics	O
,	O
hypokalemia	B-DISEASE
and	O
cardiac	B-DISEASE
arrhythmias	I-DISEASE
.	O

F10	O
had	O
fetal	B-DISEASE
akinesia	I-DISEASE
syndrome	I-DISEASE
probably	O
caused	O
by	O
neuroaxonal	B-DISEASE
dystrophy	I-DISEASE
.	O

Secondary	O
to	O
this	O
audiometric	O
hallmark	O
,	O
MYO1A	B-GENE
is	O
a	O
gene	O
with	O
variable	O
penetrance	O
.	O

Three	O
USH2	B-DISEASE
genes	O
are	O
known	O
,	O
USH2A	B-GENE
,	O
GPR98	B-GENE
(	O
also	O
known	O
as	O
VLGR1	B-GENE
)	O
,	O
and	O
DFNB31	B-GENE
.	O

,	O
2000	O
;	O
Olichon	O
et	O
al	O
.	O

Numerous	O
non	O
-	O
synonymous	O
polymorphisms	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
effect	O
in	O
cardiac	O
repolarisation	O
currents	O
.	O

It	O
might	O
be	O
speculated	O
that	O
additional	O
deeply	O
intronic	O
variants	O
that	O
affect	O
splicing	O
as	O
well	O
as	O
new	O
Usher	B-DISEASE
genes	O
will	O
even	O
further	O
increase	O
the	O
rate	O
of	O
biallelic	O
pathogenic	O
findings	O
in	O
Usher	B-DISEASE
patients	O
.	O

The	O
same	O
systematic	O
prioritization	O
process	O
was	O
subsequently	O
applied	O
to	O
all	O
variants	O
in	O
the	O
molecularly	O
undiagnosed	O
RP	B-DISEASE
cohort	O
of	O
100	O
patients	O
.	O

Portal	O
plasma	O
concentrations	O
of	O
neither	O
arginine	B-Chemical
vasopressin	I-Chemical
nor	O
oxytocin	B-Chemical
are	O
significantly	O
altered	O
in	O
this	O
paradigm	O
.	O

(	O
TIF	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

We	O
then	O
used	O
human	O
kidney	O
cell	O
line	O
HEK293	O
cells	O
to	O
examine	O
the	O
role	O
of	O
variant	O
MCM2	B-GENE
in	O
these	O
cells	O
.	O

These	O
results	O
were	O
confirmed	O
by	O
statistical	O
analysis	O
.	O

Sensory	O
epithelium	O
of	O
the	O
retina	O
was	O
dissected	O
from	O
adult	O
CD1	O
mice	O
,	O
stained	O
with	O
the	O
CIB2	B-GENE
antibody	O
,	O
and	O
imaged	O
using	O
the	O
LSM700	B-Chemical
system	O
.	O

Ethnically	O
,	O
the	O
patients	O
included	O
193	O
Han	O
(	O
82	O
.	O
1	O
%	O
)	O
,	O
13	O
Bai	O
(	O
5	O
.	O
5	O
%	O
)	O
,	O
5	O
Dai	O
(	O
2	O
.	O
1	O
%	O
)	O
,	O
7	O
Yi	O
(	O
3	O
.	O
0	O
%	O
)	O
,	O
2	O
Hani	O
(	O
0	O
.	O
9	O
%	O
)	O
,	O
3	O
Hui	O
(	O
1	O
.	O
3	O
%	O
)	O
,	O
1	O
Jingpo	O
(	O
0	O
.	O
4	O
%	O
)	O
,	O
2	O
Lahu	B-Chemical
(	O
0	O
.	O
9	O
%	O
)	O
,	O
2	O
Lisu	B-Chemical
(	O
0	O
.	O
9	O
%	O
)	O
,	O
5	O
Nazi	O
(	O
2	O
.	O
1	O
%	O
)	O
,	O
1	O
Wa	O
(	O
0	O
.	O
4	O
%	O
)	O
,	O
and	O
1	O
Yao	O
(	O
0	O
.	O
4	O
%	O
)	O
Chinese	O
.	O

The	O
contralateral	O
eyes	O
served	O
as	O
controls	O
.	O

Dimensions	O
of	O
the	O
bruising	O
on	O
the	O
heparin	B-Chemical
applied	O
areas	O
were	O
measured	O
using	O
transparent	O
millimetric	O
measuring	O
paper	O
.	O

The	O
first	O
set	O
of	O
analysis	O
was	O
the	O
five	O
-	O
generation	O
Chinese	O
hearing	B-DISEASE
loss	I-DISEASE
family	O
,	O
F013	O
,	O
a	O
total	O
of	O
22	O
subjects	O
of	O
which	O
were	O
included	O
in	O
the	O
linkage	O
study	O
(	O
II	O
:	O
2	O
,	O
III	O
:	O
1	O
-	O
5	O
,	O
III	O
:	O
7	O
,	O
III	O
:	O
9	O
-	O
11	O
,	O
IV	O
:	O
1	O
-	O
3	O
,	O
IV	O
:	O
5	O
,	O
IV	O
:	O
9	O
,	O
IV	O
:	O
11	O
,	O
IV	O
:	O
13	O
,	O
IV	O
:	O
17	O
,	O
IV	O
:	O
29	O
,	O
IV	O
:	O
31	O
-	O
32	O
,	O
V	O
:	O
1	O
)	O
and	O
four	O
individuals	O
(	O
IV	O
:	O
3	O
,	O
IV	O
:	O
5	O
,	O
IV	O
:	O
17	O
,	O
IV	O
:	O
31	O
)	O
were	O
included	O
in	O
exome	O
sequencing	O
study	O
(	O
Figure	O
1	O
)	O
.	O

An	O
in	O
vitro	O
splicing	O
assay	O
was	O
performed	O
to	O
test	O
for	O
a	O
splicing	O
alteration	O
.	O

Groups	O
ADR	B-Chemical
(	O
6	O
)	O
,	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
and	O
ADR	B-Chemical
(	O
12	O
)	O
,	O
and	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
received	O
ADR	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
i	O
.	O
v	O
.	O
)	O
twice	O
in	O
a	O
3	O
-	O
week	O
interval	O
.	O

To	O
discover	O
CNVs	O
from	O
the	O
exome	O
data	O
,	O
we	O
used	O
CoNVex	B-Chemical
(	O
ftp	O
:	O
/	O
/	O
ftp	O
.	O
sanger	O
.	O
ac	O
.	O
uk	O
/	O
pub	O
/	O
users	O
/	O
pv1	O
/	O
CoNVex	O
/	O
)	O
.	O

INTRODUCTION	O
:	O
The	O
ability	O
to	O
read	O
facial	O
expressions	O
is	O
essential	O
for	O
normal	O
human	O
social	O
interaction	O
.	O

All	O
the	O
other	O
42	O
coding	O
exons	O
were	O
also	O
sequenced	O
in	O
all	O
affected	O
members	O
,	O
but	O
no	O
other	O
mutations	O
were	O
found	O
.	O

Furthermore	O
,	O
p	B-VARIANT
.	I-VARIANT
Ala138Glu	I-VARIANT
has	O
a	O
milder	O
effect	O
than	O
p	B-VARIANT
.	I-VARIANT
Val199Met	I-VARIANT
(	O
family	O
C	O
versus	O
families	O
D	O
/	O
F	O
)	O
and	O
also	O
a	O
milder	O
effect	O
than	O
p	B-VARIANT
.	I-VARIANT
Thr70fs	I-VARIANT
(	O
family	O
B	O
versus	O
families	O
D	O
/	O
F	O
)	O
.	O

Pulmonary	B-DISEASE
hypertension	I-DISEASE
developed	O
after	O
administration	O
of	O
a	O
somatostatin	O
analogue	O
,	O
octreotide	B-Chemical
,	O
to	O
enhance	O
resolution	O
of	O
the	O
fistula	O
.	O

Auditory	O
behavioral	O
development	O
was	O
assessed	O
by	O
IT	O
-	O
MAIS	O
and	O
LittlEARS	B-Chemical
,	O
both	O
of	O
which	O
are	O
parent	O
questionnaires	O
regarding	O
a	O
young	O
infant	O
or	O
toddler	O
'	O
s	O
auditory	O
behavior	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
.	O

No	O
dimerization	O
was	O
detected	O
with	O
p	B-VARIANT
.	I-VARIANT
Asn381Ser	I-VARIANT
NARS2	B-GENE
construct	O
.	O

Of	O
the	O
1119	O
patients	O
presenting	O
for	O
testing	O
in	O
our	O
clinical	O
diagnostic	O
laboratory	O
,	O
we	O
were	O
able	O
to	O
diagnose	O
a	O
genetic	O
cause	O
of	O
deafness	B-DISEASE
in	O
440	O
persons	O
(	O
39	O
%	O
)	O
.	O

1	O
-	O
4	O
Auditory	B-DISEASE
neuropathy	I-DISEASE
is	O
a	O
distinct	O
form	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
where	O
the	O
outer	O
hair	O
cells	O
function	O
appropriately	O
but	O
sound	O
is	O
not	O
transmitted	O
properly	O
to	O
the	O
brain	O
.	O

An	O
interaction	O
between	O
FZP	B-Chemical
and	O
pentylenetetrazol	B-Chemical
(	O
PTZ	B-Chemical
)	O
was	O
shown	O
by	O
pretreating	O
mice	O
with	O
FZP	B-Chemical
before	O
PTZ	B-Chemical
challenge	O
.	O

The	O
difference	O
between	O
p	B-VARIANT
.	I-VARIANT
S647P	I-VARIANT
allele	O
frequencies	O
in	O
cases	O
and	O
controls	O
was	O
significant	O
at	O
P	O
<	O
10	O
-	O
23	O
.	O

The	O
mean	O
treatment	O
period	O
was	O
18	O
months	O
.	O

Shafique	O
S	I-Chemical
.	I-Chemical

USH2A	B-GENE
accounts	O
for	O
80	O
%	O
of	O
Usher	B-DISEASE
type	I-DISEASE
2	I-DISEASE
cases	O
(	O
Besnard	O
et	O
al	O
.	O

This	O
difference	O
seems	O
to	O
be	O
increased	O
using	O
the	O
open	O
source	O
BWA	O
mapping	O
results	O
while	O
platform	O
proprietary	O
mapping	O
software	O
show	O
a	O
lower	O
Off	O
-	O
Target	O
for	O
the	O
same	O
GS	O
-	O
FLX	O
data	O
(	O
95	O
%	O
On	O
-	O
Target	O
)	O
.	O

PCR	O
products	O
were	O
purified	O
by	O
exonuclease	O
1	O
and	O
shrimp	O
alkaline	O
phosphatase	O
reaction	O
.	O

Our	O
results	O
strongly	O
indicate	O
that	O
DFNB1	B-GENE
only	O
accounts	O
for	O
3	O
%	O
of	O
ARNSHL	B-DISEASE
in	O
the	O
Saudi	O
population	O
(	O
Table	O
1	O
)	O
.	O

For	O
the	O
families	O
that	O
could	O
not	O
be	O
excluded	O
on	O
the	O
basis	O
of	O
marker	O
discordance	O
among	O
affected	O
siblings	O
,	O
complete	O
TMPRSS3	B-GENE
(	O
13	O
exons	O
)	O
,	O
TMC1	B-GENE
(	O
24	O
exons	O
)	O
,	O
USH1C	B-GENE
(	O
28	O
exons	O
)	O
and	O
CDH23	B-GENE
(	O
70	O
exons	O
)	O
transcript	O
structures	O
,	O
comprising	O
exonic	O
and	O
flanking	O
intronic	O
regions	O
,	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
.	O

Sirolimus	B-Chemical
-	I-DISEASE
associated	O
proteinuria	B-DISEASE
and	O
renal	B-DISEASE
dysfunction	I-DISEASE
.	O

To	O
investigate	O
the	O
possible	O
effect	O
of	O
the	O
mutation	O
on	O
mRNA	O
splicing	O
,	O
we	O
performed	O
an	O
RT	O
-	O
PCR	O
analysis	O
of	O
total	O
lymphocyte	O
RNA	O
obtained	O
from	O
the	O
patient	O
.	O

Comparison	O
between	O
results	O
obtained	O
from	O
the	O
sample	O
included	O
in	O
the	O
present	O
report	O
with	O
the	O
global	O
results	O
for	O
our	O
total	O
series	O
.	O

This	O
case	O
report	O
highlights	O
the	O
fact	O
that	O
the	O
angiotensin	B-Chemical
II	I-Chemical
receptor	I-GENE
antagonist	O
losartan	B-Chemical
can	O
cause	O
serious	O
unexpected	O
complications	O
in	O
patients	O
with	O
renovascular	B-DISEASE
disease	I-DISEASE
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	O
in	O
this	O
setting	O
.	O

The	O
up	O
-	O
regulated	O
expression	O
of	O
TNC	B-GENE
gene	O
in	O
tissue	O
repair	O
and	O
neural	O
regeneration	O
was	O
seen	O
in	O
human	O
and	O
zebrafish	O
,	O
and	O
in	O
sensory	O
receptor	O
recovery	O
in	O
the	O
vestibular	O
organ	O
after	O
ototoxic	O
injury	O
in	O
birds	O
.	O

A	O
clinical	O
trial	O
of	O
hypothermia	O
in	O
patients	O
with	O
this	O
condition	O
is	O
warranted	O
.	O

The	O
large	O
-	O
scale	O
discovery	O
and	O
validation	O
studies	O
for	O
60	O
patients	O
reported	O
here	O
,	O
in	O
addition	O
to	O
the	O
previous	O
molecular	O
diagnosis	O
of	O
all	O
43	O
other	O
patients	O
with	O
definite	O
isolated	O
CI	B-DISEASE
deficiency	I-DISEASE
seen	O
at	O
our	O
diagnostic	O
laboratory	O
,	O
provide	O
the	O
largest	O
systematic	O
sequencing	O
study	O
of	O
CI	B-DISEASE
deficiency	I-DISEASE
to	O
date	O
.	O

Study	O
participants	O
gave	O
informed	O
consent	O
and	O
these	O
investigations	O
were	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
as	O
revised	O
in	O
2000	O
.	O

Gratitude	O
has	O
to	O
be	O
expressed	O
to	O
the	O
patients	O
for	O
participating	O
in	O
this	O
research	O
.	O

A	O
)	O
Relationship	O
between	O
the	O
minimum	O
depth	O
coverage	O
and	O
the	O
extent	O
of	O
basepairs	O
of	O
RefSeq	O
exons	O
sequenced	O
(	O
shown	O
in	O
percentage	O
)	O
.	O

In	O
contrast	O
,	O
the	O
radiographic	O
signs	O
of	O
MED	B-DISEASE
are	O
more	O
subtle	O
and	O
variable	O
,	O
and	O
while	O
the	O
ESDN	O
panel	O
was	O
relatively	O
successful	O
in	O
predicting	O
genotype	O
from	O
the	O
phenotype	O
,	O
MED	B-DISEASE
remains	O
more	O
difficult	O
to	O
diagnose	O
correctly	O
.	O

The	O
majority	O
of	O
these	O
aneurysms	O
were	O
smaller	O
than	O
those	O
of	O
the	O
control	O
group	O
(	O
8	O
+	O
/	O
-	O
6	O
.	O
08	O
mm	O
versus	O
11	O
+	O
/	O
-	O
5	O
.	O
4	O
mm	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Targeted	O
NGS	O
for	O
84	O
deafness	B-DISEASE
genes	O
resulted	O
in	O
identification	O
of	O
candidate	O
genes	O
in	O
7	O
of	O
15	O
families	O
and	O
revealed	O
the	O
diverse	O
spectrum	O
of	O
rare	O
deafness	B-DISEASE
genes	O
in	O
Japanese	O
subjects	O
with	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
for	O
the	O
first	O
time	O
.	O

We	O
conclude	O
that	O
these	O
three	O
CNGA1	B-GENE
variants	O
were	O
not	O
disease	O
causing	O
in	O
nature	O
,	O
at	O
least	O
from	O
the	O
phenotypic	O
observation	O
.	O

Her	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
confirmed	O
at	O
10	O
months	O
of	O
age	O
via	O
auditory	O
brainstem	O
evoked	O
response	O
testing	O
.	O

In	O
ten	O
of	O
the	O
11	O
families	O
,	O
the	O
original	O
clinical	O
diagnosis	O
/	O
description	O
was	O
clarified	O
after	O
WES	O
analysis	O
(	O
Table	O
1	O
)	O
.	O

Hereditary	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
HL	B-DISEASE
)	O
is	O
one	O
of	O
the	O
most	O
common	O
birth	O
defects	O
,	O
with	O
an	O
approximate	O
incidence	O
of	O
1	O
-	O
2	O
per	O
1	O
,	O
000	O
newborns	O
presenting	O
bilateral	B-DISEASE
sensorineural	I-DISEASE
HL	I-DISEASE
at	O
the	O
time	O
of	O
newborn	O
hearing	O
screening	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
PD	O
DH	O
.	O

The	O
purpose	O
of	O
our	O
study	O
is	O
to	O
explore	O
the	O
disease	O
-	O
related	O
gene	O
in	O
a	O
four	O
-	O
generation	O
Chinese	O
Han	O
pedigree	O
of	O
AS	B-DISEASE
.	O

Missense	O
germline	O
variants	O
were	O
filtered	O
using	O
the	O
same	O
methods	O
(	O
Supplementary	O
Figure	O
3	O
)	O
previously	O
described	O
for	O
germline	O
truncations	O
.	O

Usher	B-DISEASE
is	O
compatible	O
with	O
mutation	O
in	O
GPR98	B-GENE
(	O
affected	O
sibs	O
are	O
homozygous	O
for	O
a	O
GPR98	B-GENE
haplotype	O
)	O
;	O
USH2	B-GENE
A	I-GENE
is	O
excluded	O
by	O
haplotype	O
analysis	O
.	O

His	O
parents	O
,	O
who	O
were	O
verified	O
to	O
be	O
carriers	O
of	O
heterozygosis	O
,	O
had	O
no	O
cardiac	O
phenotype	O
.	O

The	O
percentage	O
of	O
sequences	O
on	O
target	O
for	O
all	O
samples	O
was	O
greater	O
than	O
70	O
%	O
,	O
and	O
the	O
average	O
coverage	O
of	O
the	O
samples	O
proved	O
to	O
be	O
satisfactory	O
at	O
131X	O
(	O
+	O
/	O
-	O
14	O
.	O
7	O
)	O
,	O
higher	O
than	O
the	O
expected	O
coverage	O
.	O

It	O
has	O
been	O
described	O
as	O
a	O
founder	O
mutation	O
restricted	O
to	O
the	O
Acadian	O
population	O
(	O
'	O
Acadian	O
allele	O
'	O
)	O
,	O
where	O
it	O
accounts	O
for	O
virtually	O
all	O
USH1	B-DISEASE
cases	O
[	O
5	O
,	O
8	O
,	O
17	O
]	O
and	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
the	O
9VNTR	O
(	O
t	O
,	O
t	O
)	O
allele	O
of	O
a	O
45	O
base	O
-	O
pair	O
(	O
bp	O
)	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
polymorphism	O
in	O
intron	O
5	O
of	O
the	O
USH1C	B-GENE
gene	O
[	O
17	O
]	O
.	O

Although	O
several	O
founder	O
mutations	O
underlying	O
different	O
USH	B-DISEASE
types	O
have	O
been	O
reported	O
in	O
the	O
Jewish	O
population	O
[	O
3	O
-	O
5	O
]	O
,	O
the	O
genetic	O
basis	O
for	O
USH	B-DISEASE
in	O
the	O
Arab	O
population	O
has	O
not	O
been	O
studied	O
.	O

Table	O
S4	O
.	O

The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	B-Chemical
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	B-Chemical
injection	O
.	O

Typically	O
,	O
the	O
first	O
symptom	O
of	O
the	O
disease	O
is	O
night	B-DISEASE
blindness	I-DISEASE
,	O
which	O
is	O
followed	O
by	O
a	O
loss	B-DISEASE
of	I-DISEASE
peripheral	I-DISEASE
vision	I-DISEASE
and	O
,	O
in	O
most	O
cases	O
,	O
cone	B-DISEASE
degeneration	I-DISEASE
in	O
the	O
late	O
stage	O
.	O

The	O
tectorial	O
membrane	O
of	O
the	O
inner	O
ear	O
is	O
a	O
ribbon	O
-	O
like	O
strip	O
of	O
extracellular	O
matrix	O
that	O
spirals	O
along	O
the	O
entire	O
length	O
of	O
the	O
cochlea	O
.	O

Whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
was	O
performed	O
in	O
the	O
index	O
case	O
from	O
each	O
family	O
and	O
co	O
-	O
segregation	O
of	O
candidate	O
pathogenic	O
mutations	O
was	O
tested	O
by	O
Sanger	O
sequencing	O
.	O

[	O
28	O
]	O
showed	O
that	O
the	O
(	O
c	B-VARIANT
.	I-VARIANT
5742	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
mutation	O
,	O
which	O
affects	O
splicing	O
of	O
the	O
MYO7A	B-GENE
transcript	O
and	O
truncates	O
the	O
myosin	B-GENE
VIIa	I-GENE
tail	O
domain	O
,	O
leads	O
to	O
tissue	O
-	O
specific	O
effects	O
on	O
protein	O
levels	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
I	I-DISEASE
(	O
USH1	B-DISEASE
)	O
is	O
characterized	O
by	O
severe	O
to	O
profound	O
congenital	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
prepubertal	O
onset	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
;	O
type	O
II	O
(	O
USH2	B-DISEASE
)	O
displays	O
moderate	O
to	O
severe	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
normal	O
vestibular	O
function	O
,	O
and	O
teenage	O
onset	O
of	O
RP	B-DISEASE
.	O

Vital	O
signs	O
were	O
:	O
blood	O
pressure	O
120	O
/	O
67	O
mm	O
Hg	O
,	O
heart	O
rate	O
127	O
/	O
min	O
,	O
respiratory	O
rate	O
28	O
/	O
min	O
,	O
and	O
temperature	O
97	O
F	O
.	O

D	O
-	O
1	O
agonist	O
SKF	B-Chemical
38393	I-Chemical
or	O
D	O
-	O
2	O
agonist	O
quinpirole	B-Chemical
decreased	O
the	O
catalepsy	O
induced	O
by	O
fluphenazine	B-Chemical
,	O
SCH	B-Chemical
23390	I-Chemical
or	O
sulpiride	B-Chemical
.	O

These	O
recent	O
findings	O
support	O
the	O
conclusion	O
that	O
there	O
is	O
no	O
simple	O
connection	O
between	O
the	O
gene	O
in	O
which	O
a	O
mutation	O
occurs	O
and	O
retinal	O
phenotype	O
of	O
a	O
patient	O
,	O
making	O
strict	O
categorization	O
of	O
genetic	O
disease	O
complicated	O
.	O

DESIGN	O
:	O
A	O
retrospective	O
,	O
multicenter	O
study	O
.	O

In	O
the	O
anemia	B-DISEASE
group	O
,	O
the	O
growth	O
delay	O
was	O
significantly	O
shorter	O
compared	O
with	O
nonanemic	O
controls	O
(	O
13	O
.	O
3	O
days	O
versus	O
8	O
.	O
6	O
days	O
)	O
.	O

These	O
families	O
have	O
2	O
to	O
6	O
affected	O
individuals	O
.	O

Flannick	O
for	O
assistance	O
with	O
pooled	O
sequence	O
analysis	O
,	O
I	O
.	O

In	O
mammalian	O
photoreceptors	O
,	O
the	O
usherin	B-Chemical
is	O
expressed	O
specifically	O
in	O
the	O
connecting	O
cilia	O
,	O
which	O
links	O
the	O
inner	O
and	O
outer	O
retinal	O
segments	O
;	O
this	O
would	O
appear	O
to	O
indicate	O
that	O
it	O
is	O
crucial	O
for	O
the	O
long	O
-	O
term	O
maintenance	O
of	O
photoreceptors	O
[	O
9	O
-	O
11	O
]	O
.	O

C	O
Electropherogram	O
of	O
a	O
heterozygous	O
carrier	O
of	O
the	O
OSBPL2	B-GENE
mutation	O
in	O
exon	O
3	O
(	O
deleted	O
nucleotides	O
are	O
boxed	O
)	O
.	O

In	O
a	O
patient	O
receiving	O
phenytoin	B-Chemical
who	O
presents	O
a	O
viral	O
-	O
like	O
illness	O
,	O
early	O
recognition	O
and	O
discontinuation	O
of	O
the	O
drug	O
are	O
mandatory	O
.	O

2001	O
;	O
Morton	O
and	O
Nance	O
2006	O
)	O
.	O

Hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
second	O
family	O
with	O
a	O
homozygous	O
p	B-VARIANT
.	I-VARIANT
Pro404Leu	I-VARIANT
mutation	O
was	O
reported	O
to	O
be	O
congenital	O
and	O
severe	O
to	O
profound	O
and	O
therefore	O
probably	O
prelingual	O
(	O
Masmoudi	O
et	O
al	O
.	O

Finally	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
like	O
the	O
mutation	O
positive	O
cases	O
,	O
the	O
majority	O
of	O
mutation	O
negative	O
patients	O
had	O
also	O
been	O
referred	O
by	O
geneticists	O
within	O
clinical	O
genetics	O
departments	O
including	O
six	O
from	O
members	O
of	O
the	O
ESDN	O
panel	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Glu1595Lys	I-VARIANT
mutation	O
may	O
disrupt	O
a	O
conserved	O
LDRE	B-Chemical
calcium	O
-	O
binding	O
motif	O
in	O
the	O
fifteenth	O
EC	O
domain	O
.	O

HOMER2	B-GENE
interacts	O
directly	O
with	O
CDC42	B-GENE
and	O
F	O
-	O
Actin	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutations	O
abolish	O
the	O
donor	O
and	O
acceptor	O
splice	O
sites	O
of	O
GJB2	B-GENE
intron	O
1	O
,	O
respectively	O
.	O

Based	O
on	O
this	O
methodology	O
,	O
a	O
multi	O
-	O
tiered	O
approach	O
has	O
been	O
devised	O
to	O
cost	O
-	O
effectively	O
diagnose	O
[	O
14	O
]	O
a	O
panel	O
of	O
36	O
Spanish	O
families	O
with	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
retinal	I-DISEASE
dystrophies	I-DISEASE
plus	O
5	O
patients	O
with	O
Usher	B-DISEASE
'	I-DISEASE
s	I-DISEASE
syndrome	I-DISEASE
.	O

This	O
approach	O
ensures	O
highly	O
specific	O
discrimination	O
without	O
allele	O
-	O
specific	O
hybridization	O
,	O
because	O
the	O
primer	O
to	O
be	O
extended	O
anneals	O
just	O
adjacent	O
to	O
the	O
DNA	O
base	O
that	O
needs	O
to	O
be	O
identified	O
.	O

4	O
.	O

RP11	O
families	O
often	O
display	O
incomplete	O
penetrance	O
,	O
and	O
dominant	O
inheritance	O
may	O
not	O
be	O
obvious	O
from	O
the	O
family	O
history	O
.	O

Audiometric	O
tests	O
of	O
the	O
proband	O
and	O
her	O
siblings	O
indicated	O
mild	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
and	O
normal	O
vestibular	O
function	O
while	O
patient	O
IV	O
:	O
1	O
was	O
normal	O
(	O
Figure	O
3	O
)	O
.	O

In	O
Danish	O
patients	O
this	O
procedure	O
can	O
be	O
expected	O
to	O
detect	O
causative	O
mutations	O
in	O
more	O
than	O
60	O
%	O
of	O
cases	O
.	O

Ischemic	B-DISEASE
colitis	I-DISEASE
and	O
sumatriptan	B-Chemical
use	O
.	O

Along	O
with	O
progression	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
began	O
to	O
involve	O
other	O
frequencies	O
.	O

Paclitaxel	B-Chemical
combined	O
with	O
carboplatin	B-Chemical
in	O
the	O
first	O
-	O
line	O
treatment	O
of	O
advanced	B-DISEASE
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

Therefore	O
,	O
the	O
most	O
common	O
USH1C	B-GENE
variant	O
is	O
USH1C_v2	O
(	O
also	O
known	O
as	O
variant	O
a	O
and	O
PDZ	O
-	O
73	O
;	O
see	O
Table	O
S7	O
for	O
more	O
information	O
)	O
.	O

List	O
of	O
the	O
mutations	O
excluded	O
by	O
Sanger	O
sequencing	O
in	O
ascertained	O
families	O
before	O
whole	O
exome	O
sequencing	O
.	O

Yao	O
et	O
al	O
.	O

4	O
B	O
)	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
Chinese	O
National	O
Nature	O
Science	O
Foundation	O
Research	O
Grant	O
30728030	O
,	O
30872862	O
,	O
and	O
Chinese	O
Capital	O
Medical	O
Development	O
Scientific	O
Funding	O
2005	O
-	O
1032	O
to	O
Dongyi	O
Han	O
.	O

Hypomania	B-DISEASE
-	I-DISEASE
like	I-DISEASE
syndrome	I-DISEASE
induced	O
by	O
olanzapine	B-Chemical
.	O

Three	O
out	O
of	O
four	O
previously	O
described	O
variants	O
were	O
not	O
included	O
in	O
the	O
microarray	O
analysis	O
at	O
the	O
time	O
of	O
the	O
study	O
:	O
p	B-VARIANT
.	I-VARIANT
Glu1330Stop	I-VARIANT
in	O
CRB1	B-GENE
[	O
13	O
]	O
,	O
p	B-VARIANT
.	I-VARIANT
Cys3358Tyr	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT

L	O
.	O
D	O
.	O
,	O
K	O
.	O
J	O
.	O
J	O
.	O
,	O
T	O
.	O
A	O
.	O
G	O
.	O
,	O
P	O
.	O
J	O
.	O
G	O
.	O
,	O
T	O
.	O
E	O
.	O
D	O
.	O
,	O
and	O
B	O
.	O
J	O
.	O
R	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

1d	O
)	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
456_459dupTTCC	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
795_800delCTGGTT	I-VARIANT
mutations	O
in	O
the	O
probands	O
from	O
families	O
B	O
and	O
C	O
were	O
not	O
detected	O
in	O
their	O
parents	O
,	O
suggesting	O
de	O
novo	O
mutations	O
.	O

The	O
findings	O
implicate	O
KCNQ1	B-GENE
as	O
a	O
possible	O
causal	O
gene	O
for	O
arrhythmogenic	B-DISEASE
cardiomyopathy	I-DISEASE
.	O

Kerns	O
and	O
H	O
.	O

He	O
had	O
proptosis	B-DISEASE
,	O
exophthalmos	B-DISEASE
,	O
maxillary	B-DISEASE
hypoplasia	I-DISEASE
,	O
high	B-DISEASE
arched	I-DISEASE
palate	I-DISEASE
,	O
broad	B-DISEASE
thumbs	I-DISEASE
and	O
great	B-DISEASE
toes	I-DISEASE
,	O
both	O
medially	O
deviated	O
.	O

To	O
validate	O
and	O
test	O
the	O
segregation	O
pattern	O
of	O
the	O
prioritized	O
variants	O
,	O
primers	O
were	O
designed	O
to	O
amplify	O
the	O
encompassing	O
genomic	O
region	O
.	O

Mutations	O
in	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
are	O
known	O
to	O
cause	O
Alport	B-DISEASE
syndrome	I-DISEASE
,	O
thin	B-DISEASE
basement	I-DISEASE
membrane	I-DISEASE
nephropathy	I-DISEASE
,	O
and	O
to	O
result	O
in	O
pathognomonic	O
glomerular	O
basement	O
membrane	O
findings	O
.	O

We	O
followed	O
210	O
cases	O
of	O
juvenile	B-DISEASE
rheumatoid	I-DISEASE
arthritis	I-DISEASE
closely	O
for	O
eleven	O
years	O
.	O

E	O
.	O

The	O
regression	O
coefficient	O
(	O
slope	O
)	O
was	O
called	O
annual	O
threshold	O
deterioration	O
(	O
ATD	O
)	O
,	O
expressed	O
in	O
decibels	O
per	O
year	O
.	O

As	O
a	O
scaffolding	O
protein	O
,	O
HOMER2	B-GENE
is	O
involved	O
in	O
intracellular	O
calcium	O
homeostasis	O
and	O
cytoskeletal	O
organization	O
.	O

Our	O
group	O
has	O
postulated	O
that	O
the	O
bilateral	O
nBCNC	B-DISEASE
may	O
have	O
a	O
genetic	O
etiology	O
while	O
the	O
unilateral	O
nBCNC	B-DISEASE
is	O
least	O
likely	O
to	O
have	O
a	O
genetic	O
contribution	O
[	O
12	O
]	O
.	O

Her	O
incontinence	O
resolved	O
with	O
the	O
change	O
of	O
medication	O
.	O

The	O
libraries	O
were	O
cleaned	O
and	O
size	O
-	O
selected	O
using	O
the	O
AMPure	O
DNA	O
Purification	O
kit	O
(	O
Beckman	O
Agencourt	O
,	O
Danvers	O
,	O
MA	O
)	O
.	O

Variants	O
c	B-VARIANT
.	I-VARIANT
881	I-VARIANT
-	I-VARIANT
882delAC	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
863	I-VARIANT
-	I-VARIANT
864insT	I-VARIANT
were	O
found	O
in	O
part	O
A	O
and	O
B	O
,	O
respectively	O
.	O

Several	O
routine	O
indicators	O
of	O
nephrotoxicity	B-DISEASE
,	O
the	O
enzymes	O
alkaline	O
phosphatase	O
and	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
glucosaminidase	O
,	O
and	O
the	O
molecular	O
weight	O
of	O
protein	O
excretion	O
were	O
determined	O
on	O
urine	O
samples	O
.	O

(	O
2008	O
)	O
[	O
26	O
]	O
,	O
as	O
one	O
of	O
the	O
most	O
USH2A	B-GENE
prevalent	O
mutations	O
in	O
non	O
-	O
Ashkenazi	O
Jews	O
.	O

Clinically	O
significant	O
anemia	B-DISEASE
(	O
hemoglobin	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5	O
.	O
4	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hepatitis	B-DISEASE
(	O
clinical	O
jaundice	O
with	O
alanine	B-Chemical
aminotransferase	O
>	O
5	O
times	O
upper	O
limits	O
of	O
normal	O
)	O
in	O
3	O
.	O
5	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
260	O
cells	O
/	O
microL	O
)	O
.	O

The	O
number	O
of	O
patients	O
with	O
suppression	O
of	O
HIV	O
p24	O
antigenemia	O
in	O
the	O
combination	O
and	O
zidovudine	B-Chemical
groups	O
was	O
six	O
(	O
40	O
%	O
)	O
and	O
two	O
(	O
11	O
%	O
)	O
at	O
week	O
4	O
(	O
p	O
=	O
0	O
.	O
10	O
)	O
and	O
five	O
(	O
45	O
%	O
)	O
and	O
two	O
(	O
14	O
%	O
)	O
at	O
week	O
24	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
,	O
respectively	O
.	O

The	O
patient	O
was	O
asymptomatic	O
and	O
the	O
aneurysm	B-DISEASE
was	O
detected	O
in	O
a	O
routine	O
control	O
.	O

Mechanistic	O
studies	O
in	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
systems	O
showed	O
that	O
the	O
Nrf2	B-GENE
-	O
mediated	O
protection	O
against	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
is	O
,	O
at	O
least	O
,	O
partially	O
through	O
inhibition	O
of	O
transforming	B-GENE
growth	I-GENE
factor	I-GENE
-	I-GENE
beta1	I-GENE
(	O
TGF	B-GENE
-	I-GENE
beta1	I-GENE
)	O
and	O
reduction	O
of	O
extracellular	O
matrix	O
production	O
.	O

(	O
3	O
)	O
A	O
paid	O
commercial	O
bioinformatic	O
analysis	O
platform	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
dnanexus	O
.	O
com	O
)	O
.	O

The	O
male	O
proband	O
(	O
III	O
-	O
2	O
in	O
Figure	O
1	O
C	O
)	O
,	O
born	O
after	O
an	O
uneventful	O
pregnancy	O
,	O
was	O
referred	O
for	O
craniofacial	O
assessment	O
at	O
the	O
age	O
of	O
three	O
months	O
.	O

Red	O
arrows	O
indicate	O
products	O
of	O
amplification	O
corresponding	O
to	O
deleted	O
mitochondrial	O
genomes	O
.	O

The	O
strength	O
of	O
this	O
study	O
lies	O
in	O
the	O
parallel	O
analysis	O
of	O
all	O
known	O
retinal	O
disease	O
genes	O
in	O
100	O
RP	B-DISEASE
patients	O
with	O
an	O
unknown	O
molecular	O
cause	O
of	O
disease	O
by	O
NGS	O
.	O

*	O
de	O
novo	O
-	O
mutation	O
;	O
#	O
Testicular	O
volume	O
less	O
than	O
4	O
mL	O
in	O
males	O
or	O
no	O
spontaneous	O
thelarche	O
in	O
females	O
;	O
SS	O
Testicular	O
volume	O
6	O
mL	O
at	O
the	O
age	O
of	O
33	O
;	O
$	O
?	O
A	O
brother	O
with	O
normosmic	O
HH	B-DISEASE
,	O
cleft	B-DISEASE
lip	I-DISEASE
and	I-DISEASE
palate	I-DISEASE
,	O
and	O
limb	B-DISEASE
anomalies	I-DISEASE
.	O

We	O
did	O
not	O
find	O
abnormalities	O
in	O
the	O
expression	O
and	O
distribution	O
of	O
an	O
mtDNA	O
-	O
encoded	O
subunit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	O
decrease	O
in	O
CCO	B-GENE
-	I-GENE
I	I-GENE
when	O
compared	O
with	O
nuclear	O
-	O
encoded	O
subunits	O
(	O
CCO	O
-	O
IV	O
and	O
SDH	O
-	I-GENE
fp	I-GENE
)	O
.	O

In	O
brief	O
,	O
1	O
mu	O
g	O
DNA	O
library	O
was	O
mixed	O
with	O
Buffer	O
BL	O
and	O
GenCap	B-Chemical
probe	O
(	O
MyGenostics	O
,	O
Beijing	O
)	O
,	O
heated	O
at	O
95	O
deg	O
C	O
for	O
7	O
min	O
and	O
65	O
deg	O
C	O
for	O
2	O
min	O
on	O
a	O
PCR	O
machine	O
;	O
23	O
mu	O
l	O
of	O
the	O
65	O
deg	O
C	O
prewarmed	O
Buffer	O
HY	O
(	O
MyGenostics	O
,	O
Beijing	O
)	O
was	O
then	O
added	O
to	O
the	O
mix	O
,	O
and	O
the	O
mixture	O
was	O
hold	O
at	O
65	O
deg	O
C	O
with	O
PCR	O
lid	O
heat	O
on	O
for	O
22	O
hours	O
for	O
hybridization	O
.	O

Here	O
we	O
present	O
a	O
case	O
of	O
withdrawal	O
-	O
emergent	O
RS	O
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	O
.	O

Little	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
ECE	B-GENE
-	I-GENE
1	I-GENE
mRNA	O
and	O
CNP	B-GENE
mRNA	O
.	O

Thus	O
,	O
we	O
could	O
not	O
confirm	O
its	O
pathogenicity	O
by	O
segregation	O
analysis	O
.	O

After	O
filtering	O
out	O
synonymous	O
changes	O
and	O
variants	O
found	O
in	O
<	O
85	O
%	O
of	O
reads	O
(	O
inconsistent	O
with	O
X	O
-	O
linked	O
inheritance	O
in	O
individual	O
III	O
:	O
12	O
,	O
an	O
affected	O
man	O
)	O
,	O
24	O
variants	O
remained	O
:	O
17	O
non	O
-	O
synonymous	O
variants	O
,	O
2	O
in	O
-	O
frame	O
indels	O
and	O
5	O
frameshift	O
indels	O
.	O

On	O
the	O
basis	O
of	O
their	O
clinical	O
history	O
and	O
ophthalmologic	O
,	O
audiological	O
,	O
neurophysiological	O
and	O
vestibular	O
tests	O
,	O
58	O
of	O
these	O
families	O
were	O
clinically	O
classified	O
as	O
USH2	B-DISEASE
while	O
11	O
displayed	O
atypical	B-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
.	O

Both	O
non	O
-	O
captured	O
and	O
captured	O
LM	O
-	O
PCR	O
products	O
were	O
subjected	O
to	O
quantitative	O
PCR	O
to	O
estimate	O
the	O
magnitude	O
of	O
enrichment	O
.	O

The	O
first	O
one	O
had	O
not	O
yet	O
been	O
described	O
.	O

Written	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
project	O
was	O
obtained	O
from	O
the	O
subjects	O
,	O
and	O
all	O
procedures	O
were	O
approved	O
by	O
the	O
Research	O
Ethics	O
Committee	O
of	O
the	O
National	O
Taiwan	O
University	O
Hospital	O
.	O

The	O
average	O
age	O
of	O
diagnosis	O
was	O
8	O
.	O
7	O
+	O
-	O
3	O
.	O
3	O
years	O
for	O
all	O
subjects	O
with	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
7	O
.	O
5	O
+	O
-	O
2	O
.	O
4	O
(	O
range	O
5	O
-	O
11	O
)	O
years	O
for	O
the	O
males	O
,	O
and	O
9	O
.	O
3	O
+	O
-	O
3	O
.	O
7	O
(	O
range	O
5	O
-	O
15	O
.	O
3	O
)	O
years	O
for	O
the	O
females	O
.	O

MYO7A	B-GENE
is	O
the	O
major	O
gene	O
responsible	O
for	O
USH1	B-DISEASE
and	O
mutations	O
in	O
MYO7A	B-GENE
alone	O
account	O
for	O
70	O
%	O
of	O
USH1	B-DISEASE
.	O

A	O
follow	O
-	O
up	O
analysis	O
was	O
performed	O
by	O
genotyping	O
26	O
available	O
family	O
members	O
with	O
seven	O
microsatellite	O
markers	O
(	O
D6S1595	O
,	O
D6S1644	O
,	O
D6S1613	O
,	O
D6S462	O
,	O
D6S416	O
,	O
D6S432	O
,	O
and	O
D6S433	O
)	O
positioned	O
within	O
and	O
just	O
outside	O
the	O
linked	O
region	O
from	O
the	O
SNP	O
analysis	O
(	O
S3	O
Table	O
)	O
.	O

The	O
nonsyndromic	B-DISEASE
autosomal	I-DISEASE
recessive	I-DISEASE
deafness	I-DISEASE
locus	O
DFNB49	B-GENE
was	O
initially	O
mapped	O
by	O
Ramzan	O
et	O
al	O
.	O

Of	O
the	O
59	O
cases	O
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fatal	O
outcome	O
,	O
compared	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non	O
-	O
warfarin	B-Chemical
patients	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
the	O
propranolol	B-Chemical
group	O
,	O
serum	O
potassium	B-Chemical
and	O
uric	B-Chemical
acid	I-Chemical
levels	O
rose	O
in	O
both	O
sexes	O
,	O
but	O
the	O
urea	B-Chemical
level	O
rose	O
significantly	O
in	O
women	O
only	O
.	O

GJB2	B-GENE
is	O
a	O
small	O
gene	O
but	O
harbors	O
many	O
mutations	O
.	O

We	O
identified	O
novel	O
compound	O
heterozygous	O
mutations	O
of	O
the	O
C10orf2	B-GENE
gene	O
as	O
the	O
cause	O
of	O
IOSCA	B-DISEASE
with	O
sensorimotor	B-DISEASE
polyneuropathy	I-DISEASE
and	O
myopathy	B-DISEASE
.	O

We	O
wish	O
to	O
thank	O
all	O
the	O
individuals	O
in	O
Family51	O
who	O
have	O
kindly	O
agreed	O
to	O
participate	O
in	O
this	O
study	O
.	O
Conflict	O
of	O
interest	O
statement	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
conflict	O
of	O
interest	O
exist	O
.	O

Patient	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
using	O
standard	O
techniques	O
.	O

Finally	O
,	O
the	O
DF56	O
patients	O
carried	O
a	O
c	B-VARIANT
.	I-VARIANT
2260	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
in	O
intron	O
23	O
of	O
TMC1	B-GENE
(	O
NM_138691	O
)	O
.	O

For	O
a	O
complete	O
list	O
of	O
syndromes	O
included	O
on	O
the	O
current	O
CGT	O
panel	O
see	O
Table	O
S8	O
.	O

The	O
hydrogen	O
bonds	O
around	O
E129	O
/	O
K129	B-Chemical
are	O
shown	O
as	O
dashed	O
lines	O
.	O

We	O
thank	O
all	O
members	O
of	O
the	O
Northwest	O
Genomics	O
Center	O
and	O
Genomic	O
Disorders	O
Group	O
Nijmegen	B-Chemical
,	O
as	O
well	O
as	O
personnel	O
from	O
the	O
Microarray	O
Facility	O
and	O
Sequencing	O
Facility	O
Nijmegen	O
for	O
excellent	O
technical	O
assistance	O
.	O

MD	O
participated	O
in	O
the	O
clinical	O
diagnosis	O
of	O
patients	O
.	O

Recurrent	O
dysosmia	B-DISEASE
induced	O
by	O
pyrazinamide	B-Chemical
.	O

Excluding	O
singleton	O
cases	O
and	O
subjects	O
younger	O
than	O
25	O
-	O
years	O
-	O
old	O
,	O
it	O
is	O
also	O
remarkable	O
that	O
in	O
about	O
a	O
third	O
of	O
all	O
pedigrees	O
(	O
11	O
/	O
32	O
,	O
34	O
.	O
4	O
%	O
)	O
,	O
family	O
members	O
were	O
found	O
to	O
manifest	O
both	O
pure	O
DOA	B-DISEASE
and	O
DOA	O
+	O
phenotypes	O
despite	O
carrying	O
the	O
same	O
OPA1	B-GENE
mutation	O
,	O
and	O
presumably	O
having	O
shared	O
common	O
environmental	O
influences	O
,	O
especially	O
in	O
the	O
first	O
two	O
decades	O
of	O
life	O
in	O
parent	O
-	O
offspring	O
cases	O
.	O

A	O
reversible	O
toxic	O
liver	O
damage	O
was	O
observed	O
in	O
a	O
non	O
-	O
alcoholic	O
woman	O
treated	O
with	O
disulfiram	B-Chemical
.	O

For	O
Alomone	B-Chemical
and	O
Santa	B-Chemical
Cruz	O
antibodies	O
,	O
immunizing	O
peptides	O
were	O
tested	O
for	O
their	O
ability	O
to	O
block	O
antibody	O
labeling	O
of	O
tissues	O
following	O
manufacturer	O
'	O
s	O
protocols	O
;	O
incubations	O
with	O
and	O
without	O
immunizing	O
peptides	O
were	O
processed	O
in	O
parallel	O
.	O

The	O
availability	O
of	O
molecular	O
diagnosis	O
is	O
increasing	O
the	O
number	O
of	O
USH3	B-DISEASE
cases	O
identified	O
.	O

None	O
of	O
these	O
five	O
biopsies	O
had	O
GBM	O
splitting	O
or	O
other	O
ultrastructural	O
findings	O
suggestive	O
of	O
classical	O
AS	B-DISEASE
.	O

In	O
all	O
patients	O
,	O
this	O
acute	O
disease	O
progression	O
was	O
partially	O
reversible	O
over	O
time	O
.	O

BACKGROUND	O
:	O
Doxorubicin	B-Chemical
induces	O
a	O
self	O
-	O
perpetuating	O
nephropathy	B-DISEASE
characterized	O
by	O
early	O
glomerular	O
and	O
late	O
-	O
onset	O
tubular	O
lesions	O
in	O
rats	O
.	O

Pulse	O
power	O
analysis	O
may	O
be	O
helpful	O
in	O
determining	O
the	O
etiology	O
of	O
and	O
treating	O
hypotension	B-DISEASE
during	O
cesarean	O
delivery	O
under	O
neuraxial	O
anesthesia	O
.	O

Three	O
patients	O
have	O
one	O
parent	O
with	O
similar	O
TCS	B-DISEASE
features	O
,	O
while	O
the	O
other	O
43	O
cases	O
haven	O
'	O
t	O
a	O
family	O
history	O
.	O

Total	O
peripheral	O
vascular	O
resistance	O
fell	O
from	O
15	O
.	O
1	O
to	O
12	O
.	O
2	O
mm	O
Hg	O
/	O
l	O
/	O
min	O
(	O
SED	O
+	O
/	O
-	O
1	O
.	O
03	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

This	O
patient	O
had	O
coccygeal	O
eversion	O
leading	O
to	O
a	O
tail	O
.	O

Infusion	O
regimens	O
were	O
designed	O
that	O
rapidly	O
achieved	O
and	O
maintained	O
target	O
-	O
free	O
concentrations	O
of	O
these	O
drugs	O
in	O
plasma	O
and	O
data	O
on	O
the	O
relationship	O
between	O
free	O
concentration	O
and	O
changes	O
in	O
MAPD	B-DISEASE
were	O
obtained	O
for	O
these	O
compounds	O
.	O

Mutations	O
in	O
this	O
gene	O
have	O
been	O
reported	O
to	O
cause	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1B	I-DISEASE
(	O
USH1B	B-GENE
)	O
and	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
(	O
DFNB2	B-DISEASE
,	O
DFNA11	B-DISEASE
)	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
,	O
[	O
26	O
]	O
.	O

Filtering	O
patient	O
data	O
against	O
normal	O
populations	O
and	O
inferring	O
identity	O
-	O
by	O
-	O
descent	O
(	O
IBD	O
)	O
in	O
family	O
studies	O
can	O
enrich	O
candidate	O
genes	O
[	O
4	O
,	O
6	O
]	O
.	O

This	O
enrichment	O
is	O
only	O
partially	O
explained	O
by	O
mutations	O
found	O
in	O
known	O
disease	O
-	O
causing	O
genes	O
.	O

No	O
patient	O
was	O
disabled	O
and	O
no	O
lymphoproliferative	B-DISEASE
disorder	I-DISEASE
was	O
observed	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

and	O
M	O
.	O
S	O
.	O
v	O
.	O
d	O
.	O
K	O
.	O

The	O
multivariate	O
analysis	O
showed	O
that	O
severe	O
MR	B-DISEASE
,	O
MP	O
(	O
EF	O
<	O
45	O
%	O
)	O
and	O
high	O
doses	O
of	O
MZ	B-Chemical
(	O
>	O
5mg	O
)	O
were	O
associated	O
with	O
events	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Each	O
LQTS	B-DISEASE
family	O
has	O
to	O
be	O
carefully	O
examined	O
as	O
there	O
is	O
a	O
risk	O
of	O
compound	O
heterozygosity	O
or	O
digenic	O
inheritance	O
.	O

We	O
present	O
a	O
molecular	O
model	O
of	O
the	O
motor	O
head	O
domain	O
of	O
the	O
human	O
myosin	B-GENE
VIIA	I-GENE
protein	O
.	O

The	O
remaining	O
11	O
reported	O
CLRN1	B-GENE
mutations	O
occur	O
in	O
single	O
,	O
often	O
consanguineous	O
families	O
,	O
and	O
are	O
not	O
known	O
to	O
be	O
widely	O
distributed	O
.	O

For	O
WHISP	O
controls	O
a	O
total	O
of	O
10	O
,	O
443	O
truncation	O
and	O
30	O
,	O
335	O
missense	O
variants	O
(	O
in	O
expressed	O
genes	O
)	O
remained	O
.	O

This	O
insertion	O
is	O
produced	O
near	O
the	O
end	O
of	O
exon	O
11	O
.	O

All	O
enriched	O
libraries	O
were	O
sequenced	O
on	O
the	O
Illumina	O
HiSeq	O
2000	O
(	O
Illumina	O
,	O
Inc	O
.	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
using	O
100bp	O
paired	O
-	O
end	O
reads	O
.	O

Each	O
validated	O
variant	O
was	O
tested	O
for	O
complete	O
co	O
-	O
segregation	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
proband	O
'	O
s	O
family	O
,	O
and	O
this	O
assessment	O
included	O
an	O
additional	O
28	O
affected	O
individuals	O
and	O
13	O
unaffected	O
family	O
members	O
.	O

2E	O
,	O
2G	O
)	O
were	O
used	O
as	O
positive	O
controls	O
for	O
labeling	O
sensory	O
hair	O
cells	O
and	O
spiral	O
ganglion	O
,	O
respectively	O
[	O
26	O
,	O
27	O
]	O
.	O

Run	O
statistics	O
and	O
target	O
coverage	O
of	O
NGS	O
in	O
each	O
individual	O
After	O
heterozygous	O
variations	O
were	O
sorted	O
according	O
to	O
the	O
inheritance	O
patterns	O
of	O
each	O
family	O
,	O
quality	O
control	O
filtering	O
was	O
performed	O
based	O
on	O
the	O
PHRED	O
score	O
(	O
>	O
20	O
)	O
and	O
variant	O
allele	O
frequency	O
(	O
higher	O
than	O
20	O
%	O
)	O
.	O

Rats	O
were	O
given	O
a	O
single	O
dose	O
of	O
adriamycin	B-Chemical
and	O
one	O
month	O
later	O
divided	O
into	O
four	O
groups	O
matched	O
for	O
albuminuria	O
,	O
blood	O
pressure	I-DISEASE
,	O
and	O
plasma	O
albumin	O
concentration	O
.	O

Our	O
data	O
demonstrate	O
the	O
advantage	O
of	O
WES	O
over	O
traditional	O
approaches	O
for	O
DNA	O
diagnosis	O
of	O
genetically	O
heterogeneous	O
disorders	O
caused	O
by	O
mutations	O
in	O
large	O
genes	O
.	O

Variants	O
in	O
WFS1	B-GENE
identified	O
in	O
individuals	O
with	O
WS	B-DISEASE
,	O
MODY	B-DISEASE
,	O
or	O
SNHI	B-DISEASE
.	O

This	O
data	O
confirmed	O
the	O
result	O
of	O
cDNA	O
analysis	O
.	O

M	O
.	O
S	O
.	O

Although	O
the	O
majority	O
of	O
cases	O
with	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
are	O
caused	O
by	O
nuclear	O
gene	O
defects	O
,	O
it	O
has	O
become	O
clear	O
that	O
mutations	O
in	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
can	O
also	O
cause	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
28	O
,	O
29	O
]	O
.	O

This	O
is	O
based	O
on	O
the	O
anatomic	O
relationship	O
of	O
the	O
retinal	O
images	O
and	O
the	O
visual	O
field	O
.	O

Performed	O
the	O
experiments	O
:	O
SK	O
LZ	O
.	O

Intronic	O
,	O
isocoding	O
,	O
and	O
missense	O
changes	O
were	O
also	O
analyzed	O
using	O
the	O
programs	O
NNSPLICE	O
(	O
Berkeley	O
Drosophila	O
Genome	O
Project	O
[	O
BDGP	O
]	O
University	O
of	O
California	O
Berkeley	O
;	O
Berkeley	O
,	O
CA	O
)	O
and	O
Splice	O
View	O
(	O
Institute	O
of	O
Biomedical	O
Technologies	O
,	O
Milano	O
,	O
Italy	O
)	O
to	O
predict	O
if	O
those	O
changes	O
could	O
be	O
affecting	O
,	O
creating	O
,	O
or	O
eliminating	O
donor	O
/	O
acceptor	O
splice	O
sites	O
.	O

Defects	O
in	O
the	O
DFNB31	B-DISEASE
gene	O
,	O
a	O
PDZ	O
(	O
post	O
-	O
synaptic	O
density	O
,	O
disc	O
-	O
large	O
,	O
Zo	B-Chemical
-	O
1	O
protein	O
domains	O
)	O
domain	O
-	O
containing	O
scaffold	O
protein	O
,	O
are	O
responsible	O
for	O
USH2D	B-GENE
and	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
DFNB31	B-DISEASE
)	O
[	O
25	O
]	O
,	O
[	O
26	O
]	O
.	O

One	O
Italian	O
Perrault	B-DISEASE
syndrome	I-DISEASE
family	O
,	O
with	O
two	O
affected	O
(	O
one	O
male	O
,	O
II1	O
;	O
and	O
one	O
female	O
,	O
II3	O
)	O
and	O
two	O
healthy	O
siblings	O
,	O
was	O
recruited	O
.	O

Thirty	O
-	O
two	O
male	O
patients	O
,	O
previously	O
diagnosed	O
with	O
KS	B-DISEASE
or	O
normosmic	B-DISEASE
HH	I-DISEASE
,	O
who	O
participated	O
in	O
the	O
current	O
study	O
,	O
were	O
enrolled	O
from	O
the	O
5	O
different	O
university	O
hospitals	O
in	O
Finland	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
activity	O
of	O
complex	O
II	O
,	O
which	O
does	O
not	O
have	O
mtDNA	O
encoded	O
subunits	O
.	O

All	O
genes	O
listed	O
in	O
this	O
publication	O
were	O
included	O
on	O
the	O
panel	O
.	O

A	O
two	O
tailed	O
Student	O
'	O
s	O
t	O
-	O
test	O
assuming	O
unequal	O
variances	O
was	O
used	O
to	O
determine	O
whether	O
there	O
existed	O
a	O
significant	O
difference	O
.	O

General	O
physical	O
examinations	O
were	O
conducted	O
with	O
particular	O
emphasis	O
on	O
examination	O
of	O
the	O
ears	O
,	O
intellectual	O
ability	O
,	O
syndromic	O
features	O
of	O
congenital	B-DISEASE
deafness	I-DISEASE
(	O
such	O
as	O
the	O
presence	O
of	O
white	O
hair	O
at	O
the	O
forehead	O
,	O
hyperpigmentation	B-DISEASE
,	O
heterochromia	B-DISEASE
iridis	I-DISEASE
,	O
dystopia	B-DISEASE
canthorum	I-DISEASE
,	O
and	O
broadening	O
of	O
the	O
nasal	O
root	O
)	O
.	O

Three	O
cases	O
of	O
EEG	O
changes	O
induced	O
by	O
single	O
exposure	O
to	O
enflurane	B-Chemical
anesthesia	O
are	O
reported	O
.	O

performed	O
the	O
experiments	O
,	O
collected	O
and	O
analysed	O
the	O
data	O
and	O
wrote	O
the	O
first	O
draft	O
of	O
the	O
manuscript	O
.	O

Patients	O
from	O
the	O
whole	O
-	O
exome	O
sequencing	O
trios	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
risk	O
of	O
cardiac	B-DISEASE
events	O
between	O
VNR	B-Chemical
and	O
other	O
drugs	O
[	O
odds	O
ratio	O
:	O
0	O
.	O
92	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
54	O
;	O
1	O
.	O
55	O
)	O
]	O
.	O

Blockade	O
of	O
endothelial	O
-	O
mesenchymal	O
transition	O
by	O
a	O
Smad3	B-GENE
inhibitor	O
delays	O
the	O
early	O
development	O
of	O
streptozotocin	B-Chemical
-	I-DISEASE
induced	I-DISEASE
diabetic	I-DISEASE
nephropathy	I-DISEASE
.	O

Despite	O
these	O
medical	O
problems	O
,	O
she	O
was	O
healthy	O
and	O
she	O
had	O
an	O
active	O
life	O
.	O

S1	O
)	O
.	O

We	O
chose	O
these	O
patients	O
because	O
1	O
)	O
they	O
were	O
"	O
randomly	O
"	O
selected	O
,	O
and	O
2	O
)	O
they	O
had	O
already	O
been	O
screened	O
by	O
Invader	O
assay	O
and	O
further	O
fully	O
sequenced	O
by	O
Sanger	O
sequencing	O
for	O
the	O
previously	O
found	O
common	O
and	O
frequent	O
deafness	B-DISEASE
causing	O
genes	O
i	O
.	O
e	O
.	O
,	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
,	O
KCNQ4	B-GENE
,	O
and	O
CDH23	B-GENE
.	O

De	O
novo	O
dominant	O
mutations	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
patients	O
with	O
isolated	O
RP	B-DISEASE
,	O
having	O
major	O
implications	O
for	O
genetic	O
counselling	O
.	O

Such	O
disparity	O
suggests	O
an	O
inhibition	O
of	O
creatine	B-Chemical
phosphokinase	O
.	O

Family	O
pedigrees	O
in	O
which	O
the	O
co	O
-	O
segregation	O
of	O
the	O
detected	O
mutations	O
was	O
performed	O
.	O

Rather	O
,	O
we	O
found	O
a	O
potentially	O
pathogenic	O
variant	O
(	O
c	B-VARIANT
.	I-VARIANT
G5054A	I-VARIANT
:	O
p	B-VARIANT
.	I-VARIANT
R1685Q	I-VARIANT
)	O
in	O
the	O
MYH14	B-GENE
gene	O
,	O
a	O
known	O
deafness	B-DISEASE
gene	O
in	O
DFNA4	B-GENE
locus	O
from	O
this	O
proband	O
.	O

No	O
mitochondrial	O
DNA	O
mutations	O
were	O
found	O
in	O
those	O
tested	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
we	O
screened	O
13	O
unrelated	O
subjects	O
from	O
our	O
laboratory	O
collection	O
who	O
had	O
late	O
-	O
onset	O
HI	B-DISEASE
(	O
presbycusis	O
)	O
.	O

Recombination	O
events	O
are	O
indicated	O
by	O
grey	O
background	O
.	O

The	O
diagnosis	O
of	O
metronidazole	B-Chemical
toxicity	I-DISEASE
was	O
made	O
by	O
the	O
MRI	O
findings	O
and	O
supported	O
clinically	O
.	O

7	O
,	O
8	O
Recently	O
,	O
the	O
application	O
of	O
next	O
-	O
generation	O
sequencing	O
of	O
targeted	O
regions	O
has	O
been	O
developing	O
dramatically	O
and	O
especially	O
exome	O
sequencing	O
technology	O
has	O
already	O
provided	O
an	O
new	O
powerful	O
tool	O
to	O
identify	O
causative	O
genes	O
.	O

Toxicity	O
included	O
embryolethality	B-DISEASE
,	O
teratogenicity	B-DISEASE
,	O
and	O
growth	B-DISEASE
retardation	I-DISEASE
.	O

On	O
average	O
,	O
70	O
%	O
of	O
each	O
genome	O
and	O
80	O
%	O
of	O
each	O
exome	O
had	O
>	O
40x	O
coverage	O
.	O

BACKGROUND	O
:	O
Although	O
an	O
indicator	O
of	O
renal	B-DISEASE
tubular	I-DISEASE
dysfunction	I-DISEASE
,	O
an	O
increased	O
urinary	O
N	O
-	O
acetyl	I-GENE
-	I-GENE
beta	I-GENE
-	I-GENE
D	I-GENE
-	I-GENE
glucosaminidase	I-GENE
(	O
NAG	O
)	O
activity	O
might	O
reflect	O
increased	O
lysosomal	O
activity	O
in	O
renal	O
tubular	O
cells	O
.	O

Input	O
DNA	O
signal	O
was	O
subtracted	O
from	O
ChIP	O
signal	O
.	O

Anti	O
-	O
carcinogenic	O
action	O
of	O
phenobarbital	B-Chemical
given	O
simultaneously	O
with	O
diethylnitrosamine	B-Chemical
in	O
the	O
rat	O
.	O

The	O
band	O
B	O
is	O
the	O
exon	O
skipping	O
.	O

We	O
found	O
frequent	O
arRP	B-DISEASE
-	O
causing	O
mutations	O
in	O
the	O
cyclic	B-GENE
nucleotide	I-GENE
gated	I-GENE
channel	I-GENE
alpha	I-GENE
1	I-GENE
(	O
CNGA1	B-GENE
)	O
gene	O
.	O

Such	O
treatment	O
did	O
not	O
diminish	O
the	O
ADR	B-Chemical
antitumor	O
activity	O
in	O
L1210	O
leukemia	O
and	O
in	O
Ehrlich	O
ascites	O
tumor	O
.	O

Among	O
the	O
21	O
patients	O
with	O
defective	O
kidney	O
function	O
,	O
six	O
had	O
proteinuria	B-DISEASE
,	O
nine	O
had	O
CRF	B-DISEASE
,	O
and	O
six	O
developed	O
ESRF	B-DISEASE
leading	O
to	O
kidney	O
transplantation	O
in	O
the	O
six	O
cases	O
.	O

World	O
Health	O
Organization	O
Grade	O
3	O
-	O
4	O
neutropenia	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
occurred	O
in	O
39	O
.	O
9	O
%	O
and	O
11	O
.	O
4	O
%	O
of	O
patients	O
,	O
respectively	O
.	O

Thus	O
,	O
in	O
order	O
to	O
link	O
with	O
certainty	O
the	O
Y669H	B-VARIANT
mutation	O
in	O
WFS1	B-GENE
with	O
symptoms	O
of	O
LFSNHL	B-DISEASE
,	O
future	O
research	O
will	O
involve	O
the	O
construction	O
of	O
a	O
transgenic	O
mouse	O
model	O
carrying	O
this	O
mutation	O
and	O
the	O
analysis	O
of	O
its	O
phenotypic	O
behavior	O
,	O
particularly	O
in	O
respect	O
to	O
symptoms	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

FLAG	O
-	O
CD164	B-GENE
-	O
WT	O
(	O
A	O
,	O
D	O
,	O
G	O
)	O
and	O
HA	O
-	O
CD164	B-GENE
-	O
R192	B-VARIANT
*	I-VARIANT
(	O
B	O
,	O
E	O
,	O
H	O
)	O
was	O
visualized	O
using	O
Alexa	B-Chemical
Fluor	I-Chemical
488	I-Chemical
-	O
labeled	O
secondary	O
antibody	O
(	O
green	O
)	O
and	O
Alexa	B-Chemical
Fluor	I-Chemical
568	I-Chemical
-	O
labeled	O
secondary	O
antibody	O
(	O
red	O
)	O
,	O
respectively	O
.	O

The	O
analysed	O
carbachol	B-Chemical
concentration	O
exceeded	O
the	O
supposed	O
serum	O
level	O
resulting	O
from	O
a	O
therapeutic	O
dose	O
by	O
a	O
factor	O
of	O
130	O
to	O
260	O
.	O

As	O
far	O
as	O
familial	O
PEO	B-DISEASE
is	O
concerned	O
,	O
the	O
involvement	O
of	O
PEO1	B-GENE
is	O
even	O
more	O
significant	O
:	O
the	O
occurrence	O
of	O
mutations	O
increases	O
to	O
26	O
.	O
8	O
%	O
of	O
adPEO	B-DISEASE
patients	O
in	O
our	O
cohort	O
.	O

These	O
results	O
emphasize	O
that	O
integration	O
of	O
both	O
somatic	O
and	O
protein	O
domain	O
information	O
can	O
facilitate	O
identification	O
of	O
a	O
set	O
of	O
known	O
and	O
potentially	O
pathogenic	O
missense	O
variants	O
among	O
thousands	O
of	O
rare	O
missense	O
variants	O
that	O
informs	O
functional	O
assessment	O
of	O
variants	O
of	O
unknown	O
significance	O
.	O

Segregation	O
of	O
the	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
(	O
A	O
)	O
,	O
c	B-VARIANT
.	I-VARIANT
541G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
A181	I-VARIANT
T	I-VARIANT
in	O
MYH14	B-GENE
(	O
B	O
)	O
and	O
c	B-VARIANT
.	I-VARIANT
449C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
A150	I-VARIANT
V	I-VARIANT
in	O
WSF1	B-GENE
(	O
C	O
)	O
.	O

RESULTS	O
:	O
After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
mean	O
(	O
sd	O
)	O
scores	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	O
lower	O
,	O
i	O
.	O
e	O
.	O
better	O
,	O
in	O
patients	O
on	O
bupropion	B-Chemical
SR	O
,	O
at	O
2	O
.	O
4	O
(	O
1	O
.	O
2	O
)	O
,	O
than	O
in	O
the	O
placebo	O
group	O
,	O
at	O
3	O
.	O
9	O
(	O
1	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
pathogenicity	O
of	O
p	B-VARIANT
.	I-VARIANT
V37I	I-VARIANT
is	O
controversial	O
.	O

Cardiotoxicity	B-DISEASE
is	O
not	O
an	O
uncommon	O
adverse	O
effect	O
of	O
chemotherapeutic	O
agents	O
.	O

We	O
screened	O
the	O
whole	O
exon19	O
,	O
where	O
the	O
variant	O
located	O
in	O
TNC	B-GENE
,	O
in	O
all	O
53	O
members	O
of	O
F013	O
using	O
Sanger	O
sequencing	O
.	O

(	O
DOCX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
This	O
is	O
an	O
open	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Attribution	O
License	O
(	O
)	O
,	O
which	O
permits	O
unrestricted	O
use	O
,	O
distribution	O
,	O
and	O
reproduction	O
in	O
any	O
medium	O
,	O
provided	O
the	O
original	O
work	O
is	O
properly	O
cited	O
.	O

It	O
seems	O
likely	O
that	O
there	O
are	O
additional	O
ARNSHL	B-DISEASE
-	O
causing	O
MYO15A	B-GENE
mutations	O
,	O
as	O
the	O
gene	O
is	O
large	O
and	O
mutation	O
analysis	O
is	O
rare	O
,	O
since	O
complementary	O
linkage	O
analysis	O
has	O
not	O
been	O
performed	O
in	O
East	O
Asian	O
populations	O
.	O

In	O
our	O
experience	O
and	O
according	O
to	O
the	O
literature	O
,	O
FK506	B-Chemical
does	O
not	O
seem	O
to	O
cross	O
-	O
react	O
with	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CyA	B-Chemical
)	O
,	O
an	O
immuno	O
-	O
suppressive	O
drug	O
already	O
known	O
to	O
induce	O
MAHA	B-DISEASE
.	O

In	O
those	O
individuals	O
who	O
received	O
a	O
kidney	O
transplant	O
there	O
was	O
no	O
recurrence	O
of	O
disease	O
.	O

However	O
,	O
the	O
secreted	O
(	O
Medium	O
)	O
amount	O
of	O
mutant	O
CEACAM16	B-GENE
is	O
much	O
lower	O
than	O
the	O
WT	O
CEACAM16	B-GENE
.	O

Immittance	O
testing	O
was	O
applied	O
to	O
evaluate	O
middle	O
ear	O
pressures	O
,	O
ear	O
canal	O
volumes	O
,	O
and	O
tympanic	O
membrane	O
mobility	O
.	O

The	O
immunoreactive	O
proteins	O
were	O
visualized	O
with	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
Plus	O
Western	O
Blotting	O
Detection	O
Reagents	O
;	O
Amersham	O
Biosciences	O
)	O
.	O

Here	O
,	O
the	O
authors	O
identify	O
mutations	O
in	O
GIPC3	B-GENE
in	O
mice	O
and	O
two	O
consanguineous	O
families	O
that	O
lead	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
in	O
mice	O
cause	O
defects	O
in	O
the	O
structure	O
of	O
stereocilia	O
bundles	O
and	O
audiogenic	B-DISEASE
seizures	I-DISEASE
.	O

Targeted	O
DNA	O
fragments	O
were	O
captured	O
by	O
hybridization	O
to	O
the	O
capture	O
array	O
and	O
sequenced	O
on	O
Illumina	O
HiSeq2000	O
Analyzers	O
for	O
90	O
cycles	O
per	O
read	O
.	O

Early	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
is	O
seen	O
in	O
most	O
patients	O
with	O
HDR	B-DISEASE
syndrome	I-DISEASE
,	O
and	O
these	O
patients	O
may	O
be	O
diagnosed	O
with	O
HDR	B-DISEASE
syndrome	I-DISEASE
after	O
initially	O
being	O
identified	O
with	O
hearing	B-DISEASE
problems	I-DISEASE
13	O
)	O
.	O

Finally	O
,	O
three	O
mutations	O
were	O
found	O
in	O
rarely	O
affected	O
sequences	O
.	O

As	O
result	O
,	O
12	O
novel	O
and	O
3	O
already	O
reported	O
mutations	O
were	O
characterised	O
together	O
with	O
7	O
novel	O
and	O
13	O
known	O
polymorphisms	O
.	O

These	O
results	O
indicate	O
that	O
the	O
two	O
compound	O
heterozygous	O
mutations	O
are	O
likely	O
pathogenic	O
and	O
are	O
the	O
cause	O
of	O
USH1	B-DISEASE
in	O
this	O
family	O
.	O

Sequence	O
analysis	O
demonstrated	O
that	O
the	O
c	B-VARIANT
.	I-VARIANT
5945C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
substitution	O
faithfully	O
co	O
-	O
segregated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
family	O
and	O
that	O
it	O
was	O
absent	O
in	O
200	O
unrelated	O
control	O
chromosomes	O
of	O
Chinese	O
background	O
,	O
supporting	O
the	O
hypothesis	O
that	O
it	O
represents	O
a	O
causative	O
mutation	O
,	O
not	O
a	O
rare	O
polymorphism	O
.	O

C	O
.	O

Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	O
of	O
the	O
treatments	O
on	O
renal	O
functional	O
aspects	O
in	O
models	O
of	O
chronic	O
renal	I-DISEASE
failure	I-DISEASE
,	O
and	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
mutation	O
is	O
most	O
prevalent	O
in	O
Europe	O
and	O
the	O
United	O
States	O
,	O
compared	O
with	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
in	O
East	O
Asian	O
populations	O
and	O
c	B-VARIANT
.	I-VARIANT
167delT	I-VARIANT
in	O
Jewish	O
populations	O
[	O
16	O
]	O
.	O

Neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
and	O
methylphenidate	B-Chemical
.	O

DESIGN	O
:	O
The	O
Expanded	O
Clinical	O
Evaluation	O
of	O
Lovastatin	B-Chemical
(	O
EXCEL	O
)	O
Study	O
,	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
diet	O
-	O
and	O
placebo	O
-	O
controlled	O
trial	O
,	O
in	O
which	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
lovastatin	B-Chemical
at	O
doses	O
of	O
20	O
or	O
40	O
mg	O
once	O
daily	O
,	O
or	O
20	O
or	O
40	O
mg	O
twice	O
daily	O
for	O
48	O
weeks	O
.	O

The	O
normal	O
mouse	O
cochlea	O
consist	O
of	O
1	O
.	O
75	O
turns	O
;	O
however	O
,	O
approximately	O
25	O
%	O
of	O
Brn4	O
null	O
mice	O
have	O
less	O
than	O
1	O
.	O
5	O
turns	O
,	O
indicating	O
a	O
role	O
for	O
Brn4	O
in	O
epithelial	O
-	O
mesenchymal	O
interactions	O
during	O
ear	O
development	O
[	O
49	O
]	O
.	O

After	O
fluoxetine	B-Chemical
treatment	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
improvement	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
apomorphine	B-Chemical
-	O
induced	O
dyskinesias	B-DISEASE
without	O
modification	O
of	O
parkinsonian	B-DISEASE
motor	I-DISEASE
disability	I-DISEASE
.	O

Nonsteroidal	B-DISEASE
anti	I-DISEASE
-	I-DISEASE
inflammatory	I-DISEASE
drug	I-DISEASE
-	I-DISEASE
induced	I-DISEASE
cystitis	I-DISEASE
is	O
a	O
poorly	O
recognized	O
and	O
under	O
-	O
reported	O
condition	O
.	O

The	O
patient	O
history	O
was	O
taken	O
and	O
ophthalmic	O
examinations	O
were	O
performed	O
.	O

The	O
second	O
pattern	O
is	O
stable	O
expression	O
in	O
tip	O
links	O
at	O
the	O
top	O
of	O
stereocilia	O
from	O
the	O
developmental	O
stage	O
onwards	O
until	O
ear	O
maturation	O
.	O

METHODS	O
:	O
The	O
cardiovascular	O
responses	O
to	O
standing	O
and	O
head	O
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	O
in	O
PD	B-DISEASE
patients	O
receiving	O
selegiline	B-Chemical
and	O
as	O
the	O
drug	O
was	O
withdrawn	O
.	O

2013	O
)	O
.	O

PATIENTS	O
:	O
Seventy	O
men	O
,	O
aged	O
50	O
-	O
80	O
years	O
,	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-DISEASE
cancer	I-DISEASE
.	O

Compared	O
with	O
subjects	O
with	O
cochlear	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
the	O
ECochG	O
responses	O
from	O
OPA1	B-GENE
-	O
M	O
patients	O
showed	O
similar	O
summating	O
potential	O
peak	O
latencies	O
but	O
significantly	O
larger	O
summating	O
potential	O
amplitudes	O
.	O

BACKGROUND	O
:	O
Spinal	O
anaesthesia	O
is	O
widely	O
employed	O
in	O
clinical	O
practice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
post	B-DISEASE
-	I-DISEASE
spinal	I-DISEASE
block	I-DISEASE
hypotension	I-DISEASE
.	O

Nephrotoxicity	B-DISEASE
occurred	O
in	O
a	O
similar	O
proportion	O
in	O
patients	O
treated	O
with	O
netilmicin	B-Chemical
and	O
tobramycin	B-Chemical
(	O
17	O
%	O
vs	O
11	O
%	O
)	O
.	O

Together	O
,	O
the	O
data	O
suggest	O
that	O
BLSW	O
mice	O
exhibit	O
progressive	O
SNHL	B-DISEASE
.	O

The	O
opioid	O
antagonist	O
naloxone	B-Chemical
has	O
been	O
shown	O
to	O
block	O
or	O
reverse	O
the	O
hypotensive	O
actions	O
of	O
captopril	B-Chemical
.	O

F19	O
,	O
a	O
male	O
with	O
an	O
atrial	B-DISEASE
septal	I-DISEASE
defect	I-DISEASE
,	O
esophageal	B-DISEASE
atresia	I-DISEASE
and	O
a	O
unilateral	B-DISEASE
facial	I-DISEASE
cleft	I-DISEASE
had	O
the	O
mutation	O
c	B-VARIANT
.	I-VARIANT
731G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
244R	I-VARIANT
>	I-VARIANT
Q	I-VARIANT
)	O
.	O

Animals	O
resistant	O
to	O
the	O
three	O
consecutive	O
sound	O
stimuli	O
were	O
scored	O
as	O
having	O
a	O
latency	O
of	O
180	O
s	O
.	O

These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	B-Chemical
dependence	O
.	O

Despite	O
the	O
use	O
of	O
antiepileptic	O
agents	O
,	O
another	O
GTCS	O
episode	O
recurred	O
after	O
the	O
sixth	O
dose	O
of	O
piperacillin	B-Chemical
/	I-Chemical
tazobactam	I-Chemical
.	O

The	O
exons	O
of	O
SLC26A4	B-GENE
of	O
the	O
remaining	O
227	O
patients	O
were	O
sequenced	O
individually	O
starting	O
from	O
the	O
frequently	O
mutated	O
exons	O
until	O
two	O
mutant	O
alleles	O
were	O
identified	O
.	O

Mutations	O
in	O
PCDH15	B-GENE
are	O
responsible	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
I	I-DISEASE
(	O
USH1F	B-GENE
)	O
and	O
DFNB23	B-DISEASE
.	O

PCR	O
primers	O
(	O
Supplementary	O
Table	O
5	O
)	O
were	O
designed	O
to	O
amplify	O
the	O
entire	O
cDNA	O
in	O
either	O
one	O
PCR	O
product	O
or	O
in	O
overlapping	O
segments	O
.	O

The	O
incidence	O
of	O
mood	O
switches	O
seemed	O
not	O
to	O
differ	O
between	O
patients	O
receiving	O
an	O
anticonvulsant	O
and	O
those	O
receiving	O
no	O
mood	O
stabilizer	O
.	O

A	O
male	O
patient	O
with	O
the	O
most	O
severe	O
phenotype	O
,	O
died	O
in	O
bed	O
at	O
the	O
age	O
of	O
13	O
years	O
.	O

In	O
this	O
family	O
the	O
proband	O
had	O
moderate	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
borderline	O
bilateral	O
vestibular	B-DISEASE
hypofunction	I-DISEASE
,	O
whereas	O
a	O
younger	O
affected	O
sibling	O
had	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
normal	O
vestibular	O
function	O
.	O

We	O
are	O
very	O
thankful	O
to	O
the	O
family	O
reported	O
here	O
for	O
their	O
collaboration	O
in	O
this	O
study	O
.	O

No	O
abnormalities	O
were	O
detected	O
in	O
the	O
tests	O
,	O
excluding	O
the	O
possibility	O
that	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
these	O
patients	O
was	O
syndromic	O
.	O

Audiometric	O
descriptors	O
of	O
mild	O
,	O
moderate	O
,	O
severe	O
,	O
and	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
calculated	O
according	O
to	O
the	O
British	O
Society	O
of	O
Audiology	O
descriptors	O
.	O

Hemodynamic	O
effects	O
and	O
histamine	B-Chemical
release	O
by	O
bolus	O
injection	O
of	O
0	O
.	O
35	O
mg	O
/	O
kg	O
of	O
d	B-Chemical
-	I-Chemical
tubocurarine	I-Chemical
were	O
studied	O
in	O
24	O
patients	O
.	O

Numbers	O
at	O
the	O
bottom	O
of	O
gels	O
indicate	O
the	O
proportion	O
(	O
%	O
)	O
of	O
misspliced	O
transcripts	O
compared	O
to	O
the	O
full	O
-	O
length	O
transcript	O
.	O

The	O
Glycine	B-Chemical
is	O
small	O
,	O
with	O
2	O
carbons	O
and	O
1	O
nitrogen	O
.	O

Group	O
OD	O
(	O
n	O
=	O
22	O
)	O
received	O
a	O
once	O
-	O
daily	O
dose	O
of	O
tobramycin	B-Chemical
and	O
group	O
TD	O
(	O
n	O
=	O
21	O
)	O
received	O
the	O
same	O
dose	O
divided	O
into	O
two	O
doses	O
daily	O
.	O

Haplotype	O
and	O
cosegregation	O
analyzes	O
were	O
performed	O
by	O
hand	O
from	O
the	O
raw	O
data	O
genotypes	O
.	O

Atypical	O
phenotypes	O
were	O
observed	O
in	O
9	O
patients	O
.	O

Twenty	O
-	O
six	O
of	O
the	O
mutations	O
have	O
only	O
been	O
described	O
in	O
Danish	O
LQTS	B-DISEASE
patients	O
(	O
Tables	O
1	O
,	O
2	O
,	O
3	O
)	O
,	O
18	O
have	O
not	O
been	O
reported	O
previously	O
.	O

At	O
the	O
16th	O
week	O
of	O
carcinogen	B-DISEASE
feeding	O
,	O
hyperplastic	B-DISEASE
nodules	I-DISEASE
appeared	O
and	O
advanced	O
to	O
further	O
stages	O
.	O

Arg668His	B-VARIANT
is	O
located	O
in	O
a	O
region	O
of	O
the	O
myosin	B-GENE
VIIA	I-GENE
motor	O
domain	O
that	O
is	O
highly	O
conserved	O
among	O
different	O
species	O
.	O

Systolic	O
blood	O
pressures	O
(	O
SBP	O
)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O

Striatal	O
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	B-Chemical
that	O
are	O
characteristic	O
of	O
activation	O
.	O

Systolic	O
BP	I-DISEASE
in	O
the	O
PAN	B-Chemical
group	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
weeks	O
,	O
but	O
was	O
normal	O
in	O
the	O
PAN	B-Chemical
/	O
temocapril	B-Chemical
group	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
describe	O
the	O
clinical	O
and	O
molecular	O
features	O
of	O
an	O
unusual	O
WFS	O
family	O
composed	O
by	O
four	O
affected	O
sons	O
of	O
a	O
non	O
-	O
consanguineous	O
marriage	O
.	O

C	O
:	O
16	O
%	O
denaturing	O
polyacrylamide	O
gel	O
electrophorese	O
analysis	O
for	O
the	O
heterozygous	O
mutation	O
c	B-VARIANT
.	I-VARIANT
9472_9498delTGATGAG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

In	O
the	O
present	O
study	O
we	O
conclude	O
that	O
mutations	O
in	O
POU3F4	B-GENE
cause	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
different	O
populations	O
.	O

Mutation	O
analysis	O
of	O
PCDH15	B-GENE
included	O
additional	O
exons	O
recently	O
identified	O
and	O
was	O
performed	O
by	O
direct	O
sequencing	O
.	O

and	O
D	O
.	O
T	O
.	O

To	O
obtain	O
a	O
source	O
of	O
purified	O
ELMOD3	B-GENE
,	O
His6	O
-	O
Trigger	O
factor	O
-	O
ELMOD3	B-GENE
(	O
TF	O
-	O
ELMOD3	B-GENE
)	O
fusion	O
protein	O
was	O
expressed	O
in	O
bacteria	O
,	O
and	O
the	O
recombinant	O
protein	O
was	O
purified	O
by	O
Ni	O
-	O
NTA	O
chromatography	O
.	O

SAR	O
studies	O
led	O
to	O
compound	O
14	O
with	O
excellent	O
potency	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
4	O
nM	O
)	O
,	O
selectivity	O
(	O
A	O
(	O
1	O
)	O
/	O
A	O
(	O
2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efficacy	O
(	O
MED	O
10	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
in	O
the	O
rat	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	O
model	O
for	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
.	O

Oxygen	O
consumption	O
in	O
NARS2	B-GENE
overexpressing	O
cells	O
was	O
analyzed	O
using	O
the	O
Seahorse	O
XF24	O
analyzer	O
.	O

Approximately	O
one	O
-	O
half	O
of	O
the	O
OPA1	B-GENE
mutations	O
lead	O
to	O
premature	O
termination	O
codons	O
from	O
nonsense	O
mutations	O
or	O
frameshifts	O
from	O
small	O
insertions	O
,	O
deletions	O
,	O
or	O
splice	O
site	O
mutations	O
[	O
45	O
]	O
.	O

The	O
availability	O
of	O
molecular	O
testing	O
has	O
revealed	O
phenotypic	O
variations	O
,	O
such	O
as	O
severe	O
congenital	O
forms	O
of	O
optic	B-DISEASE
atrophy	I-DISEASE
[	O
16	O
]	O
,	O
ADOA	B-DISEASE
associated	O
with	O
sensorineural	O
deafness	B-DISEASE
[	O
18	O
]	O
,	O
and	O
ADOA	B-DISEASE
associated	O
with	O
more	O
complex	O
,	O
severe	O
multi	O
-	O
organ	O
phenotypes	O
[	O
14	O
,	O
15	O
]	O
.	O

Mutation	O
screening	O
in	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
5	O
and	O
6	O
of	O
the	O
USH1C	B-GENE
gene	O
revealed	O
the	O
previously	O
reported	O
exon	O
3	O
mutation	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
a	O
homozygous	O
state	O
in	O
four	O
patients	O
(	O
one	O
of	O
the	O
two	O
corresponding	O
families	O
is	O
shown	O
in	O
Additional	O
data	O
file	O
1b	O
)	O
.	O

As	O
shown	O
in	O
Supplemental	O
Table	O
6	O
,	O
Hui	O
has	O
the	O
highest	O
frequency	O
of	O
overall	O
GJB2	B-GENE
mutations	O
,	O
followed	O
by	O
Han	O
and	O
minorities	O
in	O
Xinjiang	B-Chemical
with	O
20	O
.	O
3	O
,	O
19	O
.	O
1	O
,	O
and	O
15	O
.	O
3	O
%	O
respectively	O
.	O

Single	O
and	O
multiple	O
nucleotide	O
variants	O
,	O
including	O
small	O
insertion	O
or	O
deletions	O
that	O
would	O
affect	O
amino	O
acid	O
sequences	O
or	O
could	O
affect	O
splice	O
sites	O
,	O
were	O
annotated	O
by	O
Avadis	O
NGS	O
v	O
.	O
1	O
.	O
4	O
.	O
5	O
(	O
Strand	O
Life	O
Sciences	O
,	O
Bangalore	O
,	O
India	O
)	O
.	O

Patients	O
from	O
Tibet	O
,	O
Yunnan	O
,	O
Xinjiang	O
,	O
Heilongjiang	O
,	O
and	O
Ningxia	O
appear	O
to	O
have	O
the	O
most	O
diverse	O
mutation	O
spectrum	O
because	O
uncommon	O
mutations	O
(	O
except	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
299_c	I-VARIANT
.	I-VARIANT
300delAT	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
176_c	I-VARIANT
.	I-VARIANT
191del16	I-VARIANT
)	O
comprise	O
84	O
.	O
2	O
,	O
30	O
.	O
8	O
,	O
26	O
.	O
1	O
,	O
21	O
.	O
4	O
,	O
and	O
20	O
.	O
4	O
%	O
,	O
respectively	O
of	O
overall	O
GJB2	B-GENE
mutations	O
in	O
those	O
regions	O
.	O

Summary	O
of	O
SNPs	O
in	O
Exome	O
Sequencing	O
for	O
each	O
Sample	O
.	O

For	O
such	O
clinical	O
application	O
,	O
updated	O
information	O
regarding	O
mutation	O
spectrum	O
,	O
clinical	O
characteristics	O
and	O
genotype	O
-	O
phenotype	O
correlations	O
based	O
on	O
a	O
large	O
cohort	O
is	O
needed	O
.	O

Therefore	O
,	O
population	O
-	O
specific	O
studies	O
are	O
necessary	O
to	O
understand	O
the	O
contribution	O
of	O
mutations	O
to	O
the	O
genetic	O
load	O
.	O

While	O
the	O
mechanisms	O
underlying	O
cocaine	B-Chemical
'	O
s	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	B-Chemical
,	O
such	O
as	O
anxiety	O
.	O

37	O
)	O
.	O

Renorff	O
et	O
al	O
.	O

The	O
RD	B-DISEASE
-	O
chip	O
allows	O
to	O
genotype	O
768	O
selected	O
SNPs	O
in	O
a	O
single	O
cost	O
-	O
and	O
time	O
-	O
effective	O
step	O
and	O
is	O
designed	O
to	O
use	O
on	O
families	O
,	O
not	O
on	O
simplex	O
cases	O
.	O

All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Inclusion	O
criteria	O
and	O
determination	O
of	O
affection	O
status	O
are	O
as	O
previously	O
reported	O
27	O
.	O

Mutation	O
nomenclature	O
is	O
according	O
to	O
the	O
guidelines	O
of	O
the	O
Human	O
Genome	O
Variation	O
Society	O
[	O
28	O
]	O
and	O
was	O
verified	O
using	O
the	O
Mutalyzer	O
software	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mutalyzer	O
.	O
nl	O
/	O
2	O
.	O
0	O
/	O
)	O
.	O

Data	O
were	O
analyzed	O
with	O
statistical	O
analysis	O
software	O
GraphPad	O
Prism	O
(	O
Version	O
5	O
.	O
01	O
,	O
San	O
Diego	O
,	O
USA	O
)	O
.	O

Further	O
evaluation	O
of	O
the	O
known	O
polymorphisms	O
revealed	O
a	O
low	O
population	O
frequency	O
for	O
4	O
of	O
them	O
.	O

The	O
patient	O
'	O
s	O
Apgar	O
scores	O
were	O
9	O
and	O
10	O
at	O
1	O
and	O
5	O
minute	O
.	O

Figure	O
4	O
Overview	O
of	O
the	O
COL4A5	B-GENE
mutation	O
identified	O
in	O
Family	O
3	O
.	O

suggested	O
that	O
hotspots	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
mutations	O
are	O
variable	O
in	O
different	O
regions	O
in	O
China	O
[	O
5	O
]	O
.	O

In	O
six	O
other	O
families	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
not	O
linked	O
to	O
any	O
known	O
gene	O
,	O
suggesting	O
that	O
these	O
families	O
harbour	O
novel	O
genes	O
responsible	O
for	O
this	O
phenotype	O
.	O

81120108009	B-Chemical
)	O
to	O
QW	O
;	O
and	O
the	O
National	O
Institutes	O
of	O
Health	O
(	O
NIDCD	O
DC003544	O
,	O
DC002842	B-Chemical
and	O
DC012049	O
to	O
RJHS	O
)	O
.	O

Ultimately	O
,	O
7	O
variations	O
were	O
confirmed	O
for	O
their	O
co	O
-	O
segregation	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
these	O
families	O
(	O
Table	O
3	O
)	O
.	O

With	O
regard	O
to	O
the	O
79	O
patients	O
for	O
whom	O
data	O
on	O
vertigo	B-DISEASE
were	O
available	O
,	O
41	O
patients	O
complained	O
of	O
vertigo	B-DISEASE
and	O
38	O
did	O
not	O
.	O

All	O
children	O
who	O
experienced	O
seizures	B-DISEASE
survived	O
with	O
good	O
graft	O
function	O
and	O
remained	O
seizure	O
-	O
free	O
without	O
anti	O
-	O
epileptic	O
drugs	O
over	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
33	O
.	O
7	O
+	O
14	O
.	O
6	O
months	O
.	O

Exogenous	O
creatine	B-Chemical
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	O
exercise	O
performance	O
.	O

In	O
total	O
,	O
188	O
variants	O
were	O
identified	O
in	O
the	O
proband	O
'	O
s	O
sample	O
.	O

Proof	O
of	O
principle	O
of	O
prenatal	O
NGS	O
for	O
diagnosis	O
of	O
aneuploidy	O
and	O
chromosomal	O
rearrangements	O
has	O
been	O
established	O
(	O
6	O
,	O
7	O
)	O
.	O

A	O
:	O
Overlapping	O
audiogram	O
of	O
subjects	O
with	O
truncating	O
and	O
missense	O
mutations	O
.	O

Six	O
families	O
likely	O
had	O
causative	O
mutations	O
in	O
DFNA	B-DISEASE
genes	O
[	O
WFS1	B-GENE
(	O
n	O
=	O
2	O
)	O
,	O
ACTG1	B-GENE
,	O
POU4F3	B-GENE
,	O
COCH	B-GENE
and	O
TMC1	B-GENE
]	O
,	O
and	O
one	O
showed	O
two	O
monoallelic	O
and	O
most	O
likely	O
causative	O
mutations	O
in	O
the	O
GJB2	B-GENE
and	O
USH2A	B-GENE
genes	O
,	O
respectively	O
.	O

Figure	O
1	O
depicts	O
the	O
major	O
criteria	O
for	O
identification	O
of	O
causative	O
variants	O
in	O
the	O
affected	O
families	O
,	O
including	O
target	O
enrichment	O
,	O
massively	O
parallel	O
sequencing	O
,	O
variant	O
calling	O
,	O
and	O
data	O
filtering	O
.	O

(	O
A	O
)	O
Confocal	O
images	O
of	O
cMYC	O
-	O
tagged	O
HOMER2	B-GENE
WT	O
-	O
transfected	O
HEK293	O
cells	O
immuno	O
-	O
stained	O
with	O
Alexa	B-Chemical
-	O
Fluor	O
-	O
568	O
(	O
red	O
)	O
;	O
F	O
-	O
actin	O
immuno	O
-	O
stained	O
with	O
conjugated	O
Alexa	B-Chemical
-	I-Chemical
Fluor	I-Chemical
-	I-Chemical
647	I-Chemical
-	I-Chemical
phalloidin	I-Chemical
(	O
blue	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
screening	O
of	O
entire	O
TCOF1	B-GENE
coding	O
region	O
and	O
the	O
identification	O
of	O
a	O
spectrum	O
of	O
3	O
known	O
mutations	O
,	O
12	O
novel	O
pathogenetic	O
mutations	O
and	O
7	O
novel	O
polymorphisms	O
by	O
direct	O
sequencing	O
.	O

It	O
occurs	O
especially	O
in	O
older	O
patients	O
and	O
during	O
the	O
first	O
two	O
weeks	O
of	O
treatment	O
.	O

(	O
2013	O
)	O
identified	O
specific	O
genetic	O
etiologies	O
in	O
11	O
of	O
32	O
sporadic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
cases	O
(	O
34	O
%	O
)	O
and	O
22	O
of	O
49	O
presumed	O
recessive	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
cases	O
(	O
56	O
%	O
)	O
by	O
deep	O
sequencing	O
of	O
60	O
deafness	B-DISEASE
genes	O
,	O
but	O
this	O
cohort	O
included	O
variable	O
degrees	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Toleration	O
of	O
high	O
doses	O
of	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
inhibitors	I-Chemical
in	O
patients	O
with	O
chronic	B-DISEASE
heart	B-DISEASE
failure	I-DISEASE
:	O
results	O
from	O
the	O
ATLAS	O
trial	O
.	O

(	O
B	O
)	O
Number	O
of	O
patients	O
(	O
total	O
=	O
41	O
)	O
with	O
N	O
,	O
D	O
or	O
Ca	O
isolated	O
,	O
or	O
an	O
association	O
of	O
two	O
or	O
three	O
extrahematological	O
symptoms	O
N	O
alone	O
=	O
3	O
,	O
D	O
alone	O
=	O
19	O
,	O
Ca	O
alone	O
=	O
1	O
,	O
N	O
+	O
D	O
=	O
14	O
,	O
N	O
+	O
Ca	O
=	O
2	O
,	O
N	O
+	O
D	O
+	O
Ca	O
=	O
2	O
.	O

With	O
direct	O
DNA	O
sequencing	O
of	O
MYO7A	B-GENE
,	O
two	O
novel	O
compound	O
heterozygous	O
mutations	O
(	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
6051	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
of	O
MYO7A	B-GENE
were	O
identified	O
in	O
the	O
proband	O
.	O

For	O
family	O
4243	O
,	O
a	O
maximum	O
two	O
-	O
point	O
LOD	O
score	O
of	O
3	O
.	O
04	O
(	O
theta	O
=	O
0	O
)	O
was	O
observed	O
at	O
marker	O
rs935340	B-VARIANT
(	O
chr14	O
:	O
75	O
.	O
66	O
Mb	O
;	O
see	O
Table	O
1	O
)	O
.	O

To	O
date	O
,	O
approximately	O
130	O
distinct	O
mutations	O
in	O
WFS1	B-GENE
have	O
been	O
identified	O
in	O
WS	B-DISEASE
individuals	O
from	O
different	O
ethnic	O
backgrounds	O
,	O
and	O
these	O
include	O
a	O
variety	O
of	O
missense	O
,	O
nonsense	O
,	O
and	O
frameshift	O
insertion	O
/	O
deletion	O
mutations	O
[	O
4	O
,	O
6	O
,	O
7	O
,	O
10	O
-	O
15	O
]	O
.	O

Methods	O
for	O
detecting	O
large	O
deletions	O
or	O
duplications	O
(	O
also	O
known	O
as	O
copy	O
number	O
variants	O
)	O
in	O
targeted	O
next	O
-	O
generation	O
sequencing	O
data	O
have	O
lagged	O
behind	O
calling	O
of	O
base	O
substitutions	O
and	O
small	O
indels	O
.	O

The	O
313	O
-	O
bp	O
product	O
suggested	O
the	O
existence	O
of	O
a	O
second	O
alternative	O
acceptor	O
site	O
(	O
see	O
below	O
)	O
.	O

There	O
are	O
more	O
than	O
160	O
pathogenic	O
variants	O
described	O
in	O
previous	O
studies	O
.	O

10	O
ng	O
of	O
each	O
genomic	O
DNA	O
sample	O
was	O
amplified	O
,	O
using	O
Ion	O
AmpliSeq	O
(	O
tm	O
)	O
HiFi	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
,	O
Life	O
Technologies	O
)	O
and	O
AmpliSeq	O
(	O
tm	O
)	O
Custom	O
primer	O
pools	O
,	O
for	O
2	O
min	O
at	O
99	O
deg	O
C	O
,	O
followed	O
by	O
15	O
two	O
-	O
step	O
cycles	O
of	O
99	O
deg	O
C	O
for	O
15	O
sec	O
and	O
60	O
deg	O
C	O
for	O
4	O
min	O
,	O
ending	O
with	O
a	O
holding	O
period	O
at	O
10	O
deg	O
C	O
in	O
a	O
PCR	O
thermal	O
cycler	O
(	O
Takara	O
,	O
Shiga	O
,	O
Japan	O
)	O
.	O

This	O
portion	O
of	O
the	O
protein	O
is	O
highly	O
conserved	O
among	O
myosin	B-GENE
VIIA	I-GENE
homologs	O
and	O
seems	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
communication	O
between	O
the	O
actin	O
interface	O
and	O
nucleotide	B-Chemical
-	O
binding	O
pocket	O
[	O
22	O
]	O
.	O

The	O
lower	O
rate	O
of	O
variability	O
for	O
oncogenes	O
and	O
tumor	B-DISEASE
suppressor	O
genes	O
may	O
indicate	O
greater	O
evolutionary	O
constraint	O
.	O

Group	O
3	O
showed	O
intermediate	O
values	O
.	O

When	O
he	O
was	O
17	O
-	O
years	O
-	O
old	O
,	O
the	O
diagnosis	O
of	O
immune	O
thrombocytopenia	B-DISEASE
was	O
confirmed	O
and	O
he	O
underwent	O
splenectomy	O
without	O
any	O
increase	O
in	O
platelet	O
count	O
.	O

Though	O
our	O
family	O
is	O
not	O
large	O
,	O
a	O
moderate	O
type	O
of	O
XLAS	B-DISEASE
is	O
considered	O
due	O
to	O
the	O
mutation	O
located	O
in	O
COL4A5	B-GENE
exon	O
9	O
and	O
the	O
late	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
ESRD	I-DISEASE
(	O
ESRD	B-DISEASE
at	O
36	O
years	O
,	O
II	O
:	O
1	O
;	O
Table	O
1	O
)	O
.	O

In	O
the	O
current	O
series	O
,	O
MPS	O
successfully	O
discovered	O
rare	O
causative	O
genes	O
in	O
CI	O
patients	O
and	O
in	O
EAS	O
patients	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
G4D	I-VARIANT
mutation	O
accounts	O
for	O
only	O
0	O
.	O
3	O
%	O
of	O
GJB2	B-GENE
mutant	O
alleles	O
in	O
Chinese	O
NSHI	B-DISEASE
patients	O
and	O
was	O
recently	O
reported	O
in	O
a	O
US	O
study	O
[	O
29	O
,	O
30	O
]	O
.	O

Statins	B-Chemical
can	O
cause	O
a	O
necrotizing	B-DISEASE
myopathy	I-DISEASE
and	O
hyperCKaemia	B-DISEASE
which	O
is	O
reversible	O
on	O
cessation	O
of	O
the	O
drug	O
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
and	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
associated	O
with	O
EVA	B-DISEASE
are	O
a	O
continuum	O
of	O
disease	O
characterized	O
as	O
being	O
associated	O
with	O
congenital	O
,	O
fluctuating	O
and	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
most	O
patients	O
have	O
vertigo	B-DISEASE
and	O
/	O
or	O
goiter	B-DISEASE
.	O

An	O
ophthalmology	O
examination	O
at	O
14	O
months	O
was	O
normal	O
with	O
no	O
evidence	O
of	O
retinopathy	B-DISEASE
.	O

Targeted	O
next	O
generation	O
sequencing	O
allowed	O
us	O
to	O
detect	O
both	O
point	O
mutations	O
and	O
large	O
rearrangements	O
in	O
a	O
single	O
experiment	O
,	O
minimizing	O
the	O
economic	O
cost	O
of	O
the	O
study	O
,	O
increasing	O
the	O
detection	O
ratio	O
of	O
the	O
genetic	O
cause	O
of	O
the	O
disease	O
and	O
improving	O
the	O
genetic	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
patients	O
.	O

A	O
hemodynamic	O
,	O
volumetric	O
,	O
and	O
metabolic	O
study	O
in	O
patients	O
without	O
heart	B-DISEASE
failure	I-DISEASE
.	O

Further	O
genotyping	O
and	O
haplotyping	O
analysis	O
for	O
the	O
six	O
markers	O
(	O
D1S237	O
,	O
D1S419	O
,	O
D1S556	O
,	O
D1S229	O
,	O
D1S227	O
,	O
and	O
D1S2860	O
)	O
suggested	O
that	O
the	O
USH2A	B-GENE
gene	O
might	O
be	O
the	O
disease	O
-	O
causing	O
gene	O
in	O
this	O
family	O
(	O
Figure	O
1	O
)	O
.	O

We	O
focused	O
on	O
212	O
retinal	O
disease	O
-	O
causing	O
genes	O
registered	O
in	O
RetNet	O
database	O
updated	O
on	O
March	O
10	O
,	O
2014	O
.	O

Nevertheless	O
,	O
we	O
suggest	O
performing	O
arhinencephaly	O
,	O
endocrinology	O
and	O
olfactory	O
evaluations	O
in	O
patients	O
with	O
ectrodactyly	B-DISEASE
,	O
with	O
or	O
without	O
additional	O
malformations	O
.	O

Our	O
data	O
now	O
strongly	O
suggest	O
that	O
carriers	O
of	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
belong	O
to	O
the	O
early	O
founders	O
of	O
both	O
the	O
Acadian	O
and	O
the	O
Quebec	O
population	O
(	O
Figure	O
1b	O
)	O
.	O

She	O
had	O
normal	O
blood	O
pressure	O
,	O
normal	O
renal	O
function	O
(	O
the	O
serum	O
level	O
of	O
creatinine	B-Chemical
was	O
74	O
mu	O
mol	O
/	O
l	O
,	O
and	O
that	O
of	O
urea	B-Chemical
nitrogen	O
was	O
4	O
.	O
10	O
mmol	O
/	O
l	O
)	O
,	O
microscopic	O
hematuria	B-DISEASE
with	O
mild	O
proteinuria	B-DISEASE
(	O
0	O
.	O
87	O
g	O
/	O
24	O
h	O
)	O
,	O
and	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
on	O
pure	O
-	O
tone	O
audiometry	O
;	O
electron	O
microscopy	O
showed	O
irregular	O
thinned	O
and	O
thickened	O
areas	O
of	O
the	O
GBM	O
with	O
splitting	O
of	O
the	O
lamina	O
densa	O
(	O
Figure	O
2A	O
)	O
.	O

Takotsubo	B-DISEASE
syndrome	I-DISEASE
(	O
TS	B-DISEASE
)	O
,	O
also	O
known	O
as	O
broken	B-DISEASE
heart	I-DISEASE
syndrome	I-DISEASE
,	O
is	O
characterized	O
by	O
left	B-DISEASE
ventricle	I-DISEASE
apical	I-DISEASE
ballooning	I-DISEASE
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B-DISEASE
coronary	I-DISEASE
syndrome	I-DISEASE
(	O
ie	O
,	O
ST	O
-	O
segment	O
elevation	O
,	O
T	B-DISEASE
wave	I-DISEASE
inversions	I-DISEASE
,	O
and	O
pathologic	O
Q	I-DISEASE
waves	I-DISEASE
)	O
.	O

Blockade	O
of	O
histamine	B-Chemical
H1	O
receptors	O
may	O
reduce	O
mortality	O
in	O
pertussis	B-DISEASE
immunization	O
-	O
induced	I-DISEASE
encephalopathy	I-DISEASE
in	O
mice	O
.	O

Full	O
field	O
electroretinogram	O
were	O
performed	O
according	O
to	O
International	O
Society	O
for	O
Clinical	O
Electrophysiology	O
of	O
Vision	O
(	O
ISCEV	O
)	O
protocols	O
.	O

We	O
and	O
others	O
have	O
recently	O
reported	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
MYH9	B-GENE
-	O
RD	O
[	O
9	O
,	O
17	O
]	O
.	O

1A	O
)	O
,	O
yielded	O
on	O
average	O
5	O
.	O
2	O
Gb	O
high	O
quality	O
sequence	O
data	O
per	O
exome	O
,	O
with	O
about	O
98	O
.	O
9	O
%	O
coverage	O
of	O
the	O
target	O
and	O
a	O
70	O
x	O
mean	O
coverage	O
(	O
range	O
51	O
x	O
-	O
81	O
x	O
)	O
,	O
with	O
more	O
than	O
93	O
%	O
of	O
target	O
covered	O
>	O
10	O
x	O
(	O
Supplementary	O
Table	O
S1	O
)	O
.	O

In	O
7	O
dominant	O
probands	O
,	O
we	O
identified	O
7	O
heterozygous	O
,	O
non	O
-	O
synonymous	O
variants	O
.	O

Concerning	O
family	O
E5	O
,	O
most	O
recessive	O
RD	B-DISEASE
genes	O
were	O
discarded	O
under	O
the	O
assumption	O
of	O
claimed	O
consanguinity	O
(	O
I	O
.	O
1	O
and	O
I	O
.	O
2	O
)	O
,	O
and	O
the	O
rest	O
of	O
candidates	O
was	O
excluded	O
by	O
Sanger	O
sequencing	O
.	O

The	O
PCR	O
reaction	O
was	O
prepared	O
using	O
10	O
u	O
l	O
of	O
the	O
ligation	O
mix	O
,	O
PCR	O
primers	O
,	O
polymerase	O
,	O
buffers	O
and	O
water	O
,	O
and	O
the	O
amplification	O
was	O
then	O
performed	O
under	O
the	O
following	O
conditions	O
:	O
95	O
deg	O
C	O
for	O
30	O
sec	O
,	O
65	O
deg	O
C	O
for	O
90	O
sec	O
,	O
30	O
cycles	O
,	O
followed	O
by	O
a	O
final	O
extension	O
for	O
20	O
min	O
at	O
72	O
deg	O
C	O
.	O

The	O
massive	O
amounts	O
of	O
data	O
generated	O
by	O
NGS	O
represent	O
both	O
a	O
challenge	O
for	O
analysis	O
and	O
a	O
powerful	O
tool	O
to	O
define	O
sequence	O
variations	O
.	O

The	O
other	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

These	O
diseases	O
are	O
a	O
more	O
significant	O
issue	O
in	O
the	O
West	O
Yorkshire	O
population	O
due	O
to	O
the	O
high	O
incidence	O
of	O
first	O
cousin	O
marriage	O
and	O
consequent	O
recessive	O
disease	O
in	O
the	O
local	O
Pakistani	O
community	O
[	O
2	O
]	O
.	O

Synonymous	O
variants	O
,	O
variants	O
in	O
the	O
introns	O
,	O
common	O
variants	O
(	O
minor	O
allele	O
frequency	O
>	O
0	O
.	O
01	O
)	O
,	O
listed	O
in	O
the	O
NHLBI	O
GO	O
Exome	O
Sequencing	O
Project	O
database	O
(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
)	O
and	O
the	O
"	O
1000	O
Genomes	O
-	O
-	O
A	O
Deep	O
Catalog	O
of	O
Human	O
Genetic	O
Variation	O
"	O
(	O
http	O
:	O
/	O
/	O
browser	O
.	O
1000genomes	O
.	O
org	O
/	O
)	O
were	O
excluded	O
from	O
detailed	O
analysis	O
.	O

Taking	O
all	O
this	O
into	O
account	O
,	O
we	O
have	O
worked	O
out	O
a	O
"	O
decision	O
-	O
making	O
diagram	O
"	O
as	O
represented	O
on	O
Figure	O
S4	O
.	O

Seven	O
mutations	O
were	O
familial	O
(	O
ie	O
,	O
shown	O
to	O
be	O
inherited	O
from	O
1	O
parent	O
that	O
presented	O
signs	O
and	O
symptoms	O
of	O
WS	B-DISEASE
)	O
,	O
whereas	O
three	O
mutations	O
(	O
1	O
mutation	O
in	O
PAX3	B-GENE
and	O
2	O
in	O
MITF	B-GENE
)	O
occurred	O
de	O
novo	O
.	O

Consensus	O
statement	O
concerning	O
cardiotoxicity	O
occurring	O
during	O
haematopoietic	O
stem	O
cell	O
transplantation	O
in	O
the	O
treatment	O
of	O
autoimmune	B-DISEASE
diseases	I-DISEASE
,	O
with	O
special	O
reference	O
to	O
systemic	B-DISEASE
sclerosis	I-DISEASE
and	O
multiple	B-DISEASE
sclerosis	I-DISEASE
.	O

The	O
polymorphic	O
variation	O
present	O
in	O
Usher	B-DISEASE
genes	O
means	O
that	O
multiple	O
variants	O
are	O
likely	O
to	O
be	O
found	O
if	O
multiple	O
genes	O
are	O
sequenced	O
.	O

In	O
contrast	O
,	O
in	O
normal	O
-	O
salt	O
rats	O
creatinine	B-Chemical
clearance	O
was	O
decreased	O
but	O
to	O
a	O
lesser	O
extent	O
at	O
week	O
2	O
and	O
3	O
,	O
and	O
in	O
salt	O
-	O
loaded	O
rats	O
creatinine	B-Chemical
clearance	O
did	O
not	O
change	O
for	O
2	O
weeks	O
and	O
was	O
decreased	O
by	O
43	O
%	O
at	O
week	O
3	O
.	O

Comparison	O
between	O
results	O
obtained	O
from	O
the	O
sample	O
included	O
in	O
the	O
present	O
report	O
with	O
the	O
global	O
results	O
for	O
our	O
total	O
series	O
.	O

Genomic	O
context	O
and	O
consequences	O
of	O
FGFR2	B-GENE
mutations	O
.	O

Not	O
only	O
is	O
it	O
challenging	O
to	O
generate	O
accurate	O
sequencing	O
data	O
without	O
pseudogene	O
inclusion	O
,	O
it	O
is	O
even	O
more	O
difficult	O
interpreting	O
such	O
data	O
without	O
the	O
usual	O
reliable	O
resources	O
for	O
mutation	O
interpretation	O
,	O
as	O
these	O
databases	O
are	O
'	O
polluted	O
'	O
with	O
pseudogene	O
data	O
as	O
well	O
.	O

Failure	O
of	O
ancrod	O
in	O
the	O
treatment	O
of	O
heparin	B-Chemical
-	I-DISEASE
induced	I-DISEASE
arterial	I-DISEASE
thrombosis	I-DISEASE
.	O

Origin	O
,	O
genotype	O
and	O
clinical	O
phenotype	O
of	O
the	O
Long	B-DISEASE
QT	I-DISEASE
Syndrome	I-DISEASE
R518X	B-VARIANT
/	O
KCNQ1	B-GENE
mutation	O
in	O
Sweden	O
.	O

The	O
effects	O
of	O
CAA	B-Chemical
on	O
cysteine	B-Chemical
protease	O
activities	O
and	O
thiols	B-Chemical
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O

Status	B-DISEASE
epilepticus	I-DISEASE
(	O
P45	O
)	O
rats	O
failed	O
to	O
acquire	O
either	O
sound	O
-	O
source	O
location	O
or	O
sound	O
-	O
silence	O
discriminations	O
.	O

The	O
PS	B-DISEASE
phenotypes	O
are	O
related	O
with	O
mutations	O
in	O
two	O
fibroblast	O
growth	O
factor	O
receptors	O
(	O
FGFRs	O
)	O
,	O
FGFR1	B-GENE
and	O
FGFR2	B-GENE
(	O
8	O
,	O
11	O
)	O
.	O

The	O
electrocardiogram	O
was	O
normal	O
,	O
without	O
any	O
signs	O
of	O
dysrythmia	B-DISEASE
.	O

Pathologic	O
confirmation	O
of	O
the	O
diagnosis	O
of	O
Reye	B-DISEASE
syndrome	I-DISEASE
was	O
accomplished	O
in	O
90	O
%	O
of	O
the	O
cases	O
.	O

In	O
the	O
photoreceptor	O
cells	O
,	O
myosin	B-GENE
VIIA	I-GENE
is	O
present	O
at	O
the	O
connecting	O
cilium	O
and	O
regulates	O
opsin	O
transport	O
[	O
18	O
]	O
.	O

Audiometry	O
results	O
for	O
III	O
:	O
5	O
and	O
IV	O
:	O
1	O
.	O

Nine	O
of	O
11	O
patients	O
carrying	O
OPA1	B-GENE
mutations	O
inducing	O
haploinsufficiency	B-DISEASE
had	O
normal	O
hearing	O
function	O
.	O

Considering	O
that	O
clozapine	B-Chemical
remains	O
the	O
gold	O
standard	O
in	O
treatment	O
of	O
resistant	B-DISEASE
psychosis	I-DISEASE
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	O
and	O
paramedical	O
staff	O
involved	O
in	O
the	O
care	O
of	O
these	O
patients	O
.	O

After	O
the	O
filtrations	O
,	O
variant	O
effects	O
were	O
analyzed	O
with	O
the	O
wANNOVAR	B-Chemical
web	O
site	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
(	O
http	O
:	O
/	O
/	O
wannovar	O
.	O
usc	O
.	O
edu	O
)	O
including	O
the	O
functional	O
prediction	O
software	O
for	O
missense	O
variants	O
listed	O
below	O
.	O

Family	O
Y	O
included	O
four	O
individuals	O
with	O
prelingual	O
,	O
bilateral	O
,	O
severe	O
to	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

c	B-VARIANT
.	I-VARIANT
237	I-VARIANT
-	I-VARIANT
6T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
is	O
a	O
change	O
in	O
the	O
conserved	O
polypyrimidine	O
tract	O
flanking	O
3	O
'	O
splice	O
acceptor	O
site	O
in	O
intron	O
7	O
.	O

Echocardiographic	O
Doppler	O
studies	O
were	O
performed	O
before	O
infusion	O
and	O
after	O
15	O
min	O
of	O
infusion	O
at	O
each	O
rate	O
.	O

Targeted	O
capture	O
of	O
exome	O
sequences	O
was	O
performed	O
using	O
the	O
2	O
.	O
1M	O
NimbleGen	O
Exome	O
reagent	O
followed	O
by	O
sequencing	O
on	O
the	O
Illumina	O
platform	O
as	O
previously	O
described	O
1	O
.	O

The	O
V37I	B-VARIANT
variant	O
was	O
considered	O
a	O
pathogenic	O
mutation	O
in	O
Japanese	O
studies	O
,	O
but	O
it	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
Korean	O
control	O
or	O
patient	O
populations	O
reported	O
previously	O
[	O
6	O
,	O
10	O
,	O
46	O
]	O
.	O

Interestingly	O
,	O
a	O
Y669C	B-VARIANT
mutation	O
has	O
been	O
observed	O
in	O
a	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
patient	O
[	O
13	O
]	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
ascertain	O
whether	O
the	O
alterations	O
of	O
plasma	O
lipoproteins	O
found	O
in	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
induced	O
by	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
were	O
due	O
to	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
per	O
se	O
,	O
or	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
aminonucleoside	B-Chemical
.	O

After	O
12	O
weeks	O
,	O
rats	O
were	O
sacrificed	O
and	O
their	O
kidneys	O
harvested	O
.	O

In	O
silico	O
analysis	O
was	O
performed	O
by	O
AJR	O
.	O

PCR	O
primers	O
designed	O
to	O
amplify	O
GPR98	B-GENE
exon	O
83	O
in	O
the	O
affected	O
sibs	O
also	O
failed	O
,	O
supporting	O
a	O
homozygous	O
deletion	O
of	O
exon	O
83	O
,	O
for	O
which	O
parents	O
are	O
likely	O
to	O
be	O
hemizygous	O
.	O

The	O
distribution	O
of	O
per	O
-	O
base	O
sequencing	O
depth	O
in	O
target	O
regions	O
for	O
each	O
sample	O
.	O

CONCLUSION	O
:	O
This	O
case	O
started	O
with	O
a	O
media	O
report	O
in	O
a	O
popular	O
newspaper	O
,	O
initiated	O
by	O
published	O
,	O
peer	O
-	O
reviewed	O
research	O
on	O
herbals	O
,	O
and	O
involved	O
human	O
failure	O
in	O
a	O
case	O
history	O
,	O
medical	O
examination	O
and	O
clinical	O
treatment	O
.	O

Moreover	O
,	O
all	O
single	O
amino	O
acid	O
changes	O
were	O
located	O
within	O
conserved	O
domains	O
of	O
the	O
protein	O
(	O
Table	O
1	O
)	O
.	O

The	O
pathophysiological	O
mechanisms	O
are	O
discussed	O
in	O
the	O
light	O
of	O
these	O
observations	O
and	O
the	O
few	O
other	O
comments	O
on	O
this	O
subject	O
published	O
in	O
the	O
literature	O
.	O

Hyperprolactinemia	B-DISEASE
can	O
reduce	O
fertility	O
and	O
libido	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	O
on	O
uninterrupted	O
levodopa	B-Chemical
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	O
model	O
of	O
thoracic	B-DISEASE
aortic	I-DISEASE
aneurysm	I-DISEASE
(	O
TAA	B-DISEASE
)	O
by	O
calcium	B-Chemical
chloride	I-Chemical
(	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
)	O
-	O
induced	O
arterial	O
injury	O
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
)	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B-DISEASE
formation	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

We	O
have	O
identified	O
previously	O
unreported	O
biallelic	O
mutations	O
in	O
three	O
different	O
DFNB	B-DISEASE
genes	O
(	O
MYO15A	B-GENE
,	O
LRTOMT	B-GENE
,	O
TMC1	B-GENE
)	O
in	O
patients	O
affected	O
by	O
congenital	B-DISEASE
profound	I-DISEASE
deafness	I-DISEASE
,	O
who	O
belong	O
to	O
four	O
unrelated	O
Tunisian	O
families	O
,	O
using	O
a	O
WES	O
strategy	O
.	O

The	O
results	O
obtained	O
are	O
associated	O
with	O
the	O
beta	O
-	O
adrenoblocking	O
and	O
with	O
the	O
membrane	O
-	O
stabilizing	O
action	O
of	O
the	O
compound	O
.	O

Minor	O
neurological	B-DISEASE
dysfunction	I-DISEASE
,	O
cognitive	B-DISEASE
development	I-DISEASE
,	O
and	O
somatic	O
development	I-DISEASE
at	O
the	O
age	O
of	O
3	O
to	O
7	O
years	O
after	O
dexamethasone	B-Chemical
treatment	O
in	O
very	O
-	O
low	O
birth	O
-	O
weight	I-DISEASE
infants	O
.	O

Moreover	O
,	O
the	O
GJB2	B-GENE
screening	O
was	O
performed	O
in	O
130	O
unrelated	O
control	O
subjects	O
of	O
Altaian	O
ethnicity	O
.	O

Fei	O
Yu	O
and	O
Huijun	O
Yuan	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
performed	O
the	O
statistical	O
analysis	O
.	O

cDNA	O
and	O
protein	O
numbering	O
according	O
to	O
Ensembl	O
identifiers	O
:	O
ATP6V1B1	B-GENE
:	O
ENSG00000116039	O
,	O
and	O
ATP6V0A4	B-GENE
:	O
ENSG00000105929	O
.	O

However	O
,	O
in	O
vivo	O
studies	O
and	O
computational	O
evidence	O
have	O
suggested	O
that	O
its	O
primary	O
role	O
is	O
likely	O
in	O
fatty	B-Chemical
-	O
acid	O
metabolism	O
,	O
while	O
steroid	B-Chemical
conversion	O
is	O
only	O
a	O
secondary	O
and	O
possibly	O
minor	O
activity	O
in	O
vivo	O
[	O
21	O
]	O
.	O

The	O
MLPA	O
reactions	O
were	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mlpa	O
.	O
com	O
)	O
.	O

2	O
,	O
3	O
POU3F4	B-GENE
encodes	O
a	O
transcription	O
factor	O
,	O
which	O
belongs	O
to	O
the	O
POU	O
-	O
domain	O
family	O
and	O
is	O
comprised	O
of	O
two	O
subdomains	O
,	O
POU	O
-	O
specific	O
domain	O
and	O
a	O
homeodomain	O
.	O

Total	O
protein	O
expression	O
of	O
WT	O
and	O
G169R	B-VARIANT
CEACAM16	B-GENE
is	O
very	O
similar	O
(	O
Cells	O
)	O
;	O
total	O
beta	O
-	O
actin	O
loads	O
from	O
both	O
preparations	O
are	O
comparable	O
(	O
lower	O
panel	O
)	O
.	O

Mitochondrial	B-DISEASE
respiratory	I-DISEASE
chain	I-DISEASE
(	I-DISEASE
MRC	I-DISEASE
)	I-DISEASE
disease	I-DISEASE
represents	O
a	O
large	O
and	O
heterogeneous	O
group	O
of	O
energy	B-DISEASE
deficiency	I-DISEASE
disorders	I-DISEASE
.	O

These	O
results	O
show	O
that	O
HOMER2	B-GENE
plays	O
an	O
essential	O
role	O
in	O
the	O
normal	O
development	O
and	O
/	O
or	O
maintenance	O
of	O
hair	O
cells	O
in	O
the	O
zebrafish	O
inner	O
ear	O
and	O
that	O
the	O
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
mutation	O
has	O
a	O
dominant	O
-	O
negative	O
effect	O
on	O
this	O
process	O
.	O

The	O
locus	O
for	O
USH1G	B-GENE
was	O
mapped	O
to	O
17q24	O
-	O
25	O
[	O
2	O
]	O
,	O
and	O
in	O
2003	O
the	O
gene	O
USH1G	B-GENE
(	O
previously	O
named	O
scaffold	O
protein	O
containing	O
ankyrin	O
repeats	O
and	O
sam	O
domain	O
[	O
SANS	O
]	O
)	O
was	O
cloned	O
,	O
which	O
is	O
the	O
human	O
ortholog	O
of	O
the	O
Sans	O
gene	O
defective	O
in	O
Jackson	O
shaker	O
mutant	O
mice	O
[	O
3	O
,	O
4	O
]	O
.	O

In	O
particular	O
,	O
two	O
ESRRB	B-GENE
mutations	O
,	O
namely	O
,	O
p	B-VARIANT
.	I-VARIANT
Val342Leu	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Leu347Pro	I-VARIANT
[	O
2	O
]	O
,	O
also	O
occur	O
within	O
alpha	O
-	O
helix	O
8	O
.	O

Scheme	O
of	O
the	O
RP1	B-GENE
protein	O
and	O
overview	O
of	O
truncating	O
RP1	B-GENE
mutations	O
reported	O
in	O
this	O
study	O
(	O
mutations	O
shown	O
in	O
A	O
-	O
C	O
in	O
red	O
)	O
.	O

A	O
total	O
of	O
83	O
genes	O
are	O
found	O
within	O
the	O
linkage	O
interval	O
,	O
including	O
the	O
known	O
ARNSHI	B-DISEASE
gene	O
,	O
ESRRB	B-GENE
.	O

The	O
majority	O
of	O
patients	O
were	O
Han	O
Chinese	O
(	O
1903	O
)	O
,	O
followed	O
by	O
minorities	O
in	O
the	O
Southwest	O
region	O
(	O
125	O
)	O
,	O
Tibetan	O
(	O
119	O
)	O
,	O
Hui	B-Chemical
(	O
89	O
)	O
,	O
minorities	O
in	O
Xinjiang	B-Chemical
(	O
69	O
)	O
,	O
Mongolian	O
(	O
33	O
)	O
,	O
Maan	B-Chemical
(	O
12	O
)	O
and	O
Korean	B-Chemical
(	O
2	O
)	O
.	O

Large	O
scale	O
screening	O
of	O
selective	O
exons	O
in	O
30	O
RP	B-DISEASE
-	O
causing	O
genes	O
was	O
previously	O
performed	O
in	O
193	O
Japanese	O
RP	B-DISEASE
families	O
[	O
11	O
]	O
.	O

COL4A4	B-GENE
c	B-VARIANT
.	I-VARIANT
G2636A	I-VARIANT
,	O
a	O
novel	O
variant	O
,	O
co	O
-	O
segregated	O
with	O
renal	B-DISEASE
disease	I-DISEASE
among	O
maternal	O
relatives	O
.	O

Major	O
bleeding	O
is	O
of	O
primary	O
concern	O
in	O
patients	O
receiving	O
heparin	B-Chemical
therapy	O
.	O

An	O
increase	O
in	O
TDR	O
by	O
dl	O
-	O
sotalol	B-Chemical
facilitated	O
transmural	O
propagation	O
of	O
EADs	B-DISEASE
that	O
initiated	O
multiple	O
episodes	O
of	O
spontaneous	O
TdP	B-DISEASE
in	O
3	O
of	O
6	O
rabbit	O
left	O
ventricles	O
.	O

The	O
authors	O
present	O
three	O
patients	O
with	O
de	O
novo	O
absence	B-DISEASE
epilepsy	I-DISEASE
after	O
administration	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
.	O

p	B-VARIANT
.	I-VARIANT
C759F	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
C3267R	I-VARIANT
were	O
already	O
described	O
by	O
others	O
authors	O
as	O
damaging	O
[	O
https	O
:	O
/	O
/	O
grenada	O
.	O
lumc	O
.	O
nl	O
/	O
LOVD2	O
/	O
Usher_montpellier	O
,	O
[	O
35	O
]	O
]	O
.	O

These	O
two	O
mutations	O
occur	O
at	O
an	O
evolutionarily	O
conserved	O
nucleotide	B-Chemical
or	O
amino	B-Chemical
acid	O
(	O
in	O
red	O
)	O
.	O

(	O
XLSX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Residues	O
associated	O
with	O
known	O
gain	O
of	O
function	O
mutations	O
in	O
human	O
diseases	O
14	O
-	O
17	O
,	O
22	O
are	O
marked	O
in	O
purple	O
.	O

The	O
aspect	O
of	O
IF	O
inclusions	O
according	O
to	O
the	O
localization	O
of	O
the	O
mutation	O
is	O
presented	O
in	O
Figure	O
3	O
.	O

Objectives	O
of	O
the	O
current	O
study	O
were	O
to	O
compare	O
results	O
between	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
strains	O
when	O
ASA	B-Chemical
is	O
administered	O
on	O
GD	O
9	O
,	O
10	O
,	O
or	O
11	O
;	O
to	O
compare	O
the	O
malformation	O
patterns	O
following	O
single	O
and	O
multiple	O
dosings	O
during	O
organogenesis	O
in	O
SD	O
rats	O
;	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
maternal	O
gastrointestinal	O
toxicity	O
confounds	O
the	O
detection	O
of	O
low	O
incidence	O
malformations	O
with	O
ASA	B-Chemical
when	O
a	O
multiple	O
dosing	O
paradigm	O
is	O
used	O
.	O

All	O
CNV	O
deletion	O
events	O
were	O
annotated	O
to	O
identify	O
those	O
overlapping	O
coding	O
exons	O
and	O
those	O
that	O
were	O
intronic	O
,	O
intergenic	O
,	O
or	O
affected	O
UTR	O
exons	O
were	O
removed	O
.	O

If	O
we	O
take	O
into	O
account	O
the	O
remaining	O
32	O
USH	B-DISEASE
cases	O
analyzed	O
,	O
we	O
identified	O
in	O
22	O
patients	O
the	O
two	O
expected	O
mutated	O
alleles	O
,	O
in	O
5	O
cases	O
only	O
one	O
pathogenic	O
variant	O
and	O
in	O
one	O
case	O
,	O
RP	O
-	O
1950	O
,	O
two	O
pathogenic	O
variants	O
were	O
detected	O
in	O
two	O
different	O
USH2	B-DISEASE
genes	O
.	O

All	O
the	O
identified	O
mutations	O
were	O
confirmed	O
in	O
the	O
patients	O
and	O
their	O
extended	O
families	O
using	O
Sanger	O
sequencing	O
and	O
all	O
segregated	O
with	O
the	O
disease	O
phenotype	O
(	O
Tables	O
S2	O
and	O
S3	O
)	O
.	O

About	O
70	O
%	O
of	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
non	O
-	O
syndromic	O
,	O
wherein	O
hearing	B-DISEASE
impairment	I-DISEASE
is	O
not	O
associated	O
with	O
any	O
additional	O
clinical	O
phenotype	O
.	O

After	O
the	O
OPA1	B-GENE
gene	O
was	O
sequenced	O
,	O
a	O
previously	O
undescribed	O
heterozygous	O
splice	O
-	O
site	O
mutation	O
c	B-VARIANT
.	I-VARIANT
784	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
in	O
intron	O
7	O
was	O
detected	O
in	O
family	O
F2	O
.	O

2A	O
)	O
.	O

Plain	O
radiographs	O
of	O
our	O
patient	O
'	O
s	O
grandmother	O
(	O
A	O
)	O
and	O
father	O
(	O
B	O
)	O
show	O
end	O
-	O
stage	O
OA	B-DISEASE
,	O
while	O
a	O
radiograph	O
of	O
our	O
patient	O
'	O
s	O
mother	O
(	O
C	O
)	O
appears	O
almost	O
normal	O
.	O

Oral	O
administration	O
of	O
CBZ	B-Chemical
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuously	O
protective	O
against	O
HFDE	B-Chemical
-	O
induced	O
seizures	B-DISEASE
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	O
gain	O
over	O
8	O
weeks	O
of	O
treatment	O
.	O

(	O
g	O
,	O
i	O
)	O
Gene	O
gun	O
transfection	O
of	O
the	O
organ	O
of	O
Corti	O
hair	O
cells	O
with	O
CIB2	B-GENE
-	O
GFP	O
shows	O
predominant	O
targeting	O
of	O
CIB2	B-GENE
to	O
stereocilia	O
tips	O
,	O
particularly	O
to	O
the	O
tips	O
of	O
the	O
shorter	O
row	O
of	O
inner	O
(	O
g	O
)	O
and	O
outer	O
(	O
i	O
)	O
hair	O
cell	O
stereocilia	O
.	O

It	O
allows	O
direct	O
estimates	O
of	O
recurrence	O
risk	O
in	O
relatives	O
and	O
helps	O
family	O
planning	O
.	O

13	O
.	O
4	O
+	O
-	O
9	O
.	O
9	O
years	O
,	O
p	O
=	O
0	O
.	O
008	O
,	O
and	O
optic	B-DISEASE
atrophy	I-DISEASE
9	O
.	O
6	O
+	O
-	O
6	O
.	O
9	O
years	O
vs	O
.	O

She	O
underwent	O
liver	O
transplantation	O
with	O
an	O
uneventful	O
postoperative	O
course	O
.	O

1	O
)	O
,	O
also	O
had	O
treatment	O
pauses	O
(	O
range	O
,	O
2	O
to	O
6	O
months	O
)	O
but	O
they	O
did	O
not	O
display	O
evidence	O
for	O
reversal	O
,	O
and	O
were	O
therefore	O
restarted	O
on	O
TRT	O
due	O
to	O
symptoms	O
of	O
hypogonadism	B-DISEASE
and	O
low	B-DISEASE
serum	I-DISEASE
reproductive	I-DISEASE
hormone	I-DISEASE
values	I-DISEASE
.	O

Nevertheless	O
,	O
the	O
C	O
-	O
terminus	O
region	O
of	O
Twinkle	O
harbours	O
the	O
Walker	O
A	O
and	O
B	O
motifs	O
and	O
the	O
DNA	O
binding	O
loops	O
:	O
these	O
domains	O
are	O
very	O
well	O
conserved	O
across	O
species	O
because	O
of	O
their	O
critical	O
importance	O
for	O
the	O
protein	O
function	O
;	O
therefore	O
a	O
mutation	O
occurring	O
in	O
this	O
region	O
might	O
affect	O
not	O
only	O
the	O
structure	O
but	O
also	O
directly	O
target	O
the	O
functionality	O
of	O
the	O
enzyme	O
.	O

DESIGN	O
:	O
Randomized	O
double	O
-	O
blind	O
controlled	O
trial	O
.	O

For	O
a	O
certificate	O
,	O
please	O
see	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
textcheck	O
.	O
com	O
/	O
certificate	O
/	O
sTwy8P	O
.	O
*	O
Both	O
of	O
them	O
equally	O
contributed	O
to	O
this	O
study	O
as	O
the	O
first	O
author	O
.	O

INTRODUCTION	O
:	O
Confusion	O
is	O
an	O
adverse	O
drug	O
reaction	O
frequently	O
observed	O
with	O
valproic	B-Chemical
acid	I-Chemical
.	O

Several	O
recently	O
developed	O
mouse	O
lines	O
with	O
human	O
mutations	O
on	O
Tecta	B-GENE
provide	O
extremely	O
useful	O
information	O
for	O
understanding	O
the	O
mechanism	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
affected	O
families	O
[	O
17	O
-	O
19	O
]	O
.	O

New	O
mutations	O
detected	O
in	O
this	O
study	O
extend	O
the	O
allelic	O
heterogeneity	O
of	O
the	O
genes	O
and	O
provide	O
several	O
additional	O
variants	O
for	O
structure	O
-	O
function	O
correlation	O
studies	O
.	O

The	O
incidence	O
of	O
cardiovascular	B-DISEASE
adverse	I-DISEASE
events	O
tends	O
to	O
increase	O
with	O
the	O
daily	O
dose	O
and	O
total	O
exposure	O
time	O
.	O

Environmental	O
factors	O
such	O
as	O
drugs	O
with	O
mitochondrial	O
toxicity	O
could	O
also	O
be	O
involved	O
in	O
the	O
penetrance	O
and	O
expressivity	O
of	O
the	O
disease	O
.	O

Morphologic	O
damage	O
was	O
variable	O
but	O
was	O
proportional	O
to	O
the	O
total	O
cumulative	O
DXR	B-Chemical
dose	O
between	O
100	O
and	O
600	O
mg	O
/	O
m2	O
.	O

Variants	O
in	O
our	O
cohort	O
(	O
red	O
)	O
occur	O
at	O
residues	O
distal	O
to	O
the	O
DNA	O
binding	O
site	O
except	O
for	O
Arg	O
283	O
(	O
green	O
)	O
.	O

(	O
B	O
)	O
ACS	O
-	O
dependent	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
transfected	O
HEK293FT	O
cells	O
.	O

Given	O
its	O
large	O
capacity	O
to	O
survey	O
the	O
entire	O
genome	O
without	O
bias	O
,	O
NGS	O
is	O
suited	O
for	O
discovering	O
the	O
causative	O
mutations	O
of	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
genetic	O
heterogeneity	O
.	O

It	O
has	O
been	O
hypothesized	O
that	O
mutations	O
identified	O
in	O
patients	O
with	O
USH2	B-DISEASE
result	O
in	O
complete	O
inactivation	O
of	O
the	O
corresponding	O
mutant	O
protein	O
whereas	O
patients	O
with	O
non	O
-	O
syndromic	O
RP	B-DISEASE
can	O
also	O
carry	O
severe	O
mutations	O
,	O
but	O
never	O
in	O
both	O
alleles	O
[	O
37	O
]	O
.	O

Supine	B-DISEASE
blood	I-DISEASE
pressure	I-DISEASE
was	O
reduced	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
170	O
+	O
/	O
-	O
20	O
/	O
102	O
+	O
/	O
-	O
6	O
mmHg	O
to	O
153	O
+	O
/	O
-	O
19	O
/	O
92	O
+	O
/	O
-	O
8	O
,	O
147	O
+	O
/	O
-	O
18	O
/	O
88	O
+	O
/	O
-	O
7	O
and	O
144	O
+	O
/	O
-	O
14	O
/	O
87	O
+	O
/	O
-	O
6	O
mmHg	O
at	O
2	O
,	O
4	O
and	O
6	O
weeks	O
respectively	O
in	O
evaluable	O
patients	O
.	O

CGT	O
should	O
be	O
considered	O
for	O
the	O
latter	O
cohort	O
of	O
patients	O
.	O

DISCUSSION	O
:	O
The	O
clinical	O
and	O
histologic	O
picture	O
of	O
this	O
case	O
resembles	O
halothane	B-DISEASE
hepatitis	I-DISEASE
,	O
which	O
has	O
a	O
significant	O
mortality	O
rate	O
.	O

In	O
the	O
remaining	O
eight	O
families	O
,	O
none	O
of	O
the	O
detected	O
variants	O
co	O
-	O
segregated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
pedigrees	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
our	O
cohort	O
of	O
patients	O
,	O
we	O
identified	O
different	O
pathogenic	O
variants	O
and	O
some	O
putative	O
splicing	O
mutations	O
in	O
USH1	B-DISEASE
genes	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
,	O
[	O
18	O
]	O
.	O

Gene	O
mutation	O
of	O
genetic	B-DISEASE
skeletal	I-DISEASE
disorders	I-DISEASE
published	O
in	O
Chinese	O
biomedical	O
literature	O
from	O
1978	O
to	O
2012	O
*	O
*	O
:	O
"	O
Pedigree	O
mutation	O
"	O
,	O
that	O
is	O
an	O
identical	O
mutation	O
has	O
been	O
reported	O
in	O
more	O
than	O
one	O
affected	O
siblings	O
in	O
a	O
family	O
,	O
was	O
counted	O
as	O
one	O
case	O
.	O

(	O
B	O
)	O
The	O
superimposed	O
structures	O
between	O
the	O
wild	O
-	O
type	O
TBX1	B-GENE
(	O
cyan	O
)	O
and	O
the	O
TBX1	B-GENE
E129K	B-VARIANT
(	O
grey	O
)	O
and	O
the	O
carbon	O
atoms	O
from	O
E129	B-Chemical
and	O
its	O
mutant	O
K129	B-Chemical
are	O
colored	O
in	O
green	O
and	O
yellow	O
,	O
respectively	O
,	O
and	O
the	O
conformations	O
are	O
extracted	O
from	O
the	O
end	O
of	O
the	O
5	O
-	O
ns	O
simulations	O
.	O

Reversal	O
to	O
normal	O
heart	O
rate	O
was	O
found	O
on	O
day	O
7	O
.	O

Associate	O
Professor	O
Peder	O
Madsen	O
kindly	O
generated	O
and	O
provided	O
pcSECTAG2bzeo	O
constructs	O
with	O
CD164	B-GENE
CTRs	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

The	O
defensin	B-Chemical
cluster	O
,	O
containing	O
both	O
alpha	O
-	O
and	O
beta	O
-	O
defensins	O
,	O
was	O
previously	O
studied	O
as	O
a	O
dynamic	O
genomic	O
region	O
with	O
varying	O
copy	O
numbers	O
ranging	O
from	O
one	O
to	O
twelve	O
[	O
19	O
]	O
.	O

Before	O
treatment	O
all	O
patients	O
had	O
a	O
cardiac	O
evaluation	O
and	O
during	O
treatment	O
serial	O
ECG	O
recordings	O
were	O
performed	O
.	O

The	O
average	O
age	O
of	O
onset	O
of	O
other	O
patients	O
is	O
0	O
.	O
97	O
+	O
-	O
1	O
.	O
42	O
.	O

The	O
incidence	O
of	O
non	O
-	O
hematological	O
toxicities	O
was	O
low	O
and	O
grade	O
3	O
-	O
4	O
hematological	O
toxicities	O
were	O
reported	O
in	O
20	O
patients	O
(	O
mainly	O
lymphopenia	B-DISEASE
and	O
neutropenia	B-DISEASE
)	O
.	O

*	O
highlights	O
pedigrees	O
that	O
have	O
been	O
abbreviated	O
for	O
this	O
figure	O
.	O

Developmental	O
/	O
behavioral	O
problems	O
are	O
common	O
in	O
patients	O
with	O
RSTS	B-DISEASE
,	O
with	O
the	O
most	O
typical	O
symptoms	O
being	O
moderate	O
to	O
severe	O
mental	B-DISEASE
retardation	I-DISEASE
and	O
language	B-DISEASE
impairment	I-DISEASE
[	O
8	O
,	O
18	O
]	O
.	O

All	O
patients	O
presented	O
with	O
mixed	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Performed	O
the	O
experiments	O
:	O
TJJ	O
EMR	O
AAI	O
APJG	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
cilium	O
in	O
photoreceptors	O
appears	O
ultrastructurally	O
and	O
molecularly	O
very	O
similar	O
to	O
the	O
nasal	O
ciliated	O
epithelium	O
.	O

Isoniazid	B-Chemical
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug	O
-	O
induced	O
neuropathy	B-DISEASE
.	O

I2084fs	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
9492_9498del	I-VARIANT
TGATGAT	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

The	O
mixture	O
was	O
then	O
added	O
to	O
cells	O
in	O
DMEM	O
medium	O
that	O
contained	O
2	O
%	O
FBS	O
and	O
grown	O
for	O
two	O
days	O
.	O

BACKGROUND	O
:	O
The	O
interruption	O
of	O
oral	O
anticoagulant	O
(	O
OAC	O
)	O
administration	O
is	O
sometimes	O
indicated	O
in	O
patients	O
with	O
mechanical	O
heart	O
valves	O
,	O
mainly	O
before	O
noncardiac	O
surgery	O
,	O
non	O
-	O
surgical	O
interventions	O
,	O
and	O
pregnancy	O
.	O

A	O
comparison	O
of	O
severe	O
hemodynamic	O
disturbances	O
between	O
dexmedetomidine	B-Chemical
and	O
propofol	B-Chemical
for	O
sedation	O
in	O
neurocritical	O
care	O
patients	O
.	O

Examination	O
of	O
blood	O
smears	O
revealed	O
giant	B-DISEASE
platelets	I-DISEASE
and	O
D	O
o	O
hle	O
-	O
like	O
inclusion	O
bodies	O
.	O

All	O
of	O
the	O
above	O
studies	O
focused	O
on	O
patients	O
with	O
EVA	B-DISEASE
or	O
Pendred	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
deletion	O
segregates	O
with	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
pedigree	O
and	O
was	O
not	O
observed	O
in	O
500	O
control	O
chromosomes	O
.	O

Ocular	O
data	O
of	O
patients	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
1220delG	I-VARIANT
USH1C	B-GENE
gene	O
mutation	O
.	O

*	O
Higher	O
efficiency	O
percentages	O
are	O
obtained	O
when	O
few	O
families	O
or	O
cases	O
are	O
analysed	O
.	O

The	O
electrocardiogram	O
revealed	O
a	O
37	O
beats	O
/	O
min	O
sinus	O
bradycardia	O
.	O

Use	O
of	O
gastroprotective	O
agents	O
and	O
low	O
-	O
dose	O
aspirin	B-Chemical
was	O
allowed	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
shown	O
that	O
family	O
-	O
selective	O
inhibition	O
of	O
PDE	O
(	O
PDE1	O
,	O
PDE3	O
and	O
to	O
some	O
extent	O
also	O
PDE4	O
)	O
potentiates	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
(	O
GSIS	O
)	O
;	O
in	O
particular	O
,	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
PDE4C	B-GENE
significantly	O
enhanced	O
GSIS	O
in	O
rat	O
INS	O
-	O
1	O
(	O
832	O
/	O
13	O
)	O
cells	O
[	O
45	O
]	O
.	O

Transcriptional	O
activation	O
of	O
luciferase	O
reporter	O
constructs	O
by	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
TBX1	B-GENE
.	O

,	O
2013	O
)	O
.	O

18	O
In	O
this	O
respect	O
,	O
families	O
1	O
and	O
2	O
were	O
distinctive	O
in	O
their	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
which	O
may	O
be	O
an	O
indication	O
that	O
it	O
is	O
associated	O
with	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O

Cyclooxygenase	B-Chemical
inhibitors	I-Chemical
cause	O
complex	O
changes	O
in	O
renal	O
,	O
vascular	O
and	O
cardiac	O
prostanoid	O
profiles	O
thereby	O
increasing	O
vascular	O
resistance	O
and	O
fluid	O
retention	O
.	O

,	O
2008	O
)	O
;	O
IT	O
-	O
5	O
:	O
(	O
Amati	O
-	O
Bonneau	O
et	O
al	O
.	O

Analyzed	O
the	O
data	O
:	O
BYC	O
JK	O
JC	O
SJM	O
SIK	O
.	O

The	O
melting	O
temperature	O
used	O
to	O
amplify	O
these	O
fragments	O
was	O
55	O
deg	O
C	O
.	O

Intramuscular	O
HBIg	O
was	O
well	O
tolerated	O
in	O
all	O
patients	O
.	O

A	O
case	O
of	O
a	O
busulfan	B-Chemical
-	O
induced	O
hemorrhage	B-DISEASE
cystitis	I-DISEASE
is	O
reported	O
.	O

The	O
arginine	B-Chemical
at	O
residue	O
702	O
is	O
also	O
a	O
conserved	O
amino	O
acid	O
,	O
as	O
previously	O
reported	O
for	O
other	O
two	O
mutations	O
hitting	O
the	O
same	O
residue	O
,	O
p	B-VARIANT
.	I-VARIANT
Arg702Cys	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Arg702His	I-VARIANT
[	O
2	O
,	O
7	O
]	O
.	O

Macular	O
region	O
is	O
not	O
affected	O
in	O
both	O
eyes	O
.	O

This	O
indicates	O
that	O
hearing	B-DISEASE
impairment	I-DISEASE
associated	O
with	O
TMPRSS3	B-GENE
mutations	O
cannot	O
be	O
explained	O
by	O
inactive	O
ENaC	O
.	O

Emphasis	O
was	O
placed	O
on	O
bedside	O
clinical	O
monitoring	O
,	O
relying	O
heavily	O
on	O
the	O
heart	O
rate	O
.	O

Captured	O
PCR	O
products	O
were	O
subjected	O
to	O
Agilent	O
2100	O
Bioanalyzer	O
to	O
evaluate	O
the	O
magnitude	O
of	O
enrichment	O
.	O

However	O
,	O
we	O
also	O
found	O
a	O
homozygous	O
genotype	O
in	O
1	O
of	O
3	O
,	O
027	O
internal	O
controls	O
not	O
known	O
to	O
have	O
DPD	B-DISEASE
deficiency	I-DISEASE
.	O

Upon	O
omission	O
of	O
the	O
primary	O
antibody	O
no	O
immunostaining	O
can	O
be	O
seen	O
,	O
which	O
demonstrates	O
the	O
specificity	O
of	O
the	O
OSBPL2	B-GENE
antibody	O
(	O
inset	O
)	O
.	O

c	B-VARIANT
.	I-VARIANT
2868	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
detected	O
in	O
the	O
heterozygous	O
state	O
in	O
patient	O
RP	B-DISEASE
-	O
1323	O
,	O
who	O
is	O
also	O
a	O
carrier	O
of	O
a	O
nonsense	O
mutation	O
,	O
and	O
variant	O
c	B-VARIANT
.	I-VARIANT
3717	I-VARIANT
+	I-VARIANT
2dupT	I-VARIANT
was	O
found	O
homozygously	O
in	O
patient	O
RP	B-DISEASE
-	O
219	O
.	O

Enrichment	O
of	O
exonic	O
sequences	O
was	O
achieved	O
by	O
using	O
the	O
50	O
Mb	O
human	O
SureSelect	O
set	O
(	O
Agilent	O
)	O
,	O
which	O
targets	O
~	O
21	O
,	O
000	O
human	O
genes	O
.	O

This	O
cDNA	O
was	O
used	O
as	O
a	O
template	O
for	O
HOMER2	B-GENE
capped	O
mRNA	O
synthesis	O
using	O
an	O
Ambion	O
mMESSAGE	O
mMACHINE	O
SP6	O
kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
the	O
product	O
was	O
tested	O
for	O
quality	O
and	O
yield	O
by	O
electrophoresis	O
and	O
spectroscopy	O
(	O
NanoDrop	O
Thermo	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
before	O
injection	O
.	O

Open	O
Access	O
:	O
This	O
is	O
an	O
Open	O
Access	O
article	O
distributed	O
in	O
accordance	O
with	O
the	O
Creative	O
Commons	O
Attribution	O
Non	O
Commercial	O
(	O
CC	O
BY	O
-	O
NC	O
3	O
.	O
0	O
)	O
license	O
,	O
which	O
permits	O
others	O
to	O
distribute	O
,	O
remix	O
,	O
adapt	O
,	O
build	O
upon	O
this	O
work	O
non	O
-	O
commercially	O
,	O
and	O
license	O
their	O
derivative	O
works	O
on	O
different	O
terms	O
,	O
provided	O
the	O
original	O
work	O
is	O
properly	O
cited	O
and	O
the	O
use	O
is	O
non	O
-	O
commercial	O
.	O

Analysis	O
of	O
the	O
parents	O
'	O
DNA	O
showed	O
that	O
the	O
silent	O
variant	O
was	O
inherited	O
from	O
the	O
father	O
and	O
the	O
missense	O
change	O
from	O
the	O
mother	O
.	O

If	O
that	O
indeed	O
was	O
the	O
case	O
in	O
individual	O
E10	O
,	O
the	O
threshold	O
levels	O
at	O
around	O
9	O
years	O
of	O
age	O
would	O
suggest	O
an	O
average	O
progression	O
of	O
about	O
10	O
dB	O
/	O
year	O
at	O
2	O
-	O
8	O
kHz	O
.	O

The	O
PAX3	B-GENE
protein	O
is	O
a	O
member	O
of	O
the	O
family	O
of	O
paired	O
domain	O
proteins	O
that	O
bind	O
DNA	O
and	O
regulate	O
gene	O
expression	O
[	O
7	O
]	O
.	O

B	O
.	O

In	O
the	O
European	O
population	O
,	O
20	O
-	O
40	O
%	O
of	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
NSHL	B-DISEASE
)	O
is	O
due	O
to	O
mutations	O
in	O
GJB2	B-GENE
(	O
MIM	O
:	O
121011	O
)	O
and	O
GJB6	B-GENE
(	O
MIM	O
:	O
604418	O
)	O
,	O
together	O
comprising	O
the	O
DFNB1	O
locus	O
(	O
2	O
)	O
.	O

Mitochondria	O
supply	O
most	O
of	O
the	O
cellular	O
adenosine	B-Chemical
triphosphate	I-Chemical
(	O
ATP	B-Chemical
)	O
requirements	O
through	O
oxidative	O
phosphorylation	O
,	O
a	O
process	O
that	O
involves	O
five	O
protein	O
complexes	O
located	O
along	O
the	O
inner	O
mitochondrial	O
membrane	O
.	O

Summary	O
of	O
mutations	O
in	O
various	O
known	O
deafness	B-DISEASE
genes	O
identified	O
in	O
ARNSHL	B-DISEASE
patients	O
from	O
Saudi	O
Arabia	O
.	O

Yet	O
,	O
we	O
showed	O
gain	O
-	O
of	O
-	O
function	O
effects	O
for	O
both	O
identified	O
mutations	O
strengthening	O
the	O
notion	O
that	O
mutations	O
in	O
KCNE1	B-GENE
are	O
associated	O
with	O
AF	B-DISEASE
.	O

None	O
of	O
the	O
four	O
missense	O
mutations	O
resulted	O
in	O
noticeable	O
changes	O
of	O
CIB2	B-GENE
distribution	O
(	O
not	O
shown	O
)	O
.	O

No	O
.	O

Later	O
Akawi	O
et	O
al	O
20	O
characterised	O
two	O
families	O
who	O
both	O
had	O
biallelic	O
null	O
mutations	O
.	O

Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	B-Chemical
and	O
haloperidol	B-Chemical
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B-DISEASE
symptoms	I-DISEASE
.	O

GPN	O
participated	O
in	O
the	O
conception	O
and	O
design	O
of	O
the	O
study	O
,	O
carried	O
out	O
of	O
the	O
genetic	O
studies	O
,	O
analysis	O
data	O
,	O
revised	O
critically	O
and	O
made	O
major	O
contribution	O
to	O
the	O
manuscript	O
.	O

NR	O
=	O
Non	O
Recordable	O
;	O
ND	O
=	O
Not	O
done	O
;	O
In	O
patients	O
II	O
-	O
1	O
and	O
II	O
-	O
4	O
electroretinographic	O
responses	O
were	O
largely	O
symmetric	O
,	O
so	O
presented	O
as	O
average	O
of	O
the	O
two	O
eyes	O
.	O

Even	O
within	O
the	O
protein	O
coding	O
portion	O
of	O
the	O
genome	O
,	O
each	O
person	O
carries	O
an	O
estimated	O
400	O
-	O
500	O
protein	O
-	O
modifying	O
rare	O
variants	O
35	O
,	O
36	O
.	O

We	O
investigated	O
the	O
efficacy	O
and	O
toxicity	O
of	O
a	O
3	O
-	O
hour	O
paclitaxel	B-Chemical
infusion	O
in	O
a	O
phase	O
II	O
trial	O
in	O
patients	O
with	O
inoperable	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	B-DISEASE
.	O

Data	O
on	O
1511	O
independent	O
probands	O
and	O
1545	O
family	O
members	O
were	O
collected	O
from	O
33	O
ear	O
,	O
nose	O
and	O
throat	O
departments	O
nationwide	O
in	O
Japan	O
and	O
registered	O
in	O
our	O
gene	O
bank	O
.	O

Hypopigmented	O
patches	O
of	O
the	O
skin	O
were	O
present	O
in	O
only	O
one	O
patient	O
(	O
III	O
:	O
9	O
;	O
Table	O
2	O
)	O
.	O

Adverse	O
ocular	O
reactions	O
possibly	O
associated	O
with	O
isotretinoin	B-Chemical
.	O

No	O
significant	O
differences	O
in	O
GJB2	B-GENE
detection	O
rate	O
were	O
found	O
among	O
these	O
four	O
ethnic	O
groups	O
(	O
chi	O
2	O
=	O
2	O
.	O
4893	O
,	O
P	O
=	O
0	O
.	O
4772	O
)	O
.	O

YC	B-Chemical
and	O
LL	O
performed	O
the	O
auditory	O
evaluation	O
and	O
other	O
laboratory	O
experiments	O
.	O

This	O
interval	O
contains	O
the	O
USH1G	B-GENE
gene	O
.	O

The	O
black	O
line	O
indicates	O
2	O
SD	O
for	O
the	O
normalized	O
coverage	O
per	O
exon	O
that	O
is	O
based	O
on	O
all	O
samples	O
.	O

Detection	O
of	O
mutations	O
in	O
COL4A5	B-GENE
gene	O
in	O
males	O
with	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
AS	I-DISEASE
can	O
be	O
up	O
to	O
95	O
%	O
using	O
contemporary	O
techniques	O
[	O
5	O
]	O
.	O

Changes	O
in	O
depressive	B-DISEASE
status	O
associated	O
with	O
topical	O
beta	O
-	O
blockers	O
.	O

Rabbit	B-DISEASE
syndrome	I-DISEASE
(	O
RS	B-DISEASE
)	O
is	O
a	O
rare	O
extrapyramidal	O
side	O
effect	O
caused	O
by	O
prolonged	O
neuroleptic	B-DISEASE
medication	O
.	O

For	O
PhyloP	O
prediction	O
,	O
C	O
:	O
Conserved	O
,	O
NC	O
:	O
Not	O
conserved	O
.	O

Recently	O
,	O
two	O
spontaneous	O
mutations	O
(	O
rda	O
and	O
rda	O
2J	O
)	O
in	O
mouse	O
Elmod1	B-GENE
were	O
shown	O
to	O
result	O
in	O
profound	O
deafness	B-DISEASE
and	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
[	O
7	O
]	O
,	O
demonstrating	O
that	O
the	O
function	O
of	O
ELMOD1	B-GENE
is	O
essential	O
for	O
regulating	O
the	O
shape	O
and	O
maintenance	O
of	O
inner	O
ear	O
hair	O
cell	O
stereocilia	O
in	O
mice	O
[	O
7	O
]	O
.	O

The	O
KCNQ4	B-GENE
gene	O
,	O
which	O
encodes	O
the	O
voltage	O
-	O
gated	O
potassium	O
channel	O
KCNQ4	B-GENE
in	O
outer	O
hair	O
cells	O
,	O
has	O
been	O
identified	O
at	O
the	O
ADNSHL	B-DISEASE
DFNA2	B-DISEASE
locus	O
on	O
the	O
human	O
chromosome	O
1p34	O
[	O
37	O
]	O
.	O

Two	O
-	O
point	O
and	O
multi	O
-	O
point	O
logarithm	O
of	O
odds	O
(	O
LOD	O
)	O
scores	O
were	O
calculated	O
by	O
SuperLink	O
ver	O
.	O

In	O
Finland	O
,	O
at	O
least	O
40	O
%	O
of	O
patients	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
display	O
type	O
3	O
whereas	O
USH1	B-DISEASE
accounts	O
for	O
34	O
%	O
of	O
cases	O
,	O
and	O
USH2	B-DISEASE
represents	O
only	O
12	O
%	O
[	O
17	O
]	O
.	O

Low	O
quality	O
of	O
reads	O
(	O
<	O
20	O
)	O
and	O
genotyping	O
(	O
<	O
30	O
)	O
were	O
then	O
ruled	O
out	O
.	O

The	O
box	O
indicates	O
this	O
mutated	O
residue	O
in	O
USH2A	B-GENE
.	O

Effect	O
of	O
ketamine	B-Chemical
on	O
the	O
SA	O
node	O
of	O
the	O
dog	O
heart	O
was	O
studied	O
in	O
vivo	O
using	O
a	O
selective	O
perfusion	O
technique	O
of	O
the	O
SA	O
node	O
artery	O
.	O

To	O
further	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
XLAS	B-DISEASE
,	O
a	O
multidisciplinary	O
strategy	O
is	O
recommended	O
.	O

The	O
amplicons	O
from	O
individual	O
exons	O
were	O
purified	O
and	O
analyzed	O
with	O
cycle	O
sequencing	O
with	O
ABI	O
BigDye	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
v3	O
.	O
1	O
(	O
ABI	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
on	O
an	O
automatic	O
DNA	O
sequencer	O
(	O
ABI	O
3130	O
Genetic	O
Analyzer	O
,	O
Applied	O
Biosystems	O
)	O
.	O

The	O
heparin	B-Chemical
-	O
induced	O
platelet	O
aggregation	O
test	O
was	O
negative	O
in	O
these	O
patients	O
.	O

RESULTS	O
:	O
Impairment	B-DISEASE
of	O
cognitive	O
function	O
was	O
observed	O
6	O
to	O
8	O
hours	O
after	O
administration	O
of	O
haloperidol	B-Chemical
on	O
Day	O
2	O
but	O
was	O
not	O
evident	O
23	O
hours	O
after	O
dosing	O
.	O

The	O
information	O
obtained	O
in	O
this	O
study	O
may	O
facilitate	O
future	O
genetic	O
and	O
molecular	O
investigations	O
leading	O
to	O
a	O
clearer	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
WFS	B-DISEASE
and	O
ultimately	O
to	O
improvements	O
in	O
prevention	O
strategies	O
as	O
well	O
as	O
treatments	O
for	O
this	O
devastating	O
disease	O
.	O

In	O
conclusion	O
,	O
we	O
confirmed	O
that	O
two	O
transcription	O
factors	O
in	O
87	O
Korean	O
patients	O
caused	O
autosomal	B-DISEASE
dominant	I-DISEASE
NSHL	I-DISEASE
.	O

Sequencing	O
of	O
the	O
~	O
430	O
bp	O
product	O
confirmed	O
that	O
the	O
cryptic	O
splice	O
donor	O
within	O
exon	O
IIIc	O
was	O
preferred	O
in	O
the	O
mutant	O
allele	O
(	O
Figure	O
2	O
D	O
)	O
,	O
while	O
the	O
~	O
330	O
bp	O
product	O
demonstrated	O
complete	O
skipping	O
of	O
exon	O
IIIc	O
(	O
Figure	O
2	O
E	O
)	O
.	O

In	O
DEN	B-Chemical
+	O
PB	B-Chemical
treated	O
rats	O
,	O
the	O
survival	O
was	O
prolonged	O
and	O
the	O
tumor	O
incidence	O
decreased	O
as	O
compared	O
with	O
the	O
results	O
obtained	O
by	O
DEN	B-Chemical
alone	O
.	O

Autosomal	O
recessive	O
(	O
AR	O
)	O
mode	O
of	O
inheritance	O
,	O
complete	O
penetrance	O
,	O
disease	O
-	O
allele	O
frequency	O
of	O
0	O
.	O
001	O
,	O
existence	O
of	O
no	O
phenocopy	O
,	O
equal	O
allele	O
frequencies	O
for	O
markers	O
and	O
identical	O
meiotic	O
recombination	O
frequencies	O
in	O
both	O
sexes	O
were	O
assumed	O
for	O
LOD	O
score	O
calculations	O
.	O

Alterations	O
in	O
hepatocyte	O
TJs	O
were	O
assessed	O
by	O
double	O
-	O
immunolabeling	O
for	O
7H6	B-GENE
and	O
ZO	O
-	O
1	O
using	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
significantly	O
alleviated	O
morphine	B-Chemical
-	O
induced	O
amnesia	B-DISEASE
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	B-Chemical
-	O
treated	O
animals	O
.	O

These	O
findings	O
suggest	O
that	O
not	O
only	O
missense	O
mutation	O
but	O
also	O
in	O
frame	O
-	O
deletion	O
preserving	O
a	O
terminal	O
abnormal	O
transcript	O
,	O
could	O
lead	O
to	O
the	O
extraneurological	O
features	O
observed	O
in	O
OPA1	B-DISEASE
-	I-DISEASE
plus	I-DISEASE
patients	O
[	O
6	O
,	O
7	O
]	O
.	O

Glomerular	B-DISEASE
MH	I-DISEASE
during	O
early	O
childhood	O
is	O
a	O
common	O
feature	O
of	O
a	O
heterogeneous	O
group	O
of	O
inherited	B-DISEASE
hematuric	I-DISEASE
nephropathies	I-DISEASE
.	O

Pro88del	I-VARIANT
)	O
.	O

,	O
2005	O
)	O
;	O
FR	O
-	O
6	O
,	O
FR	O
-	O
7	O
,	O
FR	O
-	O
8	O
:	O
(	O
Amati	O
-	O
Bonneau	O
et	O
al	O
.	O

The	O
other	O
six	O
probable	O
pathogenic	O
variants	O
were	O
novel	O
:	O
2	O
nonsense	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
W717X	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S1368X	I-VARIANT
)	O
and	O
4	O
missense	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
D450E	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R1583H	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
V1778I	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT

RNA	O
prepared	O
from	O
either	O
transfected	O
or	O
patients	O
'	O
cells	O
was	O
analysed	O
by	O
reverse	O
transcription	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
as	O
previously	O
described	O
.	O

This	O
generated	O
a	O
total	O
of	O
3	O
.	O
8	O
Gb	O
of	O
sequence	O
.	O

Individuals	O
II	O
:	O
3	O
,	O
II	O
:	O
4	O
,	O
II	O
:	O
5	O
,	O
II	O
:	O
6	O
have	O
a	O
moderate	O
to	O
severe	O
form	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
(	O
Figure	O
1B	O
)	O
.	O

The	O
three	O
amino	O
acids	O
at	O
the	O
C	O
-	O
terminus	O
(	O
"	O
AKL	O
"	O
)	O
constitute	O
the	O
peroxisomal	O
targeting	O
signal	O
(	O
PTS	O
)	O
.	O

Hannover	O
Wistar	O
rats	O
were	O
dosed	O
with	O
1	O
.	O
25	O
mg	O
/	O
kg	O
DOX	B-Chemical
weekly	O
for	O
8	O
weeks	O
followed	O
by	O
a	O
4	O
week	O
off	O
-	O
dosing	O
"	O
recovery	O
"	O
period	O
.	O

The	O
proband	O
had	O
been	O
born	O
with	O
a	O
cleft	B-DISEASE
palate	I-DISEASE
and	O
subsequently	O
found	O
to	O
be	O
profoundly	O
deaf	O
with	O
no	O
recordable	O
response	O
from	O
the	O
left	O
ear	O
up	O
to	O
100	O
dB	O
and	O
only	O
a	O
barely	O
recordable	O
response	O
at	O
250	O
Hz	O
/	O
100	O
dB	O
for	O
the	O
right	O
ear	O
.	O

We	O
sequenced	O
all	O
ten	O
samples	O
for	O
all	O
three	O
collagen	O
IV	O
genes	O
,	O
COL4A3	B-GENE
/	I-GENE
A4	I-GENE
/	I-GENE
A5	I-GENE
.	O

A	O
method	O
for	O
the	O
measurement	O
of	O
tremor	B-DISEASE
,	O
and	O
a	O
comparison	O
of	O
the	O
effects	O
of	O
tocolytic	O
beta	O
-	O
mimetics	O
.	O

Finally	O
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	O
in	O
sick	O
preterm	O
children	O
as	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
of	O
delayed	O
onset	O
and	O
in	O
most	O
cases	O
bilateral	O
and	O
severe	O
.	O

The	O
platelet	O
count	O
was	O
significantly	O
lower	O
in	O
bleeders	O
than	O
in	O
nonbleeders	O
,	O
P	O
=	O
0	O
.	O
0036	O
,	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
for	O
the	O
platelet	O
size	O
between	O
the	O
two	O
groups	O
(	O
Fig	O
.	O

In	O
the	O
293	O
T	O
cell	O
line	O
,	O
the	O
variant	O
partially	O
loses	O
the	O
transactivation	O
on	O
reporter	O
with	O
the	O
conserved	O
half	O
-	O
T	O
sites	O
(	O
Figure	O
2	O
B	O
)	O
,	O
whereas	O
it	O
slightly	O
enhances	O
the	O
transactivation	O
in	O
the	O
COS7	O
cell	O
line	O
(	O
Figure	O
2	O
C	O
)	O
.	O

Results	O
showed	O
that	O
probe	O
signals	O
from	O
exons	O
23	O
to	O
32	O
of	O
the	O
USH2A	B-GENE
gene	O
(	O
see	O
the	O
x	O
-	O
axis	O
)	O
were	O
significantly	O
decreased	O
(	O
ratio	O
on	O
the	O
y	O
-	O
axis	O
is	O
about	O
0	O
.	O
5	O
)	O
indicating	O
the	O
presence	O
of	O
a	O
deletion	O
across	O
those	O
exons	O
in	O
patient	O
CF	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
molecular	O
findings	O
in	O
130	O
patients	O
referred	O
to	O
ESDN	O
,	O
which	O
includes	O
the	O
identification	O
of	O
novel	O
and	O
recurrent	O
mutations	O
in	O
over	O
100	O
patients	O
.	O

As	O
the	O
analysis	O
of	O
434	O
control	O
chromosomes	O
identified	O
this	O
variant	O
once	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
2367	I-VARIANT
+	I-VARIANT
23del	I-VARIANT
variant	O
could	O
be	O
presumably	O
classified	O
as	O
a	O
rare	O
indel	O
,	O
and	O
its	O
pathogenicity	O
remains	O
to	O
be	O
proved	O
.	O

The	O
Regional	O
Ethical	O
Review	O
Board	O
of	O
Ume	B-Chemical
a	O
University	O
approved	O
this	O
study	O
.	O

Metformin	B-Chemical
prevents	O
experimental	O
gentamicin	B-Chemical
-	I-DISEASE
induced	I-DISEASE
nephropathy	I-DISEASE
by	O
a	O
mitochondria	O
-	O
dependent	O
pathway	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
1548insG	I-VARIANT
mutation	O
resulted	O
in	O
a	O
premature	O
stop	O
codon	O
and	O
a	O
truncated	O
protein	O
with	O
only	O
526	O
amino	O
acid	O
residues	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
identify	O
the	O
involved	O
region	O
inside	O
/	O
outside	O
of	O
the	O
cochlea	O
by	O
identifying	O
the	O
responsible	O
gene	O
.	O

In	O
cases	O
of	O
bilateral	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
a	O
long	B-DISEASE
EKG	I-DISEASE
QT	I-DISEASE
interval	I-DISEASE
,	O
KCNQ1	B-GENE
/	O
KCNE1	B-GENE
was	O
sequenced	O
.	O

4	O
.	O

L	O
-	O
JW	O
reviewed	O
and	O
interpreted	O
the	O
results	O
,	O
drafted	O
and	O
revised	O
the	O
manuscript	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
TJJ	O
EMR	O
AAI	O
RAK	O
SaR	O
.	O

This	O
finding	O
,	O
which	O
concerns	O
six	O
out	O
of	O
24	O
patients	O
carrying	O
mutations	O
in	O
USH2	B-DISEASE
genes	O
,	O
calls	O
for	O
a	O
revision	O
of	O
the	O
USH2	B-DISEASE
clinical	O
features	O
.	O

Inherited	B-DISEASE
retinal	I-DISEASE
dystrophies	I-DISEASE
(	O
IRDs	B-DISEASE
)	O
comprise	O
a	O
group	O
of	O
monogenic	O
diseases	O
presenting	O
significant	O
clinical	O
and	O
genetic	O
heterogeneities	O
.	O

Mice	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injections	O
of	O
a	O
fixed	O
volume	O
/	O
g	O
body	O
weight	O
of	O
physiological	O
saline	O
carrier	O
with	O
or	O
without	O
caffeine	B-Chemical
in	O
doses	O
ranging	O
from	O
125	O
-	O
500	O
mg	O
/	O
kg	O
.	O

In	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
Usher	B-DISEASE
or	O
BOR	B-DISEASE
syndromes	I-DISEASE
,	O
the	O
diagnostic	O
rate	O
was	O
31	O
and	O
37	O
%	O
,	O
respectively	O
.	O

A	O
67	O
-	O
year	O
-	O
old	O
patient	O
,	O
with	O
primary	O
polymyositis	B-DISEASE
and	O
without	O
previous	O
evidence	O
of	O
liver	B-DISEASE
disease	I-DISEASE
,	O
developed	O
clinical	O
and	O
biochemical	O
features	O
of	O
severe	O
cholestasis	B-DISEASE
3	O
months	O
after	O
initiation	O
of	O
azathioprine	B-Chemical
therapy	O
.	O

Chronic	O
oral	O
CBZ	B-Chemical
inhibited	O
the	O
development	O
of	O
both	O
lidocaine	B-Chemical
-	O
and	O
cocaine	B-Chemical
-	O
induced	O
seizures	I-DISEASE
,	O
but	O
had	O
little	O
effect	O
on	O
the	O
fully	O
developed	O
local	O
anesthetic	I-DISEASE
seizures	I-DISEASE
.	O

In	O
those	O
cases	O
where	O
mutations	O
were	O
detected	O
,	O
we	O
performed	O
segregation	O
analysis	O
.	O

The	O
60	O
patients	O
plus	O
43	O
patient	O
controls	O
had	O
a	O
definite	O
diagnosis	O
of	O
isolated	O
CI	B-DISEASE
deficiency	I-DISEASE
,	O
based	O
on	O
spectrophotometric	O
enzyme	O
assays	O
interpreted	O
by	O
previously	O
described	O
criteria	O
5	O
,	O
42	O
.	O

Linkage	O
analysis	O
for	O
the	O
USH1B	B-GENE
and	O
USH1C	B-GENE
loci	O
in	O
the	O
family	O
FRP	B-Chemical
-	I-Chemical
284	I-Chemical
.	O

Verapamil	B-Chemical
withdrawal	O
as	O
a	O
possible	O
cause	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
a	O
hypertensive	B-DISEASE
woman	O
with	O
a	O
normal	O
coronary	O
angiogram	O
.	O

Abbreviations	O
:	O
RP	B-DISEASE
:	I-DISEASE
retinitis	B-DISEASE
pigmentosa	I-DISEASE
;	I-DISEASE
RPSP	B-DISEASE
:	I-DISEASE
RP	B-DISEASE
sine	I-DISEASE
pigmento	I-DISEASE
;	I-DISEASE
USH2	B-DISEASE
:	I-DISEASE
usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
2	I-DISEASE
;	I-DISEASE
Hom	O
:	O
homozygous	O
;	O
Het	O
:	O
heterozygous	O
;	O
NA	O
:	O
not	O
available	O
;	O
DA	O
:	O
damaging	O
;	O
T	O
:	O
tolerated	O
;	O
PD	O
:	O
probably	O
damaging	O
;	O
B	O
:	O
benign	O
;	O
DE	O
:	O
deleterious	O
.	O

Two	O
genes	O
,	O
KCNJ10	B-GENE
and	O
FOXI1	B-GENE
,	O
have	O
been	O
investigated	O
for	O
their	O
role	O
in	O
the	O
PDS	B-DISEASE
disease	O
spectrum	O
and	O
it	O
has	O
been	O
proposed	O
that	O
digenic	O
mutations	O
in	O
both	O
SLC26A4	B-GENE
and	O
either	O
FOXI1	B-GENE
or	O
KCNJ10	B-GENE
may	O
cause	O
Pendred	B-DISEASE
syndrome	I-DISEASE
[	O
19	O
,	O
21	O
]	O
.	O

A	O
single	O
novel	O
isocoding	O
variant	O
c	B-VARIANT
.	I-VARIANT
2112G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
localized	O
in	O
exon	O
8	O
,	O
was	O
identified	O
in	O
family	O
RP1600	O
,	O
but	O
a	O
deleterious	O
effect	O
on	O
splicing	O
was	O
not	O
predicted	O
with	O
in	O
silico	O
analyses	O
,	O
and	O
no	O
other	O
clear	O
mutation	O
was	O
detected	O
in	O
this	O
patient	O
.	O

Similar	O
analyses	O
to	O
those	O
reported	O
here	O
could	O
have	O
been	O
performed	O
with	O
sequence	O
data	O
from	O
other	O
sources	O
.	O

Only	O
the	O
variants	O
with	O
a	O
read	O
depth	O
greater	O
than	O
5	O
were	O
retained	O
.	O

no	O
.	O

Phosphoribosyl	B-GENE
pyrophosphate	I-GENE
synthetase	I-GENE
1	I-GENE
(	O
PRS	B-GENE
-	I-GENE
I	I-GENE
,	O
[	O
MIM	O
311850	O
]	O
)	O
is	O
an	O
ubiquitous	O
enzyme	O
with	O
an	O
essential	O
role	O
in	O
nucleotide	B-Chemical
metabolism	O
:	O
it	O
catalyzes	O
the	O
synthesis	O
of	O
phosphoribosyl	B-Chemical
pyrophosphate	I-Chemical
(	O
PRPP	B-Chemical
)	O
,	O
the	O
substrate	O
for	O
the	O
synthesis	O
of	O
purine	O
,	O
pyridine	O
,	O
and	O
pyrimidine	B-Chemical
nucleotides	I-Chemical
[	O
1	O
]	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
the	O
atypical	O
antipsychotics	O
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventional	O
neuroleptics	O
.	O

A	O
genome	O
-	O
wide	O
linkage	O
analysis	O
was	O
performed	O
using	O
Illumina	O
Cyto	O
-	O
12	O
Chip	O
containing	O
300	O
,	O
000	O
SNP	O
markers	O
.	O

Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP	O
(	O
-	O
/	O
-	O
)	O
control	O
versus	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP	O
(	O
-	O
/	O
-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	O
(	O
-	O
/	O
-	O
)	O
with	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
.	O

An	O
enhanced	O
sympathetic	O
nervous	O
system	O
activity	O
with	O
a	O
consequent	O
down	O
regulation	O
of	O
the	O
myocardial	O
beta	O
-	O
adrenergic	O
receptors	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catecholamine	B-Chemical
resistance	I-DISEASE
.	O

(	O
b	O
)	O
ECG	O
for	O
L148	B-Chemical
-	I-Chemical
02	O
,	O
a	O
5	O
-	O
year	O
-	O
old	O
boy	O
:	O
The	O
left	O
one	O
showed	O
very	O
broad	O
and	O
notched	O
or	O
bifid	O
even	O
biphasic	O
T	O
waves	O
on	O
multi	O
-	O
leads	O
(	O
arrows	O
)	O
(	O
QTc	O
600	O
ms	O
)	O
before	O
he	O
had	O
received	O
left	O
cardiac	O
sympathetic	O
denervation	O
(	O
LCSD	O
)	O
;	O
the	O
right	O
one	O
showed	O
less	O
abnormal	O
ECG	O
15	O
months	O
after	O
LCSD	O
(	O
QTc	O
490	O
ms	O
)	O
.	O

We	O
studied	O
phenotypic	O
and	O
genotypic	O
features	O
of	O
the	O
patients	O
who	O
have	O
undergone	O
reversal	O
of	O
congenital	O
HH	B-DISEASE
.	O

This	O
missense	O
variant	O
is	O
very	O
likely	O
to	O
be	O
the	O
disease	O
causing	O
variant	O
.	O

Macular	O
optical	O
coherence	O
tomography	O
was	O
normal	O
(	O
data	O
not	O
shown	O
;	O
Table	O
2	O
)	O
.	O

Southern	O
blot	O
analysis	O
of	O
muscle	O
mtDNA	O
did	O
not	O
show	O
multiple	O
-	O
deleted	O
genomes	O
(	O
Fig	O
.	O

Therefore	O
,	O
when	O
diagnosing	O
somatic	O
mosaicism	O
of	O
the	O
NLRP3	B-GENE
gene	O
based	O
solely	O
on	O
the	O
MPS	O
platform	O
,	O
we	O
could	O
not	O
use	O
the	O
same	O
approach	O
to	O
detect	O
rare	O
alleles	O
in	O
a	O
population	O
due	O
to	O
its	O
low	O
accuracy	O
.	O

We	O
also	O
confirmed	O
a	O
previously	O
published	O
mutation	O
in	O
an	O
Italian	O
family	O
suggesting	O
the	O
existence	O
of	O
a	O
mutational	O
hot	O
spot	O
in	O
OPA1	B-GENE
sequence	O
sited	O
in	O
the	O
surroundings	O
of	O
exon	O
10	O
splice	O
acceptor	O
site	O
.	O

Smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
as	O
a	O
risk	O
factor	O
for	O
HIV	B-DISEASE
infection	I-DISEASE
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O

Sensorineural	O
type	O
of	O
HI	B-DISEASE
was	O
precisely	O
defined	O
for	O
38	O
out	O
of	O
76	O
patients	O
,	O
and	O
the	O
remaining	O
patients	O
presented	O
mixed	O
(	O
conductive	O
-	O
sensorineural	O
,	O
n	O
=	O
6	O
)	O
or	O
uncertain	O
type	O
of	O
HL	B-DISEASE
.	O

Patients	O
with	O
stage	O
D2	B-DISEASE
-	O
3	I-DISEASE
disease	O
,	O
abnormal	O
hemoglobin	O
level	O
or	O
renal	O
and	O
liver	O
function	O
tests	O
that	O
were	O
higher	O
than	O
the	O
upper	O
limits	O
were	O
excluded	O
from	O
the	O
study	O
.	O

Immediately	O
,	O
tubes	O
were	O
inverted	O
about	O
5	O
times	O
and	O
labeled	O
with	O
the	O
subject	O
identification	O
code	O
.	O

These	O
findings	O
are	O
valuable	O
for	O
genetic	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
prenatal	O
testing	O
and	O
pre	O
-	O
implantation	O
diagnosis	O
in	O
EVA	B-DISEASE
families	O
.	O

(	O
B	O
)	O
A	O
normal	O
subject	O
without	O
c	B-VARIANT
.	I-VARIANT
863	I-VARIANT
-	I-VARIANT
864insT	I-VARIANT
allele	O
.	O

To	O
confirm	O
the	O
PCDH15	B-GENE
copy	O
number	O
variations	O
the	O
SALSA	O
MLPA	O
probemix	O
P292	O
was	O
employed	O
.	O

When	O
analyzed	O
base	O
-	O
by	O
-	O
base	O
,	O
all	O
samples	O
showed	O
a	O
coverage	O
distribution	O
that	O
reflected	O
high	O
coverage	O
across	O
all	O
nucleotides	O
,	O
with	O
a	O
peak	O
in	O
the	O
center	O
of	O
the	O
sequenced	O
region	O
(	O
S1	O
Fig	O
)	O
.	O

Chie	O
Naito	O
for	O
their	O
technical	O
support	O
.	O

Hearing	B-DISEASE
impairment	I-DISEASE
was	O
assessed	O
by	O
audiograms	O
across	O
a	O
range	O
of	O
frequencies	O
(	O
125	O
-	O
8000	O
Hz	O
)	O
,	O
and	O
by	O
brainstem	O
auditory	O
evoked	O
potentials	O
to	O
explore	O
the	O
central	O
conduction	O
time	O
of	O
the	O
auditory	O
pathways	O
.	O

genomics	O
.	O
org	O
.	O
cn	O
/	O
)	O
,	O
and	O
HapMap	B-Chemical
Project	O
(	O
ftp	O
:	O
/	O
/	O
ftp	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
hapmap	O
)	O
were	O
excluded	O
;	O
(	O
iii	O
)	O
Possible	O
impacts	O
of	O
variants	O
were	O
predicted	O
by	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
bii	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
is	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
disorder	O
characterized	O
by	O
visual	O
and	O
hearing	O
impairments	O
.	O

Two	O
other	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
358	I-VARIANT
+	I-VARIANT
4G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
328G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
have	O
been	O
identified	O
in	O
deaf	B-DISEASE
patients	O
from	O
Pakistan	O
and	O
Turkey	O
,	O
respectively	O
.	O

The	O
frameshift	O
mutation	O
p	B-VARIANT
.	I-VARIANT
Gln733Hisfs	I-VARIANT
*	I-VARIANT
5	I-VARIANT
is	O
predicted	O
to	O
interrupt	O
all	O
of	O
the	O
following	O
functional	O
domains	O
:	O
BAD	O
,	O
CH2	O
,	O
HAT	O
,	O
CH3	O
,	O
and	O
CTAD	O
;	O
(	O
B	O
)	O
The	O
IGFALS	B-GENE
mutation	O
site	O
affects	O
the	O
LRR	O
domain	O
and	O
(	O
C	O
)	O
the	O
TNC	B-GENE
mutation	O
one	O
of	O
the	O
EGF	O
-	O
like	O
repeats	O
.	O

Group	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
received	O
losartan	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
/	O
day	O
by	O
gavages	O
)	O
for	O
6	O
weeks	O
and	O
group	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	B-Chemical
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
MG	O
FJdC	O
FJRA	O
IdC	O
.	O

Pedigrees	O
and	O
audiograms	O
of	O
6	O
DFNA	B-DISEASE
families	O
.	O

The	O
subjects	O
had	O
been	O
classified	O
based	O
on	O
their	O
clinical	O
history	O
and	O
ophthalmologic	O
,	O
audiometric	O
,	O
and	O
vestibular	O
tests	O
.	O

Haplotype	O
analysis	O
for	O
all	O
known	O
USH1	B-DISEASE
loci	O
was	O
performed	O
in	O
each	O
family	O
.	O

Whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
has	O
become	O
a	O
highly	O
efficient	O
strategy	O
for	O
identifying	O
novel	O
causative	O
genes	O
and	O
mutations	O
involved	O
in	O
heritable	O
disease	O
[	O
2	O
]	O
.	O

Sulindac	B-Chemical
was	O
substituted	O
for	O
naproxen	B-Chemical
and	O
no	O
further	O
adverse	O
renal	O
effects	O
occurred	O
over	O
the	O
next	O
12	O
months	O
.	O

Haack	O
reports	O
no	O
disclosures	O
.	O

The	O
number	O
of	O
cells	O
and	O
cytoplasmic	O
transformation	O
of	O
astrocytes	O
and	O
microglia	O
cells	O
were	O
assessed	O
by	O
immunohistochemical	O
analyses	O
.	O

BACKGROUND	O
:	O
Cocaine	B-Chemical
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O

Tiapride	B-Chemical
in	O
levodopa	B-Chemical
-	O
induced	O
involuntary	O
movements	O
.	O

In	O
the	O
MYO1A	B-GENE
gene	O
,	O
we	O
identified	O
one	O
variant	O
with	O
a	O
G	O
to	O
A	O
substitution	O
at	O
nucleotide	O
position	O
1630	O
(	O
c	B-VARIANT
.	I-VARIANT
1630	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
patient	O
FTM	O
-	O
01	O
.	O

Liver	O
biopsy	O
showed	O
cholestasis	B-DISEASE
with	O
both	O
cytological	O
and	O
architectural	O
alterations	O
of	O
interlobular	O
bile	O
ducts	O
.	O

Hyperprolactinemia	B-DISEASE
was	O
induced	O
by	O
treatment	O
with	O
haloperidol	B-Chemical
,	O
a	O
dopamine	B-Chemical
receptor	O
antagonist	O
,	O
and	O
Palkovits	O
'	O
microdissection	O
technique	O
in	O
combination	O
with	O
high	O
-	O
performance	O
liquid	O
chromatography	O
was	O
used	O
to	O
measure	O
neurotransmitter	O
concentrations	O
in	O
several	O
areas	O
of	O
the	O
brain	O
.	O

Interestingly	O
,	O
three	O
patients	O
who	O
were	O
compound	O
heterozygotes	O
for	O
the	O
two	O
mutations	O
showed	O
Usher	B-DISEASE
syndrome	I-DISEASE
phenotypes	O
,	O
while	O
patient	O
IV	O
:	O
1	O
was	O
homozygous	O
for	O
the	O
p	B-VARIANT
.	I-VARIANT
G1734R	I-VARIANT
mutation	O
.	O

We	O
believe	O
that	O
new	O
discoveries	O
in	O
molecular	O
genetics	O
have	O
allowed	O
for	O
identification	O
of	O
the	O
genes	O
causing	O
a	O
large	O
number	O
of	O
skeletal	O
disorders	O
,	O
improving	O
the	O
means	O
of	O
their	O
classification	O
and	O
differentiation	O
.	O

A	O
significant	O
reduction	O
in	O
urinary	O
guanosine	B-Chemical
3	I-Chemical
'	I-Chemical
,	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
cyclic	I-Chemical
monophosphate	I-Chemical
(	O
cGMP	B-Chemical
)	O
excretion	O
and	O
a	O
significant	O
increase	O
in	O
renal	O
cortical	O
renin	O
and	O
endothelin	B-GENE
-	I-GENE
1	I-GENE
contents	O
were	O
also	O
observed	O
in	O
GM	B-Chemical
-	I-DISEASE
mediated	I-DISEASE
nephropathy	I-DISEASE
.	O

In	O
families	O
1	O
and	O
2	O
,	O
the	O
staining	O
pattern	O
was	O
characterized	O
by	O
numerous	O
aggregates	O
of	O
small	O
size	O
(	O
<	O
0	O
.	O
5	O
mu	O
m	O
)	O
(	O
Fig	O
.	O

A	O
)	O
Typical	O
image	O
obtained	O
in	O
most	O
patients	O
.	O

EYA	O
proteins	O
interact	O
with	O
members	O
of	O
SIX	O
and	O
DACH	O
protein	O
families	O
in	O
a	O
conserved	O
network	O
that	O
regulates	O
the	O
early	O
embryonic	O
development	O
and	O
post	O
-	O
developmentally	O
continued	O
function	O
of	O
the	O
mature	O
organ	O
of	O
Corti	O
(	O
7	O
)	O
.	O

The	O
condition	O
is	O
very	O
rare	O
with	O
an	O
estimated	O
prevalence	O
of	O
one	O
in	O
550	O
.	O
000	O
of	O
children	O
,	O
[	O
3	O
]	O
and	O
with	O
a	O
carrier	O
frequency	O
of	O
one	O
in	O
354	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R583G	I-VARIANT
affects	O
a	O
codon	O
,	O
where	O
another	O
missense	O
mutation	O
,	O
p	B-VARIANT
.	I-VARIANT
R583C	I-VARIANT
,	O
has	O
been	O
shown	O
to	O
have	O
an	O
electrophysiological	O
phenotype	O
similar	O
to	O
that	O
expected	O
for	O
a	O
LQTS	B-DISEASE
-	O
associated	O
mutation	O
[	O
42	O
]	O
.	O

In	O
patient	O
5	O
,	O
a	O
known	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
236	I-VARIANT
+	I-VARIANT
1	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
TMC1	B-GENE
had	O
to	O
be	O
confirmed	O
.	O

The	O
KCNJ10	B-GENE
mutants	O
identified	O
in	O
their	O
study	O
displayed	O
reduced	O
K	O
+	O
conductance	O
activity	O
,	O
a	O
critical	O
step	O
in	O
generating	O
endocochlear	O
potential	O
[	O
14	O
]	O
.	O

Since	O
calcium	O
channels	O
exhibit	O
a	O
constant	O
unitary	O
conductance	O
under	O
our	O
experimental	O
conditions	O
,	O
the	O
voltage	O
dependences	O
of	O
activation	O
were	O
obtained	O
by	O
fitting	O
a	O
plot	O
of	O
the	O
current	O
-	O
voltage	O
relation	O
according	O
to	O
:	O
(	O
1	O
)	O
I	O
(	O
V	O
)	O
=	O
G	O
*	O
(	O
V	O
-	O
V	O
rev	O
)	O
*	O
1	O
1	O
+	O
e	O
-	O
(	O
V	O
-	O
V	O
1	O
/	O
2	O
)	O
k	O
with	O
I	O
being	O
the	O
macroscopic	O
current	O
,	O
G	O
the	O
maximum	O
conductance	O
,	O
V	O
the	O
voltage	O
,	O
V	O
rev	O
the	O
reversal	O
potential	O
,	O
V	O
1	O
/	O
2	O
the	O
half	O
-	O
maximal	O
activation	O
and	O
k	O
the	O
slope	O
.	O

The	O
majority	O
of	O
causative	O
DFNA6	O
/	O
14	O
mutations	O
have	O
been	O
identified	O
in	O
exon	O
8	O
,	O
which	O
contains	O
the	O
conserved	O
C	O
-	O
terminal	O
domain	O
.	O

And	O
about	O
89	O
.	O
10	O
%	O
of	O
target	O
region	O
achieved	O
at	O
least	O
10	O
x	O
.	O

Bands	O
were	O
excised	O
from	O
the	O
gel	O
and	O
purified	O
(	O
the	O
313	O
and	O
317	O
bp	O
bands	O
were	O
purified	O
together	O
as	O
it	O
was	O
not	O
possible	O
to	O
excise	O
them	O
separately	O
because	O
of	O
their	O
proximity	O
in	O
the	O
gel	O
)	O
.	O

This	O
cohort	O
of	O
patients	O
consisted	O
of	O
133	O
males	O
and	O
102	O
females	O
from	O
17	O
to	O
23	O
years	O
old	O
,	O
with	O
an	O
average	O
age	O
of	O
17	O
.	O
26	O
+	O
-	O
2	O
.	O
12	O
years	O
.	O

Secondarily	O
,	O
the	O
MPS	O
system	O
used	O
in	O
this	O
study	O
,	O
is	O
not	O
effective	O
for	O
detecting	O
homo	O
-	O
polymer	O
regions	O
,	O
for	O
example	O
poly	O
C	O
stretch	O
[	O
22	O
]	O
(	O
Case	O
#	O
8	O
:	O
p	B-VARIANT
.	I-VARIANT
Lys542GlnfsX5	I-VARIANT
)	O
.	O

These	O
findings	O
further	O
support	O
the	O
use	O
of	O
NGS	O
techniques	O
that	O
allow	O
for	O
the	O
study	O
of	O
all	O
known	O
causative	O
genes	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
in	O
patients	O
independent	O
of	O
their	O
clinical	O
subtype	O
.	O

Immunostaining	O
pattern	O
of	O
alpha	O
3	O
(	O
IV	O
)	O
to	O
alpha	O
5	O
(	O
IV	O
)	O
collagen	O
chains	O
in	O
the	O
anterior	O
lens	O
capsule	O
ranged	O
from	O
decreased	O
immunofluorescence	O
to	O
normal	O
[	O
9	O
,	O
10	O
]	O
,	O
reflecting	O
a	O
genetic	O
heterogeneity	O
[	O
10	O
]	O
.	O

Unlike	O
other	O
affected	O
family	O
members	O
,	O
the	O
age	O
at	O
onset	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
of	O
individual	O
III	O
-	O
8	O
was	O
8	O
years	O
.	O

The	O
potential	O
to	O
correct	O
clinical	O
misdiagnosis	O
by	O
broadly	O
screening	O
a	O
predefined	O
gene	O
panel	O
has	O
been	O
previously	O
demonstrated	O
in	O
isolated	O
individuals	O
using	O
exome	O
sequencing	O
without	O
family	O
pedigree	O
information	O
available	O
.	O

population	O
allele	O
frequency	O
and	O
distance	O
between	O
adjacent	O
SNPs	O
)	O
.	O

As	O
we	O
observed	O
complete	O
absence	O
of	O
mutant	O
alleles	O
in	O
individuals	O
TCS21	B-DISEASE
and	O
22	O
,	O
but	O
partial	O
expression	O
in	O
TCS23	B-DISEASE
(	O
Figure	O
2	O
)	O
,	O
we	O
considered	O
that	O
NMD	B-DISEASE
was	O
present	O
,	O
but	O
with	O
variable	O
efficiency	O
.	O

(	O
1B	O
-	O
5B	O
)	O
Showing	O
lateral	O
view	O
of	O
craniofacial	O
features	O
.	O

A	O
proven	O
deleterious	O
variant	O
in	O
trans	O
to	O
a	O
novel	O
variant	O
,	O
for	O
example	O
,	O
affects	O
the	O
argument	O
in	O
favor	O
for	O
pathogenicity	O
.	O

Further	O
studies	O
are	O
needed	O
,	O
and	O
these	O
findings	O
will	O
probably	O
be	O
helpful	O
in	O
clarifying	O
the	O
pathology	O
of	O
the	O
degeneration	B-DISEASE
of	I-DISEASE
inner	I-DISEASE
retinal	I-DISEASE
cells	I-DISEASE
by	O
retrograde	B-DISEASE
transsynaptic	I-DISEASE
degeneration	I-DISEASE
in	O
patients	O
with	O
optic	B-DISEASE
nerve	I-DISEASE
atrophies	I-DISEASE
and	O
in	O
developing	O
new	O
therapies	O
.	O

The	O
mutation	O
abolishes	O
this	O
restriction	O
site	O
,	O
thus	O
retaining	O
the	O
undigested	O
528	O
bp	O
amplicon	O
in	O
affected	O
indivuduals	O
.	O

Using	O
this	O
method	O
,	O
we	O
detected	O
652	O
high	O
-	O
confidence	O
variants	O
within	O
the	O
patient	O
pools	O
(	O
Table	O
2	O
)	O
.	O

VA	O
was	O
20	O
/	O
20	O
in	O
all	O
cases	O
.	O

To	O
date	O
,	O
seven	O
loci	O
have	O
been	O
mapped	O
that	O
cause	O
USH1	B-DISEASE
,	O
USH1B	B-GENE
-	O
USH1H	B-GENE
(	O
Hereditary	O
Hearing	B-DISEASE
Loss	I-DISEASE
Homepage	O
)	O
.	O

Within	O
the	O
last	O
several	O
years	O
,	O
previously	O
rare	O
liver	B-DISEASE
tumors	O
have	O
been	O
seen	O
in	O
young	O
women	O
using	O
oral	B-Chemical
contraceptive	I-Chemical
steroids	B-Chemical
.	O

Dothiepin	B-Chemical
also	O
produced	O
fewer	O
CNS	O
and	O
cardiovascular	O
effects	O
.	O

Production	O
of	O
autochthonous	O
prostate	B-DISEASE
cancer	I-DISEASE
in	O
Lobund	O
-	O
Wistar	O
rats	O
by	O
treatments	O
with	O
N	B-Chemical
-	I-Chemical
nitroso	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylurea	I-Chemical
and	O
testosterone	B-Chemical
.	O

When	O
WGS	O
is	O
performed	O
,	O
the	O
variants	O
are	O
called	O
by	O
comparison	O
to	O
a	O
reference	O
sequence	O
.	O

We	O
conclude	O
that	O
methylphenidate	B-Chemical
mediated	I-DISEASE
vasculitis	I-DISEASE
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	B-Chemical
therapy	O
.	O

Previous	O
reports	O
have	O
favored	O
a	O
role	O
of	O
androgens	B-Chemical
in	O
the	O
pathogenesis	O
of	O
sleep	B-DISEASE
apnea	I-DISEASE
.	O

The	O
inheritance	O
of	O
RP	B-DISEASE
shows	O
various	O
patterns	O
including	O
autosomal	O
recessive	O
(	O
arRP	B-DISEASE
)	O
,	O
autosomal	O
dominant	O
,	O
X	O
-	O
linked	O
,	O
sporadic	O
(	O
spRP	B-DISEASE
)	O
,	O
mitochondrial	O
[	O
2	O
]	O
and	O
digenic	O
[	O
3	O
]	O
inheritance	O
.	O

(	O
d	O
)	O
Ca	B-Chemical
2	I-Chemical
+	O
responses	O
in	O
COS	O
-	O
7	O
cells	O
transfected	O
with	O
five	O
different	O
DsRed	O
-	O
tagged	O
CIB2	B-GENE
constructs	O
.	O

Manic	B-DISEASE
excitement	I-DISEASE
was	O
coincident	O
with	O
the	O
duration	O
of	O
action	O
of	O
triazolam	B-Chemical
.	O

Eli	O
J	O
.	O

Bortezomib	B-Chemical
and	O
high	O
-	O
dose	O
dexamethasone	B-Chemical
-	O
containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	O
infections	O
in	O
patients	O
with	O
B	O
-	O
cell	O
malignancies	O
.	O

PCRs	O
were	O
performed	O
on	O
10	O
-	O
20	O
ng	O
of	O
genomic	O
DNA	O
,	O
following	O
standard	O
procedures	O
.	O

Family	O
TB86	O
is	O
a	O
Muslim	O
Arab	O
family	O
from	O
northern	O
Israel	O
.	O

These	O
patients	O
had	O
a	O
second	O
event	O
of	O
cardiac	O
arrest	O
,	O
resulting	O
in	O
death	O
,	O
within	O
10	O
to	O
60	O
minutes	O
.	O

In	O
the	O
majority	O
of	O
OPA1	B-GENE
patients	O
the	O
ECochG	O
response	O
begins	O
with	O
an	O
abrupt	O
deflection	O
with	O
peak	O
latency	O
and	O
amplitude	O
falling	O
within	O
the	O
range	O
of	O
summating	O
potential	O
latencies	O
and	O
amplitudes	O
in	O
controls	O
with	O
normal	O
hearing	O
,	O
a	O
picture	O
consistent	O
with	O
preservation	O
of	O
inner	O
hair	O
cells	O
.	O

who	O
detected	O
one	O
or	O
two	O
mutations	O
in	O
24	O
out	O
of	O
27	O
(	O
89	O
%	O
)	O
USH1	B-DISEASE
patients	O
[	O
11	O
]	O
and	O
Le	O
Quesne	O
Stabej	O
et	O
al	O
.	O

Studies	O
were	O
performed	O
to	O
examine	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	B-Chemical
(	O
GM	B-Chemical
)	O
-	O
mediated	O
nephropathy	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Almost	O
90	O
%	O
of	O
all	O
cases	O
of	O
congenital	O
,	O
non	O
-	O
syndromic	O
,	O
severe	O
to	O
profound	O
inherited	O
deafness	B-DISEASE
display	O
an	O
autosomal	O
recessive	O
mode	O
of	O
transmission	O
(	O
DFNB	B-DISEASE
forms	O
)	O
.	O

Recently	O
,	O
a	O
mutation	O
in	O
the	O
short	O
isoform	O
of	O
USH1C	B-GENE
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
RP	B-DISEASE
and	O
late	O
-	O
onset	O
deafness	B-DISEASE
(	O
Khateb	O
et	O
al	O
.	O

All	O
affected	O
relatives	O
in	O
Family	O
BF	O
are	O
homozygous	O
for	O
pendrin	B-GENE
1001G	B-VARIANT
>	I-VARIANT
T	I-VARIANT
and	O
all	O
unaffected	O
relatives	O
are	O
heterozygous	O
or	O
wild	O
-	O
type	O
.	O

Using	O
the	O
same	O
stereotactic	O
space	O
limits	O
as	O
in	O
the	O
above	O
mentioned	O
migraine	B-DISEASE
study	O
no	O
brain	O
stem	O
activation	O
was	O
found	O
in	O
the	O
acute	O
pain	O
state	O
compared	O
to	O
the	O
pain	O
free	O
state	O
.	O

Monosodium	B-Chemical
glutamate	I-Chemical
(	O
MSG	B-Chemical
)	O
administration	O
to	O
neonatal	O
rodents	O
produces	O
convulsions	B-DISEASE
and	O
results	O
in	O
numerous	O
biochemical	O
and	O
behavioral	O
deficits	I-DISEASE
.	O

We	O
found	O
that	O
both	O
the	O
normal	O
and	O
mutated	O
CD164	B-GENE
transcripts	O
were	O
expressed	O
in	O
peripheral	O
blood	O
cells	O
(	O
Fig	O
7B	O
)	O
,	O
demonstrating	O
that	O
the	O
CD164	B-GENE
c	B-VARIANT
.	I-VARIANT
574C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
transcript	O
escapes	O
NMD	O
.	O

At	O
age	O
45	O
she	O
presented	O
with	O
nephrotic	O
range	O
proteinuria	B-DISEASE
and	O
hypertension	B-DISEASE
but	O
no	O
evidence	O
of	O
hematuria	B-DISEASE
.	O

Evidence	O
for	O
a	O
selective	O
brain	O
noradrenergic	O
involvement	O
in	O
the	O
locomotor	O
stimulant	O
effects	O
of	O
amphetamine	B-Chemical
in	O
the	O
rat	O
.	O

Arrow	O
:	O
nucleotide	O
change	O
c	B-VARIANT
.	I-VARIANT
1877C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
S680F	I-VARIANT
)	O
variant	O
.	O

In	O
consanguineous	O
family	O
136	O
we	O
suspect	O
a	O
large	O
deletion	O
of	O
exon	O
83	O
(	O
supplemental	O
figure	O
3	O
)	O
as	O
the	O
two	O
affected	O
sibs	O
in	O
this	O
family	O
shared	O
a	O
homozygous	O
GPR98	B-GENE
haplotype	O
;	O
parents	O
were	O
heterozygous	O
for	O
the	O
same	O
haplotype	O
.	O

However	O
,	O
a	O
recent	O
study	O
demonstrated	O
a	O
rapid	O
turnover	O
of	O
the	O
actin	O
filaments	O
only	O
at	O
the	O
tip	O
of	O
the	O
stereocilia	O
,	O
without	O
a	O
treadmilling	O
process	O
[	O
10	O
]	O
,	O
emphasizing	O
the	O
specific	O
role	O
of	O
proteins	O
at	O
the	O
stereocilia	O
tip	O
in	O
the	O
regulation	O
of	O
actin	O
filaments	O
.	O

Normal	O
erythrocyte	O
diameter	O
(	O
mean	O
)	O
:	O
between	O
6	O
and	O
7	O
.	O

Sequences	O
were	O
analyzed	O
with	O
Sequencing	O
Analysis	O
software	O
v	O
.	O
5	O
.	O
2	O
(	O
Applied	O
Biosystems	O
)	O
and	O
compared	O
with	O
the	O
references	O
sequences	O
of	O
each	O
gene	O
(	O
Ensembl	O
identifiers	O
:	O
ATP6V1B1	B-GENE
:	O
ENSG00000116039	O
,	O
ATP6V0A4	B-GENE
:	O
ENSG00000105929	O
and	O
SLC4A1	B-GENE
:	O
ENSG00000004939	O
)	O
,	O
using	O
SeqScape	O
software	O
v	O
.	O
2	O
.	O
5	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
evoked	O
electrical	O
activity	O
was	O
recorded	O
two	O
electrodes	O
apart	O
.	O

Although	O
we	O
did	O
not	O
find	O
the	O
mutation	O
in	O
a	O
few	O
cases	O
with	O
presbycusis	O
,	O
a	O
hypothetical	O
involvement	O
of	O
c	B-VARIANT
.	I-VARIANT

This	O
is	O
a	O
particular	O
problem	O
when	O
family	O
data	O
are	O
not	O
sufficient	O
to	O
establish	O
linkage	O
.	O

To	O
estimate	O
the	O
frequency	O
of	O
CD164	B-GENE
mutations	O
among	O
patients	O
with	O
unknown	O
cause	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
we	O
sequenced	O
all	O
coding	O
exons	O
and	O
splice	O
junctions	O
of	O
CD164	B-GENE
using	O
DNA	O
samples	O
from	O
46	O
independent	O
index	O
cases	O
.	O

These	O
can	O
also	O
be	O
part	O
of	O
the	O
behavioral	O
phenotype	O
of	O
ASD	B-DISEASE
.	O

The	O
remaining	O
25	O
patients	O
had	O
no	O
identified	O
pathogenic	O
mutation	O
in	O
any	O
of	O
the	O
genes	O
screened	O
by	O
Sanger	O
sequencing	O
.	O

At	O
48	O
h	O
posttransfection	O
protein	O
synthesis	O
was	O
stopped	O
by	O
incubating	O
the	O
cells	O
for	O
4	O
h	O
in	O
the	O
presence	O
of	O
50	O
u	O
g	O
/	O
ml	O
of	O
cycloheximide	B-Chemical
.	O

Clinical	O
evaluation	O
of	O
these	O
kindreds	O
included	O
a	O
full	O
family	O
history	O
,	O
physical	O
examination	O
,	O
urinalysis	O
with	O
qualitative	O
or	O
quantitative	O
proteinuria	B-DISEASE
and	O
serum	O
creatinine	B-Chemical
assay	O
when	O
appropriate	O
.	O

A	O
27	O
-	O
year	O
-	O
old	O
Japanese	O
woman	O
previously	O
diagnosed	O
with	O
avasucular	B-DISEASE
necrosis	I-DISEASE
(	O
AVN	B-DISEASE
)	O
of	O
the	O
femoral	O
head	O
on	O
the	O
basis	O
of	O
radiological	O
findings	O
was	O
referred	O
to	O
the	O
study	O
site	O
for	O
surgical	O
management	O
of	O
a	O
painful	O
hip	O
joint	O
.	O

Our	O
study	O
is	O
the	O
first	O
genetic	O
analysis	O
of	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
in	O
south	O
China	O
,	O
and	O
revealed	O
that	O
a	O
clear	O
genetic	O
etiology	O
accounted	O
for	O
32	O
.	O
0	O
%	O
of	O
non	O
-	O
syndromic	O
hearing	O
cases	O
in	O
patients	O
from	O
these	O
regions	O
.	O

We	O
observed	O
a	O
GJB2	B-GENE
mutation	O
distribution	O
of	O
approximately	O
20	O
%	O
that	O
was	O
responsible	O
for	O
NSHI	B-DISEASE
in	O
south	O
China	O
.	O

DNA	O
was	O
extracted	O
from	O
1	O
ml	O
of	O
peripheral	O
blood	O
using	O
the	O
QiaSymphony	O
DNA	O
Blood	O
Midi	I-Chemical
kit	O
on	O
the	O
QIAsymphony	O
SP	O
workstation	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

In	O
the	O
Norwegian	O
survey	O
,	O
no	O
patients	O
had	O
more	O
than	O
one	O
definitely	O
pathogenic	O
mutation	O
,	O
whereas	O
Kapplinger	O
et	O
al	O
.	O

This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
in	O
preventing	O
axonal	O
damage	O
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
.	O

TMC1	B-GENE
p	B-VARIANT
.	I-VARIANT
S647P	I-VARIANT
is	O
located	O
in	O
the	O
sixth	O
TMC1	B-GENE
transmembrane	O
domain	O
at	O
a	O
fully	O
conserved	O
site	O
and	O
is	O
predicted	O
to	O
be	O
damaging	O
by	O
PolyPhen2	O
and	O
SIFT	O
.	O

Sequencing	O
analysis	O
failed	O
to	O
identify	O
mutations	O
in	O
the	O
FGFR1	B-GENE
and	O
FGFR2	B-GENE
genes	O
in	O
the	O
DNA	O
isolated	O
from	O
this	O
family	O
.	O

To	O
date	O
,	O
ten	O
syndromic	B-DISEASE
or	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
genes	O
have	O
been	O
identified	O
using	O
targeted	O
genomic	O
enrichment	O
and	O
whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
:	O
TPRN	B-GENE
,	O
GPSM2	B-GENE
,	O
CEACAM16	B-GENE
,	O
SMPX	B-GENE
,	O
HSD17B4	B-GENE
,	O
HARS2	B-GENE
,	O
MASP1	B-GENE
,	O
OTOGL	B-GENE
,	O
DNMT1	B-GENE
,	O
and	O
TSPEAR	B-GENE
.	O

Neuroleptic	B-Chemical
-	O
associated	O
hyperprolactinemia	B-DISEASE
.	O

To	O
date	O
,	O
2	O
mutations	O
at	O
the	O
p	O
.	O
R75	O
amino	O
acid	O
residue	O
of	O
connexin	B-GENE
26	I-GENE
have	O
been	O
related	O
to	O
autosomal	B-DISEASE
dominant	I-DISEASE
SNHI	I-DISEASE
with	O
or	O
without	O
palmoplantar	B-DISEASE
keratoderma	I-DISEASE
:	O
p	B-VARIANT
.	I-VARIANT
R75W	I-VARIANT
[	O
31	O
]	O
,	O
[	O
32	O
]	O
and	O
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
[	O
26	O
]	O
,	O
[	O
27	O
]	O
.	O

The	O
assay	O
measures	O
the	O
rate	O
of	O
the	O
NADH	B-Chemical
absorbance	O
decrease	O
at	O
340	O
nm	O
,	O
which	O
is	O
proportional	O
to	O
the	O
rate	O
of	O
steady	O
-	O
state	O
ATP	O
hydrolysis	O
[	O
21	O
]	O
.	O

For	O
statistical	O
evaluation	O
of	O
the	O
biochemical	O
data	O
we	O
used	O
one	O
-	O
way	O
ANOVA	O
,	O
with	O
Post	O
Hoc	O
test	O
:	O
Tukey	O
'	O
s	O
test	O
.	O

Stabilization	B-DISEASE
of	O
Kaposi	B-DISEASE
'	I-DISEASE
s	I-DISEASE
sarcoma	I-DISEASE
occurred	O
in	O
the	O
remaining	O
six	O
,	O
maintained	O
until	O
the	O
end	O
of	O
the	O
trial	O
period	O
in	O
four	O
.	O

RESULTS	O
:	O
A	O
57	O
-	O
year	O
-	O
old	O
male	O
presented	O
with	O
gradual	O
loss	O
of	O
vision	O
in	O
both	O
eyes	O
with	O
intermittent	O
headaches	B-DISEASE
for	O
2	O
months	O
.	O

The	O
use	O
of	O
cidofovir	B-Chemical
in	O
severe	O
adenovirus	O
infection	O
has	O
been	O
limited	O
by	O
adverse	O
effects	O
,	O
the	O
most	O
significant	O
of	O
which	O
is	O
nephrotoxicity	B-DISEASE
.	O

In	O
the	O
most	O
common	O
pattern	O
(	O
Subject	O
4	O
)	O
electrically	O
-	O
evoked	O
ABR	O
recordings	O
showed	O
wave	O
V	O
,	O
which	O
was	O
recorded	O
with	O
increasing	O
latency	O
from	O
apical	O
to	O
basal	O
electrodes	O
(	O
Fig	O
.	O

Hearing	O
levels	O
in	O
the	O
different	O
groups	O
MD	B-DISEASE
:	O
Isolated	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
,	O
EVA	B-DISEASE
with	O
MD	B-DISEASE
:	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
with	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
,	O
EVA	B-DISEASE
:	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
without	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
,	O
IEM	B-DISEASE
:	O
other	O
types	O
of	O
inner	B-DISEASE
ear	I-DISEASE
malformations	I-DISEASE
DNA	O
sequence	O
analysis	O
of	O
SLC26A4	B-GENE
was	O
performed	O
in	O
all	O
144	O
patients	O
.	O

PCR	O
was	O
carried	O
out	O
following	O
standard	O
protocols	O
and	O
using	O
gene	O
-	O
specific	O
primers	O
that	O
amplify	O
the	O
coding	O
exons	O
and	O
adjacent	O
intronic	O
sequences	O
.	O

Under	O
the	O
assumption	O
of	O
an	O
autosomal	O
-	O
recessive	O
pattern	O
of	O
inheritance	O
,	O
only	O
variants	O
that	O
were	O
homozygous	O
or	O
compound	O
heterozygous	O
in	O
the	O
two	O
affected	O
siblings	O
and	O
heterozygous	O
in	O
their	O
parents	O
were	O
selected	O
as	O
candidates	O
.	O

d	O
Identification	O
of	O
a	O
4	O
,	O
977	O
-	O
bp	O
common	O
deletion	O
in	O
mtDNA	O
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenytoin	B-Chemical
sodium	I-Chemical
have	O
similar	O
antiarrhythmic	O
activity	O
against	O
ouabain	B-Chemical
-	O
induced	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
in	O
anesthetized	O
dogs	O
.	O

Almost	O
half	O
of	O
the	O
cases	O
was	O
related	O
to	O
a	O
warfarin	B-Chemical
-	O
drug	O
interaction	O
.	O

Neither	O
the	O
type	O
of	O
induction	O
agent	O
(	O
Althesin	B-Chemical
or	O
Thiopentone	B-Chemical
)	O
nor	O
the	O
salt	O
preparation	O
of	O
suxamethonium	B-Chemical
used	O
(	O
chloride	B-Chemical
or	O
bromide	B-Chemical
)	O
,	O
affected	O
the	O
incidence	O
of	O
scoline	B-Chemical
pain	I-DISEASE
.	O

Rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	B-Chemical
and	O
VCM	B-Chemical
plus	O
erdosteine	B-Chemical
.	O

,	O
2008	O
)	O
.	O

The	O
case	O
also	O
illustrates	O
the	O
importance	O
of	O
maintaining	O
preparedness	O
for	O
managing	O
rare	O
but	O
serious	O
reactions	O
in	O
volunteer	O
apheresis	O
blood	O
donors	O
.	O

EPS8	B-GENE
:	I-GENE
Epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
pathway	I-GENE
substrate	I-GENE
8	I-GENE
;	I-GENE
DFNB	B-DISEASE
:	I-DISEASE
Nonsyndromic	B-DISEASE
deafness	I-DISEASE
,	I-DISEASE
autosomal	I-DISEASE
recessive	I-DISEASE
;	I-DISEASE
DFNA	B-DISEASE
:	I-DISEASE
Nonsyndromic	B-DISEASE
deafness	I-DISEASE
,	I-DISEASE
autosomal	I-DISEASE
dominant	I-DISEASE
.	O

Minimum	O
ascertainment	O
criteria	O
for	O
identification	O
of	O
patients	O
were	O
the	O
coincident	O
occurrence	O
of	O
insulin	B-DISEASE
requiring	I-DISEASE
diabetes	I-DISEASE
mellitus	I-DISEASE
with	O
onset	O
before	O
age	O
30	O
years	O
and	O
bilateral	O
optic	B-DISEASE
atrophy	I-DISEASE
with	O
insidious	O
onset	O
and	O
/	O
or	O
genetic	O
confirmation	O
of	O
a	O
WFS1	B-GENE
mutation	O
prior	O
to	O
this	O
study	O
.	O

Normalized	O
relative	O
coverage	O
(	O
relative	O
product	O
coverage	O
,	O
RPC	O
)	O
of	O
every	O
target	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
of	O
patient	O
sample	O
(	O
green	O
,	O
RPC	O
P	O
.	O
)	O
and	O
average	O
relative	O
target	O
coverage	O
of	O
control	O
samples	O
(	O
blue	O
,	O
RPC	O
C	O
.	O
)	O
.	O

Glutamate	B-Chemical
evoked	O
reproducible	O
VAS	O
response	O
to	O
all	O
von	O
Frey	O
gauges	O
(	O
ICC	O
>	O
0	O
.	O
60	O
)	O
and	O
brush	O
strokes	O
(	O
ICC	O
>	O
0	O
.	O
83	O
)	O
.	O

5	O
)	O
.	O

B	O
)	O
Analysis	O
of	O
10	O
families	O
with	O
c	B-VARIANT
.	I-VARIANT
2708_2711delTTAG	I-VARIANT
mutation	O
in	O
exon	O
27	O
.	O

Based	O
on	O
incidence	O
data	O
for	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
auditory	B-DISEASE
neuropathy	I-DISEASE
,	O
we	O
excluded	O
variants	O
with	O
an	O
MAF	O
>	O
0	O
.	O
001	O
.	O

[	O
44	O
]	O
reported	O
that	O
microcysts	O
could	O
also	O
be	O
observed	O
using	O
en	O
face	O
OCT	O
imaging	O
.	O

NRA0160	B-Chemical
and	O
clozapine	B-Chemical
significantly	O
shortened	O
the	O
phencyclidine	B-Chemical
(	O
PCP	B-Chemical
)	O
-	O
induced	O
prolonged	O
swimming	O
latency	O
in	O
rats	O
in	O
a	O
water	O
maze	O
task	O
.	O

49	O
,	O
50	O
In	O
summary	O
,	O
CIB2	B-GENE
mutations	O
underlie	O
Usher	B-DISEASE
syndrome	I-DISEASE
1J	I-DISEASE
and	O
nonsyndromic	O
deafness	B-DISEASE
DFNB48	B-DISEASE
.	O

Relevant	O
non	O
-	O
indexed	O
journals	O
and	O
conference	O
abstracts	O
were	O
also	O
searched	O
.	O

In	O
addition	O
to	O
the	O
coding	O
regions	O
of	O
skeletal	B-DISEASE
disorder	I-DISEASE
genes	O
,	O
regions	O
that	O
cause	O
skeletal	B-DISEASE
disorders	I-DISEASE
when	O
deleted	O
,	O
such	O
as	O
the	O
SOX9	B-GENE
regulatory	O
region	O
associated	O
with	O
campomelic	B-DISEASE
dysplasia	I-DISEASE
were	O
included	O
in	O
the	O
panel	O
.	O

Subsequently	O
,	O
the	O
serum	O
creatinine	B-Chemical
levels	O
decreased	O
,	O
the	O
urine	O
albumin	O
/	O
creatinine	B-Chemical
ratios	O
returned	O
to	O
zero	O
,	O
and	O
the	O
leukocyturia	B-DISEASE
disappeared	O
within	O
3	O
months	O
.	O

(	O
d	O
)	O
Palestinian	O
and	O
Turkish	O
individuals	O
with	O
the	O
716A	O
(	O
239D	O
)	O
mutation	O
share	O
an	O
extended	O
haplotype	O
of	O
126	O
-	O
260	O
kilobases	O
flanking	O
pendrin	B-GENE
(	O
yellow	O
boxes	O
)	O
,	O
based	O
on	O
markers	O
polymorphic	O
among	O
wild	O
-	O
type	O
(	O
716T	O
)	O
haplotypes	O
.	O

These	O
mice	O
have	O
a	O
neomycin	B-Chemical
cassette	O
inserted	O
into	O
exon	O
3	O
of	O
Homer2	B-GENE
abolishing	O
gene	O
expression	O
[	O
31	O
]	O
.	O

CONCLUSION	O
:	O
Raloxifene	B-Chemical
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
venous	B-DISEASE
thromboembolism	I-DISEASE
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
cataracts	B-DISEASE
,	O
gallbladder	B-DISEASE
disease	I-DISEASE
,	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
,	O
or	O
endometrial	B-DISEASE
cancer	I-DISEASE
.	O

The	O
second	O
missense	O
c	B-VARIANT
.	I-VARIANT
1739	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
was	O
found	O
in	O
one	O
proband	O
(	O
case	O
15	O
.	O
1	O
)	O
in	O
heterozygosis	O
.	O

Patients	O
in	O
the	O
unilateral	O
group	O
were	O
maintained	O
in	O
the	O
lateral	O
position	O
for	O
15	O
minutes	O
following	O
spinal	O
injection	O
while	O
those	O
in	O
the	O
conventional	O
group	O
were	O
turned	O
supine	O
immediately	O
after	O
injection	O
.	O

Only	O
two	O
patients	O
carried	O
single	O
allelic	O
mutations	O
of	O
the	O
SLC26A4	B-GENE
gene	O
in	O
the	O
IEM	B-DISEASE
group	O
(	O
2	O
/	O
16	O
,	O
12	O
.	O
5	O
%	O
)	O
.	O

Clinical	O
information	O
and	O
specimens	O
were	O
obtained	O
with	O
informed	O
consent	O
in	O
accordance	O
with	O
German	O
law	O
for	O
genetic	O
diagnostics	O
.	O

For	O
this	O
locus	O
,	O
only	O
one	O
informative	O
marker	O
has	O
been	O
used	O
(	O
D11S4186	O
)	O
.	O

Size	O
and	O
location	O
of	O
the	O
homozygous	O
blocks	O
containing	O
the	O
causative	O
mutations	O
in	O
the	O
studied	O
families	O
.	O

This	O
effect	O
may	O
be	O
related	O
to	O
the	O
pharmacological	O
effect	O
of	O
this	O
drug	O
on	O
mucous	O
membranes	O
.	O

This	O
strategy	O
has	O
been	O
successfully	O
applied	O
to	O
identify	O
de	O
novo	O
point	O
mutations	O
in	O
intellectual	B-DISEASE
disability	I-DISEASE
4	O
,	O
autism	B-DISEASE
13	O
,	O
and	O
schizophrenia	B-DISEASE
14	O
,	O
15	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
diagnoses	O
of	O
all	O
patients	O
were	O
established	O
by	O
medical	O
history	O
,	O
family	O
history	O
and	O
detailed	O
clinical	O
evaluation	O
of	O
vision	O
.	O

USH1C	B-GENE
therefore	O
should	O
be	O
considered	O
a	O
candidate	O
gene	O
in	O
patients	O
with	O
USH1	B-GENE
,	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
young	O
(	O
<	O
40	O
years	O
)	O
RP	B-DISEASE
patients	O
with	O
normal	O
hearing	O
function	O
,	O
and	O
RP	B-DISEASE
patients	O
with	O
mild	O
or	O
late	O
-	O
onset	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Of	O
these	O
,	O
four	O
subjects	O
carried	O
the	O
R445H	B-VARIANT
mutation	O
.	O

One	O
of	O
the	O
advantages	O
of	O
454	O
sequencing	O
is	O
to	O
generate	O
long	O
reads	O
(	O
average	O
of	O
431	O
bp	O
in	O
this	O
study	O
)	O
,	O
but	O
this	O
reduces	O
the	O
number	O
of	O
optimized	O
alignment	O
and	O
base	O
-	O
calling	O
methods	O
that	O
are	O
available	O
.	O

ABR	O
and	O
OAE	O
testing	O
at	O
1	O
month	O
of	O
age	O
showed	O
comparable	O
bilateral	O
auditory	B-DISEASE
neuropathy	I-DISEASE
with	O
normal	O
middle	O
ear	O
function	O
.	O

The	O
amount	O
of	O
charge	O
conducted	O
by	O
the	O
I	B-GENE
Ks	I-GENE
channel	O
complex	O
was	O
calculated	O
by	O
integrating	O
the	O
area	O
under	O
the	O
curve	O
in	O
the	O
first	O
130	O
ms	O
after	O
the	O
capacitive	O
spike	O
(	O
10	O
ms	O
)	O
of	O
the	O
pulse	O
at	O
the	O
7th	O
second	O
.	O

See	O
Supplementary	O
Table	O
6	O
for	O
a	O
detailed	O
,	O
per	O
patient	O
,	O
clinical	O
overview	O
.	O
Investigation	O
of	O
the	O
OPA1	B-GENE
mutation	O
spectrum	O
in	O
autosomal	B-DISEASE
dominant	I-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
(	O
ADOA	B-DISEASE
)	O
in	O
Denmark	O
.	O

All	O
subjects	O
gave	O
prior	O
informed	O
written	O
consent	O
for	O
participation	O
in	O
the	O
project	O
and	O
the	O
Ethical	O
Committee	O
of	O
Shinshu	O
University	O
approved	O
the	O
study	O
.	O

We	O
describe	O
a	O
case	O
of	O
progressive	O
loss	B-DISEASE
of	I-DISEASE
vision	I-DISEASE
associated	O
with	O
linezolid	B-Chemical
therapy	O
.	O

To	O
test	O
whether	O
jams1	B-DISEASE
localized	O
to	O
the	O
ahl5	B-DISEASE
critical	O
region	O
,	O
we	O
tested	O
BLSW	O
.	O
CAST	O
congenic	O
mice	O
for	O
audiogenic	B-DISEASE
seizure	I-DISEASE
susceptibility	O
.	O

Audiograms	O
of	O
individuals	O
with	O
the	O
p	B-VARIANT
.	I-VARIANT
Lys836Asn	I-VARIANT
mutation	O
in	O
the	O
WFS1	B-GENE
gene	O
.	O

The	O
p	O
.	O
R244	O
residue	O
,	O
affected	O
in	O
the	O
Chinese	O
family	O
DFNB	B-DISEASE
.	O
01	O
,	O
is	O
located	O
near	O
the	O
open	O
edge	O
of	O
the	O
large	O
cleft	O
separating	O
the	O
upper	O
50	O
kDa	O
from	O
the	O
lower	O
50K	O
domain	O
[	O
26	O
]	O
.	O

Type	O
IX	O
collagen	O
connects	O
heterotypic	O
type	O
II	O
/	O
XI	O
collagen	O
fibrils	O
to	O
other	O
components	O
of	O
the	O
extracellular	O
matrix	O
.	O

MLPA	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
:	O
denaturation	O
at	O
98	O
deg	O
C	O
for	O
5	O
minutes	O
;	O
stabilization	O
at	O
25	O
deg	O
C	O
;	O
hybridization	O
at	O
95	O
deg	O
C	O
for	O
1	O
minute	O
and	O
at	O
60	O
deg	O
C	O
for	O
16	O
-	O
20	O
hours	O
,	O
stabilization	O
at	O
54	O
deg	O
C	O
;	O
ligation	O
at	O
54	O
deg	O
C	O
for	O
15	O
minutes	O
,	O
inactivation	O
at	O
98	O
deg	O
C	O
for	O
5	O
minutes	O
,	O
and	O
stabilization	O
at	O
20	O
deg	O
C	O
.	O

Nucleotide	O
sequencing	O
of	O
the	O
entire	O
WFS1	B-GENE
coding	O
region	O
confirmed	O
the	O
presence	O
of	O
two	O
different	O
mutations	O
in	O
the	O
four	O
affected	O
patients	O
:	O
one	O
allele	O
carried	O
a	O
novel	O
R177P	B-VARIANT
missense	O
mutation	O
resulting	O
from	O
a	B-VARIANT
G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
transversion	I-VARIANT
at	I-VARIANT
nucleotide	I-VARIANT
position	I-VARIANT
530	I-VARIANT
in	I-VARIANT
exon	I-VARIANT
5	I-VARIANT
(	O
Figure	O
3	O
)	O
.	O

reported	O
that	O
23	O
.	O
4	O
%	O
of	O
Hungarian	O
GJB2	B-GENE
-	O
heterozygous	O
patients	O
carried	O
the	O
splice	O
-	O
site	O
mutation	O
IVS1	B-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
the	O
5	O
'	O
UTR	O
region	O
of	O
GJB2	B-GENE
[	O
55	O
]	O
.	O

The	O
long	O
isoforms	O
(	O
HOMER1b	B-GENE
and	I-GENE
c	I-GENE
,	O
HOMER2	B-GENE
,	O
HOMER3	B-GENE
)	O
additionally	O
have	O
a	O
coiled	O
-	O
coil	O
(	O
CC	O
)	O
region	O
and	O
leucine	B-Chemical
zipper	O
motifs	O
in	O
their	O
divergent	O
C	O
-	O
termini	O
[	O
8	O
]	O
.	O

The	O
present	O
results	O
demonstrate	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
attenuates	O
the	O
effect	O
of	O
morphine	B-Chemical
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
morphine	B-Chemical
-	O
induced	O
memory	B-DISEASE
impairment	I-DISEASE
.	O

S888X	I-VARIANT
;	O
and	O
the	O
c	B-VARIANT
.	I-VARIANT
1381	I-VARIANT
A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT

WT	O
CLRN1	O
-	O
HA	O
has	O
a	O
single	O
putative	O
N	O
-	O
glycosylation	O
site	O
at	O
amino	O
acid	O
position	O
48	O
[	O
23	O
,	O
28	O
]	O
.	O

Small	O
indel	O
detection	O
was	O
performed	O
using	O
the	O
UnifiedGenotyper	O
tool	O
from	O
GATK	O
(	O
version	O
v1	O
.	O
0	O
.	O
4705	O
)	O
[	O
22	O
]	O
after	O
all	O
the	O
high	O
-	O
quality	O
reads	O
were	O
aligned	O
to	O
the	O
human	O
reference	O
genome	O
using	O
BWA	O
(	O
version	O
0	O
.	O
5	O
.	O
9	O
-	O
r16	O
)	O
[	O
23	O
]	O
.	O

It	O
codes	O
a	O
2	O
,	O
215	O
-	O
amino	O
-	O
acid	O
protein	O
,	O
myosin	B-GENE
VIIA	I-GENE
,	O
which	O
is	O
produced	O
in	O
the	O
retina	O
and	O
in	O
the	O
inner	O
ear	O
and	O
acts	O
on	O
the	O
transport	O
processes	O
through	O
the	O
cilia	O
of	O
the	O
retinal	O
photoreceptors	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
contribution	O
of	O
the	O
glycine	B-Chemical
site	O
of	O
NMDA	B-Chemical
receptors	O
in	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
.	O

All	O
affected	O
members	O
had	O
the	O
compound	O
heterozygote	O
(	O
p	B-VARIANT
.	I-VARIANT
G1734R	I-VARIANT
and	O
IVS32	B-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
mutation	O
,	O
except	O
for	O
patient	O
IV	O
:	O
1	O
,	O
who	O
is	O
homozygote	O
for	O
the	O
p	B-VARIANT
.	I-VARIANT
G1734R	I-VARIANT
mutation	O
(	O
Figure	O
4F	O
)	O
.	O

Slides	O
were	O
incubated	O
with	O
goat	O
serum	O
,	O
then	O
anti	O
-	O
human	O
nonmuscle	O
myosin	O
-	O
IIA	O
rabbit	O
polyclonal	O
antibody	O
(	O
BT561	O
and	O
BT567	O
,	O
Biomedical	O
Technology	O
,	O
CliniSciences	O
,	O
Stoughton	O
,	O
MA	O
)	O
at	O
the	O
selected	O
dilution	O
,	O
and	O
finally	O
with	O
fluorochrome	B-Chemical
-	O
labeled	O
goat	O
anti	O
-	O
rabbit	O
antibody	O
(	O
Goat	O
Anti	O
-	O
Rabbit	O
IgG	O
-	O
TRIT	O
,	O
CliniSciences	O
,	O
Stoughton	O
,	O
MA	O
)	O
.	O

Remarkably	O
,	O
in	O
14	O
of	O
41	O
families	O
that	O
we	O
did	O
not	O
find	O
COL4A3	B-GENE
/	I-GENE
A4	I-GENE
mutations	O
,	O
there	O
were	O
54	O
patients	O
who	O
had	O
solely	O
manifested	O
isolated	O
GMH	B-DISEASE
.	O

RNA	O
was	O
derived	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
the	O
three	O
patients	O
(	O
IV	O
:	O
2	O
,	O
IV	O
:	O
3	O
and	O
III	O
:	O
2	O
)	O
and	O
an	O
unaffected	O
control	O
(	O
IV	O
:	O
1	O
)	O
.	O

The	O
other	O
seven	O
known	O
CLRN1	B-GENE
mutations	O
have	O
been	O
found	O
in	O
either	O
single	O
patients	O
or	O
isolated	O
families	O
with	O
predominantly	O
European	O
ancestry	O
[	O
8	O
,	O
11	O
,	O
18	O
,	O
22	O
,	O
23	O
,	O
29	O
,	O
32	O
-	O
34	O
]	O
.	O

Stratification	O
of	O
patients	O
by	O
sex	O
,	O
age	O
,	O
extent	O
of	O
concurrent	O
smoking	O
,	O
extent	O
of	O
product	O
use	O
,	O
and	O
severity	O
of	O
adverse	O
events	O
revealed	O
no	O
clinically	O
significant	O
differences	O
between	O
the	O
lozenge	O
and	O
gum	O
.	O

Among	O
the	O
genes	O
harboring	O
mutations	O
causing	O
deafness	B-DISEASE
only	O
in	O
the	O
mouse	O
,	O
no	O
deleterious	O
mutations	O
were	O
present	O
in	O
these	O
11	O
human	O
families	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
1253delA	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Y418fsX459	I-VARIANT
)	O
appears	O
to	O
be	O
a	O
disease	O
-	O
causing	O
mutation	O
,	O
because	O
it	O
is	O
predicted	O
that	O
this	O
variant	O
escapes	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
due	O
to	O
its	O
position	O
on	O
the	O
final	O
exon	O
[	O
18	O
]	O
and	O
produces	O
a	O
truncated	O
protein	O
lacking	O
the	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
and	O
most	O
of	O
the	O
transactivation	O
domain	O
(	O
TAD	O
)	O
on	O
exon	O
9C	O
(	O
Fig	O
.	O

We	O
refer	O
to	O
these	O
as	O
germline	O
variants	O
;	O
however	O
,	O
since	O
somatic	O
mutations	O
occur	O
over	O
time	O
[	O
82	O
]	O
some	O
of	O
the	O
variants	O
may	O
have	O
been	O
acquired	O
rather	O
than	O
inherited	O
.	O

We	O
are	O
indebted	O
to	O
Dr	O
.	O

In	O
implanted	O
patients	O
,	O
aided	O
thresholds	O
were	O
measured	O
(	O
Interacoustic	O
AC30	O
Audiometer	O
connected	O
to	O
a	O
Pioneer	O
A	O
103	O
amplifier	O
,	O
JBL	O
TLX130	O
loudspeakers	O
)	O
with	O
subjects	O
wearing	O
their	O
sound	O
processor	O
on	O
user	O
settings	O
.	O

BWA	B-Chemical
mapped	O
95	O
.	O
8	O
%	O
of	O
those	O
reads	O
to	O
the	O
reference	O
genome	O
;	O
and	O
30	O
.	O
7	O
%	O
of	O
them	O
were	O
marked	O
as	O
duplicates	O
.	O

There	O
are	O
2	O
possible	O
explanations	O
for	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
these	O
families	O
:	O
(	O
1	O
)	O
pathogenic	O
mutations	O
exist	O
in	O
1	O
of	O
the	O
80	O
candidate	O
genes	O
studied	O
but	O
in	O
an	O
exon	O
that	O
was	O
not	O
covered	O
by	O
our	O
sequencing	O
(	O
approximately	O
6	O
-	O
10	O
%	O
)	O
or	O
within	O
intronic	O
regulatory	O
sequences	O
,	O
(	O
2	O
)	O
their	O
causative	O
mutation	O
is	O
in	O
an	O
as	O
-	O
yet	O
-	O
unidentified	O
hearing	B-DISEASE
loss	I-DISEASE
gene	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
currently	O
available	O
Next	O
Generation	O
Sequencing	O
(	O
NGS	B-Chemical
)	O
technologies	O
are	O
already	O
suitable	O
for	O
molecular	O
diagnostics	O
of	O
USH	B-DISEASE
.	O

We	O
took	O
(	O
1	O
-	O
P	O
)	O
as	O
a	O
measure	O
of	O
the	O
statistical	O
confidence	O
of	O
the	O
data	O
and	O
conventionally	O
set	O
a	O
threshold	O
of	O
the	O
statistical	O
confidence	O
to	O
be	O
99	O
.	O
9	O
%	O
.	O

Myopathy	B-DISEASE
,	O
defined	O
as	O
muscle	O
symptoms	O
with	O
creatine	B-Chemical
kinase	O
elevations	O
greater	O
than	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
was	O
rare	O
and	O
associated	O
with	O
the	O
highest	O
recommended	O
daily	O
dose	O
of	O
lovastatin	B-Chemical
(	O
80	O
mg	O
)	O
.	O

5F	O
,	O
5G	O
,	O
and	O
5H	O
)	O
.	O

Each	O
validated	O
variant	O
was	O
tested	O
for	O
co	O
-	O
segregation	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
proband	O
'	O
s	O
family	O
.	O

The	O
study	O
on	O
this	O
Chinese	O
family	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Family	O
#	O
51	O
)	O
was	O
approved	O
by	O
the	O
Medical	O
Ethics	O
Committee	O
of	O
Peking	O
University	O
First	O
Hospital	O
.	O

20	O
41	O
42	O
A	O
possible	O
case	O
of	O
digenic	O
inheritance	O
is	O
reported	O
in	O
one	O
(	O
out	O
of	O
75	O
)	O
USH	B-DISEASE
patients	O
who	O
segregated	O
CDH23	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
T1209A	I-VARIANT
and	O
PCDH15	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
T1867del	I-VARIANT
variants	O
20	O
;	O
however	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
T1209A	I-VARIANT
variant	O
was	O
also	O
found	O
in	O
48	O
/	O
904	O
(	O
MAF	O
=	O
5	O
.	O
3	O
%	O
)	O
alleles	O
in	O
the	O
1000	O
Genomes	O
Project	O
which	O
suggests	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
pathogenic	O
(	O
http	O
:	O
/	O
/	O
browser	O
.	O
1000genomes	O
.	O
org	O
/	O
index	O
.	O
html	O
)	O
.	O

H6908	O
,	O
Sigma	O
)	O
.	O

We	O
specifically	O
chose	O
these	O
exons	O
because	O
they	O
encode	O
important	O
structural	O
and	O
/	O
or	O
functional	O
domains	O
in	O
glycoproteins	O
that	O
are	O
structural	O
components	O
of	O
the	O
cartilage	O
growth	O
plate	O
.	O

It	O
is	O
estimated	O
that	O
it	O
affects	O
1	O
in	O
1000	O
child	O
births	O
of	O
which	O
approximately	O
60	O
%	O
cases	O
are	O
attributed	O
to	O
genetic	O
factors	O
[	O
1	O
]	O
.	O

Pure	O
-	O
tone	O
threshold	O
audiometry	O
was	O
performed	O
in	O
58	O
out	O
of	O
65	O
cases	O
and	O
confirmed	O
sensorineural	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
.	O

The	O
difference	O
may	O
due	O
to	O
the	O
relatively	O
small	O
sample	O
size	O
.	O

Recurrent	O
acute	O
interstitial	I-DISEASE
nephritis	I-DISEASE
induced	O
by	O
azithromycin	B-Chemical
.	O

S	O
.	O
F	O
.	O

PAX3	B-GENE
plays	O
a	O
regulatory	O
role	O
in	O
the	O
early	O
embryonic	O
development	O
of	O
the	O
pigment	O
system	O
[	O
22	O
]	O
and	O
is	O
required	O
to	O
expand	O
a	O
pool	O
of	O
committed	O
melanoblasts	O
or	O
restricted	O
progenitor	O
cells	O
early	O
in	O
development	O
[	O
23	O
]	O
.	O

The	O
molecular	O
genetic	O
etiology	O
of	O
ADNSHL	B-DISEASE
is	O
extremely	O
heterogeneous	O
.	O

35	O
)	O
and	O
annotated	O
using	O
the	O
snpEff	B-Chemical
software	O
tool	O
(	O
http	O
:	O
/	O
/	O
snpeff	O
.	O
sourceforge	O
.	O
net	O
/	O
)	O
,	O
as	O
well	O
as	O
visualization	O
tools	O
from	O
PerkinElmer	B-Chemical
.	O

All	O
patients	O
with	O
SLC26A4	B-GENE
mutations	O
or	O
variants	O
were	O
subjected	O
to	O
high	O
-	O
resolution	O
temporal	O
bone	O
CT	O
scan	O
to	O
verify	O
the	O
enlarged	O
vestibular	O
aqueduct	O
.	O

Four	O
cases	O
of	O
water	O
intoxication	O
in	O
connection	O
with	O
oxytocin	B-Chemical
administration	O
during	O
saline	O
-	O
induced	O
abortions	O
are	O
described	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
find	O
out	O
whether	O
the	O
metabotropic	B-GENE
receptor	I-GENE
1	I-GENE
(	O
mGluR1	B-GENE
)	O
and	O
group	O
II	O
mGluRs	O
,	O
localized	O
in	O
the	O
striatum	O
,	O
are	O
involved	O
in	O
antiparkinsonian	O
-	O
like	O
effects	O
in	O
rats	O
.	O

We	O
sequenced	O
coding	O
region	O
of	O
a	O
set	O
of	O
19	O
genes	O
(	O
Supplementary	O
Table	O
3	O
)	O
in	O
nine	O
patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
hereditary	O
nephritis	B-DISEASE
or	O
AS	B-DISEASE
and	O
five	O
FSGS	B-DISEASE
patients	O
.	O

The	O
PCR	O
programme	O
comprised	O
94	O
deg	O
C	O
for	O
3	O
min	O
,	O
94	O
deg	O
C	O
for	O
30	O
s	O
,	O
20	O
touchdown	O
cycles	O
65	O
deg	O
C	O
to	O
55	O
deg	O
C	O
,	O
20	O
cycles	O
55	O
deg	O
C	O
for	O
30	O
s	O
,	O
72	O
deg	O
C	O
for	O
1	O
min	O
,	O
and	O
72	O
deg	O
C	O
for	O
5	O
min	O
.	O

Minimum	O
coverage	O
obtained	O
with	O
different	O
enrichments	O
methods	O
.	O

Although	O
several	O
cases	O
with	O
reversal	O
of	O
HH	B-DISEASE
have	O
been	O
described	O
[	O
6	O
]	O
-	O
[	O
21	O
]	O
,	O
the	O
clinical	O
and	O
molecular	O
genetic	O
features	O
of	O
these	O
patients	O
,	O
and	O
the	O
triggers	O
leading	O
to	O
reversal	O
of	O
HH	B-DISEASE
are	O
not	O
well	O
understood	O
.	O

In	O
cells	O
transfected	O
with	O
wild	O
-	O
type	O
EDNRB	B-GENE
isoform	O
1	O
/	O
GFP	O
,	O
signals	O
were	O
detected	O
at	O
the	O
plasma	O
membrane	O
only	O
(	O
Figure	O
2A	O
)	O
.	O

Performed	O
the	O
experiments	O
:	O
XG	O
YS	O
SSH	O
YL	O
.	O

His	O
laboratory	O
values	O
showed	O
elevated	O
creatine	B-Chemical
kinase	O
and	O
transaminases	O
.	O

RA	B-Chemical
alone	O
did	O
not	O
induce	O
hyperplastic	O
changes	O
in	O
the	O
forestomach	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
University	O
of	O
W	O
u	O
rzburg	O
.	O

This	O
amplified	O
enriched	O
DNA	O
was	O
used	O
as	O
input	O
for	O
emulsion	O
PCR	O
(	O
emPCR	O
)	O
and	O
subsequent	O
massively	O
parallel	O
sequencing	O
on	O
one	O
full	O
PTP	O
of	O
a	O
Roche	O
454	O
GS	O
FLX	O
platform	O
or	O
as	O
input	O
for	O
direct	O
cluster	O
generation	O
and	O
sequencing	O
on	O
the	O
Illumina	O
MiSeq	O
system	O
(	O
2	O
x	O
150	O
bp	O
paired	O
-	O
end	O
reads	O
)	O
.	O

We	O
found	O
no	O
significant	O
differences	O
in	O
the	O
spectrum	O
or	O
prevalence	O
of	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
between	O
patients	O
from	O
Chifeng	O
City	O
and	O
those	O
from	O
Nantong	O
City	O
.	O

In	O
addition	O
,	O
sporadic	O
cases	O
(	O
sRP	B-DISEASE
)	O
have	O
been	O
described	O
,	O
representing	O
40	O
%	O
-	O
50	O
%	O
of	O
non	O
-	O
syndromic	O
RP	B-DISEASE
cases	O
[	O
1	O
]	O
.	O

The	O
data	O
were	O
subsequently	O
compared	O
with	O
the	O
wild	O
-	O
type	O
OTOF	B-GENE
(	O
NG_009937	O
.	O
1	O
,	O
NM_194248	O
.	O
2	O
)	O
and	O
PJVK	B-GENE
(	O
NG_0012186	O
.	O
1	O
,	O
NM_001042702	O
.	O
3	O
)	O
sequences	O
,	O
and	O
a	O
panel	O
of	O
105	O
controls	O
verified	O
it	O
.	O

For	O
example	O
,	O
subsequent	O
exome	O
sequencing	O
for	O
patient	O
15	O
identified	O
a	O
homozygous	O
nonsense	O
mutation	O
in	O
IMPG2	B-GENE
(	O
data	O
not	O
shown	O
)	O
.	O

Sequence	O
read	O
data	O
of	O
the	O
patient	O
in	O
this	O
article	O
has	O
been	O
deposited	O
into	O
Sequence	O
Read	O
Archive	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
sra	O
webcite	O
;	O
accession	O
number	O
SRR1106702	O
)	O
.	O

There	O
was	O
no	O
clear	O
effect	O
of	O
age	O
and	O
in	O
broad	O
terms	O
the	O
full	O
spectrum	O
of	O
variation	O
in	O
visual	O
acuity	O
was	O
present	O
throughout	O
the	O
age	O
range	O
that	O
was	O
surveyed	O
.	O

The	O
clinical	O
course	O
of	O
the	O
five	O
patients	O
with	O
compound	O
heterozygous	O
or	O
homozygous	O
CNGA1	B-GENE
mutations	O
included	O
night	B-DISEASE
blindness	I-DISEASE
from	O
childhood	O
,	O
visual	B-DISEASE
field	I-DISEASE
loss	I-DISEASE
in	O
middle	O
age	O
,	O
non	O
-	O
recordable	O
ERG	O
and	O
characteristic	O
retinal	B-DISEASE
degeneration	I-DISEASE
pattern	O
of	O
RP	B-DISEASE
,	O
which	O
were	O
consistent	O
with	O
previously	O
reported	O
phenotypes	O
of	O
CNGA1	B-GENE
mutations	O
[	O
32	O
]	O
,	O
[	O
34	O
]	O
.	O

The	O
row	O
data	O
were	O
mapped	O
using	O
the	O
Burrows	O
Wheeler	O
Aligner	O
[	O
36	O
]	O
,	O
the	O
variants	O
were	O
called	O
using	O
the	O
Unified	O
Genotyper	O
,	O
and	O
the	O
data	O
underwent	O
further	O
processing	O
and	O
quality	O
control	O
[	O
35	O
]	O
,	O
[	O
36	O
]	O
.	O

In	O
the	O
Hungarian	O
subgroup	O
,	O
all	O
homozygous	O
probands	O
had	O
bilateral	B-DISEASE
severe	I-DISEASE
to	I-DISEASE
profound	I-DISEASE
deafness	I-DISEASE
with	O
minimal	O
residual	O
hearing	O
.	O

The	O
gene	O
lists	O
were	O
further	O
curated	O
based	O
on	O
their	O
expression	O
patterns	O
,	O
functional	O
significance	O
in	O
disease	O
models	O
and	O
mutations	O
in	O
human	O
kidney	O
disease	O
.	O

Although	O
short	O
term	O
remission	O
of	O
severe	O
RA	B-DISEASE
following	O
BMT	B-DISEASE
has	O
been	O
reported	O
,	O
these	O
are	O
the	O
first	O
cases	O
for	O
which	O
prolonged	O
followup	O
has	O
been	O
available	O
.	O

Furthermore	O
,	O
four	O
of	O
these	O
five	O
variants	O
have	O
been	O
previously	O
associated	O
with	O
disease	O
and	O
are	O
curated	O
in	O
the	O
Leiden	O
Open	O
Variation	O
Database	O
(	O
https	O
:	O
/	O
/	O
granada	O
.	O
lumc	B-Chemical
.	O
nl	O
/	O
LOVD2	O
/	O
)	O
.	O

The	O
visual	O
field	O
loss	O
was	O
concentric	O
,	O
and	O
the	O
degree	O
of	O
visual	O
acuity	O
ranged	O
from	O
0	O
.	O
15	O
to	O
0	O
.	O
8	O
,	O
depending	O
on	O
the	O
age	O
at	O
ophthalmological	O
evaluation	O
and	O
the	O
degree	O
of	O
progression	O
of	O
the	O
disease	O
.	O

There	O
was	O
no	O
significant	O
family	O
history	O
(	O
Supplementary	O
Note	O
)	O
.	O

Shaltz	O
,	O
A	O
.	O

Volume	O
scans	O
were	O
quantitatively	O
analyzed	O
using	O
computer	O
-	O
assisted	O
manual	O
grading	O
software	O
(	O
3D	O
-	O
OCTOR	O
)	O
,	O
which	O
facilitates	O
manual	O
delineation	O
of	O
various	O
retinal	O
layers	O
.	O

Knowing	O
that	O
heart	O
mitochondria	O
represent	O
almost	O
40	O
%	O
of	O
heart	O
muscle	O
by	O
weight	O
,	O
we	O
conclude	O
that	O
the	O
deteriorating	O
effects	O
of	O
ADR	B-Chemical
on	O
cardiovascular	O
function	O
involve	O
mitochondrial	B-DISEASE
structural	O
and	O
functional	I-DISEASE
impairment	I-DISEASE
.	O

For	O
a	O
given	O
electrode	O
location	O
,	O
decreasing	O
current	O
levels	O
resulted	O
in	O
increased	O
latencies	O
and	O
attenuated	O
wave	O
V	O
amplitudes	O
(	O
vertical	O
dashed	O
lines	O
,	O
right	O
)	O
.	O

5A	O
)	O
.	O

We	O
identified	O
a	O
novel	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
257	I-VARIANT
-	I-VARIANT
262CCTTTC	I-VARIANT
>	I-VARIANT
GCT	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT

Cerebral	B-DISEASE
hemorrhage	I-DISEASE
associated	O
with	O
phenylpropanolamine	B-Chemical
in	O
combination	O
with	O
caffeine	B-Chemical
.	O

The	O
activity	O
of	O
the	O
firefly	B-Chemical
luciferase	O
was	O
normalised	O
to	O
that	O
of	O
renilla	O
luciferase	O
.	O

The	O
long	O
-	O
term	O
safety	O
of	O
danazol	B-Chemical
in	O
women	O
with	O
hereditary	O
angioedema	B-DISEASE
.	O

Baseline	O
,	O
liver	O
function	O
tests	O
were	O
elevated	O
in	O
two	O
patients	O
(	O
fourth	O
patient	O
:	O
ALT	O
:	O
122	O
IU	O
/	O
l	O
,	O
AST	O
:	O
111	O
IU	O
/	O
l	O
,	O
tenth	O
patient	O
:	O
ALT	O
:	O
294	O
IU	O
/	O
l	O
,	O
AST	O
:	O
274	O
IU	O
/	O
l	O
,	O
with	O
minimal	O
changes	O
in	O
the	O
liver	O
biopsy	O
in	O
both	O
)	O
.	O

Filled	O
symbols	O
for	O
males	O
(	O
squares	O
)	O
and	O
females	O
(	O
circles	O
)	O
represent	O
affected	O
individuals	O
,	O
and	O
empty	O
,	O
unaffected	O
ones	O
.	O

Swaroop	O
and	O
A	O
.	O
J	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
genetically	O
confirmed	O
case	O
of	O
USH	B-DISEASE
in	O
Korea	O
.	O

The	O
results	O
show	O
that	O
the	O
patient	O
heterozygous	O
for	O
a	O
guanine	B-Chemical
(	O
G	B-Chemical
;	O
yellow	O
peak	O
)	O
to	O
cytosine	B-Chemical
(	O
C	B-Chemical
;	O
blue	O
peak	O
)	O
exchange	O
at	O
this	O
position	O
,	O
which	O
translates	O
into	O
a	O
lysine	B-Chemical
to	O
asparagine	B-Chemical
amino	O
acid	O
substitution	O
at	O
position	O
836	O
of	O
the	O
corresponding	O
protein	O
.	O

Clinical	O
characteristics	O
,	O
medications	O
,	O
and	O
serum	O
chemistries	O
at	O
baseline	O
and	O
follow	O
-	O
up	O
time	O
periods	O
were	O
compared	O
.	O

To	O
evaluate	O
the	O
performance	O
of	O
targets	O
,	O
we	O
calculated	O
the	O
average	O
coverage	O
of	O
each	O
target	O
across	O
all	O
100	O
samples	O
(	O
Supp	O
.	O

reported	O
SCN5A	B-GENE
p	B-VARIANT
.	I-VARIANT
A572D	I-VARIANT
as	O
a	O
mutation	O
in	O
3	O
of	O
their	O
patients	O
[	O
13	O
]	O
.	O

Autosomal	B-DISEASE
Dominant	I-DISEASE
Optic	I-DISEASE
Atrophy	I-DISEASE
(	O
ADOA	B-DISEASE
)	O
is	O
due	O
in	O
about	O
60	O
-	O
70	O
%	O
of	O
cases	O
to	O
mutations	O
in	O
the	O
nuclear	O
gene	O
encoding	O
for	O
the	O
OPA1	B-GENE
protein	O
,	O
mapping	O
to	O
chromosome	O
3q28	O
-	O
29	O
.	O

a	O
Longitudinal	O
individual	O
measurements	O
of	O
individuals	O
A5	O
,	O
D4	O
,	O
D6	O
,	O
D7	O
,	O
E8	O
,	O
E9	O
,	O
E10	O
,	O
E13	O
,	O
F3	O
,	O
G3	O
,	O
H3	O
,	O
and	O
H5	O
for	O
each	O
frequency	O
separately	O
(	O
different	O
symbols	O
for	O
each	O
individual	O
;	O
Cremers	O
et	O
al	O
.	O

The	O
remaining	O
50	O
%	O
of	O
congenital	O
cases	O
are	O
attributable	O
to	O
other	O
factors	O
such	O
as	O
prenatal	O
exposure	O
to	O
measles	O
,	O
cytomegalovirus	O
,	O
premature	O
birth	O
,	O
and	O
newborn	O
meningitis	O
.	O

As	O
anticipated	O
,	O
animals	O
exhibited	O
a	O
progressive	O
increase	O
in	O
levodopa	B-Chemical
-	O
induced	O
motor	B-DISEASE
fluctuations	I-DISEASE
,	O
dyskinesia	B-DISEASE
and	O
wearing	B-DISEASE
-	I-DISEASE
off	O
,	O
that	O
correlated	O
with	O
the	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
.	O

Brain	O
MRI	O
from	O
T1	O
-	O
(	O
c	O
)	O
and	O
T2	O
-	O
weighted	O
(	O
d	O
)	O
images	O
show	O
abnormally	B-DISEASE
wide	I-DISEASE
cerebral	I-DISEASE
convolutions	I-DISEASE
and	O
thick	B-DISEASE
cortex	I-DISEASE
(	O
double	O
arrows	O
)	O
in	O
all	O
regions	O
,	O
with	O
the	O
malformation	O
more	O
severe	O
in	O
anterior	O
than	O
in	O
posterior	O
regions	O
.	O

Nineteen	O
variants	O
were	O
examined	O
in	O
nine	O
families	O
by	O
Sanger	O
sequencing	O
in	O
all	O
the	O
family	O
members	O
to	O
exclude	O
8	O
variants	O
.	O

Patient	O
USH02	O
-	O
II	O
:	O
1	O
and	O
USH03	O
-	O
II	O
:	O
1	O
were	O
screened	O
using	O
microarray	O
#	O
2	O
.	O

As	O
patient	O
3	O
was	O
part	O
of	O
routine	O
deafness	B-DISEASE
screening	O
,	O
specific	O
ethical	O
approval	O
was	O
not	O
required	O
.	O

6	O
Hitherto	O
,	O
only	O
30	O
distinct	O
deafness	B-DISEASE
genes	O
have	O
been	O
identified	O
while	O
64	O
DFNA	B-DISEASE
loci	O
have	O
been	O
mapped	O
in	O
the	O
past	O
two	O
decades	O
(	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
)	O
.	O

Such	O
ambiguities	O
highlight	O
the	O
limitations	O
of	O
traditional	O
gene	O
sequencing	O
approaches	O
that	O
examine	O
only	O
coding	O
and	O
near	O
-	O
coding	O
regions	O
of	O
known	O
causative	O
genes	O
.	O

The	O
most	O
striking	O
observation	O
in	O
this	O
study	O
was	O
a	O
significantly	O
lower	O
risk	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
recurrence	O
(	O
0	O
.	O
03	O
(	O
1	O
/	O
38	O
)	O
)	O
in	O
the	O
undiagnosed	O
group	O
than	O
in	O
the	O
control	O
group	O
segregating	O
autosomal	B-DISEASE
recessive	I-DISEASE
deafness	I-DISEASE
.	O

Tecta	B-GENE
,	O
Tectb	B-GENE
and	O
otogelin	B-GENE
are	O
proteins	O
that	O
are	O
only	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
inner	O
ear	O
and	O
they	O
account	O
for	O
~	O
50	O
%	O
of	O
the	O
protein	O
present	O
in	O
the	O
tectorial	O
membrane	O
[	O
3	O
]	O
,	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
.	O

For	O
other	O
variants	O
,	O
IVS11	B-VARIANT
+	I-VARIANT
47	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
2265C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
IVS5	B-VARIANT
+	I-VARIANT
27	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
IVS7	B-VARIANT
+	I-VARIANT
35A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
IVS7	B-VARIANT
+	I-VARIANT
40G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
intro6	B-VARIANT
-	I-VARIANT
75	I-VARIANT
-	I-VARIANT
76insTGTG	I-VARIANT
,	O
the	O
NNSPLICE	O
software	O
,	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
fruitfly	O
.	O
org	O
/	O
seq_tools	O
/	O
splice	O
.	O
html	O
was	O
used	O
for	O
analysis	O
.	O

All	O
mutations	O
were	O
detected	O
in	O
only	O
one	O
patient	O
each	O
and	O
sixteen	O
of	O
the	O
17	O
patients	O
(	O
94	O
.	O
1	O
%	O
)	O
carried	O
at	O
least	O
one	O
mutation	O
,	O
while	O
one	O
patient	O
had	O
no	O
mutations	O
.	O

Coronary	B-DISEASE
spasm	I-DISEASE
was	O
induced	O
by	O
intracoronary	O
injection	O
of	O
acetylcholine	B-Chemical
,	O
and	O
no	O
fixed	O
coronary	B-DISEASE
artery	I-DISEASE
stenosis	I-DISEASE
was	O
documented	O
on	O
angiograms	O
in	O
all	O
patients	O
.	O

In	O
the	O
present	O
study	O
,	O
cis	B-Chemical
-	I-Chemical
platin	I-Chemical
(	O
80	O
-	O
120	O
mg	O
/	O
m2BSA	O
)	O
and	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
m2BSA	O
daily	O
as	O
a	O
continuous	O
infusion	O
during	O
5	O
days	O
)	O
were	O
given	O
to	O
76	O
patients	O
before	O
radiotherapy	O
and	O
surgery	O
.	O

Additional	O
investigation	O
is	O
needed	O
to	O
provide	O
the	O
fundamental	O
information	O
required	O
for	O
an	O
accurate	O
prediction	O
of	O
the	O
genetic	O
cause	O
of	O
the	O
patients	O
diagnosed	O
with	O
NSHL	B-DISEASE
in	O
the	O
Korean	O
population	O
.	O
We	O
used	O
an	O
unbiased	O
genome	O
-	O
wide	O
approach	O
to	O
identify	O
exonic	O
variants	O
segregating	O
with	O
diabetes	B-DISEASE
in	O
a	O
multigenerational	O
Finnish	O
family	O
.	O

Oral	O
manifestations	O
of	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
"	O
:	O
a	O
case	O
report	O
.	O

The	O
N	O
-	O
and	O
C	O
-	O
terminal	O
amino	O
acid	O
sequences	O
called	O
propeptides	O
are	O
cleaved	O
after	O
the	O
secretion	O
of	O
procollagen	O
in	O
the	O
extracellular	O
matrix	O
[	O
14	O
]	O
.	O

NRA0160	B-Chemical
has	O
negligible	O
affinity	O
for	O
the	O
human	O
cloned	O
dopamine	B-Chemical
D3	O
receptor	O
(	O
Ki	O
=	O
39	O
nM	O
)	O
,	O
rat	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	I-GENE
2A	I-GENE
receptors	O
(	O
Ki	O
=	O
180	O
nM	O
)	O
and	O
rat	O
alpha1	O
adrenoceptor	O
(	O
Ki	O
=	O
237	O
nM	O
)	O
.	O

One	O
of	O
them	O
was	O
mutations	O
in	O
GJB2	B-GENE
,	O
which	O
were	O
used	O
as	O
a	O
positive	O
control	O
because	O
it	O
is	O
well	O
known	O
for	O
causing	O
severe	O
prelingual	O
hearing	B-DISEASE
loss	I-DISEASE
as	O
for	O
the	O
patient	O
SH35	O
-	O
75	O
.	O

Pretreatment	O
of	O
rats	O
with	O
sodium	B-Chemical
salicylate	I-Chemical
,	O
ED50	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
phenylbutazone	B-Chemical
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
non	O
-	O
convulsant	O
dose	O
of	O
pilocarpine	B-Chemical
,	O
200	O
mg	O
/	O
kg	O
,	O
to	O
a	O
convulsant	O
one	O
.	O

We	O
analyzed	O
the	O
nine	O
USH	B-DISEASE
genes	O
in	O
a	O
cohort	O
of	O
54	O
French	O
patients	O
,	O
of	O
whom	O
27	O
were	O
affected	O
by	O
USH1	B-DISEASE
,	O
21	O
by	O
USH2	B-DISEASE
,	O
and	O
six	O
by	O
USH3	B-DISEASE
.	O

For	O
these	O
putative	O
splicing	O
variants	O
,	O
the	O
exon	O
and	O
intronic	O
flanking	O
sequences	O
were	O
amplified	O
from	O
the	O
patient	O
'	O
s	O
DNA	O
,	O
using	O
the	O
High	O
Fidelity	O
Phusion	O
polymerase	O
(	O
Finnzymes	O
,	O
Espoo	O
,	O
Finland	O
)	O
with	O
primers	O
detailed	O
in	O
Table	O
1	O
.	O

The	O
presence	O
or	O
absence	O
of	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
aggregates	O
was	O
studied	O
using	O
an	O
immunofluorescence	O
(	O
IF	O
)	O
technique	O
adapted	O
from	O
Kunishima	O
et	O
al	O
.	O

This	O
image	O
shows	O
in	O
vitro	O
motility	O
activity	O
of	O
WT	O
(	O
open	O
bar	O
)	O
and	O
p	B-VARIANT
.	I-VARIANT
R205Q	I-VARIANT
(	O
closed	O
bar	O
)	O
.	O

Scheme	O
of	O
the	O
CRX	B-GENE
gene	O
and	O
coverage	O
plots	O
for	O
CNV	O
analysis	O
from	O
NGS	O
data	O
(	O
Illumina	O
MiSeq	O
)	O
,	O
indicating	O
a	O
heterozygous	O
deletion	O
of	O
exon	O
4	O
(	O
upper	O
panel	O
,	O
absolute	O
coverage	O
based	O
on	O
read	O
count	O
;	O
lower	O
panel	O
,	O
SeqNext	B-Chemical
CNV	O
analysis	O
)	O
.	O

In	O
the	O
five	O
USHIC	B-GENE
families	O
studied	O
,	O
six	O
new	O
changes	O
(	O
p	B-VARIANT
.	I-VARIANT
V66V	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R412H	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A1425V	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
N1667K	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
9510	I-VARIANT
+	I-VARIANT
13C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
D3253A	I-VARIANT
)	O
were	O
observed	O
as	O
heterozygous	O
variants	O
in	O
addition	O
to	O
several	O
known	O
polymorphisms	O
in	O
CDH23	B-GENE
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
commercially	O
available	O
software	O
(	O
Sigma	O
Plot	O
for	O
Windows	O
version	O
11	O
.	O
0	O
Systat	O
Software	O
Inc	O
.	O
,	O
Germany	O
)	O
.	O

(	O
A	O
)	O
Sanger	O
sequence	O
of	O
the	O
KCNQ4	B-GENE
p	B-VARIANT
.	I-VARIANT
S680F	I-VARIANT
variant	O
.	O

For	O
the	O
first	O
time	O
,	O
the	O
functional	O
non	O
-	O
splicing	O
of	O
intron	O
was	O
revealed	O
in	O
a	O
novel	O
DSPP	B-GENE
mutation	O
and	O
was	O
considered	O
as	O
the	O
causation	O
of	O
DGI	B-DISEASE
-	I-DISEASE
II	I-DISEASE
.	O

ERG	O
presentations	O
of	O
a	O
control	O
individual	O
are	O
also	O
demonstrated	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	O
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine	B-Chemical
-	O
[	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
chloroethyl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nitrosoure	I-Chemical
]	O
(	O
BCNU	B-Chemical
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	B-Chemical
upon	O
cerebellar	O
BCNU	B-Chemical
-	O
induced	O
cortical	B-DISEASE
dysplasia	I-DISEASE
,	O
using	O
histological	O
and	O
biochemical	O
analyses	O
.	O

The	O
Mini	O
Mental	O
State	O
Examination	O
was	O
conducted	O
on	O
the	O
three	O
patients	O
in	O
family	O
2423	O
(	O
III	O
:	O
1	O
,	O
III	O
:	O
9	O
and	O
III	O
:	O
11	O
)	O
.	O

Wrote	O
the	O
paper	O
:	O
YS	B-Chemical
PD	O
.	O

Outcomes	O
included	O
venous	B-DISEASE
thromboembolism	I-DISEASE
,	O
cataracts	B-DISEASE
,	O
gallbladder	B-DISEASE
disease	I-DISEASE
,	O
and	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
or	O
cancer	B-DISEASE
.	O

In	O
the	O
course	O
of	O
this	O
work	O
,	O
we	O
verified	O
that	O
RNA	O
obtained	O
from	O
saliva	O
samples	O
was	O
a	O
source	O
of	O
GJB2	B-GENE
transcripts	O
.	O

A	O
significant	O
rise	O
in	O
cTnT	O
was	O
found	O
in	O
DOX	B-Chemical
rats	O
after	O
cumulative	O
doses	O
of	O
7	O
.	O
5	O
and	O
12	O
mg	O
/	O
kg	O
in	O
comparison	O
with	O
baseline	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
signifies	O
the	O
potential	O
role	O
of	O
the	O
UPR	O
cascade	O
in	O
modulating	O
the	O
final	O
phenotype	O
in	O
patients	O
with	O
collagen	O
IV	O
nephropathies	O
.	O

This	O
outcome	O
was	O
confirmed	O
by	O
in	O
silico	O
predictions	O
(	O
Table	O
3	O
)	O
.	O

Differences	O
between	O
groups	O
were	O
analyzed	O
by	O
chi	O
square	O
statistics	O
.	O

7K1	O
and	O
7K2	O
primers	O
were	O
designed	O
by	O
primer3	O
ver	O
.	O

For	O
a	O
certificate	O
,	O
please	O
see	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
textcheck	O
.	O
com	O
/	O
certificate	O
/	O
I3NwIG	O
.	O

Two	O
hundred	O
controls	O
with	O
normal	O
hearing	O
were	O
sequenced	O
to	O
determine	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
GJB2	B-GENE
and	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
polymorphisms	O
.	O

All	O
indels	O
and	O
failing	O
variants	O
were	O
removed	O
.	O

Cells	O
were	O
incubated	O
in	O
a	O
5	O
%	O
CO2	O
-	O
humidified	O
incubator	O
at	O
37	O
deg	O
C	O
.	O

Pedigrees	O
of	O
the	O
four	O
families	O
of	O
six	O
ADOA	B-DISEASE
patients	O
.	O

Additionally	O
,	O
the	O
identification	O
of	O
less	O
striking	O
but	O
previously	O
-	O
reported	O
pathogenic	O
changes	O
would	O
also	O
suffice	O
to	O
provide	O
molecular	O
diagnoses	O
to	O
dominant	O
RD	B-DISEASE
cases	O
.	O

Finally	O
,	O
after	O
a	O
Soave	O
operation	O
,	O
the	O
patient	O
was	O
discharged	O
(	O
in	O
1968	O
)	O
in	O
excellent	O
conditions	O
.	O

Among	O
users	O
of	O
aspirin	B-Chemical
,	O
both	O
celecoxib	B-Chemical
and	O
naproxen	B-Chemical
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O

The	O
wild	O
type	O
allele	O
corresponds	O
to	O
a	O
237	O
-	O
bp	O
band	O
.	O

Although	O
both	O
LCPD	B-DISEASE
and	O
ANFH	B-DISEASE
are	O
both	O
collagenopathies	B-DISEASE
,	O
relevant	O
studies	O
have	O
not	O
reported	O
the	O
two	O
diseases	O
in	O
one	O
family	O
with	O
the	O
same	O
mutation	O
.	O

This	O
is	O
similar	O
to	O
that	O
observed	O
by	O
Abadie	O
et	O
al	O
.	O

OCT	O
imaging	O
in	O
II	O
:	O
1	O
and	O
II	O
:	O
3	O
showed	O
normal	O
macular	O
thickness	O
(	O
Figure	O
2E	O
-	O
H	O
)	O
.	O

We	O
characterize	O
the	O
clinical	O
,	O
neurophysiological	O
,	O
and	O
neuroimaging	O
findings	O
in	O
a	O
72	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
visual	B-DISEASE
loss	I-DISEASE
and	O
paresthesias	O
after	O
11	O
weeks	O
of	O
exposure	O
to	O
a	O
supratherapeutic	O
dose	O
of	O
ethambutol	B-Chemical
.	O

Four	O
unrelated	O
Tunisian	O
families	O
including	O
deaf	B-DISEASE
individuals	O
were	O
included	O
in	O
this	O
study	O
based	O
on	O
parental	O
consanguinity	O
and	O
the	O
presence	O
of	O
at	O
least	O
two	O
affected	O
siblings	O
(	O
Figure	O
1	O
)	O
.	O

A	O
and	O
B	O
show	O
the	O
result	O
for	O
IV	O
:	O
1	O
who	O
is	O
normal	O
,	O
C	O
and	O
D	O
show	O
mild	O
hearing	B-DISEASE
loss	I-DISEASE
for	O
III	O
:	O
5	O
.	O

Run	O
-	O
to	O
-	O
run	O
variations	O
in	O
the	O
error	O
occurrence	O
(	O
>	O
1	O
%	O
frequency	O
)	O
a	O
The	O
number	O
of	O
positions	O
where	O
the	O
error	O
rates	O
in	O
each	O
category	O
were	O
commonly	O
>	O
1	O
%	O
for	O
both	O
strands	O
in	O
two	O
independent	O
runs	O
.	O

MC	O
and	O
PFS	O
contributed	O
to	O
the	O
design	O
of	O
the	O
study	O
,	O
performed	O
experiments	O
and	O
data	O
analysis	O
,	O
interpretation	O
of	O
the	O
results	O
and	O
wrote	O
the	O
manuscript	O
.	O

CH	O
,	O
HLL	O
,	O
and	O
QS	O
carried	O
out	O
the	O
mutational	O
analysis	O
with	O
PCR	O
.	O

Protein	O
sequence	O
alignments	O
with	O
partial	O
type	O
II	O
collagen	O
sequences	O
from	O
multiple	O
species	O
(	O
Homo	O
sapiens	O
,	O
Mus	O
musculus	O
,	O
Rattus	O
norvegicus	O
,	O
Canis	O
lupus	O
familiaris	O
,	O
Oryctolagus	O
cuniculus	O
and	O
Gallus	O
gallus	O
)	O
were	O
analyzed	O
by	O
DNAMAN	O
software	O
.	O

Previously	O
,	O
CD164	B-GENE
have	O
been	O
studied	O
in	O
Drosophila	O
and	O
recently	O
in	O
zebrafish	O
.	O

The	O
mutant	O
transcript	O
contained	O
an	O
insertion	O
of	O
an	O
additional	O
23	O
bp	O
at	O
the	O
start	O
of	O
exon	O
9	O
which	O
corresponded	O
to	O
the	O
creation	O
of	O
an	O
acceptor	O
splice	O
site	O
by	O
the	O
mutation	O
,	O
as	O
predicted	O
by	O
in	O
silico	O
analysis	O
.	O

Copy	O
number	O
variant	O
analysis	O
was	O
performed	O
as	O
described	O
(	O
Nord	O
et	O
al	O
.	O

Specifically	O
,	O
the	O
unmyelinated	O
portion	O
of	O
auditory	O
nerve	O
terminals	O
could	O
be	O
primarily	O
involved	O
by	O
the	O
degenerative	O
process	O
due	O
to	O
the	O
high	O
metabolic	O
demand	O
for	O
spike	O
conduction	O
,	O
as	O
occurs	O
for	O
unmyelinated	O
pre	O
-	O
laminar	O
axons	O
of	O
the	O
papillo	O
-	O
macular	O
bundle	O
in	O
the	O
optic	O
nerve	O
(	O
Carelli	O
et	O
al	O
.	O

OPA1	B-GENE
mRNA	O
exists	O
as	O
eight	O
isoforms	O
as	O
a	O
result	O
of	O
alternate	O
splicing	O
of	O
exons	O
4	O
,	O
4b	O
and	O
5b	O
,	O
and	O
from	O
an	O
evolutionary	O
perspective	O
,	O
exons	O
4b	O
and	O
5b	O
are	O
only	O
found	O
in	O
higher	O
vertebrates	O
with	O
a	O
putative	O
role	O
in	O
regulating	O
cytochrome	O
c	O
release	O
during	O
apoptosis	O
(	O
Olichon	B-Chemical
et	O
al	O
.	O

A	O
genome	O
scan	O
of	O
a	O
large	O
consanguineous	O
Pakistani	O
pedigree	O
with	O
ARNSHI	B-DISEASE
established	O
linkage	O
with	O
a	O
maximum	O
multipoint	O
LOD	O
score	O
of	O
4	O
.	O
2	O
to	O
the	O
14q24	O
region	O
and	O
the	O
region	O
of	O
homozygosity	O
contained	O
the	O
ESRRB	B-GENE
gene	O
.	O

Recently	O
,	O
recessive	O
mutations	O
in	O
the	O
COL11A1	B-GENE
gene	O
have	O
been	O
demonstrated	O
to	O
result	O
in	O
fibrochondrogenesis	B-DISEASE
,	O
a	O
much	O
more	O
severe	O
skeletal	B-DISEASE
dysplasia	I-DISEASE
,	O
which	O
is	O
often	O
lethal	O
.	O

Methodologically	O
,	O
the	O
procedures	O
used	O
were	O
in	O
general	O
rather	O
simple	O
.	O

Yet	O
,	O
her	O
older	O
sister	O
,	O
who	O
carried	O
the	O
same	O
mutation	O
and	O
presented	O
with	O
similar	O
symptoms	O
,	O
displayed	O
physiologically	O
normal	O
audiometry	O
findings	O
.	O

Their	O
mother	O
suffered	O
from	O
poor	B-DISEASE
vision	I-DISEASE
and	O
died	O
at	O
the	O
age	O
of	O
38	O
for	O
breast	B-DISEASE
cancer	I-DISEASE
.	O

Chorea	O
associated	O
with	O
oral	B-Chemical
contraception	I-Chemical
.	O

Figure	O
S4	O
.	O

Bi	O
-	O
allelic	O
mutations	O
identified	O
in	O
recessive	O
deaf	B-DISEASE
probands	O
*	O
Multiplex	O
probands	O
with	O
bi	O
-	O
allelic	O
variants	O
also	O
detected	O
in	O
their	O
deaf	B-DISEASE
relatives	O
;	O
a	O
Score	O
ranges	O
from	O
-	O
14	O
(	O
not	O
conserved	O
)	O
to	O
6	O
(	O
conserved	O
)	O
;	O
b	O
Negative	O
and	O
positive	O
scores	O
indicated	O
deleterious	O
and	O
neutral	O
function	O
,	O
respectively	O
,	O
with	O
cut	O
-	O
off	O
score	O
set	O
at	O
-	O
1	O
.	O
3	O
;	O
c	O
Score	O
ranges	O
from	O
0	O
(	O
deleterious	O
)	O
to	O
1	O
(	O
neutral	O
)	O
,	O
with	O
cut	O
-	O
off	O
score	O
set	O
at	O
0	O
.	O
05	O
;	O
c	O
DC	O
:	O
Disease	O
causing	O
;	O
d	O
PO	O
:	O
Polymorphism	O
.	O

"	O
If	O
the	O
difference	O
between	O
wt	O
and	O
mut	O
is	O
>	O
0	O
.	O
05	O
,	O
it	O
is	O
"	O
unknown	O
,	O
"	O
;	O
otherwise	O
it	O
is	O
"	O
benign	O
"	O
(	O
see	O
Supp	O
.	O

A	O
frequently	O
fatal	O
,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	B-Chemical
is	O
necrotizing	B-DISEASE
eosinophilic	I-DISEASE
(	O
hypersensitivity	B-DISEASE
)	O
myocarditis	B-DISEASE
.	O

24	O
Mapping	O
of	O
mutations	O
L165S	B-VARIANT
and	O
L191S	B-VARIANT
on	O
crystal	O
structure	O
.	O

In	O
both	O
cases	O
,	O
discontinuation	O
of	O
FK506	B-Chemical
and	O
treatment	O
with	O
plasma	O
exchange	O
,	O
fresh	O
frozen	O
plasma	O
replacement	O
,	O
corticosteroids	B-Chemical
,	O
aspirin	B-Chemical
,	O
and	O
dipyridamole	B-Chemical
led	O
to	O
resolution	O
of	O
MAHA	B-DISEASE
.	O

In	O
contrast	O
,	O
in	O
the	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
/	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
compound	O
heterozygote	O
II	O
:	O
4	O
,	O
we	O
observed	O
three	O
labelled	O
PCR	O
products	O
of	O
278	O
,	O
313	O
and	O
317	O
bp	O
(	O
Figure	O
3B	O
)	O
.	O

PATIENTS	O
:	O
Twenty	O
-	O
two	O
patients	O
with	O
known	O
reversible	O
perfusion	O
defects	O
.	O

Serious	O
adverse	O
events	O
occurred	O
in	O
seven	O
women	O
:	O
six	O
cases	O
with	O
blood	B-DISEASE
loss	I-DISEASE
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
cases	O
of	O
manual	O
placenta	O
removal	O
,	O
five	O
cases	O
of	O
additional	O
oxytocics	O
administration	O
and	O
five	O
cases	O
of	O
blood	O
transfusion	O
.	O

The	O
arrhythmia	B-DISEASE
resolved	O
after	O
therapy	O
with	O
atenolol	B-Chemical
,	O
but	O
recurred	O
a	O
year	O
later	O
.	O

For	O
a	O
given	O
electrode	O
location	O
,	O
decreasing	O
current	O
levels	O
resulted	O
in	O
increased	O
latencies	O
and	O
attenuated	O
wave	O
V	O
amplitudes	O
(	O
vertical	O
dashed	O
lines	O
,	O
right	O
)	O
.	O

Such	O
cases	O
make	O
it	O
necessary	O
to	O
look	O
for	O
potential	O
effects	O
that	O
modulate	O
patient	O
outcome	O
on	O
the	O
basis	O
of	O
a	O
given	O
primary	O
defect	O
.	O

This	O
demonstrates	O
that	O
we	O
have	O
identified	O
a	O
novel	O
heterozygous	O
mutation	O
2005T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
in	O
exon	O
8	O
,	O
which	O
predicts	O
a	O
Y669H	B-VARIANT
alteration	O
(	O
Figure	O
3	O
)	O
.	O

The	O
clinical	O
phenotype	O
can	O
also	O
be	O
variable	O
,	O
ranging	O
from	O
normal	O
hearing	O
,	O
progressive	O
moderate	O
hearing	B-DISEASE
loss	I-DISEASE
starting	O
in	O
adult	O
life	O
,	O
to	O
profound	O
congenital	O
deafness	B-DISEASE
[	O
8	O
]	O
.	O

However	O
,	O
it	O
is	O
highly	O
critical	O
to	O
understand	O
the	O
occurrence	O
pattern	O
of	O
sequencing	O
errors	O
on	O
the	O
MPS	B-Chemical
platform	O
because	O
low	O
-	O
level	O
somatic	O
mosaicism	O
might	O
appear	O
at	O
a	O
rate	O
close	O
to	O
that	O
of	O
sequencing	O
errors	O
.	O

(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
none	O
of	O
patients	O
have	O
PS	B-DISEASE
.	O

This	O
suggests	O
that	O
the	O
WS	B-DISEASE
-	O
causing	O
mutant	O
p	B-VARIANT
.	I-VARIANT
His313Tyr	I-VARIANT
increases	O
ER	O
stress	O
,	O
whereas	O
the	O
less	O
severely	O
affected	O
p	B-VARIANT
.	I-VARIANT
Trp314Arg	I-VARIANT
mutant	O
may	O
be	O
pathogenic	O
due	O
to	O
a	O
defect	O
in	O
its	O
ability	O
to	O
suppress	O
the	O
ER	O
stress	O
response	O
after	O
the	O
pathway	O
is	O
activated	O
.	O

974C	I-VARIANT
>	I-VARIANT
F	I-VARIANT
)	O
in	O
SEC31B	B-GENE
(	O
MIM	O
610258	O
,	O
ENST00000370345	O
)	O
in	O
F33	O
(	O
Supplementary	O
Material	O
,	O
Table	O
S2	O
)	O
.	O

Concerning	O
the	O
major	O
candidates	O
in	O
our	O
cohort	O
,	O
CRB1	B-GENE
and	O
USH2A	B-GENE
explain	O
10	O
/	O
19	O
families	O
overall	O
,	O
in	O
accordance	O
with	O
other	O
reports	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
and	O
consistent	O
with	O
their	O
contribution	O
to	O
several	O
clinical	O
entities	O
.	O

(	O
C	O
,	O
D	O
)	O
Differences	O
between	O
the	O
alanine	O
(	O
C	O
)	O
and	O
threonine	B-Chemical
(	O
D	O
)	O
at	O
amino	O
acid	O
position	O
112	O
.	O

Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

METHODS	O
:	O
Seventy	O
Swiss	O
albino	O
female	O
mice	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
groups	O
:	O
amphetamine	B-Chemical
-	O
free	O
(	O
control	O
)	O
,	O
amphetamine	B-Chemical
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DHEA	B-Chemical
.	O

In	O
families	O
3	O
and	O
4	O
we	O
detected	O
two	O
in	O
frame	O
alterations	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
2539_2559dup	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Met847_Glu853dup	I-VARIANT
)	O
in	O
exon	O
20	O
and	O
the	O
c	B-VARIANT
.	I-VARIANT
3142_3162del	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Lys1048_Glu1054del	I-VARIANT
)	O
in	O
exon	O
24	O
(	O
Fig	O
.	O

Exome	O
sequencing	O
was	O
conducted	O
on	O
one	O
affected	O
individual	O
from	O
family	O
PKDF468	O
and	O
was	O
enriched	O
using	O
the	O
Nimblegen	O
SeqCap	O
EZ	O
Exome	O
v2	O
.	O
0	O
Library	O
(	O
Roche	O
Diagnostics	O
;	O
San	O
Francisco	O
,	O
CA	O
)	O
.	O

The	O
proband	O
,	O
a	O
57	O
-	O
year	O
-	O
old	O
man	O
,	O
was	O
referred	O
to	O
our	O
tertiary	O
referral	O
hospital	O
for	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
which	O
coexisted	O
with	O
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

(	O
b	O
)	O
Immunoblot	O
analysis	O
of	O
protein	O
extracts	O
from	O
cochlea	O
and	O
testis	O
from	O
BLSW	O
and	O
C3HeB	O
/	O
FeJ	O
(	O
C3	O
H	O
)	O
mice	O
with	O
anti	O
-	O
Gipc3	O
antiserum	O
Pb867	B-Chemical
.	O

Illumina	O
libraries	O
were	O
generated	O
from	O
fragmented	O
gDNA	O
(	O
only	O
after	O
the	O
gDNA	O
passed	O
the	O
quality	O
control	O
checks	O
)	O
using	O
NEBNext	O
reagents	O
(	O
New	O
England	O
Biolabs	O
,	O
Ipswich	O
,	O
MA	O
,	O
USA	O
;	O
catalog	O
#	O
E6040	O
)	O
,	O
and	O
the	O
resulting	O
libraries	O
were	O
subjected	O
to	O
target	O
enrichment	O
using	O
custom	O
probes	O
targeting	O
the	O
Human	O
Deafness	B-DISEASE
Gene	O
DA1	O
panel	O
(	O
Otogenetics	O
Corporation	O
)	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

DNA	O
samples	O
were	O
analysed	O
for	O
patients	O
with	O
a	O
high	O
suspicion	O
of	O
an	O
underlying	O
mitochondrial	O
genetic	O
disease	O
due	O
to	O
the	O
multi	O
-	O
system	O
pattern	O
of	O
their	O
clinical	O
presentations	O
,	O
evidence	O
of	O
a	O
mitochondrial	O
biochemical	O
defect	O
,	O
and	O
/	O
or	O
the	O
presence	O
of	O
multiple	O
mtDNA	O
deletions	O
.	O

2C	O
)	O
,	O
both	O
of	O
which	O
inherited	O
in	O
autosomal	O
recessive	O
pattern	O
.	O

In	O
aspartate	B-Chemical
,	O
glutamine	B-Chemical
and	O
glutamate	B-Chemical
levels	O
detected	O
a	O
decrease	O
of	O
5	O
.	O
21	O
%	O
,	O
13	O
.	O
55	O
%	O
and	O
21	O
.	O
80	O
%	O
,	O
respectively	O
in	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

Representative	O
current	O
traces	O
for	O
KCNE1	B-GENE
-	O
WT	O
(	O
A	O
)	O
and	O
KCNE1	B-GENE
-	O
G60D	B-VARIANT
(	O
B	O
)	O
channel	O
subunits	O
co	O
-	O
expressed	O
with	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
in	O
X	O
.	O
laevis	O
oocytes	O
in	O
a	O
1	O
:	O
1	O
molar	O
ratio	O
.	O

Distal	B-DISEASE
renal	I-DISEASE
tubular	I-DISEASE
acidosis	I-DISEASE
(	O
dRTA	B-DISEASE
)	O
is	O
defined	O
by	O
the	O
inability	O
of	O
the	O
kidney	O
to	O
acidify	O
urine	O
,	O
in	O
presence	O
of	O
metabolic	B-DISEASE
acidosis	I-DISEASE
[	O
1	O
,	O
2	O
]	O
.	O

A	O
Splice	O
View	O
program	O
was	O
used	O
to	O
assess	O
the	O
possibility	O
that	O
intron	O
sequence	O
variants	O
could	O
create	O
or	O
exclude	O
splice	O
sites	O
.	O

The	O
3	O
common	O
BRCA2	B-GENE
variants	O
c	B-VARIANT
.	I-VARIANT
865A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Asn289His	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
1114A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Asn372His	I-VARIANT
)	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
2971A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Asn991Asp	I-VARIANT
)	O
,	O
also	O
exhibit	O
significant	O
differences	O
between	O
groups	O
,	O
with	O
the	O
highest	O
frequency	O
observed	O
in	O
Central	O
Asians	O
.	O

In	O
this	O
study	O
,	O
we	O
undertook	O
a	O
comprehensive	O
clinical	O
and	O
molecular	O
approach	O
to	O
define	O
the	O
genetic	O
basis	O
of	O
PSACH	B-DISEASE
and	O
MED	B-DISEASE
in	O
a	O
cohort	O
of	O
130	O
patients	O
referred	O
to	O
ESDN	B-Chemical
.	O

Apically	O
located	O
pendrin	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
efflux	O
of	O
iodide	B-Chemical
into	O
the	O
follicular	O
lumen	O
[	O
3	O
]	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
one	O
of	O
the	O
most	O
common	O
sensory	O
disorders	O
in	O
humans	O
.	O

Consequently	O
,	O
the	O
deletion	O
of	O
such	O
a	O
heptad	O
may	O
alter	O
the	O
formation	O
of	O
myosin	O
bipolar	O
filaments	O
.	O

This	O
contained	O
10	O
novel	O
mutations	O
leading	O
to	O
amino	O
acid	O
substitutions	O
already	O
known	O
to	O
cause	O
disease	O
and	O
mutations	O
known	O
to	O
cause	O
diseases	O
other	O
than	O
STGD	B-DISEASE
.	O

These	O
complications	O
have	O
included	O
clinical	O
deterioration	O
and	O
intracranial	B-DISEASE
vascular	I-DISEASE
thrombosis	I-DISEASE
in	O
patients	O
with	O
SAH	B-DISEASE
,	O
arteriolar	B-DISEASE
and	I-DISEASE
capillary	I-DISEASE
fibrin	I-DISEASE
thrombi	I-DISEASE
in	O
patients	O
with	O
fibrinolytic	B-DISEASE
syndromes	I-DISEASE
treated	O
with	O
EACA	B-Chemical
,	O
or	O
other	O
thromboembolic	B-DISEASE
phenomena	I-DISEASE
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R668H	I-VARIANT
mutation	O
was	O
marked	O
with	O
*	O
above	O
.	O

This	O
novel	O
mutation	O
is	O
expected	O
to	O
lead	O
to	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
translation	O
after	O
insertion	O
of	O
66	O
irrelevant	O
amino	O
acids	O
,	O
starting	O
at	O
position	O
69	O
of	O
the	O
SANS	O
protein	O
(	O
p	O
.	O
L69P	O
fs	O
X66	O
)	O
.	O

The	O
DNA	O
fragments	O
containing	O
the	O
variants	O
were	O
amplified	O
by	O
PCR	O
with	O
specific	O
primers	O
and	O
were	O
sequenced	O
on	O
both	O
strands	O
using	O
the	O
Big	O
Dye	O
3	O
.	O
1	O
Terminator	O
Sequencing	O
Kit	O
.	O

The	O
presence	O
of	O
two	O
in	O
trans	O
mutations	O
in	O
III	O
-	O
1	O
may	O
explain	O
why	O
he	O
has	O
developed	O
proteinuria	B-DISEASE
early	O
and	O
suggests	O
an	O
increased	O
risk	O
of	O
renal	B-DISEASE
impairment	I-DISEASE
developing	O
at	O
younger	O
age	O
in	O
him	O
compared	O
with	O
his	O
heterozygous	O
relatives	O
.	O

No	O
mutation	O
screening	O
had	O
been	O
done	O
.	O

As	O
in	O
the	O
eye	O
,	O
the	O
alpha	O
5	O
(	O
IV	O
)	O
chain	O
is	O
normally	O
present	O
in	O
the	O
lens	O
capsule	O
,	O
Descemet	O
,	O
Bruch	O
and	O
internal	O
limiting	O
membranes	O
[	O
25	O
]	O
,	O
it	O
is	O
reasonable	O
to	O
infer	O
that	O
dysfunction	B-DISEASE
of	I-DISEASE
the	I-DISEASE
lens	I-DISEASE
capsule	I-DISEASE
,	I-DISEASE
Bruch	I-DISEASE
and	I-DISEASE
internal	I-DISEASE
limiting	I-DISEASE
membranes	I-DISEASE
resulted	O
from	O
deposit	O
of	O
abnormal	B-DISEASE
type	I-DISEASE
IV	I-DISEASE
collagen	I-DISEASE
was	O
responsible	O
for	O
this	O
severe	O
ocular	O
phenotype	O
in	O
II	O
-	O
2	O
.	O

1	O
-	O
2	O
:	O
haplotype	O
associated	O
with	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
in	O
our	O
patients	O
(	O
compound	O
heterozygosity	O
for	O
c	B-VARIANT
.	I-VARIANT
748_759	I-VARIANT
+	I-VARIANT
5del	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
respectively	O
)	O
.	O

As	O
primary	O
antibodies	O
we	O
used	O
:	O
anti	O
-	O
ORP	O
-	O
2	O
(	O
OSBPL2	B-GENE
)	O
antibody	O
(	O
goat	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
,	O
sc	O
-	O
66570	O
,	O
dilution	O
1	O
:	O
50	O
)	O
,	O
anti	O
-	O
prestin	O
antibody	O
(	O
rabbit	O
[	O
30	O
]	O
,	O
dilution	O
1	O
:	O
5000	O
)	O
,	O
and	O
anti	O
-	O
otoferlin	O
antibody	O
(	O
rabbit	O
[	O
31	O
]	O
,	O
dilution	O
1	O
:	O
10000	O
)	O
.	O

Some	O
had	O
apparently	O
milder	O
phenotypes	O
than	O
those	O
with	O
other	O
mutations	O
,	O
indicating	O
differences	O
in	O
the	O
effects	O
of	O
such	O
mutations	O
on	O
WFS1	B-GENE
protein	O
functions	O
.	O

In	O
the	O
index	O
cases	O
,	O
ATP6V1B1	B-GENE
gene	O
screening	O
resulted	O
in	O
a	O
mutation	O
detection	O
rate	O
of	O
81	O
.	O
25	O
%	O
,	O
which	O
increased	O
up	O
to	O
95	O
%	O
after	O
ATP6V0A4	B-GENE
gene	O
analysis	O
.	O

As	O
a	O
result	O
,	O
we	O
have	O
identified	O
the	O
pathogenic	O
mutation	O
of	O
17	O
out	O
of	O
the	O
36	O
families	O
,	O
and	O
3	O
of	O
the	O
5	O
isolated	O
Usher	O
patients	O
,	O
overall	O
reporting	O
14	O
novel	O
mutations	O
.	O

We	O
conclude	O
that	O
:	O
1	O
)	O
administration	O
of	O
rhIGF	O
-	O
I	O
improves	O
growth	O
and	O
GFR	O
in	O
rats	O
with	O
chronic	O
PAN	B-Chemical
nephropathy	I-DISEASE
and	O
2	O
)	O
unlike	O
rhGH	O
,	O
long	O
-	O
term	O
use	O
of	O
rhIGF	O
-	O
I	O
does	O
not	O
worsen	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
this	O
disease	O
model	O
.	O

The	O
control	O
group	O
consisted	O
of	O
82	O
patients	O
with	O
no	O
psychiatric	O
or	O
endocrinological	O
diagnoses	O
from	O
the	O
hospital	O
'	O
s	O
out	O
-	O
patient	O
clinics	O
.	O

Deafness	B-DISEASE
is	O
the	O
most	O
common	O
birth	O
defect	O
and	O
the	O
most	O
frequent	O
sensorineural	B-DISEASE
disorder	I-DISEASE
[	O
1	O
]	O
.	O

Microsatellite	O
markers	O
were	O
analyzed	O
as	O
described	O
previously	O
[	O
12	O
]	O
and	O
Sanger	O
sequencing	O
was	O
performed	O
according	O
to	O
Schraders	O
et	O
al	O
.	O

Initial	O
data	O
filtering	O
with	O
allele	O
frequencies	O
and	O
PolyPhen2	O
/	O
SIFT	O
scores	O
prioritized	O
5	O
indels	O
and	O
36	O
missense	O
variants	O
in	O
the	O
12	O
multiplex	O
families	O
.	O

Because	O
we	O
acquired	O
a	O
thorough	O
roadmap	O
from	O
whole	O
-	O
exome	O
sequencing	O
of	O
five	O
family	O
members	O
and	O
undertook	O
a	O
subsequent	O
segregation	O
study	O
using	O
Sanger	O
sequencing	O
from	O
an	O
additional	O
four	O
members	O
,	O
we	O
propose	O
a	O
novel	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

2009	O
)	O
.	O

Graphs	O
show	O
relative	O
number	O
of	O
cells	O
(	O
events	O
)	O
versus	O
fluorescence	O
intensity	O
.	O

Five	O
of	O
the	O
eight	O
patients	O
were	O
50	O
years	O
of	O
age	O
or	O
younger	O
;	O
only	O
one	O
clearly	O
had	O
antecedent	O
heart	B-DISEASE
disease	I-DISEASE
.	O

Therefore	O
,	O
the	O
most	O
rewarding	O
phenotypic	O
markers	O
leading	O
to	O
molecular	O
diagnosis	O
were	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
(	O
with	O
/	O
without	O
incomplete	B-DISEASE
partition	I-DISEASE
type	I-DISEASE
II	I-DISEASE
)	O
and	O
incomplete	B-DISEASE
partition	I-DISEASE
type	I-DISEASE
III	I-DISEASE
,	O
and	O
long	B-DISEASE
Q	I-DISEASE
-	I-DISEASE
T	I-DISEASE
syndrome	I-DISEASE
followed	O
by	O
lateral	O
semicircular	B-DISEASE
canal	I-DISEASE
dysplasia	I-DISEASE
as	O
a	O
part	O
of	O
the	O
constellation	O
of	O
anomalies	O
suggesting	O
a	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
,	O
and	O
ski	O
slope	O
type	O
high	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Table	O
1	O
)	O
.	O

7	O
.	O

Connexin	O
26	O
gap	O
junction	O
channels	O
recycle	O
potassium	B-Chemical
ions	O
as	O
part	O
of	O
a	O
mechanism	O
of	O
auditory	O
signal	O
transduction	O
in	O
inner	O
ear	O
[	O
19	O
]	O
.	O

auditory	O
brainstem	O
response	O
dominant	O
optic	B-DISEASE
atrophy	I-DISEASE
electrocochleography	O
pure	O
tone	O
average	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

In	O
this	O
study	O
,	O
the	O
concentrations	O
of	O
inhibin	O
B	O
and	O
AMH	B-Chemical
are	O
frequently	O
low	O
,	O
but	O
they	O
may	O
be	O
normal	O
,	O
including	O
patients	O
with	O
KS	B-DISEASE
.	O

Moreover	O
,	O
combined	O
genotypes	O
with	O
variants	O
such	O
as	O
M34T	B-VARIANT
,	O
V37I	B-VARIANT
,	O
or	O
R127H	B-VARIANT
could	O
have	O
a	O
phenotypic	O
expression	O
modulated	O
by	O
environmental	O
factors	O
or	O
modifier	O
genes	O
.	O

The	O
mean	O
time	O
of	O
study	O
was	O
109	O
days	O
(	O
median	O
107	O
,	O
range	O
4	O
-	O
184	O
days	O
)	O
.	O

Activation	O
of	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
/	O
KCNE1	B-GENE
channels	O
results	O
in	O
sigmoidal	O
activation	O
current	O
traces	O
.	O

So	O
although	O
the	O
findings	O
of	O
others	O
are	O
similar	O
to	O
ours	O
,	O
their	O
interpretation	O
is	O
different	O
.	O

The	O
screening	O
was	O
performed	O
in	O
19	O
probands	O
with	O
USH	B-DISEASE
already	O
screened	O
for	O
mutations	O
in	O
the	O
most	O
prevalent	O
USH1	B-DISEASE
genes	O
,	O
myosin	B-GENE
VIIA	I-GENE
(	O
MYO7A	B-GENE
)	O
and	O
cadherin	B-GENE
-	I-GENE
23	I-GENE
(	O
CDH23	B-GENE
)	O
,	O
and	O
for	O
copy	O
number	O
variants	O
in	O
PCDH15	B-GENE
.	O

INTRODUCTION	O
:	O
Acute	B-DISEASE
kidney	I-DISEASE
injury	I-DISEASE
(	O
AKI	B-DISEASE
)	O
occurs	O
in	O
7	O
%	O
of	O
hospitalized	O
and	O
66	O
%	O
of	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
patients	O
.	O

However	O
,	O
of	O
the	O
medications	O
surveyed	O
,	O
only	O
the	O
fenfluramines	B-Chemical
had	O
a	O
significant	O
preferential	O
association	O
with	O
PPH	B-DISEASE
as	O
compared	O
with	O
SPH	B-DISEASE
(	O
adjusted	O
odds	O
ratio	O
for	O
use	O
>	O
6	O
months	O
,	O
7	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
7	O
to	O
32	O
.	O
4	O
)	O
.	O

Then	O
,	O
after	O
culture	O
for	O
48	O
h	O
in	O
medium	O
containing	O
5	O
%	O
FBS	O
,	O
the	O
cells	O
were	O
harvested	O
in	O
PBS	O
,	O
washed	O
and	O
resuspended	O
in	O
PBS	O
at	O
1	O
-	O
2	O
x	O
10	O
5	O
/	O
mL	O
,	O
fixed	O
with	O
70	O
%	O
ethanol	O
to	O
make	O
cells	O
permeabilised	O
,	O
incubated	O
with	O
RNase	B-Chemical
A	O
at	O
37	O
deg	O
C	O
for	O
30	O
min	O
,	O
and	O
incubated	O
with	O
400	O
mu	O
L	O
mixed	O
liquid	O
of	O
propidium	B-Chemical
iodide	I-Chemical
and	O
PBS	O
at	O
4	O
deg	O
C	O
for	O
30	O
min	O
.	O

Drawbacks	O
of	O
our	O
approach	O
include	O
the	O
inability	O
to	O
detect	O
the	O
breakpoints	O
in	O
CNVs	O
,	O
as	O
well	O
as	O
common	O
CNVs	O
presented	O
in	O
many	O
samples	O
.	O

Siddiqi	O
MS	O
JO	O
HA	O
AB	O
M	O
.	O

2a	O
,	O
proband	O
)	O
was	O
the	O
second	O
child	O
of	O
healthy	O
,	O
non	O
-	O
consanguineous	O
Korean	O
parents	O
.	O

This	O
indicates	O
reversibility	O
in	O
captopril	B-Chemical
-	O
induced	O
renal	B-DISEASE
failure	I-DISEASE
even	O
after	O
its	O
prolonged	O
use	O
and	O
suggests	O
that	O
no	O
organic	O
damage	O
occurs	O
to	O
glomerular	O
arterioles	O
following	O
chronic	O
ACE	O
inhibition	O
.	O

These	O
ECG	O
abnormalities	O
were	O
more	O
prominent	O
when	O
patients	O
were	O
symptomatic	O
,	O
and	O
improved	O
after	O
treatment	O
.	O

Therefore	O
,	O
our	O
results	O
show	O
that	O
mutations	O
in	O
DFNB1	B-GENE
account	O
for	O
only	O
3	O
%	O
of	O
ARNSHL	B-DISEASE
in	O
patients	O
of	O
Saudi	O
Arabian	O
tribal	O
ethnicity	O
.	O

Haemodynamic	O
measurements	O
were	O
performed	O
on	O
anaesthetized	O
animals	O
,	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
for	O
biochemical	O
analysis	O
and	O
the	O
left	O
kidney	O
was	O
processed	O
for	O
morphological	O
studies	O
.	O

The	O
graph	O
shows	O
the	O
average	O
depth	O
of	O
coverage	O
(	O
black	O
line	O
)	O
in	O
the	O
region	O
chr18	O
:	O
19	O
,	O
751	O
,	O
740	O
-	O
19	O
,	O
752	O
,	O
040	O
(	O
hg19	O
coordinates	O
)	O
;	O
grey	O
shading	O
indicates	O
1	O
SD	O
from	O
the	O
mean	O
.	O

For	O
sample	O
B	O
,	O
though	O
a	O
number	O
of	O
changes	O
were	O
observed	O
,	O
only	O
compound	O
heterozygosity	O
for	O
a	O
premature	O
stop	O
codon	O
and	O
a	O
high	O
pathogenicity	O
missense	O
mutation	O
in	O
CRB1	B-GENE
fitted	O
with	O
the	O
LCA	B-DISEASE
diagnosis	O
in	O
this	O
patient	O
.	O

In	O
spite	O
of	O
the	O
substantial	O
heritability	O
,	O
few	O
genetic	O
risk	O
factors	O
for	O
ASD	B-DISEASE
have	O
been	O
identified	O
1	O
,	O
2	O
.	O

HEK	O
-	O
293T	O
cells	O
were	O
grown	O
on	O
10cm	O
plates	O
to	O
60	O
%	O
confluence	O
and	O
cotransfected	O
with	O
a	O
packaging	O
plasmid	O
(	O
pCMV	O
-	I-Chemical
delta	I-Chemical
8	I-Chemical
.	O
91	O
)	O
,	O
a	O
pseudotyping	O
plasmid	O
(	O
pMD2	O
-	O
VSVg	I-Chemical
)	O
and	O
either	O
NUBPL	B-Chemical
-	O
V5	I-Chemical
-	O
pDest	O
or	O
FOXRED1	O
-	O
V5	O
-	O
pDest	O
.	O

beta	O
-	O
Blocker	O
therapy	O
and	O
higher	O
ejection	O
fraction	O
were	O
renoprotective	O
in	O
all	O
patients	O
regardless	O
of	O
therapy	O
.	O

Results	O
were	O
validated	O
by	O
the	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
based	O
method	O
.	O

Summary	O
of	O
the	O
exome	O
sequencing	O
results	O
from	O
three	O
probands	O
with	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
Mb	O
:	O
Megabasepairs	O
.	O

In	O
addition	O
,	O
we	O
emphasize	O
that	O
candidate	O
variants	O
and	O
genes	O
nominated	O
by	O
our	O
study	O
will	O
require	O
extensive	O
experimental	O
functional	O
validation	O
as	O
well	O
as	O
replication	O
in	O
additional	O
ovarian	B-DISEASE
cancer	I-DISEASE
datasets	O
.	O

L	B-Chemical
-	I-Chemical
Dopa	I-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
decreased	O
blood	O
pressure	O
and	O
heart	O
rate	O
after	O
extracerebral	O
decarboxylase	O
inhibition	O
with	O
MK	B-Chemical
-	I-Chemical
486	I-Chemical
(	O
25	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
in	O
anesthetize	O
MAO	B-Chemical
-	O
inhibited	O
dogs	O
.	O

The	O
hearing	B-DISEASE
loss	I-DISEASE
threshold	O
of	O
the	O
mother	O
(	O
I	O
:	O
2	O
,	O
age	O
56	O
)	O
and	O
her	O
affected	O
daughters	O
(	O
II	O
:	O
1	O
,	O
age	O
36	O
;	O
and	O
II	O
:	O
3	O
,	O
age	O
22	O
)	O
showed	O
nearly	O
no	O
progression	O
based	O
on	O
a	O
comparison	O
of	O
symptoms	O
between	O
the	O
mother	O
and	O
her	O
daughters	O
.	O

(	O
a	O
)	O
Schematic	O
of	O
human	O
claudin14	O
.	O

Although	O
there	O
was	O
no	O
significant	O
difference	O
in	O
QTc	O
-	O
interval	O
between	O
LQT1	O
-	O
3	O
mutation	O
carriers	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
QTc	O
interval	O
between	O
mutation	O
carriers	O
and	O
index	O
cases	O
without	O
an	O
identified	O
mutation	O
(	O
Figure	O
1	O
)	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blinded	O
study	O
was	O
conducted	O
in	O
100	O
patients	O
randomly	O
allocated	O
into	O
five	O
groups	O
of	O
20	O
patients	O
each	O
.	O

and	O
S	O
.	O
L	O
.	O

The	O
serum	O
creatinine	B-Chemical
levels	O
of	O
patients	O
in	O
the	O
mild	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-DISEASE
group	O
,	O
which	O
included	O
7	O
episode	O
biopsies	O
,	O
were	O
statistically	O
higher	O
than	O
those	O
in	O
the	O
minimum	O
-	O
type	O
chronic	O
FK506	B-Chemical
-	O
nephropathy	B-DISEASE
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Remarkably	O
,	O
hearing	O
in	O
both	O
the	O
proband	O
and	O
his	O
mother	O
is	O
so	O
diminished	O
that	O
they	O
hardly	O
have	O
any	O
speech	O
recognition	O
.	O

,	O
2008	O
;	O
Starr	O
et	O
al	O
.	O

(	O
A	O
-	O
D	O
)	O
Auditory	O
brainstem	O
responses	O
(	O
ABR	O
)	O
to	O
broad	O
band	O
clicks	O
(	O
A	O
)	O
and	O
tone	O
bursts	O
(	O
B	O
-	O
D	O
)	O
at	O
8	O
,	O
16	O
,	O
and	O
32	O
kHz	O
in	O
P14	O
,	O
P28	O
and	O
P56	O
Homer2	B-GENE
-	O
/	O
-	O
,	O
Homer2	B-GENE
+	O
/	O
-	O
and	O
WT	O
mice	O
.	O

Tandem	O
gait	O
and	O
Romberg	O
tests	O
were	O
performed	O
to	O
evaluate	O
balance	O
.	O

This	O
case	O
highlights	O
the	O
need	O
for	O
adequate	O
labelling	O
and	O
regulation	O
of	O
such	O
products	O
.	O

Mean	O
systolic	O
blood	I-DISEASE
pressure	O
decreased	O
25	O
mmHg	O
and	O
mean	O
diastolic	O
blood	I-DISEASE
pressure	O
declined	O
15	O
mmHg	O
after	O
one	O
month	O
of	O
timolol	B-Chemical
-	O
hydrochlorothiazide	B-Chemical
therapy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
,	O
both	O
comparisons	O
)	O
.	O

Thus	O
,	O
interference	O
with	O
the	O
central	O
venous	O
infusion	O
by	O
the	O
dialysis	O
catheter	O
was	O
suspected	O
.	O

Latency	O
was	O
defined	O
relative	O
to	O
cochlear	O
microphonic	O
onset	O
in	O
milliseconds	O
.	O

Therefore	O
,	O
it	O
appeared	O
that	O
the	O
association	O
of	O
p	B-VARIANT
.	I-VARIANT
L46F	I-VARIANT
with	O
p	B-VARIANT
.	I-VARIANT
E1841K	I-VARIANT
did	O
not	O
aggravate	O
the	O
clinical	O
symptoms	O
associated	O
with	O
p	B-VARIANT
.	I-VARIANT
E1841K	I-VARIANT
alone	O
.	O

Patterns	O
of	O
sulfadiazine	B-Chemical
acute	O
nephrotoxicity	B-DISEASE
.	O

No	O
RET	B-GENE
CDS	O
pathological	O
variants	O
or	O
mutations	O
were	O
detected	O
in	O
these	O
individuals	O
.	O

,	O
2008	O
)	O
.	O

Radiographs	O
of	O
patient	O
1	O
.	O

The	O
syndrome	O
is	O
the	O
most	O
common	O
cause	O
of	O
combined	O
visual	B-DISEASE
and	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
accounting	O
for	O
more	O
than	O
50	O
%	O
of	O
adult	O
cases	O
with	O
deaf	B-DISEASE
-	I-DISEASE
blindness	I-DISEASE
[	O
1	O
]	O
.	O

Characterization	O
of	O
a	O
novel	O
BCHE	B-GENE
"	O
silent	O
"	O
allele	O
:	O
point	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
Val204Asp	I-VARIANT
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	B-DISEASE
apnea	I-DISEASE
with	O
suxamethonium	B-Chemical
.	O

Filamentous	O
actin	O
was	O
detected	O
with	O
rhodamine	B-Chemical
phalloidin	I-Chemical
(	O
Life	O
Technologies	O
)	O
in	O
PBS	O
/	O
0	O
.	O
1	O
%	O
Triton	B-Chemical
-	I-Chemical
X100	O
for	O
one	O
hour	O
.	O

Figure	O
3	O
COL4A3	B-GENE
mutation	O
identified	O
in	O
Family	O
2	O
.	O

Each	O
individual	O
was	O
anonymized	O
by	O
assigning	O
to	O
him	O
/	O
her	O
a	O
numeric	O
ID	O
;	O
confidentiality	O
and	O
protection	O
of	O
data	O
were	O
ensured	O
by	O
applying	O
international	O
recommendations	O
and	O
current	O
Spanish	O
legislation	O
(	O
Ley	O
de	O
Investigacion	O
Biomedica	O
14	O
/	O
2007	O
and	O
LOPD	O
)	O
.	O

These	O
pictures	O
were	O
made	O
using	O
UCSF	O
Chimera	O
.	O

Frameshift	O
(	O
splice	O
site	O
within	O
+	O
-	O
2	O
)	O
and	O
nonsense	O
mutations	O
were	O
categorized	O
as	O
pathogenic	O
.	O

(	O
A	O
)	O
Cytoplasmic	O
inclusion	O
in	O
neutrophils	O
(	O
Wright	O
-	O
Giemsa	O
x	O
1000	O
)	O
.	O

For	O
the	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
,	O
under	O
the	O
fourfold	O
tiling	O
of	O
120	O
bp	O
baits	O
,	O
the	O
expected	O
density	O
should	O
be	O
1	O
/	O
30	O
;	O
low	O
bait	O
density	O
was	O
defined	O
as	O
<	O
1	O
/	O
50	O
based	O
on	O
the	O
empirical	O
bait	O
density	O
distribution	O
.	O

The	O
sequence	O
and	O
structure	O
embedded	O
in	O
the	O
NC1	O
domain	O
ensures	O
that	O
the	O
only	O
three	O
types	O
of	O
trimers	O
that	O
are	O
biochemically	O
permissible	O
are	O
:	O
alpha	O
1	O
alpha	O
1	O
alpha	O
2	O
,	O
alpha	O
3	O
alpha	O
4	O
alpha	O
5	O
,	O
alpha	O
5	O
alpha	O
5	O
alpha	O
6	O
.	O

org	O
/	O
)	O
,	O
in	O
which	O
six	O
mutations	O
were	O
found	O
in	O
previously	O
reported	O
deafness	B-DISEASE
-	O
related	O
genes	O
(	O
Table	O
2	O
)	O
.	O

RESULTS	O
:	O
Overall	O
,	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study	O
.	O

Chromatograms	O
show	O
FGFR1	B-GENE
mutations	O
in	O
patients	O
1	O
-	O
6	O
with	O
Hartsfield	B-DISEASE
syndrome	I-DISEASE
,	O
along	O
with	O
their	O
parents	O
.	O

The	O
same	O
mutation	O
was	O
not	O
detected	O
in	O
101	O
control	O
Tibetan	O
individuals	O
.	O

Verification	O
of	O
sequence	O
variants	O
and	O
segregation	O
analyses	O
were	O
carried	O
out	O
by	O
Sanger	O
sequencing	O
.	O

Attenuation	O
of	O
the	O
lithium	B-Chemical
-	O
induced	O
diabetes	B-DISEASE
-	I-DISEASE
insipidus	I-DISEASE
-	O
like	O
syndrome	O
by	O
amiloride	B-Chemical
in	O
rats	O
.	O

Although	O
both	O
parents	O
(	O
III	O
-	O
1	O
and	O
III	O
-	O
2	O
)	O
and	O
grandmother	O
(	O
II	O
-	O
2	O
)	O
are	O
heterozygous	O
for	O
the	O
mutation	O
(	O
Figure	O
3	O
)	O
,	O
only	O
the	O
grandmother	O
showed	O
heterochromic	B-DISEASE
iris	I-DISEASE
(	O
Figure	O
2I	O
)	O
.	O

In	O
addition	O
to	O
gene	O
discovery	O
,	O
the	O
diagnostic	O
utility	O
of	O
MPS	B-Chemical
in	O
addressing	O
genetically	O
heterogeneous	O
nonsyndromic	O
hearing	O
loss	O
has	O
also	O
been	O
examined	O
in	O
several	O
studies	O
(	O
Table	O
3	O
)	O
.	O

Ultra	O
-	O
thin	O
sections	O
(	O
60	O
-	O
65	O
nm	O
)	O
were	O
contrasted	O
with	O
uranyl	B-Chemical
acetate	I-Chemical
and	O
lead	B-Chemical
citrate	I-Chemical
for	O
ultrastructural	O
studies	O
(	O
H	O
-	O
7650	O
,	O
Hitachi	O
,	O
Japan	O
)	O
.	O

These	O
in	O
vivo	O
markers	O
of	O
kidney	B-DISEASE
dysfunction	I-DISEASE
and	O
their	O
correction	O
by	O
metformin	B-Chemical
were	O
complemented	O
by	O
in	O
vitro	O
studies	O
of	O
mitochondrial	O
function	O
.	O

Eighty	O
-	O
five	O
unrelated	O
hearing	B-DISEASE
impaired	I-DISEASE
Roma	O
patients	O
,	O
irrespective	O
of	O
their	O
GJB2	B-GENE
status	O
,	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
the	O
identified	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
in	O
MARVELD2	B-GENE
gene	O
.	O

Of	O
the	O
20	O
animals	O
that	O
received	O
subarachnoid	O
injection	O
of	O
2	B-Chemical
-	I-Chemical
chloroprocaine	I-Chemical
-	I-Chemical
CE	I-Chemical
seven	O
(	O
35	O
%	O
)	O
developed	O
hind	O
-	O
limb	O
paralysis	O
.	O

Genotyping	O
was	O
performed	O
using	O
the	O
HumanCytoSNP	O
-	O
12	O
BeadChip	O
300K	O
SNPs	O
array	O
.	O

Wang	O
et	O
al	O
(	O
19	O
)	O
indicated	O
that	O
Eya4	B-GENE
regulates	O
Na	O
+	O
/	O
K	B-Chemical
+	O
-	O
ATPase	O
,	O
which	O
is	O
crucial	O
for	O
the	O
development	O
of	O
mechanosensory	O
cells	O
of	O
the	O
inner	O
ear	O
and	O
the	O
maintenance	O
of	O
cardiac	O
function	O
in	O
zebrafish	O
,	O
which	O
potentially	O
provides	O
a	O
mechanism	O
by	O
which	O
human	O
EYA4	B-GENE
mutations	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
heart	B-DISEASE
disease	I-DISEASE
.	O

CONCLUSIONS	O
:	O
Cabergoline	B-Chemical
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
risperidone	B-Chemical
-	O
induced	O
hyperprolactinemia	B-DISEASE
in	O
youth	O
;	O
however	O
,	O
further	O
research	O
is	O
needed	O
.	O

METHODS	O
:	O
With	O
ethical	O
approval	O
,	O
we	O
studied	O
74	O
American	O
Society	O
of	O
Anesthesiologists	O
(	O
ASA	B-DISEASE
)	O
,	O
physical	O
status	O
class	O
1	O
and	O
2	O
patients	O
scheduled	O
for	O
elective	O
unilateral	O
lower	O
limb	I-DISEASE
surgery	O
.	O

After	O
MAP	B-DISEASE
,	O
increases	O
were	O
identified	O
in	O
both	O
cardiac	O
output	O
(	O
from	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
57	O
to	O
1	O
.	O
65	O
+	O
/	O
-	O
0	O
.	O
57	O
1	O
/	O
min	O
)	O
and	O
Emax	O
(	O
from	O
1	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
9	O
to	O
2	O
.	O
41	O
+	O
/	O
-	O
1	O
.	O
31	O
mmHg	O
/	O
ml	O
)	O
.	O

Each	O
family	O
had	O
at	O
least	O
2	O
hearing	O
-	O
impaired	O
individuals	O
.	O

Although	O
II	O
:	O
2	O
and	O
II	O
:	O
3	O
died	O
during	O
the	O
course	O
of	O
the	O
study	O
,	O
DNA	O
samples	O
and	O
informed	O
consents	O
were	O
obtained	O
before	O
deceasing	O
,	O
allowing	O
us	O
to	O
include	O
those	O
subjects	O
in	O
the	O
segregation	O
analysis	O
.	O

The	O
liver	O
levels	O
of	O
beta	O
-	O
oxidation	O
metabolites	O
of	O
VPA	B-Chemical
were	O
decreased	O
by	O
day	O
14	O
,	O
while	O
the	O
levels	O
of	O
4	B-Chemical
-	I-Chemical
ene	I-Chemical
-	I-Chemical
VPA	I-Chemical
and	O
(	O
E	O
)	O
-	O
2	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diene	I-Chemical
-	I-Chemical
VPA	I-Chemical
were	O
not	O
elevated	O
throughout	O
the	O
study	O
.	O

Approximately	O
350	O
children	O
have	O
been	O
tested	O
by	O
transtympanic	O
ECochG	O
at	O
our	O
department	O
over	O
the	O
past	O
15	O
years	O
.	O

PCR	O
was	O
performed	O
with	O
PE9700	B-Chemical
thermocyclers	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Five	O
cases	O
had	O
single	O
-	O
shot	O
spinal	O
anaesthesia	O
and	O
one	O
had	O
a	O
repeat	O
spinal	O
anaesthetic	O
due	O
to	O
inadequate	O
block	O
.	O

The	O
results	O
of	O
the	O
immunohistochemical	O
studies	O
were	O
scored	O
according	O
to	O
the	O
extent	O
of	O
staining	O
.	O

2	O
)	O
.	O

This	O
change	O
resulted	O
within	O
2	O
-	O
4	O
weeks	O
in	O
the	O
50	O
-	O
200	O
%	O
increase	O
in	O
the	O
plasma	O
levels	O
of	O
these	O
neuroleptics	O
and	O
the	O
appearance	O
of	O
extrapyramidal	B-DISEASE
symptoms	O
.	O

CNV	O
throughout	O
the	O
chromosomes	O
-	O
1p13	O
.	O
3	O
,	O
4q13	O
.	O
2	O
,	O
5q35	O
.	O
3	O
,	O
8p23	O
.	O
1	O
,	O
and	O
19q13	O
.	O
4	O
have	O
distinct	O
CNVs	O
(	O
14q32	O
.	O
3	O
is	O
distinct	O
,	O
but	O
contains	O
variable	O
regions	O
associated	O
with	O
antibody	O
production	O
)	O
(	O
A	O
)	O
,	O
8p23	O
.	O
1	O
containing	O
beta	O
-	O
defensin	O
clusters	O
(	O
B	O
)	O
,	O
and	O
1p13	O
.	O
1	O
containing	O
GSTM1	B-GENE
(	O
C	O
)	O
of	O
eight	O
subjects	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
using	O
a	O
TIANamp	O
Blood	O
DNA	O
Kit	O
(	O
Tiangen	O
Biotech	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

Qin	O
(	O
Institute	O
of	O
Liver	O
Studies	O
,	O
King	O
'	O
s	O
College	O
,	O
London	O
,	O
UK	O
)	O
for	O
proofreading	O
the	O
English	O
manuscript	O
.	O
Genetic	O
tests	O
for	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
inform	O
clinical	O
management	O
of	O
patients	O
and	O
can	O
provide	O
the	O
first	O
step	O
in	O
the	O
development	O
of	O
therapeutics	O
.	O

In	O
most	O
cases	O
AF	B-DISEASE
is	O
associated	O
with	O
cardiac	O
risk	O
factors	O
such	O
as	O
hypertensive	O
,	O
ischemic	O
,	O
and	O
/	O
or	O
structural	O
heart	O
disease	O
[	O
1	O
,	O
5	O
]	O
.	O

Aspirin	B-Chemical
does	O
not	O
seem	O
to	O
affect	O
CVD	B-DISEASE
mortality	O
or	O
all	O
-	O
cause	O
mortality	O
in	O
either	O
men	O
or	O
women	O
.	O

Schematic	O
overview	O
of	O
the	O
Mito10K	O
project	O
.	O

By	O
analogy	O
to	O
KCNJ5	B-GENE
,	O
we	O
considered	O
possible	O
germline	O
CACNA1D	B-GENE
mutations	O
.	O

12	O
For	O
the	O
gene	O
-	O
level	O
score	O
,	O
we	O
used	O
the	O
Residual	O
Variation	O
Intolerance	O
Score	O
scoring	O
system	O
introduced	O
by	O
Petrovski	O
et	O
al	O
.	O

Tenascin	B-GENE
C	I-GENE
(	O
TNC	B-GENE
)	O
,	O
encoded	O
by	O
TNC	B-GENE
,	O
is	O
a	O
glycoprotein	O
expressed	O
in	O
the	O
extracellular	O
matrix	O
of	O
various	O
tissues	O
during	O
development	O
,	O
disease	O
,	O
or	O
injury	O
,	O
as	O
well	O
as	O
in	O
restricted	O
areas	O
of	O
the	O
central	O
nervous	O
system	O
involved	O
in	O
neurogenesis	O
[	O
27	O
]	O
.	O

4	O
and	O
Supplementary	O
Fig	O
.	O

We	O
observed	O
an	O
average	O
of	O
68	O
nonsynonymous	O
variants	O
per	O
individual	O
,	O
almost	O
all	O
of	O
which	O
are	O
of	O
unknown	O
clinical	O
significance	O
.	O

The	O
total	O
content	O
of	O
hydroxyproline	B-Chemical
remained	O
stable	O
during	O
the	O
first	O
2	O
days	O
of	O
treatment	O
but	O
increased	O
46	O
%	O
after	O
4	O
days	O
of	O
therapy	O
.	O

The	O
sequential	O
application	O
of	O
these	O
two	O
reactions	O
to	O
the	O
muscle	O
section	O
revealed	O
abnormal	O
COX	O
deficient	O
fibers	O
appearing	O
blue	O
.	O

Mean	O
optic	O
nerve	O
fiber	O
layer	O
thickness	O
:	O
RE	O
101	O
mu	O
m	O
,	O
LE	O
104	O
mu	O
m	O
.	O

In	O
China	O
,	O
97	O
.	O
9	O
%	O
of	O
the	O
EVA	B-DISEASE
patients	O
in	O
simplex	O
families	O
were	O
detected	O
with	O
either	O
biallelic	O
or	O
monoallelic	O
mutations	O
,	O
of	O
which	O
88	O
.	O
4	O
%	O
carried	O
biallelic	O
variants	O
and	O
9	O
.	O
5	O
%	O
had	O
a	O
monoallelic	O
mutation	O
.	O

The	O
incidence	O
and	O
severity	O
of	O
succinylcholine	B-Chemical
-	I-DISEASE
associated	I-DISEASE
myalgia	I-DISEASE
was	O
determined	O
in	O
64	O
patients	O
pretreated	O
with	O
saline	O
or	O
dexamethasone	B-Chemical
before	O
succinylcholine	B-Chemical
(	O
n	O
=	O
32	O
for	O
each	O
)	O
.	O

About	O
5	O
%	O
of	O
patients	O
referred	O
to	O
hypertension	B-DISEASE
clinics	O
(	O
1	O
to	O
10	O
million	O
people	O
world	O
-	O
wide	O
)	O
have	O
aldosterone	B-DISEASE
-	I-DISEASE
producing	I-DISEASE
adenomas	I-DISEASE
(	O
APAs	B-DISEASE
)	O
3	O
,	O
4	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
pharmacological	O
treatment	O
or	O
spontaneous	O
resolution	O
is	O
responsible	O
for	O
the	O
improvement	O
.	O

-	I-VARIANT
77C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
originally	O
named	O
-	B-VARIANT
3438C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
,	O
which	O
abolishes	O
the	O
activity	O
of	O
the	O
basal	O
promoter	O
of	O
the	O
gene	O
[	O
13	O
]	O
.	O

Patients	O
with	O
complex	O
phenotypes	O
may	O
require	O
referral	O
to	O
specialists	O
.	O

Cellular	O
mechanisms	O
which	O
account	O
for	O
disruption	O
the	O
blood	O
-	O
brain	O
barrier	O
during	O
acute	O
hypertension	B-DISEASE
are	O
not	O
clear	O
.	O

4	O
-	O
6	O
Approximately	O
60	O
%	O
of	O
CINCA	B-DISEASE
/	O
NOMID	B-DISEASE
patients	O
carry	O
heterozygous	O
germline	O
missense	O
mutations	O
in	O
the	O
NLRP3	B-GENE
coding	O
region	O
(	O
mutation	O
-	O
positive	O
patients	O
)	O
.	O

D	O
,	O
H	O
)	O
OCT	O
shows	O
bilateral	O
loss	O
of	O
IS	O
/	O
OS	O
junctions	O
and	O
decreased	O
retinal	O
thickness	O
.	O

Methylergonovine	B-Chemical
was	O
administered	O
continuously	O
at	O
a	O
rate	O
of	O
10	O
micrograms	O
/	O
min	O
up	O
to	O
50	O
micrograms	O
.	O

HT	B-DISEASE
included	O
oestrogens	B-Chemical
,	O
with	O
or	O
without	O
progestogens	B-Chemical
,	O
via	O
oral	O
,	O
transdermal	O
,	O
subcutaneous	O
or	O
transnasal	O
routes	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
the	O
association	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
visual	B-DISEASE
impairment	I-DISEASE
due	O
to	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
,	O
with	O
or	O
without	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

They	O
found	O
that	O
prevalence	O
of	O
KAL1	B-GENE
mutations	O
in	O
Brazilian	O
male	O
patients	O
with	O
KS	B-DISEASE
is	O
approximatively	O
22	O
%	O
(	O
27	O
%	O
familial	O
and	O
16	O
%	O
sporadic	O
cases	O
)	O
.	O

Three	O
probands	O
of	O
the	O
families	O
were	O
given	O
electroretinograms	O
and	O
they	O
also	O
received	O
audiometric	O
and	O
vestibular	O
tests	O
.	O

A	O
.	O

The	O
first	O
coding	O
exon	O
of	O
ACTB	B-GENE
had	O
a	O
low	O
read	O
depth	O
,	O
with	O
an	O
average	O
coverage	O
of	O
4x	O
;	O
all	O
other	O
exons	O
had	O
sufficient	O
coverage	O
to	O
call	O
variants	O
in	O
the	O
majority	O
of	O
samples	O
.	O

Gly459Glu	I-VARIANT
,	O
which	O
is	O
predicted	O
to	O
be	O
pathogenic	O
with	O
SIFT	B-Chemical
score	O
0	O
and	O
Polyphen2	B-Chemical
score	O
1	O
.	O
0	O
and	O
is	O
probably	O
a	O
pathogenic	O
missense	O
mutation	O
.	O

Data	O
visualization	O
was	O
performed	O
with	O
the	O
Integrative	O
Genomics	O
Viewer	O
51	O
.	O

(	O
B	O
and	O
F	O
)	O
Spiral	O
ganglions	O
were	O
labeled	O
with	O
anti	O
-	O
neurofilament	O
antibody	O
NF200	B-Chemical
(	O
green	O
)	O
.	O

They	O
showed	O
significantly	O
more	O
rapid	O
improvement	O
of	O
motor	O
function	O
in	O
the	O
first	O
week	O
following	O
hemorrhage	O
and	O
better	O
memory	O
retention	O
in	O
the	O
passive	O
avoidance	O
test	O
.	O

Click	O
here	O
for	O
file	O
Percentage	O
of	O
positive	O
cells	O
for	O
mesenchymal	O
cell	O
markers	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
find	O
the	O
frequency	O
of	O
COL4A3	B-GENE
/	I-GENE
A4	I-GENE
mutations	O
in	O
a	O
much	O
larger	O
Cypriot	O
population	O
with	O
FMH	B-DISEASE
that	O
did	O
not	O
necessarily	O
show	O
additional	O
renal	O
findings	O
.	O

M	O
in	O
bleeders	O
[	O
45	O
and	O
31	O
-	O
63	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
47	O
+	O
-	O
17	O
)	O
;	O
M	O
in	O
nonbleeders	O
[	O
42	O
and	O
4	O
-	O
62	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
39	O
+	O
-	O
14	O
)	O
;	O
(	O
NS	O
)	O
:	O
P	O
=	O
0	O
.	O
18	O
.	O

A	O
detailed	O
clinical	O
history	O
of	O
each	O
affected	O
member	O
was	O
collected	O
to	O
ensure	O
that	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
not	O
due	O
to	O
infections	O
,	O
ototoxic	O
drugs	O
,	O
trauma	O
or	O
premature	O
birth	O
and	O
was	O
not	O
accompanied	O
by	O
any	O
apparent	O
ear	O
,	O
eye	O
,	O
head	O
,	O
neck	O
,	O
skin	O
,	O
skeletal	O
or	O
neurological	O
abnormalities	O
.	O

Variants	O
predicted	O
to	O
be	O
deleterious	O
by	O
at	O
least	O
two	O
algorithms	O
,	O
and	O
affecting	O
conserved	O
amino	O
acids	O
were	O
prioritized	O
.	O

Among	O
the	O
109	O
patients	O
,	O
85	O
were	O
available	O
for	O
the	O
study	O
of	O
platelet	O
size	O
.	O

Among	O
them	O
,	O
40	O
were	O
screened	O
for	O
WFS1	B-GENE
mutations	O
.	O

However	O
,	O
we	O
have	O
observed	O
a	O
lower	O
frequency	O
of	O
the	O
35delG	B-VARIANT
mutant	O
allele	O
and	O
a	O
higher	O
heterogeneity	O
of	O
other	O
mutations	O
than	O
in	O
previous	O
studies	O
[	O
28	O
-	O
30	O
]	O
.	O

Cultured	O
dermal	O
fibroblasts	O
obtained	O
from	O
patients	O
were	O
incubated	O
with	O
and	O
without	O
emetine	B-Chemical
,	O
an	O
inhibitor	O
of	O
nonsense	O
mediated	O
decay	O
(	O
NMD	O
)	O
.	O

Performed	O
the	O
experiments	O
:	O
GG	O
AB	O
.	O

The	O
OPA1	B-GENE
mutation	O
is	O
described	O
according	O
to	O
the	O
OPA1	B-GENE
transcript	O
variant	O
1	O
(	O
RefSeq	O
:	O
NM_015560	O
)	O
.	O

Surreptitious	B-DISEASE
diuretic	I-DISEASE
ingestion	O
has	O
been	O
described	O
,	O
mainly	O
in	O
women	O
who	O
are	O
concerned	O
that	O
they	O
are	O
obese	O
or	O
edematous	B-DISEASE
.	O

The	O
combined	O
presence	O
of	O
the	O
two	O
variants	O
may	O
lead	O
to	O
a	O
different	O
phenotype	O
from	O
that	O
caused	O
by	O
any	O
single	O
variant	O
alone	O
in	O
the	O
homozygous	O
state	O
.	O

One	O
of	O
the	O
twins	O
developed	O
complete	O
heart	B-DISEASE
block	I-DISEASE
and	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
related	O
to	O
lopinavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
therapy	O
,	O
a	O
boosted	O
protease	O
-	O
inhibitor	O
agent	O
,	O
while	O
the	O
other	O
twin	O
developed	O
mild	O
bradycardia	B-DISEASE
.	O

The	O
coding	O
length	O
of	O
a	O
gene	O
is	O
defined	O
as	O
the	O
total	O
number	O
of	O
bases	O
predicted	O
to	O
be	O
translated	O
in	O
any	O
of	O
the	O
associated	O
transcripts	O
.	O

Results	O
from	O
our	O
study	O
are	O
intriguing	O
,	O
in	O
that	O
a	O
milder	O
auditory	O
phenotype	O
characterized	O
by	O
a	O
'	O
partial	B-DISEASE
deafness	I-DISEASE
'	O
was	O
observed	O
in	O
all	O
three	O
siblings	O
from	O
this	O
family	O
.	O

It	O
is	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
condition	O
.	O

It	O
is	O
a	O
region	O
populated	O
by	O
a	O
variety	O
of	O
ethnicities	O
but	O
mainly	O
by	O
Uyghur	O
ethnicity	O
.	O

The	O
position	O
of	O
a	O
changed	O
nucleotide	B-Chemical
is	O
indicated	O
by	O
a	O
square	O
.	O

Puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
renal	B-DISEASE
dysfunction	I-DISEASE
and	O
hyperlipidemia	B-DISEASE
were	O
also	O
suppressed	O
.	O

Enrichment	O
efficiency	O
can	O
be	O
measured	O
by	O
the	O
proportion	O
of	O
total	O
mapped	O
bases	O
that	O
overlap	O
the	O
designed	O
target	O
regions	O
(	O
on	O
-	O
target	O
proportion	O
)	O
.	O

CNVs	O
(	O
from	O
partial	O
to	O
complete	O
gene	O
deletions	O
)	O
of	O
PRPF31	B-GENE
detected	O
by	O
analysis	O
of	O
NGS	O
data	O
.	O

The	O
COCH	B-GENE
protein	O
,	O
cochlin	O
,	O
is	O
abundantly	O
expressed	O
in	O
the	O
cochlea	O
and	O
vestibular	O
system	O
of	O
the	O
inner	O
ear	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
S243X	I-VARIANT
in	O
this	O
family	O
is	O
located	O
in	O
the	O
central	O
region	O
of	O
SANS	O
,	O
which	O
directly	O
interacts	O
with	O
the	O
tail	O
domain	O
of	O
myosin	O
VIIa	O
(	O
MYO7A	B-GENE
)	O
[	O
21	O
]	O
,	O
thereby	O
linking	O
harmonin	O
with	O
the	O
actin	O
-	O
based	O
motor	O
[	O
14	O
]	O
.	O

The	O
ESP	O
dataset	O
showed	O
a	O
striking	O
ratio	O
of	O
synonymous	O
to	O
non	O
-	O
synonymous	O
substitutions	O
of	O
79	O
:	O
1	O
for	O
the	O
covered	O
portion	O
of	O
ACTB	B-GENE
and	O
ACTG1	B-GENE
combined	O
.	O

This	O
approach	O
can	O
also	O
be	O
generally	O
used	O
to	O
identify	O
low	O
-	O
level	O
somatic	O
mosaicism	O
in	O
other	O
genes	O
.	O

III	O
-	O
1	O
'	O
s	O
mother	O
(	O
II	O
-	O
2	O
)	O
also	O
developed	O
MH	B-DISEASE
and	O
proteinuria	B-DISEASE
in	O
her	O
30s	O
but	O
declined	O
renal	O
biopsy	O
.	O

Splice	O
site	O
prediction	O
software	O
online	O
(	O
splice	O
)	O
was	O
used	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
was	O
predicted	O
to	O
abolish	O
the	O
splice	O
accept	O
site	O
of	O
exon	O
43	O
,	O
which	O
would	O
lead	O
to	O
the	O
skipping	O
of	O
exon	O
43	O
.	O

2010	O
)	O
.	O

Certain	O
clues	O
,	O
including	O
the	O
onset	O
of	O
action	O
,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	B-Chemical
.	O

Variants	O
were	O
called	O
and	O
annotated	O
using	O
the	O
GATK	B-Chemical
[	O
30	O
]	O
(	O
release	O
1	O
.	O
4	O
,	O
Best	O
Practices	O
V3	O
filters	O
and	O
"	O
DP	O
<	O
6	O
"	O
)	O
and	O
ANNOVAR	B-Chemical
[	O
24	O
]	O
(	O
release	O
2012	O
March	O
08	O
)	O
software	O
packages	O
.	O

Each	O
variation	O
was	O
sequenced	O
by	O
the	O
Sanger	O
sequencing	O
method	O
using	O
an	O
ABI	O
PRISM	O
Big	O
Dye	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
v3	O
.	O
1	O
and	O
an	O
ABI	O
3130xl	O
DNA	O
sequencer	O
(	O
Applied	O
Biosystems	O
Corps	O
.	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
remaining	O
mutations	O
are	O
splice	O
site	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
small	O
indels	O
,	O
or	O
complex	O
rearrangements	O
.	O

In	O
addition	O
,	O
The	O
X	O
-	O
ray	O
of	O
the	O
family	O
members	O
III	O
-	O
6	O
,	O
III	O
-	O
7	O
,	O
IV	O
-	O
7	O
,	O
IV	O
-	O
8	O
,	O
IV	O
-	O
9	O
were	O
made	O
at	O
the	O
age	O
of	O
41	O
,	O
38	O
,	O
15	O
,	O
15	O
and	O
7	O
years	O
old	O
respectively	O
.	O

[	O
5	O
]	O
with	O
permission	O
.	O

All	O
genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
using	O
a	O
blood	O
DNA	O
extraction	O
kit	O
according	O
to	O
the	O
protocol	O
provided	O
by	O
the	O
manufacturer	O
(	O
TianGen	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

Detailed	O
clinical	O
,	O
imaging	O
,	O
and	O
laboratory	O
data	O
needed	O
to	O
be	O
described	O
for	O
case	O
reports	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	O
threshold	O
between	O
sevoflurane	B-Chemical
and	O
enflurane	B-Chemical
.	O

1	O
)	O
,	O
which	O
were	O
distributed	O
between	O
seven	O
exons	O
(	O
exons	O
9	O
,	O
10	O
,	O
11	O
,	O
13	O
,	O
14	O
,	O
16	O
,	O
and	O
18	O
)	O
and	O
comprised	O
missense	O
mutations	O
(	O
67	O
%	O
)	O
or	O
small	O
deletions	O
(	O
30	O
%	O
)	O
and	O
deletions	O
/	O
insertions	O
(	O
3	O
%	O
)	O
.	O

The	O
protein	O
encoded	O
by	O
the	O
GPR98	B-GENE
gene	O
at	O
the	O
USH2C	B-GENE
locus	O
is	O
a	O
member	O
of	O
the	O
serpentine	O
G	O
-	O
protein	O
coupled	O
receptor	O
superfamily	O
[	O
24	O
]	O
.	O

After	O
4	O
days	O
the	O
sodium	B-Chemical
increased	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fluid	O
restriction	O
was	O
relaxed	O
.	O

Renal	O
structure	O
and	O
concentrating	B-DISEASE
ability	I-DISEASE
were	O
examined	O
after	O
a	O
recovery	O
period	O
of	O
up	O
to	O
18	O
weeks	O
,	O
when	O
no	O
analgesics	O
were	O
given	O
,	O
to	O
investigate	O
whether	O
the	O
analgesic	O
-	O
induced	O
changes	O
were	O
reversible	O
.	O

She	O
is	O
currently	O
being	O
treated	O
with	O
best	O
supportive	O
care	O
.	O

Audiometric	O
measurements	O
were	O
obtained	O
at	O
specific	O
ages	O
for	O
each	O
patient	O
as	O
denoted	O
by	O
each	O
hearing	O
assessment	O
.	O

Sanger	O
sequencing	O
was	O
applied	O
to	O
these	O
samples	O
to	O
find	O
mutations	O
responsible	O
for	O
deafness	B-DISEASE
.	O

There	O
is	O
retarded	B-DISEASE
ossification	I-DISEASE
of	I-DISEASE
the	I-DISEASE
skeleton	I-DISEASE
with	O
absence	B-DISEASE
of	I-DISEASE
the	I-DISEASE
ossification	I-DISEASE
centres	I-DISEASE
of	I-DISEASE
pubic	I-DISEASE
bones	I-DISEASE
and	I-DISEASE
distal	I-DISEASE
femoral	I-DISEASE
and	I-DISEASE
proximal	I-DISEASE
tibial	I-DISEASE
epiphyses	I-DISEASE
.	O

Homozygous	O
mutations	O
in	O
KARS	B-GENE
,	O
an	O
aaRS	B-Chemical
which	O
functions	O
in	O
the	O
cytoplasm	O
as	O
well	O
as	O
the	O
mitochondria	O
,	O
have	O
been	O
shown	O
to	O
cause	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
DFNB89	B-DISEASE
)	O
[	O
14	O
]	O
.	O

Ototoxicity	B-DISEASE
occurred	O
in	O
four	O
(	O
9	O
.	O
5	O
%	O
)	O
of	O
42	O
netilmicin	B-Chemical
and	O
piperacillin	B-Chemical
and	O
in	O
12	O
(	O
22	O
%	O
)	O
of	O
54	O
tobramycin	B-Chemical
and	O
piperacillin	B-Chemical
-	O
treated	O
patients	O
.	O

A	O
)	O
Agilent	O
SureSelect	O
Human	O
all	O
Exon	O
v1	O
(	O
38	O
Mb	O
)	O
B	O
)	O
Agilent	O
SureSelect	O
Human	O
all	O
Exon	O
v2	O
(	O
44	O
Mb	O
)	O
C	O
)	O
Agilent	O
SureSelect	O
Human	O
all	O
Exon	O
(	O
50	O
Mb	O
)	O
D	O
)	O
TrueSeq	O
Exome	O
(	O
68	O
MB	O
)	O
.	O

The	O
urinary	O
output	O
should	O
be	O
monitored	O
and	O
the	O
oxytocin	B-Chemical
administration	O
discontinued	O
and	O
the	O
serum	O
electrolytes	O
checked	O
if	O
the	O
urinary	O
output	O
decreases	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
family	O
is	O
dominant	O
(	O
Figure	O
2	O
)	O
.	O

The	O
intrafamilial	O
variation	O
indicates	O
that	O
these	O
data	O
do	O
not	O
allow	O
prediction	O
of	O
the	O
phenotypic	O
outcome	O
for	O
individual	O
cases	O
.	O

Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
.	O

To	O
date	O
,	O
more	O
than	O
200	O
mutations	O
have	O
been	O
identified	O
for	O
SLC26A4	B-GENE
(	O
http	O
:	O
/	O
/	O
www	O
.	O
healthcare	O
.	O
uiowa	O
.	O
edu	O
/	O
labs	O
/	O
pendredandbor	O
/	O
slcMutations	O
.	O
htm	O
)	O
.	O

Here	O
we	O
have	O
used	O
a	O
NGS	O
-	O
based	O
approach	O
to	O
investigate	O
novel	O
mechanisms	O
of	O
combined	O
sequence	O
variations	O
and	O
CNVs	O
in	O
80	O
deafness	B-DISEASE
genes	O
that	O
cause	O
inherited	O
deafness	B-DISEASE
.	O

(	O
TIF	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
Glu340	O
residue	O
is	O
invariant	O
for	O
ESRRB	B-GENE
and	O
other	O
steroid	O
receptor	O
proteins	O
in	O
39	O
nonhuman	O
species	O
,	O
including	O
7	O
mammalian	O
,	O
1	O
avian	O
,	O
2	O
reptilian	O
,	O
3	O
amphibian	O
,	O
17	O
fish	O
,	O
2	O
ascidian	O
,	O
3	O
mollusk	O
,	O
and	O
4	O
arthropod	O
.	O

After	O
further	O
validation	O
by	O
Sanger	O
sequencing	O
,	O
segregation	O
pattern	O
,	O
and	O
evolutionary	O
conservation	O
of	O
amino	O
acid	O
residues	O
,	O
we	O
identified	O
4	O
variants	O
in	O
4	O
different	O
genes	O
,	O
which	O
might	O
lead	O
to	O
SNHI	B-DISEASE
in	O
4	O
families	O
compatible	O
with	O
autosomal	O
dominant	O
inheritance	O
.	O

2008	O
)	O
and	O
bilateral	O
RP	B-DISEASE
(	O
HP	B-Chemical
:	O
0007703	I-Chemical
)	O
(	O
Robinson	O
et	O
al	O
.	O

They	O
received	O
cochlear	O
implants	O
at	O
the	O
ages	O
of	O
3	O
years	O
and	O
9	O
months	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
data	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	B-DISEASE
deficits	I-DISEASE
due	O
to	O
Pb	B-Chemical
exposure	O
.	O

The	O
specific	O
primer	O
sets	O
were	O
selected	O
from	O
the	O
resequencing	O
amplicon	O
probe	O
sets	O
(	O
NCBI	O
)	O
or	O
designed	O
originally	O
by	O
Primer	O
-	O
BLAST	O
(	O
NCBI	O
)	O
.	O

The	O
genotyping	O
served	O
multiple	O
purposes	O
.	O

In	O
the	O
8	O
-	O
wk	O
group	O
,	O
MIBG	B-Chemical
accumulation	O
in	O
the	O
right	O
and	O
left	O
ventricular	O
wall	O
was	O
18	O
%	O
and	O
14	O
%	O
of	O
that	O
in	O
controls	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

They	O
are	O
characterized	O
by	O
moderate	O
to	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
a	O
down	O
-	O
sloping	O
configuration	O
.	O

All	O
of	O
the	O
rats	O
in	O
the	O
saline	O
-	O
treated	O
epileptic	B-DISEASE
control	O
group	O
developed	O
SRS	B-DISEASE
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treated	O
epileptic	B-DISEASE
animals	O
had	O
seizures	B-DISEASE
in	O
the	O
short	O
term	O
(	O
15	O
days	O
after	O
transplantation	O
)	O
,	O
regardless	O
of	O
the	O
BMC	O
source	O
.	O

Tumoral	B-DISEASE
calcinosis	I-DISEASE
was	O
originally	O
described	O
as	O
a	O
familial	O
condition	O
characterized	O
by	O
solitary	O
or	O
multiple	O
painless	O
,	O
periarticular	O
soft	O
-	O
tissue	O
calcium	O
masses	O
4	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
MCM2	B-GENE
as	O
a	O
novel	O
gene	O
responsible	O
for	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
of	O
autosomal	O
dominant	O
inheritance	O
in	O
a	O
Chinese	O
family	O
.	O

Recently	O
,	O
another	O
gene	O
,	O
PDZD7	B-GENE
,	O
was	O
shown	O
to	O
contribute	O
to	O
USH2	B-DISEASE
as	O
a	O
modifier	O
of	O
the	O
retinal	O
phenotype	O
on	O
a	O
USH2A	B-GENE
background	O
or	O
in	O
digenic	O
inheritance	O
with	O
GPR98	B-GENE
[	O
14	O
]	O
.	O

Mutation	O
analysis	O
-	O
sequence	O
data	O
Sequence	O
chromatogram	O
of	O
a	O
normal	O
control	O
(	O
NC	O
)	O
,	O
an	O
individual	O
heterozygous	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
728C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
S243X	I-VARIANT
)	O
mutation	O
(	O
CARRIER	B-Chemical
)	O
and	O
a	O
homozygous	O
p	B-VARIANT
.	I-VARIANT
S243X	I-VARIANT
(	O
indicated	O
by	O
an	O
arrow	O
)	O
mutation	O
in	O
an	O
affected	O
patient	O
(	O
PATIENT	O
)	O
.	O

The	O
patients	O
in	O
whom	O
we	O
did	O
not	O
identify	O
deleterious	O
COL4A	O
mutations	O
suggest	O
either	O
that	O
these	O
patients	O
need	O
reevaluation	O
of	O
clinical	O
diagnosis	O
or	O
there	O
are	O
changes	O
in	O
COL4A	O
gene	O
structures	O
that	O
were	O
not	O
identified	O
here	O
.	O

SIFT	O
,	O
http	O
:	O
/	O
/	O
sift	O
.	O
bii	O
.	O
a	O
-	O
star	O
.	O
edu	O
.	O
sg	O
/	O
9	O
.	O

Small	O
-	O
and	O
medium	O
-	O
sized	O
hepatic	O
veins	O
were	O
blocked	B-DISEASE
by	O
thrombosis	B-DISEASE
.	O

Depression	O
had	O
a	O
significant	O
negative	O
effect	O
on	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
over	O
time	O
regardless	O
of	O
ART	O
use	O
.	O

Connexin	B-GENE
26	I-GENE
,	O
a	O
gap	O
junction	O
protein	O
encoded	O
by	O
the	O
GJB2	B-GENE
gene	O
,	O
is	O
the	O
most	O
common	O
molecular	O
defect	O
in	O
nonsyndromic	B-DISEASE
autosomal	I-DISEASE
recessive	I-DISEASE
deafness	I-DISEASE
in	O
China	O
[	O
4	O
-	O
11	O
]	O
.	O

However	O
,	O
even	O
in	O
the	O
pre	O
-	O
molecular	O
era	O
,	O
patients	O
with	O
DOA	B-DISEASE
and	O
other	O
clinical	O
manifestations	O
,	O
most	O
commonly	O
sensorineural	B-DISEASE
deafness	I-DISEASE
,	O
ataxia	B-DISEASE
,	O
myopathy	B-DISEASE
and	O
progressive	B-DISEASE
external	I-DISEASE
ophthalmoplegia	I-DISEASE
,	O
were	O
recognized	O
(	O
Hoyt	B-Chemical
,	O
1980	O
;	O
Meire	B-Chemical
et	O
al	O
.	O

Each	O
patient	O
was	O
studied	O
on	O
two	O
separate	O
days	O
.	O

Importantly	O
,	O
iris	B-DISEASE
heterochromia	I-DISEASE
has	O
been	O
reported	O
in	O
a	O
13q	O
-	O
deletion	O
syndrome	O
patient	O
without	O
HSCR	B-DISEASE
[	O
43	O
]	O
as	O
well	O
as	O
in	O
infants	O
with	O
retinoblastoma	B-DISEASE
.	O

1F	O
)	O
.	O

We	O
thank	O
Chao	O
Zhang	O
and	O
Lan	O
Yu	O
for	O
auditory	O
testing	O
in	O
patients	O
,	O
Cui	O
Zhao	O
and	O
Na	O
Li	O
for	O
collecting	O
and	O
preparing	O
DNA	O
samples	O
,	O
Nan	O
Liu	O
for	O
assistance	O
with	O
PCR	O
and	O
Sanger	O
sequencing	O
.	O

S1	O
)	O
.	O

Protein	O
Data	O
Bank	O
structure	O
3GQI	O
41	O
showing	O
the	O
intracellular	O
kinase	O
domain	O
of	O
FGFR1	B-GENE
(	O
residues	O
464	O
-	O
770	O
)	O
in	O
ribbon	O
representation	O
.	O

BACKGROUND	O
:	O
Recent	O
evidence	O
suggests	O
that	O
transient	B-DISEASE
neurologic	I-DISEASE
symptoms	I-DISEASE
(	O
TNSs	B-DISEASE
)	O
frequently	O
follow	O
lidocaine	B-Chemical
spinal	O
anesthesia	O
but	O
are	O
infrequent	O
with	O
bupivacaine	B-Chemical
.	O

All	O
patients	O
showed	O
moderate	O
to	O
profound	O
bilateral	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
on	O
audiograms	O
and	O
no	O
pathient	O
with	O
mild	O
hearing	B-DISEASE
impairment	I-DISEASE
was	O
found	O
in	O
this	O
cohort	O
.	O

Hum	O
Mutat	O
33	O
:	O
144	O
-	O
157	O
,	O
2012	O
.	O

Moreover	O
,	O
the	O
patients	O
'	O
visual	O
acuity	O
was	O
normal	O
.	O

Three	O
genes	O
for	O
USH2	B-DISEASE
:	O
USH2A	B-GENE
,	O
GPR98	B-GENE
and	O
DFNB31	B-GENE
.	O

White	O
light	O
stimuli	O
(	O
with	O
an	O
intensity	O
of	O
1	O
.	O
70	O
x	O
10	O
-	O
14	O
photons	O
/	O
cm	O
2	O
/	O
sec	O
)	O
were	O
delivered	O
through	O
an	O
optical	O
fiber	O
connected	O
to	O
an	O
LED	O
.	O

Both	O
untreated	O
or	O
endoglycosidase	B-Chemical
-	O
treated	O
samples	O
were	O
resolved	O
on	O
PAGEr	B-Chemical
Gold	O
Precast	O
4	O
-	O
20	O
%	O
Tris	B-Chemical
-	I-Chemical
Glycine	I-Chemical
Gels	O
(	O
Lonza	O
,	O
Rockland	O
,	O
ME	O
)	O
,	O
and	O
subjected	O
to	O
western	O
blot	O
analysis	O
using	O
an	O
anti	O
-	O
myc	I-Chemical
antibody	O
(	O
1	O
:	O
1000	O
,	O
clone	O
4A6	O
,	O
Millipore	B-Chemical
,	O
Billerica	B-Chemical
,	O
MA	O
)	O
.	O

The	O
protective	O
role	O
of	O
Nrf2	B-GENE
in	O
streptozotocin	B-Chemical
-	O
induced	O
diabetic	B-DISEASE
nephropathy	I-DISEASE
.	O

Our	O
findings	O
expand	O
the	O
frequency	O
and	O
spectrum	O
of	O
PAX3	B-GENE
mutations	O
and	O
ethnic	O
-	O
related	O
phenotypes	O
in	O
Chinese	O
patients	O
with	O
WS1	B-DISEASE
.	O

Both	O
parents	O
are	O
heterozygotes	O
and	O
an	O
unaffected	O
sister	O
carries	O
wild	O
type	O
alleles	O
.	O

Five	O
splice	O
variants	O
of	O
the	O
gene	O
have	O
been	O
reported	O
,	O
with	O
isoforms	O
1	O
-	O
3	O
encoding	O
a	O
membrane	O
bound	O
form	O
by	O
the	O
use	O
of	O
the	O
full	O
exon	O
6	O
,	O
and	O
isoforms	O
4	O
and	O
5	O
encoding	O
a	O
soluble	O
form	O
of	O
the	O
protein	O
by	O
alternative	O
splicing	O
of	O
exon	O
6	O
or	O
the	O
alternative	O
use	O
of	O
exon	O
7	O
(	O
Fig	O
2A	O
)	O
.	O

An	O
electrode	O
placed	O
on	O
the	O
forehead	O
provided	O
a	O
ground	O
.	O

In	O
addition	O
,	O
knowledge	O
about	O
intrafamilial	O
variability	O
and	O
phenotypic	O
manifestations	O
in	O
female	O
carriers	O
is	O
limited	O
.	O

The	O
enrichment	O
of	O
targeted	O
deafness	B-DISEASE
genes	O
was	O
examined	O
by	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
,	O
comparing	O
the	O
growth	O
curves	O
of	O
captured	O
and	O
non	O
-	O
captured	O
samples	O
[	O
30	O
]	O
.	O

Until	O
methods	O
for	O
detecting	O
changes	O
within	O
homopolymers	O
are	O
improved	O
,	O
Sanger	O
sequencing	O
should	O
be	O
performed	O
systematically	O
for	O
patients	O
in	O
whom	O
one	O
pathogenic	O
variant	O
is	O
identified	O
by	O
NGS	O
.	O

Subcellular	O
locations	O
of	O
different	O
EDNRB	B-GENE
isoform	O
proteins	O
were	O
predicted	O
by	O
using	O
TargetP	O
1	O
.	O
1	O
server	O
.	O

This	O
response	O
was	O
most	O
pronounced	O
during	O
the	O
active	O
daytime	O
period	O
.	O

Abundant	O
insoluble	O
mutant	O
DSPP	B-GENE
and	O
its	O
degradation	O
products	O
(	O
dentin	O
phosphoprotein	O
,	O
DPP	O
and	O
dentin	O
sialoprotein	O
,	O
DSP	B-Chemical
)	O
expressed	O
by	O
odontoblast	O
cells	O
could	O
possibly	O
be	O
hypothesized	O
to	O
deactivate	O
or	O
indirectly	O
interfere	O
with	O
the	O
metabolism	O
of	O
other	O
proteins	O
in	O
dentin	O
and	O
result	O
in	O
the	O
phenotypes	O
of	O
DGI	B-DISEASE
.	O

We	O
have	O
captured	O
1254	O
exons	O
of	O
80	O
genes	O
(	O
Table	O
S2	O
)	O
spanning	O
480	O
kb	O
in	O
20	O
probands	O
from	O
multiplex	O
families	O
for	O
targeted	O
exome	O
sequencing	O
.	O

In	O
family	O
F5	O
,	O
one	O
allele	O
harbored	O
a	O
deletion	O
mutation	O
c	B-VARIANT
.	I-VARIANT
8483delC	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

Reduced	O
cardiotoxicity	O
of	O
doxorubicin	B-Chemical
given	O
in	O
the	O
form	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxypropyl	I-Chemical
)	I-Chemical
methacrylamide	I-Chemical
conjugates	O
:	O
and	O
experimental	O
study	O
in	O
the	O
rat	O
.	O

Heparin	B-Chemical
is	O
a	O
commonly	O
implemented	O
anticoagulant	O
used	O
to	O
treat	O
critically	O
ill	O
patients	O
.	O

With	O
the	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
,	O
deafness	B-DISEASE
genes	O
have	O
become	O
accessible	O
to	O
comprehensive	O
genetic	O
analysis	O
and	O
routine	O
genetic	O
testing	O
by	O
targeted	O
NGS	O
of	O
"	O
gene	O
panels	O
"	O
[	O
4	O
]	O
.	O

RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	O
were	O
enrolled	O
,	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum	O
.	O

Parameters	O
of	O
renal	O
hemodynamics	O
and	O
tubular	O
sodium	B-Chemical
and	O
water	O
handling	O
were	O
assessed	O
by	O
clearance	O
techniques	O
in	O
26	O
well	O
compensated	O
cirrhotic	O
patients	O
before	O
and	O
after	O
an	O
oral	O
combination	O
of	O
50	O
mg	O
of	O
indomethacin	B-Chemical
and	O
various	O
doses	O
of	O
misoprostol	B-Chemical
.	O

2	O
Internal	O
database	O
allele	O
frequency	O
does	O
not	O
include	O
the	O
family	O
on	O
this	O
table	O
with	O
a	O
given	O
variant	O
.	O

EML	O
recruited	O
and	O
phenotyped	O
the	O
patients	O
,	O
performed	O
the	O
statistical	O
analyses	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

By	O
further	O
studying	O
this	O
American	O
family	O
and	O
another	O
unrelated	O
Belgian	O
family	O
,	O
Wayne	O
et	O
al	O
(	O
7	O
)	O
identified	O
Eyes	B-GENE
absent	I-GENE
4	I-GENE
(	O
EYA4	B-GENE
)	O
,	O
a	O
member	O
of	O
the	O
vertebrate	O
EYA4	B-GENE
gene	O
family	O
of	O
transcriptional	O
activators	O
,	O
as	O
the	O
causative	O
gene	O
in	O
2001	O
.	O

Although	O
the	O
natural	O
NLS	O
has	O
been	O
disrupted	O
,	O
a	O
new	O
NLS	O
-	O
compatible	O
motif	O
(	O
RGRRRRCR	O
)	O
has	O
been	O
created	O
on	O
the	O
added	O
amino	O
acid	O
sequence	O
.	O

We	O
report	O
five	O
families	O
,	O
each	O
with	O
a	O
novel	O
MYH9	B-GENE
mutation	O
.	O

Finally	O
,	O
we	O
excluded	O
the	O
variants	O
that	O
we	O
can	O
detect	O
from	O
our	O
276	O
Korean	O
normal	O
hearing	O
control	O
chromosomes	O
.	O

They	O
described	O
the	O
method	O
and	O
results	O
in	O
the	O
text	O
.	O

The	O
bottom	O
panel	O
indicates	O
the	O
evolutionary	O
conservation	O
of	O
amino	O
acids	O
,	O
including	O
threonine	O
1188	O
,	O
in	O
vertebrate	O
species	O
.	O

Pedigree	O
,	O
PRS	O
enzymatic	O
activity	O
,	O
conservation	O
,	O
and	O
predicted	O
protein	O
structural	O
effects	O
of	O
the	O
novel	O
Gln277Pro	B-VARIANT
PRPS1	B-GENE
variant	O
.	O

E129K	B-VARIANT
,	O
located	O
within	O
the	O
conserved	O
T	O
domain	O
,	O
is	O
predicted	O
to	O
affect	O
TBX1	O
-	O
DNA	O
interaction	O
on	O
the	O
basis	O
of	O
the	O
structures	O
of	O
DNA	O
-	O
bound	O
wild	O
-	O
type	O
or	O
mutant	O
TBX1	B-GENE
(	O
Figure	O
3	O
)	O
.	O

The	O
former	O
,	O
c	B-VARIANT
.	I-VARIANT
2626_2627delGA	I-VARIANT
in	O
exon	O
15	O
(	O
Figure	O
1F	O
)	O
,	O
was	O
identified	O
in	O
patient	O
TCS	B-DISEASE
8	O
and	O
causes	O
the	O
formation	O
of	O
a	O
stop	O
codon	O
two	O
aminoacids	O
later	O
.	O

A	O
case	O
of	O
veno	O
-	O
occlusive	O
disease	O
of	O
the	O
liver	O
with	O
fatal	O
outcome	O
after	O
dacarbazine	B-Chemical
(	O
DTIC	B-Chemical
)	O
therapy	O
for	O
melanoma	B-DISEASE
is	O
reported	O
.	O

U	O
:	O
undigested	O
control	O
,	O
M	O
:	O
DNA	O
marker	O
.	O

We	O
subsequently	O
screened	O
a	O
set	O
of	O
35	O
unrelated	O
YJ	O
patients	O
with	O
retinal	O
degenerations	O
(	O
21	O
of	O
whom	O
had	O
nonsyndromic	O
RP	B-DISEASE
)	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
1220delG	I-VARIANT
mutation	O
and	O
identified	O
six	O
additional	O
index	O
RP	B-DISEASE
cases	O
who	O
were	O
homozygous	O
for	O
the	O
mutation	O
.	O

STUDY	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
compare	O
the	O
rate	O
of	O
akathisia	B-DISEASE
after	O
administration	O
of	O
intravenous	O
prochlorperazine	B-Chemical
as	O
a	O
2	O
-	O
minute	O
bolus	O
or	O
15	O
-	O
minute	O
infusion	O
.	O

Ketamine	B-Chemical
was	O
more	O
potent	O
in	O
the	O
hypophysectomized	O
chick	O
and	O
the	O
circadian	O
rhythm	O
noted	O
in	O
the	O
intact	O
chick	O
was	O
absent	O
;	O
furthermore	O
,	O
melatonin	B-Chemical
did	O
not	O
augment	O
the	O
ketamine	B-Chemical
DOC	O
whereas	O
dopamine	B-Chemical
continued	O
to	O
do	O
so	O
.	O

Indeed	O
,	O
he	O
was	O
diagnosed	O
with	O
RP	B-DISEASE
based	O
on	O
an	O
abnormal	O
electroretinogram	O
(	O
ERG	O
)	O
at	O
a	O
young	O
age	O
(	O
9	O
months	O
)	O
.	O

NPY	O
immunoreactivity	O
was	O
also	O
dramatically	O
changed	O
in	O
the	O
entorhinal	O
cortex	O
,	O
amygdala	O
and	O
sensorimotor	O
areas	O
.	O

Specificity	O
of	O
HOMER2	B-GENE
antibody	O
was	O
confirmed	O
by	O
staining	O
whole	O
mount	O
cochlea	O
from	O
Homer2	B-GENE
-	O
/	O
-	O
mice	O
(	O
S7	O
Fig	O
)	O
.	O

Contiguous	O
0	O
.	O
7	O
-	O
mm	O
scans	O
of	O
the	O
temporal	O
bone	O
were	O
acquired	O
in	O
the	O
axial	O
plane	O
and	O
reformatted	O
coronally	O
with	O
1	O
.	O
0	O
-	O
mm	O
increments	O
.	O

Levodopa	B-Chemical
-	O
induced	O
ocular	B-DISEASE
dyskinesias	I-DISEASE
in	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
.	O

Hence	O
,	O
data	O
are	O
lacking	O
on	O
the	O
frequency	O
of	O
monogenic	O
forms	O
of	O
CAKUT	B-DISEASE
in	O
large	O
cohorts	O
.	O

Variants	O
were	O
filtered	O
using	O
exome	O
data	O
from	O
35	O
Korean	O
patients	O
,	O
including	O
data	O
from	O
29	O
CMT	O
patients	O
[	O
13	O
,	O
14	O
]	O
and	O
6	O
deaf	B-DISEASE
patients	O
[	O
15	O
]	O
,	O
along	O
with	O
Korean	O
-	O
specific	O
variants	O
deposited	O
in	O
the	O
TIARA	O
database	O
[	O
16	O
]	O
.	O

French	O
Canadian	O
subjects	O
from	O
Quebec	O
with	O
USH1	B-DISEASE
were	O
identified	O
through	O
the	O
McGill	O
Ocular	O
Genetics	O
Laboratory	O
,	O
Montreal	O
Children	O
'	O
s	O
Hospital	O
Research	O
Institute	O
,	O
McGill	O
University	O
Health	O
Center	O
,	O
Montreal	O
,	O
Quebec	O
,	O
Canada	O
(	O
see	O
Additional	O
data	O
file	O
4	O
for	O
precise	O
origin	O
of	O
each	O
patient	O
)	O
.	O

Octreotide	B-Chemical
,	O
an	O
effective	O
treatment	O
for	O
acromegaly	B-DISEASE
,	O
induces	O
gall	B-DISEASE
bladder	I-DISEASE
stones	I-DISEASE
in	O
13	O
-	O
60	O
%	O
of	O
patients	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

19	O
The	O
ion	O
channel	O
defects	O
result	O
in	O
either	O
decreased	O
K	B-Chemical
+	O
efflux	O
or	O
increased	O
Na	B-Chemical
+	O
or	O
Ca	B-Chemical
2	I-Chemical
+	O
influx	O
over	O
the	O
cardiomyocyte	O
plasma	O
membrane	O
,	O
leading	O
to	O
reduced	O
repolarisation	O
and	O
increased	O
frequency	O
of	O
after	O
-	O
depolarisations	O
(	O
ADs	O
)	O
and	O
prolonged	O
refractory	O
period	O
.	O

The	O
family	O
in	O
this	O
study	O
comprised	O
six	O
affected	O
individuals	O
from	O
a	O
three	O
generation	O
pedigree	O
(	O
Fig	O
.	O

However	O
,	O
verapamil	B-Chemical
unresponsiveness	O
discriminates	O
stalk	B-DISEASE
effect	O
(	O
i	O
.	O
e	O
.	O
,	O
anatomically	O
or	O
functionally	O
inhibited	O
dopaminergic	I-DISEASE
tonus	O
)	O
from	O
other	O
causes	O
of	O
hyperprolactinemia	B-DISEASE
with	O
varying	O
degrees	O
of	O
responsiveness	O
.	O

performed	O
linkage	O
,	O
RT	O
-	O
PCR	O
,	O
mutational	O
analyses	O
,	O
and	O
cloned	O
isoforms	O
,	O
and	O
provided	O
bioinformatic	O
evaluations	O
;	O
I	O
.	O
A	O
.	O
B	O
.	O

Like	O
other	O
Arts	B-DISEASE
syndrome	I-DISEASE
mutations	O
(	O
and	O
in	O
contrast	O
to	O
CMTX5	B-DISEASE
PRPS1	B-GENE
mutations	O
)	O
,	O
it	O
is	O
predicted	O
to	O
disrupt	O
the	O
local	O
PRS	O
-	O
I	O
structure	O
.	O

While	O
the	O
SureSelect	O
50Mb	O
kit	O
shows	O
a	O
parabolic	O
relationship	O
between	O
read	O
depth	O
and	O
GC	O
content	O
,	O
the	O
depths	O
on	O
the	O
CUHK	O
-	O
V1	O
kit	O
targets	O
decrease	O
monotonically	O
with	O
GC	O
content	O
.	O

ANH	B-DISEASE
,	O
auditory	B-DISEASE
nerve	I-DISEASE
hypoplasia	I-DISEASE
;	O
CdLS	B-DISEASE
,	O
Cornelia	B-DISEASE
de	I-DISEASE
Lange	I-DISEASE
syndrome	I-DISEASE
;	O
C	B-DISEASE
-	I-DISEASE
VCA	I-DISEASE
,	O
cystic	B-DISEASE
vestibulocochlear	I-DISEASE
anomaly	I-DISEASE
;	O
EVA	B-DISEASE
,	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
;	O
HL	B-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
;	O
IEM	B-DISEASE
,	O
inner	B-DISEASE
ear	I-DISEASE
malformations	I-DISEASE
;	O
L	O
,	O
Left	O
;	O
LQT	B-DISEASE
,	O
prolonged	B-DISEASE
QT	I-DISEASE
interval	I-DISEASE
;	O
M	O
,	O
pathogenic	O
mutation	O
;	O
MCA	B-DISEASE
,	O
multiple	B-DISEASE
congenital	I-DISEASE
anomalies	I-DISEASE
;	O
Mi	O
,	O
Mild	O
;	O
Mo	O
,	O
Moderate	O
;	O
MON	B-DISEASE
,	O
Mondini	B-DISEASE
malformation	I-DISEASE
;	O
NA	O
,	O
Not	O
available	O
;	O
NL	O
,	O
normal	O
;	O
P	O
,	O
benign	O
polymorphism	O
;	O
Pr	O
,	O
Profound	O
;	O
PCWH	B-DISEASE
,	O
peripheral	B-DISEASE
demyelinating	I-DISEASE
neuropathy	I-DISEASE
,	O
central	B-DISEASE
dysmyelination	I-DISEASE
,	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
,	O
Hirschsprung	B-DISEASE
disease	I-DISEASE
;	O
R	O
,	O
Right	O
;	O
S	O
,	O
Severe	O
;	O
SCA	B-DISEASE
,	O
semicircular	B-DISEASE
canal	I-DISEASE
abnormalities	I-DISEASE
;	O
UNI	O
,	O
unilateral	O
;	O
USH	B-DISEASE
(	O
#	O
)	O
,	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
type	O
)	O
;	O
VUS	O
,	O
variant	O
of	O
uncertain	O
pathogenicity	O
;	O
WS	B-DISEASE
(	O
#	O
)	O
,	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
(	O
type	O
)	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
Thirty	O
women	O
(	O
aged	O
30	O
-	O
77	O
years	O
)	O
diagnosed	O
as	O
having	O
OAB	B-DISEASE
at	O
the	O
Gynecology	O
Clinic	O
,	O
King	O
Chulalongkorn	O
Memorial	O
Hospital	O
from	O
January	O
to	O
April	O
2004	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

Radiography	O
revealed	O
multilobulated	O
calcified	O
masses	O
,	O
leading	O
to	O
a	O
diagnosis	O
of	O
tumoral	B-DISEASE
calcinosis	I-DISEASE
(	O
Fig	O
.	O

A	O
:	O
Electropherogram	O
corresponding	O
to	O
the	O
wild	O
type	O
sequence	O
(	O
c	O
.	O
672C	O
)	O
.	O

,	O
2008	O
)	O
.	O

3	O
)	O
.	O

Spontaneous	O
glomerulosa	O
membrane	O
potential	O
oscillations	O
9	O
may	O
contribute	O
to	O
activation	O
of	O
these	O
mutant	O
channels	O
.	O

OBJECTIVE	O
:	O
The	O
globus	O
pallidus	O
plays	O
a	O
critical	O
role	O
in	O
movement	O
regulation	O
.	O

CIN	B-DISEASE
more	O
frequently	O
developed	O
in	O
patients	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
days	O
after	O
the	O
last	O
chemotherapy	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
;	O
it	O
was	O
also	O
an	O
independent	O
risk	O
factor	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

All	O
3	O
patients	O
had	O
loss	O
of	O
central	O
visual	O
acuity	O
,	O
colour	O
vision	O
(	O
Ishihara	O
)	O
and	O
visual	O
field	O
.	O

Arm	O
length	O
was	O
121	O
cm	O
,	O
lower	O
segment	O
length	O
was	O
60	O
cm	O
and	O
upper	O
segment	O
length	O
55	O
cm	O
.	O

(	O
e	O
)	O
Magnified	O
AO	O
image	O
outlined	O
in	O
orange	O
in	O
(	O
a	O
)	O
and	O
(	O
d	O
)	O
is	O
shown	O
.	O

The	O
association	O
of	O
high	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
haematuria	B-DISEASE
raised	O
the	O
suspicion	O
of	O
a	O
hereditary	B-DISEASE
nephritis	I-DISEASE
.	O

Apple	B-Chemical
-	O
Mathews	O
for	O
help	O
in	O
preparing	O
the	O
manuscript	O
.	O
Although	O
over	O
60	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
genes	O
have	O
been	O
identified	O
to	O
date	O
,	O
the	O
etiologic	O
contribution	O
of	O
most	O
deafness	B-DISEASE
genes	O
remained	O
elusive	O
.	O

However	O
,	O
only	O
longer	O
experience	O
will	O
more	O
clearly	O
define	O
the	O
incidence	O
of	O
each	O
side	O
effect	O
with	O
low	O
molecular	O
weight	O
preparations	O
.	O

Dr	O
.	O

We	O
assessed	O
the	O
presence	O
or	O
absence	O
of	O
the	O
two	O
known	O
5	O
'	O
polymorphisms	O
at	O
c	O
.	O
-	O
137	O
and	O
c	O
.	O
-	O
53	O
in	O
a	O
well	O
-	O
characterized	O
PBD	B-DISEASE
patient	O
collection	O
with	O
PEX1	B-GENE
mutations	O
[	O
12	O
]	O
.	O

Pai	O
and	O
Rawles	O
suggested	O
a	O
link	O
between	O
AF	B-DISEASE
and	O
prolongation	O
of	O
the	O
mean	O
QT	O
interval	O
[	O
32	O
]	O
.	O

Results	O
of	O
a	O
former	O
study	O
suggest	O
that	O
SLC26A4	B-GENE
could	O
be	O
considered	O
as	O
the	O
second	O
cause	O
of	O
HI	B-DISEASE
,	O
after	O
GJB2	B-GENE
,	O
in	O
Iran	O
[	O
13	O
]	O
.	O

Immittance	O
testing	O
demonstrated	O
normal	O
and	O
bone	O
conduction	O
values	O
equal	O
to	O
the	O
air	O
conduction	O
measurements	O
,	O
suggesting	O
a	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

The	O
authors	O
would	O
like	O
to	O
thank	O
all	O
patients	O
and	O
their	O
families	O
for	O
their	O
friendly	O
cooperation	O
.	O
Mutations	O
of	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
2	I-GENE
(	O
FGFR2	B-GENE
)	O
account	O
for	O
a	O
higher	O
proportion	O
of	O
genetic	O
cases	O
of	O
craniosynostosis	B-DISEASE
than	O
any	O
other	O
gene	O
,	O
and	O
are	O
associated	O
with	O
a	O
wide	O
spectrum	O
of	O
severity	O
of	O
clinical	O
problems	O
.	O

Sixty	O
-	O
seven	O
patients	O
with	O
WFS	B-DISEASE
were	O
recruited	O
nationally	O
.	O

Subjects	O
with	O
GJB2	B-GENE
mutations	O
or	O
mitochondrial	O
m	B-VARIANT
.	I-VARIANT
1555A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
or	O
3243A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
mutations	O
were	O
excluded	O
.	O

The	O
cumulative	O
distribution	O
of	O
COMP	B-GENE
missense	O
mutations	O
from	O
this	O
study	O
and	O
that	O
published	O
by	O
Kennedy	O
et	O
al	O
.	O

Thus	O
,	O
scans	O
were	O
obtained	O
on	O
14	O
subjects	O
.	O

To	O
identify	O
SNPs	O
,	O
we	O
used	O
SOAPsnp	O
software	O
and	O
bioinformatics	O
pipeline	O
.	O

*	O
Data	O
are	O
expressed	O
as	O
means	O
+	O
-	O
SD	O
.	O

The	O
average	O
hearing	O
loss	O
for	O
speech	O
frequencies	O
was	O
about	O
10	O
dB	O
after	O
prilocaine	B-Chemical
and	O
15	O
dB	O
after	O
bupivacaine	B-Chemical
.	O

All	O
mutations	O
are	O
heterozygous	O
.	O

Squares	O
represent	O
males	O
,	O
circles	O
represent	O
females	O
.	O

As	O
part	O
of	O
a	O
preoperative	O
selection	O
procedure	O
for	O
cochlear	B-DISEASE
implantation	I-DISEASE
,	O
the	O
proband	O
also	O
underwent	O
electronystagmography	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
,	O
and	O
auditory	O
steady	O
-	O
state	O
response	O
(	O
ASSR	O
)	O
testing	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
11	O
cases	O
had	O
germline	O
truncation	O
variants	O
in	O
multiple	O
cancer	O
genes	O
,	O
including	O
two	O
cases	O
with	O
BRCA1	B-GENE
and	O
BRCA2	B-GENE
variants	O
(	O
diagnosis	O
ages	O
49	O
and	O
55	O
years	O
)	O
,	O
one	O
case	O
with	O
BRCA2	B-GENE
and	O
ERCC3	B-GENE
variants	O
,	O
one	O
with	O
PALB2	B-GENE
and	O
ATM	B-GENE
variants	O
,	O
and	O
one	O
with	O
BLM	B-GENE
and	O
FANCD2	B-GENE
truncation	O
variants	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
liver	B-DISEASE
failure	I-DISEASE
that	O
resulted	O
in	O
liver	B-DISEASE
transplantation	O
.	O

19	O
Thus	O
,	O
we	O
introduced	O
a	O
position	O
-	O
and	O
strand	O
-	O
specific	O
error	O
rate	O
q	O
i	O
,	O
j	O
,	O
d	O
for	O
a	O
certain	O
error	O
category	O
j	O
in	O
amplicon	O
position	O
i	O
with	O
strand	O
d	O
based	O
on	O
the	O
sequencing	O
data	O
from	O
50	O
control	O
samples	O
.	O

Mutations	O
in	O
any	O
of	O
these	O
genes	O
can	O
lead	O
to	O
type	B-DISEASE
IV	I-DISEASE
collagen	I-DISEASE
-	I-DISEASE
related	I-DISEASE
nephropathy	I-DISEASE
in	O
which	O
there	O
is	O
disruption	O
of	O
the	O
normal	O
glomerular	O
basement	O
membrane	O
architecture	O
and	O
kidney	B-DISEASE
disease	I-DISEASE
[	O
1	O
]	O
.	O

The	O
Finminor	O
mutation	O
is	O
c	B-VARIANT
.	I-VARIANT
359T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
M120K	I-VARIANT
)	O
,	O
which	O
is	O
responsible	O
for	O
virtually	O
the	O
rest	O
of	O
the	O
CLRN1	B-GENE
alleles	O
.	O

However	O
,	O
our	O
understanding	O
of	O
HDR	B-DISEASE
syndrome	I-DISEASE
to	O
date	O
is	O
not	O
complete	O
,	O
and	O
future	O
research	O
is	O
needed	O
on	O
this	O
disease	O
.	O

Among	O
the	O
33	O
patients	O
originally	O
classified	O
as	O
USH2	B-DISEASE
,	O
two	O
potentially	O
disease	O
-	O
causing	O
USH2A	B-GENE
variants	O
were	O
found	O
in	O
22	O
(	O
66	O
.	O
6	O
%	O
)	O
cases	O
while	O
one	O
single	O
variant	O
was	O
detected	O
in	O
another	O
three	O
patients	O
(	O
9	O
.	O
1	O
%	O
)	O
for	O
a	O
total	O
of	O
47	O
/	O
66	O
(	O
71	O
.	O
2	O
%	O
)	O
alleles	O
in	O
agreement	O
with	O
the	O
detection	O
rate	O
reported	O
in	O
other	O
studies	O
that	O
investigated	O
other	O
ethnic	O
groups	O
[	O
16	O
,	O
18	O
,	O
19	O
,	O
34	O
,	O
35	O
,	O
38	O
]	O
.	O

Our	O
multiplexed	O
NGS	O
experiments	O
were	O
conducted	O
on	O
14	O
patient	O
samples	O
with	O
19	O
genes	O
commonly	O
associated	O
with	O
AS	B-DISEASE
or	O
FSGS	B-DISEASE
including	O
steroid	O
resistant	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O

Homology	O
modeling	O
was	O
performed	O
by	O
I	O
-	O
TASSER	O
20	O
,	O
using	O
as	O
templates	O
the	O
E	O
.	O

Mutations	O
in	O
exon	O
9	O
(	O
c	B-VARIANT
.	I-VARIANT
1191delT	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Asn398Metfs	I-VARIANT
*	I-VARIANT
19	I-VARIANT
)	O
and	O
exon	O
58	O
(	O
c	B-VARIANT
.	I-VARIANT
4259G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Gly1420Val	I-VARIANT
)	O
were	O
found	O
in	O
the	O
proband	O
.	O

Wrote	O
the	O
paper	O
:	O
DLB	O
JGV	O
.	O

3	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
RB	O
JB	O
KM	O
.	O

This	O
study	O
implies	O
that	O
the	O
frequency	O
of	O
DOA	B-DISEASE
is	O
much	O
lower	O
than	O
that	O
of	O
Leber	O
hereditary	O
optic	B-DISEASE
neuropathy	I-DISEASE
in	O
Chinese	O
compared	O
with	O
other	O
ethnic	O
groups	O
.	O

Microinjections	O
of	O
gamma	B-Chemical
-	I-Chemical
vinyl	I-Chemical
-	I-Chemical
GABA	I-Chemical
,	O
5	O
micrograms	O
,	O
into	O
the	O
dorsal	O
striatum	O
,	O
bilaterally	O
,	O
failed	O
to	O
prevent	O
the	O
development	O
of	O
convulsions	O
produced	O
by	O
pilocarpine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O

32	O
We	O
detected	O
a	O
common	O
GJB2	B-GENE
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
homozygous	O
mutation	O
in	O
the	O
available	O
affected	O
members	O
of	O
family	O
R5	O
with	O
profound	O
HL	B-DISEASE
and	O
suspected	O
auditory	B-DISEASE
neuropathy	I-DISEASE
.	O

2H	O
)	O
.	O

A	O
PCR	O
amplification	O
of	O
the	O
captured	O
target	O
libraries	O
was	O
performed	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
,	O
after	O
its	O
purification	O
with	O
the	O
"	O
AMPure	O
XP	O
beads	O
"	O
(	O
BECKMAN	O
CULTER	O
Inc	O
)	O
,	O
the	O
validation	O
and	O
quantification	O
of	O
the	O
enriched	O
target	O
DNA	O
in	O
each	O
library	O
was	O
performed	O
using	O
the	O
2100	O
Bioanalyzer	O
system	O
with	O
the	O
High	O
Sensitivity	O
DNA	O
Kit	O
and	O
the	O
2100	O
Expert	O
Software	O
(	O
Agilent	O
Technologies	O
Inc	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
change	O
c	B-VARIANT
.	I-VARIANT
1148C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
T383N	I-VARIANT
)	O
,	O
found	O
in	O
two	O
unrelated	O
USH2	B-DISEASE
patients	O
from	O
the	O
Netherlands	O
,	O
creates	O
four	O
new	O
putative	O
ESE	O
sites	O
,	O
whereas	O
c	B-VARIANT
.	I-VARIANT
1339G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
D447H	I-VARIANT
)	O
,	O
detected	O
in	O
one	O
USH2	B-DISEASE
patient	O
from	O
Hungary	O
,	O
suppresses	O
one	O
existing	O
ESE	O
sequence	O
and	O
creates	O
two	O
new	O
putative	O
ESE	O
sites	O
.	O

Supervised	O
the	O
study	O
:	O
NK	O
.	O

Pedigree	O
of	O
family	O
RP	B-DISEASE
-	I-Chemical
0482	I-Chemical
and	O
validation	O
by	O
Sanger	O
sequencing	O
of	O
p	B-VARIANT
.	I-VARIANT
Ser16Pro	I-VARIANT
demonstrating	O
the	O
correct	O
segregation	O
in	O
the	O
family	O
.	O

Temocapril	B-Chemical
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	B-Chemical
converting	I-GENE
enzyme	I-GENE
inhibitor	O
,	O
modulates	O
glomerular	O
injury	I-DISEASE
in	O
chronic	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	I-DISEASE
.	O

Only	O
3	O
patients	O
had	O
previously	O
reported	O
pathogenic	O
mtDNA	O
mutations	O
and	O
only	O
8	O
patients	O
had	O
recessive	O
-	O
type	O
mutations	O
in	O
known	O
disease	O
genes	O
,	O
including	O
5	O
novel	O
and	O
2	O
previously	O
reported	O
mutations	O
(	O
Table	O
3	O
)	O
.	O

Antithrombotic	B-DISEASE
drug	O
use	O
,	O
cerebral	O
microbleeds	O
,	O
and	O
intracerebral	B-DISEASE
hemorrhage	I-DISEASE
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O

Clinical	O
evaluation	O
on	O
combined	O
administration	O
of	O
oral	O
prostacyclin	B-Chemical
analogue	O
beraprost	B-Chemical
and	O
phosphodiesterase	O
inhibitor	O
cilostazol	B-Chemical
.	O

Austria	O
:	O
Werner	O
Emberger	O
,	O
Graz	O
.	O

SH23	B-Chemical
-	O
98	O
manifested	O
significant	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
over	O
5	O
years	O
,	O
and	O
parents	O
recalled	O
that	O
SH23	B-Chemical
-	O
99	O
and	O
SH23	B-Chemical
-	O
54	O
had	O
near	O
-	O
normal	O
hearing	O
and	O
speech	O
development	O
until	O
10	O
years	O
of	O
age	O
.	O

Contributed	O
to	O
the	O
writing	O
of	O
the	O
manuscript	O
:	O
KV	B-Chemical
CD	O
LP	O
M	O
.	O

coli	O
LeuRS	B-GENE
translational	O
quality	O
control	O
is	O
norvaline	B-Chemical
,	O
a	O
side	O
product	O
of	O
the	O
leucine	O
biosynthetic	O
pathway	O
that	O
accumulates	O
under	O
limited	O
-	O
oxygen	O
growth	O
conditions	O
,	O
suggesting	O
that	O
the	O
LeuRS	B-GENE
editing	O
has	O
been	O
evolutionary	O
optimized	O
to	O
eliminate	O
non	O
-	O
proteinogenic	O
norvaline	O
rather	O
than	O
isoleucine	B-Chemical
23	O
.	O

One	O
affected	O
subject	O
from	O
each	O
branch	O
was	O
subject	O
to	O
targeted	O
NGS	O
whose	O
genomic	O
DNA	O
was	O
enriched	O
either	O
by	O
whole	O
-	O
exome	O
capture	O
(	O
Agilent	O
SureSelect	O
All	O
Exon	O
50	O
Mb	O
)	O
or	O
by	O
candidate	O
genes	O
capture	O
(	O
Agilent	O
SureSelect	O
custom	O
kit	O
)	O
.	O

Ketamine	B-Chemical
induces	O
activation	O
changes	O
in	O
healthy	O
subjects	O
similar	O
to	O
those	O
observed	O
in	O
patients	O
with	O
schizophrenia	B-DISEASE
,	O
particularly	O
in	O
frontal	O
and	O
temporal	O
brain	O
regions	O
.	O

Bioinformatic	O
analysis	O
revealed	O
that	O
the	O
mutated	O
residues	O
were	O
conserved	O
across	O
species	O
(	O
Figure	O
2b	O
)	O
.	O

Subsequently	O
,	O
100	O
mu	O
l	O
of	O
these	O
pools	O
were	O
purified	O
with	O
the	O
High	O
Pure	O
PCR	O
Cleanup	O
Micro	O
Kit	O
(	O
Roche	O
Diagnostics	O
)	O
.	O

WES	O
provides	O
unprecedented	O
opportunities	O
to	O
identify	O
causative	O
DNA	O
mutations	O
in	O
rare	O
heritable	O
disorders	O
.	O

(	O
2014b	O
)	O
)	O
,	O
mandating	O
comprehensive	O
TGE	O
+	O
MPS	O
and	O
thorough	O
data	O
analysis	O
.	O

B	O
-	O
scan	O
of	O
the	O
left	O
eye	O
revealed	O
severe	O
microphthalmia	B-DISEASE
and	O
phthisis	B-DISEASE
.	O

HEK293	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
.	O

Supplementary	O
Figures	O
S1	O
-	O
S2	O
and	O
Supplementary	O
Tables	O
S1	O
-	O
S3	O
.	O

This	O
individual	O
showed	O
a	O
heterozygous	O
deletion	O
,	O
yielding	O
a	O
combined	O
six	O
heterozygous	O
deletions	O
(	O
Table	O
S3	O
)	O
.	O

Untagged	O
CD164	B-GENE
migrated	O
as	O
several	O
bands	O
with	O
predominant	O
species	O
around	O
80	O
-	O
100	O
kDa	O
under	O
reducing	O
conditions	O
(	O
Fig	O
5A	O
)	O
.	O

Heterozygous	O
mutations	O
in	O
known	O
deafness	B-DISEASE
genes	O
in	O
affected	O
families	O
and	O
hearing	O
individuals	O
.	O

D	O
K	O
,	O
XZ	O
,	O
XM	O
and	O
XY	O
participated	O
in	O
the	O
sequence	O
alignment	O
.	O

METHODS	O
:	O
We	O
present	O
the	O
first	O
case	O
report	O
of	O
a	O
woman	O
with	O
hyperthyroidism	B-DISEASE
treated	O
with	O
propylthiouracil	B-Chemical
in	O
whom	O
a	O
syndrome	O
of	O
pericarditis	B-DISEASE
,	O
fever	B-DISEASE
,	O
and	O
glomerulonephritis	B-DISEASE
developed	O
.	O

Study	O
of	O
GJB2	B-GENE
gene	O
revealed	O
that	O
30	O
.	O
4	O
%	O
of	O
the	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
Inner	O
Mongolia	O
carried	O
GJB2	B-GENE
mutations	O
.	O

*	O
Works	O
with	O
5	O
%	O
DMSO	B-Chemical
.	O

On	O
the	O
other	O
hand	O
,	O
no	O
clear	O
phenotype	O
-	O
genotype	O
correlation	O
could	O
be	O
established	O
between	O
RP	B-DISEASE
and	O
Usher	O
cases	O
.	O

These	O
studies	O
have	O
implications	O
for	O
early	O
detection	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
genetic	O
counseling	O
,	O
and	O
for	O
implementation	O
of	O
suitable	O
early	O
intervention	O
strategies	O
.	O

In	O
addition	O
to	O
these	O
cases	O
with	O
a	O
single	O
mutated	O
chromosome	O
,	O
there	O
were	O
11	O
patients	O
in	O
which	O
no	O
WFS1	B-GENE
mutations	O
were	O
identified	O
.	O

Amifostine	B-Chemical
subsequently	O
was	O
shown	O
to	O
protect	O
normal	O
tissues	O
from	O
the	O
toxic	O
effects	O
of	O
alkylating	B-Chemical
agents	I-Chemical
and	O
cisplatin	B-Chemical
without	O
decreasing	O
the	O
antitumor	O
effect	O
of	O
the	O
chemotherapy	O
.	O

Two	O
major	O
or	O
one	O
major	O
and	O
two	O
minor	O
criteria	O
must	O
be	O
found	O
in	O
an	O
individual	O
to	O
diagnose	O
WS	B-DISEASE
[	O
3	O
,	O
4	O
]	O
.	O

MRC	O
Clinical	O
Research	O
Fellowship	O
in	O
Neuro	O
-	O
ophthalmology	O
to	O
P	O
.	O
Y	O
.	O
W	O
.	O
M	O
.	O
;	O
Wellcome	O
Trust	O
Senior	O
Fellowship	O
in	O
Clinical	O
Science	O
to	O
P	O
.	O
F	O
.	O
C	O
.	O
;	O
P	O
.	O
F	O
.	O
C	O
.	O

Upon	O
sound	O
stimulation	O
,	O
the	O
relative	O
displacement	O
of	O
the	O
tectorial	O
membrane	O
with	O
regards	O
to	O
the	O
hair	O
cells	O
provokes	O
a	O
deflection	O
of	O
their	O
stererociliary	O
bundles	O
,	O
thereby	O
leading	O
to	O
the	O
opening	O
of	O
their	O
mechanotransduction	O
channel	O
[	O
2	O
]	O
.	O

Then	O
wild	O
-	O
type	O
and	O
mutant	O
myosin	B-GENE
VIIA	I-GENE
HMM	O
proteins	O
were	O
collected	O
and	O
purification	O
was	O
carried	O
out	O
with	O
Ni	B-Chemical
2	I-Chemical
+	I-Chemical
-	I-Chemical
NTA	I-Chemical
agrose	I-Chemical
column	O
.	O

Myoclonic	B-DISEASE
,	O
atonic	B-DISEASE
,	O
and	O
absence	B-DISEASE
seizures	I-DISEASE
following	O
institution	O
of	O
carbamazepine	B-Chemical
therapy	O
in	O
children	O
.	O

Homozygosity	O
mapping	O
with	O
GT	O
console	O
is	O
shown	O
for	O
TRIC	B-GENE
and	O
LHFPL5	B-GENE
as	O
genes	O
of	O
interest	O
for	O
families	O
TA12	O
and	O
SS3	O
,	O
respectively	O
.	O

(	O
A	O
)	O
Partial	O
DNA	O
sequences	O
of	O
the	O
TECTA	B-GENE
gene	O
in	O
a	O
normal	O
family	O
member	O
and	O
(	O
B	O
)	O
the	O
c	B-VARIANT
.	I-VARIANT
257	I-VARIANT
-	I-VARIANT
262CCTTTC	I-VARIANT
>	I-VARIANT
GCT	I-VARIANT
mutation	O
(	O
in	O
family	O
members	O
IV	O
:	O
2	O
,	O
IV	O
:	O
7	O
,	O
III	O
:	O
4	O
,	O
III	O
:	O
5	O
,	O
III	O
:	O
3	O
,	O
IV	O
:	O
5	O
)	O
.	O

investigated	O
CNGA1	B-GENE
exons	O
6	O
,	O
8	O
and	O
partial	O
11	O
in	O
193	O
Japanese	O
RP	B-DISEASE
families	O
and	O
found	O
a	O
single	O
heterozygous	O
CNGA1	B-GENE
variant	O
(	O
c	B-VARIANT
.	I-VARIANT
1271G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
[	O
11	O
]	O
.	O

She	O
also	O
carried	O
10	O
polymorphisms	O
(	O
rs1801213	B-VARIANT
CG	O
Het	O
,	O
rs1801212	B-VARIANT
AG	O
Het	O
,	O
rs1801206	B-VARIANT
CT	O
Het	O
[	O
V395V	B-VARIANT
associated	O
with	O
DM1	B-DISEASE
[	O
26	O
]	O
]	O
,	O
rs1801208	B-VARIANT
GA	O
Het	O
[	O
R456H	B-VARIANT
,	O
associated	O
with	O
risk	O
of	O
Type	B-DISEASE
2	I-DISEASE
Diabetes	I-DISEASE
[	O
27	O
]	O
,	O
suicide	O
[	O
28	O
]	O
non	B-DISEASE
autoimmune	I-DISEASE
Diabetes	I-DISEASE
[	O
29	O
]	O
]	O
rs1801214	B-VARIANT
CT	O
Het	O
,	O
rs1046314	B-VARIANT
AG	O
Het	O
and	O
rs1046316	B-VARIANT
AG	O
Het	O
[	O
K811K	B-VARIANT
and	O
S855S	B-VARIANT
,	O
associated	O
with	O
DM1	B-DISEASE
[	O
26	O
]	O
]	O
,	O
rs1046317	B-VARIANT
CT	O
Het	O
,	O
rs1046319	B-VARIANT
CT	O
Het	O
,	O
rs1802453	B-VARIANT
GA	O
Het	O
)	O
.	O

Earlier	O
identification	O
of	O
such	O
alterations	O
in	O
patients	O
and	O
families	O
may	O
allow	O
for	O
better	O
clinical	O
management	O
of	O
NSHL	B-DISEASE
.	O

Streptococcal	O
organisms	O
were	O
found	O
in	O
3	O
cases	O
and	O
Capnocytophaga	O
and	O
Brevibacterium	O
casei	O
in	O
1	O
patient	O
.	O

We	O
recently	O
reported	O
that	O
7	O
.	O
8	O
%	O
of	O
patients	O
with	O
autosomal	O
recessive	O
nonsyndromic	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
China	O
were	O
homozygous	O
for	O
the	O
most	O
common	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
mutation	O
in	O
GJB2	B-GENE
gene	O
and	O
8	O
.	O
5	O
%	O
of	O
them	O
carried	O
one	O
mutant	O
allele	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
mutation	O
[	O
28	O
]	O
.	O

Proteinuria	B-DISEASE
is	O
an	O
expected	O
complication	O
in	O
transplant	O
patients	O
treated	O
with	O
mammalian	B-GENE
target	I-GENE
of	I-GENE
rapamycin	B-Chemical
inhibitors	O
(	O
mTOR	O
-	O
i	O
)	O
.	O

Sequencing	O
was	O
performed	O
using	O
the	O
ABI	O
Prism	O
BigDye	O
Terminator	O
Cycle	O
Sequencing	O
Ready	O
Reaction	O
Kit	O
(	O
Perkin	O
-	O
Elmer	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
and	O
an	O
ABI	O
377	O
DNA	O
sequencer	O
.	O

Pfeiffer	B-DISEASE
syndrome	I-DISEASE
is	O
divided	O
into	O
three	O
subtypes	O
9	O
)	O
.	O

Pedigrees	O
of	O
the	O
seven	O
families	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Ascites	B-DISEASE
and	O
hydrothorax	B-DISEASE
were	O
observed	O
simultaneously	O
.	O

Other	O
neurologic	B-DISEASE
deficits	I-DISEASE
included	O
slow	O
motor	O
movements	O
in	O
three	O
(	O
17	O
%	O
)	O
and	O
increased	O
tone	O
and	O
brisk	O
deep	O
tendon	O
reflexes	O
in	O
one	O
.	O

(	B-Chemical
R	I-Chemical
)	I-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
methylhistamine	I-Chemical
(	O
RAMH	B-Chemical
)	O
(	O
5	O
microg	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
thioperamide	B-Chemical
(	O
THP	B-Chemical
)	O
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
,	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	B-DISEASE
.	O

Probands	O
with	O
mutations	O
in	O
commonly	O
screened	O
deafness	B-DISEASE
genes	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
and	O
MT	B-GENE
-	I-GENE
RNR1	I-GENE
were	O
pre	O
-	O
excluded	O
by	O
Sanger	O
sequencing	O
.	O

Given	O
the	O
seriousness	O
and	O
increasing	O
prevalence	O
of	O
adenovirus	B-DISEASE
disease	O
in	O
certain	O
hosts	O
,	O
especially	O
children	O
,	O
a	O
large	O
,	O
multicenter	O
clinical	O
trial	O
of	O
potentially	O
useful	O
anti	O
-	O
adenoviral	O
therapies	O
,	O
such	O
as	O
intravenous	O
ribavirin	B-Chemical
,	O
is	O
clearly	O
required	O
to	O
demonstrate	O
the	O
most	O
effective	O
and	O
least	O
toxic	O
therapy	O
.	O

The	O
mutations	O
included	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
176del16bp	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
299delAT	I-VARIANT
in	O
the	O
GJB2	B-GENE
gene	O
,	O
c	B-VARIANT
.	I-VARIANT
538C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
in	O
the	O
GJB3	B-GENE
gene	O
,	O
c	B-VARIANT
.	I-VARIANT
IVS7	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
2168A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
in	O
the	O
SLC26A4	B-GENE
gene	O
,	O
and	O
m	B-VARIANT
.	I-VARIANT
1555A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
m	B-VARIANT
.	I-VARIANT
1494C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
in	O
the	O
MT	B-GENE
-	I-GENE
RNR1	I-GENE
gene	O
.	O

1	O
.	O
79	O
)	O
,	O
this	O
was	O
used	O
to	O
remove	O
PCR	O
duplicates	O
in	O
the	O
sorted	O
BAM	O
files	O
;	O
(	O
d	O
)	O
GenomeAnalysisTK	O
-	O
1	O
.	O
6	O
(	O
GATK	O
-	O
1	O
.	O
6	O
)	O
.	O

CASE	O
DESCRIPTION	O
:	O
A	O
30	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
presented	O
with	O
dental	B-DISEASE
pain	I-DISEASE
,	O
bad	B-DISEASE
breath	O
,	O
and	O
self	O
-	O
reported	O
poor	O
esthetics	O
.	O

We	O
therefore	O
decided	O
to	O
extend	O
the	O
screening	O
of	O
some	O
of	O
these	O
patients	O
to	O
include	O
exons	O
1	O
-	O
7	O
of	O
COMP	B-GENE
,	O
exons	O
3	O
-	O
6	O
of	O
MATN3	B-GENE
,	O
exons	O
1	O
-	O
3	O
and	O
5	O
-	O
6	O
of	O
MATN1	B-GENE
,	O
and	O
exons	O
2	O
and	O
6	O
+	O
7	O
of	O
MATN4	B-GENE
(	O
Supp	O
.	O

Multiplex	O
Ligation	O
-	O
dependent	O
Probe	O
Amplification	O
(	O
MLPA	O
)	O
analysis	O
.	O

rDNA	O
repeats	O
are	O
not	O
present	O
in	O
the	O
reference	O
genome	O
assemblies	O
;	O
therefore	O
,	O
unique	O
reads	O
were	O
aligned	O
directly	O
to	O
the	O
human	O
rDNA	O
reference	O
sequence	O
(	O
NCBI	O
accession	O
number	O
:	O
HSU13369	O
)	O
56	O
.	O

These	O
children	O
were	O
older	O
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
recent	O
bowel	O
surgery	O
than	O
are	O
other	O
children	O
with	O
this	O
condition	O
.	O

Myocardial	O
catecholamines	B-Chemical
were	O
also	O
determined	O
in	O
14	O
subjects	O
;	O
a	O
weak	O
correlation	O
(	O
r	O
=	O
0	O
.	O
57	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
tissue	O
concentrations	O
of	O
VIP	O
and	O
norepinephrine	B-Chemical
was	O
noted	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Although	O
TBX1	B-GENE
mutations	O
have	O
been	O
identified	O
in	O
patients	O
with	O
22q11	O
.	O
2	O
deletion	O
syndrome	O
(	O
22q11	O
.	O
2DS	O
)	O
-	O
like	O
phenotypes	O
including	O
characteristic	O
craniofacial	O
features	O
,	O
cardiovascular	B-DISEASE
anomalies	I-DISEASE
,	O
hypoparathyroidism	B-DISEASE
,	O
and	O
thymic	B-DISEASE
hypoplasia	I-DISEASE
,	O
the	O
frequency	O
of	O
TBX1	B-GENE
mutations	O
remains	O
rare	O
in	O
deletion	O
-	O
negative	O
patients	O
.	O

The	O
clinical	O
diagnosis	O
of	O
ADOA	B-DISEASE
was	O
based	O
on	O
a	O
positive	O
family	O
history	O
,	O
a	O
history	O
of	O
gradually	O
bilateral	B-DISEASE
visual	I-DISEASE
impairment	I-DISEASE
beginning	O
at	O
an	O
early	O
age	O
,	O
dyschromatopsia	B-DISEASE
,	O
characteristic	O
abnormalities	O
in	O
the	O
visual	O
fields	O
(	O
cecocentral	B-DISEASE
scotomata	I-DISEASE
)	O
,	O
and	O
typical	O
abnormalities	O
of	O
the	O
optic	O
disc	O
(	O
temporal	B-DISEASE
pallor	I-DISEASE
of	I-DISEASE
the	I-DISEASE
optic	I-DISEASE
disc	I-DISEASE
)	O
.	O

Green	O
line	O
=	O
window	O
14	O
;	O
Blue	O
line	O
=	O
window	O
21	O
;	O
Red	O
line	O
=	O
window	O
28	O
.	O

A	O
naturalistic	O
auditory	O
location	O
discrimination	O
method	O
was	O
used	O
to	O
evaluate	O
this	O
question	O
using	O
an	O
animal	O
model	O
of	O
status	B-DISEASE
epilepticus	O
.	O

Figure	O
1	O
Flow	O
diagram	O
of	O
our	O
hierarchical	O
molecular	O
genetic	O
test	O
in	O
cochlear	O
implantees	O
.	O

Right	O
,	O
renal	O
biopsy	O
under	O
light	O
microscopy	O
(	O
silver	O
stain	O
)	O
of	O
proband	O
from	O
Family	O
3	O
revealed	O
only	O
very	O
mild	O
mesangial	O
proliferative	O
changes	O
.	O

Stattin	B-Chemical
E	O
.	O
L	O
.	O

Disulfide	O
bond	O
prediction	O
and	O
available	O
crystal	O
structure	O
of	O
the	O
extracellular	O
region	O
of	O
Hepsin	O
(	O
TMPRSS1	O
,	O
pdb	O
1z8g	O
)	O
suggest	O
the	O
presence	O
of	O
a	O
disulfide	O
bridge	O
involving	O
Cys386	O
and	O
Cys370	O
in	O
TMPRSS3	B-GENE
,	O
similar	O
to	O
the	O
disulphide	O
bond	O
of	O
corresponding	O
Cys338	O
and	O
Cys322	O
in	O
Hepsin	O
[	O
17	O
]	O
.	O

TCGA	O
ovarian	B-DISEASE
cancer	I-DISEASE
cases	O
were	O
classified	O
with	O
respect	O
to	O
ancestry	O
using	O
their	O
SNP	O
array	O
data	O
4	O
and	O
the	O
multi	O
-	O
dimensional	O
scaling	O
(	O
MDS	O
)	O
analysis	O
program	O
in	O
PLINK	O
.	O

A	O
near	O
drowning	O
incident	O
in	O
early	O
childhood	O
in	O
WU	O
.	O
WOLF	O
-	O
05	O
had	O
residual	O
neurologic	O
effects	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
ELMOD3	B-GENE
antibody	O
was	O
validated	O
in	O
immunoblot	O
and	O
immunofluorescence	O
analyses	O
,	O
in	O
transfected	O
cells	O
and	O
mouse	O
tissues	O
(	O
Figures	O
S4	O
and	O
S7	O
)	O
.	O

All	O
patients	O
with	O
the	O
5	O
mutations	O
presented	O
dystopia	B-DISEASE
canthorum	I-DISEASE
and	O
different	B-DISEASE
colors	I-DISEASE
of	I-DISEASE
the	I-DISEASE
irises	I-DISEASE
and	O
fundi	O
but	O
none	O
of	O
those	O
showed	O
visible	O
pigmentary	B-DISEASE
changes	I-DISEASE
on	I-DISEASE
their	I-DISEASE
hair	I-DISEASE
and	I-DISEASE
skin	I-DISEASE
,	O
indicating	O
an	O
ethnic	O
specific	O
phenotypes	O
.	O

Among	O
the	O
mutations	O
detected	O
,	O
we	O
identified	O
the	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
in	O
the	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
gene	O
and	O
novel	O
mutations	O
(	O
c	B-VARIANT
.	I-VARIANT
541G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
A181	I-VARIANT
T	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
449C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
A150	I-VARIANT
V	I-VARIANT
)	O
in	O
the	O
genes	O
encoding	O
MYH14	B-GENE
and	O
WFS1	B-GENE
,	O
respectively	O
.	O

After	O
quetiapine	B-Chemical
was	O
discontinued	O
,	O
her	O
white	O
blood	O
cell	O
count	O
returned	O
to	O
normal	O
.	O

Plasma	O
concentration	O
of	O
AVP	B-Chemical
and	O
transcripts	O
of	O
AVP	B-Chemical
gene	O
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	O
increased	O
in	O
the	O
Li	B-Chemical
-	O
treated	O
rats	O
compared	O
with	O
controls	O
.	O

Bottillo	O
.	O

Mouse	O
studies	O
were	O
carried	O
out	O
in	O
accordance	O
with	O
UK	O
Home	O
Office	O
regulations	O
and	O
the	O
UK	O
Animals	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
of	O
1986	O
(	O
ASPA	O
)	O
under	O
a	O
UK	O
Home	O
Office	O
licence	O
,	O
and	O
the	O
study	O
was	O
approved	O
by	O
the	O
Wellcome	O
Trust	O
Sanger	O
Institute	O
'	O
s	O
Ethical	O
Review	O
Committee	O
.	O

Before	O
admission	O
,	O
he	O
had	O
been	O
taking	O
nicergoline	B-Chemical
and	O
bendazac	B-Chemical
lysine	I-Chemical
due	O
to	O
retinal	B-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
at	O
ophthalmologic	O
department	O
.	O

Mutations	O
of	O
the	O
OPA1	B-GENE
gene	O
result	O
in	O
a	O
loss	O
of	O
function	O
in	O
most	O
ADOA	B-DISEASE
patients	O
indicating	O
that	O
haploinsufficiency	B-DISEASE
is	O
involved	O
in	O
the	O
pathomechanism	O
of	O
the	O
disease	O
[	O
21	O
]	O
.	O

This	O
work	O
was	O
supported	O
by	O
Chinese	O
National	O
Nature	O
Science	O
Foundation	O
Research	O
Grant	O
(	O
30572015	O
,	O
30728030	O
,	O
30872862	O
)	O
,	O
Beijing	O
Nature	O
Science	O
Foundation	O
Research	O
Grant	O
(	O
7062062	O
)	O
to	O
Dr	O
.	O

Survival	O
for	O
patients	O
with	O
advanced	O
head	O
and	O
neck	O
carcinoma	I-DISEASE
and	O
esophageal	O
carcinoma	I-DISEASE
is	O
poor	O
with	O
radiotherapy	O
and	O
/	O
or	O
surgery	O
.	O

Nevertheless	O
,	O
the	O
existence	O
of	O
a	O
putative	O
defective	O
splicing	O
isoform	O
,	O
as	O
predicted	O
by	O
in	O
silico	O
analysis	O
cannot	O
be	O
ruled	O
out	O
,	O
as	O
it	O
would	O
be	O
degraded	O
by	O
nonsense	O
-	O
mediated	O
decay	O
and	O
thus	O
,	O
would	O
not	O
be	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

In	O
vitro	O
motility	O
of	O
Rhodamine	B-Chemical
-	O
labelled	O
F	O
-	O
actin	O
was	O
measured	O
using	O
a	O
cooled	O
-	O
CCD	O
camera	O
(	O
Sensi	B-Chemical
Cam	O
QE	I-Chemical
,	O
Cooke	O
Co	O
.	O
)	O
equipped	O
with	O
an	O
Olympus	B-Chemical
IX	I-Chemical
-	I-Chemical
51	O
-	O
based	O
fluorescence	O
microscope	O
[	O
20	O
]	O
.	O

Homozygosity	O
for	O
the	O
CDH23	B-GENE
mutation	O
IVS45	B-VARIANT
-	I-VARIANT
9G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
found	O
in	O
patients	O
303	O
and	O
1235	O
,	O
while	O
patient	O
860	O
was	O
compound	O
heterozygous	O
for	O
IVS45	B-VARIANT
-	I-VARIANT
9G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
the	O
novel	O
nonsense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
R736X	I-VARIANT
.	O

This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
finding	O
in	O
Asian	O
people	O
.	O

The	O
serotonin	B-Chemical
-	I-GENE
1A	I-GENE
receptor	I-GENE
agonist	O
,	O
8	B-Chemical
-	I-Chemical
OH	I-Chemical
-	I-Chemical
DPAT	I-Chemical
,	O
induced	O
a	O
significant	O
disruption	O
of	O
PPI	B-DISEASE
in	O
all	O
groups	O
.	O

Yang	O
et	O
al	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
144	O
variants	O
were	O
detected	O
:	O
25	O
were	O
truncating	O
mutations	O
and	O
five	O
were	O
splice	O
-	O
site	O
mutations	O
(	O
located	O
at	O
the	O
conserved	O
AG	O
/	O
GT	O
dinucleotides	O
of	O
the	O
splice	O
site	O
)	O
.	O

A	O
relative	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
ergic	O
deficiency	O
might	O
occur	O
because	O
diazepam	B-Chemical
,	O
a	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
mimetic	O
agent	O
,	O
was	O
strikingly	O
effective	O
.	O

All	O
probands	O
and	O
controls	O
were	O
also	O
screened	O
by	O
PCR	O
and	O
restriction	O
enzyme	O
digest	O
for	O
previously	O
published	O
Palestinian	O
and	O
Lebanese	O
deafness	B-DISEASE
alleles	O
of	O
otoferlin	B-GENE
,	O
[	O
9	O
]	O
TECTA	B-GENE
,	O
[	O
10	O
]	O
otoancorin	B-GENE
[	O
7	O
]	O
and	O
whirlin	B-GENE
[	O
11	O
]	O
.	O

LRAT	O
was	O
discarded	O
after	O
sequencing	O
of	O
all	O
exons	O
,	O
whereas	O
direct	O
screening	O
of	O
MERTK	B-GENE
exon	O
16	O
identified	O
the	O
expected	O
mutation	O
c	B-VARIANT
.	I-VARIANT
2189	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
in	O
homozygosis	O
,	O
again	O
supporting	O
a	O
founder	O
effect	O
.	O

Alleles	O
that	O
occur	O
with	O
a	O
frequency	O
above	O
1	O
%	O
in	O
the	O
1000	O
genomes	O
project	O
(	O
Pollard	O
et	O
al	O
.	O

Moreover	O
,	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
this	O
beta	B-Chemical
-	I-Chemical
carboline	I-Chemical
reduced	O
markedly	O
the	O
increase	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
binding	O
and	O
the	O
convulsions	O
induced	O
by	O
isoniazid	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

To	O
access	O
the	O
data	O
,	O
click	O
or	O
select	O
the	O
words	O
"	O
Appendix	O
1	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

HEK293T	O
cells	O
and	O
COS7	O
cells	O
(	O
ATCC	O
,	O
Manassas	O
,	O
VA	O
,	O
USA	O
)	O
were	O
grown	O
in	O
Dulbecco	B-Chemical
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
Medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
FBS	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

This	O
study	O
was	O
performed	O
according	O
to	O
the	O
protocol	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

Two	O
of	O
these	O
regions	O
were	O
shared	O
between	O
the	O
two	O
affected	O
sisters	O
,	O
the	O
largest	O
being	O
a	O
38	O
.	O
98	O
-	O
Mb	O
region	O
on	O
chromosome	O
11	O
between	O
the	O
markers	O
rs1395558	B-VARIANT
and	O
rs724759	B-VARIANT
(	O
Table	O
S2	O
)	O
.	O

In	O
addition	O
,	O
sequences	O
from	O
219	O
ethnicity	O
-	O
matched	O
negative	O
samples	O
were	O
examined	O
.	O

Experiments	O
in	O
mice	O
tested	O
previous	O
evidence	O
that	O
activation	O
of	O
cholinergic	O
systems	O
promotes	O
catalepsy	O
and	O
that	O
cholinergic	O
mechanisms	O
need	O
to	O
be	O
intact	O
for	O
full	O
expression	O
of	O
neuroleptic	B-Chemical
-	O
induced	O
catalepsy	O
.	O

B	O
:	O
c	B-VARIANT
.	I-VARIANT
8483delC	I-VARIANT
created	O
an	O
MslI	O
restriction	O
site	O
that	O
cosegregated	O
with	O
the	O
affected	O
individuals	O
and	O
the	O
carriers	O
(	O
150	O
bp	O
,	O
340	O
bp	O
,	O
and	O
490	O
bp	O
)	O
,	O
but	O
not	O
with	O
unaffected	O
individuals	O
and	O
normal	O
control	O
(	O
490	O
bp	O
)	O
.	O

It	O
was	O
located	O
in	O
exon	O
6	O
and	O
it	O
caused	O
a	O
stop	O
codon	O
19	O
codons	O
later	O
.	O

Finding	O
the	O
other	O
mutation	O
underlying	O
the	O
disease	O
in	O
such	O
patients	O
will	O
give	O
a	O
new	O
insight	O
into	O
the	O
molecular	O
pathogenesis	O
of	O
USH	B-DISEASE
.	O

Patient	O
2	O
,	O
the	O
child	O
had	O
the	O
following	O
measurements	O
at	O
birth	O
:	O
weight	O
1780	O
gr	O
(	O
10	O
-	O
25th	O
centile	O
)	O
,	O
length	O
32	O
cm	O
(	O
-	O
4	O
DS	O
)	O
and	O
OFD	O
32	O
cm	O
(	O
75th	O
centile	O
)	O
.	O

1c	O
)	O
were	O
found	O
to	O
be	O
homozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
192G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Glu64Asp	I-VARIANT
)	O
in	O
CIB2	B-GENE
.	O

Molecular	O
analysis	O
of	O
the	O
FGFR1	B-GENE
and	O
FGFR2	B-GENE
genes	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
sequencing	O
identified	O
mutations	O
in	O
exxons	O
8	O
and	O
10	O
of	O
FGFR2	B-GENE
in	O
three	O
of	O
the	O
families	O
.	O

"	O
STGD	B-DISEASE
-	O
like	O
"	O
autosomal	O
dominant	O
diseases	O
can	O
be	O
caused	O
by	O
mutations	O
in	O
PROM1	B-GENE
4	O
and	O
ELOVL4	B-GENE
5	O
.	O

1996	O
)	O
but	O
also	O
for	O
postlingual	O
(	O
DFNB8	B-DISEASE
,	O
OMIM	O
601072	O
;	O
Veske	O
et	O
al	O
.	O

We	O
detected	O
mutations	O
in	O
29	O
.	O
5	O
%	O
overall	O
,	O
and	O
the	O
41	O
.	O
8	O
%	O
detection	O
rate	O
for	O
congenital	O
or	O
early	O
onset	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
was	O
especially	O
remarkable	O
.	O

This	O
study	O
showed	O
that	O
24	O
.	O
1	O
%	O
(	O
28	O
/	O
116	O
)	O
of	O
patients	O
diagnosed	O
EVA	B-DISEASE
with	O
MD	B-DISEASE
had	O
biallelic	O
mutations	O
in	O
SLC26A4	B-GENE
,	O
but	O
only	O
11	O
.	O
1	O
%	O
(	O
38	O
/	O
341	O
)	O
of	O
patients	O
with	O
isolated	O
EVA	B-DISEASE
had	O
biallelic	O
mutations	O
in	O
SLC26A4	B-GENE
.	O

From	O
the	O
remaining	O
177	O
probands	O
,	O
100	O
were	O
selected	O
for	O
the	O
targeted	O
NGS	O
analysis	O
.	O

The	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
was	O
used	O
to	O
measure	O
pain	O
intensity	O
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
time	O
the	O
pain	O
period	O
.	O

The	O
proband	O
is	O
an	O
adult	O
Italian	O
male	O
with	O
a	O
clinical	O
history	O
characterized	O
by	O
visual	B-DISEASE
impairment	I-DISEASE
since	O
childhood	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
clinical	O
significance	O
of	O
genetic	O
variants	O
in	O
butyrylcholinesterase	B-GENE
gene	I-GENE
(	O
BCHE	B-GENE
)	O
in	O
patients	O
with	O
a	O
suspected	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
after	O
ECT	O
.	O

2012	O
;	O
Besnard	B-Chemical
et	O
al	O
.	O

That	O
demonstrates	O
once	O
again	O
the	O
mutation	O
-	O
specific	O
nature	O
of	O
PRS	B-GENE
-	I-GENE
I	I-GENE
phenotypes	O
[	O
7	O
,	O
11	O
]	O
.	O

Differences	O
between	O
ancestry	O
groups	O
are	O
also	O
reflected	O
in	O
the	O
allele	O
frequencies	O
of	O
cancer	O
-	O
gene	O
variants	O
.	O

After	O
the	O
RD	B-DISEASE
-	O
chip	O
analysis	O
discarded	O
all	O
known	O
RD	B-DISEASE
genes	O
,	O
Whole	O
Exome	O
Sequencing	O
(	O
WES	O
)	O
was	O
undertaken	O
in	O
two	O
pedigrees	O
.	O

3B	O
and	O
3C	O
)	O
.	O

BAJ	O
:	O
analysis	O
,	O
interpretation	O
of	O
data	O
.	O

A	O
short	O
clinical	O
history	O
and	O
mutational	O
findings	O
of	O
each	O
family	O
are	O
discussed	O
in	O
more	O
detail	O
below	O
and	O
summarized	O
in	O
Table	O
1	O
.	O

In	O
contrast	O
to	O
the	O
western	O
population	O
where	O
large	O
cohort	O
studies	O
have	O
been	O
performed	O
on	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
,	O
limited	O
information	O
is	O
available	O
concerning	O
genetic	O
mutations	O
of	O
this	O
syndrome	O
in	O
the	O
East	O
Asian	O
population	O
,	O
and	O
a	O
total	O
of	O
16	O
mutations	O
in	O
the	O
EYA1	B-GENE
gene	O
have	O
been	O
reported	O
including	O
7	O
nonsense	O
,	O
3	O
frameshift	O
,	O
3	O
splice	O
-	O
site	O
,	O
2	O
missense	O
mutations	O
,	O
and	O
1	O
partial	O
deletion	O
[	O
17	O
]	O
.	O

The	O
rat	O
received	O
either	O
alpha	B-Chemical
-	I-Chemical
TC	I-Chemical
(	O
20	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
for	O
3	O
days	O
and	O
30	O
min	O
prior	O
to	O
MA	B-Chemical
administration	O
or	O
DFO	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
)	O
subcutaneously	O
30	O
min	O
before	O
MA	B-Chemical
administration	O
.	O

JQL	O
performed	O
sequence	O
alignment	O
,	O
analyzed	O
and	O
summarized	O
the	O
data	O
,	O
and	O
wrote	O
part	O
of	O
the	O
paper	O
.	O

On	O
fundoscopy	O
,	O
half	O
of	O
the	O
patients	O
showed	O
typical	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
while	O
the	O
other	O
half	O
presented	O
an	O
atypical	O
clinical	O
picture	O
with	O
rare	O
or	O
absent	O
pigment	O
clumping	O
.	O

The	O
underlying	O
locus	O
,	O
juvenile	O
audiogenic	O
monogenic	O
seizure	B-DISEASE
1	O
(	O
jams1	B-DISEASE
)	O
,	O
localizes	O
to	O
a	O
1	O
.	O
6cM	O
region	O
that	O
overlaps	O
with	O
the	O
ahl5	B-DISEASE
interval	O
12	O
.	O

The	O
cost	O
of	O
the	O
pre	O
-	O
exome	O
genetic	O
testing	O
was	O
calculated	O
for	O
six	O
patients	O
who	O
were	O
felt	O
to	O
have	O
a	O
typical	O
evaluation	O
from	O
three	O
different	O
clinicians	O
in	O
two	O
provinces	O
.	O

1a	O
)	O
.	O

Overall	O
,	O
12	O
of	O
30	O
(	O
40	O
%	O
)	O
probands	O
carried	O
a	O
mutation	O
in	O
either	O
FGFR1	B-GENE
(	O
9	O
probands	O
)	O
or	O
KAL1	B-GENE
(	O
3	O
probands	O
)	O
(	O
Table	O
1	O
)	O
.	O

These	O
mutations	O
were	O
not	O
found	O
in	O
150	O
normal	O
DNA	O
samples	O
.	O

Genes	O
are	O
arranged	O
by	O
chromosome	O
.	O

Findings	O
of	O
this	O
study	O
are	O
based	O
on	O
the	O
detailed	O
clinical	O
investigation	O
of	O
a	O
mutation	O
positive	O
cohort	O
.	O

Twenty	O
-	O
two	O
of	O
30	O
individuals	O
(	O
16	O
of	O
23	O
index	O
probands	O
)	O
and	O
8	O
of	O
9	O
controls	O
were	O
sequenced	O
with	O
the	O
80	O
-	O
gene	O
panel	O
,	O
and	O
8	O
individuals	O
(	O
7	O
probands	O
and	O
1	O
control	O
)	O
were	O
sequenced	O
with	O
the	O
129	O
-	O
gene	O
panel	O
.	O

However	O
,	O
we	O
did	O
not	O
find	O
novel	O
or	O
known	O
variants	O
in	O
genes	O
known	O
to	O
cause	O
FSGS	B-DISEASE
in	O
this	O
cohort	O
.	O

Coding	O
region	O
and	O
splice	O
junction	O
variants	O
(	O
6bp	O
)	O
common	O
to	O
probands	O
II	O
.	O
1	O
and	O
II	O
.	O
3	O
were	O
filtered	O
using	O
the	O
Annovar	O
"	O
filtered	O
annotation	O
"	O
functions	O
tool	O
[	O
59	O
]	O
.	O

Sodium	O
nitroprusside	B-Chemical
is	O
a	O
non	O
-	O
selective	O
arteriolar	O
and	O
venous	O
vasodilator	O
that	O
can	O
produce	O
redistribution	O
of	O
blood	O
flow	O
away	O
from	O
the	O
kidney	O
during	O
induced	O
hypotension	B-DISEASE
.	O

Primers	O
for	O
the	O
housekeeping	O
GAPDH	O
gene	O
were	O
used	O
as	O
internal	O
control	O
.	O

C	O
:	O
Right	O
;	O
Schematic	O
representation	O
of	O
the	O
aberrant	O
COL4A5	B-GENE
cDNA	O
resulting	O
from	O
the	O
splice	O
site	O
mutation	O
.	O

However	O
,	O
in	O
EDNRB	B-GENE
isoform	O
3	O
(	O
NP_001188326	O
.	O
1	O
;	O
532	O
amino	O
acids	O
)	O
the	O
replacement	O
is	O
at	O
Met91	O
(	O
M91V	B-VARIANT
)	O
and	O
is	O
predicted	O
benign	O
by	O
PolyPhen	O
[	O
30	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
persistent	O
hiccups	B-DISEASE
associated	O
by	O
azithromycin	B-Chemical
therapy	O
.	O

In	O
8	O
of	O
the	O
23	O
probands	O
,	O
targeted	O
NGS	O
identified	O
a	O
pathogenic	O
mutation	O
in	O
a	O
gene	O
associated	O
with	O
dominant	B-DISEASE
HL	I-DISEASE
(	O
ACTG1	B-GENE
,	O
CCDC50	B-GENE
,	O
EYA4	B-GENE
,	O
MYH14	B-GENE
,	O
MYO6	B-GENE
,	O
TCF21	B-GENE
,	O
and	O
twice	O
in	O
MYO1A	B-GENE
)	O
.	O

Both	O
parents	O
were	O
healthy	O
and	O
had	O
no	O
familial	O
history	O
of	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
or	O
psychiatric	B-DISEASE
disorders	I-DISEASE
.	O

In	O
3	O
patients	O
a	O
pre	O
-	O
existing	O
neuralgia	B-DISEASE
increased	O
to	O
excruciating	O
intensity	O
and	O
in	O
2	O
of	O
these	O
cases	O
myoclonus	B-DISEASE
occurred	O
simultaneously	O
.	O

We	O
thank	O
Sharat	O
Chandra	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
and	O
helpful	O
discussions	O
.	O
Primary	B-DISEASE
distal	I-DISEASE
renal	I-DISEASE
tubular	I-DISEASE
acidosis	I-DISEASE
(	O
dRTA	B-DISEASE
)	O
caused	O
by	O
mutations	O
in	O
the	O
genes	O
that	O
codify	O
for	O
the	O
H	O
+	O
-	O
ATPase	O
pump	O
subunits	O
is	O
a	O
heterogeneous	O
disease	O
with	O
a	O
poor	O
phenotype	O
-	O
genotype	O
correlation	O
.	O

Hearing	O
levels	O
of	O
the	O
right	O
ear	O
and	O
left	O
ear	O
are	O
marked	O
with	O
red	O
and	O
blue	O
lines	O
,	O
respectively	O
.	O

Shunichi	O
Tomiyama	O
(	O
Nippon	O
Medical	O
School	O
Tama	O
Nagayama	O
Hospital	O
)	O
,	O
Drs	O
.	O

Even	O
more	O
important	O
was	O
the	O
observation	O
that	O
some	O
mutations	O
differentially	O
activate	O
the	O
UPR	O
pathway	O
,	O
thereby	O
contributing	O
to	O
an	O
intracellular	O
phenotype	O
which	O
is	O
expected	O
to	O
complicate	O
the	O
phenotype	O
because	O
of	O
the	O
defective	O
GBM	O
.	O

There	O
are	O
currently	O
64	O
mapped	O
loci	O
for	O
this	O
condition	O
,	O
but	O
only	O
25	O
causative	O
genes	O
have	O
been	O
identified	O
.	O

Three	O
hundred	O
and	O
seven	O
patients	O
had	O
two	O
confirmed	O
pathogenic	O
mutations	O
,	O
including	O
178	O
homozygotes	O
and	O
129	O
compound	O
heterozygotes	O
.	O

*	O
Three	O
cases	O
carried	O
double	O
mutations	O
(	O
cases	O
1	O
to	O
3	O
in	O
Table	O
5	O
)	O
.	O

The	O
authors	O
herein	O
describe	O
a	O
34	O
-	O
year	O
-	O
old	O
Korean	O
woman	O
with	O
the	O
typical	O
clinical	O
manifestation	O
of	O
USH2	B-DISEASE
;	I-DISEASE
she	O
had	O
bilateral	O
hearing	B-DISEASE
disturbance	I-DISEASE
and	O
progressive	O
visual	B-DISEASE
deterioration	I-DISEASE
,	O
without	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

Distribution	O
of	O
Events	O
Per	O
Family	O
.	O

Flestolol	B-Chemical
produced	O
a	O
dose	O
-	O
dependent	O
attenuation	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
tachycardia	B-DISEASE
.	O

Acute	B-DISEASE
encephalopathy	I-DISEASE
and	O
cerebral	B-DISEASE
vasospasm	I-DISEASE
after	O
multiagent	O
chemotherapy	O
including	O
PEG	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
and	O
intrathecal	O
cytarabine	B-Chemical
for	O
the	O
treatment	O
of	O
acute	B-DISEASE
lymphoblastic	B-DISEASE
leukemia	I-DISEASE
.	O

Black	O
points	O
on	O
the	O
left	O
hand	O
side	O
of	O
the	O
map	O
represent	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
homozygous	O
probands	O
in	O
the	O
Czech	O
Republic	O
,	O
Slovakia	O
and	O
Hungary	O
.	O

These	O
activities	O
are	O
so	O
low	O
as	O
to	O
be	O
at	O
or	O
near	O
the	O
lower	O
limits	O
of	O
our	O
assay	O
.	O

The	O
penetrance	O
parameters	O
f	O
0	O
,	O
f	O
1	O
,	O
and	O
f	O
2	O
were	O
also	O
defined	O
using	O
conventional	O
notation	O
as	O
below	O
.	O

CONCLUSIONS	O
:	O
Although	O
levobupivacaine	B-Chemical
may	O
have	O
a	O
safer	O
cardiac	O
toxicity	O
profile	O
than	O
racemic	O
bupivacaine	B-Chemical
,	O
if	O
adequate	O
amounts	O
of	O
levobupivacaine	B-Chemical
reach	O
the	O
circulation	O
,	O
it	O
will	O
result	O
in	O
convulsions	O
.	O

CONCLUSIONS	O
:	O
Diagnosis	O
of	O
drug	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
hiccups	I-DISEASE
is	O
difficult	O
and	O
often	O
achieved	O
only	O
by	O
a	O
process	O
of	O
elimination	O
.	O

These	O
variants	O
were	O
selected	O
according	O
to	O
bioinformatic	O
analysis	O
.	O

The	O
proband	O
denied	O
any	O
surgical	O
intervention	O
.	O

His	O
mother	O
'	O
s	O
obstetric	O
history	O
was	O
gravida	O
1	O
,	O
para	O
0	O
,	O
and	O
was	O
unremarkable	O
.	O

Cells	O
were	O
collected	O
by	O
centrifugation	O
.	O

There	O
were	O
six	O
patients	O
in	O
whom	O
either	O
optic	B-DISEASE
atrophy	I-DISEASE
(	O
i	O
.	O
e	O
.	O

Indeed	O
,	O
genomewide	O
array	O
comparative	O
genomic	O
hybridization	O
(	O
CGH	O
)	O
has	O
identified	O
multiple	O
disease	O
-	O
associated	O
copy	O
-	O
number	O
changes	O
[	O
10	O
]	O
,	O
and	O
exome	O
sequencing	O
has	O
discovered	O
multiple	O
disease	O
-	O
causing	O
gene	O
mutations	O
[	O
11	O
]	O
.	O

There	O
were	O
24	O
missense	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
P76S	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
T94I	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
P123S	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
M147V	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
P297Q	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
K369E	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A372V	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
N392Y	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
G396E	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
T410M	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A434T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
G439R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S448L	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
T527P	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
I529S	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S532I	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
C565Y	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R581S	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S657N	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
V659L	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S666F	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
T721M	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
H723R	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
H723Y	I-VARIANT
)	O
.	O

Hereditary	B-DISEASE
Hearing	I-DISEASE
Loss	I-DISEASE
(	O
HHL	B-DISEASE
)	O
includes	O
a	O
broad	O
range	O
of	O
disorders	O
that	O
affect	O
infants	O
,	O
children	O
and	O
adults	O
[	O
1	O
]	O
.	O

In	O
the	O
control	O
group	O
of	O
502	O
normal	O
hearing	O
Hungarian	O
Romanies	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
was	O
found	O
in	O
5	O
heterozygous	O
individuals	O
.	O

The	O
most	O
likely	O
RET	O
haplotypes	O
of	O
the	O
pedigree	O
(	O
A	O
,	O
C	O
,	O
G	O
,	O
T	O
to	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
)	O
.	O

Combinational	O
strategy	O
of	O
linkage	O
analysis	O
and	O
exome	O
sequencing	O
identifies	O
a	O
novel	O
CEACAM16	B-GENE
mutation	O
as	O
causing	O
ADNSHL	B-DISEASE
.	O

(	O
XLS	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Firstly	O
,	O
none	O
of	O
our	O
subjects	O
had	O
deletions	O
or	O
protein	O
-	O
truncating	O
mutations	O
,	O
which	O
are	O
an	O
indication	O
of	O
haploinsufficiency	O
.	O

Pretreatment	O
of	O
rats	O
with	O
thiosemicarbazide	B-Chemical
for	O
30	O
minutes	O
abolished	O
the	O
anesthetic	O
action	O
as	O
well	O
as	O
the	O
respiratory	O
depressant	O
action	O
of	O
thiopental	B-Chemical
.	O

MYH1	B-GENE
(	O
NM_005963	O
)	O
,	O
MYH4	B-GENE
(	O
NM_017533	O
)	O
,	O
MYH2	B-GENE
(	O
NM_017534	O
)	O
,	O
MYH8	B-GENE
(	O
NM_002472	O
)	O
,	O
MYH3	B-GENE
(	O
NM_002470	O
)	O
,	O
MYH13	B-GENE
(	O
NM_003802	O
)	O
,	O
MYH7	B-GENE
(	O
MN_000257	O
)	O
,	O
MYH6	B-GENE
(	O
NM_002471	O
)	O
,	O
MYH9	B-GENE
(	O
AB191263	O
)	O
,	O
MYH10	B-GENE
(	O
NM_005964	O
)	O
,	O
MYH11	B-GENE
(	O
NM_002474	O
)	O
,	O
and	O
MYH14	B-GENE
(	O
AY165122	O
)	O
;	O
D	O
)	O
Ribbon	O
structure	O
of	O
the	O
smooth	O
muscle	O
myosin	O
motor	O
domain	O
(	O
1br2	O
)	O
.	O

Hearing	O
loss	O
(	O
HL	B-DISEASE
)	O
is	O
the	O
most	O
common	O
sensorineural	O
disorder	O
.	O

The	O
vestibular	O
reflection	O
of	O
the	O
two	O
patients	O
was	O
normal	O
.	O

Serum	O
levels	O
known	O
to	O
be	O
effective	O
against	O
neuroblastoma	O
in	O
vitro	O
were	O
achieved	O
at	O
this	O
dose	O
.	O

5	B-Chemical
-	I-Chemical
Fluorouracil	I-Chemical
cardiotoxicity	O
induced	O
by	O
alpha	B-Chemical
-	I-Chemical
fluoro	I-Chemical
-	I-Chemical
beta	I-Chemical
-	I-Chemical
alanine	I-Chemical
.	O

The	O
vestibular	O
function	O
may	O
also	O
be	O
impaired	O
,	O
which	O
causes	O
a	O
delay	O
in	O
motor	O
development	O
and	O
walking	O
in	O
those	O
affected	O
compared	O
to	O
normal	O
children	O
.	O

Figure	O
4	O
Cochlear	O
potentials	O
recorded	O
from	O
OPA1	B-GENE
-	O
M	O
patients	O
.	O

Four	O
(	O
57	O
%	O
,	O
average	O
age	O
15	O
.	O
6	O
years	O
)	O
of	O
the	O
males	O
has	O
severe	O
microsmia	B-DISEASE
or	O
total	O
anosmia	B-DISEASE
,	O
while	O
one	O
had	O
normal	O
olfaction	O
at	O
age	O
7	O
.	O
3	O
and	O
two	O
others	O
had	O
mild	O
to	O
moderate	O
defects	O
(	O
ages	O
14	O
.	O
3	O
and	O
11	O
.	O
9	O
)	O
.	O

This	O
is	O
consistent	O
with	O
our	O
functional	O
data	O
showing	O
that	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
lacking	O
the	O
sorting	O
motif	O
is	O
accumulated	O
on	O
the	O
cell	O
surface	O
.	O

Forty	O
-	O
five	O
minutes	O
later	O
,	O
the	O
animals	O
were	O
randomly	O
treated	O
with	O
PCC	B-Chemical
(	O
100	O
U	O
/	O
kg	O
)	O
or	O
saline	O
i	O
.	O
v	O
.	O
(	O
n	O
=	O
12	O
per	O
group	O
)	O
.	O

Denatured	O
samples	O
were	O
electrophoresed	O
on	O
a	O
16	O
%	O
nondenaturing	O
polyacrylamide	O
gel	O
,	O
with	O
an	O
acrylamide	B-Chemical
:	O
bisacrylamide	O
ratio	O
of	O
49	O
:	O
1	O
,	O
for	O
12	O
-	O
16	O
h	O
at	O
300	O
v	O
and	O
4	O
deg	O
C	O
,	O
before	O
gels	O
were	O
silver	O
-	O
stained	O
and	O
analyzed	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Hypoparathyroidism	B-DISEASE
in	O
HDR	B-DISEASE
syndrome	I-DISEASE
can	O
range	O
from	O
asymptomatic	O
to	O
myalgia	B-DISEASE
,	O
sensory	B-DISEASE
problems	I-DISEASE
,	O
and	O
a	O
pronounced	O
tetany	O
pattern	O
caused	O
by	O
hypocalcemia	B-DISEASE
.	O

Similarly	O
,	O
clinician	O
ratings	O
showed	O
reductions	O
in	O
the	O
anger	O
subscale	O
of	O
the	O
Children	O
'	O
s	O
Psychiatric	O
Rating	O
Scale	O
.	O

Alternative	O
strategies	O
include	O
direct	O
sequencing	O
of	O
USH	B-DISEASE
gene	O
coding	O
exons	O
[	O
27	O
-	O
30	O
]	O
.	O

Both	O
p	B-VARIANT
.	I-VARIANT
Ser87Ile	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Ala94Val	I-VARIANT
mutations	O
affect	O
amino	O
acid	O
residues	O
that	O
are	O
conserved	O
among	O
36	O
claudin	O
14	O
orthologs	O
(	O
Figure	O
3c	O
)	O
.	O

(	O
D	O
)	O
A	O
normal	O
subject	O
without	O
c	B-VARIANT
.	I-VARIANT
881	I-VARIANT
-	I-VARIANT
882delAC	I-VARIANT
allele	O
.	O

(	O
Patient	O
n	O
deg	O
2	O
suddenly	O
died	O
at	O
the	O
age	O
of	O
13	O
years	O
)	O
.	O

None	O
of	O
his	O
living	O
family	O
members	O
were	O
available	O
for	O
clinical	O
or	O
genetic	O
studies	O
.	O

(	O
B	O
and	O
C	O
)	O
IF	O
blood	O
smears	O
(	O
n	O
=	O
79	O
,	O
positive	O
73	O
)	O
.	O

The	O
pathogenic	O
potential	O
of	O
the	O
three	O
other	O
variants	O
(	O
p	B-VARIANT
.	I-VARIANT
D450E	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
V1778I	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
E1803A	I-VARIANT
)	O
is	O
less	O
clear	O
,	O
because	O
1	O
)	O
all	O
of	O
them	O
have	O
been	O
found	O
in	O
the	O
heterozygous	O
state	O
without	O
accompanying	O
mutation	O
in	O
the	O
other	O
allele	O
,	O
and	O
2	O
)	O
p	B-VARIANT
.	I-VARIANT
D450E	I-VARIANT
was	O
found	O
in	O
controls	O
.	O

We	O
generalized	O
this	O
method	O
to	O
identify	O
34	O
additional	O
candidates	O
14	O
,	O
three	O
of	O
which	O
have	O
been	O
shown	O
to	O
harbor	O
mutations	O
causing	O
inherited	O
forms	O
of	O
CI	B-DISEASE
deficiency	I-DISEASE
14	O
,	O
18	O
,	O
19	O
.	O

The	O
contralateral	O
control	O
eyes	O
,	O
which	O
did	O
not	O
receive	O
dexamethasone	B-Chemical
,	O
maintained	O
a	O
stable	O
intraocular	B-DISEASE
pressure	I-DISEASE
during	O
the	O
same	O
period	O
.	O

Among	O
them	O
,	O
a	O
novel	O
variant	O
resulting	O
in	O
p	B-VARIANT
.	I-VARIANT
M305T	I-VARIANT
,	O
in	O
ACTG1	B-GENE
on	O
chr17	O
was	O
validated	O
with	O
Sanger	O
sequencing	O
(	O
red	O
dot	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
exercise	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
tachycardia	I-DISEASE
results	O
largely	O
from	O
beta	O
1	O
-	O
receptor	O
activation	O
that	O
is	O
blocked	O
by	O
both	O
cardioselective	O
and	O
nonselective	O
drugs	O
,	O
whereas	O
isoproterenol	B-Chemical
activates	O
both	O
beta	O
1	O
-	O
and	O
beta	O
2	O
-	O
receptors	O
so	O
that	O
after	O
cardioselective	O
blockade	O
there	O
remains	O
a	O
beta	O
2	O
-	O
component	O
that	O
can	O
be	O
blocked	O
with	O
a	O
nonselective	O
drug	O
.	O

We	O
performed	O
homozygosity	O
mapping	O
using	O
whole	O
-	O
genome	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
arrays	O
in	O
six	O
patients	O
who	O
belong	O
to	O
two	O
YJ	O
families	O
followed	O
by	O
whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
analysis	O
.	O

Groups	O
were	O
compared	O
with	O
a	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

This	O
group	O
also	O
includes	O
patient	O
ZS01	O
with	O
a	O
homozygous	O
deletion	O
of	O
115	O
amino	O
acids	O
.	O

Autosomal	B-DISEASE
dominant	I-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
(	O
ADOA	B-DISEASE
;	O
OMIM	O
165500	O
)	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
OPA1	B-GENE
gene	O
[	O
1	O
,	O
2	O
]	O
.	O

He	O
harbored	O
an	O
in	O
-	O
frame	O
deletion	O
,	O
1620delGTG	B-VARIANT
,	O
causing	O
the	O
loss	O
of	O
one	O
Valine	O
residue	O
(	O
V540del	B-VARIANT
)	O
and	O
a	O
missense	O
mutation	O
G674R	B-VARIANT
resulting	O
in	O
the	O
substitution	O
of	O
Glycine	B-Chemical
with	O
Arginine	B-Chemical
at	O
codon	O
674	O
.	O

Click	O
here	O
for	O
file	O
Results	O
of	O
mutation	O
screening	O
in	O
patient	O
1881	O
in	O
the	O
genes	O
PCDH15	B-GENE
(	O
USH1F	B-GENE
)	O
,	O
SANS	B-GENE
(	O
USH1G	B-GENE
)	O
and	O
USH3A	B-GENE
(	O
no	O
mutations	O
found	O
)	O
.	O

These	O
patients	O
were	O
subjected	O
to	O
mutation	O
screening	O
of	O
the	O
exons	O
that	O
had	O
not	O
been	O
analyzed	O
.	O

SHL	B-DISEASE
comprises	O
the	O
remaining	O
30	O
%	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
cases	O
,	O
and	O
it	O
appears	O
accompanied	O
by	O
other	O
medical	O
or	O
physical	O
findings	O
.	O

Therefore	O
,	O
CDH23	B-GENE
,	O
as	O
well	O
as	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
,	O
should	O
be	O
included	O
in	O
screening	O
.	O

(	O
DOCX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Novel	O
intronic	O
variants	O
UV2	O
:	O
probably	O
non	O
-	O
pathogenic	O
mutations	O
;	O
-	O
:	O
neutral	O
variants	O
.	O

8c	O
,	O
d	O
)	O
.	O

These	O
results	O
do	O
not	O
support	O
a	O
possible	O
digenic	O
inheritance	O
between	O
CDH23	B-GENE
and	O
PCDH15	B-GENE
in	O
this	O
family	O
.	O

We	O
validated	O
34	O
as	O
being	O
truly	O
de	O
novo	O
(	O
Table	O
1	O
and	O
Supplementary	O
Material	O
,	O
Table	O
S2	O
)	O
.	O

Most	O
of	O
the	O
variants	O
are	O
very	O
rare	O
-	O
65	O
%	O
are	O
found	O
in	O
only	O
a	O
single	O
individual	O
and	O
75	O
%	O
are	O
in	O
2	O
or	O
fewer	O
,	O
with	O
MAF	O
<	O
0	O
.	O
22	O
%	O
.	O

Herein	O
we	O
describe	O
transient	O
myocardial	O
hypertrophy	I-DISEASE
induced	O
by	O
tacrolimus	B-Chemical
after	O
heart	O
transplantation	O
.	O

The	O
pathogenicity	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
T1209A	I-VARIANT
mutation	O
in	O
CDH23	B-GENE
[	O
18	O
,	O
55	O
]	O
is	O
,	O
however	O
,	O
questionable	O
since	O
we	O
found	O
it	O
in	O
five	O
alleles	O
from	O
the	O
control	O
population	O
.	O

While	O
both	O
proteins	O
are	O
potentially	O
interacting	O
partners	O
for	O
HOMER2	B-GENE
,	O
to	O
date	O
only	O
an	O
interaction	O
with	O
TRPC1	B-GENE
(	O
MIM	O
602343	O
)	O
has	O
been	O
established	O
[	O
13	O
]	O
.	O

Their	O
differential	O
diagnosis	O
is	O
difficult	O
and	O
essential	O
for	O
subsequent	O
patient	O
'	O
s	O
management	O
.	O

of	O
alleles	O
:	O
Number	O
of	O
alleles	O
identified	O
in	O
patients	O
.	O

Patients	O
who	O
developed	O
renal	B-DISEASE
insufficiency	I-DISEASE
had	O
lower	O
baseline	O
body	O
weight	O
and	O
higher	O
baseline	O
serum	O
creatinine	B-Chemical
,	O
required	O
higher	O
doses	O
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	B-Chemical
diuretics	I-DISEASE
than	O
controls	O
.	O

Hiroshi	O
Ogawa	O
and	O
Koichi	O
Omori	O
(	O
Fukushima	O
Medical	O
University	O
)	O
,	O
Drs	O
.	O

Adenosine	B-Chemical
antagonists	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benefit	O
in	O
some	O
ischaemic	O
and	O
nephrotoxic	O
models	O
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
(	O
ARF	B-DISEASE
)	O
.	O

To	O
facilitate	O
clear	O
description	O
of	O
variants	O
with	O
respect	O
to	O
their	O
pathogenicity	O
,	O
we	O
have	O
used	O
a	O
grading	O
system	O
along	O
the	O
guidelines	O
provided	O
by	O
the	O
Clinical	O
and	O
Molecular	O
Genetics	O
Society	O
,	O
a	O
constituent	O
member	O
of	O
the	O
British	O
Society	O
of	O
Human	O
Genetics	O
.	O

Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O

Pedigree	O
and	O
mutation	O
analysis	O
.	O

Green	O
line	O
=	O
window	O
14	O
;	O
Blue	O
line	O
=	O
window	O
21	O
;	O
Red	O
line	O
=	O
window	O
28	O
.	O

The	O
preparation	O
of	O
the	O
pooled	O
libraries	O
for	O
sequencing	O
on	O
the	O
MiSeq	O
platform	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

11	O
)	O
,	O
whereby	O
the	O
ahl5	B-DISEASE
QTL	O
accounts	O
for	O
~	O
60	O
%	O
of	O
the	O
variation	O
observed	O
.	O

Neuromuscular	O
monitoring	O
after	O
each	O
precurarizing	O
dose	O
was	O
recorded	O
from	O
the	O
adductor	O
pollicis	O
muscle	O
using	O
acceleromyography	O
with	O
train	O
-	O
of	O
-	O
four	O
stimulation	O
of	O
the	O
ulnar	O
nerve	O
.	O

(	O
A	O
)	O
Family	O
tree	O
of	O
the	O
affected	O
proband	O
(	O
II	O
-	O
3	O
)	O
.	O

The	O
study	O
subjects	O
have	O
an	O
average	O
of	O
14	O
HGMD	O
variants	O
(	O
range	O
:	O
4	O
-	O
25	O
)	O
,	O
2	O
variants	O
in	O
the	O
deleterious	O
class	O
(	O
range	O
:	O
0	O
-	O
4	O
)	O
,	O
and	O
52	O
VUS	O
(	O
range	O
:	O
34	O
-	O
78	O
)	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
analysis	O
revealed	O
a	O
total	O
of	O
233	O
,	O
572	O
variants	O
,	O
only	O
311	O
remained	O
(	O
Table	O
1	O
)	O
after	O
applying	O
the	O
same	O
filters	O
used	O
in	O
family	O
MOL0486	O
.	O

The	O
impact	O
of	O
splice	O
site	O
variants	O
was	O
assessed	O
using	O
splice	O
site	O
prediction	O
programmes	O
NNSPLICE	O
v0	O
.	O
9	O
[	O
56	O
]	O
,	O
NetGene2	O
[	O
57	O
]	O
,	O
[	O
58	O
]	O
,	O
SpliceView	O
[	O
59	O
]	O
and	O
ESEfinder	O
[	O
60	O
]	O
.	O

In	O
the	O
controls	O
,	O
the	O
GTN	B-Chemical
-	O
induced	O
headache	O
gradually	O
disappeared	O
,	O
whereas	O
in	O
migraineurs	B-DISEASE
peak	O
headache	O
intensity	O
occurred	O
at	O
a	O
mean	O
time	O
of	O
240	O
min	O
post	O
-	O
infusion	O
.	O

U1157	B-Chemical
carried	O
a	O
newly	O
described	O
variant	O
in	O
position	O
+	O
5	O
of	O
exon	O
63	O
,	O
and	O
a	O
minigene	O
analysis	O
was	O
performed	O
to	O
assess	O
the	O
impact	O
of	O
the	O
substitution	O
on	O
the	O
splicing	O
process	O
.	O

The	O
maximum	O
two	O
-	O
point	O
LOD	O
score	O
of	O
4	O
.	O
57	O
(	O
=	O
0	O
)	O
was	O
obtained	O
with	O
marker	O
D9S177	B-Chemical
in	O
chromosomal	O
region	O
9q33	O
(	O
Table	O
1	O
)	O
.	O

Neuropsychiatric	B-DISEASE
side	I-DISEASE
effects	O
after	O
the	O
use	O
of	O
mefloquine	B-Chemical
.	O

Of	O
note	O
,	O
the	O
436	O
genes	O
on	O
the	O
Sanger	O
cancer	O
gene	O
list	O
contained	O
gene	O
clusters	O
(	O
IGH	O
@	O
,	O
IGK	O
@	O
,	O
IGL	O
@	O
)	O
.	O

1	O
Diagnostic	O
rates	O
are	O
dependent	O
on	O
patient	O
-	O
specific	O
clinical	O
and	O
phenotypic	O
characteristics	O
and	O
are	O
shown	O
as	O
the	O
percentage	O
of	O
patients	O
with	O
the	O
noted	O
characteristic	O
.	O

To	O
identify	O
pathogenic	O
variants	O
,	O
we	O
filtered	O
out	O
polymorphisms	O
using	O
the	O
dbSNP131	O
and	O
the	O
Korean	O
exome	O
data	O
.	O

However	O
,	O
incidence	O
of	O
synophrys	B-DISEASE
in	O
patients	O
with	O
WS1	B-DISEASE
was	O
reported	O
as	O
85	O
%	O
in	O
a	O
review	O
published	O
in	O
2009	O
[	O
17	O
]	O
.	O

EVA	B-DISEASE
is	O
always	O
detected	O
in	O
the	O
ears	O
of	O
patients	O
with	O
PS	B-DISEASE
by	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
[	O
16	O
]	O
.	O

And	O
a	O
Mondini	B-DISEASE
cochlea	I-DISEASE
(	O
isolated	B-DISEASE
Mondini	I-DISEASE
)	O
occurs	O
only	O
when	O
the	O
two	O
and	O
a	O
half	O
turns	O
of	O
the	O
cochlea	O
are	O
replaced	O
by	O
a	O
single	O
cavity	O
in	O
the	O
apical	O
region	O
because	O
of	O
the	O
absence	B-DISEASE
of	I-DISEASE
the	I-DISEASE
interscalar	I-DISEASE
septum	I-DISEASE
[	O
9	O
-	O
11	O
]	O
.	O

We	O
paid	O
considerable	O
attention	O
to	O
these	O
features	O
because	O
additional	O
associated	O
clinical	O
manifestations	O
(	O
chronic	B-DISEASE
progressive	I-DISEASE
external	I-DISEASE
ophthalmoplegia	I-DISEASE
,	O
ataxia	B-DISEASE
,	O
sensorineural	B-DISEASE
deafness	I-DISEASE
,	O
sensory	B-DISEASE
-	I-DISEASE
motor	I-DISEASE
neuropathy	I-DISEASE
,	O
and	O
myopathy	B-DISEASE
[	O
18	O
,	O
19	O
]	O
)	O
,	O
the	O
syndromic	O
forms	O
of	O
ADOA	B-DISEASE
or	O
ADOA	B-DISEASE
plus	O
[	O
16	O
]	O
,	O
account	O
for	O
20	O
%	O
of	O
all	O
DOA	B-DISEASE
cases	O
with	O
OPA1	B-GENE
mutation	O
[	O
20	O
]	O
and	O
could	O
be	O
missed	O
,	O
particularly	O
in	O
patients	O
with	O
a	O
mild	O
to	O
moderate	O
degree	O
of	O
ptosis	B-DISEASE
or	O
ophthalmoplegia	B-DISEASE
[	O
19	O
]	O
.	O

Side	O
effects	O
are	O
relatively	O
few	O
and	O
prominently	O
gastrointestinal	O
.	O

Green	O
edges	O
represent	O
direct	O
connections	O
between	O
genes	O
harboring	O
de	O
novo	O
variants	O
(	O
left	O
)	O
and	O
prior	O
ASD	B-DISEASE
genes	O
.	O

IF	O
is	O
proposed	O
as	O
a	O
reliable	O
and	O
more	O
sensitive	O
technique	O
(	O
Savoia	B-Chemical
et	O
al	O
.	O

(	O
F	O
)	O
The	O
quantitative	O
analysis	O
of	O
Western	O
blotting	O
result	O
was	O
performed	O
using	O
Image	O
J	O
software	O
.	O

None	O
of	O
the	O
10	O
individuals	O
with	O
copy	O
-	O
neutral	O
LOH	O
exhibited	O
a	O
homozygous	O
pathogenic	O
mutation	O
;	O
one	O
(	O
no	O
.	O

Furthermore	O
,	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
increases	O
in	O
renal	O
cytokine	O
content	O
were	O
also	O
decreased	O
.	O

A	O
significant	O
number	O
of	O
patients	O
with	O
Pendred	B-DISEASE
syndrome	I-DISEASE
and	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
EVA	I-DISEASE
show	O
only	O
one	O
mutation	O
in	O
SLC26A4	B-GENE
.	O

Electron	O
transport	O
through	O
mitochondrial	O
complex	O
II	O
was	O
not	O
enhanced	O
,	O
which	O
is	O
consistent	O
with	O
the	O
fact	O
that	O
the	O
architecture	O
of	O
mitochondrial	O
complex	O
II	O
is	O
completely	O
nuclear	O
encoded	O
.	O

Currents	O
were	O
recorded	O
from	O
transfections	O
with	O
plasmids	O
from	O
at	O
least	O
two	O
preparations	O
of	O
each	O
CACNA1D	B-GENE
construct	O
.	O

DSPP	B-GENE
gene	O
is	O
located	O
on	O
chromosome	O
4q21	O
.	O
3	O
and	O
encodes	O
the	O
major	O
noncollagenous	O
protein	O
in	O
tooth	O
dentin	O
.	O

The	O
significance	O
and	O
implications	O
of	O
the	O
findings	O
from	O
this	O
family	O
was	O
discussed	O
in	O
light	O
of	O
the	O
mutation	O
spectrum	O
of	O
HL	B-DISEASE
.	O

19	O
The	O
CDH23	B-GENE
gene	O
encodes	O
a	O
calcium	B-GENE
-	I-GENE
dependent	I-GENE
cell	I-GENE
-	I-GENE
adhesion	I-GENE
protein	I-GENE
(	O
cadherin	B-GENE
)	O
with	O
27	O
EC	O
cadherin	B-GENE
domains	O
.	O

Because	O
chip	O
-	O
based	O
analysis	O
for	O
previously	O
reported	O
mutations	O
detects	O
only	O
a	O
fraction	O
of	O
the	O
causative	O
alleles	O
[	O
8	O
]	O
,	O
and	O
gene	O
-	O
by	O
-	O
gene	O
analysis	O
by	O
Sanger	O
sequencing	O
is	O
too	O
laborious	O
and	O
expensive	O
,	O
genetic	O
testing	O
has	O
been	O
the	O
exception	O
until	O
recently	O
.	O

These	O
strategies	O
should	O
pave	O
the	O
way	O
to	O
clinical	O
sequencing	O
and	O
high	O
throughput	O
mutation	O
discovery	O
studies	O
compared	O
to	O
single	O
gene	O
approaches	O
that	O
are	O
now	O
inefficient	O
and	O
costly	O
.	O

As	O
wider	O
use	O
confirms	O
their	O
safety	O
profile	O
,	O
they	O
will	O
gain	O
increasing	O
importance	O
in	O
the	O
therapeutic	O
approach	O
to	O
hypercholesterolaemia	B-DISEASE
and	O
its	O
consequences	O
.	O

Verapamil	B-Chemical
stimulation	O
test	O
in	O
hyperprolactinemia	B-DISEASE
:	O
loss	O
of	O
prolactin	O
response	O
in	O
anatomic	O
or	O
functional	O
stalk	O
effect	O
.	O

The	O
human	O
embryonic	O
kidney	O
cell	O
line	O
,	O
HEK	B-Chemical
-	O
293	O
(	O
cat	O
.	O

Mutational	O
analysis	O
in	O
nonsyndromic	O
CTDs	B-DISEASE
patients	O
only	O
detected	O
a	O
insertion	O
of	O
30	O
bp	O
within	O
exon	O
9c	O
of	O
TBX1	B-GENE
,	O
caused	O
polyalanine	O
stretches	O
[	O
5	O
,	O
6	O
]	O
.	O

Although	O
Acadians	B-Chemical
and	O
Quebecers	O
are	O
both	O
French	O
Canadian	O
,	O
Acadia	B-Chemical
was	O
founded	O
four	O
years	O
prior	O
to	O
Quebec	O
and	O
in	O
a	O
geographically	O
separate	O
area	O
now	O
corresponding	O
to	O
New	O
Brunswick	O
and	O
Nova	O
Scotia	O
.	O

We	O
communicate	O
a	O
case	O
in	O
a	O
previously	O
healthy	O
person	O
,	O
a	O
fact	O
not	O
found	O
in	O
the	O
recent	O
literature	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
starts	O
in	O
childhood	O
or	O
adolescence	O
,	O
and	O
usually	O
follows	O
the	O
onset	O
of	O
visual	O
symptoms	O
(	O
Yu	O
-	O
Wai	O
-	O
Man	O
et	O
al	O
.	O

In	O
turn	O
,	O
these	O
strands	O
recruit	O
additional	O
vertically	O
oriented	O
TJ	O
strands	O
to	O
form	O
a	O
central	O
tube	O
structure	O
surrounded	O
by	O
central	O
sealing	O
elements	O
in	O
the	O
extracellular	O
space	O
at	O
TC	O
locations	O
[	O
4	O
-	O
7	O
]	O
.	O

However	O
,	O
a	O
paucity	O
of	O
disease	O
causing	O
ABCA4	B-GENE
mutations	O
was	O
observed	O
in	O
our	O
French	O
Canadian	O
cohort	O
.	O

generated	O
the	O
Cib2	B-GENE
mutant	O
flies	O
,	O
conducted	O
light	O
stress	O
analysis	O
,	O
light	O
microscopic	O
imaging	O
of	O
fly	O
eyes	O
;	O
R	O
.	O
S	O
.	O
H	O
.	O

DESIGN	O
:	O
Randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Duchenne	B-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
(	O
DMD	B-DISEASE
)	O
is	O
the	O
most	O
common	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
recessive	I-DISEASE
disease	I-DISEASE
.	O

AoD	O
,	O
age	O
of	O
diagnosis	O
of	O
diabetes	B-DISEASE
;	O
M	O
,	O
p	B-VARIANT
.	I-VARIANT
Trp314Arg	I-VARIANT
variant	O
;	O
N	O
,	O
reference	O
allele	O
;	O
?	O
,	O
unknown	O
;	O
*	O
exome	O
sequenced	O
.	O

How	O
might	O
this	O
intrafamilial	O
continuum	O
of	O
PRPS1	B-GENE
disease	O
clusters	O
be	O
explained	O
?	O
Our	O
results	O
indicate	O
that	O
the	O
respective	O
phenotypic	O
presentation	O
seems	O
to	O
be	O
determined	O
by	O
(	O
1	O
.	O
)	O
the	O
exact	O
PRPS1	B-GENE
mutation	O
(	O
in	O
males	O
)	O
and	O
(	O
2	O
.	O
)	O
the	O
residual	O
enzyme	O
activity	O
,	O
which	O
in	O
turn	O
is	O
largely	O
influenced	O
by	O
the	O
degree	O
of	O
skewed	O
X	O
-	O
inactivation	O
(	O
in	O
females	O
)	O
.	O

Oral	O
administration	O
of	O
betaine	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	O
ventricular	O
remodeling	O
.	O

Twenty	O
-	O
two	O
mutations	O
were	O
found	O
in	O
KCNQ1	B-GENE
,	O
28	O
in	O
KCNH2	B-GENE
,	O
9	O
in	O
SCN5A	B-GENE
,	O
3	O
in	O
KCNE1	B-GENE
and	O
2	O
in	O
KCNE2	B-GENE
.	O

Then	O
the	O
absence	O
of	O
normal	O
tenascin	O
-	O
C	O
was	O
supposed	O
to	O
cause	O
irreversible	O
injuries	O
in	O
cochlea	O
and	O
caused	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Myosin	B-GENE
VIIA	I-GENE
has	O
been	O
implicated	O
in	O
recessively	O
inherited	O
Usher	B-GENE
syndrome	I-GENE
type	I-GENE
1B	I-GENE
(	O
USH1B	B-DISEASE
)	O
[	O
8	O
]	O
,	O
atypical	B-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
(	O
USH3	B-DISEASE
)	O
[	O
9	O
]	O
,	O
nonsyndromic	O
recessive	O
(	O
Deafness	B-DISEASE
,	O
Neurosensory	O
,	O
Autosomal	O
Recessive	O
2	O
[	O
DFNB2	B-GENE
]	O
)	O
[	O
10	O
]	O
,	O
and	O
dominant	O
(	O
DFNA11	B-GENE
)	O
[	O
11	O
]	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
HL	B-DISEASE
)	O
.	O

Nucleotide	O
numbering	O
of	O
OPA1	B-GENE
gene	O
mutations	O
reflects	O
cDNA	O
numbering	O
with	O
+	O
1	O
corresponding	O
to	O
the	O
A	O
of	O
the	O
ATG	O
translation	O
initiation	O
codon	O
of	O
the	O
GenBank	O
reference	O
sequence	O
NM_015560	O
.	O
2	O
.	O

2004	O
;	O
Dreyer	O
et	O
al	O
.	O

To	O
measure	O
mechanotransduction	O
,	O
the	O
hair	O
bundles	O
were	O
stimulated	O
with	O
a	O
fire	O
polished	O
glass	O
probe	O
that	O
fit	O
the	O
shape	O
of	O
the	O
bundles	O
.	O

Moreover	O
,	O
the	O
dopaminergic	O
control	O
of	O
epilepsy	B-DISEASE
-	O
induced	O
neurodegeneration	B-DISEASE
seems	O
to	O
be	O
mediated	O
by	O
distinct	O
interactions	O
of	O
D2R	B-GENE
signaling	O
with	O
these	O
two	O
neurotransmitters	O
.	O

The	O
pairwise	O
Wilcoxon	O
test	O
followed	O
by	O
a	O
Benjamini	O
-	O
Hochberg	O
multiple	O
testing	O
correction	O
was	O
used	O
to	O
determine	O
whether	O
there	O
was	O
a	O
significant	O
difference	O
in	O
the	O
number	O
of	O
variants	O
in	O
the	O
control	O
versus	O
case	O
groups	O
.	O

Thirty	O
to	O
135	O
min	O
after	O
the	O
injection	O
of	O
crystalline	O
insulin	O
,	O
ISO	B-Chemical
was	O
given	O
subcutaneously	O
and	O
when	O
ISO	B-Chemical
induced	O
fibrosis	B-DISEASE
in	O
the	O
myocardium	O
was	O
morphometrically	O
analyzed	O
7	O
days	O
later	O
,	O
a	O
highly	O
significant	O
correlation	O
(	O
r	O
=	O
0	O
.	O
83	O
,	O
2	O
p	O
=	O
0	O
.	O
006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	O
glucose	B-Chemical
after	O
insulin	O
treatment	O
appeared	O
.	O

The	O
clinical	O
examination	O
and	O
MRI	O
confirmed	O
the	O
diagnosis	O
of	O
isolated	O
bilateral	O
optic	B-DISEASE
neuropathy	I-DISEASE
in	O
our	O
patient	O
.	O

AIM	O
:	O
This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	O
and	O
pain	O
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-Chemical
.	O

Thus	O
,	O
while	O
WES	O
may	O
provide	O
a	O
method	O
to	O
identify	O
CNV	O
regions	O
with	O
highly	O
similar	O
sequences	O
,	O
determining	O
accurate	O
copy	O
numbers	O
can	O
prove	O
difficult	O
.	O

For	O
example	O
,	O
the	O
mutation	O
detection	O
rates	O
in	O
the	O
Tibetan	O
population	O
and	O
minorities	O
in	O
the	O
Southwest	O
region	O
and	O
Uygur	O
populations	O
were	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
Han	O
,	O
Hui	O
and	O
Mongolian	O
populations	O
.	O

It	O
is	O
noteworthy	O
that	O
the	O
majority	O
of	O
causative	O
mutations	O
in	O
STRC	B-GENE
involved	O
large	O
CNVs	O
(	O
99	O
%	O
)	O
,	O
underscoring	O
the	O
requirement	O
that	O
all	O
comprehensive	O
genetic	O
testing	O
panels	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
include	O
CNV	O
detection	O
.	O

Clinical	O
and	O
genetic	O
findings	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

2001	O
;	O
Masmoudi	B-Chemical
et	O
al	O
.	O

Three	O
genes	O
are	O
involved	O
in	O
USH2	B-DISEASE
,	O
namely	O
,	O
USH2A	B-GENE
(	O
USH2A	B-GENE
)	O
,	O
GPR98	B-GENE
(	O
USH2C	B-GENE
)	O
,	O
and	O
DFNB31	B-GENE
(	O
USH2D	B-GENE
)	O
.	O

RESULTS	O
:	O
Sensitivity	O
to	O
several	O
convulsion	O
endpoints	O
induced	O
by	O
nicotine	B-Chemical
,	O
carbachol	B-Chemical
,	O
and	O
neostigmine	B-Chemical
were	O
significantly	O
greater	O
in	O
WSR	B-DISEASE
versus	O
WSP	B-DISEASE
mice	O
.	O

The	O
mutation	O
found	O
in	O
patient	O
ARRP04	O
-	O
IV	O
:	O
4	O
was	O
a	O
recurrent	O
one	O
,	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
Figure	O
2	O
)	O
.	O

Due	O
to	O
inaccurate	O
sequencing	O
of	O
homopolymers	O
by	O
Roche	O
454	O
pyrosequencing	O
,	O
small	O
indels	O
in	O
homopolymer	O
stretches	O
were	O
filtered	O
using	O
stringent	O
criteria	O
(	O
bidirectional	O
occurrence	O
in	O
at	O
least	O
20	O
%	O
of	O
the	O
forward	O
reads	O
and	O
40	O
%	O
of	O
the	O
reverse	O
reads	O
or	O
vice	O
versa	O
)	O
and	O
visual	O
inspection	O
in	O
the	O
SeqNext	O
software	O
.	O

Many	O
of	O
ARNSHL	B-DISEASE
genes	O
consist	O
of	O
long	O
and	O
/	O
or	O
many	O
exons	O
making	O
conventional	O
genetic	O
methods	O
to	O
screen	O
for	O
mutations	O
extremely	O
expensive	O
and	O
time	O
-	O
consuming	O
(	O
e	O
.	O
g	O
.	O

average	O
of	O
125	O
,	O
250	O
,	O
and	O
500	O
Hz	O
.	O

The	O
.	O
822G	B-VARIANT
<	I-VARIANT
C	I-VARIANT
allele	O
also	O
results	O
in	O
abnormal	O
splicing	O
of	O
intron	O
7	O
in	O
patient	O
lymphoblastoid	O
cell	O
lines	O
.	O

All	O
patients	O
had	O
permanent	O
hearing	B-DISEASE
loss	I-DISEASE
not	O
caused	O
by	O
infections	O
,	O
exposure	O
to	O
drugs	O
or	O
other	O
prenatal	O
or	O
perinatal	O
etiology	O
of	O
deafness	B-DISEASE
.	O

CDH23	B-GENE
mutations	O
detected	O
in	O
this	O
study	O
1	O
Prediction	O
of	O
a	O
change	O
being	O
damaging	O
(	O
<	O
0	O
.	O
05	O
)	O
or	O
tolerated	O
.	O

She	O
progressed	O
to	O
ESRD	B-DISEASE
at	O
age	O
57	O
.	O

Murdock	B-Chemical
and	O
The	O
MURDOCK	O
Study	O
Community	O
Registry	O
and	O
Biorepository	O
;	O
Dr	O
.	O

Nitroglycerin	B-Chemical
,	O
up	O
to	O
0	O
.	O
3	O
micrograms	O
/	O
kg	O
,	O
selectively	O
increased	O
circumflex	O
artery	O
diameter	O
(	O
CxAD	O
)	O
without	O
simultaneously	O
affecting	O
any	O
other	O
cardiac	O
or	O
systemic	O
hemodynamic	O
parameter	O
.	O

Ten	O
patients	O
(	O
11	O
.	O
5	O
%	O
)	O
reached	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
(	O
ESKD	B-DISEASE
)	O
at	O
ages	O
ranging	O
from	O
37	O
-	O
69	O
-	O
yo	O
(	O
mean	O
50	O
,	O
1	O
-	O
yo	O
)	O
.	O

At	O
1	O
-	O
minute	O
intervals	O
during	O
the	O
procedural	O
sedation	O
,	O
until	O
the	O
patient	O
regained	O
baseline	O
mental	O
status	O
at	O
the	O
end	O
of	O
the	O
procedure	O
,	O
a	O
word	O
from	O
a	O
standardized	O
list	O
was	O
read	O
aloud	O
,	O
and	O
the	O
patient	O
was	O
asked	O
to	O
immediately	O
repeat	O
the	O
word	O
to	O
the	O
investigator	O
.	O

By	O
6	O
h	O
,	O
vasogenic	B-DISEASE
edema	I-DISEASE
covered	O
the	O
lesioned	O
SNR	O
.	O

3	O
,	O
S4	O
)	O
.	O

Systematic	O
Sanger	O
sequencing	O
of	O
all	O
359	O
variants	O
confirmed	O
283	O
variants	O
(	O
79	O
%	O
)	O
in	O
the	O
total	O
RP	B-DISEASE
cohort	O
.	O

Cataract	O
and	O
band	O
keratopathy	I-DISEASE
occurred	O
in	O
only	O
22	O
and	O
13	O
%	O
of	O
our	O
group	O
,	O
respectively	O
.	O

Many	O
of	O
the	O
cases	O
available	O
to	O
us	O
were	O
diagnosed	O
based	O
on	O
clinical	O
features	O
alone	O
,	O
rather	O
than	O
on	O
detailed	O
analysis	O
of	O
x	O
-	O
rays	O
,	O
which	O
is	O
the	O
gold	O
standard	O
for	O
some	O
skeletal	B-DISEASE
disorders	I-DISEASE
,	O
mainly	O
nonsyndromic	O
diagnoses	O
.	O

Etiology	O
of	O
hypercalcemia	B-DISEASE
in	O
hemodialysis	B-DISEASE
patients	O
on	O
calcium	B-Chemical
carbonate	I-Chemical
therapy	O
.	O

GJB2	B-GENE
mutations	O
were	O
detected	O
in	O
23	O
.	O
7	O
%	O
of	O
the	O
patients	O
(	O
18	O
out	O
of	O
76	O
)	O
(	O
Table	O
1	O
)	O
.	O

We	O
also	O
obtained	O
tissue	O
samples	O
from	O
TCS16	B-DISEASE
,	O
from	O
three	O
other	O
patients	O
(	O
TCS21	B-DISEASE
to	O
23	O
)	O
,	O
and	O
from	O
six	O
controls	O
submitted	O
to	O
reconstructive	O
plastic	O
surgery	O
at	O
University	O
of	O
S	O
a	O
o	O
Paulo	O
Medical	O
School	O
.	O

This	O
was	O
confirmed	O
by	O
segregation	O
analysis	O
of	O
the	O
variants	O
.	O

Recently	O
,	O
narrow	B-DISEASE
bony	I-DISEASE
cochlear	I-DISEASE
nerve	I-DISEASE
canal	I-DISEASE
(	O
nBCNC	B-DISEASE
)	O
has	O
been	O
recognized	O
and	O
spotlighted	O
as	O
the	O
most	O
frequent	O
inner	O
ear	O
anomaly	O
[	O
11	O
]	O
.	O

The	O
patients	O
were	O
clinically	O
examined	O
,	O
and	O
reversal	O
of	O
HH	B-DISEASE
was	O
assessed	O
after	O
treatment	O
withdrawal	O
.	O

Recently	O
,	O
a	O
positron	O
emission	O
tomography	O
scan	O
using	O
Fluorine	B-Chemical
-	I-Chemical
18	I-Chemical
L	I-Chemical
-	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
(	O
18	B-Chemical
-	I-Chemical
fluoro	I-Chemical
DOPA	I-Chemical
-	O
TC	I-Chemical
-	O
PET	O
-	O
scan	O
)	O
has	O
been	O
used	O
to	O
distinguish	O
focal	O
from	O
diffuse	O
forms	O
.	O

G490	O
,	O
D623	O
,	O
and	O
N628	O
are	O
in	O
close	O
proximity	O
to	O
the	O
ATP	O
'	O
s	O
phosphates	O
or	O
coordinating	O
magnesium	O
.	O

Iridocyclitis	B-DISEASE
was	O
seen	O
most	O
frequently	O
in	O
young	O
female	O
patients	O
(	O
0	O
to	O
4	O
years	O
)	O
with	O
the	O
monoarticular	O
or	O
pauciatricular	O
form	O
of	O
the	O
arthritis	B-DISEASE
.	O

Eight	O
of	O
13	O
participants	O
were	O
rated	O
as	O
responders	O
on	O
the	O
basis	O
of	O
their	O
improvement	O
scores	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
scale	O
.	O

The	O
mutations	O
were	O
predicted	O
to	O
affect	O
protein	O
function	O
,	O
with	O
polyphen	O
2	O
score	O
of	O
0	O
.	O
99	O
and	O
SIFT	O
score	O
of	O
0	O
.	O
01	O
for	O
MYH14	B-GENE
p	B-VARIANT
.	I-VARIANT
A181	I-VARIANT
T	I-VARIANT
and	O
polyphen	O
2	O
score	O
of	O
0	O
.	O
964	O
for	O
WFS1	B-GENE
p	B-VARIANT
.	I-VARIANT
A150	I-VARIANT
V	I-VARIANT
[	O
13	O
]	O
.	O

By	O
20	O
years	O
of	O
age	O
,	O
ataxia	B-DISEASE
had	O
become	O
more	O
severe	O
,	O
and	O
a	O
follow	O
-	O
up	O
MRI	O
was	O
performed	O
.	O

Complete	O
resolution	O
of	O
symptoms	O
within	O
1	O
-	O
4	O
days	O
was	O
accompanied	O
by	O
normalisation	O
of	O
ADC	B-DISEASE
abnormalities	I-DISEASE
.	O

A	O
parametric	O
linkage	O
analysis	O
was	O
run	O
assuming	O
a	O
fully	O
penetrant	O
autosomal	O
dominant	O
model	O
.	O

This	O
method	O
is	O
useful	O
in	O
some	O
populations	O
.	O

Because	O
the	O
Gln	B-Chemical
side	O
chain	O
contains	O
the	O
-	O
NH	I-Chemical
2	I-Chemical
group	O
,	O
it	O
is	O
possible	O
that	O
it	O
can	O
still	O
form	O
a	O
hydrogen	O
bond	O
with	O
the	O
Glu	B-Chemical
side	O
chain	O
in	O
switch	O
II	O
,	O
but	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
the	O
active	O
site	O
pockets	O
are	O
slightly	O
different	O
between	O
myosin	O
II	O
and	O
myosin	B-GENE
VI	I-GENE
.	O

The	O
de	O
novo	O
nature	O
of	O
these	O
events	O
could	O
enable	O
couples	O
to	O
be	O
counseled	O
as	O
to	O
their	O
low	O
recurrence	O
risk	O
.	O

Additionally	O
,	O
variants	O
were	O
annotated	O
with	O
frequencies	O
of	O
the	O
variants	O
in	O
(	O
1	O
)	O
all	O
100	O
blindness	O
samples	O
,	O
(	O
2	O
)	O
an	O
internal	O
database	O
of	O
86	O
exomes	O
,	O
(	O
3	O
)	O
an	O
internal	O
database	O
with	O
known	O
pathogenic	O
blindness	O
mutations	O
,	O
and	O
(	O
4	O
)	O
an	O
internal	O
database	O
with	O
mutations	O
from	O
the	O
professional	O
version	O
of	O
the	O
Human	O
Gene	O
Mutation	O
Database	O
(	O
HGMD	O
)	O
.	O

Brainstem	B-DISEASE
dysgenesis	I-DISEASE
in	O
an	O
infant	O
prenatally	O
exposed	O
to	O
cocaine	B-Chemical
.	O

We	O
are	O
thankful	O
to	O
Lucia	B-Chemical
Valent	I-Chemical
i	O
nov	O
a	O
for	O
preparing	O
some	O
of	O
the	O
figures	O
.	O
To	O
analyze	O
the	O
spectrum	O
of	O
sequence	O
variants	O
in	O
the	O
MYO7A	B-GENE
and	O
USH2A	B-GENE
genes	O
in	O
a	O
group	O
of	O
Italian	O
patients	O
affected	O
by	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
.	O

No	O
.	O

Diabetes	B-DISEASE
mellitus	I-DISEASE
was	O
the	O
major	O
cause	O
of	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O

CASE	O
SUMMARY	O
:	O
A	O
42	O
-	O
year	O
-	O
old	O
white	O
man	O
developed	O
acute	O
hypertension	B-DISEASE
with	O
severe	O
headache	O
and	O
vomiting	O
2	O
hours	O
after	O
the	O
first	O
doses	O
of	O
amisulpride	B-Chemical
100	O
mg	O
and	O
tiapride	B-Chemical
100	O
mg	O
.	O

Behavioural	O
and	O
mental	O
disturbances	O
started	O
at	O
age	O
16	O
years	O
,	O
yet	O
the	O
patient	O
was	O
still	O
able	O
to	O
finish	O
secondary	O
school	O
.	O

High	O
-	O
resolution	O
,	O
thin	O
-	O
section	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
the	O
temporal	O
bone	O
were	O
used	O
to	O
detect	O
any	O
congenital	O
malformations	O
in	O
two	O
children	O
(	O
IIIC	O
:	O
2	O
and	O
IIIC	O
:	O
3	O
)	O
prior	O
to	O
cochlear	O
implant	O
surgery	O
.	O

Further	O
studies	O
of	O
the	O
properties	O
of	O
single	O
channels	O
and	O
the	O
impact	O
of	O
these	O
mutations	O
in	O
engineered	O
animal	O
models	O
will	O
be	O
of	O
interest	O
.	O

Array	O
data	O
were	O
analyzed	O
using	O
GenomeStudio	O
version	O
2011	O
.	O
1	O
(	O
Illumina	O
)	O
and	O
the	O
QuantiSNP	O
2	O
.	O
2	O
copy	O
-	O
number	O
detection	O
algorithm	O
.	O

Since	O
18	O
of	O
the	O
22	O
patients	O
were	O
initially	O
receiving	O
deferoxamine	B-Chemical
doses	O
in	O
excess	O
of	O
the	O
commonly	O
recommended	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
,	O
therapy	O
was	O
restarted	O
with	O
lower	O
doses	O
,	O
usually	O
50	O
mg	O
/	O
kg	O
per	O
dose	O
or	O
less	O
depending	O
on	O
the	O
degree	O
of	O
auditory	O
abnormality	O
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	O
no	O
further	O
toxicity	O
was	O
demonstrated	O
.	O

In	O
this	O
study	O
,	O
micropenis	B-DISEASE
and	O
/	O
or	O
cryptorchidism	B-DISEASE
were	O
present	O
in	O
all	O
of	O
the	O
boys	O
in	O
whom	O
the	O
information	O
was	O
available	O
except	O
one	O
.	O

RESULTS	O
:	O
The	O
reported	O
use	O
of	O
antibacterials	O
increased	O
during	O
pregnancy	O
,	O
peaking	O
during	O
the	O
third	O
month	O
.	O

The	O
CD164	B-GENE
c	B-VARIANT
.	I-VARIANT
574C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
genotyping	O
assays	O
were	O
developed	O
by	O
TIB	O
MOLBIOL	O
(	O
Berlin	O
,	O
Germany	O
)	O
for	O
the	O
LightCycler	O
480	O
instrument	O
(	O
Roche	O
,	O
Hvidovre	O
,	O
Denmark	O
)	O
.	O

In	O
this	O
work	O
we	O
have	O
described	O
the	O
clinical	O
and	O
molecular	O
features	O
of	O
four	O
Mexican	O
siblings	O
who	O
have	O
WS	B-DISEASE
.	O

A	O
,	O
Schematic	O
representation	O
of	O
genomic	O
region	O
affected	O
by	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutations	O
(	O
not	O
to	O
scale	O
)	O
.	O

Secondary	O
antibody	O
was	O
Alexa	B-Chemical
Fluor	I-Chemical
488	I-Chemical
goat	O
anti	O
-	O
rabbit	O
IgG	O
.	O

Furthermore	O
,	O
increased	O
phosphorylation	O
of	O
MAPK	B-GENE
family	O
members	O
,	O
especially	O
the	O
P	B-GENE
-	O
P38	I-GENE
/	O
P38	O
ratio	O
was	O
found	O
in	O
cardiac	O
tissues	O
.	O

These	O
three	O
USH2	B-DISEASE
proteins	O
are	O
part	O
of	O
the	O
Usher	O
protein	O
complex	O
,	O
in	O
which	O
USH1	B-DISEASE
and	O
USH2	B-DISEASE
proteins	O
are	O
assembled	O
in	O
a	O
multiprotein	O
scaffold	O
with	O
a	O
major	O
function	O
in	O
the	O
cochlea	O
hair	O
cells	O
as	O
well	O
as	O
in	O
the	O
photoreceptor	O
cells	O
[	O
6	O
-	O
8	O
]	O
.	O

RESULTS	O
:	O
Acetaminophen	B-Chemical
-	O
induced	O
ALF	B-DISEASE
patients	O
undergoing	O
LT	O
had	O
a	O
greater	O
severity	O
of	O
pre	O
-	O
LT	O
illness	O
reflected	O
by	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
and	O
requirement	O
for	O
organ	O
support	I-DISEASE
compared	O
with	O
the	O
other	O
two	O
groups	O
.	O

Both	O
novel	O
mutations	O
segregated	O
with	O
the	O
phenotype	O
.	O

No	O
known	O
or	O
potential	O
pathogenic	O
mtDNA	O
variants	O
were	O
identified	O
.	O

After	O
being	O
informed	O
,	O
200	O
Han	O
Chinese	O
control	O
subjects	O
(	O
between	O
the	O
ages	O
of	O
30	O
and	O
65	O
)	O
,	O
whose	O
health	O
physical	O
examination	O
items	O
contained	O
PTA	O
and	O
the	O
result	O
showed	O
the	O
hearing	O
threshold	O
was	O
less	O
than	O
15	O
dB	O
HL	B-DISEASE
,	O
were	O
also	O
collected	O
through	O
health	O
management	O
center	O
,	O
Xiangya	O
Hospital	O
,	O
Central	O
South	O
University	O
.	O

Genomic	O
DNA	O
from	O
the	O
proband	O
of	O
each	O
family	O
was	O
prepared	O
from	O
peripheral	O
blood	O
leukocytes	O
as	O
previously	O
described	O
[	O
23	O
]	O
.	O

All	O
active	O
treatments	O
were	O
associated	O
with	O
significantly	O
reduced	O
MSSBP	B-DISEASE
and	O
MSDBP	B-DISEASE
during	O
the	O
core	O
8	O
-	O
week	O
study	O
,	O
with	O
each	O
monotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
combination	O
therapy	O
(	O
VAL	B-Chemical
and	O
HCTZ	B-Chemical
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

After	O
stopping	O
the	O
beta	O
-	O
agonist	O
,	O
and	O
after	O
a	O
week	O
with	O
the	O
atenolol	B-Chemical
,	O
the	O
arrhythmia	B-DISEASE
disappeared	O
.	O

The	O
11	O
-	O
year	O
-	O
old	O
elder	O
brother	O
of	O
the	O
index	O
patient	O
had	O
a	O
history	O
of	O
Hirschsprung	B-DISEASE
disease	I-DISEASE
that	O
required	O
surgery	O
at	O
the	O
age	O
of	O
3	O
months	O
.	O

Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
Analysis	O
was	O
performed	O
by	O
calculating	O
the	O
variant	O
allele	O
frequency	O
of	O
both	O
SNV	O
and	O
short	O
indels	O
using	O
our	O
internally	O
developed	O
tool	O
bam	O
-	O
readcount	O
(	O
https	O
:	O
/	O
/	O
github	O
.	O
com	O
/	O
genome	O
/	O
bam	O
-	O
readcount	O
)	O
for	O
SNVs	O
and	O
Samtools	O
mpileup	O
6	O
/	O
VarScan	O
7	O
for	O
indels	O
.	O

The	O
pathogenicity	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
T1209A	I-VARIANT
mutation	O
in	O
CDH23	B-GENE
[	O
18	O
,	O
55	O
]	O
is	O
,	O
however	O
,	O
questionable	O
since	O
we	O
found	O
it	O
in	O
five	O
alleles	O
from	O
the	O
control	O
population	O
.	O

Haplotype	O
analysis	O
suggests	O
a	O
founder	O
effect	O
and	O
an	O
ancestral	O
origin	O
for	O
these	O
three	O
mutations	O
.	O

Fig	O
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
gradual	O
introduction	O
of	O
quetiapine	B-Chemical
(	O
up	O
to	O
600	O
mg	O
/	O
day	O
)	O
,	O
the	O
patient	O
presented	O
severe	O
agitation	B-DISEASE
without	O
an	O
environmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
absence	O
of	O
a	O
history	O
of	O
aggressiveness	B-DISEASE
or	O
personality	B-DISEASE
disorder	I-DISEASE
.	O

Fig	O
.	O

Our	O
diagnostic	O
yield	O
of	O
10	O
%	O
is	O
comparable	O
to	O
,	O
and	O
supplementary	O
to	O
,	O
the	O
diagnostic	O
yield	O
of	O
existing	O
microarray	O
testing	O
for	O
large	O
chromosomal	O
rearrangements	O
and	O
targeted	O
CNV	O
detection	O
.	O

Genetic	O
and	O
molecular	O
mechanism	O
of	O
the	O
missense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
5765	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
at	O
the	O
donor	O
splice	O
site	O
of	O
intron	O
40	O
.	O

To	O
measure	O
the	O
activity	O
of	O
complex	O
V	O
,	O
we	O
first	O
disrupted	O
cells	O
by	O
freezing	O
in	O
liquid	O
nitrogen	O
,	O
followed	O
by	O
rapid	O
thawing	O
at	O
37	O
deg	O
C	O
.	O

This	O
study	O
identified	O
truncating	O
mutations	O
of	O
CDH23	B-GENE
in	O
combination	O
with	O
heterozygous	O
missense	O
alleles	O
in	O
a	O
Japanese	O
population	O
of	O
patients	O
with	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
.	O

Three	O
of	O
these	O
are	O
predicted	O
to	O
have	O
benign	O
effects	O
by	O
PolyPhen	O
,	O
and	O
one	O
,	O
p	B-VARIANT
.	I-VARIANT
Arg1835Gln	I-VARIANT
,	O
is	O
predicted	O
to	O
be	O
probably	O
damaging	O
.	O

No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	I-DISEASE
were	O
identified	O
.	O

Serum	O
LH	O
and	O
FSH	B-Chemical
levels	O
measured	O
before	O
and	O
/	O
or	O
after	O
the	O
cessation	O
of	O
the	O
hormone	O
therapy	O
were	O
quantified	O
with	O
time	O
-	O
resolved	O
immunofluorometric	O
assays	O
(	O
AutoDELFIA	O
,	O
Wallac	O
,	O
Turku	O
,	O
Finland	O
)	O
.	O

Choi	O
)	O
.	O
This	O
is	O
an	O
Open	O
Access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Attribution	O
License	O
(	O
)	O
,	O
which	O
permits	O
unrestricted	O
use	O
,	O
distribution	O
,	O
and	O
reproduction	O
in	O
any	O
medium	O
,	O
provided	O
the	O
original	O
work	O
is	O
properly	O
cited	O
.	O

Cases	O
of	O
delayed	B-DISEASE
hemolytic	I-DISEASE
anemia	I-DISEASE
have	O
been	O
described	O
after	O
treatment	O
with	O
injectable	O
artesunate	B-Chemical
,	O
the	O
current	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
-	O
recommended	O
first	O
-	O
line	O
drug	O
for	O
the	O
treatment	O
of	O
severe	O
malaria	O
.	O

At	O
admission	O
simvastatin	B-Chemical
and	O
all	O
antiviral	O
drugs	O
were	O
discontinued	O
because	O
toxicity	O
due	O
to	O
a	O
drug	O
-	O
drug	O
interaction	O
was	O
suspected	O
.	O

Many	O
CNVs	O
have	O
been	O
associated	O
with	O
either	O
resistance	O
to	O
diseases	O
or	O
identified	O
as	O
the	O
cause	O
of	O
diseases	O
.	O

4	O
.	O
8	O
)	O
and	O
Adobe	O
Photoshop	O
.	O

M	O
,	O
male	O
;	O
F	O
female	O
;	O
Y	O
,	O
yes	O
;	O
N	O
,	O
No	O
;	O
U	O
,	O
unknown	O
or	O
not	O
applicable	O
;	O
NA	O
,	O
data	O
not	O
available	O
or	O
not	O
applicable	O
AA	O
,	O
African	O
American	O
;	O
Cau	O
,	O
Caucasian	O
LM	O
,	O
Light	O
Microscopy	O
;	O
EM	O
,	O
Electron	O
Microscopy	O
;	O
GBM	O
,	O
Glomerular	O
Basement	O
Membrane	O
;	O
FP	O
,	O
Foot	O
Process	O
.	O

Such	O
systemic	O
lipopolysaccharide	B-Chemical
treatment	O
mitigated	O
methamphetamine	B-Chemical
-	O
induced	O
striatal	O
dopamine	B-Chemical
and	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Radtke	O
,	O
and	O
S	O
.	O
R	O
.	O

Met305	O
is	O
located	O
close	O
to	O
the	O
ATP	B-Chemical
binding	O
site	O
of	O
ACTG1	B-GENE
(	O
C	O
)	O
.	O

Participants	O
completed	O
a	O
drug	O
history	O
questionnaire	O
,	O
Beck	O
Depression	O
Inventory	O
,	O
Barratt	O
Impulsiveness	O
Scale	O
,	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
,	O
and	O
Wechsler	O
Memory	O
Scale	O
-	O
Revised	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychometric	O
measures	O
.	O

Full	O
-	O
field	O
visual	O
evoked	O
potentials	O
(	O
ffVEP	O
)	O
were	O
ofreduced	O
amplitudes	O
and	O
somewhat	O
prolongedlatencies	O
with	O
occasionalabnormal	O
configurations	O
,	O
including	O
"	O
spike	O
-	O
trains	O
"	O
.	O

Captured	O
PCR	O
products	O
were	O
subjected	O
to	O
Agilent	O
2100	O
Bioanalyzer	O
to	O
evaluate	O
the	O
magnitude	O
of	O
enrichment	O
.	O

AIFM1	B-GENE
has	O
at	O
least	O
two	O
functions	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
,	O
the	O
pore	O
-	O
forming	O
alpha	O
-	O
subunit	O
of	O
the	O
I	B-GENE
Ks	I-GENE
channel	O
,	O
have	O
been	O
associated	O
with	O
AF	B-DISEASE
.	O

In	O
our	O
patient	O
,	O
there	O
was	O
no	O
other	O
etiology	O
identified	O
that	O
could	O
explain	O
QT	B-DISEASE
prolongation	I-DISEASE
or	O
TDP	O
The	O
complete	O
disappearance	O
of	O
NSVT	B-DISEASE
and	O
premature	B-DISEASE
ventricular	I-DISEASE
contractions	O
followed	O
by	O
normalization	O
of	O
QT	O
interval	O
after	O
the	O
drug	O
was	O
stopped	O
strongly	O
suggests	O
fluconazole	B-Chemical
as	O
the	O
etiology	O
.	O

In	O
one	O
patient	O
no	O
point	O
mutation	O
was	O
identified	O
,	O
and	O
the	O
quantitative	O
analysis	O
could	O
not	O
be	O
performed	O
(	O
RP	O
-	O
531	O
)	O
.	O

We	O
attained	O
full	O
diagnosis	O
for	O
22	O
of	O
them	O
,	O
whose	O
pedigrees	O
are	O
displayed	O
in	O
Figure	O
2	O
.	O

Magnitude	O
and	O
temporal	O
progression	O
of	O
wave	O
I	O
amplitude	O
of	O
afferent	O
neurons	O
correlate	O
with	O
susceptibility	O
and	O
resistance	O
to	O
audiogenic	B-DISEASE
seizures	I-DISEASE
.	O

Function	O
of	O
proteins	O
with	O
missense	O
variations	O
was	O
assessed	O
by	O
Polymorphism	O
Phenotyping	O
-	O
2	O
(	O
PolyPhen	O
-	O
2	O
,	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
and	O
Sorting	O
Intolerant	O
From	O
Tolerant	O
(	O
SIFT	O
,	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
and	O
that	O
of	O
proteins	O
with	O
in	O
-	O
frame	O
amino	O
acid	O
deletions	O
was	O
evaluated	O
by	O
PROVEAN	O
predictions	O
(	O
http	O
:	O
/	O
/	O
provean	O
.	O
jcvi	O
.	O
org	O
/	O
index	O
.	O
php	O
)	O
.	O

The	O
index	O
patient	O
(	O
subject	O
II	O
-	O
2	O
)	O
showed	O
an	O
overlapping	O
phenotype	O
combining	O
features	O
of	O
both	O
CMTX5	B-DISEASE
and	O
(	O
mild	O
,	O
relatively	O
late	O
-	O
onset	O
)	O
Arts	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
patient	O
skin	O
fibroblasts	O
and	O
control	O
skin	O
fibroblasts	O
were	O
obtained	O
from	O
skin	O
biopsies	O
.	O

The	O
effect	O
of	O
a	O
splice	O
site	O
mutation	O
was	O
also	O
assessed	O
by	O
RT	O
-	O
PCR	O
analysis	O
of	O
lymphoid	O
RNAs	O
obtained	O
from	O
affected	O
and	O
control	O
individuals	O
.	O

Patients	O
with	O
KS	B-DISEASE
usually	O
lack	O
puberty	O
,	O
but	O
the	O
reproductive	O
phenotype	O
may	O
vary	O
from	O
severe	O
hypogonadism	B-DISEASE
(	O
cryptorchidism	B-DISEASE
or	O
micropenis	B-DISEASE
in	O
male	O
infants	O
)	O
to	O
reversal	O
of	O
hypogonadotropism	B-DISEASE
later	O
in	O
life	O
[	O
4	O
,	O
5	O
]	O
.	O

After	O
the	O
exclusion	O
of	O
GJB2	B-GENE
mutations	O
and	O
of	O
most	O
mutations	O
previously	O
identified	O
in	O
deaf	B-DISEASE
individuals	O
from	O
Tunisia	O
,	O
we	O
carried	O
out	O
WES	O
in	O
six	O
deaf	B-DISEASE
patients	O
from	O
four	O
unrelated	O
consanguineous	O
Tunisian	O
families	O
.	O

Aliquots	O
from	O
DNAse	O
treated	O
RNAs	O
were	O
used	O
for	O
amplification	O
of	O
an	O
intronic	O
region	O
of	O
MLH1	O
gene	O
as	O
a	O
control	O
for	O
DNA	O
contamination	O
(	O
primers	O
sequences	O
on	O
request	O
)	O
.	O

Comparison	O
of	O
aqueous	O
and	O
gellan	O
ophthalmic	O
timolol	B-Chemical
with	O
placebo	O
on	O
the	O
24	O
-	O
hour	O
heart	O
rate	O
response	O
in	O
patients	O
on	O
treatment	O
for	O
glaucoma	O
.	O

(	O
Milan	O
)	O
and	O
Andrea	O
Mascagni	O
Mr	O
(	O
Genoa	O
)	O
.	O

Ninety	O
percent	O
of	O
the	O
reads	O
were	O
mapped	O
onto	O
a	O
human	O
reference	O
genome	O
,	O
achieving	O
20	O
.	O
7	O
-	O
45	O
.	O
4	O
x	O
coverage	O
(	O
44	O
%	O
on	O
target	O
reads	O
;	O
Table	O
S1	O
)	O
.	O

Ongoing	O
tubular	O
injury	O
may	O
be	O
a	O
prerequisite	O
for	O
renal	O
injury	O
by	O
melphalan	B-Chemical
as	O
evidenced	O
by	O
the	O
active	O
urinary	O
sediment	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
an	O
eighth	O
mutation	O
in	O
a	O
family	O
in	O
which	O
progressive	O
non	O
-	O
syndromic	O
autosomal	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
segregates	O
with	O
the	O
DFNA11	B-DISEASE
locus	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
with	O
respect	O
to	O
the	O
present	O
article	O
.	O

Scale	O
bar	O
:	O
10	O
u	O
m	O
.	O

These	O
trials	O
have	O
been	O
largely	O
successful	O
,	O
in	O
part	O
due	O
to	O
several	O
unique	O
features	O
of	O
the	O
eye	O
8	O
.	O

A	O
transient	O
neurological	O
deficit	O
following	O
intrathecal	O
injection	O
of	O
1	O
%	O
hyperbaric	O
bupivacaine	B-Chemical
for	O
unilateral	O
spinal	O
anaesthesia	O
.	O

Parents	O
of	O
patient	O
2	O
were	O
unavailable	O
.	O

Recent	O
development	O
of	O
vaccine	O
for	O
prevention	O
is	O
reported	O
to	O
be	O
successful	O
in	O
reducing	O
the	O
size	O
of	O
chronically	O
infected	O
carriers	O
,	O
although	O
the	O
standard	O
medical	O
therapies	O
have	O
not	O
been	O
established	O
up	O
to	O
now	O
.	O

1B	O
)	O
.	O

Zvi	O
Farfel	O
,	O
Dr	O
.	O

We	O
expect	O
the	O
list	O
of	O
CAKUT	B-DISEASE
-	O
causing	O
genes	O
to	O
keep	O
growing	O
with	O
the	O
increasing	O
application	O
of	O
next	O
generation	O
sequencing	O
techniques	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
is	O
a	O
genetically	O
heterogeneous	O
condition	O
with	O
ten	O
disease	O
-	O
causing	O
genes	O
.	O

There	O
was	O
no	O
obvious	O
staining	O
at	O
the	O
stereocilia	O
bundle	O
(	O
Fig	O
.	O

Fundus	O
images	O
were	O
obtained	O
with	O
an	O
infrared	O
AO	O
retinal	O
camera	O
(	O
rtx1	O
,	O
Imagine	O
Eyes	O
,	O
Orsay	O
,	O
France	O
)	O
[	O
33	O
]	O
.	O

Data	O
were	O
analyzed	O
from	O
all	O
747	O
consecutive	O
patients	O
who	O
received	O
dexmedetomidine	B-Chemical
for	O
MRI	O
sedation	O
from	O
April	O
2005	O
to	O
April	O
2007	O
.	O

Two	O
elderly	O
patients	O
with	O
a	O
history	O
of	O
either	O
cerebral	B-DISEASE
vascular	I-DISEASE
accident	I-DISEASE
(	O
CVA	B-DISEASE
)	O
or	O
head	B-DISEASE
trauma	I-DISEASE
and	O
no	O
evidence	O
of	O
renal	B-DISEASE
disease	O
developed	O
seizures	B-DISEASE
while	O
receiving	O
maximum	O
doses	O
of	O
imipenem	B-Chemical
/	I-Chemical
cilastatin	I-Chemical
.	O

Stickler	B-DISEASE
syndrome	I-DISEASE
is	O
usually	O
a	O
dominant	O
disorder	O
due	O
to	O
mutations	O
in	O
the	O
collagen	O
genes	O
COL2A1	B-GENE
,	O
COL11A1	B-GENE
and	O
COL11A2	B-GENE
.	O

Based	O
on	O
bioinformatics	O
predictions	O
a	O
number	O
of	O
these	O
variants	O
were	O
predicted	O
to	O
be	O
probably	O
damaging	O
using	O
the	O
PolyPhen	O
2	O
software	O
(	O
Table	O
1	O
)	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
WFS1	B-GENE
be	O
involved	O
in	O
tonotopic	O
arrangement	O
.	O

However	O
,	O
we	O
did	O
not	O
detect	O
any	O
mutations	O
,	O
supporting	O
the	O
fact	O
that	O
mutations	O
in	O
WDR11	B-GENE
are	O
rarely	O
involved	O
in	O
congenital	O
HH	B-DISEASE
,	O
at	O
least	O
in	O
the	O
Finnish	O
population	O
.	O

Physical	O
examination	O
findings	O
included	O
height	O
150	O
cm	O
(	O
25	O
-	O
50	O
percentile	O
)	O
,	O
weight	O
57	O
.	O
0	O
kg	O
(	O
75	O
-	O
90	O
percentile	O
)	O
,	O
blood	O
pressure	O
100	O
/	O
60	O
mmHg	O
,	O
heart	O
rate	O
80	O
bpm	O
,	O
respiratory	O
rate	O
20	O
/	O
min	O
,	O
and	O
temperature	O
36	O
.	O
9	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
progesterone	B-Chemical
can	O
potentiate	O
bupivacaine	B-Chemical
arrhythmogenicity	B-DISEASE
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

1	O
)	O
.	O

We	O
therefore	O
examined	O
the	O
effect	O
of	O
local	O
anesthesia	O
on	O
vocal	O
cord	O
function	O
to	O
better	O
understand	O
its	O
possible	O
consequences	O
.	O

The	O
other	O
identified	O
change	O
was	O
a	O
novel	O
missense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
1381	I-VARIANT
A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
resulting	O
in	O
the	O
substitution	O
of	O
Treonine	B-Chemical
with	O
Proline	O
at	O
codon	O
461	O
.	O

In	O
research	O
towards	O
the	O
development	O
of	O
new	O
atypical	B-DISEASE
antipsychotic	I-DISEASE
agents	O
,	O
one	O
strategy	O
is	O
that	O
the	O
dopaminergic	O
system	O
can	O
be	O
modulated	O
through	O
manipulation	O
of	O
the	O
serotonergic	B-GENE
system	O
.	O

For	O
the	O
95	O
samples	O
,	O
we	O
obtained	O
a	O
mean	O
of	O
3	O
mu	O
g	O
DNA	O
,	O
but	O
12	O
samples	O
had	O
less	O
than	O
the	O
required	O
0	O
.	O
2	O
mu	O
g	O
DNA	O
for	O
exome	O
sequencing	O
.	O

The	O
duration	O
of	O
the	O
summating	O
potential	O
-	O
compound	O
action	O
potential	O
complex	O
,	O
as	O
measured	O
from	O
initial	O
negative	O
deflection	O
to	O
return	O
to	O
baseline	O
,	O
is	O
relatively	O
constant	O
at	O
suprathreshold	O
intensities	O
but	O
broadens	O
at	O
low	O
stimulus	O
level	O
.	O

Peripheral	O
venous	O
blood	O
samples	O
(	O
3	O
-	O
5	O
ml	O
)	O
were	O
collected	O
from	O
both	O
NSD	B-DISEASE
patients	O
and	O
control	O
subjects	O
.	O

The	O
two	O
most	O
prevalent	O
genes	O
known	O
to	O
cause	O
arRP	B-DISEASE
are	O
eyes	O
shut	O
homolog	O
(	O
EYS	B-GENE
;	O
MIM	O
#	O
602772	O
)	O
[	O
6	O
]	O
,	O
which	O
has	O
been	O
reported	O
to	O
account	O
in	O
different	O
population	O
-	O
based	O
studies	O
for	O
up	O
to	O
18	O
%	O
of	O
arRP	B-DISEASE
[	O
7	O
]	O
,	O
and	O
Usher	B-GENE
syndrome	I-GENE
type	I-GENE
2A	I-GENE
(	O
USH2A	B-GENE
)	O
(	O
MIM	O
#	O
608400	O
)	O
,	O
found	O
in	O
around	O
5	O
%	O
of	O
arRP	B-DISEASE
cases	O
[	O
8	O
]	O
.	O

For	O
recessive	O
deafness	B-DISEASE
genes	O
,	O
bi	O
-	O
allelic	O
mutations	O
were	O
identified	O
in	O
19	O
simplex	O
and	O
9	O
multiplex	O
probands	O
,	O
respectively	O
.	O

Pure	O
tone	O
sound	O
field	O
audiograms	O
are	O
represented	O
by	O
unaided	O
(	O
S	O
)	O
,	O
Aided	O
(	O
A	O
)	O
,	O
and	O
Implanted	O
(	O
I	O
)	O
.	O

In	O
patients	O
with	O
progressive	O
hearing	B-DISEASE
impairment	I-DISEASE
and	O
a	O
possible	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
,	O
TMPRSS3	B-GENE
mutations	O
should	O
be	O
considered	O
.	O

In	O
eight	O
patients	O
,	O
mutations	O
were	O
identified	O
in	O
genes	O
that	O
had	O
not	O
been	O
previously	O
sequenced	O
.	O

Family	O
E	O
is	O
previously	O
described	O
by	O
Cremers	O
et	O
al	O
.	O

Germline	O
mutations	O
in	O
either	O
of	O
these	O
tumor	B-DISEASE
suppressor	O
genes	O
are	O
associated	O
with	O
hereditary	B-DISEASE
breast	I-DISEASE
and	I-DISEASE
ovarian	I-DISEASE
cancer	I-DISEASE
syndrome	I-DISEASE
,	O
which	O
accounts	O
for	O
an	O
estimated	O
2	O
-	O
8	O
%	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
cases	O
worldwide	O
[	O
47	O
]	O
.	O

Of	O
the	O
three	O
mutations	O
,	O
two	O
(	O
p	B-VARIANT
.	I-VARIANT
Glu1595Lys	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Asn342Ser	I-VARIANT
)	O
affected	O
highly	O
conserved	O
EC	O
calcium	O
-	O
binding	O
sites	O
(	O
Figure	O
2	O
B	O
and	O
D	O
)	O
.	O

A	O
full	O
-	O
shaded	O
icon	O
denotes	O
ESRD	B-DISEASE
;	O
a	O
3	O
/	O
4	O
-	O
shaded	O
icon	O
denotes	O
impaired	O
renal	O
function	O
;	O
individual	O
with	O
unknown	O
phenotype	O
is	O
indicated	O
in	O
gray	O
.	O

RESULTS	O
:	O
From	O
a	O
database	O
of	O
452	O
patients	O
receiving	O
Botox	B-Chemical
,	O
352	O
patients	O
had	O
been	O
diagnosed	O
with	O
ADSD	B-DISEASE
.	O

Physicians	O
who	O
prescribe	O
molindone	B-Chemical
should	O
be	O
aware	O
of	O
this	O
reaction	O
.	O

We	O
will	O
further	O
analyze	O
the	O
mutation	O
in	O
all	O
exome	O
of	O
each	O
family	O
,	O
because	O
it	O
may	O
not	O
be	O
present	O
in	O
80	O
candidate	O
genes	O
studied	O
here	O
.	O

The	O
protection	O
by	O
overexpression	O
of	O
superoxide	B-Chemical
dismutase	O
supports	O
the	O
hypothesis	O
that	O
oxidant	O
stress	O
plays	O
a	O
significant	O
role	O
in	O
aminoglycoside	B-Chemical
-	O
induced	O
ototoxicity	O
.	O

Apple	O
-	O
Mathews	O
for	O
help	O
in	O
preparing	O
the	O
manuscript	O
.	O
Conflict	O
of	O
interest	O
The	O
authors	O
have	O
no	O
conflicts	O
of	O
interest	O
to	O
disclose	O
.	O

Thus	O
,	O
the	O
results	O
exemplify	O
the	O
usefulness	O
of	O
exome	O
sequencing	O
in	O
the	O
identification	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
familial	O
disorders	O
.	O

At	O
present	O
,	O
six	O
families	O
were	O
identified	O
with	O
segregation	O
of	O
NSHL	B-DISEASE
linked	O
to	O
the	O
DFNA10	B-DISEASE
locus	O
(	O
7	O
,	O
10	O
-	O
13	O
)	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
recommend	O
that	O
all	O
Israeli	O
Jewish	O
probands	O
of	O
Moroccan	O
ancestry	O
be	O
screened	O
for	O
the	O
four	O
TMC1	B-GENE
mutations	O
,	O
as	O
well	O
as	O
for	O
the	O
most	O
common	O
GJB2	B-GENE
mutations	O
,	O
prior	O
to	O
conducting	O
MPS	O
.	O

Daily	O
treatment	O
of	O
cocaine	B-Chemical
increased	O
[	O
(	O
3	O
)	O
H	O
]	O
norepinephrine	B-Chemical
uptake	O
into	O
the	O
hippocampus	O
.	O

The	O
mean	O
doses	O
of	O
MZ	B-Chemical
and	O
FL	B-Chemical
were	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
and	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
,	O
respectively	O
.	O

This	O
generated	O
6	O
.	O
1	O
and	O
8	O
.	O
2	O
Gb	O
of	O
mapped	O
sequences	O
with	O
a	O
mean	O
coverage	O
of	O
80	O
-	O
fold	O
and	O
101	O
-	O
fold	O
,	O
a	O
30	O
-	O
fold	O
coverage	O
of	O
89	O
%	O
and	O
89	O
%	O
of	O
the	O
target	O
sequences	O
and	O
a	O
10	O
-	O
fold	O
coverage	O
of	O
96	O
%	O
and	O
95	O
%	O
of	O
the	O
target	O
sequences	O
.	O

Figure	O
3	O
illustrates	O
that	O
most	O
of	O
the	O
progression	O
at	O
the	O
higher	O
frequencies	O
,	O
in	O
the	O
absence	O
of	O
a	O
pronounced	O
congenital	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
already	O
occurred	O
before	O
the	O
age	O
of	O
10	O
years	O
.	O

Estrogen	O
-	O
replacement	O
therapy	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
either	O
the	O
efficacy	O
or	O
safety	O
profile	O
of	O
lovastatin	B-Chemical
.	O

In	O
aggregate	O
,	O
16	O
%	O
of	O
diagnoses	O
implicated	O
STRC	B-GENE
.	O

Third	O
,	O
we	O
selected	O
de	O
novo	O
variants	O
in	O
the	O
trio	O
by	O
restricting	O
to	O
variants	O
with	O
heterozygous	O
genotype	O
in	O
the	O
patient	O
and	O
homozygous	O
reference	O
in	O
the	O
parents	O
,	O
and	O
unknown	O
in	O
dbSNP	O
v135	O
.	O

K61K	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
F146F	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
T186T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
T186T	I-VARIANT
is	O
heterozygous	O
with	O
a	O
single	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
)	O
.	O

1987	O
)	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
EA	O
RR	O
MA	O
MDL	O
TJ	O
JMM	O
.	O

We	O
found	O
most	O
likely	O
responsible	O
genes	O
for	O
nine	O
out	O
of	O
thirteen	O
AD	O
families	O
.	O

We	O
additionally	O
investigated	O
spiral	O
ganglion	O
morphology	O
and	O
found	O
no	O
obvious	O
indication	O
of	O
spiral	O
ganglion	O
degeneration	O
in	O
Homer2	B-GENE
-	O
/	O
-	O
mice	O
as	O
compared	O
to	O
their	O
WT	O
littermates	O
(	O
S5	O
Fig	O
)	O
.	O

The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
,	O
anticoagulated	O
with	O
unfractionated	O
heparin	B-Chemical
,	O
and	O
given	O
intravenous	O
diltiazem	B-Chemical
for	O
rate	O
control	O
and	O
intravenous	O
amiodarone	B-Chemical
for	O
rate	O
and	O
rhythm	O
control	O
.	O

His	O
older	O
sister	O
(	O
II	O
:	O
1	O
,	O
MYO7A	B-GENE
homozygote	O
)	O
had	O
a	O
milder	O
retinal	O
phenotype	O
.	O

Arrows	O
indicate	O
probands	O
in	O
each	O
family	O
.	O

C	O
and	O
D	O
)	O
Electron	O
microscopy	O
from	O
the	O
same	O
individual	O
showing	O
two	O
different	O
capillary	O
loops	O
.	O

The	O
variants	O
c	B-VARIANT
.	I-VARIANT
721C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg241Gly	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
4411T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ser1471Pro	I-VARIANT
)	O
have	O
already	O
been	O
reported	O
in	O
Italian	O
patients	O
with	O
USH	B-DISEASE
(	O
[	O
15	O
]	O
and	O
[	O
22	O
]	O
respectively	O
)	O
,	O
and	O
the	O
repeated	O
detection	O
in	O
various	O
small	O
series	O
of	O
Italian	O
patients	O
suggests	O
that	O
these	O
variants	O
may	O
be	O
a	O
recurrent	O
variant	O
in	O
Italian	O
patients	O
with	O
USH	B-DISEASE
,	O
even	O
if	O
c	B-VARIANT
.	I-VARIANT
721C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg241Gly	I-VARIANT
)	O
has	O
been	O
reported	O
in	O
other	O
ethnic	O
groups	O
[	O
16	O
]	O
.	O

However	O
,	O
a	O
common	O
frameshift	O
polymorphism	O
questioned	O
essentiality	O
of	O
this	O
gene	O
[	O
36	O
]	O
.	O

showed	O
that	O
TMPRSS3	B-GENE
in	O
mice	O
maintains	O
normal	O
expression	O
of	O
KCNMA1	B-GENE
potassium	O
channels	O
and	O
normal	O
outward	O
K	B-Chemical
+	O
currents	O
in	O
inner	O
hair	O
cells	O
(	O
IHCs	O
)	O
[	O
17	O
]	O
.	O

Two	O
pathogenic	O
or	O
presumably	O
pathogenic	O
mutations	O
in	O
PCDH15	B-GENE
,	O
specifically	O
,	O
a	O
nonsense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
R991X	I-VARIANT
)	O
[	O
27	O
]	O
and	O
a	O
novel	O
missense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
R1273S	I-VARIANT
)	O
,	O
were	O
found	O
in	O
two	O
patients	O
.	O

An	O
additional	O
five	O
individuals	O
(	O
two	O
affected	O
and	O
three	O
unaffected	O
)	O
(	O
blue	O
)	O
were	O
recruited	O
for	O
Sanger	O
validation	O
and	O
further	O
filtering	O
.	O

The	O
mutation	O
spectrum	O
and	O
prevalence	O
of	O
mutations	O
vary	O
significantly	O
among	O
different	O
ethnic	O
groups	O
.	O

In	O
this	O
respect	O
,	O
combining	O
advanced	O
ophthalmological	O
evaluation	O
,	O
including	O
funduscopy	O
with	O
careful	O
examination	O
of	O
the	O
peripheral	O
retina	O
and	O
electroretinogram	O
in	O
selected	O
cases	O
,	O
together	O
with	O
molecular	O
diagnosis	O
by	O
targeted	O
USH	B-DISEASE
exome	O
sequencing	O
[	O
16	O
]	O
or	O
WES	O
(	O
this	O
study	O
)	O
could	O
be	O
a	O
powerful	O
strategy	O
.	O

Moreover	O
,	O
seven	O
novel	O
polymorphisms	O
were	O
also	O
described	O
.	O

In	O
family	O
7	O
(	O
Figure	O
1	O
G	O
)	O
,	O
subjects	O
II	O
:	O
1	O
and	O
II	O
:	O
2	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
did	O
not	O
have	O
candidate	O
mutations	O
in	O
the	O
first	O
61	O
genes	O
.	O

Table	O
with	O
results	O
of	O
an	O
in	O
silico	O
analysis	O
of	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
PEX1	B-GENE
5	O
'	O
region	O
.	O

Thought	O
to	O
be	O
untypical	O
MED	B-DISEASE
for	O
the	O
following	O
reasons	O
;	O
patient	O
ESDN	O
-	O
00809	O
had	O
unusual	O
acetabula	O
and	O
flared	O
iliac	O
wings	O
,	O
there	O
were	O
also	O
not	O
typical	O
metacarpal	O
changes	O
with	O
proximal	O
pointing	O
,	O
normal	O
spine	O
and	O
"	O
mouse	O
-	O
ear	O
"	O
ilia	O
;	O
patient	O
ESDN	O
-	O
00049	O
had	O
high	O
vertebral	O
bodies	O
and	O
rather	O
slender	O
tubular	O
bones	O
,	O
unusually	O
severe	O
involvement	O
of	O
the	O
proximal	O
humerus	O
,	O
absence	O
of	O
epiphyseal	O
abnormalities	O
of	O
the	O
short	O
tubular	O
bones	O
,	O
and	O
relatively	O
normal	O
carpal	O
bones	O
;	O
patient	O
ESDN	O
-	O
00323	O
had	O
an	O
unusual	O
pelvic	O
appearance	O
and	O
over	O
modeled	O
proximal	O
tibia	O
,	O
proximal	O
pointing	O
of	O
the	O
metacarpals	O
,	O
quite	O
generalized	O
changes	O
in	O
the	O
hand	O
and	O
carpal	O
bones	O
,	O
and	O
also	O
significant	O
changes	O
in	O
the	O
spine	O
.	O

Sonomicrometry	O
crystals	O
were	O
implanted	O
around	O
the	O
mitral	O
annulus	O
and	O
left	O
ventricle	O
to	O
measure	O
geometry	O
and	O
regional	O
function	O
.	O

In	O
family	O
PKDF406	B-Chemical
,	O
linkage	O
analysis	O
was	O
undertaken	O
using	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
for	O
many	O
of	O
the	O
reported	O
recessive	B-DISEASE
nonsyndromic	I-DISEASE
deafness	I-DISEASE
loci	O
.	O

The	O
remaining	O
WFS1	B-GENE
variant	O
(	O
c	B-VARIANT
.	I-VARIANT
940T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Trp314Arg	I-VARIANT
)	O
segregated	O
completely	O
with	O
affection	O
status	O
for	O
the	O
13	O
affected	O
and	O
unaffected	O
individuals	O
tested	O
(	O
Fig	O
.	O

Military	O
conscript	O
screening	O
,	O
however	O
,	O
may	O
not	O
be	O
the	O
optimal	O
method	O
to	O
ascertain	O
the	O
incidence	O
of	O
KS	B-DISEASE
because	O
the	O
sense	O
of	O
smell	O
is	O
not	O
typically	O
asked	O
for	O
,	O
and	O
patients	O
with	O
mild	O
reproductive	O
phenotype	O
may	O
escape	O
detection	O
.	O

The	O
number	O
of	O
CCR2	B-GENE
positive	O
cells	O
was	O
determined	O
using	O
stereology	O
probes	O
in	O
the	O
hippocampus	O
.	O

Massively	O
parallel	O
DNA	O
sequencing	O
(	O
MPS	O
)	O
technology	O
is	O
an	O
obvious	O
method	O
of	O
choice	O
to	O
identify	O
somatic	O
mosaicism	O
,	O
and	O
this	O
approach	O
has	O
been	O
already	O
reported	O
by	O
other	O
groups	O
.	O

Among	O
the	O
three	O
known	O
genes	O
responsible	O
for	O
USH2	B-DISEASE
,	O
results	O
from	O
large	O
European	O
cohorts	O
[	O
9	O
-	O
12	O
]	O
have	O
shown	O
that	O
USH2A	B-GENE
is	O
by	O
far	O
the	O
most	O
frequently	O
involved	O
gene	O
and	O
accounts	O
for	O
at	O
least	O
75	O
%	O
of	O
USH2	B-DISEASE
cases	O
.	O

Targeted	O
sequencing	O
of	O
HPE	B-DISEASE
or	O
ectrodactyly	B-DISEASE
genes	O
in	O
selected	O
patients	O
has	O
failed	O
to	O
identify	O
mutations	O
,	O
and	O
no	O
convincing	O
copy	O
number	O
variants	O
were	O
found	O
.	O

They	O
may	O
preserve	O
a	O
residual	O
activity	O
of	O
the	O
protein	O
,	O
thus	O
causing	O
less	O
severe	O
hearing	O
,	O
balance	O
and	O
visual	O
impairments	O
.	O

DNA	O
sequence	O
variations	O
were	O
identified	O
by	O
comparison	O
of	O
subject	O
DNA	O
sequence	O
to	O
GJB2	B-GENE
reference	O
sequences	O
,	O
Genebank	O
Accession	O
Number	O
AY280971	O
.	O

Her	O
cognitive	O
development	O
was	O
normal	O
,	O
but	O
she	O
had	O
severe	O
speech	O
and	O
language	O
delay	O
.	O

A	O
sequencing	O
control	O
in	O
intron	O
18	O
overlapping	O
with	O
both	O
LR	O
products	O
was	O
included	O
for	O
pseudogene	O
exclusion	O
confirmation	O
.	O

All	O
pathogenic	O
variants	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

Seven	O
patients	O
had	O
a	O
skin	B-DISEASE
rash	I-DISEASE
,	O
three	O
eosinophilia	B-DISEASE
and	O
one	O
interstitial	B-DISEASE
nephritis	I-DISEASE
.	O

Five	O
mutations	O
were	O
detected	O
in	O
the	O
MITF	B-GENE
gene	O
:	O
one	O
missense	O
mutation	O
,	O
one	O
non	O
-	O
sense	O
mutation	O
,	O
one	O
large	O
deletion	O
and	O
one	O
large	O
duplication	O
.	O

The	O
nucleotide	O
1	O
is	O
its	O
first	O
nucleotide	O
of	O
the	O
translation	O
initiation	O
codon	O
.	O

A	O
slow	O
bolus	O
of	O
subhypnotic	O
doses	O
of	O
ketamine	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
or	O
0	O
.	O
50	O
mg	O
/	O
kg	O
)	O
was	O
given	O
to	O
10	O
cancer	O
patients	O
whose	O
pain	O
was	O
unrelieved	O
by	O
morphine	B-Chemical
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

Neutropenia	B-DISEASE
was	O
the	O
principal	O
toxic	O
effect	O
,	O
and	O
the	O
overall	O
frequency	O
of	O
grade	O
4	O
neutropenia	B-DISEASE
after	O
the	O
first	O
treatment	O
of	O
CCNU	B-Chemical
/	O
CTX	B-Chemical
was	O
30	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
19	O
-	O
43	O
%	O
)	O
.	O

The	O
most	O
common	O
signs	O
of	O
cardiotoxicity	B-DISEASE
were	O
chest	B-DISEASE
pain	I-DISEASE
,	O
ST	B-DISEASE
-	I-DISEASE
T	I-DISEASE
wave	I-DISEASE
changes	O
and	O
atrial	B-DISEASE
fibrillation	I-DISEASE
.	O

Both	O
plasma	O
pethidine	B-Chemical
and	O
norpethidine	B-Chemical
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	I-DISEASE
excitation	I-DISEASE
.	O

Dr	O
.	O

This	O
gene	O
encodes	O
a	O
197	O
amino	O
acid	O
transmembrane	O
sialomucin	O
(	O
known	O
as	O
endolyn	B-GENE
,	O
MUC	B-GENE
-	I-GENE
24	I-GENE
or	O
CD164	B-GENE
)	O
,	O
which	O
is	O
widely	O
expressed	O
and	O
involved	O
in	O
cell	O
adhesion	O
and	O
migration	O
.	O

4	O
and	O
5	O
:	O
Haplotypes	O
associated	O
with	O
novel	O
mutations	O
c	B-VARIANT
.	I-VARIANT
748_759	I-VARIANT
+	I-VARIANT
5del	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R155X	I-VARIANT
,	O
respectively	O
.	O

Coronal	O
(	O
A	O
)	O
and	O
axial	O
(	O
B	O
and	O
C	O
)	O
CT	O
images	O
of	O
the	O
right	O
femoral	O
head	O
show	O
a	O
concave	O
articular	O
surface	O
and	O
a	O
free	O
body	O
in	O
the	O
hip	O
joint	O
of	O
the	O
left	O
femoral	O
head	O
.	O

They	O
received	O
cochlear	O
implants	O
at	O
the	O
ages	O
of	O
3	O
years	O
and	O
9	O
months	O
,	O
respectively	O
.	O

Concomitant	O
curcumin	B-Chemical
administration	O
prevented	O
the	O
cognitive	B-DISEASE
impairment	I-DISEASE
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	O
drugs	O
.	O

For	O
mtDNA	O
variants	O
,	O
we	O
achieved	O
high	O
sensitivity	O
and	O
specificity	O
in	O
genomic	O
DNA	O
of	O
HapMap	O
controls	O
(	O
96	O
%	O
and	O
100	O
%	O
,	O
respectively	O
)	O
but	O
much	O
lower	O
sensitivity	O
for	O
patient	O
controls	O
(	O
32	O
%	O
)	O
due	O
to	O
the	O
non	O
-	O
uniform	O
distribution	O
of	O
mtDNA	O
within	O
each	O
pool	O
.	O

A	O
minor	O
proportion	O
of	O
mutations	O
were	O
identified	O
at	O
genetic	O
departments	O
at	O
Skejby	O
University	O
Hospital	O
,	O
Rigshospitalet	O
as	O
well	O
as	O
in	O
Norway	O
and	O
the	O
Netherlands	O
using	O
other	O
,	O
but	O
similar	O
,	O
technologies	O
.	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low	O
-	O
frequency	O
rTMS	O
on	O
dyskinesias	O
in	O
PD	B-DISEASE
.	O

To	O
determine	O
the	O
cause	O
of	O
exon	O
10	O
skipping	O
,	O
we	O
performed	O
Sanger	O
sequencing	O
of	O
exon	O
10	O
and	O
the	O
flanking	O
intronic	O
regions	O
(	O
an	O
area	O
of	O
previous	O
poor	O
high	O
throughput	O
sequence	O
coverage	O
)	O
.	O

To	O
determine	O
the	O
effect	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
9948G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
on	O
splicing	O
,	O
a	O
minigene	O
approach	O
was	O
used	O
.	O

The	O
cardiomyopathy	B-DISEASE
(	O
CM	B-DISEASE
)	O
produced	O
by	O
the	O
anticancer	O
drug	O
doxorubicin	B-Chemical
(	O
DXR	B-Chemical
)	O
(	O
Adriamycin	B-Chemical
)	O
provides	O
a	O
unique	O
opportunity	O
to	O
analyze	O
dose	O
-	O
effect	O
and	O
structure	O
-	O
function	O
relationships	O
during	O
development	O
of	O
myocardial	O
disease	I-DISEASE
.	O

The	O
report	O
cited	O
above	O
of	O
de	O
novo	O
c	B-VARIANT
.	I-VARIANT
937C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
His313Tyr	I-VARIANT
mutations	O
in	O
two	O
individuals	O
with	O
WS	B-DISEASE
seems	O
to	O
indicate	O
that	O
WS	B-DISEASE
can	O
rarely	O
be	O
caused	O
by	O
heterozygous	O
mutations	O
.	O

The	O
progression	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
caused	O
by	O
a	O
mutation	O
in	O
any	O
of	O
these	O
three	O
loci	O
exhibits	O
different	O
characteristics	O
.	O

The	O
disease	O
occurred	O
subsequent	O
to	O
the	O
initiation	O
of	O
heparin	B-Chemical
therapy	O
for	O
suspected	O
pelvic	B-DISEASE
thrombophlebitis	I-DISEASE
and	O
cleared	O
rapidly	O
subsequent	O
to	O
its	O
discontinuation	O
.	O

Regarding	O
the	O
molecular	O
genetic	O
diagnosis	O
of	O
GJB2	B-GENE
negative	O
cases	O
without	O
any	O
characteristic	O
phenotypic	O
marker	O
,	O
TRS	B-Chemical
-	O
204	O
can	O
provide	O
a	O
convincing	O
answer	O
in	O
one	O
fourth	O
of	O
such	O
cases	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
the	O
documentation	O
of	O
this	O
clinical	O
case	O
is	O
to	O
make	O
clinicians	O
aware	O
of	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
"	O
and	O
the	O
medical	O
risks	O
associated	O
with	O
this	O
serious	O
condition	O
.	O

Response	O
was	O
not	O
influenced	O
by	O
the	O
initial	O
neutrophil	O
count	O
,	O
with	O
a	O
62	O
%	O
cure	O
rate	O
for	O
39	O
episodes	O
associated	O
with	O
severe	O
neutropenia	O
.	O

25	O
,	O
36	O
Previous	O
studies	O
have	O
identified	O
mutations	O
in	O
TECTA	B-GENE
can	O
lead	O
to	O
DFNA12	B-DISEASE
or	O
DFNB21	B-DISEASE
.	O

*	O
*	O
This	O
mutation	O
was	O
found	O
in	O
a	O
female	O
patient	O
.	O

The	O
conserved	O
motifs	O
within	O
EC	O
domains	O
might	O
facilitate	O
the	O
interpretation	O
for	O
a	O
subset	O
of	O
the	O
missense	O
mutations	O
.	O

Stable	O
transfected	O
cells	O
HEK	O
cells	O
were	O
generated	O
in	O
T75	O
flasks	O
using	O
a	O
total	O
of	O
11	O
.	O
25	O
mu	O
g	O
DNA	O
(	O
pcDNA3	O
.	O
1	O
-	O
CD164	B-GENE
-	O
WT	O
-	O
Zeo	O
,	O
pcDNA3	O
.	O
1	O
-	O
CD164	B-GENE
-	O
WT	O
-	O
Hyg	O
or	O
pcDNA3	O
.	O
1	O
-	O
CD164	B-GENE
-	O
R192	B-VARIANT
*	I-VARIANT
-	O
Neo	O
)	O
and	O
33	O
.	O
75	O
mu	O
l	O
X	O
-	O
tremeGENE	O
9	O
transfection	O
reagent	O
and	O
selection	O
of	O
transfected	O
cells	O
were	O
done	O
using	O
medium	O
containing	O
antibiotics	O
(	O
Zeocine	B-Chemical
100	O
mu	O
g	O
/	O
ml	O
(	O
Invitrogen	B-Chemical
)	O
,	O
Hygromycin	B-Chemical
100	O
mu	O
g	O
/	O
ml	O
(	O
Invitrogen	B-Chemical
)	O
,	O
or	O
Neomycine	B-Chemical
(	O
G418	B-Chemical
)	O
1	O
.	O
5	O
mg	O
/	O
ml	O
(	O
VWR	O
,	O
Herlev	O
,	O
Denmark	O
)	O
)	O
.	O

In	O
the	O
intact	O
male	O
and	O
female	O
rat	O
,	O
no	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	B-Chemical
and	O
hepatic	O
accumulation	O
of	O
triglyceride	B-Chemical
.	O

One	O
patient	O
,	O
a	O
27	O
-	O
year	O
-	O
old	O
woman	O
,	O
had	O
c	B-VARIANT
.	I-VARIANT
2728A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
in	O
exon	O
22	O
(	O
p	B-VARIANT
.	I-VARIANT
K910Q	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
4270G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
in	O
exon	O
31	O
(	O
p	B-VARIANT
.	I-VARIANT
D1424N	I-VARIANT
)	O
,	O
probably	O
present	O
in	O
different	O
chromosomes	O
(	O
Capria	O
et	O
al	O
.	O

RESULTS	O
:	O
Hypothyroidism	B-DISEASE
developed	O
in	O
40	O
patients	O
,	O
excluding	O
8	O
patients	O
who	O
were	O
hypothyroid	B-DISEASE
at	O
baseline	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
leukocytes	O
,	O
using	O
the	O
QiaSymphony	O
DNA	O
Blood	O
Midi	O
kit	O
on	O
the	O
QIAsymphony	O
SP	O
workstation	O
(	O
Qiagen	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

This	O
result	O
suggests	O
that	O
the	O
p	B-VARIANT
.	I-VARIANT
D187H	I-VARIANT
variant	O
could	O
collapse	O
the	O
polymerization	O
-	O
depolymerization	O
balance	O
of	O
microtubules	O
,	O
which	O
leads	O
to	O
the	O
destruction	B-DISEASE
of	I-DISEASE
cellular	I-DISEASE
homeostasis	I-DISEASE
in	I-DISEASE
normal	I-DISEASE
hair	I-DISEASE
cells	I-DISEASE
[	O
24	O
]	O
.	O

A	O
combination	O
of	O
haplotype	O
analysis	O
and	O
genome	O
-	O
wide	O
homozygosity	O
mapping	O
indicated	O
linkage	O
to	O
the	O
USH1B	B-GENE
locus	O
in	O
two	O
families	O
,	O
USH1C	B-GENE
in	O
one	O
family	O
and	O
USH1G	B-GENE
in	O
another	O
family	O
.	O

Advances	O
in	O
molecular	O
genetics	O
,	O
including	O
the	O
discovery	O
of	O
the	O
COL4A	O
family	O
of	O
genes	O
,	O
have	O
led	O
to	O
the	O
use	O
of	O
genetic	O
testing	O
in	O
confirming	O
a	O
diagnosis	O
of	O
AS	B-DISEASE
.	O

Click	O
here	O
for	O
file	O
Clinical	O
findings	O
from	O
families	O
with	O
c	B-VARIANT
.	I-VARIANT
983A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
2708_2711delTTAG	I-VARIANT
mutations	O
.	O

A	O
series	O
of	O
six	O
cases	O
.	O

B	O
,	O
C	O
,	O
E	O
and	O
G	O
are	O
12	O
mm	O
adjacent	O
sections	O
.	O

Screening	O
of	O
the	O
TJP2	B-GENE
gene	O
with	O
regard	O
to	O
c	B-VARIANT
.	I-VARIANT
3562A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
in	O
other	O
members	O
(	O
I	O
-	O
1	O
,	O
I	O
-	O
2	O
,	O
II	O
-	O
4	O
)	O
of	O
the	O
family	O
revealed	O
its	O
presence	O
only	O
in	O
the	O
affected	O
individual	O
(	O
I	O
-	O
2	O
)	O
and	O
its	O
absence	O
in	O
unaffected	O
individuals	O
(	O
I	O
-	O
1	O
and	O
II	O
-	O
4	O
)	O
of	O
the	O
family	O
.	O

conceived	O
and	O
analysed	O
experiments	O
(	O
Figs	O
5c	O
,	O
7a	O
-	O
f	O
)	O
and	O
A	O
.	O

This	O
impairment	O
was	O
not	O
related	O
to	O
the	O
increase	O
in	O
hearing	O
thresholds	O
,	O
as	O
performance	O
on	O
speech	O
audiometry	O
was	O
remarkably	O
poorer	O
compared	O
to	O
control	O
subjects	O
showing	O
cochlear	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
a	O
comparable	O
amount	O
of	O
hearing	O
threshold	O
elevation	O
.	O

These	O
results	O
suggest	O
that	O
betaxolol	B-Chemical
could	O
be	O
less	O
of	O
a	O
depression	O
-	O
inducer	O
than	O
timolol	B-Chemical
in	O
predisposed	O
patients	O
.	O

The	O
precise	O
frequency	O
will	O
be	O
determined	O
by	O
future	O
mutation	O
analysis	O
of	O
a	O
large	O
patient	O
cohort	O
,	O
but	O
is	O
estimated	O
to	O
be	O
high	O
.	O

Thus	O
,	O
CAA	B-Chemical
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	B-Chemical
,	O
mediating	O
its	O
toxicity	O
on	O
hRPTEC	O
.	O

Butyrylcholinesterase	O
deficiency	O
is	O
characterized	O
by	O
prolonged	B-DISEASE
apnea	B-DISEASE
after	O
the	O
use	O
of	O
muscle	O
relaxants	O
(	O
suxamethonium	B-Chemical
or	O
mivacurium	B-Chemical
)	O
in	O
patients	O
who	O
have	O
mutations	O
in	O
the	O
BCHE	B-GENE
gene	O
.	O

We	O
believe	O
the	O
final	O
decision	O
to	O
continue	O
the	O
pregnancy	O
was	O
supported	O
by	O
her	O
good	O
self	O
image	O
despite	O
the	O
physical	O
diversity	O
.	O

Whether	O
this	O
individual	O
develops	O
RP	B-DISEASE
depends	O
on	O
the	O
nature	O
of	O
his	O
deafness	B-DISEASE
(	O
genetic	O
versus	O
environmentally	O
-	O
caused	O
)	O
,	O
and	O
of	O
the	O
additional	O
mutation	O
(	O
s	O
)	O
he	O
carries	O
(	O
if	O
at	O
all	O
)	O
,	O
and	O
cannot	O
be	O
predicted	O
at	O
this	O
stage	O
.	O

PTA	O
was	O
calculated	O
as	O
an	O
average	O
of	O
the	O
threshold	O
measured	O
at	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
2	O
.	O
0	O
and	O
4	O
.	O
0	O
KHz	O
[	O
6	O
]	O
,	O
and	O
air	O
-	O
conduction	O
threshold	O
measurements	O
were	O
performed	O
at	O
125	O
-	O
8000	O
Hz	O
.	O

A	O
five	O
ml	O
venous	O
blood	O
sample	O
was	O
drawn	O
into	O
an	O
ethylenediamine	B-Chemical
tetraacetic	I-Chemical
acid	I-Chemical
(	O
EDTA	B-Chemical
)	O
sample	O
tube	O
.	O

The	O
ratio	O
of	O
mutations	O
in	O
known	O
versus	O
unknown	O
genes	O
in	O
the	O
present	O
study	O
(	O
4	O
:	O
6	O
)	O
,	O
however	O
,	O
suggests	O
that	O
in	O
this	O
cohort	O
of	O
156	O
families	O
,	O
a	O
large	O
number	O
of	O
novel	O
genes	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
still	O
await	O
discovery	O
.	O

Sequence	O
variants	O
of	O
interest	O
identified	O
by	O
high	O
-	O
throughput	O
sequencing	O
were	O
verified	O
by	O
Sanger	O
sequencing	O
following	O
PCR	O
amplification	O
of	O
the	O
respective	O
coding	O
exons	O
and	O
adjacent	O
intronic	O
sequences	O
by	O
standard	O
protocols	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
congenital	O
and	O
stable	O
.	O

Gastrointestinal	O
tolerability	O
of	O
etoricoxib	B-Chemical
in	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
patients	O
:	O
results	O
of	O
the	O
etoricoxib	B-Chemical
vs	O
diclofenac	B-Chemical
sodium	I-Chemical
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE	O
-	O
II	O
)	O
.	O

R	O
o	O
nnefarth	O
(	O
Jena	O
)	O
,	O
P	O
.	O

Here	O
,	O
p	B-VARIANT
.	I-VARIANT
Ser6ProfsX2	I-VARIANT
denotes	O
a	O
frameshift	O
change	O
with	O
Serine	O
6	O
as	O
the	O
first	O
affected	O
amino	O
acid	O
,	O
changing	O
into	O
a	O
Proline	O
and	O
the	O
new	O
reading	O
frame	O
ending	O
with	O
stop	O
codon	O
X	O
at	O
position	O
2	O
in	O
the	O
shifted	O
reading	O
frame	O
.	O
[	O
15	O
]	O
A	O
substitution	O
of	O
either	O
the	O
first	O
or	O
the	O
last	O
two	O
nucleotides	O
of	O
a	O
particular	O
exon	O
has	O
the	O
capacity	O
to	O
alter	O
proper	O
mRNA	O
splicing	O
,	O
regardless	O
of	O
whether	O
the	O
nucleotide	O
substitution	O
codes	O
for	O
a	O
different	O
amino	O
acid	O
(	O
missense	O
mutation	O
)	O
,	O
produces	O
a	O
stop	O
codon	O
(	O
nonsense	O
mutation	O
)	O
or	O
does	O
not	O
alter	O
the	O
open	O
reading	O
frame	O
at	O
all	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
synonymous	O
or	O
silent	O
single	O
nucleotide	O
substitution	O
)	O
.	O

1	O
B	O
)	O
.	O

[	O
27	O
]	O
showed	O
that	O
the	O
p	B-VARIANT
.	I-VARIANT
A397D	I-VARIANT
missense	O
mutation	O
associated	O
with	O
USH	B-DISEASE
abolished	O
the	O
actin	O
-	O
activated	O
ATPase	O
activity	O
completely	O
.	O

The	O
specificity	O
of	O
Sanger	O
sequencing	O
is	O
known	O
to	O
be	O
extremely	O
high	O
,	O
but	O
the	O
cost	O
of	O
analyzing	O
CDH23	B-GENE
by	O
Sanger	O
sequencing	O
is	O
also	O
extremely	O
high	O
.	O

The	O
English	O
in	O
this	O
document	O
has	O
been	O
checked	O
by	O
at	O
least	O
two	O
professional	O
editors	O
,	O
both	O
native	O
speakers	O
of	O
English	O
.	O

DISCUSSION	B-DISEASE
:	O
Drug	O
-	O
induced	O
symptoms	O
of	O
pheochromocytoma	B-DISEASE
are	O
often	O
associated	O
with	O
the	O
use	O
of	O
substituted	O
benzamide	B-Chemical
drugs	O
,	O
but	O
the	O
underlying	O
mechanism	O
is	O
unknown	O
.	O

We	O
studied	O
25	O
children	O
(	O
19	O
boys	O
and	O
6	O
girls	O
)	O
from	O
20	O
unrelated	O
families	O
of	O
Tunisian	O
origin	O
,	O
who	O
had	O
been	O
clinically	O
diagnosed	O
of	O
primary	O
dRTA	B-DISEASE
[	O
19	O
]	O
.	O

Funding	O
:	O
This	O
work	O
was	O
supported	O
by	O
the	O
Big	O
Lottery	O
(	O
through	O
Sense	O
UK	O
)	O
,	O
Deafness	B-DISEASE
Research	O
UK	O
,	O
the	O
RP	B-DISEASE
Fighting	O
Blindness	B-DISEASE
charity	O
(	O
Retinitis	O
Pigmentosa	O
Society	O
of	O
the	O
UK	O
)	O
,	O
Moorfields	O
Special	O
Trustees	O
,	O
Foundation	O
Fighting	O
Blindness	B-DISEASE
,	O
Jeans	O
for	O
Genes	O
,	O
NIHR	O
Biomedical	O
Research	O
Centre	O
(	O
BMRC	O
)	O
,	O
Comprehensive	O
Biomedical	O
Research	O
Centre	O
(	O
CBRC	O
)	O
and	O
the	O
Wellcome	O
Trust	O
.	O

Prolonged	O
apnea	I-DISEASE
in	O
our	O
case	O
ensued	O
because	O
the	O
information	O
about	O
suicidal	O
attempt	O
by	O
OP	B-Chemical
compound	I-Chemical
was	O
concealed	O
from	O
the	O
treating	O
team	O
.	O

i	B-Chemical
-	I-Chemical
phosphate	I-Chemical
:	O
inorganic	O
phosphate	O
;	O
SD	O
:	O
standard	O
deviation	O
;	O
F	O
:	O
female	O
;	O
M	O
:	O
male	O
;	O
and	O
N	O
.	O
E	O
.	O
:	O
not	O
examined	O
.	O

Fourteen	O
disease	O
-	O
causing	O
mutations	O
were	O
identified	O
,	O
eight	O
(	O
including	O
the	O
founder	O
mutation	O
)	O
in	O
KCNQ1	B-GENE
,	O
five	O
in	O
KCNH2	B-GENE
and	O
one	O
in	O
KCNE1	B-GENE
.	O

[	O
31	O
]	O
described	O
p	B-VARIANT
.	I-VARIANT
R776C	I-VARIANT
as	O
an	O
exception	O
,	O
with	O
an	O
arginine	B-Chemical
located	O
on	O
the	O
extreme	O
C	O
-	O
terminus	O
of	O
SLC26A4	B-GENE
(	O
a	O
780	O
amino	O
acid	O
protein	O
)	O
.	O

However	O
,	O
Wang	O
et	O
al	O
.	O

Brown	O
:	O
transmembrane	O
domain	O
.	O

(	O
A	O
)	O
wild	O
type	O
trimer	O
(	O
B	O
)	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
mutant	O
trimer	O
.	O

We	O
report	O
a	O
case	O
of	O
ranitidine	B-Chemical
-	O
induced	O
acute	O
interstitial	I-DISEASE
nephritis	I-DISEASE
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	O
allograft	O
presenting	O
with	O
acute	O
allograft	O
dysfunction	O
within	O
48	O
hours	O
of	O
exposure	O
to	O
the	O
drug	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Glu1595Lys	I-VARIANT
mutation	O
reduces	O
the	O
numbers	O
of	O
oxygen	B-Chemical
atoms	O
binding	O
calcium	B-Chemical
.	O

Structural	O
analysis	O
of	O
USH2A	B-GENE
performed	O
with	O
the	O
HOPE	O
server	O
[	O
28	O
]	O
suggests	O
that	O
the	O
original	O
wild	O
-	O
type	O
residues	O
and	O
the	O
newly	O
introduced	O
mutant	O
residues	O
differ	O
in	O
size	O
,	O
charge	O
,	O
and	O
hydrophobicity	O
values	O
.	O

One	O
patient	O
was	O
heterozygous	O
for	O
497A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
which	O
results	O
in	O
replacement	O
of	O
asparagine	B-Chemical
with	O
serine	O
at	O
position	O
166	O
of	O
Cx31	O
.	O

These	O
results	O
provide	O
empirical	O
support	O
for	O
conducting	O
a	O
further	O
study	O
of	O
bupropion	B-Chemical
.	O

The	O
molecular	O
analysis	O
of	O
the	O
USH2A	B-GENE
gene	O
in	O
88	O
unrelated	O
USH	B-DISEASE
Spanish	O
patients	O
revealed	O
37	O
different	O
pathogenic	O
mutations	O
.	O

Her	O
brother	O
is	O
an	O
11	O
-	O
year	O
-	O
old	O
boy	O
who	O
developed	O
a	O
progressive	O
visual	B-DISEASE
loss	I-DISEASE
at	O
the	O
age	O
of	O
10	O
years	O
with	O
a	O
current	O
visual	O
acuity	O
of	O
4	O
/	O
10	O
bilaterally	O
.	O

To	O
date	O
,	O
only	O
three	O
ILDR1	B-GENE
variants	O
,	O
including	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
,	O
have	O
been	O
reported	O
to	O
reside	O
in	O
this	O
domain	O
.	O

This	O
was	O
done	O
by	O
using	O
the	O
query	O
sequence	O
and	O
searching	O
against	O
the	O
database	O
of	O
sequences	O
from	O
the	O
Protein	O
Data	O
Bank	O
(	O
PDB	O
)	O
[	O
19	O
]	O
using	O
BLAST	O
.	O

The	O
participants	O
underwent	O
a	O
complete	O
physical	O
examination	O
,	O
including	O
mirror	B-DISEASE
movement	I-DISEASE
assessment	O
,	O
and	O
measurement	O
of	O
testicular	O
volume	O
with	O
a	O
ruler	O
(	O
length	O
x	O
width	O
2	O
x	O
0	O
.	O
52	O
)	O
.	O

The	O
ischiadic	O
bones	O
are	O
broad	O
.	O

(	O
A	O
)	O
Audiograms	O
of	O
the	O
proband	O
(	O
IV	O
:	O
11	O
)	O
.	O

also	O
receives	O
funding	O
from	O
the	O
Parkinson	O
'	O
s	O
Disease	O
Society	O
(	O
UK	O
)	O
,	O
the	O
Medical	O
Research	O
Council	O
Translational	O
Muscle	O
Centre	O
,	O
and	O
the	O
UK	O
NIHR	O
Biomedical	O
Research	O
Centre	O
in	O
Ageing	O
and	O
Age	O
related	O
disease	O
.	O

We	O
can	O
infer	O
that	O
the	O
de	O
novo	O
sequence	O
changes	O
of	O
the	O
TNC	B-GENE
and	O
IGFALS	B-GENE
genes	O
,	O
featuring	O
as	O
missense	O
mutations	O
observed	O
in	O
our	O
study	O
could	O
potentially	O
explain	O
any	O
additional	O
phenotypes	O
in	O
patients	O
with	O
RSTS	B-DISEASE
,	O
but	O
experimental	O
validation	O
is	O
required	O
to	O
establish	O
disease	O
causation	O
.	O

We	O
identified	O
four	O
different	O
mutations	O
as	O
follows	O
:	O
a	O
previously	O
undescribed	O
heterozygous	O
splice	O
-	O
site	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
784	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
in	O
intron	O
7	O
,	O
a	O
previously	O
reported	O
heterozygous	O
in	O
-	O
frame	O
deletion	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
876_878delTGT	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Val294del	I-VARIANT
)	O
,	O
in	O
exon	O
9	O
leading	O
to	O
a	O
one	O
amino	O
acid	O
deletion	O
,	O
a	O
previously	O
reported	O
frameshift	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
2366delA	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Asn789Metfs	I-VARIANT
*	I-VARIANT
11	I-VARIANT
)	O
,	O
in	O
exon	O
24	O
and	O
a	O
previously	O
reported	O
splice	O
-	O
site	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1140	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
in	O
intron	O
11	O
of	O
the	O
OPA1	B-GENE
gene	O
.	O

Genetic	O
testing	O
is	O
usually	O
restricted	O
to	O
a	O
small	O
subset	O
of	O
genes	O
according	O
to	O
the	O
patient	O
'	O
s	O
phenotype	O
[	O
4	O
]	O
.	O

In	O
the	O
probands	O
,	O
the	O
diagnosis	O
of	O
MYH9	B-GENE
-	O
RD	O
was	O
suspected	O
because	O
of	O
the	O
finding	O
of	O
giant	B-DISEASE
platelets	I-DISEASE
and	O
typical	O
D	O
o	O
hle	O
-	O
like	O
basophilic	O
inclusions	O
in	O
neutrophils	O
,	O
which	O
was	O
associated	O
with	O
the	O
extra	B-DISEASE
-	I-DISEASE
hematological	I-DISEASE
manifestations	I-DISEASE
of	O
the	O
disease	O
in	O
some	O
cases	O
(	O
Table	O
1	O
)	O
.	O

Risk	O
of	O
nephropathy	B-DISEASE
after	O
consumption	O
of	O
nonionic	O
contrast	B-Chemical
media	I-Chemical
by	O
children	O
undergoing	O
cardiac	O
angiography	O
:	O
a	O
prospective	O
study	O
.	O

O	O
ur	O
cohort	O
had	O
5	O
USH	B-DISEASE
II	I-DISEASE
cases	O
as	O
isolated	O
patients	O
or	O
small	O
pedigrees	O
,	O
which	O
when	O
directly	O
tested	O
for	O
described	O
mutations	O
in	O
USH2A	B-GENE
(	O
Asper	O
Biotech	O
)	O
,	O
only	O
4	O
out	O
of	O
10	O
mutated	O
alleles	O
were	O
identified	O
,	O
all	O
in	O
heterozygosis	O
.	O

RESULTS	O
:	O
Five	O
hundred	O
and	O
eighty	O
-	O
three	O
cases	O
and	O
1190	O
controls	O
were	O
included	O
in	O
the	O
analysis	O
.	O

We	O
describe	O
3	O
episodes	O
of	O
microangiopathic	B-DISEASE
hemolytic	I-DISEASE
anemia	I-DISEASE
(	O
MAHA	B-DISEASE
)	O
in	O
2	O
solid	O
organ	O
recipients	O
under	O
FK506	B-Chemical
(	O
tacrolimus	B-Chemical
)	O
therapy	O
.	O

K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
,	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
I	B-GENE
Ks	I-GENE
current	O
,	O
has	O
repeatedly	O
been	O
associated	O
with	O
AF	B-DISEASE
[	O
6	O
]	O
.	O

In	O
total	O
,	O
42	O
unrelated	O
European	O
patients	O
and	O
two	O
affected	O
sisters	O
(	O
12	O
-	O
0880	O
and	O
12	O
-	O
0878	O
in	O
Table	O
1	O
)	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
were	O
included	O
in	O
this	O
study	O
.	O

SLC26A4	B-GENE
encodes	O
an	O
anion	O
(	O
chloride	O
/	O
iodide	B-Chemical
)	O
transporter	O
transmembrane	O
protein	O
,	O
pendrin	O
,	O
which	O
is	O
expressed	O
in	O
the	O
thyroid	O
,	O
kidney	O
,	O
and	O
cochlea	O
[	O
20	O
,	O
21	O
]	O
.	O

Four	O
genes	O
-	O
SRSF2	B-GENE
,	O
U2AF1	B-GENE
,	O
MAP2K4	B-GENE
,	O
and	O
GNAQ	B-GENE
-	O
have	O
no	O
nonsynonymous	O
variants	O
in	O
our	O
cohort	O
,	O
36	O
genes	O
have	O
variants	O
in	O
fewer	O
than	O
10	O
individuals	O
,	O
and	O
35	O
have	O
variants	O
in	O
over	O
half	O
of	O
the	O
individuals	O
(	O
Figure	O
4A	O
)	O
.	O

However	O
,	O
this	O
responsiveness	O
is	O
lost	O
in	O
aging	O
rats	O
with	O
chronically	O
high	O
serum	O
PRL	B-DISEASE
levels	O
.	O

However	O
,	O
it	O
is	O
of	O
utmost	O
importance	O
to	O
raise	O
awareness	O
about	O
the	O
possibility	O
that	O
congenital	B-DISEASE
deafness	I-DISEASE
reveals	O
USH	B-DISEASE
,	O
because	O
early	O
diagnosis	O
of	O
this	O
dual	O
sensory	B-DISEASE
disorder	I-DISEASE
is	O
crucial	O
and	O
urges	O
on	O
cochlear	O
implant	O
in	O
the	O
affected	O
children	O
.	O

The	O
dissected	O
cochlear	O
sensory	O
epithelial	O
layer	O
was	O
fixed	O
in	O
4	B-Chemical
%	O
paraformaldehyde	B-Chemical
,	O
washed	O
several	O
times	O
,	O
and	O
incubated	O
in	O
a	O
blocking	O
solution	O
(	O
10	O
%	O
goat	O
serum	O
/	O
PBS	O
/	O
0	O
.	O
25	I-Chemical
%	O
Triton	I-Chemical
X	I-Chemical
-	I-Chemical
100	O
)	O
for	O
1	O
h	O
.	O

Pure	O
-	O
tone	O
audiometry	O
was	O
performed	O
in	O
a	O
sound	O
-	O
controlled	O
room	O
at	O
frequencies	O
ranging	O
from	O
250	O
to	O
8000	O
Hz	O
,	O
according	O
to	O
standard	O
protocols	O
.	O

Interestingly	O
,	O
while	O
we	O
found	O
disease	O
causing	O
ABCA4	B-GENE
mutations	O
in	O
61	O
%	O
(	O
19	O
/	O
31	O
)	O
and	O
59	O
%	O
(	O
23	O
/	O
39	O
)	O
of	O
our	O
Chinese	O
and	O
Canadian	O
cohorts	O
,	O
respectively	O
,	O
only	O
33	O
%	O
(	O
6	O
/	O
18	O
)	O
of	O
our	O
French	O
Canadian	O
cohort	O
was	O
resolved	O
by	O
leveraging	O
ABCA4	B-GENE
mutations	O
.	O

These	O
results	O
suggest	O
that	O
endothelial	O
cells	O
treated	O
simultaneously	O
with	O
EPO	O
and	O
IL	O
-	O
3	O
have	O
a	O
negative	O
effect	O
on	O
erythroid	O
cell	O
production	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
62	O
-	O
year	O
-	O
old	O
man	O
who	O
was	O
administered	O
sodium	B-Chemical
valproate	I-Chemical
(	O
VPA	B-Chemical
)	O
and	O
who	O
subsequently	O
developed	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	I-DISEASE
of	O
antidiuretic	B-DISEASE
hormone	I-DISEASE
(	O
SIADH	B-DISEASE
)	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
an	O
extremely	O
common	O
problem	O
worldwide	O
,	O
and	O
it	O
is	O
one	O
of	O
the	O
most	O
genetically	O
heterogeneous	O
disorders	O
occurring	O
in	O
humans	O
.	O

In	O
addition	O
,	O
a	O
review	O
of	O
the	O
more	O
recent	O
literature	O
was	O
performed	O
to	O
include	O
skeletal	B-DISEASE
disorder	I-DISEASE
-	O
associated	O
genes	O
identified	O
since	O
the	O
publication	O
of	O
the	O
2010	O
nosology	O
[	O
11	O
,	O
31	O
-	O
70	O
]	O
.	O

It	O
also	O
shows	O
a	O
high	O
frequency	O
of	O
associated	O
malformations	O
(	O
39	O
%	O
)	O
with	O
HH	B-DISEASE
including	O
the	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
in	O
4	O
boys	O
.	O

The	O
risk	O
and	O
associated	O
factors	O
of	O
methamphetamine	B-Chemical
psychosis	I-DISEASE
in	O
methamphetamine	B-Chemical
-	O
dependent	O
patients	O
in	O
Malaysia	O
.	O

Wild	O
-	O
type	O
EDNRB	B-GENE
variant	O
1	O
cDNA	O
(	O
RefSeq	O
:	O
NM_000115	B-Chemical
.	O
1	O
)	O
cloned	O
in	O
a	O
pCMV6	O
expression	O
vector	O
(	O
pCMV6	O
-	O
EDNRB	B-GENE
-	O
v1	O
-	O
GFP	O
)	O
with	O
a	O
variant	O
of	O
green	O
fluorescent	O
protein	O
tag	O
at	O
the	O
C	O
-	O
terminal	O
end	O
(	O
Turbo	O
-	O
GFP	O
;	O
Origene	B-Chemical
)	O
and	O
an	O
empty	O
pCMV6	O
-	O
GFP	O
expression	O
vector	O
were	O
obtained	O
from	O
Origene	B-Chemical
Technologies	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

The	O
arrow	O
shows	O
the	O
proband	O
IV	O
12	O
.	O

Homozygosity	O
mapping	O
analysis	O
in	O
the	O
remaining	O
3	O
sibships	O
generated	O
multiple	O
regions	O
of	O
homozygosity	O
that	O
was	O
shared	O
only	O
among	O
affected	O
individuals	O
.	O

The	O
symbols	O
for	O
affected	O
family	O
member	O
are	O
filled	O
.	O

Most	O
affected	O
individuals	O
carry	O
recessive	O
mutations	O
in	O
the	O
Wolfram	B-GENE
syndrome	I-GENE
1	I-GENE
gene	I-GENE
(	O
WFS1	B-GENE
)	O
.	O

Our	O
findings	O
indicate	O
that	O
beta2	O
-	O
adrenoceptor	O
overstimulation	O
during	O
an	O
early	O
critical	O
period	O
results	O
in	O
microglial	O
activation	O
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	O
and	O
behavioral	O
abnormalities	O
,	O
similar	O
to	O
those	O
described	O
in	O
autism	B-DISEASE
.	O

Thomas	B-Chemical
Friedman	O
from	O
NIH	O
)	O
.	O

Depressed	O
hepatic	O
secretion	O
of	O
triglyceride	B-Chemical
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
hepatic	O
triglyceride	B-Chemical
,	O
indicating	O
that	O
additional	O
mechanisms	O
must	O
be	O
involved	O
in	O
the	O
production	O
of	O
the	O
triglyceride	B-Chemical
-	O
rich	O
fatty	O
liver	O
in	O
response	O
to	O
tetracycline	B-Chemical
.	O

A	O
low	O
dose	O
and	O
prompt	O
discontinuation	O
of	O
the	O
drug	O
is	O
recommended	O
particularly	O
in	O
individuals	O
with	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
glaucoma	B-DISEASE
or	O
who	O
are	O
heavy	O
smokers	O
.	O

When	O
the	O
carbamazepine	B-Chemical
was	O
discontinued	O
,	O
two	O
of	O
the	O
children	O
returned	O
to	O
their	O
former	O
state	O
very	O
quickly	O
,	O
two	O
had	O
the	O
minor	O
motor	O
seizures	I-DISEASE
resolve	O
in	O
3	O
and	O
6	O
months	O
,	O
and	O
one	O
had	O
the	O
seizures	B-DISEASE
persist	O
.	O

HIT	B-DISEASE
must	O
be	O
acknowledged	O
for	O
its	O
intense	O
predilection	O
for	O
thrombosis	B-DISEASE
and	O
suspected	O
whenever	O
thrombosis	B-DISEASE
occurs	O
after	O
heparin	B-Chemical
exposure	O
.	O

Goodship	O
(	O
Newcastle	O
)	O
,	O
J	O
.	O

Nimodipine	B-Chemical
treatment	O
resulted	O
in	O
a	O
statistically	O
significant	O
reduction	O
in	O
systolic	O
BP	B-DISEASE
(	O
SBP	O
)	O
and	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
compared	O
with	O
placebo	O
during	O
the	O
first	O
few	O
days	O
.	O

An	O
overall	O
description	O
of	O
the	O
molecular	O
epidemiological	O
findings	O
of	O
SLC26A4	B-GENE
in	O
China	O
is	O
provided	O
.	O

Previous	O
reports	O
have	O
suggested	O
that	O
pain	O
associated	O
with	O
the	O
injection	O
of	O
lidocaine	B-Chemical
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution	O
.	O

Nicotine	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine	B-Chemical
-	O
but	O
not	O
pentylenetetrazole	B-Chemical
-	O
induced	O
anxiety	O
.	O

Although	O
a	O
clinical	O
diagnosis	O
of	O
the	O
Usher	B-DISEASE
subtype	O
is	O
more	O
difficult	O
in	O
early	O
childhood	O
due	O
to	O
the	O
different	O
age	O
of	O
onset	O
of	O
the	O
symptoms	O
,	O
an	O
early	O
diagnosis	O
is	O
critical	O
for	O
appropriate	O
educational	O
and	O
patient	O
management	O
choices	O
.	O

Broader	O
sequencing	O
,	O
combined	O
with	O
functional	O
validation	O
,	O
will	O
be	O
required	O
to	O
fully	O
elucidate	O
the	O
molecular	O
basis	O
of	O
these	O
remaining	O
cases	O
.	O

Spatio	O
-	O
temporally	O
accumulation	O
of	O
dysfunction	O
myosin	B-GENE
VIIA	I-GENE
molecules	O
at	O
actin	O
bundles	O
might	O
confer	O
a	O
dominant	O
negative	O
effect	O
on	O
wild	O
-	O
type	O
myosin	O
molecules	O
.	O

Schematic	O
representation	O
of	O
the	O
in	O
-	O
frame	O
mutations	O
identified	O
in	O
families	O
3	O
and	O
4	O
.	O

We	O
previously	O
reported	O
that	O
PEO1	B-GENE
mutations	O
occur	O
in	O
17	O
.	O
9	O
%	O
of	O
PEO	B-DISEASE
cases	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
with	O
muscle	O
multiple	O
mtDNA	O
deletions	O
[	O
13	O
]	O
.	O

Evaluated	O
for	O
renal	O
anomalies	O
only	O
in	O
patients	O
6	O
,	O
8	O
,	O
and	O
10	O
;	O
?	O
:	O
renal	O
ultrasonography	O
not	O
performed	O
.	O

About	O
50	O
-	O
60	O
%	O
of	O
these	O
cases	O
have	O
a	O
genetic	O
cause	O
.	O

The	O
ratio	O
RPA	O
was	O
calculated	O
as	O
the	O
RPA	O
of	O
the	O
patient	O
versus	O
controls	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
ML	O
.	O

Affected	O
males	O
'	O
middle	O
and	O
inner	B-DISEASE
ear	I-DISEASE
anomalies	I-DISEASE
were	O
within	O
the	O
expected	O
spectrum	O
.	O

Only	O
one	O
of	O
these	O
variants	O
was	O
in	O
WFS1	B-GENE
,	O
a	O
gene	O
responsible	O
for	O
dominant	B-DISEASE
HL	I-DISEASE
,	O
and	O
all	O
variants	O
in	O
genes	O
responsible	O
for	O
recessive	B-DISEASE
HL	I-DISEASE
were	O
heterozygous	O
.	O

Overall	O
,	O
three	O
probands	O
had	O
fathered	O
a	O
child	O
during	O
TRT	O
(	O
#	O
1	O
and	O
#	O
4	O
)	O
or	O
without	O
it	O
(	O
#	O
2	O
)	O
.	O

This	O
approach	O
allowed	O
us	O
to	O
identify	O
the	O
pathogenic	O
mutation	O
in	O
17	O
families	O
out	O
of	O
36	O
(	O
47	O
,	O
2	O
%	O
)	O
,	O
depicted	O
in	O
Figure	O
2	O
:	O
2	O
/	O
2	O
in	O
X	O
-	O
linked	O
families	O
,	O
6	O
/	O
18	O
of	O
recessive	O
non	O
-	O
consanguineous	O
families	O
(	O
33	O
,	O
3	O
%	O
)	O
,	O
8	O
/	O
10	O
recessive	O
consanguineous	O
families	O
(	O
80	O
%	O
)	O
and	O
1	O
/	O
6	O
of	O
dominant	O
families	O
(	O
16	O
,	O
6	O
%	O
)	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A123D	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
L150P	I-VARIANT
mutants	O
degraded	O
more	O
rapidly	O
than	O
p	B-VARIANT
.	I-VARIANT
M120K	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
I153_L154delinsM	I-VARIANT
.	O

-	O
The	O
polymorphism	O
phenotyping	O
program	O
,	O
PolyPhen	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph	O
/	O
)	O
uses	O
sequence	O
conservation	O
,	O
structure	O
and	O
SWISS	O
-	O
PROT	O
annotation	O
to	O
characterize	O
an	O
amino	O
acid	O
substitution	O
as	O
benign	O
,	O
possibly	O
deleterious	O
or	O
probably	O
deleterious	O
.	O

d	O
Siblings	O
.	O

Copy	O
number	O
variation	O
(	O
CNV	O
)	O
analysis	O
was	O
performed	O
using	O
a	O
custom	O
-	O
designed	O
Comparative	O
Genomic	O
Hybridization	O
(	O
CGH	O
)	O
microarray	O
(	O
Agilent	O
Technologies	O
,	O
Inc	O
)	O
.	O

The	O
prevalence	O
of	O
childhood	O
hearing	B-DISEASE
loss	I-DISEASE
patients	O
with	O
mutations	O
in	O
other	O
deafness	B-DISEASE
-	O
related	O
genes	O
is	O
likely	O
to	O
be	O
less	O
than	O
1	O
%	O
[	O
1	O
]	O
.	O

Both	O
were	O
reported	O
to	O
be	O
in	O
good	O
health	O
.	O

In	O
the	O
different	O
groups	O
,	O
the	O
detection	O
rate	O
of	O
the	O
SLC26A4	B-GENE
mutation	O
differed	O
.	O

OPA1	B-GENE
consists	O
of	O
five	O
domains	O
:	O
the	O
mitochondrial	O
target	O
signal	O
(	O
MTS	O
)	O
,	O
N	O
-	O
terminal	O
coiled	O
-	O
coil	O
domain	O
,	O
GTPase	O
domain	O
,	O
dynamin	O
central	O
region	O
,	O
and	O
C	O
-	O
terminal	O
coiled	O
-	O
coil	O
domain	O
.	O

This	O
results	O
in	O
cell	O
depolarization	O
,	O
activation	O
of	O
voltage	O
-	O
gated	O
Ca	O
2	O
+	O
channels	O
,	O
aldosterone	O
production	O
and	O
cell	O
proliferation	O
.	O

Ketamine	B-Chemical
can	O
improve	O
morphine	B-Chemical
analgesia	I-DISEASE
in	O
difficult	B-DISEASE
pain	I-DISEASE
syndromes	I-DISEASE
,	O
such	O
as	O
neuropathic	B-DISEASE
pain	I-DISEASE
.	O

GJB2	B-GENE
is	O
the	O
most	O
prevalent	O
causative	O
gene	O
,	O
and	O
the	O
major	O
(	O
commonly	O
found	O
)	O
gene	O
mutations	O
cause	O
30	O
-	O
40	O
%	O
of	O
deafness	B-DISEASE
while	O
the	O
remainder	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
the	O
result	O
of	O
various	O
rare	O
genes	O
/	O
mutations	O
that	O
have	O
been	O
difficult	O
to	O
diagnose	O
by	O
the	O
conventional	O
one	O
-	O
by	O
-	O
one	O
approach	O
.	O

,	O
2004	O
)	O
.	O

Authors	O
'	O
contributions	O
KM	O
,	O
HM	O
,	O
and	O
TM	O
interpreted	O
the	O
data	O
and	O
drafted	O
the	O
manuscript	O
.	O

Orthologous	O
alignments	O
illustrate	O
strong	O
evolutionary	O
conservation	O
in	O
mutated	O
positions	O
,	O
including	O
the	O
recurrent	O
variant	O
c	B-VARIANT
.	I-VARIANT
3893A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
Fig	O
.	O

This	O
process	O
were	O
performed	O
using	O
an	O
Ion	O
OneTouch	O
(	O
tm	O
)	O
ES	O
system	O
(	O
Life	O
Technologies	O
)	O
.	O

We	O
also	O
found	O
a	O
majority	O
of	O
missense	O
mutations	O
,	O
with	O
six	O
exons	O
preferentially	O
affected	O
(	O
2	O
,	O
17	O
,	O
27	O
,	O
31	O
,	O
39	O
,	O
41	O
)	O
,	O
rare	O
small	O
deletions	O
in	O
exon	O
25	O
and	O
nonsense	O
and	O
frameshift	O
alterations	O
restricted	O
to	O
exon	O
41	O
.	O

Our	O
result	O
clearly	O
shows	O
that	O
a	O
diverse	O
genotype	O
-	O
phenotype	O
correlation	O
can	O
exist	O
,	O
even	O
within	O
the	O
same	O
domain	O
of	O
the	O
protein	O
,	O
proposing	O
a	O
possible	O
"	O
variant	O
to	O
phenotype	O
correlation	O
"	O
beyond	O
"	O
gene	O
to	O
phenotype	O
"	O
or	O
"	O
domain	O
to	O
phenotype	O
"	O
correlations	O
.	O

The	O
X	O
-	O
ray	O
of	O
the	O
family	O
members	O
III	O
-	O
6	O
,	O
III	O
-	O
7	O
,	O
IV	O
-	O
7	O
,	O
IV	O
-	O
8	O
,	O
and	O
IV	O
-	O
9	O
were	O
made	O
at	O
the	O
age	O
of	O
41	O
,	O
38	O
,	O
15	O
,	O
15	O
and	O
7	O
years	O
old	O
respectively	O
.	O

Because	O
intensity	O
of	O
alcohol	B-Chemical
consumption	O
is	O
associated	O
with	O
poorer	O
fetal	O
outcomes	O
,	O
separate	O
analyses	O
were	O
conducted	O
for	O
the	O
heavy	O
(	O
average	O
of	O
>	O
or	O
=	O
5	O
drinks	O
per	O
drinking	O
day	O
)	O
alcohol	B-Chemical
consumers	O
.	O

SNPs	O
were	O
genotyped	O
using	O
the	O
Golden	O
Gate	O
Array	O
(	O
Illumina	O
)	O
platform	O
following	O
the	O
instructions	O
,	O
protocol	O
and	O
software	O
provided	O
by	O
the	O
manufacturers	O
.	O

The	O
present	O
study	O
is	O
the	O
first	O
to	O
show	O
that	O
CDH23	B-GENE
mutations	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
Koreans	O
.	O

Pedigree	O
and	O
analysis	O
of	O
a	O
Tunisian	O
family	O
segregating	O
autosomal	O
recessive	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
variability	O
in	O
the	O
diagnosis	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

BACKGROUND	O
:	O
Clomiphene	B-Chemical
citrate	I-Chemical
(	O
CC	B-Chemical
)	O
is	O
commonly	O
prescribed	O
for	O
ovulation	B-DISEASE
induction	O
.	O

B	O
:	O
Mutant	O
sequence	O
in	O
proband	O
F4	O
III	O
:	O
1	O
.	O

Bioinformatic	O
analysis	O
revealed	O
that	O
the	O
mutated	O
residues	O
were	O
conserved	O
across	O
species	O
(	O
Figure	O
2b	O
)	O
.	O

The	O
two	O
patients	O
having	O
a	O
germline	O
V2148D	B-VARIANT
variant	O
in	O
NF1	B-GENE
,	O
developed	O
ovarian	B-DISEASE
cancer	I-DISEASE
at	O
age	O
36	O
and	O
45	O
years	O
.	O

Blockade	O
of	O
both	O
D	O
-	O
1	O
and	O
D	O
-	O
2	O
dopamine	B-Chemical
receptors	O
may	O
induce	O
catalepsy	O
in	O
mice	O
.	O

The	O
novel	O
NM_000307	O
.	O
4	O
:	O
c	B-VARIANT
.	I-VARIANT
772delG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Glu258ArgfsX30	I-VARIANT
)	I-VARIANT
)	O
mutation	O
truncates	O
the	O
protein	O
within	O
POU	O
-	O
specific	O
domain	O
.	O

SETTING	O
:	O
Twenty	O
-	O
nine	O
university	O
,	O
university	O
-	O
affiliated	O
,	O
or	O
community	O
hospitals	O
during	O
a	O
6	O
-	O
year	O
period	O
(	O
total	O
of	O
117	O
cumulative	O
hospital	O
-	O
years	O
)	O
.	O

In	O
contrast	O
,	O
ABRs	O
were	O
absent	O
in	O
6	O
of	O
10	O
subjects	O
of	O
the	O
OPA1	B-GENE
-	O
M	O
group	O
(	O
Table	O
1	O
)	O
.	O

Electron	O
microscopy	O
revealed	O
irregular	O
thickening	O
and	O
splitting	O
of	O
the	O
glomerular	O
basement	O
membranes	O
(	O
GBMs	O
)	O
.	O

The	O
PCR	O
products	O
were	O
treated	O
with	O
ExoSAP	B-Chemical
-	O
IT	O
(	O
GE	O
Healthcare	O
Bio	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
and	O
by	O
incubation	O
at	O
37	O
deg	O
C	O
for	O
60	O
min	O
,	O
and	O
inactivation	O
at	O
80	O
deg	O
C	O
for	O
15	O
min	O
.	O

The	O
possibilities	O
include	O
mutations	O
occurring	O
in	O
the	O
promoter	O
region	O
,	O
other	O
intronic	O
regions	O
,	O
or	O
in	O
the	O
3	O
'	O
-	O
or	O
5	O
'	O
-	O
untranslated	O
region	O
.	O

Recently	O
,	O
mutations	O
in	O
mt	O
-	O
aaRS	O
(	O
ARS2	B-GENE
)	O
and	O
cytoplasmic	O
aaRS	O
(	O
ARS	O
)	O
have	O
been	O
associated	O
with	O
human	O
diseases	O
such	O
as	O
Charcot	B-DISEASE
-	I-DISEASE
Marie	I-DISEASE
-	I-DISEASE
Tooth	I-DISEASE
disease	I-DISEASE
,	O
Perrault	B-DISEASE
syndrome	I-DISEASE
(	O
LARS2	B-GENE
,	O
HARS2	B-GENE
)	O
[	O
39	O
,	O
40	O
]	O
,	O
and	O
pontocerebellar	B-DISEASE
hypoplasia	I-DISEASE
,	O
all	O
of	O
which	O
include	O
sensorineural	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
Table	O
2	O
)	O
.	O

Library	O
preparation	O
,	O
qualification	O
,	O
and	O
NGS	O
on	O
the	O
Illumina	B-Chemical
HiSeq2000	O
platform	O
(	O
Illumina	B-Chemical
,	O
Inc	O
.	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
were	O
performed	O
in	O
collaboration	O
with	O
BGI	B-Chemical
-	O
Shenzhen	O
(	O
Shenzhen	O
,	O
Guangdong	O
,	O
China	O
)	O
per	O
the	O
manufacturer	O
'	O
s	O
instructions	O
[	O
18	O
]	O
.	O

Induction	O
of	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
and	O
decrease	O
of	O
aortic	O
pressure	O
.	O

Consanguinity	O
exits	O
in	O
family	O
USH02	B-Chemical
.	O

The	O
DNA	O
from	O
the	O
chorion	O
was	O
extracted	O
using	O
a	O
chorion	O
DNA	O
extraction	O
kit	O
(	O
TianGen	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

Array	O
CGH	O
similarly	O
shows	O
adequate	O
resolution	O
to	O
detect	O
a	O
45	O
kb	O
deletion	O
.	O

We	O
compared	O
the	O
effects	O
of	O
single	O
doses	O
of	O
50	O
mg	O
atenolol	B-Chemical
(	O
cardioselective	O
)	O
,	O
40	O
mg	O
propranolol	B-Chemical
(	O
nonselective	O
)	O
,	O
and	O
placebo	O
on	O
both	O
exercise	O
-	O
and	O
isoproterenol	B-Chemical
-	O
induced	O
tachycardia	B-DISEASE
in	O
two	O
experiments	O
involving	O
nine	O
normal	O
subjects	O
.	O

None	O
of	O
these	O
variants	O
were	O
detected	O
in	O
100	O
ethnically	O
matched	O
normal	O
control	O
subjects	O
.	O

In	O
the	O
latter	O
,	O
the	O
morphology	O
of	O
ECochG	O
waveforms	O
is	O
preserved	O
as	O
both	O
summating	O
potential	O
and	O
compound	O
action	O
potential	O
had	O
peak	O
latencies	O
and	O
durations	O
comparable	O
to	O
controls	O
with	O
normal	O
hearing	O
,	O
whereas	O
the	O
amplitudes	O
were	O
remarkably	O
smaller	O
.	O

Variations	O
identified	O
in	O
CLDN14	B-GENE
showed	O
8	O
single	O
nucleotide	O
variations	O
in	O
48	O
unrelated	O
Korean	O
patients	O
(	O
Table	O
2	O
)	O
.	O

Pfeiffer	B-DISEASE
syndrome	I-DISEASE
occurs	O
in	O
approximately	O
1	O
:	O
100	O
,	O
000	O
live	O
births	O
.	O

The	O
drug	O
is	O
known	O
to	O
cause	O
a	O
variety	O
of	O
acute	O
toxic	O
effects	O
,	O
ranging	O
from	O
nausea	B-DISEASE
,	O
restlessness	B-DISEASE
,	O
insomnia	B-DISEASE
,	O
ataxia	B-DISEASE
,	O
slurred	O
speech	I-DISEASE
and	O
nystagmus	B-DISEASE
to	O
mood	O
changes	O
,	O
perceptual	O
alterations	O
,	O
inattention	O
,	O
disorientation	B-DISEASE
and	O
aggressive	O
behavior	O
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O
Devlin	O
et	O
al	O
1985	O
;	O
McCarthy	O
1971	O
;	O
Dodds	O
and	O
Revai	O
1967	O
;	O
Degkwitz	O
1964	O
;	O
Hildebrand	O
et	O
al	O
1989	O
)	O
.	O

We	O
used	O
PolyPhen	B-Chemical
-	O
2	O
software	O
(	O
DeLano	B-Chemical
Scientific	O
LLC	O
)	O
to	O
study	O
3D	O
structure	O
of	O
the	O
protein	O
,	O
and	O
found	O
that	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
V1773M	I-VARIANT
)	O
changes	O
the	O
shape	O
of	O
the	O
protein	O
in	O
this	O
region	O
,	O
which	O
may	O
alter	O
its	O
ability	O
to	O
bind	O
to	O
other	O
molecules	O
.	O

The	O
Institutional	O
Review	O
Board	O
and	O
the	O
Ethics	O
Committee	O
of	O
Catholic	O
University	O
of	O
Bras	O
i	O
lia	O
approved	O
the	O
protocols	O
used	O
(	O
CEP	O
/	O
UCB	O
056	O
/	O
2011	O
)	O
.	O

The	O
girl	O
died	O
seven	O
days	O
,	O
the	O
man	O
four	O
weeks	O
after	O
intrathecal	O
injection	O
of	O
vincristine	B-Chemical
.	O

These	O
disorders	O
of	O
mtDNA	O
maintenance	O
constitute	O
an	O
important	O
group	O
of	O
human	O
genetic	O
diseases	O
and	O
they	O
manifest	O
as	O
an	O
array	O
of	O
clinical	O
syndromes	O
ranging	O
from	O
severe	B-DISEASE
infantile	I-DISEASE
encephalomyopathy	I-DISEASE
,	O
hepatic	B-DISEASE
failure	I-DISEASE
and	O
epilepsy	B-DISEASE
,	O
to	O
late	O
-	O
onset	O
ataxia	B-DISEASE
,	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
and	O
myopathy	B-DISEASE
,	O
or	O
isolated	O
progressive	B-DISEASE
external	I-DISEASE
ophthalmoplegia	I-DISEASE
.	O

1	O
)	O
.	O

However	O
,	O
these	O
mutations	O
are	O
located	O
throughout	O
the	O
gene	O
without	O
any	O
identified	O
mutational	O
hot	O
spot	O
.	O

ABRs	O
:	O
auditory	O
brainstem	O
responses	O
;	O
AN	B-DISEASE
:	I-DISEASE
auditory	B-DISEASE
neuropathy	I-DISEASE
;	I-DISEASE
AR	B-DISEASE
:	I-DISEASE
abnormal	B-DISEASE
acoustic	I-DISEASE
reflex	I-DISEASE
;	I-DISEASE
CMs	O
:	O
cochlear	O
microphonics	O
;	O
DPOAEs	B-DISEASE
:	I-DISEASE
distortion	B-DISEASE
product	I-DISEASE
otoacoustic	I-DISEASE
emissions	I-DISEASE
;	I-DISEASE
IHC	O
:	O
inner	O
hair	O
cell	O
;	O
NMD	B-DISEASE
:	I-DISEASE
nonsense	B-DISEASE
-	I-DISEASE
mediated	I-DISEASE
mRNA	I-DISEASE
decay	I-DISEASE
;	I-DISEASE
NSRAN	B-DISEASE
:	I-DISEASE
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
recessive	I-DISEASE
auditory	I-DISEASE
neuropathy	I-DISEASE
;	I-DISEASE
OAEs	O
:	O
otoacoustic	O
emissions	O
;	O
TEOAEs	O
:	O
transient	O
evoked	O
otoacoustic	O
emissions	O
;	O
TS	B-DISEASE
-	I-DISEASE
AN	I-DISEASE
:	I-DISEASE
temperature	B-DISEASE
-	I-DISEASE
sensitive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
auditory	I-DISEASE
neuropathy	I-DISEASE
;	I-DISEASE
TS	B-DISEASE
-	I-DISEASE
NSRAN	I-DISEASE
:	I-DISEASE
temperature	B-DISEASE
-	I-DISEASE
sensitive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
recessive	I-DISEASE
auditory	I-DISEASE
neuropathy	I-DISEASE
.	O

All	O
the	O
assessments	O
were	O
performed	O
with	O
the	O
approval	O
of	O
the	O
Medical	O
Ethics	O
Committee	O
of	O
Shanghai	O
Children	O
'	O
s	O
Medical	O
Centre	O
(	O
SCMC	O
)	O
and	O
the	O
Medical	O
Ethics	O
Committee	O
of	O
Xinhua	O
hospital	O
.	O

Furthermore	O
,	O
transient	O
hemoglobinuria	I-DISEASE
was	O
noted	O
approximately	O
60	O
minutes	O
postinjection	O
of	O
WR242511	B-Chemical
(	O
3	O
.	O
5	O
or	O
7	O
.	O
0	O
mg	O
/	O
kg	O
)	O
,	O
and	O
2	O
lethalities	O
occurred	O
(	O
one	O
IV	O
and	O
one	O
PO	O
)	O
following	O
the	O
7	O
.	O
0	O
mg	O
/	O
kg	O
dose	O
.	O

Nonsense	O
mutations	O
,	O
splice	O
-	O
site	O
mutations	O
,	O
and	O
missense	O
mutations	O
were	O
chosen	O
according	O
to	O
this	O
algorithm	O
.	O

WS	B-DISEASE
is	O
a	O
rare	O
progressive	O
neurodegenerative	O
disorder	O
usually	O
characterized	O
by	O
diabetes	B-DISEASE
insipidus	I-DISEASE
,	O
early	O
-	O
onset	O
diabetes	B-DISEASE
,	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
and	O
deafness	B-DISEASE
(	O
hence	O
the	O
acronym	O
DIDMOAD	O
)	O
,	O
with	O
diabetes	B-DISEASE
and	O
optic	B-DISEASE
atrophy	I-DISEASE
being	O
the	O
most	O
consistent	O
features	O
(	O
17	O
,	O
24	O
)	O
.	O

Coagulation	O
test	O
results	O
were	O
not	O
remarkable	O
.	O

2012	O
;	O
Dai	O
et	O
al	O
.	O

The	O
effects	O
of	O
the	O
amino	O
acid	O
substitutions	O
in	O
TMPRSS3	B-GENE
on	O
its	O
structure	O
were	O
analyzed	O
using	O
the	O
Project	O
HOPE	O
web	O
server	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
cmbi	O
.	O
ru	O
.	O
nl	O
/	O
hope	O
;	O
Venselaar	O
et	O
al	O
.	O

She	O
received	O
a	O
second	O
cycle	O
of	O
nelarabine	B-Chemical
without	O
additional	O
IT	O
prophylaxis	O
one	O
month	O
later	O
.	O

Capsaicin	B-Chemical
injection	O
reliably	O
induced	O
a	O
dose	O
-	O
dependent	O
flare	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
any	O
difference	O
within	O
or	O
across	O
sessions	O
.	O

Eighty	O
-	O
one	O
consecutive	O
patients	O
(	O
54	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
,	O
and	O
20	O
with	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
)	O
with	O
inducible	O
sustained	B-DISEASE
ventricular	I-DISEASE
tachycardia	I-DISEASE
or	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
received	O
oral	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
to	O
prevent	O
induction	O
of	O
the	O
ventricular	B-DISEASE
tachyarrhythmia	I-DISEASE
.	O

NA	O
:	O
Not	O
applicable	O
.	O

Both	O
MYO7A	B-GENE
c	B-VARIANT
.	I-VARIANT
73G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G25R	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
C154X	I-VARIANT
)	O
were	O
predicted	O
to	O
be	O
damaging	O
(	O
according	O
to	O
GenBank	O
accession	O
number	O
NM_000260	O
.	O
3	O
)	O
[	O
9	O
]	O
,	O
[	O
30	O
]	O
.	O

Effect	O
of	O
prostaglandin	B-Chemical
synthetase	O
inhibitors	O
on	O
experimentally	O
induced	O
convulsions	B-DISEASE
in	O
rats	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
allele	O
of	O
slightly	O
longer	O
GJB2	B-GENE
transcripts	O
,	O
with	O
38	O
bp	O
of	O
intronic	O
sequence	O
inserted	O
in	O
the	O
5	O
'	O
UTR	O
,	O
but	O
otherwise	O
encoding	O
wild	O
-	O
type	O
Cx26	B-GENE
.	O

In	O
single	O
dose	O
studies	O
,	O
DH	B-DISEASE
,	O
MD	O
,	O
and	O
VSD	B-DISEASE
were	O
induced	O
on	O
GDs	O
9	O
and	O
10	O
.	O

EVA	B-DISEASE
,	O
diagnosed	O
based	O
on	O
the	O
criteria	O
of	O
a	O
greater	O
than	O
1	O
.	O
5	O
-	O
mm	O
diameter	O
at	O
the	O
midpoint	O
between	O
the	O
common	O
crus	O
and	O
the	O
external	O
aperture	O
,	O
is	O
detected	O
in	O
the	O
ears	O
of	O
patients	O
with	O
PS	B-DISEASE
by	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
[	O
9	O
]	O
.	O

We	O
note	O
that	O
NHEJ	O
-	O
mediated	O
large	O
deletions	O
have	O
been	O
reported	O
in	O
many	O
diseases	O
[	O
48	O
]	O
.	O

Sequencing	O
of	O
the	O
USH2A	B-GENE
gene	O
revealed	O
17	O
sequence	O
variants	O
in	O
this	O
study	O
,	O
eight	O
of	O
which	O
were	O
pathogenic	O
mutations	O
(	O
Table	O
4	O
)	O
.	O

Either	O
one	O
or	O
two	O
affected	O
members	O
of	O
each	O
family	O
underwent	O
WES	O
based	O
on	O
the	O
availability	O
of	O
sufficient	O
DNA	O
.	O

A	O
single	O
18	O
.	O
4	O
mg	O
/	O
kg	O
(	O
i	O
.	O
p	O
.	O
)	O
dose	O
of	O
(	O
+	O
/	O
-	O
)	O
-	O
amphetamine	B-Chemical
hemisulfate	O
,	O
given	O
to	O
rats	O
pretreated	O
with	O
iprindole	B-Chemical
,	O
resulted	O
in	O
persistent	O
depletion	O
of	O
dopamine	B-Chemical
in	O
the	O
striatum	O
1	O
week	O
later	O
.	O

The	O
arrow	O
indicates	O
the	O
proband	O
.	O

Polybrene	B-Chemical
at	O
4	O
mu	O
g	O
/	O
ml	O
was	O
added	O
to	O
increase	O
the	O
transduction	O
efficiency	O
.	O

To	O
validate	O
in	O
silico	O
prediction	O
of	O
the	O
impact	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
1935G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
on	O
splicing	O
,	O
wild	O
-	O
type	O
and	O
corresponding	O
mutated	O
genomic	O
fragments	O
were	O
subcloned	O
into	O
expression	O
vectors	O
p	O
(	O
13	O
,	O
17	O
)	O
/	O
cytomegalovirus	O
(	O
CMV	B-Chemical
)	O
and	O
transfected	O
into	O
HeLa	O
cells	O
.	O

We	O
investigate	O
whether	O
abnormalities	O
in	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
uptake	O
contribute	O
to	O
this	O
deficiency	O
.	O

The	O
girl	O
showed	O
typical	O
morphological	O
findings	O
of	O
RSTS	B-DISEASE
,	O
including	O
abnormal	O
features	O
of	O
the	O
face	O
,	O
fingers	O
,	O
and	O
toes	O
,	O
as	O
well	O
as	O
growth	B-DISEASE
retardation	I-DISEASE
.	O

(	O
a	O
)	O
Table	O
of	O
indels	O
appearing	O
in	O
four	O
or	O
more	O
probands	O
in	O
our	O
population	O
(	O
n	O
=	O
11	O
)	O
.	O

For	O
sumatriptan	B-Chemical
,	O
tightness	B-DISEASE
in	O
the	O
chest	O
caused	O
by	O
an	O
unknown	O
mechanism	O
has	O
been	O
reported	O
in	O
3	O
-	O
5	O
%	O
of	O
users	O
.	O

Cumulative	O
doses	O
of	O
doxorubicin	B-Chemical
were	O
225	O
-	O
550	O
mg	O
/	O
m2	O
(	O
median	O
dose	O
360	O
)	O
.	O

This	O
patient	O
had	O
hearing	O
threshold	O
changes	O
(	O
15	O
-	O
20	O
dB	O
)	O
at	O
6	O
-	O
10	O
kHz	O
on	O
the	O
opposite	O
side	O
also	O
.	O

After	O
template	O
preparation	O
for	O
pyrosequencing	O
,	O
an	O
automated	O
Pyrosequencing	O
instrument	O
,	O
PSQ96	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
,	O
was	O
used	O
to	O
perform	O
genotyping	O
.	O

A	O
maximum	O
two	O
-	O
point	O
LOD	O
score	O
of	O
5	O
.	O
10	O
(	O
theta	O
=	O
0	O
)	O
was	O
obtained	O
for	O
marker	O
D11S937	B-Chemical
.	O

Serious	O
adverse	O
effects	O
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	O
of	I-DISEASE
cardiac	O
contractility	O
and	O
conduction	O
,	O
especially	O
when	O
the	O
drug	O
is	O
combined	O
with	O
beta	O
-	O
blocking	O
agents	O
.	O

For	O
transient	O
expression	O
,	O
Lipofectamine	B-Chemical
(	O
Invitrogen	O
)	O
was	O
used	O
to	O
transfect	O
HEK293T	O
or	O
HeLa	O
cells	O
with	O
a	O
constant	O
amount	O
of	O
plasmid	O
DNA	O
(	O
1	O
mu	O
g	O
or	O
2	O
mu	O
g	O
)	O
of	O
pcDNA3	O
.	O
1	O
-	O
Gipc3	B-GENE
or	O
pcDNA3	O
.	O
1	O
-	O
Gipc3	B-GENE
343A	O
.	O

The	O
remaining	O
4	O
FC	O
patients	O
have	O
disease	O
likely	O
caused	O
by	O
mutations	O
in	O
other	O
retinal	B-DISEASE
disease	I-DISEASE
genes	O
(	O
Table	O
1	O
)	O
.	O

(	O
2005	O
)	O
described	O
a	O
cLQTS	B-DISEASE
patient	O
harbouring	O
double	O
mutations	O
(	O
KCNQ1	B-GENE
:	O
pR591H	B-VARIANT
;	O
KCNH2	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
R328C	I-VARIANT
)	O
.	O

The	O
expression	O
in	O
the	O
hair	O
cells	O
was	O
weaker	O
than	O
in	O
the	O
other	O
cell	O
types	O
,	O
consistent	O
with	O
the	O
mRNA	O
expression	O
pattern	O
of	O
cd164	B-GENE
in	O
the	O
Shared	O
Harvard	O
Inner	O
-	O
Ear	O
Laboratory	O
Database	O
(	O
SHIELD	O
)	O
database	O
.	O

They	O
also	O
provide	O
evidence	O
for	O
estradiol	B-Chemical
-	O
dependent	O
and	O
brain	O
region	O
-	O
specific	O
regulation	O
of	O
PRL	O
-	O
R	O
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	O
.	O

Phase	O
2	O
trial	O
of	O
liposomal	O
doxorubicin	B-Chemical
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
platinum	B-Chemical
/	O
paclitaxel	B-Chemical
-	O
refractory	O
ovarian	B-DISEASE
and	O
fallopian	O
tube	I-DISEASE
cancers	I-DISEASE
and	O
primary	O
carcinoma	B-DISEASE
of	I-DISEASE
the	I-DISEASE
peritoneum	I-DISEASE
.	O

The	O
7	O
dominant	O
probands	O
had	O
late	O
-	O
onset	O
,	O
progressive	O
,	O
moderate	O
-	O
to	O
-	O
severe	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

His	O
renal	O
function	O
has	O
remained	O
stable	O
over	O
29	O
years	O
of	O
follow	O
-	O
up	O
(	O
serum	O
creatinine	B-Chemical
93	O
u	O
mol	O
/	O
L	O
aged	O
54	O
years	O
)	O
.	O

A	O
majority	O
of	O
the	O
nodules	O
showed	O
a	O
considerable	O
number	O
of	O
peroxisomes	B-DISEASE
and	O
the	O
inductive	O
proliferation	O
of	O
peroxisomes	O
.	O

Atherosclerosis	B-DISEASE
could	O
produce	O
gastric	B-DISEASE
hemorrhagic	I-DISEASE
ulcer	I-DISEASE
via	O
aggravation	O
of	O
gastric	B-DISEASE
acid	I-DISEASE
back	O
-	O
diffusion	O
,	O
LPO	O
generation	O
,	O
histamine	B-Chemical
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	B-Chemical
in	O
rats	O
.	O

Mutations	O
of	O
the	O
OPA1	B-GENE
gene	O
result	O
in	O
a	O
loss	O
of	O
function	O
in	O
most	O
ADOA	B-DISEASE
patients	O
indicating	O
that	O
haploinsufficiency	B-DISEASE
is	O
involved	O
in	O
the	O
pathomechanism	O
of	O
the	O
disease	O
[	O
21	O
]	O
.	O

As	O
a	O
final	O
step	O
,	O
these	O
variants	O
were	O
screened	O
against	O
the	O
control	O
group	O
and	O
were	O
removed	O
unless	O
already	O
established	O
as	O
a	O
deafness	B-DISEASE
-	I-DISEASE
associated	I-DISEASE
damaging	O
mutation	O
.	O

Meta	O
-	O
analyses	O
of	O
larger	O
cohorts	O
are	O
needed	O
for	O
a	O
statistically	O
sound	O
analysis	O
of	O
further	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

N	O
.	O
d	O
.	O

Reversible	O
dilated	I-DISEASE
cardiomyopathy	I-DISEASE
related	O
to	O
amphotericin	B-Chemical
B	I-Chemical
therapy	O
.	O

All	O
subjects	O
or	O
next	O
of	O
kin	O
,	O
caretakers	O
,	O
or	O
guardians	O
on	O
the	O
behalf	O
of	O
the	O
minors	O
/	O
children	O
gave	O
prior	O
written	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
project	O
,	O
and	O
the	O
Ethical	O
Committee	O
of	O
Shinshu	O
University	O
approved	O
the	O
study	O
and	O
the	O
consent	O
procedure	O
.	O

Scheme	O
of	O
the	O
multiphasic	O
analysis	O
of	O
WES	O
data	O
(	O
C	O
)	O
.	O

Seizures	O
disappeared	O
in	O
71	O
%	O
of	O
the	O
patients	O
with	O
generalized	B-DISEASE
seizures	I-DISEASE
and	O
89	O
%	O
of	O
partial	B-DISEASE
seizures	I-DISEASE
.	O

8	O
Mutations	O
of	O
all	O
three	O
genes	O
can	O
result	O
in	O
different	O
types	O
of	O
Stickler	B-DISEASE
syndrome	I-DISEASE
(	O
MIM	O
108300	O
,	O
604841	O
,	O
184840	O
)	O
,	O
9	O
-	O
11	O
which	O
is	O
usually	O
an	O
autosomal	O
dominant	O
disorder	O
with	O
variable	O
phenotype	O
that	O
includes	O
myopia	B-DISEASE
,	O
retinal	O
detachment	O
,	O
premature	O
osteoarthritis	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
facial	O
dysmorphism	O
and	O
midline	O
clefting	O
that	O
can	O
manifest	O
as	O
Pierre	O
Robin	O
sequence	O
,	O
or	O
an	O
isolated	O
cleft	B-DISEASE
palate	I-DISEASE
.	O

Ocular	O
fundus	O
examination	O
revealed	O
different	O
colors	O
between	O
two	O
fundi	O
(	O
Figure	O
2	O
)	O
,	O
which	O
have	O
not	O
been	O
described	O
before	O
.	O

By	O
November	O
1984	O
the	O
Committee	O
on	O
Safety	O
of	O
Medicines	O
had	O
received	O
82	O
reports	O
of	O
possible	O
hepatotoxicity	O
associated	O
with	O
the	O
drug	O
,	O
including	O
five	O
deaths	O
.	O

MB9	O
had	O
a	O
mild	O
peripheral	O
RP	B-DISEASE
,	O
while	O
MB60	O
had	O
only	O
some	O
pigments	O
.	O

AO	O
images	O
showed	O
microcysts	O
in	O
the	O
en	O
face	O
images	O
of	O
the	O
INL	O
.	O

In	O
humans	O
,	O
mutations	O
of	O
the	O
CLDN14	B-GENE
gene	O
at	O
DFNB29	B-GENE
locus	O
on	O
chromosome	O
21	O
lead	O
to	O
autosomal	B-DISEASE
recessive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ARNSHL	B-DISEASE
)	O
[	O
7	O
]	O
.	O

recently	O
found	O
mutations	O
in	O
91	O
%	O
of	O
the	O
patients	O
tested	O
,	O
improving	O
the	O
molecular	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
greatly	O
[	O
11	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
two	O
novel	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E1248K	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
6051	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
donor	O
splice	O
site	O
mutation	O
in	O
intron	O
44	O
)	O
,	O
of	O
MYO7A	B-GENE
in	O
a	O
Chinese	O
non	O
-	O
consanguineous	O
family	O
with	O
USH1	B-DISEASE
.	O

Histochemical	O
and	O
molecular	O
studies	O
performed	O
on	O
skeletal	O
muscle	O
biopsies	O
from	O
patients	O
with	O
both	O
pure	O
DOA	B-DISEASE
and	O
DOA	O
+	O
features	O
have	O
also	O
provided	O
some	O
interesting	O
insights	O
into	O
the	O
possible	O
disease	O
mechanisms	O
involved	O
in	O
retinal	B-DISEASE
ganglion	I-DISEASE
cell	I-DISEASE
loss	I-DISEASE
and	O
optic	B-DISEASE
nerve	I-DISEASE
degeneration	I-DISEASE
.	O

Pedigree	O
,	O
PRS	O
enzymatic	O
activity	O
,	O
conservation	O
,	O
and	O
predicted	O
protein	O
structural	O
effects	O
of	O
the	O
novel	O
Gln277Pro	B-VARIANT
PRPS1	B-GENE
variant	O
.	O

Mutations	O
in	O
the	O
CREBBP	B-GENE
gene	O
have	O
been	O
extensively	O
reported	O
in	O
RSTS	B-DISEASE
patients	O
,	O
while	O
potential	O
missense	O
mutations	O
in	O
TNC	B-GENE
and	O
IGFALS	B-GENE
genes	O
have	O
not	O
previously	O
been	O
associated	O
with	O
RSTS	B-DISEASE
.	O

SLC26A4	B-GENE
mutations	O
were	O
detected	O
in	O
nearly	O
15	O
%	O
of	O
2352	O
non	O
-	O
syndromic	O
Chinese	O
hearing	B-DISEASE
impairment	I-DISEASE
patients	O
,	O
with	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
being	O
the	O
most	O
prevalent	O
.	O

A	O
36	O
year	O
-	O
old	O
male	O
patient	O
from	O
non	O
-	O
consanguineous	O
German	O
parents	O
(	O
subject	O
II	O
-	O
2	O
;	O
for	O
pedigree	O
,	O
see	O
Figure	O
1	O
A	O
;	O
for	O
clinical	O
details	O
see	O
Table	O
1	O
)	O
presented	O
with	O
prelingual	O
hearing	B-DISEASE
loss	I-DISEASE
since	O
birth	O
,	O
recurrent	O
severe	O
infections	O
from	O
age	O
6	O
to	O
8	O
years	O
with	O
subsequent	O
partially	O
remitting	O
bulbar	O
paresis	O
and	O
flaccid	O
tetraparesis	O
which	O
never	O
fully	O
resolved	O
,	O
and	O
progressive	O
visual	B-DISEASE
loss	I-DISEASE
due	O
to	O
optic	B-DISEASE
atrophy	I-DISEASE
since	O
age	O
12	O
years	O
(	O
current	O
vision	O
at	O
age	O
36	O
years	O
:	O
0	O
.	O
1	O
right	O
eye	O
,	O
0	O
.	O
3	O
left	O
eye	O
)	O
.	O

Schematic	O
of	O
the	O
FGFR1	B-GENE
mutations	O
at	O
protein	O
level	O
.	O

The	O
patients	O
often	O
have	O
difficulty	O
maintaining	O
their	O
balance	O
owing	O
to	O
problems	O
in	O
the	O
vestibular	O
system	O
.	O

A	O
decrease	O
in	O
Hb	O
levels	O
between	O
2	O
and	O
5	O
g	O
/	O
dL	O
was	O
detected	O
in	O
23	O
(	O
11	O
.	O
4	O
%	O
)	O
patients	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

We	O
used	O
HotNet	O
version	O
1	O
.	O
1	O
and	O
an	O
interaction	O
network	O
from	O
iRefIndex	O
9	O
68	O
containing	O
212	O
,	O
746	O
interactions	O
among	O
14	O
,	O
384	O
proteins	O
,	O
using	O
parameter	O
t	O
=	O
0	O
.	O
05	O
to	O
derive	O
the	O
influence	O
graph	O
.	O

The	O
expression	O
analysis	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	B-Chemical
promoted	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
handling	O
proteins	O
.	O

This	O
variant	O
resides	O
in	O
the	O
entactin	O
(	O
ENT	O
)	O
domain	O
and	O
co	O
-	O
segregated	O
perfectly	O
with	O
non	O
-	O
progressive	O
high	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
the	O
family	O
.	O

The	O
fraction	O
of	O
positions	O
where	O
a	O
certain	O
error	O
occurred	O
with	O
the	O
error	O
rate	O
for	O
insertions	O
,	O
deletions	O
,	O
and	O
mismatches	O
.	O

Intradermal	O
injections	O
of	O
glutamate	B-Chemical
and	O
capsaicin	B-Chemical
are	O
attractive	O
to	O
use	O
in	O
human	O
experimental	O
pain	O
models	O
because	O
hyperalgesia	B-DISEASE
and	O
allodynia	I-DISEASE
mimic	O
isolated	O
aspects	O
of	O
clinical	O
pain	O
disorders	O
.	O

These	O
mutations	O
were	O
not	O
found	O
in	O
150	O
normal	O
DNA	O
samples	O
.	O

Safety	O
of	O
capecitabine	B-Chemical
:	O
a	O
review	O
.	O

The	O
first	O
one	O
had	O
not	O
yet	O
been	O
described	O
.	O

The	O
gene	O
list	O
was	O
derived	O
from	O
microarrays	O
of	O
human	O
and	O
mouse	O
podocyte	O
cell	O
lines	O
and	O
glomeruli	O
from	O
human	O
kidney	O
biopsies	O
.	O

Our	O
study	O
corroborates	O
the	O
extreme	O
heterogeneity	O
of	O
ARNSHL	B-DISEASE
.	O

OBJECTIVE	O
:	O
Post	O
-	O
mortem	O
studies	O
have	O
reported	O
abnormalities	O
of	O
the	O
cholinergic	O
system	O
in	O
autism	B-DISEASE
.	O

The	O
variant	O
is	O
predicted	O
to	O
cause	O
a	O
truncation	O
of	O
CD164	B-GENE
by	O
introducing	O
a	O
premature	O
stop	O
codon	O
at	O
amino	O
acid	O
position	O
192	O
(	O
p	B-VARIANT
.	I-VARIANT
R192	I-VARIANT
*	I-VARIANT
)	O
[	O
UniProtKB	O
NP_006007	O
.	O
2	O
]	O
)	O
and	O
is	O
not	O
present	O
in	O
any	O
available	O
databases	O
.	O

In	O
controls	O
,	O
no	O
predictive	O
values	O
for	O
renal	O
parameters	O
were	O
observed	O
.	O

Illumina	O
sequencing	O
adapters	O
containing	O
6	O
bp	O
sequence	O
tags	O
were	O
ligated	O
to	O
the	O
samples	O
,	O
with	O
each	O
DNA	O
sample	O
being	O
ligated	O
to	O
a	O
different	O
tag	O
.	O

Obviously	O
,	O
this	O
strategy	O
only	O
applies	O
to	O
Danish	O
ADOA	B-DISEASE
patients	O
,	O
however	O
,	O
it	O
must	O
be	O
emphasized	O
that	O
for	O
other	O
populations	O
the	O
fraction	O
of	O
deletions	O
detectable	O
by	O
MLPA	O
analysis	O
and	O
mutations	O
detectable	O
by	O
DNA	O
sequence	O
analysis	O
must	O
be	O
determined	O
and	O
probably	O
both	O
kinds	O
of	O
analyses	O
must	O
be	O
performed	O
to	O
achieve	O
a	O
high	O
detection	O
rate	O
.	O

In	O
seventeen	O
Roma	O
patients	O
(	O
5	O
Slovak	O
,	O
5	O
Czech	O
and	O
7	O
Hungarian	O
)	O
,	O
we	O
genotyped	O
21	O
biallelic	O
polymorphisms	O
spanning	O
approxximately	O
5	O
.	O
34	O
Mb	O
around	O
the	O
mutation	O
.	O

Functional	O
studies	O
were	O
performed	O
using	O
either	O
minigenes	O
as	O
splicing	O
reporters	O
or	O
cultured	O
cells	O
obtained	O
from	O
a	O
heterozygous	O
carrier	O
.	O

Although	O
anterior	B-DISEASE
lenticonus	I-DISEASE
has	O
long	O
been	O
recognized	O
as	B-DISEASE
a	O
characteristic	O
ocular	O
manifestation	O
of	O
AS	B-DISEASE
,	O
posterior	B-DISEASE
lenticonus	I-DISEASE
has	O
rarely	O
been	O
reported	O
to	O
be	O
associated	O
with	O
AS	B-DISEASE
[	O
16	O
]	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
USH2A	B-GENE
in	O
USH2	B-DISEASE
,	O
mutation	O
screening	O
was	O
undertaken	O
in	O
three	O
Chinese	O
families	O
with	O
USH2	B-DISEASE
.	O

(	O
2	O
)	O
For	O
families	O
which	O
are	O
wild	O
-	O
type	O
at	O
the	O
commonly	O
mutant	O
genes	O
,	O
we	O
tested	O
for	O
linkage	O
of	O
the	O
phenotype	O
to	O
all	O
known	O
disease	O
genes	O
by	O
a	O
'	O
subgenome	O
scan	O
'	O
consisting	O
of	O
markers	O
intragenic	O
or	O
immediately	O
flanking	O
all	O
genes	O
known	O
to	O
be	O
associated	O
with	O
the	O
phenotype	O
.	O

Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	B-Chemical
(	O
2	O
defects	O
)	O
,	O
penicillins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
cephalosporins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
and	O
quinolones	B-Chemical
(	O
1	O
defect	O
)	O
.	O

The	O
blue	O
line	O
shows	O
the	O
lower	O
limit	O
of	O
coverage	O
appropriate	O
to	O
perform	O
CNV	O
analyses	O
(	O
250x	O
)	O
.	O

This	O
novel	O
model	O
of	O
OCD	B-DISEASE
demonstrates	O
that	O
drug	O
exposure	O
during	O
a	O
sensitive	O
period	O
can	O
program	O
disease	O
-	O
like	O
systems	O
permanently	O
,	O
which	O
could	O
have	O
implications	O
for	O
current	O
and	O
future	O
therapeutic	O
strategies	O
for	O
this	O
and	O
other	O
psychiatric	B-DISEASE
disorders	I-DISEASE
.	O

The	O
MYO7A	B-GENE
encodes	O
a	O
protein	O
classified	O
as	O
an	O
unconventional	O
myosin	O
.	O

A	O
primary	O
network	O
(	O
score	O
53	O
)	O
containing	O
28	O
of	O
the	O
seed	O
proteins	O
was	O
generated	O
and	O
shows	O
multiple	O
interactions	O
between	O
molecules	O
.	O

Sensory	O
nerve	O
action	O
potentials	O
(	O
SNAPs	O
)	O
of	O
the	O
median	O
,	O
ulnar	O
,	O
and	O
sural	O
nerves	O
were	O
absent	O
in	O
both	O
patients	O
.	O

The	O
pedigree	O
shows	O
autosomal	O
recessive	O
inheritance	O
of	O
compound	O
heterozygous	O
NARS2	B-GENE
variants	O
[	O
c	B-VARIANT
.	I-VARIANT
969T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Tyr323	I-VARIANT
*	I-VARIANT
]	O
and	O
[	O
c	B-VARIANT
.	I-VARIANT
1142A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Asn381Ser	I-VARIANT
]	O
.	O

Niacin	B-Chemical
extended	I-Chemical
-	I-Chemical
release	I-Chemical
/	I-Chemical
lovastatin	I-Chemical
1	O
,	O
000	O
/	O
40	O
mg	O
,	O
dosed	O
as	O
initial	O
therapy	O
,	O
was	O
associated	O
with	O
good	O
compliance	O
and	O
safety	O
and	O
had	O
very	O
low	O
incidences	O
of	O
increased	O
liver	O
and	O
muscle	O
enzymes	O
.	O

C	O
.	O

A	O
series	O
of	O
aryl	B-Chemical
-	I-Chemical
piperazine	I-Chemical
analogues	O
of	O
buspirone	B-Chemical
and	O
other	O
5	B-Chemical
-	I-Chemical
hydroxytryptaminergic	I-Chemical
agonists	I-Chemical
were	O
tested	O
for	O
their	O
ability	O
to	O
reverse	O
haloperidol	B-Chemical
induced	O
catalepsy	O
.	O

The	O
HW	O
helix	O
contains	O
the	O
actin	O
-	O
binding	O
motif	O
,	O
and	O
the	O
strand	O
is	O
part	O
of	O
the	O
central	O
beta	O
sheet	O
or	O
transducer	O
region	O
,	O
which	O
concerted	O
distortion	O
led	O
to	O
conformational	O
changes	O
of	O
the	O
motor	O
domain	O
.	O

The	O
area	O
under	O
the	O
plasma	O
concentration	O
time	O
curve	O
at	O
90	O
min	O
was	O
4	O
-	O
12	O
times	O
greater	O
than	O
for	O
oral	O
drug	O
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absorption	O
-	O
limiting	O
process	O
in	O
the	O
intestine	O
,	O
and	O
providing	O
an	O
alternate	O
form	O
of	O
administration	O
for	O
quaternary	O
drugs	O
.	O

SOLiD	O
data	O
were	O
initially	O
processed	O
using	O
the	O
ICS	O
software	O
to	O
obtain	O
primary	O
sequence	O
analysis	O
consisting	O
of	O
image	O
analysis	O
and	O
basecalling	O
colorspace	O
fasta	O
sequence	O
.	O

In	O
35	O
patients	O
(	O
ages	O
20	O
to	O
86	O
yr	O
)	O
receiving	O
cimetidine	B-Chemical
therapeutically	O
two	O
serum	O
samples	O
and	O
all	O
urine	O
formed	O
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	O
of	O
cimetidine	B-Chemical
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
and	O
for	O
creatinine	B-Chemical
.	O

Pergolide	B-Chemical
was	O
discontinued	O
in	O
10	O
patients	O
with	O
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
,	O
resulting	O
in	O
a	O
lower	O
regurgitation	O
grade	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	O
and	O
the	O
two	O
patients	O
with	O
heart	B-DISEASE
failure	I-DISEASE
returned	O
to	O
nearly	O
normal	O
clinical	O
examination	O
.	O

USH1	B-DISEASE
patient	O
U1170	O
carried	O
mutations	O
in	O
MYO7A	B-GENE
,	O
a	O
truncating	O
mutation	O
and	O
a	O
newly	O
described	O
missense	O
,	O
p	O
.	O
(	O
Gly158Arg	B-VARIANT
)	O
.	O

Patients	O
'	O
genomic	O
DNA	O
was	O
extracted	O
either	O
from	O
fresh	O
or	O
frozen	O
whole	O
blood	O
samples	O
with	O
Puregene	O
(	O
tm	O
)	O
Genomic	O
DNA	O
Purification	O
Kit	O
(	O
Gentra	O
Systems	O
,	O
MN	O
)	O
or	O
from	O
saliva	O
with	O
Oragene	B-Chemical
(	O
tm	B-Chemical
)	O
kits	O
(	O
DNA	O
Genotek	O
Inc	O
.	O
,	O
Ontario	O
,	O
Canada	O
)	O
.	O

Throughout	O
the	O
study	O
(	O
20	O
weeks	O
)	O
,	O
deaths	O
related	O
to	O
cardiotoxicity	B-DISEASE
were	O
observed	O
only	O
in	O
animals	O
that	O
received	O
either	O
free	O
DOX	B-Chemical
or	O
the	O
mixture	O
of	O
HPMA	B-Chemical
copolymer	O
and	O
free	O
DOX	B-Chemical
;	O
in	O
these	O
cases	O
,	O
histological	O
investigations	O
revealed	O
marked	O
changes	O
in	O
the	O
heart	O
that	O
were	O
consistent	O
with	O
DOX	B-Chemical
-	O
induced	O
cardiotoxicity	B-DISEASE
.	O

As	O
such	O
,	O
it	O
is	O
unlikely	O
that	O
GJB4	B-GENE
p	B-VARIANT
.	I-VARIANT
C169W	I-VARIANT
leads	O
to	O
ADNSHL	B-DISEASE
given	O
its	O
high	O
allele	O
frequency	O
in	O
the	O
population	O
.	O

(	O
A	O
)	O
Mean	O
coverage	O
of	O
80	O
x	O
over	O
the	O
targeted	O
region	O
was	O
achieved	O
;	O
A	O
portion	O
of	O
the	O
sequenced	O
region	O
is	O
shown	O
.	O

Before	O
being	O
introduced	O
into	O
THP	O
-	O
1	O
cells	O
(	O
10	O
6	O
)	O
using	O
a	O
Cell	O
Line	O
Nucleofector	O
Kit	O
V	O
(	O
Amaxa	O
Biosystems	O
,	O
Cologne	O
,	O
Germany	O
)	O
,	O
phorbol	B-Chemical
myristate	I-Chemical
acetate	I-Chemical
(	O
10	O
ng	O
/	O
ml	O
)	O
was	O
added	O
to	O
enhance	O
transient	O
expression	O
of	O
NLRP3	B-GENE
gene	O
with	O
minimizing	O
spontaneous	O
cell	O
death	O
.	O

At	O
the	O
centerpiece	O
of	O
this	O
intricate	O
system	O
are	O
the	O
outer	O
and	O
inner	O
hair	O
cells	O
(	O
OHCs	O
,	O
IHCs	O
)	O
-	O
-	O
key	O
structures	O
in	O
the	O
mechanotransduction	O
process	O
by	O
which	O
mechanical	O
stimuli	O
are	O
translated	O
into	O
electrical	O
impulses	O
[	O
4	O
]	O
.	O

The	O
interval	O
changes	O
over	O
3	O
years	O
in	O
patient	O
II	O
-	O
2	O
revealed	O
slow	O
disease	O
progression	O
.	O

About	O
20	O
%	O
-	O
30	O
%	O
RP	B-DISEASE
patients	O
have	O
extra	B-DISEASE
-	I-DISEASE
ocular	I-DISEASE
diseases	I-DISEASE
,	O
which	O
are	O
included	O
in	O
more	O
than	O
30	O
different	O
syndromes	O
[	O
1	O
]	O
.	O

We	O
identified	O
two	O
deleterious	O
nonallelic	O
COL4A3	B-GENE
mutations	O
,	O
one	O
novel	O
and	O
the	O
other	O
previously	O
reported	O
in	O
an	O
Alport	B-DISEASE
syndrome	I-DISEASE
(	O
AS	B-DISEASE
)	O
patient	O
.	O

that	O
showed	O
the	O
degree	O
of	O
proteinuria	B-DISEASE
in	O
mice	O
with	O
a	O
COL4A4	B-GENE
mutation	O
is	O
dependent	O
on	O
their	O
genetic	O
background	O
26	O
.	O

The	O
most	O
-	O
common	O
inner	O
ear	O
deformity	O
,	O
EVA	B-DISEASE
,	O
is	O
rare	O
in	O
the	O
Chinese	O
Tibetan	O
hearing	O
-	O
loss	O
population	O
.	O

(	O
DOCX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

A	O
recent	O
study	O
proposed	O
that	O
single	O
mutations	O
in	O
both	O
SLC26A4	B-GENE
and	O
KCNJ10	B-GENE
lead	O
to	O
digenic	O
NSEVA	B-DISEASE
.	O

Nifedipine	B-Chemical
significantly	O
improved	O
kidney	O
function	O
as	O
indicated	O
by	O
a	O
significant	O
lowering	O
of	O
serum	O
creatinine	B-Chemical
levels	O
at	O
6	O
and	O
12	O
months	O
.	O

"	O
This	O
will	O
initiate	O
the	O
download	O
of	O
a	O
pdf	O
archive	O
that	O
contains	O
the	O
table	O
.	O
Participating	O
institutions	O
:	O
see	O
Acknowledgments	O
Mutations	O
in	O
SLC26A4	B-GENE
cause	O
a	O
broad	O
phenotypic	O
spectrum	O
,	O
from	O
typical	O
Pendred	B-DISEASE
syndrome	I-DISEASE
to	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
associated	O
with	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
.	O

Older	O
age	O
was	O
significantly	O
correlated	O
with	O
the	O
CHF	B-DISEASE
development	O
;	O
with	O
median	O
ages	O
for	O
the	O
entire	O
group	O
and	O
for	O
patients	O
developing	O
CHF	B-DISEASE
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O

Most	O
of	O
the	O
mutations	O
(	O
[	O
?	O
]	O
60	O
%	O
)	O
in	O
the	O
published	O
surveys	O
have	O
not	O
been	O
reported	O
previously	O
,	O
whereas	O
we	O
only	O
identified	O
28	O
%	O
novel	O
mutations	O
in	O
this	O
study	O
.	O

It	O
is	O
our	O
hope	O
that	O
the	O
more	O
severe	O
LQTS	B-DISEASE
phenotype	O
seen	O
in	O
the	O
father	O
can	O
help	O
support	O
Lahtinen	O
AM	O
et	O
al	O
.	O
'	O
s	O
[	O
37	O
]	O
proposition	O
that	O
the	O
KCNE1	B-GENE
-	O
D85N	B-VARIANT
mutation	O
might	O
preferentially	O
affect	O
males	O
.	O

rerio	O
;	O
OR	O
(	O
b	O
)	O
the	O
given	O
disease	O
causing	O
allele	O
is	O
supported	O
by	O
functional	O
data	O
.	O

Intracavitary	O
chemotherapy	O
in	O
recurrent	O
glioblastoma	B-DISEASE
using	O
cubic	O
phases	O
is	O
feasible	O
and	O
safe	O
,	O
yet	O
the	O
clinical	O
benefit	O
remains	O
to	O
be	O
examined	O
in	O
a	O
clinical	O
phase	O
II	O
study	O
.	O

In	O
F20	O
,	O
a	O
male	O
fetus	O
with	O
increased	O
nuchal	O
translucency	O
(	O
>	O
3	O
.	O
5	O
mm	O
)	O
,	O
tricuspid	O
regurgitation	O
and	O
abnormal	O
legs	O
and	O
feet	O
with	O
an	O
extended	O
posture	O
and	O
bilateral	B-DISEASE
talipes	I-DISEASE
equinovarus	I-DISEASE
anomaly	O
,	O
we	O
found	O
c	B-VARIANT
.	I-VARIANT
3490G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
1164G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
in	O
COL2A1	B-GENE
(	O
MIM	O
120140	O
,	O
ENST00000380518	O
)	O
.	O

We	O
analyzed	O
119	O
trios	O
to	O
identify	O
both	O
diagnostic	O
genotypes	O
in	O
known	O
genes	O
and	O
candidate	O
genotypes	O
in	O
novel	O
genes	O
.	O

We	O
identified	O
deleterious	O
mutations	O
in	O
CDH23	B-GENE
,	O
MYO15A	B-GENE
,	O
TECTA	B-GENE
,	O
TMC1	B-GENE
,	O
and	O
WFS1	B-GENE
.	O

The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use	O
.	O

2002	O
;	O
Seri	O
et	O
al	O
.	O

(	O
D	O
)	O
Confocal	O
images	O
of	O
COS7	O
cells	O
co	O
-	O
transfected	O
with	O
cMYC	O
-	O
tagged	O
HOMER2	B-GENE
WT	O
and	O
FLAG	O
-	O
tagged	O
HOMER2	B-GENE
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
immuno	O
-	O
stained	O
with	O
Alexa	B-Chemical
-	I-Chemical
Fluor	I-Chemical
-	O
568	O
and	O
Alexa	B-Chemical
-	I-Chemical
Fluor	I-Chemical
-	O
488	O
,	O
respectively	O
;	O
cell	O
nuclei	O
stained	O
with	O
DAPI	B-Chemical
(	O
blue	O
)	O
.	O

Affected	O
subject	O
III	O
-	O
4	O
from	O
Branch	O
A	O
and	O
III	O
-	O
13	O
from	O
Branch	O
B	O
were	O
selected	O
for	O
sequencing	O
.	O

Four	O
of	O
these	O
were	O
excluded	O
because	O
they	O
were	O
synonymous	O
variants	O
.	O

A	O
Graphical	O
view	O
of	O
the	O
LOD	O
score	O
calculation	O
of	O
genome	O
-	O
wide	O
SNP	O
mapping	O
.	O

The	O
mutation	O
analysis	O
of	O
the	O
DMD	B-DISEASE
gene	O
was	O
performed	O
using	O
multiplex	O
PCR	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
technique	O
and	O
a	O
kit	O
from	O
MRC	O
-	O
Holland	O
,	O
Amsterdam	O
,	O
the	O
Netherlands	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

(	O
A	O
)	O
Pedigree	O
for	O
family	O
2	O
.	O

Baseline	O
renal	O
ACE	B-DISEASE
did	O
not	O
correlate	O
with	O
focal	O
glomerulosclerosis	I-DISEASE
(	O
r	O
=	O
0	O
.	O
22	O
,	O
NS	O
)	O
.	O

Individual	O
III	O
-	O
1	O
(	O
Figure	O
1	O
A	O
)	O
was	O
born	O
after	O
a	O
normal	O
pregnancy	O
and	O
was	O
referred	O
for	O
craniofacial	O
assessment	O
at	O
two	O
years	O
of	O
age	O
because	O
prominent	O
eyes	O
and	O
a	O
head	O
tilt	O
.	O

Effects	O
of	O
long	O
-	O
term	O
pretreatment	O
with	O
isoproterenol	B-Chemical
on	O
bromocriptine	B-Chemical
-	O
induced	O
tachycardia	B-DISEASE
in	O
conscious	O
rats	O
.	O

RNA	B-DISEASE
polymerase	I-DISEASE
III	I-DISEASE
(	I-DISEASE
POLR3	I-DISEASE
)	I-DISEASE
-	I-DISEASE
related	I-DISEASE
leukodystrophy	I-DISEASE
or	O
4H	B-DISEASE
(	I-DISEASE
Hypomyelination	B-DISEASE
,	I-DISEASE
Hypodontia	B-DISEASE
and	I-DISEASE
Hypogonadotropic	B-DISEASE
Hypogonadism	I-DISEASE
)	I-DISEASE
leukodystrophy	I-DISEASE
(	O
MIM	O
607694	O
,	O
614381	O
)	O
3	O
was	O
found	O
to	O
be	O
caused	O
by	O
recessive	O
mutations	O
in	O
POLR3A	B-GENE
(	O
MIM	O
614258	O
)	O
or	O
POLR3B	B-GENE
(	O
MIM	O
614366	O
)	O
4	O
5	O
6	O
7	O
8	O
9	O
and	O
is	O
characterized	O
by	O
an	O
expanding	O
spectrum	O
of	O
clinical	O
3	O
10	O
and	O
radiological	O
features	O
10	O
11	O
12	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
FGFR2	B-GENE
are	O
associated	O
with	O
craniosynostosis	B-DISEASE
.	O

2004	O
;	O
Chen	O
et	O
al	O
.	O

CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	B-Chemical
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	B-Chemical
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	B-Chemical
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O

A	O
number	O
of	O
neurodegenerative	B-DISEASE
disorders	I-DISEASE
including	O
Alzheimer	B-DISEASE
'	I-DISEASE
s	I-DISEASE
,	O
Huntington	B-DISEASE
'	I-DISEASE
s	I-DISEASE
,	O
and	O
prion	B-DISEASE
diseases	I-DISEASE
have	O
also	O
been	O
proposed	O
as	O
disorders	O
of	O
the	O
ER	O
stress	O
response	O
,	O
suggesting	O
that	O
WFS	B-DISEASE
may	O
also	O
represent	O
a	O
useful	O
model	O
of	O
much	O
more	O
common	O
neurodegenerative	B-DISEASE
diseases	I-DISEASE
[	O
33	O
]	O
.	O

The	O
mutation	O
was	O
also	O
present	O
,	O
in	O
the	O
heterozygous	O
state	O
,	O
in	O
one	O
clinically	O
unaffected	O
sibling	O
and	O
in	O
both	O
unaffected	O
parents	O
,	O
and	O
was	O
absent	O
from	O
the	O
other	O
two	O
unaffected	O
siblings	O
.	O

Male	O
rats	O
that	O
received	O
prenatal	O
dexamethasone	B-Chemical
on	O
days	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	O
had	O
elevated	O
blood	O
pressures	I-DISEASE
at	O
6	O
months	O
of	O
age	O
;	O
the	O
latter	O
group	O
did	O
not	O
have	O
a	O
reduction	O
in	O
glomerular	O
number	O
.	O

The	O
difficulty	O
to	O
detect	O
inclusions	O
in	O
cases	O
with	O
R702	O
mutations	O
such	O
as	O
R702H	B-VARIANT
can	O
be	O
explained	O
by	O
their	O
low	O
polyA	B-Chemical
(	O
+	O
)	O
RNA	O
content	O
(	O
Kunishima	B-Chemical
et	O
al	O
.	O

The	O
positions	O
of	O
the	O
C	O
>	O
T	O
and	O
G	O
>	O
A	O
transitions	O
(	O
numbered	O
according	O
to	O
NM_015340	O
.	O
3	O
cDNA	O
)	O
is	O
indicated	O
by	O
an	O
arrow	O
.	O

The	O
second	O
aim	O
was	O
to	O
initiate	O
prioritized	O
linkage	O
analysis	O
(	O
in	O
families	O
of	O
three	O
or	O
more	O
affected	O
individuals	O
)	O
and	O
homozygosity	O
mapping	O
(	O
in	O
families	O
with	O
two	O
affected	O
sib	O
-	O
pair	O
individuals	O
)	O
of	O
other	O
known	O
deafness	B-DISEASE
loci	O
for	O
families	O
in	O
which	O
DFNB1	B-GENE
has	O
been	O
excluded	O
.	O

Our	O
results	O
(	O
see	O
Fig	O
.	O

Visual	O
acuity	O
was	O
0	O
.	O
05	O
in	O
both	O
eyes	O
,	O
and	O
he	O
presented	O
with	O
pseudophakia	B-Chemical
.	O

2	O
.	O

Four	O
other	O
cases	O
with	O
chromodomain	O
helicase	O
DNA	O
binding	O
protein	O
7	O
(	O
CHD7	B-GENE
)	O
mutation	O
in	O
CHARGE	B-DISEASE
were	O
diagnosed	O
elsewhere	O
before	O
the	O
study	O
.	O

The	O
eight	O
additional	O
mutations	O
found	O
in	O
these	O
patients	O
were	O
amino	O
acid	O
substitutions	O
that	O
were	O
predicted	O
"	O
probably	O
damaging	O
"	O
and	O
"	O
not	O
tolerated	O
"	O
by	O
Polyphen	B-Chemical
and	O
SIFT	B-Chemical
program	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
'	O
long	O
-	O
term	O
'	O
group	O
had	O
significant	O
glomerular	O
and	O
tubular	O
lesions	I-DISEASE
,	O
depressed	O
activities	O
of	O
mtDNA	B-GENE
-	O
encoded	O
NADH	O
dehydrogenase	O
and	O
cytochrome	O
-	I-GENE
c	I-GENE
oxidase	O
(	O
COX	B-GENE
)	O
and	O
increased	O
citrate	B-Chemical
synthase	O
activity	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
cases	O
of	O
psychogenic	B-DISEASE
parasitosis	O
occurring	O
during	O
interferon	O
therapy	O
have	O
been	O
described	O
in	O
the	O
literature	O
.	O

These	O
antibiotics	B-Chemical
have	O
the	O
unique	O
capability	O
to	O
promote	O
translation	O
read	O
-	O
through	O
of	O
PTCs	B-DISEASE
but	O
not	O
of	O
normal	O
termination	O
codons	O
,	O
resulting	O
in	O
restoration	O
of	O
normally	O
functioning	O
proteins	O
[	O
36	O
-	O
39	O
]	O
.	O

The	O
vertebral	O
bodies	O
are	O
flattened	O
and	O
elongated	O
.	O

Knowledge	O
of	O
these	O
ER	O
stress	O
-	O
enhancing	O
factors	O
may	O
be	O
important	O
in	O
the	O
clinical	O
management	O
of	O
patients	O
with	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
muscle	O
biopsy	O
was	O
taken	O
from	O
the	O
left	O
vastus	O
lateralis	O
muscle	O
under	O
local	O
anesthesia	O
.	O

Damhuis	O
,	O
A	O
.	O

The	O
tridimesional	O
model	O
of	O
PRS	B-GENE
-	I-GENE
I	I-GENE
with	O
p	B-VARIANT
.	I-VARIANT
Ser16Pro	I-VARIANT
indicated	O
that	O
Ser16	O
is	O
located	O
in	O
the	O
first	O
alpha	O
-	O
helix	O
of	O
the	O
protein	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
Figure	O
1	O
D	O
)	O
.	O

Best	O
-	O
corrected	O
visual	O
acuity	O
ranged	O
from	O
20	O
/	O
25	O
to	O
20	O
/	O
400	O
(	O
0	O
.	O
1	O
-	O
1	O
.	O
3	O
logMAR	O
units	O
)	O
.	O

Angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
protein	O
,	O
a	O
component	O
of	O
tTJs	O
,	O
provides	O
a	O
strong	O
barrier	O
property	O
to	O
the	O
epithelium	O
in	O
cultured	O
epithelial	O
cells	O
.	O

IF	O
is	O
proposed	O
as	O
a	O
reliable	O
and	O
more	O
sensitive	O
technique	O
(	O
Savoia	B-Chemical
et	O
al	O
.	O

The	O
function	O
of	O
wolframin	B-GENE
in	O
the	O
inner	O
ear	O
and	O
the	O
mechanisms	O
by	O
which	O
missense	O
mutations	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
have	O
not	O
been	O
extensively	O
explored	O
[	O
32	O
]	O
.	O

B	O
-	O
cells	O
autoantibodies	O
were	O
absent	O
.	O

Patient	O
28	O
also	O
had	O
an	O
observed	O
novel	O
exonic	O
hit	O
and	O
is	O
thus	O
considered	O
solved	O
.	O

Forty	O
-	O
three	O
percent	O
(	O
43	O
%	O
)	O
,	O
or	O
1	O
,	O
166	O
,	O
of	O
the	O
variants	O
are	O
novel	O
(	O
not	O
in	O
dbSNP	O
)	O
,	O
all	O
with	O
MAFs	O
between	O
0	O
.	O
07	O
%	O
and	O
1	O
.	O
4	O
%	O
.	O

The	O
UCSC	O
genome	O
browser	O
(	O
http	O
:	O
/	O
/	O
genome	O
.	O
ucsc	O
.	O
edu	O
/	O
cgi	O
-	O
bin	O
/	O
hgTables	O
?	O
org	O
=	O
Human	O
&	O
db	O
=	O
hg19	O
&	O
hgsid	O
=	O
192997943	O
&	O
hgta_doMainPage	O
=	O
1	O
)	O
was	O
used	O
to	O
obtain	O
the	O
start	O
and	O
end	O
sites	O
of	O
each	O
exon	O
including	O
known	O
isoforms	O
and	O
75	O
bp	O
of	O
flanking	O
regions	O
were	O
additionally	O
included	O
to	O
cover	O
the	O
exon	O
-	O
intron	O
boundaries	O
and	O
the	O
splice	O
junctions	O
.	O

Although	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
mutations	O
were	O
absent	O
in	O
our	O
patients	O
,	O
our	O
results	O
show	O
that	O
CDH23	B-GENE
mutation	O
caused	O
ARNSHL	B-DISEASE
in	O
2	O
of	O
13	O
(	O
15	O
%	O
)	O
affected	O
Korean	O
families	O
and	O
that	O
3	O
of	O
93	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
carried	O
a	O
heterozygous	O
mutation	O
.	O

Diabetes	B-DISEASE
of	O
4	O
months	O
duration	O
also	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
,	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
,	O
effects	O
which	O
were	O
reversed	O
by	O
insulin	O
treatment	O
for	O
the	O
final	O
2	O
months	O
of	O
the	O
study	O
.	O

S2	O
)	O
.	O

For	O
the	O
c	B-VARIANT
.	I-VARIANT
2289	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
variant	O
the	O
different	O
results	O
obtained	O
by	O
both	O
methods	O
are	O
due	O
to	O
the	O
minigene	O
construction	O
did	O
not	O
contain	O
the	O
entire	O
intron	O
21	O
of	O
the	O
CDH23	B-GENE
gene	O
.	O

In	O
the	O
clinical	O
field	O
,	O
identification	O
of	O
these	O
hearing	B-DISEASE
loss	I-DISEASE
genes	O
has	O
greatly	O
aided	O
genetic	O
counselling	O
on	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Computed	O
tomography	O
of	O
brain	O
and	O
electroencephalogram	O
were	O
unremarkable	O
.	O

The	O
most	O
dramatic	O
hemodynamic	O
changes	O
occurred	O
after	O
each	O
cocaine	B-Chemical
bolus	O
in	O
the	O
C	O
+	O
E	O
and	O
C	O
only	O
groups	O
;	O
however	O
,	O
persistent	O
hemodynamic	O
changes	O
occurred	O
in	O
the	O
C	O
+	O
E	O
group	O
.	O

Also	O
shown	O
on	O
the	O
alignment	O
are	O
the	O
missense	O
mutations	O
that	O
cause	O
either	O
MED	B-DISEASE
(	O
*	O
)	O
,	O
PSACH	B-DISEASE
(	O
^	O
)	O
,	O
or	O
both	O
(	O
+	O
)	O
phenotypes	O
.	O

BUN	B-Chemical
and	O
creatinine	B-Chemical
increased	O
by	O
>	O
50	O
%	O
of	O
baseline	O
levels	O
in	O
54	O
and	O
45	O
%	O
of	O
Group	O
A	O
patients	O
,	O
respectively	O
,	O
compared	O
to	O
only	O
20	O
and	O
10	O
%	O
of	O
Group	O
B	O
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

All	O
10	O
exons	O
of	O
PAX3	B-GENE
and	O
all	O
9	O
exons	O
of	O
MITF	B-GENE
were	O
PCR	O
-	O
amplified	O
and	O
directly	O
sequenced	O
.	O

Histopathological	O
examination	O
of	O
kidney	O
,	O
heart	O
and	O
lung	O
sections	O
revealed	O
moderate	O
to	O
massive	O
tissue	O
damage	O
with	O
a	O
variety	O
of	O
morphological	O
aberrations	O
by	O
all	O
the	O
three	O
drugs	O
in	O
the	O
absence	O
of	O
GSPE	B-Chemical
preexposure	O
than	O
in	O
its	O
presence	O
.	O

Retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
;	O
OMIM	O
#	O
268000	O
)	O
is	O
a	O
heterogeneous	O
group	O
of	O
inherited	O
disorders	O
characterized	O
by	O
visual	B-DISEASE
field	I-DISEASE
loss	I-DISEASE
,	O
night	B-DISEASE
blindness	I-DISEASE
,	O
abnormal	B-DISEASE
color	I-DISEASE
vision	I-DISEASE
and	O
fundus	B-DISEASE
degeneration	I-DISEASE
.	O

Gene	O
analysis	O
of	O
COL4A5	B-GENE
was	O
performed	O
in	O
II	O
-	O
2	O
,	O
III	O
-	O
1	O
and	O
I	O
-	O
2	O
with	O
approval	O
from	O
the	O
Ethical	O
Committee	O
of	O
Peking	O
University	O
First	O
Hospital	O
.	O

3	O
Solve	O
rate	O
and	O
implicated	O
genes	O
across	O
ethnicities	O
.	O

The	O
nucleotide	O
change	O
was	O
a	O
heterozygous	O
G	O
>	O
T	O
at	O
position	O
833	O
(	O
arrow	O
)	O
,	O
resulting	O
in	O
Cys278Phe	B-VARIANT
.	O

None	O
of	O
these	O
variants	O
were	O
detected	O
among	O
100	O
healthy	O
Chinese	O
individuals	O
.	O

This	O
predominant	O
localisation	O
in	O
exons	O
2	O
-	O
6	O
has	O
previously	O
been	O
described	O
.	O

Transport	O
activity	O
of	O
wild	O
-	O
type	O
pendrin	O
and	O
10	O
mutant	O
pendrins	O
.	O

The	O
significance	O
of	O
these	O
syndromal	O
DOA	B-DISEASE
variants	O
was	O
recently	O
highlighted	O
by	O
the	O
identification	O
of	O
cytochrome	O
c	O
oxidase	O
(	O
COX	O
)	O
-	O
deficient	O
muscle	O
fibres	O
and	O
multiple	O
mtDNA	O
deletions	O
in	O
skeletal	O
muscle	O
biopsies	O
from	O
these	O
patients	O
,	O
implicating	O
a	O
previously	O
unsuspected	O
role	O
of	O
OPA1	B-GENE
in	O
mtDNA	O
maintenance	O
(	O
Amati	B-Chemical
-	O
Bonneau	O
et	O
al	O
.	O

The	O
relative	O
amount	O
for	O
each	O
transcript	O
was	O
calculated	O
by	O
a	O
standard	O
curve	O
of	O
cycle	O
thresholds	O
for	O
serial	O
dilutions	O
of	O
cDNA	O
samples	O
and	O
normalized	O
to	O
the	O
amount	O
of	O
beta	O
-	O
actin	O
.	O

Splice	O
mutation	O
;	O
causes	O
USH2A	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
Pro2533Asnfs	I-VARIANT
*	I-VARIANT
5	I-VARIANT
.	O

The	O
heads	O
of	O
all	O
samples	O
were	O
dissected	O
in	O
PBS	O
before	O
fixation	O
for	O
two	O
days	O
in	O
10	O
%	O
formalin	O
at	O
4	O
deg	O
C	O
,	O
washing	O
,	O
dehydrating	O
and	O
embedding	O
in	O
paraffin	O
wax	O
.	O

DNA	O
encompassing	O
this	O
region	O
and	O
inserted	O
tags	O
were	O
synthesized	O
by	O
Gene	O
Oracle	O
Inc	O
(	O
Mountain	O
View	O
,	O
CA	O
,	O
USA	O
)	O
and	O
cloned	O
into	O
CD164	B-GENE
or	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
in	O
pcDNA3	O
.	O
1	O
.	O

Immunofluorescence	O
and	O
electron	O
microscopy	O
detected	O
no	O
immunoglobulin	O
A	O
(	O
Ig	O
A	O
)	O
deposition	O
.	O

Analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
used	O
to	O
compare	O
data	O
among	O
the	O
groups	O
,	O
with	O
post	O
-	O
hoc	O
analysis	O
using	O
Scheff	B-Chemical
e	O
'	O
s	O
test	O
.	O

Another	O
brother	O
had	O
no	O
variants	O
.	O

The	O
mtDNA	O
target	O
regions	O
showed	O
substantially	O
higher	O
coverage	O
(	O
10	O
,	O
144X	O
median	O
coverage	O
)	O
.	O

The	O
genomic	O
regions	O
of	O
interest	O
were	O
amplified	O
by	O
PCR	O
and	O
subsequently	O
analyzed	O
by	O
double	O
strand	O
sequencing	O
to	O
detect	O
the	O
mutations	O
.	O

It	O
is	O
more	O
effective	O
,	O
cost	O
-	O
effective	O
,	O
and	O
provides	O
high	O
sequencing	O
accuracy	O
.	O

There	O
is	O
no	O
significant	O
statistic	O
difference	O
between	O
the	O
two	O
groups	O
(	O
P	O
value	O
0	O
.	O
09	O
,	O
t	O
=	O
1	O
.	O
71	O
)	O
.	O

Of	O
the	O
529	O
CNVs	O
identified	O
,	O
160	O
intersected	O
with	O
genes	O
(	O
genic	O
-	O
CNVs	O
;	O
131	O
genes	O
disrupted	O
)	O
and	O
369	O
CNVs	O
were	O
in	O
non	O
-	O
coding	O
regions	O
of	O
the	O
genome	O
.	O

Of	O
patients	O
expressing	O
a	O
preference	O
(	O
89	O
.	O
1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	B-Chemical
to	O
ergotamine	B-Chemical
/	O
caffeine	B-Chemical
(	O
69	O
.	O
9	O
vs	O
.	O
30	O
.	O
1	O
%	O
,	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
.	O

Another	O
set	O
of	O
22	O
variants	O
is	O
located	O
in	O
the	O
UTRs	O
and	O
are	O
all	O
reported	O
as	O
polymorphisms	O
.	O

Furthermore	O
,	O
the	O
high	O
coverage	O
obtained	O
in	O
our	O
study	O
allowed	O
us	O
to	O
detect	O
large	O
rearrangements	O
.	O

Furthermore	O
,	O
differences	O
in	O
triggers	O
such	O
as	O
the	O
well	O
-	O
documented	O
beta	B-Chemical
-	O
adrenergic	O
stimulation	O
[	O
36	O
]	O
or	O
the	O
more	O
recently	O
described	O
modulation	O
by	O
natriuretic	B-Chemical
peptide	I-Chemical
precursor	O
A	O
may	O
be	O
involved	O
[	O
23	O
,	O
37	O
]	O
.	O

Splice	O
site	O
mutations	O
were	O
predicted	O
with	O
the	O
Splice	O
Site	O
Prediction	O
by	O
Neural	O
Network	O
[	O
32	O
]	O
.	O

Follow	O
-	O
up	O
studies	O
revealed	O
progression	O
of	O
atrophic	B-DISEASE
changes	I-DISEASE
.	O

He	O
was	O
unable	O
to	O
perceive	O
and	O
describe	O
his	O
own	O
physical	O
problems	O
during	O
medical	O
visits	O
,	O
rejected	O
social	O
contacts	O
,	O
and	O
neglected	O
the	O
need	O
for	O
medical	O
and	O
rehabilitative	O
treatment	O
.	O

The	O
mental	B-DISEASE
retardation	I-DISEASE
and	O
cognitive	O
phenotype	O
in	O
patients	O
with	O
RSTS	B-DISEASE
may	O
be	O
derived	O
from	O
impairments	O
to	O
the	O
function	O
of	O
CREB	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
[	O
2	O
,	O
13	O
]	O
.	O

FD	O
and	O
CP	O
conceived	O
of	O
the	O
study	O
and	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
.	O

Taken	O
together	O
,	O
we	O
identified	O
an	O
OPA1	B-GENE
mutation	O
in	O
a	O
family	O
with	O
ADOA	B-DISEASE
by	O
filling	O
the	O
missing	O
CNGS	O
data	O
.	O

Gellermann	O
(	O
Berlin	O
)	O
,	O
J	O
.	O

'	O
VNTR	O
'	O
designates	O
the	O
45	O
bp	O
variable	O
number	O
of	O
tandem	O
repeat	O
polymorphism	O
in	O
intron	O
5	O
,	O
which	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
.	O

However	O
,	O
the	O
detection	O
of	O
a	O
mild	O
visual	O
phenotype	O
requires	O
patients	O
to	O
be	O
followed	O
with	O
ophthalmoscopy	O
and	O
at	O
least	O
one	O
electroretinography	O
.	O

Antibodies	O
included	O
NDUFS4	B-GENE
(	O
MS104	O
,	O
Mitosciences	O
)	O
at	O
1	O
:	O
1000	O
,	O
Porin	O
(	O
529534	O
,	O
Calbiochem	O
)	O
at	O
1	O
:	O
10000	O
,	O
Complex	O
II	O
70kD	O
subunit	O
(	O
A	O
-	O
1142	O
.	O

Jin	O
et	O
al	O
.	O

The	O
patients	O
were	O
70	O
Danish	O
LQTS	B-DISEASE
probands	O
from	O
unrelated	O
families	O
where	O
mutation	O
screening	O
in	O
the	O
five	O
LQTS	B-DISEASE
associated	O
genes	O
KCNQ1	B-GENE
,	O
KCNH2	B-GENE
,	O
KCNE1	B-GENE
,	O
KCNE2	B-GENE
and	O
SCN5A	B-GENE
had	O
led	O
to	O
the	O
identification	O
of	O
a	O
disease	O
-	O
causing	O
mutation	O
.	O

In	O
one	O
of	O
the	O
5	O
patients	O
the	O
bradycardia	B-DISEASE
was	O
associated	O
with	O
complaints	O
of	O
substernal	O
pressure	I-DISEASE
.	O

No	O
percentages	O
are	O
calculated	O
if	O
there	O
are	O
less	O
than	O
10	O
cases	O
.	O

A	O
full	O
-	O
shaded	O
icon	O
denotes	O
ESRD	B-DISEASE
;	O
individuals	O
with	O
microscopic	B-DISEASE
hematuria	I-DISEASE
and	O
proteinuria	B-DISEASE
but	O
with	O
normal	O
renal	O
function	O
are	O
indicated	O
with	O
a	O
half	O
-	O
shaded	O
icon	O
;	O
individual	O
with	O
unknown	O
phenotype	O
is	O
indicated	O
in	O
gray	O
.	O

Sanger	O
sequencing	O
confirmed	O
the	O
co	O
-	O
segregation	O
of	O
the	O
homozygote	O
mutation	O
with	O
HL	B-DISEASE
in	O
Branch	O
B	O
(	O
Figure	O
1a	O
)	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
mutation	O
was	O
absent	O
in	O
an	O
ethnically	O
matched	O
control	O
group	O
,	O
affected	O
a	O
conserved	O
amino	O
acid	O
,	O
and	O
was	O
predicted	O
by	O
multiple	O
algorithms	O
to	O
be	O
pathogenic	O
.	O

34	O
Both	O
are	O
present	O
in	O
immature	O
chondrocytes	O
but	O
disappear	O
as	O
these	O
cartilage	O
precursors	O
differentiate	O
and	O
mature	O
.	O

Steady	O
-	O
state	O
pharmacokinetics	O
of	O
indinavir	B-Chemical
were	O
done	O
at	O
week	O
4	O
after	O
the	O
initiation	O
of	O
indinavir	B-Chemical
.	O

They	O
received	O
a	O
standard	O
ophthalmologic	O
examination	O
,	O
visual	O
field	O
testing	O
,	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
scan	O
,	O
and	O
electrophysiological	O
tests	O
.	O

3e	O
,	O
f	O
)	O
.	O

CNVs	O
from	O
the	O
exome	O
data	O
were	O
denoted	O
using	O
the	O
CoNVex	O
program	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
the	O
altered	O
gene	O
,	O
we	O
first	O
performed	O
a	O
genetic	O
linkage	O
analysis	O
of	O
fluorescent	O
dye	O
-	O
labeled	O
polymorphic	O
microsatellite	O
markers	O
covering	O
all	O
known	O
loci	O
for	O
USH	B-DISEASE
.	O

Immuno	O
/	O
histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum	O
,	O
and	O
levels	O
of	O
malondialdehyde	B-Chemical
and	O
superoxide	B-Chemical
dismutase	O
were	O
determined	O
.	O

Clinical	O
findings	O
in	O
parents	O
of	O
two	O
families	O
with	O
Pfeiffer	B-DISEASE
syndrome	I-DISEASE
(	O
PS	B-DISEASE
)	O
.	O

Urine	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
D	O
-	O
glucosaminidase	O
-	O
-	O
a	O
marker	O
of	O
tubular	O
damage	O
?	O

More	O
than	O
90	O
%	O
of	O
the	O
target	O
genomic	O
sequences	O
were	O
successfully	O
designed	O
to	O
be	O
captured	O
by	O
the	O
SureSelect	O
Target	O
Enrichment	O
System	O
(	O
Agilent	O
Technologies	O
,	O
CA	O
,	O
USA	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

He	O
was	O
the	O
only	O
case	O
that	O
did	O
not	O
have	O
either	O
a	O
micropenis	B-DISEASE
or	O
cryptorchidism	B-DISEASE
.	O

Necrotising	B-DISEASE
fasciitis	I-DISEASE
after	O
bortezomib	B-Chemical
and	O
dexamethasone	B-Chemical
-	O
containing	O
regimen	O
in	O
an	O
elderly	O
patient	O
of	O
Waldenstrom	B-DISEASE
macroglobulinaemia	I-DISEASE
.	O

Aided	O
thresholds	O
were	O
obtained	O
from	O
all	O
implanted	O
patients	O
in	O
the	O
free	O
-	O
field	O
at	O
frequencies	O
from	O
0	O
.	O
25	O
to	O
4	O
kHz	O
.	O

No	O
significant	O
differences	O
in	O
GJB2	B-GENE
mutation	O
spectra	O
were	O
found	O
among	O
different	O
ethnicities	O
in	O
the	O
Chinese	O
population	O
,	O
although	O
the	O
numbers	O
in	O
the	O
non	O
-	O
Han	O
populations	O
were	O
too	O
small	O
to	O
allow	O
final	O
conclusions	O
to	O
be	O
reached	O
in	O
our	O
study	O
.	O

Cardioprotective	O
effects	O
of	O
Picrorrhiza	O
kurroa	O
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	O
stress	O
in	O
rats	O
.	O

Sequencing	O
of	O
the	O
complete	O
CDS	O
of	O
the	O
EDNRB	B-GENE
gene	O
revealed	O
a	O
c	B-VARIANT
.	I-VARIANT
1A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
heterozygous	O
DNA	O
change	O
in	O
the	O
NM_000115	O
.	O
3	O
sequence	O
.	O

In	O
addition	O
to	O
our	O
highlighted	O
cases	O
,	O
we	O
review	O
the	O
history	O
,	O
classification	O
,	O
pathophysiologic	O
features	O
,	O
and	O
treatment	O
of	O
milk	B-DISEASE
-	I-DISEASE
alkali	I-DISEASE
syndrome	I-DISEASE
and	O
summarize	O
the	O
cases	O
reported	O
from	O
early	O
1995	O
to	O
November	O
2003	O
.	O

F	O
-	O
actin	O
was	O
immuno	O
-	O
stained	O
with	O
Alexa	O
-	I-Chemical
Fluor	I-Chemical
-	O
647	I-Chemical
-	O
phalloidin	I-Chemical
(	O
Invitrogen	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
;	O
1	O
:	O
500	O
)	O
.	O

Overall	O
,	O
we	O
could	O
find	O
causative	O
variants	O
in	O
51	O
(	O
54	O
.	O
8	O
%	O
)	O
of	O
the	O
93	O
cochlear	O
implantees	O
.	O

(	O
B	O
)	O
When	O
the	O
cells	O
were	O
treated	O
with	O
cytochalasin	B-Chemical
D	O
(	O
Cyto	B-Chemical
-	I-Chemical
D	I-Chemical
)	O
,	O
GFP	O
-	O
ELMOD3	B-GENE
was	O
internalized	O
,	O
and	O
no	O
or	O
negligible	O
localization	O
at	O
the	O
cell	O
membrane	O
was	O
observed	O
.	O

The	O
majority	O
of	O
patients	O
in	O
both	O
subgroups	O
harboured	O
multiple	O
mtDNA	O
deletions	O
,	O
but	O
in	O
a	O
few	O
patients	O
with	O
DOA	O
+	O
features	O
,	O
both	O
COX	O
-	O
deficiency	O
and	O
secondary	O
mtDNA	O
deletions	O
were	O
not	O
present	O
,	O
even	O
when	O
using	O
long	O
-	O
range	O
PCR	O
,	O
a	O
highly	O
sensitive	O
technique	O
that	O
preferentially	O
amplifies	O
smaller	O
mtDNA	O
species	O
(	O
Lightowlers	O
et	O
al	O
.	O

CREBBP	B-GENE
mutations	O
are	O
found	O
in	O
50	O
%	O
-	O
60	O
%	O
of	O
RSTS	B-DISEASE
cases	O
,	O
whereas	O
EP300	B-GENE
(	O
OMIM	O
602700	O
)	O
mutations	O
are	O
found	O
in	O
5	O
%	O
of	O
the	O
cases	O
[	O
7	O
,	O
8	O
]	O
.	O

Interspecies	O
conservation	O
of	O
amino	O
acid	O
residues	O
mutated	O
in	O
patients	O
carrying	O
presumably	O
pathogenic	O
mutations	O
in	O
several	O
USH	B-DISEASE
genes	O
.	O

39	O
In	O
nine	O
out	O
of	O
121	O
(	O
7	O
.	O
4	O
%	O
)	O
USH2	B-DISEASE
families	O
,	O
no	O
possibly	O
pathogenic	O
variants	O
were	O
identified	O
.	O

Ahmed	O
et	O
al	O
.	O

The	O
electroretinogram	O
(	O
ERG	O
)	O
was	O
measured	O
according	O
to	O
the	O
standards	O
of	O
the	O
International	O
Society	O
for	O
Clinical	O
Electrophysiology	O
of	O
Vision	O
[	O
27	O
]	O
beginning	O
after	O
30	O
min	O
of	O
dark	O
adaption	O
using	O
10	O
-	O
u	O
s	O
xenon	B-Chemical
flashes	O
in	O
a	O
Ganzfeld	O
bowl	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
is	O
one	O
of	O
the	O
largest	O
to	O
date	O
concerning	O
WFS	B-DISEASE
.	O

Olfaction	O
was	O
assessed	O
with	O
the	O
40	O
-	O
item	O
smell	O
testing	O
(	O
University	O
of	O
Pennsylvania	O
Smell	O
Identification	O
Test	O
,	O
UPSIT	O
,	O
Sensonics	O
Inc	O
,	O
Haddon	O
Heights	O
,	O
NJ	O
)	O
,	O
and	O
individuals	O
scoring	O
<	O
5	O
th	O
percentile	O
for	O
age	O
in	O
UPSIT	B-Chemical
,	O
were	O
classified	O
as	O
anosmic	O
.	O

After	O
removing	O
variants	O
suspected	O
to	O
be	O
non	O
-	O
pathogenic	O
based	O
on	O
previous	O
published	O
findings	O
(	O
ATM	B-GENE
F1463C	B-VARIANT
34	O
,	O
BRCA1	B-GENE
L668F	B-VARIANT
and	O
P1637L	B-VARIANT
32	O
,	O
PALB2	B-GENE
H1170Y	B-VARIANT
35	O
,	O
SMO	B-GENE
36	O
and	O
TSC2	B-GENE
37	O
,	O
38	O
)	O
,	O
the	O
missense	O
list	O
includes	O
variants	O
from	O
several	O
genes	O
including	O
the	O
two	O
known	O
pathogenic	O
BRCA1	B-GENE
variants	O
(	O
G1788V	B-VARIANT
and	O
R1699W	B-VARIANT
)	O
,	O
four	O
BRIP1	B-GENE
variants	O
,	O
three	O
ATM	B-GENE
variants	O
,	O
four	O
NF1	B-GENE
variants	O
,	O
and	O
one	O
TP53	B-GENE
variant	O
previously	O
identified	O
in	O
breast	B-DISEASE
cancer	I-DISEASE
39	O
(	O
Table	O
2	O
)	O
.	O

Broken	O
lines	O
to	O
the	O
5	O
th	O
and	O
95	O
th	O
percentiles	O
[	O
16	O
]	O
.	O

Based	O
on	O
these	O
findings	O
,	O
the	O
hearing	B-DISEASE
dysfunction	I-DISEASE
found	O
in	O
OPA1	B-GENE
patients	O
could	O
be	O
considered	O
essentially	O
as	O
a	O
neural	O
rather	O
than	O
a	O
receptor	O
disorder	O
and	O
thus	O
qualified	O
as	O
'	O
post	B-DISEASE
-	I-DISEASE
synaptic	I-DISEASE
auditory	I-DISEASE
neuropathy	I-DISEASE
'	O
(	O
Starr	O
et	O
al	O
.	O

In	O
the	O
case	O
of	O
homozygosity	O
for	O
marker	O
alleles	O
of	O
a	O
specific	O
USH1	B-DISEASE
locus	O
,	O
the	O
coding	O
region	O
of	O
the	O
corresponding	O
gene	O
was	O
sequenced	O
.	O

The	O
phenotypic	O
characteristics	O
of	O
the	O
WSD	B-DISEASE
cohort	O
compared	O
with	O
the	O
data	O
of	O
24	O
,	O
164	O
patients	O
with	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
from	O
the	O
DPV	O
database	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

In	O
this	O
study	O
,	O
we	O
use	O
the	O
aforementioned	O
microarray	O
chip	O
to	O
examine	O
and	O
analyze	O
nine	O
loci	O
of	O
four	O
deafness	O
-	O
associated	O
genes	O
among	O
Uyghur	O
and	O
Han	O
Chinese	O
NSD	B-DISEASE
patients	O
residing	O
in	O
Xinjiang	O
,	O
in	O
aiming	O
to	O
characterize	O
nine	O
loci	O
of	O
four	O
deafness	O
-	O
associated	O
genes	O
of	O
Uyghur	O
NSD	B-DISEASE
patients	O
in	O
comparison	O
with	O
Han	O
Chinese	O
patients	O
.	O

Genotypes	O
of	O
participating	O
family	O
members	O
are	O
shown	O
below	O
each	O
symbol	O
in	O
single	O
letter	O
amino	O
acid	O
nomenclature	O
:	O
P	O
for	O
Proline	O
and	O
R	O
for	O
Arginine	B-Chemical
.	O

Antithymocyte	B-Chemical
globulin	I-Chemical
in	O
the	O
treatment	O
of	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
-	O
induced	O
aplastic	B-DISEASE
anemia	I-DISEASE
.	O

The	O
ratio	O
of	O
glomerular	O
tuft	O
area	O
to	O
the	O
area	O
of	O
Bowman	O
'	O
s	O
capsules	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	B-Chemical
group	O
was	O
significantly	O
increased	O
,	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
the	O
PAN	B-Chemical
/	O
temocapril	B-Chemical
group	O
.	O

As	O
in	O
the	O
eye	O
,	O
the	O
alpha	O
5	O
(	O
IV	O
)	O
chain	O
is	O
normally	O
present	O
in	O
the	O
lens	O
capsule	O
,	O
Descemet	O
,	O
Bruch	O
and	O
internal	O
limiting	O
membranes	O
[	O
25	O
]	O
,	O
it	O
is	O
reasonable	O
to	O
infer	O
that	O
dysfunction	B-DISEASE
of	I-DISEASE
the	I-DISEASE
lens	I-DISEASE
capsule	I-DISEASE
,	I-DISEASE
Bruch	I-DISEASE
and	I-DISEASE
internal	I-DISEASE
limiting	I-DISEASE
membranes	I-DISEASE
resulted	O
from	O
deposit	O
of	O
abnormal	B-DISEASE
type	I-DISEASE
IV	I-DISEASE
collagen	I-DISEASE
was	O
responsible	O
for	O
this	O
severe	O
ocular	O
phenotype	O
in	O
II	O
-	O
2	O
.	O

This	O
pilot	O
trial	O
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
glutamate	B-Chemical
supplementation	O
for	O
preventing	O
PAC	B-Chemical
-	O
induced	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
in	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blinded	O
clinical	O
and	O
electro	O
-	O
diagnostic	O
study	O
.	O

Allele	O
frequencies	O
were	O
calculated	O
from	O
founders	O
.	O

,	O
2013	O
)	O
.	O

The	O
tRNALeu	B-GENE
(	O
black	O
ribbon	O
)	O
,	O
and	O
the	O
leucine	B-Chemical
-	I-Chemical
adenylate	I-Chemical
analogue	O
(	O
black	O
sticks	O
)	O
are	O
docked	O
in	O
the	O
catalytic	O
domain	O
.	O

The	O
information	O
on	O
sociodemographic	O
background	O
and	O
drug	O
use	O
history	O
was	O
obtained	O
from	O
interview	O
or	O
medical	O
records	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
optic	B-DISEASE
neuropathy	I-DISEASE
between	O
1	O
to	O
6	O
months	O
(	O
mean	O
=	O
2	O
.	O
9	O
months	O
)	O
after	O
starting	O
ethambutol	B-Chemical
therapy	O
at	O
a	O
dosage	O
ranging	O
from	O
13	O
to	O
20	O
mg	O
/	O
kg	O
/	O
day	O
(	O
mean	O
=	O
17	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

Identification	O
of	O
a	O
rare	O
loss	O
-	O
of	O
-	O
function	O
variant	O
in	O
the	O
KCNQ1	B-GENE
gene	O
in	O
the	O
index	O
case	O
suggests	O
broadening	O
the	O
spectrum	O
of	O
AC	B-DISEASE
to	O
encompass	O
not	O
only	O
the	O
classic	B-DISEASE
arrhythmogenic	I-DISEASE
right	I-DISEASE
ventricular	I-DISEASE
cardiomyopathy	I-DISEASE
and	O
left	B-DISEASE
ventricular	I-DISEASE
-	I-DISEASE
dominant	I-DISEASE
arrhythmogenic	I-DISEASE
cardiomyopathy	I-DISEASE
,	O
but	O
also	O
a	O
subset	O
of	O
cardiomyopathies	B-DISEASE
,	O
whose	O
primary	O
manifestation	O
is	O
ventricular	B-DISEASE
tachyarrhythmias	I-DISEASE
occurring	O
initially	O
in	O
the	O
absence	O
of	O
a	O
discernible	O
left	B-DISEASE
ventricular	I-DISEASE
dysfunction	I-DISEASE
or	O
disproportionate	O
to	O
it	O
.	O

An	O
integrated	O
characterization	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
in	O
doxorubicin	B-Chemical
-	I-DISEASE
induced	O
cardiotoxicity	B-DISEASE
.	O

This	O
strategy	O
has	O
proven	O
to	O
be	O
effective	O
as	O
only	O
eight	O
variants	O
per	O
patient	O
remained	O
after	O
this	O
screening	O
.	O

Overall	O
,	O
98	O
.	O
0	O
%	O
of	O
the	O
targeted	O
disease	O
gene	O
regions	O
were	O
sequenced	O
and	O
94	O
.	O
1	O
%	O
of	O
the	O
targeted	O
bases	O
were	O
sequenced	O
with	O
>	O
10X	O
depth	O
,	O
allowing	O
us	O
to	O
accurately	O
assess	O
SNPs	O
.	O

The	O
amino	O
acid	O
substitution	O
p	B-VARIANT
.	I-VARIANT
R350W	I-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
1048C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
affected	O
a	O
highly	O
conserved	O
nucleotide	O
at	O
the	O
cDNA	O
level	O
with	O
a	O
score	O
of	O
0	O
.	O
9	O
(	O
0	O
-	O
1	O
)	O
.	O

KF17837	B-Chemical
also	O
reduced	O
the	O
catalepsy	O
induced	O
by	O
haloperidol	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
and	O
by	O
reserpine	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
refractive	O
error	O
and	O
axial	O
length	O
were	O
not	O
significantly	O
different	O
in	O
all	O
six	O
patients	O
.	O

Missense	O
mutations	O
c	B-VARIANT
.	I-VARIANT
1030C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
L344F	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
778A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
T260A	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
1264C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R422W	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
1265G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R422Q	I-VARIANT
)	O
were	O
identified	O
in	O
family	O
0223	O
(	O
A	O
)	O
,	O
7170	O
(	O
B	O
)	O
,	O
2724	O
(	O
C	O
)	O
and	O
2423	O
(	O
D	O
)	O
,	O
respectively	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
141_142delTG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg50Alafs	I-VARIANT
*	I-VARIANT
103	I-VARIANT
)	O
mutation	O
in	O
OSBPL2	B-GENE
was	O
present	O
in	O
half	O
of	O
the	O
reads	O
covering	O
this	O
region	O
of	O
the	O
gene	O
.	O

These	O
data	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
natural	O
history	O
of	O
the	O
clinical	O
features	O
of	O
this	O
complex	O
syndrome	O
,	O
which	O
could	O
facilitate	O
diagnosis	O
with	O
WFS	B-DISEASE
and	O
ultimately	O
be	O
useful	O
in	O
future	O
therapeutic	O
trials	O
.	O

She	O
had	O
menarche	O
at	O
the	O
age	O
of	O
13	O
years	O
and	O
regular	O
menses	O
until	O
the	O
age	O
of	O
28	O
years	O
,	O
when	O
she	O
experienced	O
phases	O
of	O
polymenorrhea	B-DISEASE
and	O
oligomenorrhea	B-DISEASE
before	O
being	O
hospitalized	O
for	O
secondary	B-DISEASE
amenorrhea	I-DISEASE
.	O

PE	O
:	O
Pseudoexon	O
40	O
.	O

This	O
classification	O
is	O
in	O
line	O
with	O
the	O
guidelines	O
published	O
by	O
the	O
clinical	O
and	O
molecular	O
genetics	O
society	O
(	O
http	O
:	O
/	O
/	O
cmgdweb	O
.	O
shared	O
.	O
hosting	O
.	O
zen	O
.	O
co	O
.	O
uk	O
/	O
BPGs	O
/	O
Best_Practice_Guidelines	O
.	O
htm	O
)	O
.	O

RESULTS	O
:	O
Compared	O
to	O
controls	O
,	O
aortic	B-DISEASE
regurgitation	I-DISEASE
(	O
OR	O
:	O
3	O
.	O
1	O
;	O
95	O
%	O
IC	O
:	O
1	O
.	O
1	O
-	O
8	O
.	O
8	O
)	O
and	O
mitral	B-DISEASE
regurgitation	I-DISEASE
(	O
OR	O
:	O
10	O
.	O
7	O
;	O
95	O
%	O
IC	O
:	O
2	O
.	O
1	O
-	O
53	O
)	O
were	O
more	O
frequent	O
in	O
PD	O
patients	O
(	O
tricuspid	O
:	O
NS	O
)	O
.	O

The	O
median	O
age	O
of	O
the	O
patients	O
at	O
the	O
time	O
of	O
DNA	O
analysis	O
was	O
15	O
,	O
1	O
years	O
(	O
range	O
12	O
-	O
23	O
)	O
.	O

[	O
37	O
]	O
developed	O
a	O
targeted	O
NGS	O
panel	O
where	O
9	O
USH	B-DISEASE
genes	O
,	O
2	O
candidate	O
USH	B-DISEASE
genes	O
(	O
VEZT	B-GENE
and	O
PDZD7	B-GENE
)	O
,	O
seven	O
hearing	B-DISEASE
-	I-DISEASE
loss	I-DISEASE
genes	O
and	O
CHM	O
were	O
included	O
.	O

Signal	O
processing	O
parameters	O
were	O
changed	O
to	O
use	O
less	O
stringent	O
quality	O
filtering	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	B-Chemical
and	O
the	O
risk	O
of	O
bladder	B-DISEASE
cancer	I-DISEASE
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B-DISEASE
'	I-DISEASE
s	I-DISEASE
granulomatosis	I-DISEASE
.	O

Diuretics	O
may	O
induce	O
hypokalemia	B-DISEASE
,	O
hypocalcemia	B-DISEASE
and	O
hypomagnesemia	B-DISEASE
.	O

These	O
findings	O
point	O
to	O
a	O
neural	O
rather	O
than	O
a	O
receptor	O
origin	O
for	O
the	O
generation	O
of	O
the	O
prolonged	O
negative	O
potentials	O
recorded	O
from	O
OPA1	B-GENE
-	O
M	O
patients	O
.	O

Thromboembolic	B-DISEASE
and	O
other	O
complications	O
of	O
oral	B-Chemical
contraceptive	I-Chemical
therapy	O
in	O
relationship	O
to	O
pretreatment	O
levels	O
of	O
blood	O
coagulation	O
factors	O
:	O
summary	O
report	O
of	O
a	O
ten	O
-	O
year	O
study	O
.	O

Their	O
father	O
had	O
a	O
high	O
arched	O
palate	O
and	O
mild	O
,	O
asymptomatic	O
high	O
tone	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

In	O
p	B-VARIANT
.	I-VARIANT
I210del	I-VARIANT
,	O
conservation	O
analysis	O
by	O
ConSeq	O
,	O
showed	O
that	O
the	O
deleted	O
isoleucine	O
is	O
located	O
in	O
a	O
stretch	O
of	O
conserved	O
and	O
buried	O
hydrophobic	O
residues	O
of	O
the	O
first	O
transmembrane	O
domain	O
of	O
TMC1	B-GENE
.	O

The	O
second	O
twin	O
,	O
a	O
male	O
,	O
had	O
some	O
features	O
of	O
Potter	B-DISEASE
'	I-DISEASE
s	O
facies	I-DISEASE
,	O
hypoplastic	B-DISEASE
lungs	I-DISEASE
,	O
absent	O
kidneys	I-DISEASE
and	O
ureters	B-DISEASE
,	O
and	O
talipes	B-DISEASE
equinovarus	I-DISEASE
.	O

In	O
our	O
study	O
,	O
almost	O
half	O
of	O
the	O
mutations	O
have	O
not	O
been	O
previously	O
described	O
in	O
the	O
literature	O
,	O
confirming	O
a	O
high	O
rate	O
of	O
novel	O
variants	O
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

Yongyi	O
Yuan	O
,	O
PLA	O
General	O
Hospital	O
Culturing	O
Foundation	O
(	O
12KMM32	O
)	O
to	O
Dr	O
.	O
Jiandong	O
Zhao	O
,	O
Chinese	O
National	O
Nature	O
Science	O
Foundation	O
Research	O
Grant	O
(	O
81000415	O
)	O
,	O
Beijing	O
Nova	O
programme	O
(	O
2010B081	O
)	O
and	O
State	O
863	O
High	O
Technology	O
R	O
&	O
D	O
Key	O
Project	O
of	O
China	O
(	O
2012AA020101	O
)	O
to	O
Dr	O
.	O

SigmaST	O
,	O
the	O
sum	O
of	O
ST	O
-	O
segment	O
elevations	O
in	O
16	O
precordial	O
leads	O
,	O
decreased	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
with	O
intravenous	O
nitroglycerin	B-Chemical
.	O

The	O
other	O
was	O
a	O
G	O
to	O
A	O
change	O
at	O
the	O
conserved	O
donor	O
splice	O
site	O
in	O
intron	O
44	O
(	O
c	B-VARIANT
.	I-VARIANT
6051	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
;	I-VARIANT
Figure	O
4B	O
)	O
.	O

Scale	O
bar	O
applies	O
to	O
all	O
panels	O
and	O
is	O
10	O
u	O
m	O
.	O

Fig	O
.	O

There	O
seemed	O
to	O
be	O
no	O
direct	O
correlation	O
between	O
the	O
dose	O
or	O
duration	O
used	O
and	O
the	O
severity	O
of	O
bone	O
marrow	O
suppression	O
.	O

Next	O
-	O
generation	O
sequencing	O
can	O
now	O
be	O
performed	O
rapidly	O
and	O
at	O
minimal	O
cost	O
,	O
allowing	O
analysis	O
of	O
the	O
coding	O
regions	O
(	O
exome	O
)	O
of	O
the	O
human	O
genome	O
in	O
single	O
individuals	O
or	O
small	O
families	O
,	O
including	O
patients	O
in	O
whom	O
a	O
clear	O
genotype	O
-	O
phenotype	O
correlation	O
is	O
absent	O
or	O
for	O
clinically	O
and	O
genetically	O
heterogeneous	O
conditions	O
.	O

Homozygotes	O
for	O
each	O
mutation	O
had	O
congenital	O
moderate	O
to	O
profound	O
SNHL	B-DISEASE
,	O
normal	O
vestibular	O
function	O
,	O
and	O
mild	O
RP	B-DISEASE
.	O

The	O
criteria	O
used	O
were	O
as	O
follows	O
:	O
(	O
i	O
)	O
the	O
putative	O
membrane	O
location	O
for	O
each	O
chain	O
was	O
plausible	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
C	O
-	O
terminus	O
of	O
each	O
domain	O
was	O
not	O
buried	O
inside	O
the	O
complex	O
)	O
,	O
(	O
ii	O
)	O
the	O
interface	O
energy	O
score	O
,	O
and	O
(	O
iii	O
)	O
the	O
number	O
of	O
polar	O
interactions	O
between	O
interface	O
residues	O
capable	O
of	O
forming	O
hydrogen	O
bonds	O
.	O

His	O
retinal	B-DISEASE
dysfunction	I-DISEASE
was	O
diagnosed	O
as	O
early	O
as	O
9	O
months	O
of	O
age	O
,	O
based	O
on	O
severely	O
reduced	O
ERG	O
responses	O
measured	O
using	O
a	O
short	O
protocol	O
(	O
without	O
full	O
dark	O
adaptation	O
;	O
Table	O
1	O
)	O
.	O

Based	O
on	O
this	O
pipeline	O
,	O
we	O
successfully	O
identified	O
four	O
cases	O
of	O
somatic	O
mosaicism	O
among	O
10	O
apparently	O
mutation	O
-	O
negative	O
CINCA	B-DISEASE
/	O
NOMID	B-DISEASE
patients	O
.	O

The	O
unaffected	O
individuals	O
(	O
II	O
-	O
2	O
and	O
III	O
-	O
2	O
)	O
of	O
the	O
KNUF24	O
family	O
are	O
her	O
sister	O
and	O
daughter	O
,	O
respectively	O
.	O

English	O
terms	O
for	O
disorders	O
were	O
included	O
since	O
most	O
Chinese	O
biomedical	O
articles	O
contain	O
an	O
English	O
abstract	O
.	O

1	O
Unless	O
additional	O
clinical	O
symptoms	O
hint	O
at	O
specific	O
genes	O
(	O
i	O
.	O
e	O
.	O
,	O
goiter	B-DISEASE
suggesting	O
SLC26A4	B-GENE
or	O
auditory	B-DISEASE
neuropathy	I-DISEASE
suggesting	O
OTOF	B-GENE
)	O
,	O
the	O
vast	O
majority	O
of	O
GJB2	B-GENE
mutation	O
-	O
negative	O
probands	O
remain	O
without	O
genetic	O
diagnoses	O
.	O

The	O
biopsy	O
was	O
insufficient	O
to	O
allow	O
EM	O
analysis	O
.	O

Exons	O
are	O
indicated	O
by	O
rectangles	O
that	O
are	O
wider	O
for	O
the	O
coding	O
regions	O
.	O

Among	O
the	O
16	O
families	O
we	O
found	O
causative	O
mutations	O
,	O
we	O
had	O
molecular	O
results	O
and	O
variable	O
clinical	O
information	O
for	O
87	O
patients	O
(	O
38M	O
/	O
49F	O
)	O
at	O
ages	O
ranging	O
from	O
4	O
-	O
78	O
years	O
.	O

Patients	O
U1157	B-Chemical
and	O
U1163	O
were	O
found	O
to	O
have	O
CDH23	B-GENE
alterations	O
.	O

We	O
did	O
not	O
identify	O
a	O
molecular	O
etiology	O
for	O
the	O
clinical	O
presentation	O
of	O
cerebellar	O
ataxia	B-DISEASE
in	O
54	O
%	O
of	O
the	O
families	O
.	O

ELMOD3	B-GENE
was	O
immunostained	O
in	O
green	O
while	O
kinocilia	O
were	O
highlighted	O
with	O
acetylated	B-Chemical
-	O
tubulin	I-Chemical
antibody	O
(	O
red	O
)	O
.	O

Efficacy	O
and	O
safety	O
of	O
granisetron	B-Chemical
,	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
-	I-GENE
3	I-GENE
receptor	I-GENE
antagonist	O
,	O
in	O
the	O
prevention	O
of	O
nausea	B-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
induced	O
by	O
high	O
-	O
dose	O
cisplatin	B-Chemical
.	O

2A	O
)	O
,	O
result	O
in	O
an	O
isoleucine	O
to	O
lysine	B-Chemical
substitution	O
(	O
p	B-VARIANT
.	I-VARIANT
I411K	I-VARIANT
)	O
.	O

METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	O
Register	O
a	O
cohort	O
of	O
1065	O
patients	O
with	O
Wegener	B-DISEASE
'	I-DISEASE
s	I-DISEASE
granulomatosis	I-DISEASE
,	O
1969	O
-	O
95	O
,	O
was	O
identified	O
.	O

Two	O
homozygous	O
missense	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
P2762A	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
G3320C	I-VARIANT
)	O
were	O
found	O
in	O
one	O
individual	O
family	O
suggesting	O
a	O
potential	O
double	O
hit	O
effect	O
.	O

Reprocessed	O
electron	O
micrographs	O
of	O
the	O
renal	O
biopsy	O
from	O
patient	O
III	O
-	O
1	O
of	O
family	O
1	O
.	O

RESULTS	O
:	O
One	O
hundred	O
sixty	O
-	O
five	O
courses	O
were	O
administered	O
,	O
with	O
a	O
median	O
of	O
3	O
.	O

Indels	O
were	O
processed	O
with	O
direct	O
filtering	O
.	O

Cross	O
-	O
sectional	O
analysis	O
was	O
performed	O
using	O
linear	O
regression	O
analysis	O
to	O
determine	O
the	O
local	O
average	O
slope	O
,	O
called	O
deterioration	O
rate	O
,	O
in	O
the	O
score	O
-	O
against	O
-	O
age	O
plot	O
and	O
deterioration	O
gradient	O
in	O
the	O
score	O
-	O
against	O
-	O
PTA	O
1	O
,	O
2	O
,	O
4	O
kHz	O
plot	O
.	O

The	O
overall	O
prevalence	O
of	O
patients	O
carrying	O
two	O
pathogenic	O
mutations	O
in	O
different	O
alleles	O
of	O
the	O
same	O
gene	O
was	O
75	O
%	O
.	O

As	O
predicted	O
by	O
in	O
silico	O
analysis	O
,	O
the	O
currently	O
identified	O
BSND	B-GENE
mutation	O
p	B-VARIANT
.	I-VARIANT
Val33Leu	I-VARIANT
residing	O
in	O
the	O
transmembranal	O
region	O
might	O
result	O
in	O
the	O
malfunctioning	O
of	O
chloride	O
channels	O
CLCNKA	O
and	O
CLCNKB	O
.	O

Clinical	O
,	O
biological	O
and	O
evolutionary	O
analyses	O
of	O
pendrin	B-GENE
716T	B-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
V239D	B-VARIANT
)	O
from	O
Family	O
Y	O
.	O

Color	O
vision	O
examination	O
in	O
previous	O
studies	O
has	O
shown	O
that	O
mixed	O
color	O
defect	O
accounts	O
for	O
more	O
than	O
80	O
%	O
of	O
the	O
color	O
deficits	O
documented	O
[	O
8	O
]	O
.	O

Although	O
the	O
majority	O
of	O
our	O
deaf	O
probands	O
were	O
singleton	O
(	O
sporadic	O
)	O
cases	O
,	O
monogenic	O
Mendelian	O
disorder	O
was	O
documented	O
in	O
more	O
than	O
half	O
of	O
our	O
cases	O
.	O

We	O
are	O
indebted	O
to	O
our	O
patients	O
,	O
their	O
families	O
and	O
primary	O
care	O
physicians	O
for	O
their	O
cooperation	O
in	O
this	O
study	O
.	O

The	O
SLC26A4	B-GENE
mutation	O
spectrum	O
varies	O
widely	O
among	O
ethnic	O
groups	O
.	O

Dr	O
.	O

All	O
three	O
had	O
been	O
diagnosed	O
earlier	O
with	O
epilepsy	B-DISEASE
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	O
)	O
findings	O
were	O
abnormal	O
.	O

1E	O
and	O
1F	O
)	O
.	O

On	O
the	O
basis	O
of	O
this	O
genetic	O
diagnosis	O
strategy	O
in	O
patients	O
with	O
dRTA	B-DISEASE
,	O
which	O
is	O
based	O
on	O
the	O
presence	O
of	O
SNHL	B-DISEASE
,	O
the	O
initial	O
ATP6V1B1	B-GENE
gene	O
screening	O
resulted	O
in	O
a	O
mutation	O
detection	O
rate	O
of	O
81	O
.	O
25	O
%	O
(	O
26	O
/	O
32	O
alleles	O
)	O
.	O

The	O
improvement	O
in	O
ipsilateral	B-DISEASE
dyskinesias	B-DISEASE
was	O
lost	O
after	O
one	O
year	O
,	O
and	O
the	O
improvements	O
in	O
postural	O
stability	O
and	O
gait	O
lasted	O
only	O
three	O
to	O
six	O
months	O
.	O

(	O
c	O
)	O
Compound	O
heterozygosity	O
for	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
in	O
two	O
brothers	O
.	O

Cyclophosphamide	B-Chemical
(	O
CP	B-Chemical
)	O
,	O
an	O
antitumoral	O
agent	O
known	O
to	O
produce	O
toxic	O
effects	O
on	O
the	O
bladder	O
wall	O
through	O
its	O
main	O
toxic	O
metabolite	O
acrolein	B-Chemical
,	O
was	O
used	O
to	O
induce	O
cystitis	B-DISEASE
.	O

Desvenlafaxine	B-Chemical
was	O
ceased	O
and	O
fluid	O
restriction	O
implemented	O
.	O

Similarly	O
,	O
USH1C	B-GENE
,	O
which	O
is	O
known	O
to	O
interact	O
with	O
CDH23	B-GENE
,	O
was	O
analyzed	O
in	O
the	O
three	O
families	O
carrying	O
heterozygous	O
changes	O
in	O
CDH23	B-GENE
(	O
Table	O
2D	O
)	O
.	O

We	O
then	O
recruited	O
additional	O
family	O
members	O
who	O
were	O
not	O
typed	O
with	O
Affymetrix	O
6	O
.	O
0	O
chips	O
to	O
evaluate	O
co	O
-	O
segregation	O
of	O
these	O
variants	O
.	O

A	O
total	O
of	O
43	O
.	O
3	O
million	O
non	O
-	O
duplicated	O
reads	O
could	O
be	O
mapped	O
to	O
the	O
genome	O
.	O

This	O
strategy	O
is	O
significantly	O
more	O
efficient	O
than	O
the	O
microarray	O
investigation	O
and	O
may	O
represent	O
an	O
alternative	O
to	O
the	O
NGS	O
technology	O
that	O
is	O
presently	O
not	O
available	O
in	O
all	O
laboratories	O
.	O

High	O
doses	O
caused	O
an	O
apparent	O
central	O
excitation	O
,	O
most	O
clearly	O
seen	O
as	O
clonic	B-DISEASE
convulsions	I-DISEASE
,	O
superimposed	O
on	O
general	O
depression	O
.	O

In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
months	O
on	O
thalidomide	B-Chemical
,	O
subclinical	O
evidence	O
of	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
was	O
found	O
in	O
four	O
before	O
treatment	O
,	O
but	O
in	O
all	O
seven	O
at	O
repeat	O
testing	O
.	O

The	O
skipping	O
of	O
exon	O
43	O
doesn	O
'	O
t	O
result	O
in	O
the	O
interruption	O
of	O
the	O
reading	O
frame	O
.	O

Genotypes	O
were	O
called	O
using	O
the	O
Genotyping	O
Console	O
(	O
Affymetrix	O
)	O
and	O
uploaded	O
to	O
the	O
BCSNP	O
data	O
management	O
platform	O
(	O
BC	O
Platforms	O
,	O
Espoo	O
,	O
Finland	O
)	O
.	O

In	O
fact	O
,	O
the	O
nasal	O
and	O
temporal	O
fields	O
were	O
not	O
preserved	O
and	O
only	O
the	O
central	O
field	O
was	O
maintained	O
.	O

During	O
this	O
period	O
,	O
no	O
drug	O
resistant	O
mutant	O
HBV	B-DISEASE
emerged	O
,	O
and	O
the	O
serum	O
HBV	O
-	O
DNA	O
level	O
was	O
continuously	O
suppressed	O
.	O

Multiple	O
statistically	O
significant	O
peaks	O
at	O
8p23	O
.	O
1	O
and	O
GSTM1	B-GENE
were	O
identified	O
,	O
and	O
were	O
identical	O
to	O
plots	O
from	O
the	O
first	O
approach	O
.	O

These	O
conclusions	O
from	O
previous	O
biochemical	O
studies	O
provide	O
convincing	O
evidence	O
that	O
p	B-VARIANT
.	I-VARIANT
D187H	I-VARIANT
is	O
a	O
novel	O
mutation	O
that	O
has	O
pathogenic	O
effects	O
on	O
the	O
normal	O
functions	O
of	O
gamma	O
-	O
actin	O
in	O
the	O
hair	O
cells	O
.	O

Assessment	O
by	O
conventional	O
static	O
perimetry	O
may	O
neither	O
be	O
sufficiently	O
sensitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
retinal	B-DISEASE
toxicity	I-DISEASE
associated	O
with	O
VGB	B-Chemical
.	O

The	O
administration	O
of	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
for	O
21days	O
caused	O
a	O
significant	O
impairment	O
of	O
learning	O
and	O
memory	I-DISEASE
as	O
well	O
as	O
an	O
increased	O
oxidative	I-DISEASE
stress	I-DISEASE
.	O

GJB2	B-GENE
sequence	O
variations	O
identified	O
in	O
patients	O
a	O
dominant	O
mutation	O
;	O
b	O
cis	O
-	O
configuration	O
of	O
V27I	B-VARIANT
and	O
E114G	B-VARIANT
was	O
confirmed	O
by	O
family	O
studies	O
in	O
5	O
/	O
7	O
patients	O
,	O
c	O
the	O
[	O
V27I	B-VARIANT
;	I-VARIANT
E114G	B-VARIANT
]	O
allele	O
of	O
this	O
proband	O
is	O
known	O
to	O
be	O
of	O
Altaian	O
origin	O
(	O
maternal	O
branch	O
)	O
.	O

In	O
another	O
series	O
of	O
measurements	O
,	O
reproducibility	O
and	O
reference	O
values	O
of	O
the	O
tremor	O
was	O
assessed	O
in	O
65	O
healthy	O
subjects	O
in	O
three	O
sessions	O
,	O
at	O
9	O
a	O
.	O
m	O
.	O
,	O
4	O
p	O
.	O
m	O
.	O
and	O
9	O
a	O
.	O
m	O
.	O
,	O
respectively	O
,	O
1	O
week	O
later	O
.	O

In	O
addition	O
,	O
the	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
also	O
included	O
the	O
full	O
length	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
as	O
a	O
single	O
target	O
.	O

Scheper	B-Chemical
and	O
co	O
-	O
authors	O
first	O
linked	O
mutations	O
in	O
DARS2	B-GENE
,	O
encoding	O
the	O
mitochondrial	B-GENE
aspartyl	I-GENE
-	I-GENE
tRNA	I-GENE
synthetase	I-GENE
,	O
to	O
leukoencephalopathy	B-DISEASE
with	I-DISEASE
brain	I-DISEASE
stem	I-DISEASE
and	I-DISEASE
spinal	I-DISEASE
cord	I-DISEASE
involvement	I-DISEASE
and	I-DISEASE
lactate	I-DISEASE
elevation	I-DISEASE
in	I-DISEASE
brain	I-DISEASE
(	O
LBSL	B-DISEASE
;	O
MIM	O
:	O
611105	O
)	O
[	O
5	O
]	O
.	O

Haplotypes	O
and	O
sequencing	O
analyses	O
of	O
GPR98	B-GENE
and	O
DFNB31	B-GENE
were	O
performed	O
as	O
already	O
described	O
[	O
12	O
]	O
.	O

Institutional	O
review	O
boards	O
at	O
NIH	O
and	O
University	O
of	O
Virginia	O
approved	O
the	O
animal	O
studies	O
.	O

A111377	O
to	O
B	O
.	O
Y	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
2299delG	I-VARIANT
was	O
the	O
most	O
common	O
mutation	O
with	O
an	O
allele	O
frequency	O
of	O
14	O
-	O
50	O
%	O
in	O
patients	O
from	O
Europe	O
and	O
North	O
America	O
[	O
6	O
,	O
11	O
-	O
13	O
,	O
15	O
-	O
19	O
]	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

1	O
)	O
.	O

The	O
missense	O
variants	O
accounted	O
for	O
60	O
.	O
76	O
%	O
(	O
48	O
/	O
79	O
,	O
excluding	O
the	O
UTR	O
variant	O
and	O
intron	O
variants	O
)	O
of	O
all	O
the	O
SLC26A4	B-GENE
variants	O
.	O

Additionally	O
,	O
two	O
new	O
disease	O
genes	O
were	O
identified	O
,	O
one	O
in	O
a	O
consanguineous	O
family	O
and	O
one	O
in	O
a	O
nonconsanguineous	O
family	O
,	O
and	O
subsequently	O
validated	O
in	O
a	O
research	O
setting	O
(	O
unpublished	O
data	O
)	O
for	O
a	O
combined	O
molecular	O
diagnosis	O
rate	O
of	O
46	O
%	O
.	O

Performed	O
the	O
experiments	O
:	O
T	O
-	O
JK	O
HRK	O
J	O
-	O
IB	O
.	O

We	O
then	O
subjected	O
the	O
mutation	O
-	O
negative	O
cases	O
to	O
exome	O
sequencing	O
and	O
identified	O
novel	O
causative	O
variants	O
in	O
the	O
MYH14	B-GENE
and	O
WFS1	B-GENE
genes	O
.	O

The	O
Covaris	O
protocol	O
was	O
set	O
as	O
follows	O
:	O
3	O
min	O
total	O
duration	O
,	O
duty	O
cycle	O
10	O
%	O
,	O
intensity	O
5	O
,	O
and	O
200	O
cycles	O
per	O
burst	O
.	O

Whole	O
exome	O
capture	O
was	O
performed	O
with	O
the	O
Agilent	O
SureSelectXT	O
Human	O
All	O
Exon	O
V4	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Click	O
here	O
for	O
file	O
Candidate	O
variants	O
identified	O
in	O
this	O
study	O
.	O

The	O
family	O
history	O
revealed	O
that	O
the	O
onset	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
pre	O
-	O
lingual	O
,	O
with	O
no	O
clear	O
vestibular	O
impairment	O
among	O
the	O
deaf	O
individuals	O
.	O

VCM	B-Chemical
administration	O
to	O
control	O
rats	O
significantly	O
increased	O
renal	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
and	O
urinary	O
N	I-GENE
-	I-GENE
acetyl	I-GENE
-	I-GENE
beta	I-GENE
-	I-GENE
d	I-GENE
-	I-GENE
glucosaminidase	I-GENE
(	O
NAG	O
,	O
a	O
marker	O
of	O
renal	O
tubular	O
injury	O
)	O
excretion	O
but	O
decreased	O
superoxide	B-Chemical
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
activities	O
.	O

M	O
o	O
llerogHustruChastine	O
Mc	O
-	I-Chemical
Kinney	O
M	O
o	O
ller	O
Foundation	O
.	O

Similarly	O
,	O
in	O
the	O
inner	O
ear	O
,	O
pendrin	O
is	O
thought	O
to	O
mediate	O
Cl	O
-	O
/	O
HCO	O
3	O
-	O
exchange	O
,	O
and	O
is	O
therefore	O
involved	O
in	O
the	O
conditioning	O
of	O
endolymphatic	O
fluid	O
,	O
presumably	O
due	O
to	O
HCO	O
3	O
-	O
secretion	O
[	O
5	O
]	O
.	O

In	O
addition	O
,	O
in	O
one	O
case	O
(	O
family	O
28	O
,	O
557	O
)	O
,	O
a	O
de	O
novo	O
mutation	O
in	O
the	O
recessive	O
gene	O
USH2A	B-GENE
(	O
MIM	O
#	O
608	O
,	O
400	O
)	O
was	O
identified	O
,	O
with	O
the	O
second	O
mutation	O
being	O
inherited	O
from	O
the	O
mother	O
(	O
Fig	O
.	O

C	O
:	O
DNA	O
sequencing	O
profile	O
showing	O
the	O
c	B-VARIANT
.	I-VARIANT
73G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutations	O
in	O
MYO7A	B-GENE
.	O

Nested	O
PCRs	O
(	O
Table	O
S2	O
)	O
and	O
sequencing	O
continued	O
after	O
LR	O
-	O
PCR	O
products	O
were	O
verified	O
negative	O
for	O
a	O
three	O
-	O
nucleotide	O
frameshift	O
,	O
indicative	O
of	O
pSTRC	O
sequence	O
.	O

In	O
vitro	O
functional	O
studies	O
(	O
Born	O
'	O
s	O
method	O
)	O
showed	O
normal	O
platelet	O
aggregation	O
after	O
stimulation	O
with	O
collagen	B-Chemical
,	O
ristocetin	B-Chemical
,	O
and	O
ADP	B-Chemical
.	O

Java	O
and	O
R	O
code	O
that	O
can	O
be	O
used	O
to	O
derive	O
the	O
read	O
counts	O
from	O
bam	O
files	O
as	O
well	O
as	O
the	O
normalized	O
exon	O
-	O
specific	O
coverage	O
are	O
provided	O
as	O
supporting	O
information	O
(	O
bam2readcounts	O
.	O
zip	O
)	O
.	O

Sequence	O
reads	O
were	O
aligned	O
to	O
the	O
human	O
genome	O
reference	O
sequence	O
(	O
build	O
hg19	O
)	O
and	O
variants	O
were	O
called	O
and	O
annotated	O
using	O
the	O
DNAnexus	O
software	O
package	O
.	O

A	O
.	O

Among	O
all	O
,	O
interpretation	O
of	O
genetic	O
datasets	O
is	O
most	O
important	O
while	O
also	O
most	O
problematic	O
[	O
4	O
]	O
.	O

We	O
identified	O
three	O
CDH23	B-GENE
mutations	O
,	O
comprising	O
two	O
previously	O
reported	O
pathological	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
Pro240Leu	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Glu1595Lys	I-VARIANT
,	O
and	O
one	O
novel	O
mutation	O
,	O
p	B-VARIANT
.	I-VARIANT
Asn342Ser	I-VARIANT
(	O
Table	O
2	O
)	O
.	O

In	O
vitro	O
aggregation	O
studies	O
revealed	O
a	O
moderately	O
reduced	O
response	O
to	O
all	O
tested	O
agonists	O
,	O
including	O
ADP	B-Chemical
,	O
epinephrine	B-Chemical
,	O
collagen	O
and	O
ristocetin	B-Chemical
.	O

Six	O
exons	O
were	O
preferentially	O
affected	O
,	O
2	O
in	O
the	O
MD	O
(	O
exon	O
2	O
and	O
17	O
)	O
and	O
4	O
in	O
the	O
TD	O
(	O
exons	O
27	O
,	O
31	O
,	O
39	O
,	O
and	O
41	O
.	O

Unexpected	O
hyperkalemia	B-DISEASE
was	O
observed	O
in	O
a	O
1	O
month	O
old	O
patient	O
(	O
case	O
13	O
.	O
1	O
)	O
,	O
possibly	O
due	O
to	O
extreme	O
acidosis	O
and	O
potential	O
inadequate	O
blood	O
draw	O
(	O
Table	O
1	O
)	O
.	O

5A	O
and	O
5B	O
)	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
the	O
allele	O
frequencies	O
of	O
several	O
common	O
deafness	B-DISEASE
mutations	O
are	O
higher	O
than	O
1	O
%	O
in	O
the	O
general	O
population	O
,	O
e	O
.	O
g	O
.	O
,	O
GJB2	B-GENE
p	O
.	O
V37I	B-Chemical
(	O
~	O
10	O
%	O
in	O
some	O
East	O
Asian	O
general	O
populations	O
)	O
[	O
43	O
]	O
,	O
[	O
44	O
]	O
,	O
c	B-Chemical
.	O
235delC	I-Chemical
(	O
~	O
1	O
.	O
5	O
%	O
in	O
the	O
Chinese	O
general	O
population	O
)	O
[	O
45	O
]	O
,	O
and	O
c	O
.	O
35delG	O
(	O
~	O
1	O
.	O
3	O
%	O
in	O
the	O
European	O
general	O
population	O
)	O
[	O
46	O
]	O
.	O

There	O
was	O
a	O
deficiency	O
in	O
the	O
activity	O
of	O
the	O
terminal	O
enzyme	O
of	O
respiratory	O
chain	O
,	O
COX	O
.	O

Comparison	O
of	O
i	O
.	O
v	O
.	O
glycopyrrolate	B-Chemical
and	O
atropine	B-Chemical
in	O
the	O
prevention	O
of	O
bradycardia	B-DISEASE
and	O
arrhythmias	B-DISEASE
following	O
repeated	O
doses	O
of	O
suxamethonium	B-Chemical
in	O
children	O
.	O

DNA	O
libraries	O
were	O
created	O
from	O
the	O
probands	O
of	O
the	O
12	O
multiplex	O
families	O
with	O
SNHI	B-DISEASE
(	O
Table	O
1	O
)	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
76	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
persistent	O
hiccups	B-DISEASE
after	O
beginning	O
azithromycin	B-Chemical
for	O
the	O
treatment	O
of	O
pharyngitis	B-DISEASE
.	O

Individual	O
II	O
:	O
3	O
was	O
heterozygous	O
for	O
this	O
mutation	O
,	O
and	O
no	O
other	O
MYO7A	B-GENE
mutation	O
was	O
detected	O
.	O

Active	B-DISEASE
vasculitis	B-DISEASE
was	O
noted	O
in	O
36	O
.	O
3	O
%	O
patients	O
at	O
baseline	O
and	O
0	O
%	O
at	O
3	O
years	O
of	O
follow	O
-	O
up	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
and	O
the	O
previously	O
published	O
MLPA	O
study	O
have	O
lead	O
us	O
to	O
perform	O
mutational	O
analysis	O
in	O
the	O
most	O
cost	O
-	O
effective	O
manner	O
:	O
initially	O
targeted	O
analysis	O
for	O
c	B-VARIANT
.	I-VARIANT
2826_2836delinsGGATGCTCCA	I-VARIANT
followed	O
by	O
MLPA	O
analysis	O
for	O
deletions	O
and	O
duplications	O
are	O
performed	O
.	O

Afferent	B-DISEASE
pupillary	I-DISEASE
defects	I-DISEASE
were	O
uncommon	O
in	O
the	O
group	O
with	O
only	O
one	O
patient	O
exhibiting	O
a	O
trace	O
of	O
afferent	O
pupillary	O
defect	O
in	O
both	O
eyes	O
(	O
F2	O
II	O
:	O
1	O
)	O
.	O

We	O
found	O
two	O
novel	O
nonsense	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
Q136X	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
W114X	I-VARIANT
,	O
of	O
POU3F4	B-GENE
co	O
-	O
segregating	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
these	O
two	O
families	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
50	O
(	O
race	O
matched	O
)	O
controls	O
with	O
normal	O
hearing	O
were	O
screened	O
for	O
SLC26A4	B-GENE
mutations	O
by	O
DHPLC	O
followed	O
by	O
sequencing	O
analysis	O
.	O

The	O
average	O
age	O
of	O
onset	O
of	O
patients	O
with	O
EVA	B-DISEASE
and	O
/	O
or	O
other	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
is	O
1	O
.	O
56	O
+	O
-	O
1	O
.	O
23	O
.	O

It	O
is	O
difficult	O
to	O
determine	O
the	O
exact	O
prevalence	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
homozygotes	O
in	O
Slovakia	O
due	O
to	O
missing	O
data	O
describing	O
the	O
number	O
of	O
deaf	B-DISEASE
Romanies	O
in	O
the	O
country	O
.	O

Her	O
best	O
-	O
corrected	O
visual	O
acuity	O
was	O
0	O
.	O
4	O
in	O
both	O
eyes	O
,	O
but	O
she	O
experienced	O
a	O
rapid	O
progression	O
of	O
visual	O
loss	O
in	O
the	O
last	O
year	O
.	O

Etiological	O
studies	O
have	O
shown	O
that	O
approximately	O
two	O
-	O
thirds	O
of	O
congenital	O
/	O
early	O
-	O
onset	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
developed	O
countries	O
is	O
estimated	O
to	O
be	O
due	O
to	O
genetic	O
causes	O
[	O
1	O
]	O
.	O

It	O
is	O
likely	O
that	O
the	O
family	O
described	O
here	O
carries	O
the	O
mutation	O
on	O
the	O
founder	O
haplotype	O
.	O

The	O
relative	O
positions	O
of	O
WFS1	B-GENE
mutations	O
within	O
the	O
putative	O
WFS1	B-GENE
protein	O
topology	O
are	O
indicated	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
safety	O
of	O
lidocaine	B-Chemical
in	O
the	O
setting	O
of	O
cocaine	B-Chemical
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
(	O
MI	B-DISEASE
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
three	O
alkylxanthines	B-Chemical
with	O
different	O
potencies	O
as	O
adenosine	B-Chemical
antagonists	O
8	B-Chemical
-	I-Chemical
phenyltheophylline	I-Chemical
,	O
theophylline	B-Chemical
and	O
enprofylline	B-Chemical
,	O
were	O
examined	O
in	O
rats	O
developing	O
acute	O
renal	O
failure	I-DISEASE
after	O
4	O
daily	O
injections	O
of	O
gentamicin	B-Chemical
(	O
200	O
mg	O
kg	O
-	O
1	O
)	O
.	O

Coverages	O
were	O
calculated	O
by	O
GATK	O
.	O

For	O
this	O
,	O
we	O
performed	O
co	O
-	O
immunoprecipitation	O
studies	O
using	O
GFP	O
-	O
and	O
HA	B-Chemical
-	O
tagged	O
wild	O
type	O
and	O
mutant	O
proteins	O
that	O
were	O
co	O
-	O
expressed	O
in	O
HEK293T	O
cells	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
case	O
control	O
study	O
of	O
heart	B-DISEASE
failure	I-DISEASE
patients	O
treated	O
with	O
spironolactone	B-Chemical
in	O
our	O
clinical	O
practice	O
.	O

Avraham	O
,	O
Doris	O
K	O
.	O

Mean	O
arterial	O
blood	O
pressure	O
in	O
mice	O
treated	O
with	O
NIMO	B-Chemical
alone	O
decreased	O
from	O
88	O
.	O
1	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
to	O
80	O
.	O
0	O
+	O
/	O
-	O
2	O
.	O
9	O
mm	O
Hg	O
.	O

c	O
In	O
-	O
frame	O
skipping	O
of	O
exon	O
12	O
(	O
p	B-VARIANT
.	I-VARIANT
T381	I-VARIANT
-	I-VARIANT
N404del	I-VARIANT
)	O
.	O

Two	O
intronic	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
1566	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
453	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
in	O
TMC1	B-GENE
are	O
proposed	O
to	O
affect	O
splicing	O
,	O
leading	O
to	O
a	O
frameshift	O
and	O
formation	O
of	O
a	O
non	O
-	O
functional	O
protein	O
.	O

Anencephaly	B-DISEASE
has	O
been	O
suggested	O
to	O
develop	O
from	O
exencephaly	B-DISEASE
;	O
however	O
,	O
there	O
is	O
little	O
direct	O
experimental	O
evidence	O
to	O
support	O
this	O
,	O
and	O
the	O
mechanism	O
of	O
transformation	O
remains	O
unclear	O
.	O

Therefore	O
,	O
old	O
age	O
may	O
be	O
a	O
risk	O
factor	O
for	O
developing	O
this	O
complication	O
.	O

Electron	O
microscopy	O
disclosed	O
many	O
secretory	O
granules	O
,	O
slightly	O
distorted	O
rough	O
endoplasmic	O
reticulum	O
,	O
and	O
partially	O
dilated	O
Golgi	O
cisternae	O
in	O
the	O
prolactinoma	O
cells	O
.	O

2	O
.	O
0	O
)	O
.	O

The	O
MMSE	O
scores	O
of	O
patients	O
III	O
:	O
1	O
,	O
III	O
:	O
9	O
and	O
III	O
:	O
11	O
from	O
family	O
2423	O
were	O
in	O
the	O
normal	O
range	O
(	O
27	O
-	O
30	O
)	O
:	O
28	O
,	O
27	O
and	O
28	O
,	O
respectively	O
with	O
their	O
corresponding	O
educational	O
backgrounds	O
of	O
junior	O
college	O
,	O
high	O
school	O
and	O
middle	O
school	O
.	O

and	O
A	O
.	O
H	O
.	O

RAST	O
for	O
BPO	B-Chemical
-	I-Chemical
PLL	I-Chemical
and	O
AX	B-Chemical
-	O
PLL	O
was	O
done	O
.	O

Given	O
VIP	O
'	O
s	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	O
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
would	O
exhibit	O
enhanced	O
inflammatory	O
mediator	O
expression	O
after	O
cystitis	B-DISEASE
.	O

Dose	O
intensity	O
did	O
not	O
add	O
information	O
to	O
models	O
.	O

Usher	B-DISEASE
Syndrome	I-DISEASE
Missense	O
Analysis	O
is	O
a	O
web	O
-	O
based	O
tool	O
dedicated	O
to	O
analysis	O
of	O
missense	O
variants	O
in	O
Usher	B-DISEASE
genes	O
available	O
through	O
USHbases	O
.	O

4A	O
)	O
.	O

Benign	O
,	O
Possibly	O
Damaging	O
,	O
and	O
Probably	O
Damaging	O
as	O
defined	O
by	O
PolyPhen2	O
Long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
(	O
LQTS	B-DISEASE
)	O
is	O
an	O
inherited	O
arrhythmic	O
disorder	O
characterised	O
by	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
ECG	O
,	O
presence	O
of	O
syncope	B-DISEASE
and	O
sudden	O
death	O
.	O

The	O
likelihood	O
that	O
bupropion	B-Chemical
induced	O
hepatotoxicity	B-DISEASE
in	O
our	O
patient	O
was	O
possible	O
,	O
based	O
on	O
the	O
Naranjo	O
probability	O
scale	O
.	O

No	O
other	O
mutations	O
in	O
KCNJ10	B-GENE
were	O
detected	O
.	O

The	O
pendrin	B-GENE
V239D	B-VARIANT
mutant	O
was	O
created	O
by	O
PCR	O
mutagenesis	O
using	O
the	O
QuickChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Stratagene	O
)	O
and	O
subcloned	O
into	O
the	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
expression	O
vector	O
pEYFP	O
-	O
C1	O
(	O
Clontech	O
)	O
.	O

We	O
appreciate	O
Liping	O
Guan	O
,	O
Jingjing	O
Xiao	O
,	O
and	O
Jingjing	O
Jiang	O
from	O
BGI	O
-	O
Shenzhen	O
(	O
Shenzhen	O
,	O
Guangdong	O
,	O
China	O
)	O
for	O
technical	O
support	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Based	O
on	O
these	O
facts	O
,	O
our	O
working	O
hypothesis	O
was	O
that	O
family	O
TB128	O
might	O
segregate	O
recessive	O
mutations	O
of	O
two	O
different	O
genes	O
,	O
independently	O
causing	O
RP	B-DISEASE
and	O
HL	B-DISEASE
,	O
and	O
mimicking	O
the	O
USH1	B-DISEASE
phenotype	O
.	O

Indomethacin	B-Chemical
induced	O
hypotension	B-DISEASE
in	O
sodium	B-Chemical
and	O
volume	O
depleted	O
rats	O
.	O

Genomic	O
DNA	O
(	O
gDNA	O
)	O
was	O
extracted	O
from	O
peripheral	O
blood	O
using	O
a	O
blood	O
DNA	O
extraction	O
kit	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Tiangen	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

-	O
-	O
:	O
homozygous	O
wild	O
type	O
status	O
,	O
+	O
-	O
heterozygous	O
status	O
,	O
+	O
+	O
homozygous	O
mutated	O
status	O
.	O

Higher	O
metoprolol	B-Chemical
/	O
alpha	B-Chemical
-	I-Chemical
hydroxymetoprolol	I-Chemical
ratios	O
in	O
PMs	O
were	O
predictive	O
for	O
higher	O
R	O
-	O
/	O
S	O
-	O
isomer	O
ratios	O
of	O
unchanged	O
drug	O
.	O

They	O
may	O
,	O
therefore	O
,	O
be	O
even	O
more	O
valuable	O
than	O
previously	O
recognised	O
.	O

Seizures	O
associated	O
with	O
levofloxacin	B-Chemical
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O

We	O
need	O
more	O
evidence	O
on	O
the	O
safety	O
of	O
HT	B-DISEASE
for	O
menopausal	B-DISEASE
symptom	I-DISEASE
control	O
,	O
though	O
short	O
-	O
term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
healthy	O
younger	O
women	O
.	O

Symptoms	O
usually	O
manifest	O
in	O
the	O
first	O
decade	O
of	O
life	O
,	O
and	O
,	O
in	O
most	O
cases	O
,	O
visual	B-DISEASE
impairment	I-DISEASE
develops	O
gradually	O
over	O
many	O
years	O
.	O

We	O
used	O
targeted	O
exome	O
sequencing	O
and	O
designed	O
a	O
1	O
.	O
4Mb	O
panel	O
for	O
simultaneous	O
testing	O
of	O
more	O
than	O
4	O
,	O
800	O
exons	O
in	O
309	O
genes	O
involved	O
in	O
skeletal	B-DISEASE
disorders	I-DISEASE
.	O

Use	O
of	O
glycopyrronium	B-Chemical
5	O
micrograms	O
kg	O
-	O
1	O
provided	O
greater	O
cardiovascular	O
stability	O
and	O
,	O
given	O
1	O
min	O
before	O
the	O
edrophonium	B-Chemical
,	O
was	O
sufficient	O
to	O
minimize	O
early	O
,	O
edrophonium	B-Chemical
-	O
induced	O
bradycardias	B-DISEASE
.	O

Interestingly	O
,	O
MED	B-DISEASE
patient	O
ESDN	B-Chemical
-	O
00594	B-Chemical
was	O
found	O
to	O
have	O
two	O
potential	O
COMP	B-GENE
missense	O
mutations	O
;	O
p	B-VARIANT
.	I-VARIANT
Gly501Asp	I-VARIANT
in	O
the	O
Type	O
III	O
-	O
repeat	O
region	O
and	O
p	B-VARIANT
.	I-VARIANT
Gln756Arg	I-VARIANT
in	O
the	O
CTD	O
(	O
Table	O
3	O
)	O
.	O

Chickens	O
given	O
200	O
ppm	O
corticosterone	B-Chemical
without	O
TOTP	B-Chemical
or	O
DFP	B-Chemical
had	O
significantly	O
elevated	O
activity	O
of	O
plasma	O
cholinesterase	O
and	O
significantly	O
inhibited	O
activity	O
of	O
liver	O
carboxylesterase	O
.	O

Neither	O
ECG	O
[	O
sinus	O
-	O
cycle	O
length	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTc	O
interval	O
,	O
or	O
U	O
wave	O
]	O
nor	O
clinical	O
parameters	O
identified	O
patients	O
at	O
risk	O
for	O
torsades	O
de	O
pointes	O
.	O

Subsequent	O
sequencing	O
analysis	O
of	O
CRB1	B-GENE
confirmed	O
the	O
same	O
causative	O
mutation	O
,	O
supporting	O
common	O
ancestry	O
.	O

Effects	O
of	O
aminophylline	B-Chemical
on	O
the	O
threshold	O
for	O
initiating	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
during	O
respiratory	B-DISEASE
failure	I-DISEASE
.	O

Five	O
patients	O
with	O
idiopathic	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
who	O
had	O
physiologic	O
and	O
biochemical	O
evidence	O
of	O
severe	O
autonomic	B-DISEASE
dysfunction	I-DISEASE
were	O
included	O
in	O
the	O
study	O
.	O

Control	O
rats	O
were	O
found	O
to	O
have	O
a	O
lower	O
capacity	O
to	O
transport	O
deoxycholic	B-Chemical
acid	I-Chemical
than	O
taurodeoxycholic	B-Chemical
acid	I-Chemical
,	O
and	O
both	O
were	O
decreased	O
by	O
ethinyl	B-Chemical
estradiol	I-Chemical
treatment	O
.	O

The	O
mutational	O
spectrum	O
included	O
missense	O
,	O
nonsense	O
,	O
and	O
splice	O
site	O
mutations	O
as	O
well	O
as	O
smaller	O
deletions	O
and	O
insertions	O
,	O
which	O
were	O
commonly	O
associated	O
with	O
a	O
shift	O
of	O
the	O
WFS1	B-GENE
reading	O
frame	O
.	O

For	O
measurement	O
of	O
hearing	O
,	O
all	O
patients	O
underwent	O
pure	O
tone	O
audiometry	O
(	O
PTA	O
)	O
test	O
for	O
air	O
conduction	O
at	O
a	O
range	O
of	O
frequencies	O
from	O
250	O
to	O
8	O
,	O
000	O
Hz	O
.	O

A	O
recent	O
study	O
applied	O
to	O
USH	B-DISEASE
compared	O
two	O
different	O
enrichment	O
methods	O
and	O
reported	O
a	O
higher	O
efficiency	O
in	O
mutation	O
detection	O
using	O
a	O
Long	O
-	O
Range	O
PCR	O
targeted	O
approach	O
compared	O
to	O
whole	O
-	O
exome	O
capture	O
(	O
Licastro	O
et	O
al	O
.	O

The	O
molecular	O
etiology	O
of	O
the	O
patient	O
carrying	O
7444G	B-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
remains	O
to	O
be	O
identified	O
.	O

In	O
patients	O
DF25	O
-	O
V	O
.	O
3	O
and	O
DF99	O
-	O
IV	O
.	O
1	O
,	O
a	O
nonsense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
52A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Lys18	I-VARIANT
*	I-VARIANT
)	O
,	O
and	O
a	O
frameshift	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1195_1196delAG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Leu399Alafs	I-VARIANT
*	I-VARIANT
24	I-VARIANT
)	O
,	O
were	O
identified	O
in	O
exon	O
1	O
and	O
2	O
of	O
USH1G	B-GENE
(	O
NM_173477	O
)	O
,	O
respectively	O
.	O

The	O
arrow	O
indicates	O
the	O
changed	O
base	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
dose	O
of	O
TNA	B-Chemical
,	O
she	O
had	O
an	O
episode	O
of	O
generalized	O
tonic	B-DISEASE
clonic	I-DISEASE
convulsions	I-DISEASE
.	O

Haemorrhagic	B-DISEASE
myocarditis	I-DISEASE
is	O
a	O
rare	O
but	O
important	O
complication	O
of	O
cyclophosphamide	B-Chemical
therapy	O
.	O

5E	O
.	O

WFS1	B-GENE
encodes	O
for	O
wolframin	B-GENE
,	O
a	O
protein	O
known	O
to	O
contain	O
nine	O
predicted	O
transmembrane	O
domains	O
.	O

For	O
in	O
silico	O
analysis	O
of	O
the	O
missense	O
mutations	O
,	O
PolyPhen	O
-	O
2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
index	O
.	O
shtml	O
)	O
,	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
and	O
Mutation	O
Taster	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mutationtaster	O
.	O
org	O
/	O
)	O
were	O
used	O
for	O
the	O
prediction	O
of	O
the	O
effect	O
of	O
amino	O
acid	O
substitutions	O
on	O
protein	O
function	O
.	O

A	O
diverse	O
genotype	O
/	O
phenotype	O
presentation	O
was	O
found	O
in	O
kindred	O
L151	O
[	O
Figures	O
3	O
and	O
4	O
]	O
.	O

Genotype	O
/	O
phenotype	O
studies	O
have	O
been	O
reported	O
showing	O
that	O
individuals	O
with	O
mutations	O
in	O
the	O
motor	O
domain	O
of	O
myosin	B-GENE
-	I-GENE
9	I-GENE
have	O
more	O
severe	O
thrombocytopenia	B-DISEASE
and	O
higher	O
risk	O
of	O
developing	O
nephropathy	B-DISEASE
and	O
deafness	B-DISEASE
[	O
8	O
-	O
10	O
]	O
.	O

1	O
C	O
)	O
.	O

In	O
the	O
other	O
infant	O
cross	O
-	O
sectional	O
echocardiography	O
provided	O
reassurance	O
that	O
the	O
infant	O
did	O
not	O
have	O
Ebstein	B-DISEASE
'	I-DISEASE
s	I-DISEASE
anomaly	I-DISEASE
.	O

Even	O
though	O
we	O
could	O
not	O
construct	O
haplotypes	O
due	O
to	O
a	O
lack	O
of	O
parental	O
DNA	O
samples	O
to	O
determine	O
linkage	O
,	O
the	O
markers	O
better	O
delineated	O
the	O
candidate	O
region	O
.	O

Based	O
on	O
the	O
severity	O
and	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
age	O
at	O
onset	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
,	O
and	O
presence	O
or	O
absence	O
of	O
vestibular	B-DISEASE
impairment	I-DISEASE
,	O
the	O
majority	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
cases	O
can	O
be	O
classified	O
into	O
three	O
clinical	O
subtypes	O
.	O

Patients	O
with	O
negative	O
coronary	O
CTA	O
(	O
maximal	O
stenosis	O
less	O
than	O
50	O
%	O
)	O
were	O
discharged	O
.	O

Our	O
study	O
provides	O
new	O
insights	O
into	O
the	O
genes	O
that	O
are	O
necessary	O
for	O
the	O
function	O
of	O
brain	O
and	O
inner	O
ear	O
sensory	O
cells	O
in	O
humans	O
.	O

Compound	O
1	O
is	O
a	O
potent	O
A	O
(	O
2A	O
)	O
/	O
A	O
(	O
1	O
)	O
receptor	O
antagonist	O
in	O
vitro	O
(	O
A	O
(	O
2A	O
)	O
K	O
(	O
i	O
)	O
=	O
4	O
.	O
1	O
nM	O
;	O
A	O
(	O
1	O
)	O
K	O
(	O
i	O
)	O
=	O
17	O
.	O
0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	O
,	O
after	O
oral	O
administration	O
,	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
including	O
mouse	O
and	O
rat	O
models	O
of	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	O
,	O
mouse	O
model	O
of	O
reserpine	B-Chemical
-	O
induced	O
akinesia	B-DISEASE
,	O
rat	O
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
(	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
)	O
lesion	O
model	O
of	O
drug	O
-	O
induced	O
rotation	O
,	O
and	O
MPTP	B-Chemical
-	O
treated	O
non	O
-	O
human	O
primate	O
model	O
.	O

Since	O
EYA4	B-GENE
and	O
GRHL2	B-GENE
were	O
identified	O
as	O
the	O
transcription	O
factors	O
for	O
the	O
DFNA10	B-GENE
and	O
DFNA28	B-GENE
,	O
8	O
EYA4	B-GENE
mutations	O
and	O
2	O
GRHL2	B-GENE
mutations	O
have	O
been	O
reported	O
worldwide	O
.	O

Target	O
exon	O
sequencing	O
using	O
massively	O
parallel	O
DNA	O
sequencing	O
is	O
a	O
new	O
powerful	O
strategy	O
to	O
discover	O
rare	O
causative	O
genes	O
in	O
Mendelian	O
disorders	O
such	O
as	O
deafness	B-DISEASE
.	O

Our	O
results	O
confirm	O
that	O
trio	O
-	O
based	O
exome	O
sequencing	O
is	O
a	O
powerful	O
approach	O
to	O
discover	O
the	O
genes	O
causing	O
sporadic	B-DISEASE
developmental	I-DISEASE
disorders	I-DISEASE
,	O
emphasize	O
the	O
overlapping	O
roles	O
of	O
cytoplasmic	O
actins	O
in	O
development	O
,	O
and	O
suggest	O
that	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
is	O
the	O
predominant	O
phenotype	O
associated	O
with	O
mutations	O
of	O
these	O
two	O
genes	O
.	O

Researchers	O
have	O
used	O
different	O
target	O
enrichment	O
methods	O
such	O
as	O
solid	O
phase	O
capture	O
arrays	O
[	O
9	O
]	O
,	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
or	O
PCR	O
amplicons	O
based	O
approaches	O
[	O
8	O
]	O
,	O
[	O
11	O
]	O
as	O
opposed	O
to	O
liquid	O
phase	O
capture	O
[	O
10	O
]	O
,	O
[	O
13	O
]	O
and	O
have	O
run	O
the	O
libraries	O
on	O
different	O
machines	O
such	O
as	O
the	O
Roche	O
454	O
[	O
8	O
]	O
,	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
or	O
the	O
ABI	O
SOLiD	O
[	O
13	O
]	O
rather	O
than	O
the	O
Illumina	O
Genome	O
Analyser	O
[	O
8	O
]	O
-	O
[	O
11	O
]	O
.	O

These	O
results	O
suggest	O
that	O
OPA1	B-GENE
mutations	O
are	O
the	O
most	O
common	O
cause	O
for	O
patients	O
with	O
suspected	O
hereditary	O
optic	B-DISEASE
atrophy	I-DISEASE
.	O

Fourteen	O
genes	O
(	O
ACTG1	B-GENE
,	O
COL9A3	B-GENE
,	O
EYA4	B-GENE
,	O
GATA3	B-GENE
,	O
KCNJ10	B-GENE
,	O
LHFPL5	B-GENE
,	O
MARVELD2	B-GENE
,	O
MYO1F	B-GENE
,	O
MYO3A	B-GENE
,	O
MYO6	B-GENE
,	O
OTOA	B-GENE
,	O
TCF21	B-GENE
,	O
TMC1	B-GENE
,	O
and	O
TMIE	B-GENE
)	O
displayed	O
a	O
single	O
variant	O
,	O
six	O
(	O
ERCC2	B-GENE
,	O
ESPN	B-GENE
,	O
OTOR	B-GENE
,	O
TMPRSS5	B-GENE
,	O
USH1C	B-GENE
,	O
and	O
WSF1	B-GENE
)	O
two	O
variants	O
,	O
seven	O
(	O
GJB3	B-GENE
,	O
DSPP	B-GENE
,	O
MYH9	B-GENE
,	O
MYO1C	B-GENE
,	O
PCDH15	B-GENE
,	O
SPINK5	B-GENE
,	O
and	O
TECTA	B-GENE
)	O
three	O
variants	O
,	O
seven	O
(	O
CCDC50	B-GENE
,	O
CDH23	B-GENE
,	O
GJB2	B-GENE
,	O
MYO1A	B-GENE
,	O
MYO15A	B-GENE
,	O
SLC26A4	B-GENE
,	O
and	O
TRIOBP	B-GENE
)	O
four	O
variants	O
,	O
three	O
(	O
GJB4	B-GENE
,	O
MYO7A	B-GENE
,	O
and	O
OTOF	B-GENE
)	O
five	O
variants	O
,	O
and	O
one	O
(	O
MYH14	B-GENE
)	O
seven	O
variants	O
that	O
met	O
the	O
criteria	O
for	O
potential	O
pathogenicity	O
,	O
evolutionary	O
conservation	O
,	O
and	O
additional	O
filtering	O
criteria	O
such	O
as	O
depth	O
and	O
quality	O
(	O
Supplementary	O
Table	O
S4	O
online	O
)	O
.	O

Following	O
analysis	O
of	O
the	O
other	O
affected	O
case	O
(	O
2910	O
)	O
,	O
both	O
EYS	B-GENE
variants	O
were	O
homozygous	O
and	O
Sanger	O
sequencing	O
of	O
the	O
EYS	B-GENE
terminal	O
exon	O
that	O
was	O
not	O
covered	O
by	O
the	O
capture	O
reagent	O
failed	O
to	O
identify	O
any	O
other	O
changes	O
.	O

[	O
15	O
]	O
.	O

Genetic	O
cause	O
of	O
sensorineural	O
disorders	O
such	O
as	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
and	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
extraordinarily	O
heterogeneous	O
.	O

Both	O
were	O
diagnosed	O
with	O
RP	B-DISEASE
at	O
the	O
age	O
of	O
9	O
(	O
Table	O
2	O
)	O
.	O

Pure	O
-	O
tone	O
audiometry	O
testing	O
showed	O
that	O
her	O
father	O
had	O
moderate	O
high	O
-	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
whereas	O
her	O
mother	O
had	O
normal	O
hearing	O
.	O

Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	B-DISEASE
hemorrhage	I-DISEASE
and	O
mucosal	B-DISEASE
ulceration	I-DISEASE
produced	O
in	O
atherosclerotic	B-DISEASE
rats	O
are	O
lacking	O
.	O

Primers	O
were	O
pooled	O
to	O
generate	O
6	O
-	O
plex	O
primer	O
pools	O
per	O
PCR	O
with	O
a	O
final	O
concentration	O
of	O
1	O
QM	O
per	O
primer	O
.	O

These	O
signs	O
can	O
be	O
isolated	O
(	O
isolated	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
(	O
HH	B-DISEASE
)	O
)	O
[	O
1	O
]	O
or	O
associated	O
with	O
symptoms	O
like	O
hypoglycemia	O
,	O
jaundice	O
and	O
decreased	O
growth	O
rate	O
in	O
cases	O
where	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
is	O
associated	O
with	O
other	O
hypothalamic	B-DISEASE
-	I-DISEASE
pituitary	I-DISEASE
deficiencies	I-DISEASE
[	O
2	O
]	O
.	O

Cephalosporin	B-Chemical
antibiotics	I-DISEASE
cause	O
a	O
variety	O
of	O
hematologic	B-DISEASE
disturbances	I-DISEASE
in	O
man	O
,	O
the	O
pathogeneses	O
and	O
hematopathology	B-DISEASE
of	O
which	O
remain	O
poorly	O
characterized	O
.	O

About	O
45	O
%	O
of	O
COL4A5	B-GENE
mutations	O
are	O
missense	O
mutations	O
.	O

This	O
suggests	O
that	O
the	O
genetic	O
heterogeneity	O
of	O
USH	B-DISEASE
is	O
much	O
higher	O
and	O
makes	O
the	O
NGS	O
technologies	O
cost	O
-	O
effective	O
in	O
terms	O
of	O
diagnostic	O
power	O
only	O
in	O
the	O
cases	O
due	O
to	O
mutations	O
in	O
the	O
known	O
genes	O
.	O

2007BAI18B12	O
)	O
,	O
the	O
Natural	O
Science	O
Foundation	O
of	O
Guangdong	O
Province	O
Key	O
Project	O
(	O
Grant	O
No	O
.	O

Some	O
of	O
the	O
affected	O
family	O
members	O
underwent	O
speech	O
audiometry	O
,	O
vestibulo	O
-	O
ocular	O
examination	O
,	O
and	O
high	O
-	O
resolution	O
spiral	O
computed	O
tomography	O
imaging	O
of	O
the	O
temporal	O
bones	O
.	O

Here	O
,	O
2	O
cases	O
of	O
urinary	B-DISEASE
bladder	I-DISEASE
retention	I-DISEASE
leading	O
to	O
renal	B-DISEASE
pelvocalyceal	I-DISEASE
dilatation	I-DISEASE
mimicking	O
hydronephrosis	B-DISEASE
as	O
a	O
result	O
of	O
continuous	O
infusion	O
of	O
fentanyl	B-Chemical
are	O
reported	O
.	O

To	O
confirm	O
the	O
APOL1deletion	O
variation	O
(	O
rs71785313	B-VARIANT
)	O
,	O
also	O
known	O
as	B-DISEASE
G2	O
,	O
in	O
the	O
two	O
African	O
American	O
(	O
AA	O
)	O
FSGS	B-DISEASE
patients	O
,	O
Sanger	O
sequencing	O
was	O
performed	O
using	O
the	O
APOL1_I	O
/	O
D_rs71785313	O
primer	O
set	O
(	O
Supplemental	O
Table	O
S2	O
)	O
.	O

Next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
is	O
accelerating	O
the	O
qualitative	O
improvement	O
of	O
mutational	O
studies	O
for	O
numerous	O
heterogeneous	O
disorders	O
due	O
to	O
its	O
ability	O
to	O
perform	O
simultaneous	O
and	O
massively	O
parallel	O
sequencing	O
.	O

The	O
ages	O
of	O
the	O
affected	O
females	O
are	O
marked	O
in	O
years	O
(	O
Yr	O
)	O
next	O
to	O
the	O
symbols	O
.	O

Increased	O
Ca	B-Chemical
2	I-Chemical
+	O
influx	O
due	O
to	O
CACNA1D	B-GENE
mutations	O
phenocopies	O
the	O
consequence	O
of	O
KCNJ5	B-GENE
mutations	O
,	O
which	O
cause	O
increased	O
Ca	B-Chemical
2	I-Chemical
+	I-Chemical
influx	O
by	O
depolarizing	O
glomerulosa	O
cells	O
.	O

Availability	O
of	O
data	O
showing	O
reduced	O
staining	O
of	O
collagen	O
(	O
IV	O
)	O
in	O
the	O
glomerular	O
basement	O
membrane	O
would	O
have	O
provided	O
supportive	O
evidence	O
that	O
the	O
phenotype	O
observed	O
in	O
this	O
cohort	O
of	O
patients	O
are	O
due	O
to	O
rare	O
variants	O
in	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
genes	O
,	O
unfortunately	O
this	O
was	O
not	O
possible	O
because	O
of	O
our	O
inability	O
to	O
access	O
suitable	O
tissue	O
for	O
immunostaining	O
.	O

2005	O
)	O
.	O

It	O
has	O
been	O
shown	O
by	O
multiple	O
studies	O
that	O
the	O
detection	O
rates	O
of	O
TMPRSS3	B-GENE
mutations	O
are	O
variable	O
in	O
different	O
ethnic	O
groups	O
[	O
10	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

One	O
patient	O
showed	O
no	O
changes	O
in	O
SAP	O
amplitude	O
.	O

The	O
differential	O
effects	O
of	O
bupivacaine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
prostaglandin	B-Chemical
E2	I-Chemical
release	O
,	O
cyclooxygenase	O
gene	O
expression	O
and	O
pain	O
in	O
a	O
clinical	O
pain	O
model	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
hyperkinetic	B-DISEASE
delirium	I-DISEASE
connected	O
with	O
a	O
high	O
serum	O
total	O
fluoxetine	B-Chemical
(	O
fluoxetine	B-Chemical
plus	O
desmethylfluoxetine	B-Chemical
)	O
concentration	O
.	O

A	O
total	O
of	O
125	O
deaf	B-DISEASE
probands	O
were	O
void	O
of	O
mutations	O
in	O
the	O
three	O
common	O
deafness	B-DISEASE
genes	O
and	O
proceeded	O
through	O
the	O
targeted	O
exon	O
capturing	O
and	O
NGS	O
.	O

In	O
the	O
Korean	O
population	O
,	O
there	O
have	O
been	O
only	O
3	O
case	O
reports	O
of	O
patients	O
with	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
carrying	O
EYA1	B-GENE
mutations	O
,	O
and	O
this	O
study	O
adds	O
to	O
the	O
genotypic	O
and	O
phenotypic	O
spectrum	O
of	O
BOR	B-DISEASE
syndrome	O
in	O
the	O
East	O
Asian	O
population	O
[	O
15	O
]	O
,	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O

The	O
present	O
study	O
revealed	O
that	O
its	O
sensitivity	O
for	O
CHD23	B-GENE
was	O
18	O
.	O
1	O
%	O
at	O
best	O
.	O

The	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
variants	O
did	O
not	O
cluster	O
in	O
any	O
particular	O
region	O
of	O
either	O
gene	O
.	O

Seventeen	O
patients	O
(	O
17	O
/	O
20	O
=	O
85	O
%	O
)	O
who	O
harbored	O
two	O
mutations	O
in	O
SLC26A4	B-GENE
gene	O
.	O

The	O
nomenclature	O
of	O
the	O
alterations	O
was	O
adopted	O
according	O
to	O
the	O
guidelines	O
of	O
the	O
human	O
variation	O
society	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hgvs	O
.	O
org	O
/	O
)	O
.	O

Haplotype	O
IDs	O
and	O
respective	O
patients	O
are	O
given	O
in	O
the	O
left	O
column	O
.	O

USH2A	B-GENE
is	O
the	O
most	O
frequently	O
mutated	O
gene	O
in	O
USH2	B-DISEASE
patients	O
and	O
mutations	O
in	O
USH2A	B-GENE
alone	O
account	O
for	O
85	O
%	O
of	O
USH2	B-DISEASE
while	O
mutations	O
in	O
GPR98	B-GENE
account	O
for	O
6	O
%	O
of	O
USH2	B-DISEASE
in	O
the	O
French	O
and	O
other	O
Caucasian	O
populations	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

22	O
noted	O
that	O
most	O
missense	O
mutations	O
in	O
the	O
Ca	B-Chemical
2	I-Chemical
+	I-Chemical
-	I-Chemical
binding	O
motifs	O
were	O
only	O
observed	O
in	O
DFNB12	B-DISEASE
patients	O
,	O
which	O
led	O
to	O
the	O
suggestion	O
that	O
the	O
impairment	O
of	O
Ca	B-Chemical
2	I-Chemical
+	I-Chemical
binding	O
may	O
not	O
diminish	O
cadherin	O
'	O
s	O
function	O
in	O
retina	O
.	O

Rivolta	B-Chemical
et	O
al	O
.	O

II	O
-	O
5	O
'	O
s	O
son	O
(	O
III	O
-	O
2	O
)	O
developed	O
heavy	O
proteinuria	B-DISEASE
and	O
edema	O
at	O
age	O
2	O
and	O
progressed	O
to	O
CKD3	B-DISEASE
(	O
GFR	O
of	O
55	O
ml	O
/	O
min	O
)	O
at	O
age	O
30	O
.	O

Coexistence	O
of	O
cerebral	B-DISEASE
venous	I-DISEASE
sinus	I-DISEASE
and	O
internal	O
carotid	I-DISEASE
artery	I-DISEASE
thrombosis	I-DISEASE
associated	O
with	O
exogenous	O
sex	O
hormones	O
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
amiodarone	B-Chemical
-	I-DISEASE
induced	I-DISEASE
pulmonary	I-DISEASE
toxicity	I-DISEASE
are	O
characteristic	O
but	O
nonspecific	O
.	O

Although	O
both	O
dl	O
-	O
sotalol	B-Chemical
and	O
azimilide	B-Chemical
rarely	O
induced	O
EADs	B-DISEASE
in	O
canine	O
left	O
ventricles	O
,	O
they	O
produced	O
frequent	O
EADs	B-DISEASE
in	O
rabbits	O
,	O
in	O
which	O
more	O
pronounced	O
QT	B-DISEASE
prolongation	O
was	O
seen	O
.	O

The	O
evolutionary	O
conservation	O
for	O
at	O
each	O
variant	O
position	O
was	O
measured	O
by	O
Genome	O
Evolutionary	O
Rare	O
Profiling	O
(	O
GERP	O
)	O
and	O
PhyloP	O
.	O

05	O
)	O
.	O

Primer	O
sequences	O
,	O
as	O
well	O
as	O
the	O
specific	O
PCR	O
conditions	O
for	O
each	O
primer	O
couple	O
are	O
available	O
on	O
request	O
.	O

Three	O
clinical	O
subtypes	O
(	O
USH1	B-DISEASE
,	O
USH2	B-DISEASE
,	O
and	O
USH3	B-DISEASE
)	O
are	O
distinguished	O
according	O
to	O
the	O
severity	O
and	O
progression	O
of	O
deafness	B-DISEASE
,	O
presence	O
or	O
absence	O
of	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
age	O
at	O
onset	O
of	O
the	O
visual	O
loss	O
due	O
to	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	O
)	O
[	O
7	O
]	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fourteen	O
children	O
(	O
average	O
age	O
,	O
5	O
.	O
3	O
years	O
;	O
range	O
,	O
twelve	O
months	O
to	O
ten	O
years	O
and	O
ten	O
months	O
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	O
fracture	O
or	O
dislocation	O
in	O
the	O
emergency	O
department	O
at	O
a	O
level	O
-	O
I	O
trauma	O
center	O
were	O
prospectively	O
evaluated	O
.	O

Sho	O
Hashimoto	O
at	O
the	O
National	O
Hospital	O
Organization	O
Sendai	O
Medical	O
Center	O
,	O
Dr	O
.	O

Unusually	O
,	O
in	O
two	O
families	O
,	O
DE	O
-	O
1	O
and	O
NO	O
-	O
1	O
,	O
affected	O
family	O
members	O
harboured	O
two	O
different	O
OPA1	B-GENE
mutations	O
.	O

Observe	O
the	O
broad	O
thumb	O
in	O
ID	O
;	O
Note	O
clinodactyly	B-DISEASE
in	O
father	O
of	O
the	O
family	O
5	O
(	O
IID	O
)	O
.	O

Wang	O
et	O
al	O
.	O

CentiMorgan	O
distances	O
were	O
obtained	O
from	O
the	O
Map	O
-	O
O	O
-	O
Mat	O
database	O
for	O
microsatellites	O
(	O
http	O
:	O
/	O
/	O
compgen	O
.	O
rutgers	O
.	O
edu	O
/	O
Mapomat	O
/	O
)	O
.	O

Several	O
explanations	O
are	O
possible	O
for	O
deafness	B-DISEASE
in	O
this	O
child	O
:	O
he	O
may	O
carry	O
a	O
second	O
MYO7A	B-GENE
mutation	O
located	O
within	O
an	O
intron	O
or	O
in	O
a	O
regulatory	O
region	O
,	O
which	O
therefore	O
we	O
failed	O
to	O
detect	O
;	O
alternatively	O
,	O
his	O
deafness	B-DISEASE
may	O
be	O
due	O
to	O
mutation	O
(	O
s	O
)	O
in	O
a	O
different	O
gene	O
(	O
independent	O
segregation	O
of	O
mutations	O
in	O
more	O
than	O
one	O
deafness	B-DISEASE
-	O
causing	O
gene	O
within	O
the	O
same	O
family	O
has	O
been	O
previously	O
reported	O
[	O
4	O
]	O
)	O
.	O

RESULTS	O
:	O
Nicotine	B-Chemical
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenic	O
effect	O
,	O
apparent	O
with	O
decreases	O
in	O
open	O
-	O
arm	O
time	O
and	O
entry	O
.	O

Recent	O
reports	O
on	O
mutated	O
tricellulin	B-GENE
knock	O
-	O
in	O
mice	O
,	O
which	O
lack	O
tricellulin	B-GENE
at	O
TJs	O
,	O
showed	O
disrupted	O
bicellular	O
and	O
tricellular	O
TJ	O
strands	O
in	O
the	O
inner	O
ear	O
epithelia	O
and	O
rapid	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
accompanied	O
by	O
loss	B-DISEASE
of	I-DISEASE
cochlear	I-DISEASE
hair	I-DISEASE
cells	I-DISEASE
[	O
16	O
]	O
.	O

(	O
http	O
:	O
/	O
/	O
www	O
.	O
ch	O
.	O
embnet	O
.	O
org	O
/	O
software	O
/	O
COILS_form	O
.	O
html	O
)	O
.	O

We	O
believe	O
this	O
is	O
the	O
first	O
complete	O
report	O
of	O
dominant	O
inheritance	O
of	O
an	O
adult	O
-	O
onset	O
diabetes	B-DISEASE
phenotype	O
(	O
without	O
other	O
syndromic	O
features	O
of	O
WS	B-DISEASE
)	O
associated	O
with	O
a	O
missense	O
mutation	O
in	O
WFS1	B-GENE
.	O

Likewise	O
,	O
we	O
cannot	O
really	O
state	O
anything	O
about	O
the	O
cost	O
-	O
effectiveness	O
of	O
including	O
more	O
genes	O
in	O
the	O
basic	O
screen	O
or	O
the	O
suitability	O
or	O
cost	O
-	O
effectiveness	O
of	O
MLPA	O
analysis	O
of	O
the	O
five	O
genes	O
.	O

Hypothalamic	O
prolactin	O
receptor	I-GENE
messenger	O
ribonucleic	B-Chemical
acid	I-Chemical
levels	O
,	O
prolactin	B-GENE
signaling	O
,	O
and	O
hyperprolactinemic	O
inhibition	O
of	O
pulsatile	O
luteinizing	O
hormone	O
secretion	O
are	O
dependent	O
on	O
estradiol	B-Chemical
.	O

The	O
polypyrimidine	B-Chemical
tract	O
is	O
one	O
of	O
the	O
cis	O
-	O
acting	O
elements	O
in	O
the	O
splicing	O
machinery	O
that	O
is	O
recognized	O
by	O
several	O
protein	O
factors	O
to	O
form	O
a	O
functional	O
spliceosome	O
[	O
25	O
]	O
.	O

Both	O
87C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
and	O
357C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
are	O
silent	O
variants	O
.	O

This	O
indicates	O
that	O
EDNRB	B-GENE
isoform	O
1	O
protein	O
translocated	O
to	O
the	O
cell	O
surface	O
and	O
fulfilled	O
its	O
functional	O
property	O
as	O
a	O
cell	O
surface	O
receptor	O
.	O

METHODS	O
:	O
Data	O
were	O
analyzed	O
from	O
four	O
similarly	O
designed	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
3	O
-	O
to	O
12	O
-	O
week	O
studies	O
.	O

Author	O
Contributions	O
D	O
.	O
T	O
.	O
P	O
.	O
,	O
W	O
.	O
B	O
.	O
D	O
.	O
,	O
A	O
.	O
V	O
.	O

Heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-DISEASE
:	O
a	O
practical	O
review	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
RP	O
RWP	O
DLP	O
.	O

Further	O
haplotype	O
analysis	O
suggested	O
that	O
USH2A	B-GENE
may	O
be	O
the	O
disease	O
-	O
causing	O
gene	O
of	O
this	O
family	O
(	O
Figure	O
1	O
)	O
.	O

Therefore	O
,	O
we	O
considered	O
that	O
this	O
novel	O
missense	O
variant	O
in	O
MCM2	B-GENE
was	O
responsible	O
for	O
the	O
autosomal	B-DISEASE
dominant	I-DISEASE
deafness	I-DISEASE
in	O
this	O
pedigree	O
.	O

Supraventricular	B-DISEASE
tachycardia	I-DISEASE
developed	O
in	O
one	O
patient	O
receiving	O
Thorazine	B-Chemical
(	O
chlorpromazine	B-Chemical
)	O
.	O

In	O
contrast	O
,	O
the	O
mutation	O
panorama	O
in	O
this	O
Swedish	O
cohort	O
is	O
characterised	O
by	O
two	O
founder	O
mutations	O
in	O
the	O
KCNQ1	B-GENE
gene	O
that	O
accounts	O
for	O
one	O
-	O
fourth	O
of	O
the	O
identified	O
mutations	O
.	O

The	O
position	O
of	O
the	O
residues	O
involved	O
in	O
the	O
mutations	O
are	O
shaded	O
.	O

To	O
assess	O
the	O
analytical	O
sensitivity	O
of	O
this	O
approach	O
,	O
we	O
checked	O
whether	O
687	O
variants	O
(	O
from	O
24	O
patients	O
screened	O
in	O
several	O
genes	O
)	O
,	O
which	O
had	O
been	O
previously	O
detected	O
by	O
Sanger	O
sequencing	O
,	O
were	O
also	O
detected	O
with	O
NGS	O
.	O

In	O
the	O
process	O
of	O
sequence	O
variant	O
calling	O
,	O
a	O
)	O
we	O
selected	O
those	O
variants	O
that	O
were	O
located	O
in	O
translated	O
regions	O
;	O
b	O
)	O
we	O
selected	O
those	O
variants	O
supported	O
by	O
reads	O
on	O
both	O
DNA	O
strands	O
in	O
human	O
genome	O
;	O
c	O
)	O
we	O
removed	O
those	O
variants	O
deposited	O
in	O
the	O
dbSNP	O
database	O
(	O
version	O
135	O
)	O
,	O
1000	O
human	O
genome	O
dataset	O
,	O
and	O
in	O
our	O
in	O
-	O
house	O
exome	O
database	O
that	O
includes	O
healthy	O
individuals	O
and	O
patients	O
with	O
non	O
-	O
ocular	O
conditions	O
.	O

S1	O
-	O
2	O
)	O
is	O
a	O
result	O
of	O
the	O
destruction	O
of	O
the	O
canonical	O
splice	O
acceptor	O
and	O
creating	O
a	O
new	O
splice	O
acceptor	O
insert	O
site	O
.	O

No	O
differences	O
were	O
seen	O
following	O
cytochrome	O
oxidase	O
(	O
Fig	O
.	O

One	O
hundred	O
twelve	O
genes	O
listed	O
in	O
Table	O
S1	O
,	O
including	O
54	O
genes	O
reported	O
to	O
be	O
causative	O
of	O
non	O
-	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Hereditary	O
Hearing	B-DISEASE
loss	I-DISEASE
Homepage	O
;	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
/	O
)	O
and	O
22	O
reported	O
to	O
cause	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
selected	O
for	O
sequencing	O
.	O

We	O
screened	O
17	O
Japanese	O
USH1	B-DISEASE
patients	O
(	O
aged	O
9	O
to	O
64	O
years	O
)	O
:	O
three	O
from	O
autosomal	O
recessive	O
families	O
(	O
non	O
-	O
affected	O
parents	O
and	O
two	O
or	O
more	O
affected	O
siblings	O
)	O
,	O
and	O
14	O
from	O
sporadic	O
families	O
.	O

No	O
systemic	O
side	O
-	O
effects	O
were	O
observed	O
.	O

The	O
age	O
of	O
onset	O
ranged	O
from	O
5	O
to	O
12	O
years	O
.	O

Our	O
custom	O
-	O
made	O
antibody	O
against	O
mouse	O
recognizes	O
mouse	O
ELMOD3	B-GENE
isoform	O
b	O
.	O

Genome	O
-	O
wide	O
SNP	O
genotyping	O
was	O
performed	O
in	O
six	O
members	O
of	O
the	O
family	O
(	O
III	O
-	O
1	O
,	O
III	O
-	O
2	O
,	O
IV	O
-	O
3	O
,	O
IV	O
-	O
5	O
,	O
IV	O
-	O
6	O
,	O
and	O
IV	O
-	O
7	O
)	O
using	O
Affymetrix	O
6	O
.	O
0	O
arrays	O
.	O

In	O
category	O
B	O
,	O
two	O
affected	O
siblings	O
and	O
an	O
unaffected	O
parent	O
underwent	O
WES	O
in	O
most	O
instances	O
.	O

Written	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
.	O

Whenever	O
possible	O
,	O
samples	O
from	O
additional	O
family	O
members	O
were	O
used	O
to	O
perform	O
segregation	O
analysis	O
of	O
the	O
sequence	O
variants	O
identified	O
in	O
the	O
index	O
patient	O
.	O

The	O
ratio	O
of	O
EVA	B-DISEASE
in	O
the	O
minorities	O
was	O
14	O
.	O
63	O
%	O
(	O
6	O
/	O
41	O
)	O
.	O

The	O
toxicity	O
of	O
Renografin	B-Chemical
76	I-Chemical
%	I-Chemical
was	O
compared	O
with	O
that	O
of	O
Hypaque	B-Chemical
76	I-Chemical
%	I-Chemical
by	O
selective	O
injection	O
of	O
each	O
into	O
the	O
right	O
coronary	O
artery	O
of	O
dogs	O
.	O

DNAs	O
were	O
then	O
extracted	O
by	O
QIAamp	O
DNA	O
Blood	O
Mini	O
Kit	O
(	O
QIAGEN	B-Chemical
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

RESULTS	O
:	O
Of	O
the	O
77	O
patients	O
enrolled	O
in	O
the	O
study	O
,	O
73	O
%	O
were	O
male	O
and	O
27	O
%	O
were	O
female	O
.	O

As	O
for	O
individual	O
III	O
-	O
1	O
in	O
family	O
TB63	O
,	O
the	O
situation	O
is	O
more	O
complex	O
.	O

G	O
-	O
actin	O
was	O
extracted	O
from	O
the	O
rabbit	O
skeletal	O
muscle	O
using	O
Spudish	O
-	O
wati	I-Chemical
method	O
[	O
20	O
]	O
.	O

METHODS	O
:	O
Twenty	O
-	O
three	O
dogs	O
were	O
randomized	O
to	O
receive	O
either	O
1	O
)	O
three	O
intravenous	O
(	O
IV	O
)	O
boluses	O
of	O
cocaine	B-Chemical
7	O
.	O
5	O
mg	O
/	O
kg	O
with	O
ethanol	B-Chemical
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infusion	O
(	O
C	O
+	O
E	O
,	O
n	O
=	O
8	O
)	O
,	O
2	O
)	O
three	O
cocaine	B-Chemical
boluses	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
ethanol	B-Chemical
infusion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
placebo	O
boluses	O
and	O
infusion	O
(	O
n	O
=	O
4	O
)	O
.	O

A	O
genotype	O
-	O
phenotype	O
correlation	O
study	O
suggested	O
that	O
USH1D	B-DISEASE
was	O
usually	O
associated	O
with	O
nonsense	O
,	O
whereas	O
DFNB12	B-DISEASE
with	O
missense	O
mutations	O
[	O
5	O
]	O
.	O

Complementary	O
techniques	O
such	O
as	O
western	O
immunoblotting	O
and	O
immunohistochemistry	O
were	O
performed	O
to	O
investigate	O
the	O
validity	O
of	O
the	O
data	O
obtained	O
using	O
the	O
proteomic	O
approach	O
.	O

RESULTS	O
:	O
Since	O
2005	O
,	O
the	O
10	O
-	O
min	O
loading	O
dose	O
of	O
our	O
dexmedetomidine	B-Chemical
protocol	O
increased	O
from	O
2	O
to	O
3	O
microg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
and	O
the	O
infusion	O
rate	O
increased	O
from	O
1	O
to	O
1	O
.	O
5	O
to	O
2	O
microg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
h	O
(	O
-	O
1	O
)	O
.	O

A	O
large	O
proportion	O
of	O
Palestinian	O
families	O
are	O
likely	O
to	O
have	O
hearing	B-DISEASE
loss	I-DISEASE
due	O
to	O
as	O
yet	O
unknown	O
genes	O
.	O

However	O
,	O
only	O
one	O
region	O
included	O
in	O
the	O
final	O
design	O
showed	O
a	O
mean	O
coverage	O
lower	O
than	O
40x	O
in	O
our	O
samples	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Glu236Ala	I-VARIANT
mutation	O
introduces	O
a	O
non	O
-	O
polar	O
amino	O
acid	O
(	O
alanine	O
)	O
instead	O
of	O
an	O
acidic	O
residue	O
and	O
possibly	O
interferes	O
with	O
the	O
stability	O
between	O
the	O
secondary	O
structures	O
of	O
the	O
protein	O
(	O
Figure	O
1	O
A	O
)	O
.	O

Primers	O
used	O
to	O
screen	O
KCNJ10	B-GENE
and	O
FOXI1	B-GENE
The	O
complete	O
coding	O
regions	O
and	O
splice	O
sites	O
of	O
the	O
KCNJ10	B-GENE
and	O
FOXI1	B-GENE
exons	O
were	O
subjected	O
to	O
bidirectional	O
sequencing	O
using	O
ABI	O
PRISM	O
Big	O
Dye	O
Terminator	O
cycle	O
sequencing	O
ready	O
reaction	O
kit	O
(	O
Applied	O
Biosystems	O
)	O
and	O
analysed	O
on	O
an	O
ABI3730	O
Genetic	O
Analyser	O
(	O
Applied	O
Biosystems	O
)	O
using	O
standard	O
protocols	O
.	O

The	O
GFP	O
antibody	O
was	O
used	O
as	O
a	O
loading	O
and	O
transfection	O
control	O
.	O

Eddy	O
et	O
al	O
.	O

p	B-VARIANT
.	I-VARIANT
S1114P	I-VARIANT
associated	O
with	O
p	B-VARIANT
.	I-VARIANT
D1424N	I-VARIANT
in	O
the	O
propositus	O
and	O
his	O
three	O
sons	O
.	O

Pathologically	O
,	O
granular	O
cytoplasmic	O
changes	O
were	O
found	O
in	O
cardiac	O
myocytes	O
,	O
indicating	O
enlarged	O
,	O
damaged	O
mitochondria	O
.	O

(	O
C	O
)	O
Dual	O
COX	O
-	O
SDH	O
histochemistry	O
performed	O
on	O
20	O
u	O
m	O
thick	O
cryostat	O
sections	O
showing	O
the	O
presence	O
of	O
COX	O
-	O
deficient	O
muscle	O
fibres	O
(	O
33	O
/	O
1100	O
,	O
3	O
.	O
00	O
%	O
)	O
.	O

Autosomal	B-DISEASE
dominant	I-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
(	O
ADOA	B-DISEASE
)	O
is	O
the	O
most	O
frequent	O
form	O
of	O
hereditary	O
optic	B-DISEASE
neuropathy	I-DISEASE
and	O
occurs	O
due	O
to	O
the	O
degeneration	O
of	O
the	O
retinal	O
ganglion	O
cells	O
.	O

Both	O
type	O
1	O
and	O
type	O
2	O
diabetes	B-DISEASE
have	O
been	O
shown	O
to	O
result	O
from	O
a	O
variety	O
of	O
genetic	O
risk	O
factors	O
and	O
environmental	O
components	O
.	O

His	O
condition	O
was	O
further	O
complicated	O
by	O
sepsis	B-DISEASE
and	O
coagulopathy	B-DISEASE
.	O

The	O
combined	O
load	O
of	O
physical	O
,	O
mental	O
and	O
behavioural	O
disturbances	O
required	O
an	O
institutionalization	O
in	O
long	O
-	O
term	O
care	O
since	O
age	O
35	O
years	O
.	O

Except	O
for	O
a	O
recurring	O
5	O
bp	O
deletion	O
in	O
exon	O
24	O
that	O
is	O
responsible	O
for	O
17	O
%	O
of	O
the	O
cases	O
,	O
mutations	O
are	O
usually	O
family	O
-	O
specific	O
[	O
3	O
]	O
.	O

Tail	O
blood	O
pressure	O
,	O
urinary	O
NOx	O
excretion	O
,	O
plasma	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
,	O
and	O
endothelial	O
and	O
inducible	O
NOS	O
(	O
eNOS	O
and	O
iNOS	O
)	O
isotypes	O
in	O
the	O
aorta	O
and	O
kidney	O
were	O
measured	O
.	O

One	O
patient	O
was	O
heterozygous	O
for	O
mutations	O
in	O
both	O
USH	B-DISEASE
genes	O
having	O
received	O
the	O
USH2A	B-GENE
variant	O
from	O
the	O
unaffected	O
father	O
and	O
the	O
MYO7A	B-GENE
variant	O
from	O
the	O
unaffected	O
mother	O
.	O

The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	O
treated	O
with	O
DOX	B-Chemical
preceded	O
by	O
monoHER	B-Chemical
and	O
those	O
in	O
mice	O
treated	O
with	O
saline	O
ranged	O
from	O
1	O
.	O
6	O
to	O
2	O
.	O
8	O
(	O
mean	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
4	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O

We	O
report	O
here	O
on	O
one	O
of	O
these	O
families	O
,	O
in	O
which	O
we	O
identified	O
a	O
new	O
causative	O
deafness	B-DISEASE
gene	O
.	O

More	O
than	O
78	O
%	O
of	O
the	O
target	O
regions	O
were	O
covered	O
by	O
10	O
or	O
more	O
reads	O
,	O
demonstrating	O
the	O
high	O
quality	O
of	O
the	O
sequencing	O
(	O
Table	O
2	O
)	O
.	O

In	O
addition	O
,	O
various	O
questionnaires	O
were	O
used	O
to	O
evaluate	O
other	O
psychiatric	O
features	O
.	O

,	O
2009	O
;	O
Santarelli	O
,	O
2010	O
)	O
.	O

Oral	O
bovine	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O

As	O
described	O
above	O
,	O
we	O
revealed	O
that	O
a	O
read	O
depth	O
of	O
~	O
350	O
for	O
each	O
strand	O
of	O
each	O
amplicon	O
would	O
be	O
sufficient	O
to	O
detect	O
somatic	O
mosaicism	O
as	O
low	O
as	O
1	O
%	O
with	O
statistical	O
confidence	O
.	O

Qualitative	O
assessments	O
showed	O
two	O
arterial	O
irregularities	O
in	O
the	O
distal	O
vasculature	O
in	O
each	O
group	O
.	O

F	O
-	O
actin	O
was	O
immuno	O
-	O
stained	O
with	O
Alexa	O
-	I-Chemical
Fluor	I-Chemical
-	O
647	I-Chemical
-	O
phalloidin	I-Chemical
(	O
Invitrogen	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
;	O
1	O
:	O
500	O
)	O
.	O

Plasmid	O
DNAs	O
from	O
20	O
positive	O
clones	O
were	O
purified	O
with	O
the	O
Qiagen	O
Plasmid	O
Purification	O
Kit	O
(	O
Qiagen	O
,	O
CA	O
,	O
USA	O
)	O
and	O
sequenced	O
with	O
an	O
automated	O
sequencer	O
(	O
Bio	O
Matrix	O
Research	O
;	O
Chiba	O
,	O
Japan	O
)	O
.	O

A	O
large	O
proportion	O
of	O
cases	O
,	O
65	O
/	O
70	O
had	O
MLPA	O
analysis	O
performed	O
in	O
order	O
to	O
detect	O
larger	O
insertion	O
/	O
deletion	O
mutations	O
and	O
a	O
single	O
case	O
with	O
a	O
three	O
exon	O
deletion	O
in	O
KCNQ1	B-GENE
was	O
identified	O
.	O

Data	O
was	O
processed	O
with	O
Picard	B-Chemical
(	O
http	O
:	O
/	O
/	O
picard	B-Chemical
.	O
sourceforge	O
.	O
net	O
/	O
)	O
,	O
which	O
utilizes	O
base	O
quality	O
-	O
score	O
recalibration	O
and	O
local	O
realignment	O
at	O
known	O
indels	O
8	O
and	O
BWA	O
7	O
for	O
mapping	O
reads	O
to	O
hg19	B-Chemical
.	O

[	O
28	O
]	O
found	O
two	O
homozygous	O
missense	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
92C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
P31L	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
461T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
L154W	I-VARIANT
)	O
,	O
in	O
two	O
consanguineous	O
Pakistani	O
families	O
with	O
isolated	O
RP	B-DISEASE
and	O
no	O
audiological	O
symptoms	O
.	O

As	O
previously	O
reported	O
,	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
our	O
Invader	O
techniques	O
and	O
additional	O
direct	O
sequencing	O
revealed	O
only	O
one	O
mutant	O
GJB2	B-GENE
or	O
SLC26A4	B-GENE
allele	O
causing	O
deafness	B-DISEASE
by	O
recessive	O
pattern	O
.	O

(	O
a	O
)	O
Family	O
pedigree	O
of	O
JSNY	B-Chemical
-	I-Chemical
045	I-Chemical
and	O
audiograms	O
of	O
two	O
deaf	B-DISEASE
siblings	O
and	O
their	O
parents	O
.	O

Patients	O
referred	O
to	O
the	O
national	O
Stickler	B-DISEASE
syndrome	I-DISEASE
diagnostic	O
service	O
for	O
England	O
,	O
UK	O
were	O
assessed	O
clinically	O
and	O
subsequently	O
sequenced	O
for	O
mutations	O
in	O
COL11A1	B-GENE
.	O

Hypotension	O
was	O
induced	O
for	O
236	O
.	O
9	O
+	O
/	O
-	O
15	O
.	O
1	O
min	O
by	O
increasing	O
the	O
isoflurane	B-Chemical
inspired	O
concentration	O
to	O
maintain	O
a	O
mean	O
arterial	O
pressure	O
of	O
59	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
mmHg	O
.	O

A	O
second	O
form	O
of	O
WS	B-DISEASE
,	O
WFS2	B-GENE
,	O
maps	O
to	O
4q22	O
-	O
q25	O
[	O
16	O
]	O
and	O
has	O
been	O
recently	O
demonstrated	O
to	O
be	O
caused	O
by	O
homozygous	O
mutations	O
in	O
a	O
highly	O
conserved	O
zinc	O
-	O
finger	O
gene	O
,	O
ZCD2	B-GENE
[	O
17	O
]	O
.	O

Neither	O
this	O
manuscript	O
nor	O
one	O
with	O
substantially	O
similar	O
content	O
under	O
our	O
authorship	O
has	O
been	O
published	O
or	O
is	O
being	O
considered	O
for	O
publication	O
elsewhere	O
.	O
Stickler	B-DISEASE
syndromes	I-DISEASE
types	O
1	O
,	O
2	O
and	O
3	O
are	O
usually	O
dominant	O
disorders	O
caused	O
by	O
mutations	O
in	O
the	O
genes	O
COL2A1	B-GENE
,	O
COL11A1	B-GENE
and	O
COL11A2	B-GENE
that	O
encode	O
the	O
fibrillar	O
collagens	O
types	O
II	O
and	O
XI	O
present	O
in	O
cartilage	O
and	O
vitreous	O
.	O

Mean	O
function	O
is	O
displayed	O
for	O
the	O
OPA1	B-GENE
-	O
H	O
group	O
,	O
whereas	O
articulation	O
curves	O
from	O
individual	O
ears	O
have	O
been	O
considered	O
for	O
the	O
OPA1	B-GENE
-	O
M	O
patients	O
due	O
to	O
the	O
high	O
variability	O
of	O
scores	O
.	O

We	O
are	O
in	O
the	O
process	O
of	O
investigating	O
it	O
further	O
with	O
the	O
likelihood	O
that	O
it	O
may	O
represent	O
another	O
founder	O
mutation	O
.	O

As	O
shown	O
in	O
Supplementary	O
Material	O
,	O
Table	O
S1	O
,	O
the	O
Human	O
Deafness	B-DISEASE
DA1	O
Panel	O
was	O
designed	O
to	O
enrich	O
for	O
all	O
coding	O
sequences	O
(	O
CDSs	O
)	O
and	O
splicing	O
sites	O
of	O
80	O
confirmed	O
human	O
deafness	B-DISEASE
genes	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
a	O
common	O
sensory	O
disorder	O
.	O

PCPA	B-Chemical
significantly	O
and	O
substantially	O
depleted	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
in	O
all	O
brain	O
regions	O
examined	O
.	O

However	O
,	O
the	O
inclusion	O
of	O
these	O
patients	O
was	O
important	O
for	O
identifying	O
phenotypic	O
outliers	O
of	O
the	O
"	O
classical	O
"	O
PSACH	B-DISEASE
and	O
MED	B-DISEASE
disease	O
spectrum	O
and	O
to	O
also	O
identify	O
specific	O
radiographic	O
and	O
/	O
or	O
clinical	O
features	O
that	O
are	O
generally	O
uncharacteristic	O
of	O
molecularly	O
confirmed	O
MED	B-DISEASE
.	O

Differential	O
effects	O
of	O
systemically	O
administered	O
ketamine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
dynamic	O
and	O
static	O
hyperalgesia	B-DISEASE
induced	O
by	O
intradermal	O
capsaicin	B-Chemical
in	O
humans	O
.	O

This	O
is	O
essentially	O
due	O
to	O
the	O
size	O
and	O
composition	O
of	O
control	O
samples	O
[	O
23	O
]	O
;	O
for	O
review	O
see	O
[	O
4	O
]	O
.	O

Mutations	O
were	O
defined	O
as	O
disease	O
causing	O
only	O
if	O
these	O
criteria	O
were	O
fulfilled	O
.	O

Table	O
1	O
Clinical	O
and	O
audiological	O
data	O
from	O
the	O
OPA1	B-GENE
-	O
M	O
group	O
R	O
/	O
L	O
=	O
right	O
ear	O
/	O
left	O
ear	O
;	O
N	O
=	O
normal	O
;	O
Mod	O
=	O
moderate	O
;	O
Sev	O
=	O
severe	O
;	O
Prof	O
=	O
profound	O
;	O
PTA	O
=	O
pure	O
tone	O
average	O
(	O
average	O
thresholds	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
4	O
kHz	O
)	O
;	O
LF	O
=	O
low	O
frequencies	O
(	O
average	O
thresholds	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
kHz	O
)	O
;	O
HF	O
=	O
high	O
frequencies	O
(	O
average	O
thresholds	O
at	O
4	O
,	O
8	O
kHz	O
)	O
;	O
ABS	O
=	O
absent	O
;	O
OAEs	O
=	O
otoacoustic	O
emissions	O
;	O
CI	O
=	O
cochlear	O
implant	O
;	O
eABR	O
=	O
electrically	O
evoked	O
ABR	O
;	O
electr	O
.	O

In	O
theory	O
,	O
half	O
of	O
the	O
mutation	O
carriers	O
within	O
a	O
cLQTS	B-DISEASE
family	O
may	O
be	O
missed	O
if	O
only	O
one	O
of	O
the	O
mutations	O
in	O
a	O
compound	O
heterozygote	O
or	O
double	O
heterozygote	O
is	O
identified	O
through	O
selective	O
screening	O
for	O
only	O
one	O
mutation	O
or	O
the	O
selective	O
screening	O
of	O
only	O
one	O
of	O
the	O
involved	O
genes	O
.	O

Consequently	O
,	O
the	O
vast	O
majority	O
of	O
current	O
Czech	O
Romanies	O
also	O
originate	O
from	O
Slovakia	O
.	O

Test	O
group	O
:	O
patients	O
carrying	O
sequence	O
variants	O
in	O
USH	B-DISEASE
genes	O
previously	O
detected	O
Samples	O
that	O
failed	O
in	O
the	O
amplification	O
process	O
are	O
marked	O
with	O
SS	B-Chemical
.	O

Development	O
of	O
the	O
obstructive	B-DISEASE
sleep	I-DISEASE
apnea	I-DISEASE
syndrome	I-DISEASE
must	O
be	O
considered	O
a	O
possible	O
side	O
effect	O
of	O
androgen	B-Chemical
therapy	O
.	O

[	O
34	O
]	O
screened	O
SLC26A4	B-GENE
,	O
FOXI1	B-GENE
and	O
KCNJ10	B-GENE
(	O
as	O
well	O
as	O
GJB2	B-GENE
)	O
in	O
patients	O
with	O
bilateral	O
deafness	B-DISEASE
and	O
inner	O
ear	O
malformations	O
and	O
found	O
no	O
mutations	O
in	O
FOXI1	B-GENE
or	O
KCNJ10	B-GENE
in	O
the	O
15	O
who	O
had	O
one	O
or	O
zero	O
SLC26A4	B-GENE
mutations	O
;	O
Mercer	O
et	O
al	O
.	O

Probands	O
are	O
arrowed	O
.	O

QuickChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Stratagene	O
,	O
Cambridge	O
,	O
UK	O
)	O
was	O
used	O
for	O
site	O
-	O
specific	O
mutagenesis	O
to	O
introduce	O
the	O
P185	O
mutation	O
(	O
S4	O
Table	O
)	O
.	O

Band	O
C	O
is	O
the	O
heteroduplex	O
formation	O
from	O
band	O
A	O
and	O
band	O
B	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
1289A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
was	O
inherited	O
from	O
the	O
patient	O
'	O
s	O
mother	O
,	O
and	O
is	O
predicted	O
to	O
cause	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
asparagine	B-Chemical
residue	O
with	O
a	O
serine	O
(	O
p	B-VARIANT
.	I-VARIANT
N430S	I-VARIANT
)	O
(	O
Supplementary	O
Fig	O
.	O

Five	O
causative	O
genes	O
have	O
been	O
identified	O
:	O
USH1B	B-GENE
,	O
encoding	O
myosin	B-GENE
VIIa	I-GENE
;	I-GENE
USH1C	B-GENE
,	O
encoding	O
harmonin	B-GENE
(	O
USH1C	B-GENE
)	O
;	O
USH1D	B-GENE
,	O
encoding	O
cadherin	B-GENE
23	I-GENE
(	O
CDH23	B-GENE
)	O
;	O
USH1F	B-GENE
,	O
encoding	O
protocadherin	B-GENE
15	I-GENE
(	O
PCDH15	B-GENE
)	O
;	O
and	O
USH1G	O
,	O
encoding	O
SANS	O
.	O

PCR	O
was	O
performed	O
and	O
the	O
amplified	O
products	O
were	O
purified	O
by	O
Montage	O
PCR96	O
Cleanup	O
reagents	O
(	O
Millipore	O
)	O
.	O

Their	O
genomic	O
DNAs	O
were	O
enriched	O
by	O
a	O
commercial	O
whole	O
-	O
exome	O
kit	O
and	O
a	O
custom	O
designed	O
HL	B-DISEASE
kit	O
(	O
CUHK	B-Chemical
-	O
HL	B-DISEASE
V1	O
)	O
targeting	O
252	O
known	O
and	O
candidate	O
HL	B-DISEASE
genes	O
,	O
respectively	O
.	O

1	O
;	O
Cremers	B-Chemical
et	O
al	O
.	O

The	O
24	O
hour	O
excretion	O
of	O
iodine	B-Chemical
was	O
3657	O
(	O
mcg	O
(	O
25	O
-	O
756	O
(	O
mcg	O
)	O
.	O

We	O
designed	O
the	O
present	O
study	O
to	O
investigate	O
whether	O
an	O
inflammatory	O
reaction	O
contributes	O
to	O
this	O
myalgia	O
.	O

The	O
mean	O
coverage	O
of	O
each	O
sample	O
ranged	O
from	O
40	O
.	O
3X	O
to	O
51	O
.	O
3X	O
,	O
and	O
87	O
.	O
0	O
%	O
to	O
90	O
.	O
5	O
%	O
of	O
the	O
targeted	O
exome	O
had	O
at	O
least	O
10	O
reads	O
.	O

Pure	O
-	O
tone	O
audiometry	O
(	O
PTA	O
)	O
was	O
performed	O
on	O
every	O
affected	O
family	O
member	O
.	O

So	O
far	O
,	O
a	O
comprehensive	O
molecular	O
diagnosis	O
of	O
USH	B-DISEASE
has	O
been	O
hampered	O
both	O
by	O
the	O
genetic	O
heterogeneity	O
of	O
the	O
disease	O
and	O
the	O
large	O
number	O
of	O
exons	O
for	O
six	O
out	O
of	O
the	O
nine	O
known	O
USH	B-DISEASE
genes	O
.	O

Furthermore	O
,	O
11	O
mutations	O
were	O
identified	O
in	O
13	O
non	O
-	O
founder	O
probands	O
.	O

After	O
duplicated	O
reads	O
were	O
removed	O
,	O
sequences	O
were	O
aligned	O
to	O
the	O
human	O
genome	O
reference	O
sequence	O
(	O
build	O
hg19	O
)	O
using	O
BFAST	O
[	O
29	O
]	O
(	O
0	O
.	O
7	O
.	O
0a	O
,	O
"	O
-	O
a	O
2	O
"	O
mode	O
)	O
and	O
a	O
maximum	O
of	O
two	O
mismatches	O
allowed	O
.	O

In	O
addition	O
,	O
these	O
data	O
indicate	O
a	O
direct	O
role	O
of	O
the	O
pituitary	O
in	O
the	O
augmentation	O
of	O
ketamine	B-Chemical
DOC	O
induced	O
by	O
melatonin	B-Chemical
.	O

The	O
reads	O
were	O
aligned	O
to	O
the	O
human	O
genome	O
sequence	O
,	O
hg19	O
,	O
using	O
Novoalign	O
(	O
v2	O
.	O
08	O
.	O
01	O
)	O
.	O

Informed	O
consent	O
for	O
genetic	O
testing	O
was	O
obtained	O
from	O
all	O
participants	O
after	O
the	O
nature	O
and	O
possible	O
consequences	O
of	O
the	O
study	O
were	O
explained	O
.	O

Noteworthy	O
,	O
two	O
homozygous	O
missense	O
variations	O
were	O
revealed	O
as	O
RP	B-DISEASE
causative	O
for	O
patient	O
ARRP03	O
-	O
IV	O
:	O
3	O
,	O
implying	O
a	O
putative	O
double	O
hit	O
effect	O
.	O

These	O
results	O
support	O
sequence	O
analysis	O
of	O
TMC1	B-GENE
in	O
clinical	O
diagnostic	O
testing	O
of	O
individuals	O
with	O
ARNSHL	O
,	O
as	O
families	O
with	O
an	O
affected	O
child	O
both	O
parents	O
of	O
which	O
are	O
carriers	O
have	O
a	O
25	O
%	O
risk	O
of	O
recurrence	O
.	O

In	O
this	O
interval	O
,	O
there	O
were	O
398	O
annotated	O
genes	O
.	O

Genetic	O
testing	O
is	O
the	O
gold	O
standard	O
in	O
diagnosing	O
collagen	B-DISEASE
IV	I-DISEASE
-	I-DISEASE
related	I-DISEASE
nephropathies	I-DISEASE
.	O

The	O
probability	O
of	O
finding	O
the	O
identical	O
somatic	O
mutation	O
at	O
any	O
base	O
in	O
the	O
exome	O
3	O
times	O
by	O
chance	O
among	O
64	O
tumors	O
,	O
given	O
the	O
observed	O
somatic	O
mutation	O
rate	O
,	O
is	O
3	O
.	O
0	O
x	O
10	O
-	O
8	O
;	O
including	O
the	O
tumor	O
with	O
somatic	O
mutation	O
at	O
the	O
homologous	O
base	O
in	O
exon	O
8B	O
,	O
the	O
probability	O
of	O
seeing	O
either	O
of	O
these	O
mutations	O
in	O
4	O
of	O
64	O
tumors	O
is	O
2	O
.	O
2	O
x	O
10	O
-	O
12	O
(	O
Online	O
Methods	O
)	O
.	O

In	O
contrast	O
,	O
our	O
findings	O
suggest	O
that	O
both	O
isoforms	O
have	O
significant	O
overlapping	O
but	O
non	O
-	O
redundant	O
functions	O
during	O
human	O
development	O
,	O
as	O
illustrated	O
by	O
the	O
indistinguishable	O
clinical	O
presentation	O
of	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
patients	O
carrying	O
mutations	O
in	O
ACTB	B-GENE
and	O
ACTG1	B-GENE
(	O
Table	O
3	O
and	O
Supplementary	O
Table	O
6	O
)	O
.	O

[	O
33	O
]	O
(	O
n	O
=	O
430	O
)	O
and	O
Bukhari	B-Chemical
et	O
al	O
.	O

Acadians	O
to	O
a	O
great	O
extent	O
came	O
from	O
different	O
parts	O
of	O
France	O
than	O
do	O
Quebecois	O
.	O

These	O
factors	O
increase	O
the	O
complexity	O
of	O
determining	O
the	O
real	O
etiology	O
of	O
isolated	O
MD	B-DISEASE
,	O
and	O
our	O
observations	O
hint	O
that	O
ethnic	O
background	O
is	O
apparently	O
important	O
and	O
may	O
affect	O
the	O
etiologic	O
explanation	O
of	O
isolated	O
MD	B-DISEASE
.	O

Comprehensive	O
clinical	O
and	O
developmental	O
measurements	O
were	O
done	O
.	O

The	O
F	O
340	O
/	O
F	O
380	O
ratio	O
images	O
were	O
calculated	O
and	O
pixel	O
values	O
were	O
converted	O
to	O
intracellular	O
Ca	B-Chemical
2	I-Chemical
+	O
concentration	O
using	O
calibration	O
curve	O
obtained	O
with	O
Fura	B-Chemical
-	I-Chemical
2	O
Calibration	O
Kit	O
(	O
Molecular	O
Probes	O
)	O
.	O

Hydrocortisone	B-Chemical
acetate	I-Chemical
(	O
50	O
mg	O
)	O
was	O
given	O
orally	O
every	O
6	O
hours	O
for	O
24	O
hours	O
after	O
a	O
5	O
-	O
day	O
fixed	O
-	O
salt	O
diet	O
(	O
150	O
mmol	O
/	O
d	O
)	O
.	O

Thus	O
,	O
we	O
believe	O
that	O
the	O
presence	O
of	O
the	O
GST	O
moiety	O
at	O
the	O
N	O
-	O
terminus	O
does	O
not	O
interfere	O
with	O
access	O
to	O
the	O
substrate	O
or	O
with	O
enzymatic	O
activity	O
in	O
our	O
assay	O
.	O

Response	O
to	O
treatment	O
was	O
estimated	O
by	O
the	O
visual	O
analog	O
scale	O
for	O
severity	O
of	O
pain	O
.	O

Detailed	O
clinical	O
information	O
on	O
affected	O
family	O
members	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

The	O
Altaians	B-Chemical
currently	O
living	O
in	O
small	O
settlements	O
in	O
the	O
distant	O
regions	O
of	O
the	O
Altai	O
Republic	O
have	O
mainly	O
retained	O
their	O
native	O
language	O
,	O
ethnic	O
identity	O
,	O
and	O
traditional	O
marriage	O
structure	O
(	O
patrilineal	O
clan	O
exogamy	O
)	O
[	O
20	O
,	O
21	O
]	O
.	O

J	O
)	O
The	O
rod	O
-	O
mediated	O
ERG	O
b	O
-	O
wave	O
is	O
within	O
normal	O
amplitude	O
and	O
peak	O
time	O
limits	O
(	O
OU	O
)	O
.	O

The	O
physical	O
examinations	O
of	O
all	O
participating	O
members	O
revealed	O
no	O
signs	O
of	O
systemic	O
illness	O
or	O
dysmorphic	O
features	O
.	O

The	O
present	O
family	O
E	O
was	O
previously	O
described	O
as	O
family	O
2	O
in	O
a	O
report	O
on	O
autosomal	O
recessive	O
progressive	O
high	O
-	O
frequency	O
hearing	B-DISEASE
impairment	I-DISEASE
with	O
childhood	O
onset	O
(	O
Cremers	O
et	O
al	O
.	O

The	O
main	O
NGS	O
sequencing	O
platforms	O
were	O
used	O
:	O
SOLiD	O
for	O
whole	O
exome	O
sequencing	O
,	O
Illumina	O
(	O
Genome	O
Analyzer	O
II	O
)	O
and	O
Roche	O
454	O
(	O
GS	O
FLX	O
)	O
for	O
the	O
Long	O
-	O
PCR	O
sequencing	O
.	O

Recent	O
findings	O
in	O
a	O
bipolar	O
patient	O
receiving	O
maintenance	O
lithium	B-Chemical
therapy	O
who	O
developed	O
hypercalcemia	B-DISEASE
and	O
severe	O
bradyarrhythmia	B-DISEASE
prompted	O
the	O
authors	O
to	O
conduct	O
a	O
retrospective	O
study	O
of	O
bipolar	O
patients	O
with	O
lithium	B-Chemical
-	O
associated	O
hypercalcemia	B-DISEASE
.	O

The	O
novel	O
synonymous	O
variant	O
c	B-VARIANT
.	I-VARIANT
1722C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
was	O
identified	O
in	O
1	O
patient	O
in	O
this	O
study	O
.	O

B	O
.	O

METHOD	O
:	O
We	O
searched	O
the	O
Eli	O
Lilly	O
and	O
Company	O
'	O
s	O
computerized	O
adverse	O
event	O
database	O
for	O
all	O
reported	O
cases	O
of	O
hyponatremia	B-DISEASE
and	O
/	O
or	O
SIADH	B-DISEASE
as	O
of	O
1	O
November	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincristine	B-Chemical
.	O

Genetic	O
testing	O
for	O
OPA1	B-GENE
mutations	O
assist	O
in	O
the	O
diagnosis	O
.	O

14	O
In	O
adult	O
vestibular	O
hair	O
cells	O
,	O
CIB2	B-GENE
was	O
also	O
localized	O
along	O
the	O
length	O
of	O
stereocilia	O
and	O
concentrated	O
in	O
patches	O
toward	O
the	O
tips	O
of	O
stereocilia	O
(	O
Fig	O
.	O

D	O
.	O

The	O
myocardial	O
content	O
of	O
catecholamines	B-Chemical
was	O
estimated	O
in	O
these	O
8	O
day	O
diabetic	O
rats	O
.	O

However	O
,	O
the	O
frequency	O
of	O
these	O
syndromal	O
'	O
dominant	O
optic	B-DISEASE
atrophy	I-DISEASE
plus	O
'	O
variants	O
and	O
the	O
extent	O
of	O
neurological	O
involvement	O
have	O
not	O
been	O
established	O
.	O

By	O
virtue	O
of	O
the	O
recent	O
development	O
of	O
massively	O
parallel	O
DNA	O
sequencing	O
technologies	O
,	O
access	O
to	O
genomic	O
composition	O
has	O
become	O
easier	O
than	O
ever	O
.	O

The	O
mutation	O
spectrum	O
of	O
SLC26A4	B-GENE
varies	O
widely	O
among	O
ethnic	O
groups	O
[	O
12	O
]	O
.	O

Scale	O
bar	O
is	O
5	O
mu	O
m	O
.	O

2012	O
)	O
.	O

By	O
10	O
months	O
of	O
age	O
,	O
he	O
had	O
developed	O
laryngomalacia	B-DISEASE
with	O
pharyngeal	B-DISEASE
hypotonia	I-DISEASE
,	O
his	O
condition	O
progressed	O
and	O
he	O
died	O
of	O
respiratory	B-DISEASE
failure	I-DISEASE
at	O
15	O
months	O
of	O
age	O
.	O

The	O
thresholds	O
of	O
individuals	O
D4	O
and	O
G3	B-Chemical
were	O
higher	O
compared	O
with	O
the	O
thresholds	O
of	O
their	O
sibs	O
,	O
and	O
therefore	O
individuals	O
D4	O
and	O
G3	O
were	O
excluded	O
from	O
the	O
genotype	O
-	O
phenotype	O
assessment	O
.	O

Typical	O
initial	O
symptoms	O
include	O
night	B-DISEASE
blindness	I-DISEASE
,	O
restriction	O
of	O
visual	O
field	O
,	O
bone	O
spicule	O
-	O
like	O
pigmentation	O
,	O
attenuation	O
of	O
retinal	O
vessels	O
,	O
and	O
waxy	O
disc	O
pallor	O
.	O

Other	O
reported	O
frame	O
-	O
shift	O
mutations	O
;	O
1	O
c	B-VARIANT
.	I-VARIANT
388	I-VARIANT
-	I-VARIANT
c	I-VARIANT
.	I-VARIANT
397del10	I-VARIANT
and	O
3	O
c	B-VARIANT
.	I-VARIANT
605	I-VARIANT
-	I-VARIANT
c	I-VARIANT
.	I-VARIANT
606ins46	I-VARIANT
,	O
as	O
well	O
as	O
nonsense	O
mutations	O
;	O
3	O
p	B-VARIANT
.	I-VARIANT
E47X	I-VARIANT
,	O
account	O
for	O
a	O
small	O
fraction	O
(	O
1	O
.	O
0	O
%	O
)	O
of	O
GJB2	B-GENE
mutant	O
alleles	O
.	O

Seizures	O
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2	B-GENE
.	O

Additional	O
genes	O
were	O
selected	O
for	O
sequence	O
analysis	O
based	O
on	O
clinical	O
findings	O
.	O

S	B-Chemical
-	I-Chemical
312	I-Chemical
,	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
,	O
but	O
not	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
l	I-Chemical
,	O
L	O
-	O
type	O
calcium	B-Chemical
channel	O
antagonists	O
,	O
showed	O
anticonvulsant	O
effects	O
on	O
the	O
audiogenic	O
tonic	O
convulsions	O
in	O
DBA	O
/	O
2	O
mice	O
;	O
and	O
their	O
ED50	O
values	O
were	O
18	O
.	O
4	O
(	O
12	O
.	O
8	O
-	O
27	O
.	O
1	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
and	O
15	O
.	O
0	O
(	O
10	O
.	O
2	O
-	O
23	O
.	O
7	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
flunarizine	B-Chemical
was	O
34	O
.	O
0	O
(	O
26	O
.	O
0	O
-	O
44	O
.	O
8	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O

DNA	O
mutation	O
numbering	O
is	O
based	O
on	O
cDNA	O
sequence	O
with	O
a	O
'	O
c	O
.	O

+	O
+	O
Patient	O
7	O
has	O
severe	O
microcephaly	O
(	O
head	O
circumference	O
of	O
15	O
cm	O
at	O
20	O
weeks	O
)	O
,	O
hydrocephaly	O
,	O
and	O
severe	O
disruption	O
of	O
the	O
telencephalic	O
architecture	O
.	O

After	O
incubation	O
,	O
the	O
eyes	O
were	O
morphologically	O
characterized	O
by	O
light	O
microscopy	O
,	O
transmission	O
and	O
scanning	O
electron	O
microscopy	O
,	O
and	O
scanning	O
laser	O
confocal	O
microscopy	O
.	O

Five	O
types	O
of	O
GJB3	B-GENE
variant	O
were	O
detected	O
in	O
the	O
control	O
group	O
:	O
357C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
N119N	B-VARIANT
)	O
,	O
87C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
F29F	B-VARIANT
)	O
,	O
327C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
H109H	B-VARIANT
)	O
,	O
250A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
V84I	B-VARIANT
)	O
,	O
and	O
580G	B-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
A194T	B-VARIANT
)	O
.	O

A	O
case	O
of	O
fatal	O
aplastic	B-DISEASE
anemia	I-DISEASE
is	O
described	O
in	O
which	O
no	O
drugs	O
other	O
than	O
allopurinol	B-Chemical
and	O
indomethacin	B-Chemical
were	O
given	O
.	O

Heterozygosity	O
for	O
MYO7A	B-GENE
p	B-VARIANT
.	I-VARIANT
T381M	I-VARIANT
has	O
been	O
documented	O
in	O
3	O
unrelated	O
patients	O
with	O
nonsyndromic	B-DISEASE
SNHI	I-DISEASE
from	O
Taiwan	O
[	O
28	O
]	O
,	O
and	O
co	O
-	O
segregated	O
with	O
the	O
phenotype	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
pedigree	O
of	O
Family	O
DE3050	O
(	O
Figure	O
2B	O
)	O
.	O

Because	O
HOMER1a	B-GENE
lacks	O
the	O
CC	O
domain	O
,	O
it	O
cannot	O
form	O
multimers	O
but	O
it	O
can	O
still	O
competitively	O
bind	O
the	O
target	O
proteins	O
of	O
HOMER1b	B-GENE
and	I-GENE
1c	I-GENE
,	O
suggesting	O
that	O
relative	O
expression	O
of	O
each	O
of	O
these	O
homer	O
proteins	O
is	O
critical	O
[	O
27	O
-	O
29	O
]	O
.	O

Hemodynamic	O
measurements	O
in	O
1	O
of	O
the	O
patients	O
demonstrated	O
an	O
increase	O
in	O
total	O
peripheral	O
resistance	O
and	O
essentially	O
no	O
change	O
in	O
cardiac	O
output	O
following	O
propranolol	B-Chemical
therapy	O
.	O

Figure	O
1	O
.	O

The	O
remaining	O
29	O
TCS	B-DISEASE
patients	O
,	O
negative	O
to	O
the	O
TCOF1	B-GENE
screening	O
,	O
have	O
to	O
be	O
clinically	O
revaluated	O
.	O

YI	O
is	O
the	O
senior	O
author	O
and	O
was	O
responsible	O
for	O
final	O
proofreading	O
of	O
the	O
article	O
.	O

Cases	O
of	O
rare	O
diseases	O
were	O
more	O
frequently	O
reported	O
in	O
large	O
municipalities	O
such	O
as	O
Beijing	O
and	O
Shanghai	O
instead	O
of	O
areas	O
with	O
a	O
larger	O
population	O
but	O
a	O
relatively	O
lower	O
level	O
of	O
development	O
such	O
as	O
Sichuan	O
and	O
Henan	O
Provinces	O
.	O

Laboratory	O
investigations	O
were	O
done	O
to	O
exclude	O
other	O
causes	O
of	O
arteritis	B-DISEASE
,	O
such	O
as	O
syphilis	B-DISEASE
,	O
hepatitis	B-DISEASE
,	O
Lyme	B-DISEASE
disease	I-DISEASE
,	O
or	O
systemic	B-DISEASE
lupus	I-DISEASE
erythromatosis	I-DISEASE
.	O

ESP5400	B-Chemical
and	O
100g2012feb	O
are	O
the	O
allele	O
frequency	O
in	O
each	O
5400	O
exome	O
and	O
1000	O
genome	O
project	O
.	O

This	O
type	O
of	O
lesion	O
broadens	O
the	O
spectrum	O
of	O
liver	B-DISEASE
injury	I-DISEASE
due	O
to	O
this	O
drug	O
combination	O
,	O
mainly	O
represented	O
by	O
a	O
benign	B-DISEASE
cholestatic	I-DISEASE
syndrome	I-DISEASE
.	O

a	O
.	O

Experiments	O
with	O
poor	O
data	O
quality	O
were	O
repeated	O
.	O

Top	O
left	O
:	O
fundus	O
image	O
with	O
scan	O
cube	O
overlay	O
.	O

These	O
disorders	O
often	O
affect	O
the	O
entire	O
skeletal	O
system	O
.	O

Finally	O
,	O
PCR	O
amplification	O
was	O
performed	O
with	O
the	O
specific	O
SALSA	O
FAM	O
PCR	O
primers	O
.	O

A	O
total	O
of	O
190	O
probands	O
with	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
was	O
recruited	O
in	O
our	O
study	O
,	O
including	O
137	O
simplex	O
and	O
53	O
multiplex	O
probands	O
.	O

The	O
visual	O
fields	O
represent	O
an	O
average	O
of	O
both	O
eyes	O
.	O

All	O
of	O
the	O
patients	O
were	O
females	O
and	O
their	O
age	O
at	O
the	O
time	O
of	O
diagnosis	O
ranged	O
from	O
1	O
to	O
43	O
years	O
(	O
Table	O
1	O
)	O
.	O

These	O
include	O
the	O
genes	O
KAL1	B-GENE
,	O
FGFR1	B-GENE
,	O
FGF8	B-GENE
which	O
encodes	O
the	O
ligand	O
of	O
FGFR1	B-GENE
,	O
PROKR2	B-GENE
and	O
PROK2	B-GENE
,	O
NELF	B-GENE
(	O
nasal	O
embryonic	O
factor	O
)	O
and	O
mutations	O
in	O
CHD7	B-GENE
associated	O
with	O
the	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
.	O

Overall	O
,	O
in	O
high	O
-	O
risk	O
patients	O
,	O
warfarin	B-Chemical
is	O
superior	O
to	O
aspirin	B-Chemical
in	O
preventing	O
strokes	O
,	O
with	O
a	O
relative	O
risk	O
reduction	O
of	O
36	O
%	O
.	O

Tests	O
were	O
administered	O
at	O
70	O
dB	O
(	O
A	O
)	O
in	O
quiet	O
,	O
and	O
in	O
the	O
presence	O
of	O
competing	O
noise	O
presented	O
at	O
two	O
signal	O
-	O
to	O
-	O
noise	O
ratios	O
(	O
+	O
10	O
,	O
+	O
5	O
)	O
.	O

Ali	O
et	O
al	O
.	O

METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2	O
%	O
lidocaine	B-Chemical
or	O
0	O
.	O
5	O
%	O
bupivacaine	B-Chemical
before	O
surgery	O
and	O
either	O
rofecoxib	B-Chemical
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O

7162	O
)	O
with	O
autosomal	B-DISEASE
recessive	I-DISEASE
USH1	I-DISEASE
.	O

Furthermore	O
,	O
because	O
the	O
variant	O
is	O
located	O
between	O
the	O
actin	O
binding	O
region	O
and	O
the	O
ATP	O
-	O
binding	O
(	O
198	O
-	O
205	O
th	O
)	O
domain	O
of	O
the	O
myosin	O
head	O
-	O
like	O
domain	O
of	O
MYH14	B-GENE
,	O
the	O
mutation	O
is	O
more	O
likely	O
to	O
affect	O
the	O
binding	O
activity	O
of	O
the	O
protein	O
.	O

DNAs	O
were	O
extracted	O
by	O
the	O
standard	O
phenol	B-Chemical
/	O
chloroform	B-Chemical
method	O
.	O

We	O
categorized	O
the	O
phenotypes	O
at	O
72	O
hours	O
post	O
-	O
fertilization	O
(	O
hpf	O
)	O
into	O
class	O
I	O
(	O
normal	O
like	O
)	O
,	O
class	O
II	O
(	O
tail	B-DISEASE
defect	I-DISEASE
)	O
,	O
class	O
III	O
(	O
tail	B-DISEASE
defect	I-DISEASE
,	O
micro	B-DISEASE
-	I-DISEASE
ophthalmia	I-DISEASE
,	O
blood	B-DISEASE
pooling	I-DISEASE
)	O
and	O
class	O
IV	O
(	O
hypo	B-DISEASE
-	I-DISEASE
pigmentation	I-DISEASE
,	O
micro	B-DISEASE
-	I-DISEASE
ophthalmia	I-DISEASE
,	O
tail	B-DISEASE
defects	I-DISEASE
and	O
retarded	B-DISEASE
development	I-DISEASE
;	O
Fig	O
.	O

A	O
prospective	O
clinical	O
trial	O
is	O
suggested	O
to	O
quantify	O
the	O
risk	O
of	O
cardiac	O
complications	O
to	O
patients	O
receiving	O
phenothiazines	B-Chemical
or	O
tricyclic	O
antidepressant	O
drugs	O
.	O

The	O
visual	O
field	O
showed	O
an	O
anular	O
scotoma	O
reduced	O
by	O
15	O
deg	O
.	O

In	O
(	O
c	O
)	O
is	O
shown	O
a	O
52	O
bp	O
deletion	O
in	O
COL4A4	B-GENE
which	O
encompasses	O
50	O
bp	O
of	O
exon	O
20	O
plus	O
the	O
two	O
conserved	O
gt	O
bp	O
at	O
the	O
donor	O
site	O
of	O
intron	O
20	O
.	O

Sequencing	O
showed	O
that	O
the	O
278	O
/	O
279	O
bp	O
and	O
317	O
bp	O
fragments	O
did	O
correspond	O
to	O
the	O
transcripts	O
generated	O
by	O
use	O
of	O
the	O
known	O
site	O
and	O
the	O
alternative	O
site	O
1	O
,	O
respectively	O
(	O
Figure	O
4	O
)	O
.	O

The	O
major	O
effect	O
was	O
on	O
dystonia	B-DISEASE
subscore	O
.	O

2007	O
;	O
Besnard	B-Chemical
et	O
al	O
.	O

BCVA	O
=	O
decimal	O
corrective	O
visual	O
acuity	O
;	O
ERG	O
=	O
electroretinography	O
;	O
M	O
=	O
male	O
;	O
F	O
=	O
female	O
.	O

CONCLUSION	O
:	O
Autophagic	B-DISEASE
cardiomyocyte	I-DISEASE
death	I-DISEASE
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
heart	B-DISEASE
failure	I-DISEASE
in	O
rats	O
induced	O
by	O
adriamycin	B-Chemical
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	O
of	O
delta	B-Chemical
9	I-Chemical
-	I-Chemical
tetrahydrocannabinol	I-Chemical
(	O
THC	B-Chemical
)	O
,	O
the	O
effect	O
of	O
pretreatment	O
with	O
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
(	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
)	O
or	O
with	O
desipramine	B-Chemical
and	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
and	O
lesions	O
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	O
in	O
rats	O
.	O

Four	O
patients	O
(	O
III	O
:	O
1	O
,	O
III	O
:	O
3	O
,	O
III	O
:	O
5	O
)	O
are	O
affected	O
with	O
USH2	B-DISEASE
,	O
and	O
patient	O
(	O
IV	O
:	O
1	O
)	O
displays	O
nonsyndromic	O
RP	B-DISEASE
symptom	O
.	O

A	O
retrospective	O
cohort	O
study	O
.	O

PCR	O
products	O
were	O
purified	O
and	O
sequenced	O
with	O
a	O
BigDye	O
Terminator	O
v3	O
.	O
1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
and	O
ABI	B-Chemical
3730	O
DNA	O
Sequencer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
with	O
Chromas	O
Lite	O
v2	O
.	O
01	O
(	O
Technelysium	O
Pty	O
Ltd	O
.	O
,	O
Tewantin	O
,	O
QLD	O
,	O
Australia	O
)	O
software	O
.	O

However	O
,	O
adverse	O
effects	O
include	O
cardiac	O
toxicity	O
.	O

A	O
metabolic	O
drug	O
interaction	O
between	O
flecainide	B-Chemical
and	O
paroxetine	B-Chemical
,	O
which	O
the	O
patient	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
years	O
,	O
was	O
considered	O
.	O

Routine	O
EKG	O
monitoring	O
during	O
infusional	O
cyclophosphamide	B-Chemical
did	O
not	O
predict	O
CHF	B-DISEASE
development	O
.	O

Candidate	O
variants	O
identified	O
in	O
this	O
study	O
.	O

The	O
missense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
I5126T	I-VARIANT
in	O
USH2A	B-GENE
has	O
been	O
reported	O
as	O
likely	O
pathogenic	O
[	O
87	O
]	O
.	O

In	O
addition	O
,	O
P240	O
of	O
CDH23	B-GENE
is	O
on	O
the	O
extracellular	O
cadherin	O
1	O
domain	O
,	O
and	O
R283	B-Chemical
of	O
PCDH15	B-GENE
is	O
on	O
the	O
extracellular	O
cadherin	O
2	O
domain	O
,	O
which	O
are	O
considered	O
to	O
interact	O
with	O
each	O
other	O
for	O
tip	O
-	O
link	O
bound	O
[	O
49	O
]	O
,	O
raising	O
the	O
possibility	O
that	O
the	O
double	O
heterozygous	O
mutations	O
could	O
lead	O
to	O
a	O
destabilized	O
tip	O
-	O
link	O
.	O

Neither	O
c	B-VARIANT
.	I-VARIANT
161T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
nor	O
c	B-VARIANT
.	I-VARIANT
368C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
were	O
found	O
from	O
the	O
90	O
CEPH	O
control	O
samples	O
nor	O
the	O
19	O
Finnish	O
patients	O
we	O
sequenced	O
.	O

However	O
,	O
the	O
K	O
ATPase	O
of	O
M6	O
Full	O
WT	O
in	O
ethylene	B-Chemical
glycol	I-Chemical
tetraacetic	I-Chemical
acid	I-Chemical
(	O
EGTA	B-Chemical
)	O
was	O
more	O
than	O
10	O
-	O
fold	O
higher	O
than	O
that	O
in	O
0	O
.	O
1	O
mM	O
CaCl	B-Chemical
2	O
and	O
that	O
of	O
M6S1	O
in	O
EGTA	B-Chemical
[	O
20	O
]	O
.	O

Figure	O
1	O
Articulation	O
gain	O
curves	O
from	O
patients	O
with	O
DOA	B-DISEASE
.	O

With	O
a	O
few	O
exceptions	O
,	O
there	O
are	O
no	O
ophthalmologic	O
characteristics	O
specifically	O
associated	O
with	O
the	O
genetic	O
subtypes	O
of	O
RP	B-DISEASE
,	O
impeding	O
the	O
prioritization	O
of	O
genes	O
for	O
analysis	O
by	O
Sanger	O
sequencing	O
.	O

(	O
A	O
)	O
The	O
exome	O
coverage	O
of	O
the	O
five	O
longest	O
autozygous	O
regions	O
.	O

We	O
analyzed	O
population	O
differences	O
in	O
allele	O
frequencies	O
for	O
common	O
variants	O
,	O
since	O
most	O
rare	O
variants	O
are	O
found	O
in	O
a	O
single	O
individual	O
.	O

The	O
small	O
number	O
of	O
patients	O
evaluated	O
in	O
this	O
study	O
limits	O
the	O
number	O
of	O
genetic	O
variants	O
identified	O
.	O

Likewise	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
BLSW	O
mice	O
at	O
8	O
weeks	O
of	O
age	O
occurs	O
without	O
a	O
noticeable	O
hair	B-DISEASE
cell	I-DISEASE
loss	I-DISEASE
.	O

Furthermore	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
ocular	O
abnormality	O
happened	O
in	O
90	O
%	O
and	O
35	O
%	O
of	O
male	O
patients	O
,	O
respectively	O
[	O
10	O
]	O
.	O

The	O
pedigree	O
contains	O
two	O
affected	O
male	O
siblings	O
(	O
1D	O
)	O
.	O

Two	O
weeks	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
her	O
hematocrit	O
had	O
decreased	O
from	O
44	O
.	O
1	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
and	O
she	O
had	O
a	O
positive	O
direct	O
Coombs	O
antiglobulin	O
test	O
and	O
an	O
elevated	O
indirect	O
bilirubin	B-Chemical
.	O

Imaging	O
was	O
performed	O
on	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
using	O
40	O
x	O
oil	O
-	O
immersion	O
objective	O
.	O

So	O
it	O
is	O
also	O
considered	O
benign	O
.	O

The	O
mutations	O
detected	O
by	O
the	O
analysis	O
formulated	O
using	O
the	O
MPS	O
platform	O
in	O
this	O
study	O
are	O
listed	O
in	O
Table	O
3	O
.	O

The	O
variant	O
c	B-VARIANT
.	I-VARIANT
895_896del	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
E299Sfs	I-VARIANT
*	I-VARIANT
21	I-VARIANT
,	O
was	O
clearly	O
pathogenic	O
and	O
produced	O
a	O
truncated	O
protein	O
.	O

Due	O
to	O
its	O
genetic	O
heterogeneity	O
,	O
comprehensive	O
diagnostic	O
testing	O
has	O
not	O
previously	O
been	O
completed	O
in	O
a	O
large	O
multiethnic	O
cohort	O
.	O

In	O
particular	O
,	O
the	O
mutations	O
described	O
here	O
are	O
associated	O
with	O
variable	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
features	O
and	O
affected	O
families	O
should	O
be	O
counselled	O
as	O
such	O
.	O

DNA	O
samples	O
were	O
analysed	O
for	O
patients	O
with	O
a	O
high	O
suspicion	O
of	O
an	O
underlying	O
mitochondrial	O
genetic	O
disease	O
due	O
to	O
the	O
multi	O
-	O
system	O
pattern	O
of	O
their	O
clinical	O
presentations	O
,	O
evidence	O
of	O
a	O
mitochondrial	O
biochemical	O
defect	O
,	O
and	O
/	O
or	O
the	O
presence	O
of	O
multiple	O
mtDNA	O
deletions	O
.	O

Filtering	O
reduced	O
the	O
total	O
number	O
of	O
putative	O
pathogenic	O
variants	O
from	O
14	O
,	O
144	O
to	O
48	O
(	O
99	O
.	O
7	O
%	O
reduction	O
)	O
,	O
whereas	O
only	O
one	O
of	O
the	O
known	O
causative	O
variants	O
was	O
eliminated	O
during	O
the	O
course	O
of	O
the	O
filtering	O
.	O

a	O
-	O
b	O
NADH	O
-	O
TR	O
staining	O
revealed	O
a	O
scattering	O
of	O
small	O
,	O
angulated	O
,	O
or	O
elongated	O
myofibers	O
with	O
condensed	O
positive	O
reactions	O
(	O
arrows	O
)	O
.	O

The	O
present	O
study	O
identifies	O
two	O
novel	O
mutations	O
in	O
PEO1	B-GENE
gene	O
associated	O
with	O
PEO	B-DISEASE
.	O

However	O
,	O
identification	O
of	O
a	O
short	O
-	O
acting	O
local	O
anesthetic	O
to	O
substitute	O
for	O
lidocaine	B-Chemical
for	O
brief	O
surgical	O
procedures	O
remains	O
an	O
important	O
goal	O
.	O

Silver	B-Chemical
;	O
D	O
.	O
H	O
.	O

All	O
exons	O
and	O
exons	O
-	O
intron	O
boundaries	O
of	O
EYA1	B-GENE
,	O
SIX1	B-GENE
and	O
SIX5	B-GENE
gene	O
were	O
amplified	O
by	O
Polymerase	O
Chain	O
Reaction	O
(	O
PCR	O
)	O
with	O
specific	O
primers	O
(	O
Table	O
S1	O
)	O
designed	O
using	O
Primer	O
3	O
software	O
(	O
http	O
:	O
/	O
/	O
frodo	O
.	O
wi	O
.	O
mit	O
.	O
edu	O
/	O
)	O
.	O

Renal	O
function	O
was	O
normal	O
.	O

Further	O
controlled	O
trials	O
are	O
warranted	O
.	O

JW	O
help	O
to	O
collect	O
samples	O
and	O
screen	O
the	O
individuals	O
.	O

Intradermal	O
glutamate	B-Chemical
and	O
capsaicin	B-Chemical
injections	O
:	O
intra	O
-	O
and	O
interindividual	O
variability	O
of	O
provoked	O
hyperalgesia	B-DISEASE
and	I-DISEASE
allodynia	I-DISEASE
.	O

Of	O
interest	O
,	O
2	O
patients	O
had	O
recessive	O
-	O
type	O
mutations	O
in	O
candidate	O
disease	O
genes	O
(	O
NUBPL	B-GENE
,	O
FOXRED1	B-GENE
)	O
(	O
Table	O
3	O
)	O
.	O

Results	O
showed	O
that	O
MM	B-DISEASE
individuals	O
were	O
significantly	O
less	O
tolerant	O
of	O
CP	B-DISEASE
pain	O
than	O
control	O
subjects	O
,	O
replicating	O
previous	O
work	O
.	O

(	O
e	O
)	O
ABR	O
thresholds	O
(	O
dBSPL	O
)	O
at	O
click	O
(	O
orange	O
)	O
,	O
8	O
(	O
green	O
)	O
,	O
16	O
(	O
purple	O
)	O
and	O
32	O
kHz	O
(	O
red	O
)	O
of	O
NIH	O
Swiss	O
homozygous	O
for	O
the	O
wild	O
-	O
type	O
(	O
343G	O
/	O
G	O
;	O
n	O
=	O
9	O
)	O
and	O
mutant	O
(	O
343A	O
/	O
A	O
;	O
n	O
=	O
9	O
)	O
Gipc3	B-GENE
alleles	O
.	O

In	O
these	O
cases	O
,	O
in	O
which	O
the	O
second	O
mutated	O
allele	O
escapes	O
detection	O
,	O
the	O
region	O
that	O
contains	O
the	O
mutation	O
may	O
have	O
been	O
excluded	O
from	O
our	O
study	O
.	O

All	O
mutations	O
identified	O
are	O
predicted	O
to	O
affect	O
the	O
POU	O
-	O
specific	O
or	O
POU	O
homeo	O
domains	O
of	O
the	O
protein	O
and	O
co	O
-	O
segregated	O
with	O
deafness	B-DISEASE
in	O
all	O
families	O
.	O

Before	O
SeqScape	O
2	O
.	O
6	O
analysis	O
,	O
all	O
known	O
CDH23	B-GENE
mutations	O
within	O
69	O
coding	O
regions	O
and	O
flanking	O
10	O
-	O
bp	O
sequences	O
of	O
transcript	O
variant	O
1	O
archived	O
in	O
the	O
BIOBASE	O
HGMD	O
database	O
(	O
last	O
visited	O
on	O
October	O
2014	O
;	O
BIOBASE	O
,	O
MA	O
,	O
USA	O
)	O
were	O
entered	O
into	O
the	O
SeqScape	O
project	O
files	O
to	O
enable	O
detection	O
of	O
novel	O
variants	O
.	O

The	O
occurrence	O
of	O
these	O
histological	O
findings	O
is	O
frequently	O
detected	O
in	O
OPA1	B-GENE
-	O
mutated	O
patients	O
with	O
a	O
4	O
-	O
to	O
-	O
1	O
ratio	O
in	O
OPA1	B-DISEASE
-	I-DISEASE
plus	I-DISEASE
patients	O
respect	O
to	O
individuals	O
with	O
pure	O
optic	O
nerve	O
involvement	O
[	O
14	O
]	O
.	O

Sequence	O
analysis	O
of	O
NDP	B-GENE
among	O
affected	O
members	O
of	O
this	O
family	O
revealed	O
a	O
novel	O
single	O
nucleotide	O
deletion	O
c	B-VARIANT
.	I-VARIANT
49delG	I-VARIANT
causing	O
a	O
frameshift	O
and	O
premature	O
truncation	O
(	O
p	B-VARIANT
.	I-VARIANT
V17fsX1	I-VARIANT
)	O
of	O
the	O
encoded	O
protein	O
.	O

Dose	O
-	O
related	O
beneficial	O
and	O
adverse	O
effects	O
of	O
dietary	O
corticosterone	B-Chemical
on	O
organophosphorus	B-Chemical
-	O
induced	O
delayed	B-DISEASE
neuropathy	I-DISEASE
in	O
chickens	O
.	O

Total	O
genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
following	O
standard	O
procedures	O
.	O

Asenapine	B-Chemical
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	O
or	O
of	O
manic	O
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	O
I	I-DISEASE
disorder	O
with	O
or	O
without	O
psychotic	O
features	O
.	O

The	O
most	O
frequent	O
mutation	O
in	O
this	O
study	O
was	O
p	B-VARIANT
.	I-VARIANT
P240L	I-VARIANT
,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
of	O
the	O
Japanese	O
population	O
[	O
12	O
,	O
14	O
]	O
.	O

This	O
flow	O
was	O
measured	O
by	O
using	O
a	O
differential	O
pressure	O
transducer	O
,	O
passed	O
through	O
a	O
polygraph	O
,	O
and	O
from	O
this	O
to	O
a	O
computer	O
with	O
custom	O
software	O
that	O
derived	O
ventilation	O
(	O
VE	O
)	O
,	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
inspiratory	O
time	O
(	O
TI	O
)	O
,	O
expiratory	O
time	O
(	O
TE	O
)	O
,	O
breathing	O
frequency	O
(	O
f	O
)	O
,	O
and	O
mean	O
inspiratory	O
flow	O
(	O
VT	O
/	O
TI	O
)	O
on	O
a	O
breath	O
-	O
by	O
-	O
breath	O
basis	O
.	O

We	O
calculated	O
the	O
mean	O
level	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
over	O
all	O
frequencies	O
and	O
at	O
each	O
frequency	O
based	O
upon	O
the	O
pure	O
tone	O
audiograms	O
.	O

Ophthalmologic	O
examination	O
included	O
best	O
corrected	O
visual	O
acuity	O
determination	O
,	O
funduscopy	O
,	O
fluorescein	O
retinal	O
angiography	O
,	O
and	O
Goldmann	O
kinetic	O
perimetry	O
.	O

After	O
explaining	O
the	O
nature	O
of	O
this	O
study	O
,	O
informed	O
consents	O
adhering	O
to	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
were	O
obtained	O
from	O
all	O
patients	O
and	O
their	O
relatives	O
.	O

Modifying	O
genetic	O
factors	O
may	O
explain	O
the	O
difference	O
in	O
onset	O
between	O
the	O
two	O
families	O
with	O
this	O
mutation	O
.	O

We	O
sequenced	O
the	O
MYO6	B-GENE
and	O
MYO1A	B-GENE
genes	O
in	O
53	O
unrelated	O
Korean	O
ADNSHL	B-DISEASE
patients	O
.	O

As	O
already	O
reported	O
in	O
other	O
studies	O
,	O
HHL	B-DISEASE
especially	O
in	O
Middle	O
Eastern	O
populations	O
is	O
highly	O
heterogeneous	O
,	O
both	O
in	O
the	O
number	O
of	O
genes	O
involved	O
and	O
in	O
the	O
number	O
of	O
alleles	O
at	O
each	O
gene	O
[	O
5	O
]	O
.	O

Multiple	O
mutations	O
responsible	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
identified	O
by	O
the	O
combination	O
of	O
targeted	O
capture	O
and	O
MPS	O
technology	O
.	O

To	O
decipher	O
the	O
link	O
between	O
F	O
-	O
actin	O
and	O
ELMOD3	B-GENE
,	O
we	O
performed	O
a	O
two	O
-	O
color	O
stochastic	O
optical	O
reconstruction	O
microscopy	O
(	O
STORM	O
)	O
imaging	O
of	O
EGFP	O
-	O
ELMOD3	B-GENE
transfected	O
MDCK	O
cells	O
.	O

This	O
study	O
suggests	O
that	O
mutations	O
in	O
the	O
TNC	B-GENE
gene	O
could	O
contribute	O
to	O
sensory	B-DISEASE
impairment	I-DISEASE
in	O
ASD	B-DISEASE
,	O
including	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Exon	O
16	O
splicing	O
pattern	O
associated	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
1935G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
.	O

Genomic	O
DNA	O
products	O
(	O
concentration	O
=	O
100	O
~	O
150	O
ng	O
/	O
u	O
l	O
;	O
OD260	O
/	O
OD280	O
=	O
1	O
.	O
7	O
~	O
1	O
.	O
9	O
)	O
were	O
purified	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
and	O
stored	O
in	O
a	O
-	O
20	O
deg	O
C	O
freezer	O
.	O

5	O
B	O
)	O
.	O

The	O
recurrent	O
mutations	O
p	B-VARIANT
.	I-VARIANT
Thr120Met	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Arg121Trp	I-VARIANT
[	O
Cotterill	B-Chemical
et	O
al	O
.	O
,	O
2005	O
;	O
Jackson	O
et	O
al	O
.	O
,	O
2004	O
]	O
were	O
each	O
identified	O
in	O
more	O
than	O
one	O
patient	O
.	O

No	O
carrier	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
637G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
was	O
found	O
in	O
the	O
500	O
ancestry	O
-	O
matched	O
control	O
chromosomes	O
,	O
the	O
1000	O
Genome	O
Project	O
or	O
the	O
NHLBI	O
EVS	O
database	O
.	O

This	O
is	O
the	O
first	O
human	O
missense	O
mutation	O
showing	O
that	O
TBX1	B-GENE
is	O
a	O
candidate	O
causing	O
isolated	O
CTDs	B-DISEASE
in	O
Chinese	O
patients	O
without	O
22q11	O
.	O
2	O
deletion	O
.	O

Therefore	O
,	O
the	O
most	O
common	O
USH1C	B-GENE
variant	O
is	O
USH1C_v2	O
(	O
also	O
known	O
as	O
variant	O
a	O
and	O
PDZ	O
-	O
73	O
;	O
see	O
Table	O
S7	O
for	O
more	O
information	O
)	O
.	O

Tiapride	B-Chemical
,	O
a	O
substituted	O
benzamide	B-Chemical
derivative	O
closely	O
related	O
to	O
metoclopramide	B-Chemical
,	O
reduced	O
levodopa	B-Chemical
-	O
induced	O
peak	O
dose	O
involuntary	I-DISEASE
movements	O
in	O
16	O
patients	O
with	O
idiopathic	B-DISEASE
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
.	O

The	O
hazards	O
of	O
optic	O
nerve	I-DISEASE
toxicity	O
due	O
to	O
ethambutol	B-Chemical
are	O
known	O
.	O

However	O
,	O
patient	O
124	O
is	O
obviously	O
an	O
accidental	O
carrier	O
of	O
p	B-VARIANT
.	I-VARIANT
Glu1750	I-VARIANT
*	I-VARIANT
RP1	B-GENE
.	O

At	O
the	O
time	O
of	O
birth	O
,	O
he	O
weighed	O
2	O
.	O
950	O
g	O
and	O
measured	O
48	O
cm	O
.	O

(	O
C	O
,	O
D	O
)	O
Magnified	O
ribbon	O
model	O
of	O
the	O
F3	O
subdomain	O
superimposed	O
with	O
predicted	O
surface	O
hydrophobicity	O
in	O
the	O
wild	O
type	O
(	O
C	O
)	O
and	O
the	O
p	B-VARIANT
.	I-VARIANT
W2160G	I-VARIANT
mutant	O
(	O
D	O
)	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
dCib2	B-Chemical
is	O
necessary	O
to	O
achieve	O
a	O
strong	O
,	O
sustained	O
photoresponse	O
and	O
to	O
track	O
fast	O
light	O
stimuli	O
,	O
phenotypes	O
consistent	O
with	O
transiently	O
elevated	O
intracellular	O
Ca	O
2	O
+	O
concentrations	O
.	O

Sixty	O
-	O
two	O
patients	O
(	O
88	O
.	O
6	O
%	O
)	O
are	O
alive	O
with	O
functioning	O
grafts	O
686	O
+	O
/	O
-	O
362	O
days	O
(	O
range	O
,	O
154	O
-	O
1433	O
days	O
)	O
after	O
conversion	O
.	O

One	O
of	O
these	O
biallelic	O
variants	O
was	O
a	O
conservative	O
missense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1110A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E730D	I-VARIANT
)	O
,	O
in	O
BNC2	B-GENE
(	O
gene	O
ID	O
:	O
54796	O
,	O
NM_01763	B-VARIANT
)	O
,	O
predicted	O
to	O
be	O
nonpathogenic	O
by	O
PolyPhen	O
-	O
2	O
,	O
SIFT	O
,	O
and	O
Mutation	O
Taster	O
software	O
.	O

New	O
,	O
novel	O
variant	O
,	O
first	O
described	O
in	O
this	O
article	O
.	O

In	O
general	O
,	O
these	O
findings	O
raise	O
the	O
question	O
regarding	O
potential	O
mechanisms	O
involved	O
in	O
the	O
effect	O
of	O
different	O
subunit	O
mutations	O
of	O
the	O
same	O
proton	O
pump	O
over	O
hearing	O
ability	O
[	O
9	O
]	O
.	O

First	O
,	O
the	O
analytical	O
strategy	O
we	O
adopted	O
was	O
labor	O
intensive	O
and	O
not	O
scalable	O
.	O

The	O
following	O
second	O
screening	O
based	O
on	O
TaqMan	O
assay	O
followed	O
by	O
Sanger	O
sequencing	O
confirmed	O
10	O
"	O
possibly	O
pathologic	O
"	O
mutations	O
(	O
Table	O
1	O
)	O
and	O
17	O
variants	O
with	O
uncertain	O
pathogenicity	O
(	O
Table	O
2	O
)	O
in	O
a	O
large	O
cohort	O
of	O
the	O
patients	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	B-Chemical
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	B-Chemical
in	O
addition	O
to	O
fentanyl	B-Chemical
.	O

To	O
increase	O
display	O
resolution	O
,	O
cochlear	O
slices	O
were	O
imaged	O
over	O
a	O
distance	O
of	O
several	O
micrometers	O
(	O
30	O
x	O
0	O
,	O
27	O
mu	O
m	O
,	O
~	O
8	O
mu	O
m	O
)	O
in	O
an	O
image	O
stack	O
along	O
the	O
z	O
-	O
axis	O
(	O
z	O
-	O
stack	O
)	O
,	O
followed	O
by	O
3	O
-	O
dimensional	O
deconvolution	O
using	O
cellSens	O
Dimension	O
module	O
with	O
the	O
advanced	O
maximum	O
likelihood	O
estimation	O
algorithm	O
(	O
ADVMLE	O
;	O
OSIS	O
)	O
.	O

Moreover	O
,	O
an	O
additional	O
132	O
patients	O
'	O
chromosomes	O
from	O
Qatar	O
,	O
6	O
from	O
Oman	O
and	O
52	O
from	O
Italy	O
were	O
negative	O
for	O
the	O
presence	O
of	O
this	O
variant	O
(	O
our	O
internal	O
database	O
)	O
.	O

E	O
.	O
S	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
14368C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
variant	O
was	O
generated	O
by	O
site	O
-	O
directed	O
mutagenesis	O
(	O
QuikChange	O
II	O
;	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
CA	O
)	O
.	O

3	O
.	O

The	O
mitochondrial	O
helicase	O
Twinkle	O
is	O
a	O
key	O
player	O
of	O
replisome	O
machinery	O
.	O

The	O
mean	O
lowest	O
BIS	O
score	O
corresponding	O
to	O
the	O
ability	O
of	O
the	O
patient	O
to	O
immediately	O
repeat	O
words	O
read	O
from	O
the	O
list	O
was	O
77	O
.	O
1	O
(	O
95	O
%	O
CI	O
=	O
74	O
.	O
3	O
to	O
80	O
.	O
0	O
)	O
.	O

3	O
)	O
.	O

Segregation	O
analysis	O
for	O
the	O
variants	O
p	B-VARIANT
.	I-VARIANT
R350W	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
G769G	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
T383N	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
D447H	I-VARIANT
could	O
not	O
be	O
performed	O
.	O

Reads	O
were	O
aligned	O
to	O
hg19	O
using	O
BWA	O
12	O
.	O

MED	B-DISEASE
patient	O
ESDN	O
-	O
01003	O
was	O
heterozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
186	I-VARIANT
+	I-VARIANT
4a	I-VARIANT
>	I-VARIANT
c	I-VARIANT
(	O
i	O
.	O
e	O
.	O
,	O
+	O
7	O
in	O
consensus	O
sequence	O
)	O
,	O
which	O
has	O
not	O
been	O
previously	O
described	O
.	O

This	O
is	O
in	O
line	O
with	O
the	O
data	O
from	O
a	O
meta	O
-	O
analysis	O
by	O
Cano	O
et	O
al	O
.	O

The	O
convulsant	O
activity	O
of	O
bupivacaine	B-Chemical
was	O
not	O
significantly	O
modified	O
but	O
calcium	B-Chemical
channel	O
blockers	O
decreased	O
the	O
time	O
of	O
latency	O
to	O
obtain	O
bupivacaine	B-Chemical
-	O
induced	O
convulsions	B-DISEASE
;	O
this	O
effect	O
was	O
less	O
pronounced	O
with	O
bepridil	B-Chemical
.	O

In	O
contrast	O
to	O
actin	O
staining	O
,	O
ELMOD3	B-GENE
immunoreactivity	O
was	O
not	O
uniform	O
along	O
the	O
length	O
of	O
each	O
stereocilium	O
and	O
the	O
protein	O
seemed	O
to	O
be	O
excluded	O
from	O
a	O
region	O
near	O
the	O
tip	O
(	O
Figure	O
3E	O
)	O
.	O

Cardiac	O
examination	O
was	O
normal	O
.	O

*	O
USH	O
NC	O
:	O
Clinical	O
data	O
not	O
available	O
to	O
classify	O
the	O
patients	O
into	O
any	O
subtype	O
.	O

Genetic	O
screening	O
through	O
traditional	O
approaches	O
,	O
such	O
as	O
direct	O
sequencing	O
is	O
therefore	O
difficult	O
.	O

(	O
B	O
)	O
Multi	O
species	O
alignment	O
shows	O
that	O
both	O
the	O
COL4A3	B-GENE
mutation	O
reference	O
amino	O
acids	O
Col4A3_	B-VARIANT
695_G	I-VARIANT
and	O
Col4A3_1474_L	B-VARIANT
,	O
the	O
SALL2_G792R	B-VARIANT
and	O
the	O
MYH9_L46F	B-VARIANT
are	O
highly	O
conserved	O
among	O
species	O
.	O

Discussion	O
with	O
the	O
treating	O
physicians	O
followed	O
by	O
Sanger	O
validation	O
established	O
the	O
diagnoses	O
for	O
a	O
total	O
of	O
29	O
patients	O
(	O
Supplementary	O
Table	O
S6	O
online	O
)	O
.	O

Raw	O
image	O
files	O
were	O
processed	O
on	O
the	O
Illumina	B-Chemical
Pipeline	O
V	O
.	O
1	O
.	O
6	O
using	O
default	O
parameters	O
,	O
and	O
sequences	O
generated	O
as	O
75	O
-	O
90	O
bp	O
paired	O
-	O
end	O
reads	O
were	O
aligned	O
to	O
NCBI37	B-Chemical
/	O
hg19	B-Chemical
assembly	O
.	O

In	O
a	O
sixth	O
patient	O
the	O
biopsy	O
showed	O
FSGS	B-DISEASE
but	O
no	O
EM	O
studies	O
were	O
available	O
.	O

AS	O
and	O
JK	O
worked	O
on	O
DNA	O
sequencing	O
and	O
interpreting	O
the	O
data	O
.	O

Vasopressin	B-Chemical
as	O
a	O
possible	O
contributor	O
to	O
hypertension	B-DISEASE
.	O

Median	O
thickness	O
of	O
the	O
neurosensory	O
retina	O
was	O
statistically	O
significant	O
lower	O
in	O
ADOA	B-DISEASE
patients	O
compared	O
to	O
healthy	O
controls	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

S	O
.	O

The	O
classification	O
system	O
for	O
unknown	O
variants	O
is	O
the	O
same	O
as	O
that	O
used	O
in	O
USHbases	O
and	O
is	O
as	O
follows	O
:	O
UV1	O
:	O
variant	O
certainly	O
neutral	O
;	O
UV2	O
:	O
variant	O
likely	O
neutral	O
;	O
UV3	O
:	O
variant	O
likely	O
pathogenic	O
;	O
UV4	O
:	O
variant	O
certainly	O
pathogenic	O
.	O

The	O
proteins	O
encoded	O
,	O
also	O
known	O
as	O
usherins	O
,	O
are	O
multidomain	O
proteins	O
.	O

This	O
work	O
was	O
supported	O
by	O
Fondation	O
R	O
&	O
G	O
Strittmatter	O
(	O
under	O
the	O
aegis	O
of	O
Fondation	O
de	O
France	O
)	O
,	O
FAUN	O
Stiftung	O
(	O
Suchert	O
Foundation	O
)	O
,	O
EC	O
-	O
FP7	O
TREATRUSH	O
(	O
HEALTH	O
-	O
F2	O
-	O
2010	O
-	O
242013	O
)	O
,	O
Foundation	O
Fighting	O
Blindness	B-DISEASE
,	O
LHW	O
-	O
Stiftung	O
,	O
Fondation	O
Orange	I-Chemical
,	O
The	O
Conny	B-Chemical
-	I-Chemical
Maeva	I-Chemical
Charitable	O
Foundation	O
,	O
Genoscope	O
-	O
CNRG	O
project	O
AP2005	O
,	O
and	O
S	B-Chemical
'	O
entendre	I-Chemical
Foundation	O
.	O
Usher	B-DISEASE
syndrome	I-DISEASE
is	O
an	O
autosomal	O
recessive	O
disease	O
that	O
associates	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
and	O
,	O
in	O
some	O
cases	O
,	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

Nine	O
patients	O
exhibited	O
mild	O
to	O
moderate	O
extrapyramidal	O
concomitant	O
symptoms	O
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O

Large	O
differences	O
,	O
regarded	O
as	O
statistically	O
significant	O
,	O
between	O
the	O
mexiletine	B-Chemical
and	O
placebo	O
groups	O
were	O
noted	O
in	O
that	O
end	O
point	O
at	O
months	O
1	O
and	O
4	O
,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	O
12	O
.	O

Third	O
group	O
received	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
24	O
h	O
after	O
injection	O
with	O
normal	O
saline	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
.	O

One	O
affected	O
male	O
was	O
in	O
the	O
family	O
(	O
2D	O
)	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
built	O
a	O
structural	O
model	O
based	O
on	O
the	O
motor	O
domain	O
structure	O
of	O
chick	O
smooth	O
muscle	O
myosin	O
(	O
PDB	O
ID	O
:	O
3JO4	O
)	O
,	O
which	O
shares	O
high	O
sequence	O
identity	O
with	O
the	O
motor	O
domain	O
of	O
human	O
myosin	B-GENE
VIIA	I-GENE
.	O

Amiodarone	B-Chemical
represents	O
an	O
effective	O
antiarrhythmic	O
drug	O
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	B-DISEASE
fibrillation	I-DISEASE
(	O
AF	B-DISEASE
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O

Eighty	O
-	O
one	O
renal	O
,	O
seventeen	O
heart	O
,	O
and	O
twenty	O
-	O
four	O
liver	O
transplant	O
patients	O
were	O
followed	O
for	O
infection	O
.	O

Large	O
numbers	O
of	O
studies	O
have	O
identified	O
many	O
deafness	B-DISEASE
genes	O
whose	O
functions	O
are	O
essential	O
for	O
normal	O
hearing	O
[	O
2	O
]	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O

Pentobarbital	B-Chemical
,	O
scopolamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
protected	O
the	O
brain	B-DISEASE
damage	I-DISEASE
by	O
pilocarpine	B-Chemical
,	O
though	O
in	O
the	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
-	O
treated	O
group	O
,	O
the	O
pyramidal	O
cells	O
of	O
hippocampus	O
appeared	O
darker	O
than	O
normal	O
.	O

Thus	O
,	O
we	O
could	O
analyse	O
~	O
100	O
patient	O
samples	O
with	O
a	O
single	O
run	O
(	O
~	O
10	O
h	O
)	O
using	O
this	O
MPS	O
platform	O
.	O

Our	O
observations	O
also	O
suggested	O
another	O
possibility	O
that	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R348C	I-VARIANT
)	O
is	O
a	O
benign	O
variant	O
in	O
the	O
Chinese	O
population	O
.	O

6e	O
,	O
f	O
)	O
.	O

Only	O
one	O
of	O
these	O
missense	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
F29L	I-VARIANT
,	O
had	O
been	O
demonstrated	O
to	O
have	O
an	O
in	O
vitro	O
electrophysiological	O
effect	O
compatible	O
with	O
LQTS	B-DISEASE
[	O
43	O
]	O
,	O
so	O
the	O
remainder	O
were	O
considered	O
disease	O
-	O
associated	O
based	O
on	O
the	O
evolutionary	O
conservation	O
of	O
the	O
involved	O
amino	O
acid	O
residue	O
and	O
the	O
absence	O
of	O
the	O
mutation	O
among	O
364	O
control	O
alleles	O
as	O
well	O
as	O
a	O
previously	O
reported	O
association	O
with	O
LQTS	B-DISEASE
.	O

Since	O
bupivacaine	B-Chemical
and	O
epinephrine	B-Chemical
may	O
both	O
precipitate	O
dysrhythmias	B-DISEASE
,	O
circulating	O
bupivacaine	B-Chemical
during	O
regional	O
anesthesia	O
could	O
potentiate	O
dysrhythmogenic	O
effects	O
of	O
epinephrine	B-Chemical
.	O

The	O
geographical	O
distribution	O
covered	O
six	O
provinces	O
(	O
Figure	O
1	O
)	O
.	O

But	O
that	O
is	O
not	O
exclusive	O
since	O
previous	O
reports	O
have	O
revealed	O
mutations	O
in	O
near	O
sites	O
(	O
p	B-VARIANT
.	I-VARIANT
Gly955Ser	I-VARIANT
)	O
in	O
patients	O
with	O
USH	B-DISEASE
type	I-DISEASE
1	I-DISEASE
[	O
49	O
]	O
.	O

A	O
7	O
-	O
year	O
-	O
old	O
girl	O
with	O
an	O
unusual	O
reaction	O
to	O
induction	O
chemotherapy	O
for	O
precursor	B-DISEASE
B	I-DISEASE
-	I-DISEASE
cell	I-DISEASE
acute	I-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
(	O
ALL	B-DISEASE
)	O
is	O
described	O
.	O

This	O
analysis	O
led	O
us	O
to	O
amplify	O
a	O
5	O
.	O
5	O
kb	O
PCR	O
fragment	O
containing	O
the	O
deletion	O
flanking	O
regions	O
(	O
Figure	O
2C	O
,	O
2D	O
)	O
.	O

Dobutamine	B-Chemical
induced	O
ischaemia	O
could	O
therefore	O
be	O
used	O
to	O
study	O
the	O
pathophysiology	O
of	O
this	O
phenomenon	O
further	O
in	O
patients	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	O
.	O

In	O
addition	O
,	O
one	O
biodegradable	O
conjugate	O
containing	O
galactosamine	B-Chemical
was	O
used	O
;	O
this	O
residue	O
was	O
targeted	O
to	O
the	O
liver	O
.	O

Idraparinux	B-Chemical
,	O
a	O
Factor	O
Xa	O
inhibitor	O
,	O
is	O
being	O
evaluated	O
in	O
patients	O
with	O
atrial	B-DISEASE
fibrillation	I-DISEASE
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
venous	O
leukocytes	O
.	O

Furthermore	O
,	O
concomitant	O
disease	O
,	O
use	O
of	O
medication	O
,	O
and	O
any	O
other	O
possible	O
causes	O
of	O
acquired	O
hearing	B-DISEASE
impairment	I-DISEASE
were	O
ruled	O
out	O
.	O

These	O
results	O
further	O
support	O
the	O
view	O
that	O
calcium	B-Chemical
ions	O
in	O
excess	O
have	O
an	O
atropine	B-Chemical
-	O
like	O
action	O
also	O
in	O
the	O
central	O
nervous	O
system	O
.	O

(	O
DOCX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Carboplatin	B-Chemical
was	O
given	O
at	O
a	O
fixed	O
target	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
of	O
6	O
.	O
0	O
by	O
the	O
Calvert	O
formula	O
,	O
whereas	O
paclitaxel	B-Chemical
was	O
escalated	O
in	O
patient	O
cohorts	O
from	O
150	O
mg	O
/	O
m2	O
(	O
dose	O
level	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg	O
/	O
m2	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
cells	O
were	O
harvested	O
and	O
homogenized	O
with	O
sonication	B-Chemical
in	O
lysis	O
buffer	O
(	O
50mM	O
Tris	O
HCl	I-Chemical
pH7	O
.	O
4	O
,	O
100mM	O
NaCl	B-Chemical
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
2mM	O
Na3VO4	B-Chemical
)	O
containing	O
a	O
protease	O
inhibitor	O
mixture	O
(	O
#	O
P8340	O
,	O
Sigma	O
)	O
.	O

3	O
)	O
.	O

In	O
our	O
USH	B-DISEASE
families	O
,	O
mutations	O
in	O
the	O
USH2A	B-GENE
gene	O
predispose	O
the	O
disease	O
,	O
suggesting	O
the	O
high	O
prevalence	O
of	O
the	O
USH2A	B-GENE
mutation	O
in	O
Chinese	O
USH	B-DISEASE
population	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
7873	I-VARIANT
T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
*	I-VARIANT
2625Gluext	I-VARIANT
*	I-VARIANT
11	I-VARIANT
)	O
mutation	O
appears	O
to	O
be	O
a	O
deleterious	O
mutation	O
leading	O
to	O
the	O
disruption	O
of	O
the	O
stop	O
codon	O
and	O
introducing	O
the	O
codons	O
for	O
11	O
additional	O
amino	O
acids	O
(	O
Figure	O
2C	O
)	O
.	O

For	O
the	O
32	O
kHz	O
stimulus	O
tg	O
+	O
A	I-Chemical
/	I-Chemical
A	O
mice	O
had	O
thresholds	O
that	O
were	O
elevated	O
compared	O
with	O
tg	O
(	O
+	O
/	O
-	O
)	O
G	O
/	O
A	O
heterozygotes	O
(	O
71	O
+	O
-	O
9	O
dBSPL	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
although	O
these	O
thresholds	O
were	O
still	O
lower	O
than	O
those	O
of	O
tg	O
-	O
A	O
/	O
A	O
(	O
92	O
+	O
-	O
8	O
dBSPL	O
)	O
.	O

In	O
summary	O
,	O
the	O
identification	O
here	O
of	O
a	O
recessive	O
form	O
of	O
type	B-DISEASE
2	I-DISEASE
Stickler	I-DISEASE
syndrome	I-DISEASE
,	O
associated	O
with	O
unusually	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
highlights	O
the	O
necessity	O
for	O
a	O
detailed	O
examination	O
of	O
both	O
parents	O
and	O
a	O
detailed	O
gene	O
analysis	O
.	O

Exome	O
sequencing	O
was	O
then	O
undertaken	O
and	O
identified	O
a	O
new	O
mutation	O
in	O
GUCY2D	B-GENE
,	O
c	B-VARIANT
.	I-VARIANT
2747T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
.	O

Inherited	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
Middle	O
Eastern	O
populations	O
is	O
highly	O
heterogeneous	O
,	O
both	O
in	O
the	O
number	O
of	O
genes	O
involved	O
and	O
in	O
the	O
number	O
of	O
alleles	O
at	O
each	O
gene	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
allele	O
from	O
the	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
one	O
(	O
which	O
would	O
be	O
1	O
-	O
bp	O
shorter	O
)	O
.	O

The	O
peroxins	O
PEX5	B-GENE
and	O
PEX7	B-GENE
are	O
cytosol	O
-	O
based	O
import	O
receptors	O
for	O
peroxisomal	O
matrix	O
proteins	O
.	O

Because	O
of	O
difficulties	O
with	O
respiration	O
a	O
naso	O
-	O
tracheal	O
tube	O
was	O
inserted	O
and	O
breathing	O
was	O
aided	O
by	O
mechanical	O
ventilation	O
.	O

Venous	O
pain	I-DISEASE
occurred	O
in	O
68	O
%	O
of	O
patients	O
and	O
50	O
%	O
had	O
redness	B-DISEASE
,	O
pain	O
or	O
swelling	O
related	O
to	O
the	O
injection	O
site	O
,	O
in	O
some	O
cases	O
lasting	O
up	O
to	O
three	O
weeks	O
after	O
anaesthesia	O
.	O

Increased	O
anxiogenic	O
effects	O
of	O
caffeine	B-Chemical
in	O
panic	B-DISEASE
disorders	I-DISEASE
.	O

Threonine	B-Chemical
is	O
on	O
the	O
surface	O
and	O
accessible	O
to	O
possible	O
phosphorylation	O
events	O
[	O
31	O
]	O
.	O

CNVs	O
are	O
important	O
factors	O
for	O
human	O
genetic	O
and	O
phenotypic	O
diversity	O
.	O

Altogether	O
,	O
data	O
suggest	O
that	O
the	O
c	B-VARIANT
-	I-VARIANT
248	I-VARIANT
G	I-VARIANT
/	I-VARIANT
A	I-VARIANT
transition	O
may	O
affect	O
the	O
EDN3	B-GENE
expression	O
levels	O
.	O

PCR	O
was	O
performed	O
using	O
AmpliTaq	B-Chemical
Gold	I-Chemical
360	I-Chemical
Master	O
mix	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
with	O
50	O
ng	O
genomic	O
DNA	O
and	O
10	O
pmol	O
of	O
each	O
primer	O
in	O
a	O
total	O
volume	O
of	O
25	O
u	O
l	O
.	O

Although	O
the	O
amino	O
acids	O
are	O
also	O
demonstrated	O
to	O
be	O
highly	O
conserved	O
from	O
the	O
zebrafish	O
to	O
humans	O
,	O
and	O
absent	O
in	O
the	O
control	O
,	O
and	O
a	O
batch	O
of	O
pathogenic	O
missense	O
mutations	O
were	O
located	O
outside	O
the	O
functional	O
domains	O
,	O
whether	O
these	O
variations	O
are	O
harmless	O
variants	O
or	O
pathogenic	O
mutations	O
are	O
difficult	O
to	O
establish	O
because	O
we	O
were	O
unable	O
to	O
find	O
other	O
pathogenic	O
mutations	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
the	O
most	O
common	O
sensory	O
deficit	O
in	O
humans	O
,	O
affecting	O
278	O
million	O
individuals	O
worldwide	O
and	O
1	O
in	O
500	O
newborns	O
(	O
1	O
,	O
2	O
)	O
.	O

Cell	O
lysates	O
were	O
subjected	O
to	O
PNGase	O
(	O
PNG	O
,	O
upper	O
panel	O
)	O
or	O
EndoH	O
f	O
(	O
EH	O
,	O
lower	O
panel	O
)	O
digestion	O
.	O

1C	O
)	O
were	O
heterozygous	O
for	O
this	O
mutation	O
,	O
while	O
the	O
mutation	O
was	O
not	O
observed	O
in	O
family	O
members	O
with	O
normal	O
hearing	O
or	O
in	O
100	O
unrelated	O
subjects	O
.	O

Pure	O
-	O
tone	O
average	O
(	O
PTA	O
)	O
was	O
calculated	O
as	O
the	O
average	O
of	O
the	O
threshold	O
measured	O
at	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
2	O
.	O
0	O
,	O
and	O
4	O
.	O
0	O
kHz	O
and	O
was	O
used	O
to	O
compare	O
subgroups	O
of	O
patients	O
.	O

1	O
Minor	O
allele	O
frequency	O
is	O
from	O
dbSNP137	O
database	O
accessed	O
on	O
10	O
/	O
17	O
/	O
2012	O
.	O

The	O
splicing	O
variant	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2	I-VARIANT
A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
may	O
result	O
in	O
the	O
skipping	O
of	O
exon	O
43	O
of	O
USH2A	B-GENE
.	O

This	O
case	O
contributes	O
to	O
the	O
previous	O
observations	O
that	O
non	O
-	O
metastasizing	O
hepatic	I-DISEASE
neoplasms	I-DISEASE
and	O
peliosis	B-DISEASE
can	O
develop	O
in	O
patients	O
with	O
androgen	B-Chemical
-	O
and	O
corticosteroid	B-Chemical
-	O
treated	O
Fanconi	B-DISEASE
'	I-DISEASE
s	I-DISEASE
anemia	I-DISEASE
.	O

However	O
,	O
only	O
four	O
patients	O
with	O
CTDs	B-DISEASE
have	O
been	O
reported	O
with	O
atypical	O
distal	O
22q11	O
.	O
2	O
deletion	O
that	O
involves	O
CRKL	B-GENE
,	O
but	O
not	O
TBX1	B-GENE
so	O
far	O
[	O
8	O
]	O
.	O

The	O
quality	O
of	O
the	O
reads	O
and	O
the	O
consensus	O
sequence	O
were	O
calculated	O
by	O
SOAPsnp	O
.	O

Only	O
the	O
novel	O
missense	O
change	O
in	O
exon	O
1	O
of	O
PRPS1	B-GENE
,	O
c	B-VARIANT
.	I-VARIANT
46	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Ser16Pro	I-VARIANT
(	O
NM_001204402	O
)	O
,	O
completely	O
segregated	O
in	O
all	O
four	O
affecteds	O
and	O
eight	O
unaffected	O
members	O
of	O
family	O
RP	B-DISEASE
-	O
0482	O
(	O
Figure	O
1	O
A	O
)	O
and	O
was	O
absent	O
in	O
controls	O
(	O
258	O
X	O
chromosomes	O
total	O
)	O
.	O

The	O
two	O
signals	O
co	O
-	O
localized	O
for	O
wild	O
type	O
and	O
mutant	O
NARS2	B-GENE
,	O
suggesting	O
that	O
both	O
mutations	O
do	O
not	O
affect	O
NARS2	B-GENE
targeting	O
to	O
the	O
mitochondria	O
.	O

During	O
follow	O
-	O
up	O
(	O
median	O
5	O
years	O
)	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
rejection	O
(	O
acute	O
and	O
chronic	O
)	O
,	O
graft	O
failure	O
or	O
survival	O
between	O
the	O
groups	O
(	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-DISEASE
1	O
year	O
87	O
%	O
,	O
5	O
years	O
75	O
%	O
;	O
non	O
-	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-DISEASE
88	O
%	O
,	O
78	O
%	O
;	O
CLD	B-DISEASE
93	O
%	O
,	O
82	O
%	O
:	O
P	O
>	O
0	O
.	O
6	O
log	O
rank	O
)	O
.	O

Differential	O
effects	O
of	O
gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
(	O
lindane	B-Chemical
)	O
on	O
pharmacologically	O
-	I-DISEASE
induced	I-DISEASE
seizures	I-DISEASE
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
CA	O
.	O

This	O
study	O
was	O
presented	O
as	O
a	O
poster	O
at	O
the	O
International	O
Meeting	O
of	O
the	O
European	O
Science	O
Foundation	O
(	O
Rare	O
Diseases	O
II	O
:	O
Hearing	O
and	O
sight	O
loss	O
,	O
22	O
-	O
27	O
November	O
2009	O
Sant	O
Feliu	B-Chemical
de	O
Guixols	I-Chemical
,	O
Spain	O
)	O
and	O
the	O
International	O
Meeting	O
of	O
the	O
SIRCOVA	O
(	O
19	O
June	O
2010	O
,	O
Valencia	O
,	O
Spain	O
)	O
.	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Two	O
weeks	O
before	O
his	O
admission	O
,	O
sorafenib	B-Chemical
had	O
been	O
started	O
.	O

Combined	O
androgen	O
blockade	O
-	O
induced	O
anemia	B-DISEASE
in	O
prostate	B-DISEASE
cancer	I-DISEASE
patients	O
without	O
bone	O
involvement	O
.	O

Thirteen	O
patients	O
were	O
included	O
in	O
this	O
group	O
.	O

MD	B-Chemical
mutations	O
were	O
associated	O
with	O
a	O
significantly	O
higher	O
percentage	O
of	O
bleeders	O
(	O
65	O
%	O
)	O
as	O
compared	O
to	O
those	O
affecting	O
the	O
TD	O
(	O
33	O
.	O
9	O
%	O
)	O
,	O
P	O
=	O
0	O
.	O
045	O
(	O
Fig	O
.	O

The	O
function	O
of	O
OSBPL2	B-GENE
in	O
the	O
hearing	O
process	O
remains	O
to	O
be	O
determined	O
.	O

Bradykinin	B-Chemical
receptors	O
antagonists	O
and	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
inhibitors	O
in	O
vincristine	B-Chemical
and	O
streptozotocin	B-Chemical
induced	O
hyperalgesia	B-DISEASE
in	O
chemotherapy	B-DISEASE
and	O
diabetic	B-DISEASE
neuropathy	I-DISEASE
rat	O
model	O
.	O

Serum	O
blood	O
urea	B-Chemical
and	O
creatinine	B-Chemical
concentrations	O
increased	O
significantly	O
in	O
rats	O
given	O
an	O
iv	O
infusion	O
of	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
3	O
mg	O
/	O
kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dose	O
of	O
NS	O
-	O
718	O
.	O

Calcium	O
channel	O
expression	O
in	O
human	O
adrenal	O
cortex	O
was	O
extracted	O
from	O
a	O
previously	O
described	O
dataset	O
1	O
.	O

Twelve	O
patients	O
with	O
liver	O
disease	O
related	O
to	O
methyldopa	B-Chemical
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O

We	O
also	O
observed	O
that	O
transient	O
severe	O
glucose	O
deprivation	O
in	O
patients	O
with	O
WSD	B-DISEASE
was	O
accompanied	O
by	O
an	O
acute	O
,	O
partially	O
reversible	O
,	O
neurologic	B-DISEASE
or	I-DISEASE
visual	I-DISEASE
deterioration	I-DISEASE
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
blockade	O
of	O
mGluR5	B-GENE
by	O
MPEP	B-Chemical
may	O
protect	O
dopaminergic	O
neurones	O
against	O
methamphetamine	B-Chemical
-	O
induced	O
toxicity	O
.	O

Of	O
the	O
8	O
cases	O
for	O
which	O
the	O
pathogenic	O
mutation	O
could	O
not	O
be	O
identified	O
,	O
the	O
absence	O
of	O
zero	O
-	O
coverage	O
targeted	O
regions	O
suggested	O
that	O
a	O
homozygous	O
deletion	O
removing	O
an	O
exon	O
(	O
s	O
)	O
was	O
not	O
the	O
cause	O
of	O
disease	O
in	O
these	O
patients	O
.	O

Figure	O
S2	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
influence	O
of	O
hyperprolactinemia	B-DISEASE
,	O
induced	O
by	O
haloperidol	B-Chemical
(	O
HAL	B-Chemical
)	O
on	O
age	O
related	O
morphology	O
and	O
function	O
changes	O
of	O
epithelial	O
cells	O
in	O
rat	O
prostate	O
lateral	O
lobe	O
.	O

The	O
co	O
-	O
administration	O
of	O
aspirin	B-Chemical
with	O
N	B-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
5	I-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
furyl	I-Chemical
)	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiazolyl	I-Chemical
]	I-Chemical
-	I-Chemical
formamide	I-Chemical
(	O
FANFT	B-Chemical
)	O
to	O
rats	O
resulted	O
in	O
a	O
reduced	O
incidence	O
of	O
FANFT	B-Chemical
-	O
induced	O
bladder	I-DISEASE
carcinomas	I-DISEASE
but	O
a	O
concomitant	O
induction	O
of	O
forestomach	O
tumors	O
.	O

4	O
Furthermore	O
,	O
autosomal	B-DISEASE
dominant	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ADNSHL	B-DISEASE
/	O
DFNA	B-DISEASE
)	O
accounts	O
for	O
20	O
-	O
25	O
%	O
of	O
hereditary	O
nonsyndromic	B-DISEASE
sensorineural	I-DISEASE
deafness	I-DISEASE
cases	O
and	O
is	O
most	O
often	O
postlingual	O
in	O
onset	O
.	O

For	O
immunohistochemistry	O
on	O
cryosections	O
,	O
the	O
temporal	O
bone	O
of	O
mature	O
mice	O
was	O
dissected	O
on	O
ice	O
and	O
immediately	O
fixed	O
using	O
Zamboni	O
'	O
s	O
fixative	O
[	O
29	O
]	O
containing	O
picric	B-Chemical
acid	I-Chemical
by	O
infusion	O
through	O
the	O
round	O
and	O
oval	O
window	O
and	O
incubated	O
for	O
15	O
min	O
on	O
ice	O
,	O
followed	O
by	O
rinsing	O
with	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
and	O
decalcification	O
in	O
rapid	O
bone	O
decalcifier	I-Chemical
(	O
Eurobio	B-Chemical
,	O
Fisher	O
-	O
Scientific	O
)	O
.	O

We	O
compared	O
the	O
severity	O
of	O
mis	O
-	O
sense	O
changes	O
in	O
pendrin	B-GENE
with	O
naturally	O
occurring	O
variation	O
across	O
all	O
proteins	O
in	O
the	O
family	O
.	O

MAT	O
and	O
GVC	O
performed	O
the	O
linkage	O
studies	O
.	O

Brown	O
;	O
and	O
S	O
.	O

for	O
backcross	O
progeny	O
tg	O
(	O
+	O
/	O
-	O
)	O
G	O
/	O
A	O
(	O
green	O
,	O
n	O
=	O
20	O
)	O
,	O
tg	O
+	O
A	O
/	O
A	O
(	O
blue	O
,	O
n	O
=	O
36	O
)	O
and	O
tg	O
-	O
A	O
/	O
A	O
(	O
red	O
,	O
n	O
=	O
37	O
)	O
.	O

In	O
the	O
patients	O
with	O
predicted	O
complete	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
,	O
ages	O
at	O
the	O
onsets	O
of	O
both	O
DM	B-DISEASE
and	O
OA	B-DISEASE
were	O
significantly	O
earlier	O
than	O
those	O
in	O
patients	O
with	O
predicted	O
partial	O
-	O
loss	O
-	O
of	O
function	O
mutations	O
.	O

A	O
total	O
of	O
43	O
.	O
3	O
million	O
non	O
-	O
duplicated	O
reads	O
could	O
be	O
mapped	O
to	O
the	O
genome	O
.	O

Of	O
the	O
33	O
potentially	O
pathogenic	O
variants	O
identified	O
in	O
these	O
genes	O
,	O
23	O
were	O
new	O
and	O
the	O
remaining	O
have	O
been	O
previously	O
reported	O
.	O

3A	O
and	O
3B	O
)	O
.	O

These	O
nine	O
rare	O
missense	O
variants	O
were	O
further	O
evaluated	O
for	O
an	O
effect	O
on	O
exonic	O
splice	O
enhancers	O
by	O
using	O
the	O
RESCUE	O
-	O
ESE	O
program	O
.	O

average	O
of	O
500	O
,	O
1000	O
,	O
2000	O
and	O
4000	O
Hz	O
.	O

The	O
mean	O
age	O
was	O
25	O
years	O
(	O
min	O
4	O
;	O
max	O
47	O
)	O
.	O

1a	O
)	O
.	O

7	O
+	O
/	O
-	O
5	O
.	O

A	O
,	O
E	O
)	O
Fundus	O
photographs	O
of	O
patient	O
55	O
show	O
an	O
atrophic	B-DISEASE
maculopathy	I-DISEASE
involving	O
the	O
fovea	O
in	O
the	O
OD	O
with	O
clumps	O
of	O
pigmentation	O
in	O
the	O
macular	O
area	O
.	O

We	O
next	O
examined	O
the	O
run	O
-	O
to	O
-	O
run	O
variation	O
of	O
the	O
sequencing	O
error	O
rate	O
for	O
NLRP3	B-GENE
exons	O
.	O

We	O
analyzed	O
135	O
unrelated	O
Korean	O
patients	O
,	O
87	O
patients	O
of	O
whom	O
had	O
ADNSHL	B-DISEASE
and	O
48	O
of	O
whom	O
had	O
ARNSHL	B-DISEASE
or	O
possible	O
sporadic	O
,	O
bilateral	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Segmentally	O
duplicated	O
regions	O
were	O
not	O
excluded	O
because	O
this	O
would	O
preclude	O
identifying	O
causative	O
alleles	O
in	O
genes	O
such	O
as	O
STRC	B-GENE
[	O
10	O
]	O
and	O
OTOA	B-GENE
[	O
5	O
]	O
.	O

The	O
detailed	O
clinical	O
data	O
of	O
affected	O
subjects	O
of	O
family	O
JX	B-Chemical
-	I-Chemical
H016	I-Chemical
were	O
summarized	O
in	O
Table	O
2	O
.	O

However	O
,	O
the	O
present	O
40	O
-	O
year	O
-	O
old	O
patient	O
showed	O
completely	O
different	O
performance	O
after	O
EAS	O
,	O
indicating	O
that	O
CI	O
is	O
not	O
a	O
contraindication	O
and	O
CI	O
and	O
/	O
or	O
EAS	O
can	O
be	O
a	O
recommended	O
therapeutic	O
option	O
.	O

Nonsense	O
,	O
frameshift	O
,	O
and	O
canonical	O
splice	O
site	O
variants	O
(	O
i	O
.	O
e	O
.	O

A	O
man	O
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	O
,	O
chill	O
,	O
vomiting	O
,	O
jaundice	O
.	O

Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	B-Chemical
rats	O
had	O
higher	O
basal	O
levels	O
of	O
superoxide	B-Chemical
compared	O
with	O
those	O
from	O
control	O
rats	O
.	O

The	O
USH2A	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
Glu767SerfsX21	I-VARIANT
mutation	O
was	O
the	O
most	O
common	O
mutation	O
in	O
the	O
entire	O
USH	B-DISEASE
cohort	O
,	O
accounting	O
for	O
31	O
%	O
of	O
all	O
USH2	B-DISEASE
alleles	O
and	O
33	O
.	O
7	O
%	O
of	O
identified	O
pathogenic	O
/	O
UV4	O
/	O
UV3	O
USH2A	B-GENE
alleles	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-DISEASE
starts	O
.	O

The	O
underlying	O
mechanisms	O
accounting	O
for	O
the	O
high	O
prevalence	O
of	O
certain	O
founder	O
GJB2	B-GENE
alleles	O
are	O
unknown	O
.	O

Together	O
with	O
the	O
fact	O
that	O
a	O
large	O
number	O
of	O
coding	O
exons	O
exist	O
in	O
these	O
genes	O
,	O
traditional	O
screening	O
of	O
each	O
region	O
is	O
infeasible	O
for	O
clinical	O
application	O
.	O

The	O
threshold	O
of	O
auditory	O
brainstem	O
response	O
was	O
60	O
dB	O
HL	O
on	O
both	O
sides	O
.	O

The	O
long	O
isoform	O
of	O
each	O
USH	B-DISEASE
protein	O
is	O
shown	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
crocins	B-Chemical
on	O
sporadic	B-DISEASE
Alzheimer	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
induced	O
by	O
intracerebroventricular	O
(	O
icv	O
)	O
streptozocin	B-Chemical
(	O
STZ	B-Chemical
)	O
in	O
male	O
rats	O
was	O
investigated	O
.	O

The	O
results	O
indicate	O
that	O
the	O
deprived	O
area	O
of	O
A1	O
undergoes	O
extensive	O
reorganization	O
and	O
becomes	O
responsive	O
to	O
intact	O
cochlear	O
frequencies	O
.	O

Serum	O
creatinine	B-Chemical
values	O
did	O
not	O
change	O
significantly	O
:	O
1	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
8	O
mg	O
/	O
dL	O
before	O
SRL	B-Chemical
therapy	O
and	O
2	O
.	O
53	O
+	O
/	O
-	O
1	O
.	O
9	O
mg	O
/	O
dL	O
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.	O
14	O
)	O
.	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
from	O
patients	O
and	O
their	O
lineal	O
relatives	O
.	O

Homozygous	O
mouse	O
knockouts	O
for	O
Par3	B-Chemical
are	O
embryonic	O
lethal	O
and	O
have	O
growth	B-DISEASE
retardation	I-DISEASE
,	O
heart	B-DISEASE
and	I-DISEASE
brain	I-DISEASE
defects	I-DISEASE
and	O
short	B-DISEASE
tails	I-DISEASE
(	O
24	O
)	O
,	O
and	O
zebrafish	O
Pard3	B-GENE
knockdowns	O
have	O
hydrocephalus	B-DISEASE
(	O
23	O
)	O
.	O

Among	O
all	O
animals	O
,	O
glomerular	O
and	O
tubular	O
injury	O
were	O
inversely	O
correlated	O
with	O
mtDNA	O
levels	O
,	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
activities	O
and	O
with	O
the	O
expression	O
of	O
the	O
mtDNA	O
-	O
encoded	O
respiratory	O
chain	O
subunit	O
COX	B-GENE
-	I-GENE
I	I-GENE
.	O

Kinin	B-GENE
B2	I-GENE
receptor	O
deletion	O
and	O
blockage	O
ameliorates	O
cisplatin	B-Chemical
-	O
induced	O
acute	O
renal	O
injury	O
.	O

Figure	O
2	O
ABRs	O
recorded	O
at	O
90	O
dB	O
nHL	O
from	O
one	O
control	O
with	O
normal	O
hearing	O
and	O
three	O
subjects	O
with	O
DOA	B-DISEASE
,	O
one	O
included	O
in	O
the	O
OPA1	B-GENE
-	O
H	O
and	O
two	O
in	O
the	O
OPA1	B-GENE
-	O
M	O
group	O
.	O

Coverage	O
and	O
depth	O
calculations	O
were	O
further	O
performed	O
.	O

These	O
features	O
on	O
light	O
microscopy	O
had	O
,	O
over	O
time	O
,	O
been	O
mistranslated	O
into	O
a	O
diagnostic	O
label	O
of	O
MPGN	B-DISEASE
.	O

Analyzed	O
the	O
data	O
:	O
WR	O
XC	O
YL	I-Chemical
XL	I-Chemical
.	O

(	O
b	O
)	O
IGV	O
view	O
of	O
a	O
tRNA	O
-	O
Met	O
gene	O
transcribed	O
by	O
POLR3	O
.	O

We	O
enrolled	O
a	O
Caucasian	O
woman	O
(	O
patient	O
1184405	O
)	O
whose	O
past	O
medical	O
history	O
is	O
significant	O
for	O
vesicoureteral	B-DISEASE
reflux	I-DISEASE
(	O
VUR	B-DISEASE
)	O
diagnosed	O
at	O
age	O
two	O
,	O
several	O
urinary	O
tract	O
infections	O
and	O
hydronephrosis	B-DISEASE
.	O

Interestingly	O
,	O
a	O
patient	O
homozygous	O
for	O
mutations	O
of	O
PDE6B	B-GENE
and	O
G	B-GENE
protein	I-GENE
-	I-GENE
coupled	I-GENE
receptor	I-GENE
98	I-GENE
(	O
GPR98	B-GENE
)	O
,	O
the	O
gene	O
underlying	O
USH2C	B-GENE
,	O
has	O
been	O
previously	O
reported	O
.	O

Beneficial	O
effect	O
of	O
oral	O
galactose	B-Chemical
was	O
independent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galactose	B-Chemical
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O

File	O
S1	O
contains	O
the	O
following	O
files	O
.	O

Therefore	O
,	O
most	O
reports	O
on	O
rare	O
diseases	O
in	O
China	O
are	O
unavailable	O
to	O
international	O
readers	O
.	O

Tryptophan	B-Chemical
2160	O
on	O
the	O
C	O
-	O
terminal	O
4	O
.	O
1	O
protein	O
-	O
ezrin	O
-	O
radixin	O
-	O
moesin	O
(	O
FERM	O
)	O
domain	O
is	O
indicated	O
by	O
an	O
arrow	O
.	O

Calcium	B-Chemical
carbonate	I-Chemical
toxicity	O
:	O
the	O
updated	O
milk	B-DISEASE
-	I-DISEASE
alkali	I-DISEASE
syndrome	I-DISEASE
;	O
report	O
of	O
3	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

Contract	O
grant	O
sponsors	O
:	O
Wellcome	O
Trust	O
(	O
071161	O
/	O
Z	O
/	O
03	O
/	O
Z	O
,	O
084353	O
/	O
Z	O
/	O
07	O
/	O
Z	O
to	O
M	O
.	O
D	O
.	O
B	O
.	O
)	O
;	O
The	O
European	O
Commission	O
FP5	O
(	O
QLG1	O
-	O
CT	O
-	O
2001	O
-	O
02188	I-Chemical
)	O
and	O
FP6	O
(	O
LSHM	O
-	O
CT	O
-	O
2007	O
-	O
037471	I-Chemical
)	O
;	O
The	O
Swiss	O
National	O
Science	O
Foundation	O
(	O
FN	O
310030	O
-	O
132940	O
/	O
BONAFE	O
Luisa	O
)	O
;	O
The	O
Leenaards	B-Chemical
Foundation	O
in	O
Lausanne	O
(	O
to	O
A	O
.	O
S	O
.	O
F	O
.	O
)	O
.	O

Individuals	O
1	O
-	O
93	O
were	O
run	O
on	O
Illumina	O
Omni1	O
-	O
Quad	O
microarrays	O
.	O

Our	O
analysis	O
of	O
the	O
mitochondrial	O
network	O
showed	O
that	O
fibroblasts	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
2794C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
contained	O
a	O
larger	O
proportion	O
of	O
short	O
mitochondria	O
than	O
controls	O
(	O
Figure	O
6	O
)	O
.	O

On	O
a	O
low	O
-	O
salt	B-Chemical
(	O
LS	O
)	O
diet	O
,	O
male	O
DS	O
had	O
higher	O
levels	O
of	O
intrarenal	O
angiotensinogen	O
mRNA	O
than	O
females	O
.	O

G	O
.	O
S	O
.	O
G	O
.	O

We	O
are	O
aware	O
that	O
hematology	O
analyzers	O
can	O
miss	O
large	O
platelets	O
,	O
underestimating	O
the	O
platelet	O
count	O
.	O

Estrogen	O
prevents	O
cholesteryl	B-Chemical
ester	I-Chemical
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	O
protease	O
inhibitor	O
ritonavir	B-Chemical
.	O

The	O
disease	O
-	O
causing	O
gene	O
in	O
family	O
FR1	O
was	O
mapped	O
to	O
the	O
USH2A	B-GENE
locus	O
on	O
chromosome	O
1q41	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
reported	O
that	O
DTDST	B-GENE
mutations	O
are	O
not	O
a	O
common	O
cause	O
of	O
MED	B-DISEASE
in	O
some	O
Asian	O
populations	O
[	O
Itoh	O
et	O
al	O
.	O
,	O
2006	O
]	O
.	O

C	O
Electropherogram	O
of	O
a	O
heterozygous	O
carrier	O
of	O
the	O
OSBPL2	B-GENE
mutation	O
in	O
exon	O
3	O
(	O
deleted	O
nucleotides	O
are	O
boxed	O
)	O
.	O

Dysfunction	O
of	O
ion	O
transport	O
affects	O
iodide	O
organification	O
for	O
thyroid	O
hormone	O
biosynthesis	O
[	O
4	O
]	O
resulting	O
in	O
goitre	B-DISEASE
[	O
1	O
,	O
3	O
,	O
12	O
]	O
,	O
which	O
distinguishes	O
it	O
from	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
EVA	I-DISEASE
.	O

The	O
hearing	O
level	O
of	O
the	O
prelingual	O
or	O
early	O
-	O
onset	O
deaf	B-DISEASE
probands	O
should	O
exceed	O
70	O
dB	O
.	O

The	O
symbols	O
for	O
deceased	O
family	O
members	O
have	O
a	O
slash	O
.	O

Approximately	O
99	O
%	O
and	O
98	O
.	O
98	O
%	O
(	O
2739	O
Mb	O
and	O
2942	O
Mb	O
in	O
length	O
,	O
respectively	O
)	O
of	O
the	O
targeted	O
bases	O
were	O
covered	O
sufficiently	O
to	O
pass	O
our	O
thresholds	O
for	O
calling	O
SNPs	O
and	O
short	O
insertions	O
or	O
deletions	O
(	O
indels	O
)	O
.	O

The	O
differences	O
in	O
thickness	O
values	O
between	O
patients	O
and	O
controls	O
were	O
not	O
only	O
found	O
in	O
adult	O
patients	O
but	O
also	O
in	O
the	O
two	O
children	O
of	O
4	O
and	O
11	O
years	O
of	O
age	O
with	O
recent	O
diagnosis	O
of	O
the	O
disease	O
.	O

Because	O
ER	O
stress	O
has	O
been	O
recognized	O
as	O
contributing	O
to	O
insulin	B-DISEASE
resistance	I-DISEASE
in	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
(	O
5	O
,	O
22	O
)	O
,	O
the	O
dissection	O
of	O
pathogenic	O
mechanisms	O
in	O
monogenic	O
ER	O
stress	O
-	O
mediated	O
beta	B-DISEASE
-	I-DISEASE
cell	I-DISEASE
loss	I-DISEASE
may	O
also	O
contribute	O
to	O
the	O
understanding	O
of	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
pathogenesis	O
.	O

The	O
AO	O
and	O
IR	O
images	O
of	O
Patient	O
1	O
-	O
II	O
-	O
1	O
.	O

Indeed	O
,	O
sex	O
-	O
dependent	O
penetrance	O
of	O
the	O
mutations	O
in	O
KS	B-DISEASE
genes	O
yet	O
-	O
to	O
-	O
be	O
discovered	O
could	O
contribute	O
to	O
the	O
higher	O
incidence	O
of	O
KS	B-DISEASE
in	O
men	O
worldwide	O
.	O

We	O
studied	O
the	O
role	O
of	O
xanthine	B-Chemical
oxidase	O
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
,	O
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-DISEASE
(	O
dex	B-Chemical
-	O
HT	B-DISEASE
)	O
.	O

All	O
sequences	O
were	O
analyzed	O
with	O
the	O
Sequencher	O
software	O
(	O
Gene	O
Codes	O
,	O
Ann	O
Arbor	O
,	O
MI	O
)	O
.	O

Two	O
mutations	O
were	O
found	O
,	O
p	B-VARIANT
.	I-VARIANT
I57T	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
V65M	I-VARIANT
,	O
both	O
previously	O
described	O
in	O
other	O
populations	O
as	O
associated	O
with	O
LQTS	B-DISEASE
[	O
57	O
,	O
58	O
]	O
and	O
shown	O
to	O
interfere	O
with	O
Kv7	O
.	O
1	O
function	O
[	O
59	O
]	O
in	O
a	O
way	O
compatible	O
with	O
an	O
association	O
with	O
LQTS	B-DISEASE
.	O

Squares	O
represent	O
males	O
,	O
circles	O
represent	O
females	O
.	O

This	O
calls	O
for	O
attention	O
when	O
ketoconazole	B-Chemical
is	O
administered	O
to	O
patients	O
with	O
risk	O
factors	O
for	O
acquired	B-DISEASE
long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
.	O

Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
pacemaker	O
insertion	O
associated	O
with	O
amiodarone	B-Chemical
use	O
,	O
controlling	O
for	O
baseline	O
risk	O
factors	O
and	O
exposure	O
to	O
sotalol	B-Chemical
,	O
Class	O
I	O
antiarrhythmic	O
agents	O
,	O
beta	O
-	O
blockers	O
,	O
calcium	B-Chemical
channel	O
blockers	O
,	O
and	O
digoxin	B-Chemical
.	O

3c	O
-	O
3d	O
)	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

However	O
,	O
the	O
role	O
of	O
wolframin	B-Chemical
and	O
its	O
implication	O
in	O
the	O
etiology	O
of	O
LFSNHL	B-DISEASE
in	O
humans	O
is	O
still	O
unclear	O
.	O

Then	O
the	O
monoclonal	O
flora	O
was	O
picked	O
up	O
and	O
mass	O
cultured	O
in	O
LB	O
medium	O
with	O
ampicillin	B-Chemical
.	O

Independently	O
of	O
these	O
events	O
,	O
a	O
second	O
patient	O
(	O
III	O
-	O
1	O
)	O
was	O
referred	O
to	O
the	O
same	O
clinic	O
at	O
the	O
age	O
of	O
ten	O
years	O
with	O
a	O
scaphocephalic	O
head	O
shape	O
.	O

The	O
second	O
aim	O
was	O
to	O
analyze	O
the	O
USH1	B-DISEASE
transcripts	O
,	O
obtained	O
from	O
the	O
nasal	O
epithelium	O
cells	O
of	O
our	O
patients	O
,	O
in	O
order	O
to	O
corroborate	O
the	O
observed	O
effect	O
of	O
mutations	O
by	O
minigenes	O
in	O
patient	O
'	O
s	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
phenytoin	B-Chemical
medication	O
and	O
cerebellar	O
atrophy	O
in	O
patients	O
who	O
had	O
experienced	O
clinical	O
intoxication	O
.	O

More	O
detail	O
and	O
descriptions	O
regarding	O
how	O
the	O
specific	O
activities	O
were	O
calculated	O
from	O
this	O
assay	O
can	O
be	O
found	O
in	O
the	O
report	O
by	O
Bowzard	O
et	O
al	O
[	O
29	O
]	O
.	O

Other	O
known	O
reasons	O
for	O
seizures	B-DISEASE
were	O
ruled	O
out	O
and	O
the	O
convulsions	B-DISEASE
stopped	O
a	O
few	O
hours	O
after	O
cessation	O
of	O
morphine	B-Chemical
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
months	O
.	O

This	O
agent	O
inhibits	O
Urd	B-Chemical
catabolism	O
and	O
,	O
in	O
vivo	O
,	O
increases	O
the	O
plasma	O
concentration	O
of	O
Urd	B-Chemical
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
without	O
Urd	B-Chemical
-	O
related	O
toxicity	O
.	O

Multiple	O
sequence	O
alignment	O
of	O
PRPS1	B-GENE
across	O
species	O
using	O
ClustalW	O
[	O
14	O
]	O
confirms	O
that	O
p	O
.	O
Ser16	O
is	O
identical	O
from	O
human	O
to	O
zebrafish	O
.	O

(	O
A	O
)	O
The	O
nonsense	O
mutation	O
was	O
identified	O
in	O
exon	O
6	O
,	O
used	O
by	O
the	O
three	O
membrane	O
bound	O
isoforms	O
of	O
CD164	B-GENE
.	O

The	O
phenotype	O
of	O
the	O
reported	O
patients	O
is	O
consistent	O
with	O
the	O
current	O
model	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

The	O
patient	O
had	O
no	O
apparent	O
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	O
of	O
bradyarrhythmias	B-DISEASE
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	B-Chemical
.	O

This	O
substitution	O
resulted	O
in	O
a	O
change	O
in	O
the	O
codon	O
at	O
amino	O
acid	O
position	O
393	O
from	O
a	O
glutamine	B-Chemical
to	O
a	O
stop	O
codon	O
(	O
p	B-VARIANT
.	I-VARIANT
Q393X	I-VARIANT
)	O
,	O
producing	O
a	O
truncated	O
protein	O
lacking	O
the	O
Eya	O
VR	O
domain	O
(	O
S1	O
Fig	O
.	O

Therefore	O
,	O
if	O
OAE	O
is	O
not	O
tested	O
at	O
a	O
very	O
early	O
age	O
,	O
patients	O
with	O
OTOF	B-GENE
mutations	O
are	O
not	O
deemed	O
to	O
have	O
ANSD	B-DISEASE
(	O
i	O
.	O
e	O
.	O
,	O
hidden	O
ANSD	B-DISEASE
)	O
.	O

The	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
accounted	O
for	O
64	O
.	O
63	O
%	O
(	O
53	O
/	O
82	O
,	O
counting	O
only	O
the	O
definite	O
pathogenic	O
and	O
most	O
likely	O
pathogenic	O
variants	O
)	O
of	O
all	O
SLC26A4	B-GENE
mutant	O
alleles	O
in	O
this	O
population	O
(	O
Table	O
2	O
)	O
.	O

Vestibular	O
function	O
was	O
evaluated	O
by	O
tandem	O
gait	O
and	O
Romberg	O
testing	O
.	O

Over	O
the	O
long	O
-	O
term	O
chronic	O
phase	O
(	O
120	O
days	O
after	O
transplantation	O
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
treated	O
epileptic	B-DISEASE
animals	O
had	O
seizures	B-DISEASE
,	O
but	O
with	O
a	O
lower	O
frequency	O
and	O
duration	O
compared	O
to	O
the	O
epileptic	O
control	O
group	O
.	O

Increased	O
serum	O
soluble	O
Fas	O
in	O
patients	O
with	O
acute	O
liver	B-DISEASE
failure	O
due	O
to	O
paracetamol	B-Chemical
overdose	I-DISEASE
.	O

Samocha	O
,	O
Aniko	O
Sabo	O
,	O
and	O
Chiao	O
-	O
Feng	O
Lin	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

In	O
summary	O
,	O
using	O
a	O
combination	O
of	O
linkage	O
analysis	O
and	O
exome	O
-	O
sequencing	O
enabled	O
us	O
to	O
use	O
a	O
single	O
pedigree	O
to	O
identify	O
a	O
novel	O
hearing	B-DISEASE
loss	I-DISEASE
gene	O
.	O

1D	O
)	O
.	O

The	O
most	O
prevalent	O
mutation	O
in	O
this	O
patient	O
cohort	O
was	O
235delC	B-VARIANT
,	O
which	O
has	O
also	O
been	O
reported	O
to	O
be	O
the	O
most	O
prevalent	O
mutation	O
in	O
other	O
Asian	O
populations	O
[	O
6	O
,	O
46	O
]	O
.	O

More	O
than	O
60	O
genes	O
have	O
been	O
implicated	O
in	O
nonsyndromic	B-DISEASE
RP	I-DISEASE
(	O
RetNet	O
)	O
.	O

TEOAE	O
tests	O
were	O
conducted	O
on	O
the	O
same	O
day	O
as	O
the	O
pure	O
tone	O
test	O
.	O

20	O
-	O
22	O
The	O
current	O
estimate	O
for	O
the	O
somatic	O
(	O
de	O
novo	O
)	O
mutation	O
rate	O
is	O
1	O
-	O
2	O
x	O
10	O
-	O
8	O
residues	O
/	O
generation	O
/	O
haploid	O
,	O
and	O
this	O
estimate	O
is	O
sufficiently	O
low	O
that	O
we	O
would	O
expect	O
to	O
never	O
observe	O
somatic	O
mosaicism	O
in	O
the	O
NLRP3	B-GENE
gene	O
by	O
chance	O
;	O
although	O
the	O
error	O
rate	O
of	O
the	O
high	O
-	O
fidelity	O
DNA	O
polymerase	O
used	O
to	O
produce	O
the	O
amplicons	O
is	O
two	O
orders	O
of	O
magnitude	O
larger	O
than	O
the	O
somatic	O
mutation	O
rate	O
,	O
23	O
,	O
24	O
we	O
could	O
not	O
detect	O
PCR	O
-	O
generated	O
mosaicism	O
higher	O
than	O
1	O
%	O
in	O
the	O
454	O
sequencing	O
error	O
maps	O
.	O

This	O
study	O
received	O
funding	O
from	O
the	O
European	O
Community	O
'	O
s	O
Seventh	O
Framework	O
Programme	O
(	O
FP7	O
/	O
2008	O
-	O
2012	O
)	O
under	O
grant	O
agreement	O
No	O
.	O

Histological	O
changes	O
evident	O
in	O
model	O
and	O
intervention	O
groups	O
rats	O
'	O
bladder	O
included	O
edema	B-DISEASE
,	O
vasodilation	B-DISEASE
,	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
.	O

The	O
mastoid	O
air	O
cells	O
and	O
middle	O
ear	O
cleft	O
were	O
well	O
-	O
aerated	O
bilaterally	O
.	O

Significant	O
obsessive	O
-	O
compulsive	O
behavior	O
ensued	O
but	O
diminished	O
over	O
several	O
weeks	O
when	O
methylphenidate	B-Chemical
was	O
replaced	O
by	O
fluvoxamine	B-Chemical
.	O

Both	O
of	O
these	O
residues	O
are	O
conserved	O
in	O
murine	O
COMP	B-GENE
and	O
the	O
substitution	O
of	O
glycine	B-Chemical
and	O
proline	B-Chemical
residues	O
in	O
the	O
EGF	O
-	O
like	O
repeats	O
of	O
fibrilin	O
-	O
1	O
has	O
been	O
shown	O
to	O
cause	O
Marfan	O
Syndrome	O
[	O
Arbustini	O
et	O
al	O
.	O
,	O
2005	O
;	O
Collod	B-Chemical
-	O
Beroud	I-Chemical
et	O
al	O
.	O
,	O
1999	O
]	O
.	O

In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	B-Chemical
therapy	O
.	O

The	O
resulting	O
cDNA	O
products	O
were	O
numbered	O
according	O
to	O
NCBI	O
Reference	O
Sequence	O
:	O
NM_000141	O
.	O
4	O
.	O

In	O
our	O
study	O
,	O
we	O
identified	O
the	O
causative	O
genes	O
and	O
mutations	O
in	O
all	O
the	O
11	O
families	O
we	O
analyzed	O
,	O
which	O
corroborate	O
previous	O
observations	O
in	O
the	O
field	O
.	O

To	O
address	O
this	O
challenge	O
,	O
we	O
developed	O
a	O
new	O
pipeline	O
to	O
detect	O
low	O
-	O
level	O
somatic	O
mosaicism	O
with	O
statistical	O
confidence	O
using	O
base	O
position	O
-	O
and	O
strand	O
-	O
specific	O
error	O
rate	O
maps	O
for	O
the	O
NLRP3	B-GENE
amplicons	O
to	O
be	O
studied	O
.	O

Antitumor	O
activity	O
was	O
studied	O
using	O
a	O
tumor	O
growth	O
delay	O
assay	O
.	O

Dobutamine	B-Chemical
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
useful	O
and	O
safe	O
provocation	O
test	O
for	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O

Longitudinal	O
assessment	O
of	O
air	O
conduction	O
audiograms	O
in	O
a	O
phase	O
III	O
clinical	O
trial	O
of	O
difluoromethylornithine	B-Chemical
and	O
sulindac	B-Chemical
for	O
prevention	O
of	O
sporadic	O
colorectal	I-DISEASE
adenomas	I-DISEASE
.	O

After	O
applying	O
topical	O
glycopyrrolate	B-Chemical
,	O
the	O
subjective	O
effect	O
was	O
excellent	O
(	O
no	O
sweating	O
after	O
eating	O
hot	O
spicy	O
food	O
)	O
in	O
10	O
patients	O
(	O
77	O
%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
reduced	O
sweating	O
)	O
in	O
3	O
patients	O
(	O
23	O
%	O
)	O
.	O

The	O
reaction	O
was	O
incubated	O
overnight	O
at	O
65	O
deg	O
C	O
for	O
Taq	O
a	O
I	O
and	O
37	O
deg	O
C	O
for	O
MslI	O
and	O
EcoRV	O
.	O

Tetramers	O
composed	O
of	O
purely	O
wild	O
-	O
type	O
monomers	O
in	O
this	O
family	O
would	O
occur	O
infrequently	O
(	O
1	O
/	O
16	O
)	O
.	O

The	O
PCDH15	B-GENE
gene	O
is	O
involved	O
in	O
11	O
%	O
-	O
19	O
%	O
[	O
9	O
,	O
11	O
-	O
13	O
]	O
,	O
whereas	O
the	O
remaining	O
USH1	B-DISEASE
genes	O
play	O
a	O
minor	O
role	O
in	O
the	O
disease	O
,	O
its	O
prevalence	O
lower	O
than	O
10	O
%	O
[	O
9	O
,	O
11	O
,	O
14	O
,	O
15	O
]	O
.	O

Splice	O
-	O
site	O
finder	O
:	O
if	O
wt	O
>	O
50	O
and	O
mut	O
<	O
50	O
,	O
then	O
the	O
prediction	O
is	O
"	O
pathogenic	O
.	O

After	O
a	O
median	O
follow	O
-	O
up	O
of	O
22	O
months	O
,	O
the	O
median	O
progression	O
free	O
survival	O
rate	O
was	O
7	O
months	O
,	O
and	O
the	O
median	O
survival	O
time	O
was	O
16	O
months	O
.	O

Further	O
population	O
-	O
based	O
and	O
functional	O
studies	O
are	O
recommended	O
.	O

a	O
,	O
this	O
study	O
.	O

Identification	O
of	O
causative	O
genes	O
for	O
hereditary	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
NSHL	B-DISEASE
)	O
is	O
important	O
to	O
decide	O
treatment	O
modalities	O
and	O
to	O
counsel	O
the	O
patients	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
study	O
groups	O
included	O
65	O
women	O
with	O
OAB	B-DISEASE
and	O
20	O
without	O
bladder	O
symptoms	O
who	O
served	O
as	O
controls	O
.	O

In	O
addition	O
,	O
mutations	O
in	O
three	O
corresponding	O
genes	O
(	O
usherin	O
USH2A	B-GENE
[	O
14	O
]	O
,	O
G	O
protein	O
-	O
coupled	O
receptor	O
98	O
;	O
GPR98	B-GENE
[	O
15	O
]	O
,	O
and	O
deafness	B-DISEASE
,	O
autosomal	O
recessive	O
31	O
;	O
DFNB31	B-GENE
[	O
16	O
]	O
)	O
have	O
been	O
reported	O
so	O
far	O
in	O
USH2	B-DISEASE
,	O
and	O
USH3	B-DISEASE
is	O
caused	O
by	O
mutations	O
in	O
the	O
clarin	O
1	O
(	O
CLRN1	B-GENE
)	O
[	O
17	O
]	O
gene	O
.	O

CaCl2	B-Chemical
therapy	O
may	O
possibly	O
worsen	O
both	O
cardiovascular	B-DISEASE
and	O
central	O
nervous	I-DISEASE
system	I-DISEASE
toxicity	I-DISEASE
.	O

Next	O
,	O
6	O
ul	O
of	O
mineral	O
oil	O
(	O
Sigma	O
,	O
St	O
.	O

4	O
)	O
.	O

WES	O
identified	O
2	O
novel	O
and	O
2	O
known	O
pathogenic	O
COL4A3	B-GENE
/	O
COL4A4	B-GENE
/	O
COL4A5	B-GENE
mutations	O
in	O
3	O
families	O
with	O
previously	O
unexplained	O
inherited	O
kidney	B-DISEASE
disease	I-DISEASE
.	O

He	O
had	O
been	O
well	O
until	O
the	O
morning	O
of	O
presentation	O
when	O
he	O
took	O
1	O
/	O
2	O
tab	O
of	O
venlafaxine	B-Chemical
.	O

The	O
size	O
-	O
selected	O
,	O
adapter	O
-	O
modified	O
DNA	O
fragments	O
were	O
amplified	O
using	O
adapter	O
-	O
specific	O
primers	O
1	O
.	O
1	O
and	O
2	O
.	O
1	O
with	O
Phusion	O
DNA	O
polymerase	O
using	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

It	O
provides	O
molecular	O
insights	O
for	O
clinical	O
genetic	O
diagnosis	O
and	O
treatment	O
of	O
optic	B-DISEASE
atrophy	I-DISEASE
.	O

The	O
absence	O
of	O
adrenal	B-DISEASE
hyperplasia	I-DISEASE
by	O
CT	O
scan	O
in	O
subject	O
1555	O
-	O
1	O
at	O
age	O
9	O
is	O
noteworthy	O
.	O

KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
was	O
not	O
found	O
in	O
ESP	O
6500	O
and	O
was	O
regarded	O
as	O
a	O
pathogenic	O
SNV	O
by	O
1000	O
Genomes	O
.	O

Although	O
statins	B-Chemical
are	O
generally	O
well	O
-	O
tolerated	O
drugs	O
,	O
recent	O
cases	O
of	O
drug	B-DISEASE
-	O
induced	O
liver	B-DISEASE
injury	I-DISEASE
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

None	O
of	O
the	O
affected	O
family	O
members	O
reported	O
hearing	O
or	O
visual	O
impairment	O
.	O

Taqman	O
probes	O
used	O
for	O
real	O
time	O
relative	O
expression	O
analysis	O
of	O
ELMOD3	B-GENE
/	O
Elmod3	B-GENE
isoforms	O
.	O

The	O
study	O
is	O
designed	O
as	O
a	O
retrospective	O
observational	O
case	O
series	O
.	O

The	O
location	O
of	O
the	O
AIFM1	B-GENE
gene	O
is	O
indicated	O
(	O
Mb	O
,	O
million	O
bps	O
)	O
.	O

There	O
is	O
evidence	O
that	O
variations	O
in	O
genes	O
encoding	O
ion	O
channel	O
subunits	O
are	O
associated	O
with	O
familial	O
predisposition	O
for	O
AF	B-DISEASE
.	O

Those	O
with	O
point	O
mutations	O
displayed	O
goiter	B-DISEASE
18	O
)	O
,	O
unilateral	O
megaencephaly	B-DISEASE
with	O
seizures	B-DISEASE
19	O
)	O
,	O
familial	B-DISEASE
urological	I-DISEASE
abnormalities	I-DISEASE
12	O
)	O
,	O
bilateral	O
cataracts	B-DISEASE
,	O
basal	B-DISEASE
ganglia	I-DISEASE
calcification	I-DISEASE
,	O
and	O
psoriasis	B-DISEASE
20	O
)	O
.	O

He	O
had	O
no	O
personal	O
or	O
familial	O
history	O
of	O
a	O
bleeding	B-DISEASE
tendency	O
.	O

If	O
no	O
candidate	O
variants	O
were	O
found	O
,	O
the	O
23	O
genes	O
responsible	O
for	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
subjected	O
to	O
the	O
same	O
procedures	O
.	O

Both	O
parents	O
(	O
SH23	B-Chemical
-	O
97	O
and	O
SH23	O
-	O
54	O
)	O
showed	O
normal	O
hearing	O
,	O
indicating	O
autosomal	B-DISEASE
recessive	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
(	O
Fig	O
.	O

In	O
the	O
inner	O
ears	O
of	O
mice	O
and	O
rats	O
,	O
USH2A	B-GENE
isoform	O
b	O
is	O
a	O
component	O
of	O
the	O
ankle	O
links	O
that	O
connect	O
the	O
differentiating	O
stereocilia	O
of	O
the	O
hair	O
cells	O
[	O
9	O
]	O
.	O

ILM	O
:	O
inner	O
limiting	O
membrane	O
;	O
RPE	O
:	O
retinal	O
pigment	O
epithelium	O
.	O

Among	O
Ashkenazi	O
Jews	O
,	O
the	O
single	O
mutation	O
c	B-VARIANT
.	I-VARIANT
144T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
)	O
is	O
responsible	O
for	O
approximately	O
40	O
%	O
of	O
USH	B-DISEASE
cases	O
,	O
which	O
means	O
virtually	O
100	O
%	O
of	O
the	O
USH3	B-DISEASE
cases	O
in	O
the	O
Ashkenazi	O
population	O
[	O
19	O
]	O
.	O

We	O
identified	O
the	O
homopolymer	O
regions	O
,	O
defined	O
as	O
6	O
or	O
more	O
repeats	O
of	O
the	O
same	O
base	O
,	O
located	O
in	O
the	O
exonic	O
regions	O
of	O
the	O
15	O
deafness	B-DISEASE
genes	O
(	O
Table	O
1	O
)	O
.	O

AIM	O
:	O
To	O
report	O
a	O
case	O
of	O
optic	B-DISEASE
and	I-DISEASE
peripheral	I-DISEASE
neuropathy	I-DISEASE
after	O
chronic	O
use	O
of	O
disulfiram	B-Chemical
for	O
alcohol	O
dependence	O
management	O
.	O

DFNB31	B-GENE
encodes	O
the	O
post	B-GENE
synaptic	I-GENE
density	I-GENE
protein	I-GENE
(	O
PSD95	B-GENE
)	O
,	O
Drosophila	B-GENE
disc	I-GENE
large	I-GENE
tumor	I-GENE
suppressor	I-GENE
(	O
Dlg1	B-GENE
)	O
,	O
and	O
zonula	B-GENE
occludens	I-GENE
-	I-GENE
1	I-GENE
protein	I-GENE
(	O
ZO	B-GENE
-	I-GENE
1	I-GENE
)	O
(	O
PDZ	O
)	O
domain	O
-	O
containing	O
scaffold	O
protein	O
,	O
whirlin	B-GENE
.	O

Here	O
we	O
investigated	O
57	O
Greek	O
-	O
Cypriot	O
families	O
presenting	O
glomerular	B-DISEASE
microscopic	I-DISEASE
hematuria	I-DISEASE
(	O
GMH	B-DISEASE
)	O
,	O
with	O
or	O
without	O
proteinuria	B-DISEASE
or	O
chronic	O
kidney	O
function	O
decline	O
,	O
but	O
excluded	O
classical	O
AS	B-DISEASE
.	O

As	O
WES	O
typically	O
identifies	O
many	O
thousands	O
of	O
exomic	O
variants	O
,	O
a	O
selection	O
strategy	O
is	O
important	O
to	O
facilitate	O
the	O
identification	O
of	O
the	O
mutation	O
that	O
causes	O
the	O
disease	O
[	O
13	O
,	O
14	O
]	O
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions	O
,	O
total	O
serum	O
cholesterol	B-Chemical
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice	O
.	O

An	O
arginine	B-Chemical
residue	O
at	O
position	O
177	O
is	O
evolutionarily	O
conserved	O
among	O
Wolframin	O
proteins	O
in	O
several	O
species	O
,	O
indicating	O
its	O
biologic	O
significance	O
.	O

It	O
is	O
also	O
expressed	O
in	O
skeletal	O
muscle	O
,	O
heart	O
,	O
liver	O
,	O
spleen	O
,	O
lung	O
and	O
kidney	O
.	O

The	O
specific	O
positioning	O
of	O
TJs	O
at	O
the	O
apical	O
part	O
of	O
the	O
lateral	O
membrane	O
enables	O
them	O
to	O
play	O
critical	O
roles	O
as	O
both	O
zippers	O
that	O
seal	O
intercellular	O
spaces	O
tightly	O
[	O
2	O
]	O
and	O
as	O
barriers	O
that	O
regulate	O
ion	O
-	O
and	O
size	O
-	O
selective	O
paracellular	O
permeability	O
in	O
epithelial	O
cells	O
[	O
35	O
-	O
]	O
.	O

Data	O
provided	O
here	O
served	O
as	O
a	O
basis	O
to	O
explain	O
how	O
CNVs	O
disrupt	O
normal	O
functions	O
of	O
deafness	B-DISEASE
genes	O
.	O

DOA	B-DISEASE
exhibits	O
marked	O
inter	O
-	O
and	O
intrafamilial	O
variable	O
phenotypes	O
[	O
9	O
,	O
12	O
,	O
13	O
]	O
;	O
for	O
instance	O
,	O
about	O
25	O
%	O
of	O
patients	O
were	O
found	O
to	O
have	O
optic	B-DISEASE
atrophy	I-DISEASE
with	O
fundus	O
examination	O
but	O
without	O
a	O
complaint	O
of	O
visual	O
deterioration	O
[	O
11	O
,	O
14	O
]	O
.	O

This	O
cardioprotection	B-DISEASE
is	O
accompanied	O
by	O
decreased	O
cardiac	B-DISEASE
oxidative	I-DISEASE
stress	O
and	O
triglycerides	B-Chemical
and	O
increased	O
cardiac	O
fatty	O
-	O
acid	O
oxidation	O
,	O
ATP	B-Chemical
synthesis	O
,	O
and	O
upregulated	O
JAK	O
/	O
STAT3	B-GENE
pathway	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
This	O
is	O
the	O
first	O
reported	O
case	O
of	O
central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
after	O
treatment	O
with	O
CC	B-Chemical
.	O

Apomorphine	B-Chemical
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
.	O

Animals	O
were	O
evaluated	O
for	O
parkinsonian	B-DISEASE
disability	O
,	O
dyskinesia	B-DISEASE
and	O
on	O
-	O
time	O
(	O
motor	B-DISEASE
fluctuations	I-DISEASE
)	O
and	O
neuropsychiatric	B-DISEASE
-	I-DISEASE
like	I-DISEASE
behaviors	I-DISEASE
on	O
Day	O
0	O
(	O
prior	O
to	O
levodopa	B-Chemical
)	O
and	O
on	O
Days	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
treatment	O
using	O
post	O
hoc	O
DVD	O
analysis	O
by	O
a	O
trained	O
rater	O
,	O
blind	O
to	O
the	O
treatment	O
day	O
.	O

Several	O
of	O
the	O
substitution	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
V116M	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
G243R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
C386R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
V372M	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R445C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R63W	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R89H	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R620C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
D918N	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
E1701K	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S2527L	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
E31G	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R84W	I-VARIANT
)	O
were	O
predicted	O
to	O
have	O
severe	O
detrimental	O
effects	O
by	O
SIFT	O
and	O
POLYPHEN	O
analysis	O
(	O
Table	O
2	O
)	O
.	O

The	O
arrow	O
points	O
to	O
the	O
region	O
of	O
retinal	O
thinning	O
in	O
patient	O
'	O
s	O
macula	O
.	O

Figure	O
5	O
shows	O
the	O
recordings	O
obtained	O
at	O
100	O
dB	O
SPL	O
from	O
one	O
control	O
subject	O
with	O
normal	O
hearing	O
and	O
two	O
representative	O
OPA1	B-GENE
-	O
M	O
patients	O
in	O
response	O
to	O
the	O
click	O
stimulation	O
sequence	O
reported	O
at	O
the	O
bottom	O
of	O
the	O
graph	O
.	O

(	O
C	O
)	O
Intra	O
oral	O
view	O
,	O
with	O
high	B-DISEASE
arched	I-DISEASE
palate	I-DISEASE
in	O
proband	O
1	O
(	O
1C	O
)	O
,	O
2	O
(	O
2C	O
)	O
,	O
3	O
(	O
3C	O
)	O
and	O
5	O
(	O
5C	O
)	O
;	O
(	O
D	O
)	O
Patients	O
feet	O
.	O

The	O
first	O
case	O
involved	O
a	O
59	O
-	O
year	O
-	O
old	O
man	O
who	O
used	O
Dormex	B-Chemical
,	O
which	O
contains	O
hydrogen	B-Chemical
cyanamide	I-Chemical
,	O
without	O
protection	O
after	O
consuming	O
a	O
large	O
amount	O
of	O
alcohol	B-Chemical
during	O
a	O
meal	O
.	O

Genomic	O
DNA	O
was	O
immediately	O
isolated	O
from	O
these	O
samples	O
using	O
standard	O
techniques	O
.	O

Mulheisen	O
for	O
their	O
technical	O
assistance	O
and	O
discussion	O
of	O
the	O
results	O
.	O

The	O
library	O
was	O
purified	O
prior	O
to	O
quantification	O
using	O
an	O
Agilent	O
2100	O
Bioanalyzer	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
+	O
-	O
s	O
.	O
e	O
.	O
m	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Using	O
whole	O
exome	O
sequencing	O
,	O
we	O
identified	O
a	O
missense	O
variant	O
(	O
c	B-VARIANT
.	I-VARIANT
130C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R44C	I-VARIANT
)	O
in	O
the	O
MCM2	B-GENE
gene	O
,	O
which	O
has	O
a	O
pro	O
-	O
apoptosis	O
effect	O
and	O
is	O
involved	O
in	O
the	O
initiation	O
of	O
eukaryotic	O
genome	O
replication	O
.	O

At	O
least	O
eight	O
members	O
of	O
this	O
family	O
presented	O
with	O
diabetes	B-DISEASE
with	O
age	O
of	O
diagnosis	O
ranging	O
from	O
18	O
to	O
51	O
years	O
and	O
a	O
pattern	O
suggesting	O
autosomal	O
dominant	O
inheritance	O
.	O

Comparison	O
between	O
the	O
MYO7A	B-GENE
group	O
and	O
CDH23	B-GENE
group	O
,	O
MYO7A	B-GENE
and	O
Control	O
group	O
and	O
CDH23	B-GENE
group	O
and	O
Control	O
group	O
.	O

Macular	O
thickness	O
:	O
RE	O
274	O
mu	O
m	O
,	O
LE	O
260	O
mu	O
m	O
.	O

Of	O
the	O
3	O
,	O
635	O
exome	O
-	O
wide	O
truncation	O
variants	O
,	O
84	O
and	O
10	O
germline	O
variants	O
matched	O
precisely	O
or	O
within	O
+	O
-	O
5	O
amino	O
acids	O
to	O
reported	O
variants	O
in	O
COSMIC	O
and	O
OMIM	O
,	O
respectively	O
(	O
Supplementary	O
Data	O
11	O
)	O
.	O

The	O
haplotypes	O
in	O
Slovak	O
(	O
SK	O
)	O
,	O
Czech	O
(	O
CZ	O
)	O
,	O
Hungarian	O
(	O
HU	O
)	O
Roma	O
and	O
Pakistani	O
patients	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
,	O
and	O
haplotypes	O
in	O
Slovak	O
Roma	O
controls	O
without	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
.	O

Patients	O
with	O
a	O
single	O
mutation	O
on	O
the	O
above	O
four	O
exons	O
were	O
screened	O
for	O
the	O
other	O
exons	O
in	O
SLC26A4	B-GENE
.	O

Unlike	O
general	O
toxicity	O
data	O
,	O
their	O
prenatal	O
toxic	O
effects	O
were	O
not	O
extensively	O
studied	O
before	O
.	O

Prevalence	O
of	O
non	O
-	O
syndromic	O
RP	B-DISEASE
is	O
approximately	O
1	O
in	O
4	O
,	O
000	O
[	O
3	O
]	O
.	O

Alpha	O
-	O
tectorin	I-Chemical
is	O
the	O
most	O
important	O
noncollagenous	O
component	O
of	O
the	O
tectorial	O
membrane	O
and	O
the	O
otolith	O
membrane	O
in	O
the	O
maculae	O
of	O
the	O
vestibular	O
system	O
.	O

Out	O
of	O
a	O
total	O
of	O
88	O
courses	O
of	O
this	O
treatment	O
we	O
observed	O
10	O
episodes	O
of	O
asymptomatic	O
microscopic	B-DISEASE
haematuria	I-DISEASE
and	O
no	O
episodes	O
of	O
gross	O
haematuria	O
.	O

To	O
minimize	O
the	O
number	O
of	O
variants	O
tied	O
with	O
ancestral	O
origins	O
,	O
only	O
missense	O
germline	O
variants	O
from	O
individuals	O
classified	O
as	O
Caucasian	O
by	O
Plink	O
were	O
used	O
for	O
downstream	O
significance	O
testing	O
.	O

All	O
frame	O
shift	O
mutations	O
,	O
nonsense	O
mutations	O
,	O
and	O
mutations	O
of	O
the	O
first	O
two	O
nucleotides	O
of	O
canonical	O
intron	O
splice	O
acceptor	O
or	O
donor	O
sites	O
have	O
been	O
classified	O
as	O
pathogenic	O
.	O

N	O
.	O
C	O
.	O
,	O
J	O
.	O
R	O
.	O
H	O
.	O

Two	O
of	O
the	O
unrelated	O
fetuses	O
had	O
de	O
novo	O
missense	O
mutations	O
in	O
PARD3B	B-GENE
.	O

B	O
Sequence	O
of	O
the	O
transcript	O
derived	O
from	O
the	O
c	B-VARIANT
.	I-VARIANT

The	O
rats	O
treated	O
with	O
DFP	B-Chemical
-	O
atropine	B-Chemical
showed	O
severe	O
typical	O
OP	B-Chemical
-	O
induced	O
toxicity	O
signs	O
.	O

The	O
biological	O
criteria	O
comprise	O
presence	O
in	O
the	O
literature	O
and	O
databases	O
,	O
frequency	O
in	O
control	O
DNAs	O
,	O
and	O
allelic	O
position	O
.	O

Missplicing	O
percentages	O
were	O
measured	O
using	O
the	O
Alpha	O
Imager	O
2200	O
(	O
version	O
3	O
.	O
1	O
.	O
2	O
)	O
software	O
(	O
AlphaInnotech	O
Corporation	O
,	O
San	O
Francisco	O
,	O
CA	O
,	O
USA	O
)	O
.	O

(	O
Figure	O
3	O
)	O
.	O

The	O
y	O
-	O
axis	O
gives	O
the	O
R	O
CNV	O
ratio	O
calculated	O
for	O
CNVs	O
.	O

Thereby	O
,	O
a	O
clinical	O
study	O
of	O
the	O
combined	O
administration	O
of	O
the	O
two	O
agents	O
was	O
attempted	O
.	O

(	O
B	O
-	O
C	O
)	O
In	O
the	O
vestibular	O
end	O
organs	O
,	O
ELMOD3	B-GENE
immunostaining	O
was	O
localized	O
within	O
the	O
hair	O
cell	O
and	O
supporting	O
cell	O
bodies	O
in	O
the	O
saccule	O
(	O
B	O
)	O
and	O
utricule	O
(	O
C	O
)	O
at	O
P14	O
,	O
but	O
no	O
immunoreactivity	O
was	O
observed	O
in	O
the	O
vestibular	O
hair	O
bundles	O
.	O

The	O
cDNA	O
sequences	O
for	O
otogelin	B-GENE
and	O
Tecta	B-GENE
predict	O
large	O
,	O
modular	O
glycoproteins	O
(	O
313	O
and	O
239	O
kDa	O
respectively	O
)	O
,	O
whilst	O
the	O
sequence	O
for	O
Tectb	B-GENE
encodes	O
a	O
much	O
smaller	O
protein	O
(	O
36	O
kDa	O
)	O
.	O

Alternatively	O
,	O
it	O
is	O
possible	O
that	O
disease	O
-	O
causing	O
mutations	O
are	O
restrictively	O
distributed	O
in	O
genes	O
because	O
they	O
can	O
only	O
disrupt	O
biological	O
function	O
in	O
limited	O
ways	O
or	O
would	O
otherwise	O
be	O
nonviable	O
.	O

Family	O
1	O
.	O

The	O
underlying	O
pathology	O
of	O
glucocorticoid	O
-	I-DISEASE
induced	O
glaucoma	I-DISEASE
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lack	O
of	O
an	O
appropriate	O
animal	O
model	O
.	O

Scale	O
bar	O
:	O
10	O
u	O
m	O
.	O

Indels	O
were	O
identified	O
from	O
within	O
unaligned	O
reads	O
,	O
and	O
were	O
supported	O
by	O
>	O
=	O
10	O
unaligned	O
reads	O
on	O
each	O
strand	O
that	O
contained	O
an	O
insertion	O
/	O
deletion	O
preceding	O
an	O
exact	O
20bp	O
match	O
to	O
a	O
targeted	O
exon	O
,	O
excluding	O
indels	O
adjacent	O
to	O
homopolymer	O
runs	O
(	O
see	O
Supplementary	O
Note	O
)	O
.	O

Resting	O
forearm	O
vascular	O
resistance	O
remained	O
unchanged	O
,	O
but	O
the	O
reflex	O
response	O
to	O
the	O
cold	O
pressor	O
test	O
was	O
accentuated	O
,	O
the	O
rise	O
in	O
resistance	O
increasing	O
from	O
10	O
.	O
5	O
mm	O
Hg	O
/	O
ml	O
/	O
100	O
ml	O
/	O
min	O
(	O
R	O
units	O
)	O
before	O
treatment	O
to	O
32	O
.	O
6	O
R	O
units	O
after	O
treatment	O
(	O
SED	O
+	O
/	O
-	O
6	O
.	O
4	O
,	O
p	O
less	O
than	O
0	O
.	O
025	O
)	O
.	O

In	O
patients	O
with	O
HDR	B-DISEASE
syndrome	I-DISEASE
,	O
hypoparathyroidism	B-DISEASE
can	O
be	O
asymptomatic	O
,	O
but	O
can	O
also	O
present	O
as	O
sensory	B-DISEASE
problems	I-DISEASE
,	O
myalgia	B-DISEASE
,	O
and	O
hypocalcemia	B-DISEASE
severe	O
enough	O
to	O
cause	O
seizures	B-DISEASE
.	O

To	O
this	O
aim	O
,	O
36	O
families	O
(	O
with	O
at	O
least	O
four	O
available	O
samples	O
)	O
affected	O
with	O
retinal	B-DISEASE
dystrophies	I-DISEASE
(	O
Retinitis	B-DISEASE
Pigmentosa	I-DISEASE
,	O
Leber	B-DISEASE
Congenital	I-DISEASE
Amaurosis	I-DISEASE
,	O
Cone	B-DISEASE
-	I-DISEASE
rod	I-DISEASE
Dystrophy	I-DISEASE
or	O
Cone	B-DISEASE
Dystrophy	I-DISEASE
)	O
were	O
analyzed	O
with	O
our	O
optimized	O
in	O
house	O
RD	B-DISEASE
-	O
chip	O
that	O
genotyped	O
768	O
SNP	O
markers	O
spanning	O
the	O
100	O
most	O
prevalent	O
RD	B-DISEASE
genes	O
reported	O
at	O
that	O
moment	O
(	O
Figure	O
1	O
)	O
.	O

The	O
most	O
prevalent	O
USH2A	B-GENE
mutation	O
in	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
RP	I-DISEASE
,	O
p	B-VARIANT
.	I-VARIANT
C759F	I-VARIANT
[	O
32	O
]	O
,	O
[	O
41	O
]	O
,	O
was	O
also	O
present	O
in	O
three	O
families	O
of	O
our	O
cohort	O
.	O

All	O
detected	O
mutations	O
result	O
in	O
a	O
truncated	O
protein	O
;	O
deleterious	O
missense	O
mutations	O
were	O
not	O
found	O
.	O

Bait	O
generation	O
and	O
library	O
preparation	O
were	O
done	O
using	O
the	O
eArray	B-Chemical
tool	O
provided	O
by	O
the	O
manufacturer	O
(	O
Agilent	O
technologies	O
,	O
(	O
https	O
:	O
/	O
/	O
earray	O
.	O
chem	O
.	O
agilent	B-Chemical
.	O
com	O
/	O
earray	O
)	O
)	O
.	O

Sanger	O
sequencing	O
confirmed	O
one	O
novel	O
missense	O
variant	O
in	O
the	O
second	O
longest	O
autozygous	O
region	O
on	O
chr8	O
(	O
76476256A	B-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
in	O
HNF4G	B-GENE
(	O
MIM	O
605966	O
)	O
and	O
one	O
novel	O
missense	O
variant	O
in	O
the	O
third	O
longest	O
autozygous	O
region	O
on	O
chr19	O
(	O
2917947C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
in	O
ZNF57	B-GENE
(	O
no	O
MIM	O
number	O
available	O
)	O
(	O
nucelotide	O
numbers	O
are	O
according	O
to	O
Hg19	O
)	O
.	O

Deletions	O
and	O
selected	O
SNVs	O
were	O
validated	O
by	O
Sanger	O
resequencing	O
,	O
performed	O
on	O
genomic	O
DNA	O
,	O
using	O
ABI	O
3130XL	O
and	O
BigDye	O
v3	O
.	O
1	O
Terminators	O
(	O
Applied	O
Biosystems	O
)	O
as	O
per	O
manufacturer	O
'	O
s	O
protocols	O
.	O

10	O
)	O
.	O

His	O
vision	O
was	O
6	O
/	O
15	O
and	O
2	O
/	O
60	O
in	O
the	O
right	O
and	O
left	O
eyes	O
,	O
respectively	O
.	O

METHODS	O
:	O
Urinary	O
pH	O
,	O
albumin	O
,	O
creatinine	B-Chemical
,	O
the	O
presence	O
of	O
erythrocytes	O
,	O
leukocytes	O
,	O
bacteria	O
and	O
crystals	O
,	O
and	O
culture	O
were	O
analyzed	O
every	O
3	O
months	O
for	O
96	O
weeks	O
.	O

Lithium	B-Chemical
also	O
caused	O
proteinuria	B-DISEASE
and	O
systolic	B-DISEASE
hypertension	I-DISEASE
in	O
absence	O
of	O
glomerulosclerosis	B-DISEASE
.	O

It	O
is	O
not	O
possible	O
to	O
say	O
which	O
is	O
most	O
likely	O
to	O
be	O
causative	O
,	O
as	O
none	O
of	O
the	O
candidate	O
genes	O
are	O
known	O
to	O
harbor	O
variants	O
that	O
cause	O
the	O
exact	O
phenotype	O
reported	O
here	O
.	O

Homozygosity	O
mapping	O
is	O
an	O
efficient	O
tool	O
for	O
identifying	O
the	O
underlying	O
genetic	O
defects	O
in	O
such	O
families	O
.	O

(	O
A	O
)	O
Serial	O
cerebral	O
MRI	O
with	O
fluid	O
-	O
attenuated	O
inversion	O
recovery	O
sequence	O
demonstrates	O
normal	O
signal	O
intensity	O
in	O
bilateral	O
centrum	O
semiovale	O
(	O
left	O
panel	O
)	O
and	O
periventricular	O
and	O
subcortical	O
white	O
matter	O
(	O
right	O
panel	O
)	O
.	O

METHODS	O
:	O
All	O
patients	O
taking	O
Vigabatrin	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
other	O
antiepileptic	O
drugs	O
for	O
at	O
least	O
5	O
years	O
(	O
range	O
5	O
-	O
12	O
years	O
)	O
were	O
entered	O
into	O
a	O
visual	O
surveillance	O
programme	O
.	O

Sixty	O
-	O
five	O
trios	O
were	O
recruited	O
at	O
the	O
Genome	O
Sequencing	O
Clinic	O
at	O
Duke	O
University	O
Medical	O
Center	O
,	O
and	O
48	O
were	O
recruited	O
at	O
the	O
pediatric	O
clinic	O
of	O
the	O
Sheba	O
Medical	O
Center	O
in	O
Tel	O
HaShomer	O
,	O
Israel	O
.	O

Figure	O
S5	O
shows	O
representative	O
images	O
of	O
membrane	O
expression	O
patterns	O
of	O
the	O
10	O
mutant	O
pendrins	O
.	O

3	O
,	O
overlapping	O
audiograms	O
of	O
the	O
patients	O
with	O
only	O
one	O
mutation	O
was	O
similar	O
to	O
that	O
with	O
the	O
patients	O
with	O
two	O
mutations	O
(	O
high	O
frequency	O
involved	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
with	O
residual	O
hearing	O
at	O
the	O
lower	O
frequencies	O
)	O
.	O

Myotonia	B-DISEASE
congenita	I-DISEASE
(	O
MC	B-DISEASE
)	O
is	O
caused	O
by	O
a	O
defect	O
in	O
the	O
skeletal	O
muscle	O
chloride	B-Chemical
channel	O
function	O
,	O
which	O
may	O
cause	O
sustained	O
membrane	O
depolarisation	I-DISEASE
.	O

Since	O
both	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
alleles	O
appear	O
to	O
be	O
transcribed	O
,	O
we	O
counted	O
the	O
numbers	O
of	O
wild	O
type	O
and	O
mutant	O
clones	O
we	O
obtained	O
,	O
and	O
found	O
no	O
significant	O
difference	O
in	O
their	O
numbers	O
(	O
30	O
clones	O
of	O
wild	O
type	O
versus	O
22	O
mutant	O
)	O
(	O
Fig	O
.	O

The	O
complementary	O
deoxyribonucleic	O
acid	O
(	O
cDNA	O
)	O
sequence	O
of	O
COL2A1	B-GENE
was	O
obtained	O
from	O
GenBank	O
(	O
accession	O
no	O
.	O

Although	O
low	O
concentrations	O
(	O
less	O
than	O
or	O
equal	O
to	O
50	O
ppm	O
)	O
of	O
corticosterone	B-Chemical
had	O
beneficial	O
effects	O
on	O
TOTP	B-Chemical
-	O
induced	I-DISEASE
neuropathy	I-DISEASE
,	O
greater	O
than	O
or	O
equal	O
to	O
200	O
ppm	O
exacerbated	O
clinical	O
signs	O
in	O
chickens	O
given	O
either	O
TOTP	B-Chemical
or	O
DFP	B-Chemical
.	O

Intracerebroventricular	O
injection	O
of	O
atropine	B-Chemical
,	O
hexamethonium	B-Chemical
,	O
and	O
naloxone	B-Chemical
also	O
decreased	O
catalepsy	B-DISEASE
induced	O
by	O
morphine	B-Chemical
plus	O
nicotine	B-Chemical
.	O

reported	O
three	O
families	O
with	O
AVN	B-DISEASE
which	O
were	O
carriers	O
of	O
the	O
COL2A1	B-GENE
mutation	O
[	O
2	O
]	O
.	O

Between	O
March	O
2006	O
and	O
October	O
2009	O
,	O
the	O
department	O
of	O
Clinical	O
Genetics	O
in	O
Ume	O
a	O
was	O
to	O
our	O
knowledge	O
the	O
only	O
laboratory	O
in	O
Sweden	O
screening	O
the	O
LQTS	B-DISEASE
genes	O
.	O

The	O
high	O
success	O
rate	O
in	O
this	O
cohort	O
may	O
be	O
influenced	O
by	O
the	O
pediatric	B-DISEASE
focus	O
of	O
this	O
study	O
as	O
the	O
presentation	O
of	O
ataxia	B-DISEASE
in	O
this	O
patient	O
population	O
is	O
more	O
likely	O
to	O
be	O
due	O
to	O
autosomal	O
recessive	O
disease	O
,	O
hence	O
is	O
more	O
readily	O
detected	O
in	O
the	O
analysis	O
of	O
a	O
single	O
exome	O
than	O
a	O
dominant	O
disorder	O
.	O

One	O
of	O
the	O
patients	O
developed	O
cardiac	B-DISEASE
failure	O
after	O
30	O
mg	O
m	O
-	O
2	O
MMC	B-Chemical
and	O
only	O
150	O
mg	O
m	O
-	O
2	O
doxorubicin	B-Chemical
.	O

Partial	O
or	O
complete	O
loss	O
of	O
function	O
of	O
WFS1	B-GENE
protein	O
gives	O
rise	O
to	O
WS	B-DISEASE
,	O
whereas	O
missense	O
changes	O
in	O
the	O
COOH	O
-	O
terminal	O
domain	O
typically	O
cause	O
SNHI	B-DISEASE
(	O
Fig	O
.	O

The	O
patients	O
examined	O
in	O
this	O
study	O
underwent	O
a	O
screening	O
visit	O
at	O
the	O
diagnostic	O
centers	O
of	O
either	O
Trieste	O
or	O
Naples	O
that	O
included	O
a	O
basic	O
ophthalmic	O
consultation	O
,	O
central	O
visual	O
acuity	O
(	O
CVA	O
)	O
,	O
Goldman	O
visual	O
field	O
(	O
GVF	O
)	O
,	O
fundus	O
oculi	O
,	O
standard	O
electroretinography	O
(	O
ERG	O
)	O
,	O
and	O
a	O
series	O
of	O
periodic	O
control	O
visits	O
.	O

Diffusion	O
weighted	O
imaging	O
(	O
DWI	O
)	O
of	O
all	O
patients	O
revealed	O
well	O
demarcated	O
hyperintense	O
lesions	O
within	O
the	O
subcortical	O
white	O
matter	O
of	O
the	O
cerebral	O
hemispheres	O
and	O
the	O
corpus	O
callosum	O
,	O
corresponding	O
to	O
areas	O
of	O
decreased	O
proton	O
diffusion	O
on	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
maps	O
(	O
available	O
in	O
21	O
/	O
27	O
patients	O
)	O
.	O

In	O
these	O
families	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
could	O
be	O
due	O
to	O
mutations	O
in	O
non	O
-	O
captured	O
regions	O
of	O
genes	O
in	O
our	O
pools	O
or	O
by	O
as	O
-	O
yet	O
-	O
unknown	O
genes	O
.	O

Kannu	O
et	O
al	O
.	O

We	O
used	O
site	O
-	O
directed	O
mutagenesis	O
to	O
introduce	O
several	O
mutations	O
with	O
the	O
following	O
reasoning	O
:	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G1334E	I-VARIANT
)	I-VARIANT
was	O
previously	O
shown	O
to	O
induce	O
UPR	O
activation	O
[	O
19	O
]	O
and	O
served	O
as	O
a	O
positive	O
control	O
;	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G871C	I-VARIANT
)	I-VARIANT
is	O
a	O
founder	O
mutation	O
in	O
the	O
Cypriot	O
population	O
,	O
predisposing	O
to	O
severe	O
CRF	B-DISEASE
/	O
ESKD	B-DISEASE
(	O
ref	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
samples	O
using	O
a	O
FlexiGene	O
DNA	O
extraction	O
kit	O
(	O
QIAGEN	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

This	O
provides	O
for	O
the	O
first	O
time	O
quantitative	O
evidence	O
that	O
WS	O
can	O
cause	O
profound	O
vestibular	B-DISEASE
loss	I-DISEASE
in	O
a	O
subset	O
of	O
subjects	O
.	O

We	O
studied	O
the	O
effects	O
of	O
terbutaline	B-Chemical
on	O
microglial	O
activation	O
in	O
different	O
brain	O
regions	O
and	O
behavioral	O
outcomes	O
in	O
developing	O
rats	O
.	O

In	O
addition	O
to	O
the	O
concordant	O
variants	O
described	O
above	O
(	O
NGS	O
vs	O
.	O

Liver	O
transaminase	O
levels	O
were	O
normal	O
:	O
the	O
AST	O
level	O
was	O
23	O
mu	O
/	O
L	O
,	O
and	O
the	O
ALT	O
level	O
was	O
38	O
mu	O
/	O
L	O
.	O

Black	O
filled	O
symbols	O
represented	O
individuals	O
affected	O
with	O
WS1	B-DISEASE
in	O
each	O
family	O
.	O

The	O
local	O
Ethics	O
Committee	O
approved	O
molecular	O
analyses	O
and	O
consent	O
to	O
genetic	O
testing	O
was	O
obtained	O
from	O
adult	O
probands	O
or	O
parents	O
in	O
the	O
case	O
of	O
minors	O
.	O

We	O
did	O
not	O
use	O
a	O
filter	O
for	O
read	O
depth	O
and	O
included	O
even	O
variants	O
with	O
1	O
x	O
coverage	O
because	O
we	O
were	O
searching	O
for	O
homozygous	O
variants	O
.	O

These	O
data	O
were	O
confirmed	O
by	O
histology	O
.	O

In	O
the	O
first	O
subject	O
group	O
,	O
we	O
analyzed	O
a	O
total	O
of	O
621	O
probands	O
,	O
and	O
492	O
underwent	O
clinical	O
selection	O
for	O
CDH23	B-GENE
gene	O
testing	O
after	O
excluding	O
individuals	O
with	O
GJB2	B-GENE
mutations	O
and	O
mitochondrial	O
deafness	B-DISEASE
.	O

Neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
is	O
thought	O
to	O
be	O
a	O
result	O
of	O
dopamine	B-Chemical
D2	I-DISEASE
receptor	I-DISEASE
blockade	I-DISEASE
in	I-DISEASE
the	I-DISEASE
striatum	I-DISEASE
of	I-DISEASE
the	I-DISEASE
basal	O
ganglia	O
.	O

Hydroxytyrosol	B-Chemical
ameliorates	O
oxidative	O
stress	O
and	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
in	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-DISEASE
in	O
rats	O
with	O
breast	B-DISEASE
cancer	I-DISEASE
.	O

The	O
mutational	O
screening	O
of	O
CHI	B-DISEASE
causative	O
genes	O
is	O
usually	O
carried	O
out	O
by	O
PCR	O
amplifications	O
and	O
direct	O
Sanger	O
sequencing	O
,	O
using	O
an	O
iterative	O
approach	O
based	O
on	O
clinical	O
features	O
and	O
/	O
or	O
on	O
medical	O
treatment	O
response	O
[	O
2	O
]	O
.	O

His	O
medical	O
history	O
was	O
unremarkable	O
,	O
except	O
for	O
minor	O
fractures	O
of	O
the	O
fingers	O
and	O
foot	O
.	O

=	O
stimulating	O
electrode	O
number	O
;	O
NT	O
=	O
not	O
tested	O
.	O

The	O
MYH14	B-GENE
gene	O
was	O
identified	O
as	O
a	O
causal	O
gene	O
of	O
DFNA4	B-DISEASE
deafness	I-DISEASE
[	O
17	O
]	O
.	O

The	O
nonsense	O
c	B-VARIANT
.	I-VARIANT
16C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
was	O
previously	O
described	O
in	O
a	O
Pakistani	O
family	O
[	O
11	O
]	O
.	O

Additional	O
neuronanatomical	O
studies	O
,	O
including	O
cresyl	B-Chemical
violet	I-Chemical
staining	O
,	O
neuronal	B-DISEASE
degeneration	I-DISEASE
methods	O
,	O
and	O
histochemical	O
localization	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
suggested	O
that	O
the	O
decrease	O
in	O
the	O
number	O
of	O
GAD	B-GENE
mRNA	O
-	O
containing	O
neurons	O
was	O
related	O
to	O
neuronal	B-DISEASE
loss	I-DISEASE
rather	O
than	O
to	O
a	O
decrease	O
in	O
GAD	B-GENE
mRNA	O
levels	O
.	O

Among	O
the	O
113	O
human	O
cadherin	O
superfamily	O
members	O
,	O
CDH23	B-GENE
is	O
one	O
of	O
11	O
that	O
are	O
solely	O
responsible	O
for	O
hereditary	O
diseases	O
[	O
1	O
]	O
.	O

As	O
a	O
result	O
,	O
we	O
identified	O
a	O
homozygous	O
genotype	O
(	O
p	O
.	O
Leu440ArgfsTer19	B-Chemical
)	O
that	O
has	O
not	O
been	O
previously	O
reported	O
in	O
SPG49	B-DISEASE
patients	O
.	O

Each	O
run	O
yielded	O
at	O
least	O
3	O
.	O
4	O
Gb	O
of	O
high	O
-	O
quality	O
data	O
(	O
>	O
=	O
Q30	O
)	O
.	O

Screening	O
of	O
additional	O
families	O
in	O
a	O
relevant	O
population	O
was	O
performed	O
.	O

Following	O
placement	O
of	O
subcutaneous	O
electrodes	O
in	O
each	O
animal	O
'	O
s	O
left	O
gastrocnemius	O
muscle	O
,	O
rigidity	O
was	O
assessed	O
by	O
analyzing	O
root	O
-	O
mean	O
-	O
square	O
electromyographic	O
activity	O
.	O

WSD	B-DISEASE
patients	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
their	O
mean	O
HbA	O
1c	O
during	O
childhood	O
and	O
adolescence	O
:	O
one	O
group	O
consisting	O
of	O
probands	O
with	O
a	O
good	O
control	O
of	O
diabetes	B-DISEASE
,	O
as	O
evidenced	O
by	O
a	O
mean	O
HbA	O
1c	O
<	O
=	O
7	O
.	O
5	O
%	O
and	O
the	O
other	O
group	O
with	O
a	O
mean	O
HbA	O
1c	O
>	O
7	O
.	O
5	O
%	O
,	O
indicative	O
of	O
a	O
state	O
of	O
chronic	B-DISEASE
hyperglycemia	I-DISEASE
.	O

Expressions	O
of	O
the	O
myosin	O
-	O
VIIa	O
protein	O
in	O
the	O
cochlear	O
hair	O
cells	O
,	O
retinal	O
photoreceptors	O
,	O
and	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
have	O
been	O
detected	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
.	O

Next	O
we	O
prioritized	O
the	O
898	O
discovered	O
variants	O
to	O
focus	O
our	O
attention	O
on	O
those	O
that	O
are	O
likely	O
to	O
underlie	O
a	O
rare	O
and	O
devastating	O
phenotype	O
(	O
Figure	O
2a	O
)	O
.	O

Abbreviations	O
:	O
Hetero	O
,	O
Heterozygous	O
;	O
PrD	O
,	O
probably	O
damaging	O
;	O
SSA	O
,	O
splicing	O
site	O
abolished	O
;	O
D	O
,	O
damaging	O
;	O
T	O
,	O
tolerated	O
;	O
NA	O
,	O
not	O
analyzed	O
.	O

In	O
the	O
present	O
study	O
,	O
for	O
example	O
,	O
the	O
high	O
allele	O
frequency	O
of	O
USH2A	B-GENE
with	O
the	O
p	B-VARIANT
.	I-VARIANT
R449H	I-VARIANT
variant	O
in	O
Japanese	O
control	O
subjects	O
implied	O
that	O
pathogenicity	O
of	O
this	O
variant	O
was	O
unlikely	O
.	O

Screening	O
of	O
additional	O
Yemenite	O
Jewish	O
patients	O
revealed	O
a	O
total	O
of	O
16	O
homozygous	O
RP	B-DISEASE
patients	O
(	O
with	O
a	O
carrier	O
frequency	O
of	O
0	O
.	O
008	O
in	O
controls	O
)	O
.	O

In	O
conclusion	O
,	O
antitumor	O
activity	O
,	O
cardiotoxicity	B-DISEASE
,	O
and	O
nephrotoxicity	B-DISEASE
were	O
studied	O
simultaneously	O
in	O
the	O
same	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

These	O
results	O
show	O
that	O
curcumin	B-Chemical
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	O
of	O
cognitive	O
functions	O
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O

It	O
was	O
concluded	O
that	O
coenzyme	B-Chemical
Q10	I-Chemical
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	B-Chemical
nephrotoxicity	O
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O

In	O
vitro	O
analyses	O
were	O
performed	O
to	O
evaluate	O
the	O
functional	O
consequence	O
at	O
the	O
RNA	O
level	O
of	O
variant	O
c	B-VARIANT
.	I-VARIANT
14368C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
.	O

EPS8	B-GENE
-	I-GENE
3	I-GENE
F	O
forward	O
primer	O
:	O
5	O
'	O
-	O
CGTGGTGATTATAGTGCATTGG	O
-	O
3	O
'	O
and	O
EPS8	B-GENE
-	I-GENE
3R	I-GENE
reverse	O
primer	O
:	O
5	O
'	O
-	O
ATCACTGCCTCATTCCAAAC	O
-	O
3	O
'	O
were	O
used	O
to	O
amplify	O
and	O
sequence	O
EPS8	B-GENE
exon	O
3	O
.	O

HZ	O
,	O
JL	O
and	O
XZ	O
participated	O
in	O
data	O
analysis	O
.	O

Variants	O
observed	O
in	O
patient	O
3	O
The	O
variant	O
analysis	O
of	O
patient	O
4	O
revealed	O
a	O
new	O
homozygous	O
missense	O
mutation	O
in	O
the	O
OTOF	B-GENE
gene	O
(	O
exon	O
26	O
:	O
c	B-VARIANT
.	I-VARIANT
3263	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Leu1088Pro	I-VARIANT
)	O
)	O
.	O

Amphetamine	B-Chemical
treatment	O
significantly	O
disrupted	O
PPI	B-DISEASE
in	O
both	O
non	O
-	O
deprived	O
groups	O
,	O
but	O
was	O
absent	O
in	O
both	O
maternally	O
deprived	O
groups	O
.	O

TJ	O
carried	O
out	O
the	O
Splice	O
-	O
site	O
predictions	O
and	O
drafted	O
the	O
manuscript	O
.	O

All	O
variants	O
passing	O
filter	O
criteria	O
were	O
validated	O
with	O
Sanger	O
sequencing	O
to	O
confirm	O
familial	O
segregation	O
and	O
absence	O
in	O
the	O
control	O
population	O
.	O

DNA	O
samples	O
were	O
analyzed	O
for	O
sequence	O
variants	O
of	O
the	O
MYO7A	B-GENE
gene	O
(	O
for	O
USH1	B-DISEASE
)	O
and	O
the	O
USH2A	B-GENE
gene	O
(	O
for	O
USH2	B-DISEASE
)	O
with	O
direct	O
sequencing	O
techniques	O
.	O

In	O
addition	O
,	O
minor	O
EEG	O
abnormalities	O
occurred	O
.	O

We	O
conclude	O
that	O
phenytoin	B-Chemical
overdosage	O
does	O
not	O
necessarily	O
result	O
in	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	B-Chemical
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
in	O
the	O
remaining	O
patients	O
.	O

A	O
MYO15A	B-GENE
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
9478C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
L3160F	I-VARIANT
)	O
)	O
was	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

Similarly	O
,	O
heterozygous	O
carriers	O
of	O
WFS1	B-GENE
mutations	O
have	O
an	O
increased	O
incidence	O
of	O
psychiatric	B-DISEASE
disorders	I-DISEASE
including	O
endogenous	B-DISEASE
depression	I-DISEASE
,	O
suicide	B-DISEASE
attempts	I-DISEASE
,	O
short	B-DISEASE
-	I-DISEASE
term	I-DISEASE
memory	I-DISEASE
loss	I-DISEASE
,	O
and	O
anxiety	B-DISEASE
[	O
22	O
]	O
.	O

The	O
Homer2	B-GENE
-	O
/	O
-	O
colony	O
was	O
maintained	O
on	O
a	O
C57BL	O
/	O
6J	O
background	O
.	O

Among	O
them	O
,	O
28	O
patients	O
with	O
isolated	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
(	O
MD	B-DISEASE
group	O
)	O
,	O
50	O
patients	O
with	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
with	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
(	O
EVA	B-DISEASE
with	O
MD	B-DISEASE
group	O
)	O
,	O
50	O
patients	O
with	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
without	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
(	O
EVA	B-DISEASE
group	O
)	O
,	O
and	O
16	O
patients	O
with	O
other	O
types	O
of	O
inner	B-DISEASE
ear	I-DISEASE
malformations	I-DISEASE
(	O
IEM	B-DISEASE
group	O
)	O
were	O
identified	O
.	O

Confocal	O
microscopy	O
was	O
used	O
to	O
measure	O
intracellular	O
free	O
-	O
calcium	B-Chemical
concentrations	O
(	O
[	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
)	O
in	O
isolated	O
myocytes	O
.	O

Thirty	O
-	O
nine	O
(	O
48	O
%	O
)	O
of	O
these	O
mutations	O
,	O
i	O
.	O
e	O
.	O

ARK	O
contributed	O
to	O
DNA	O
preparation	O
and	O
Sanger	O
sequencing	O
.	O

In	O
three	O
patients	O
,	O
MYO7A	B-GENE
and	O
USH2A	B-GENE
sequencing	O
and	O
MLPA	O
analysis	O
detected	O
only	O
a	O
monoallelic	O
variant	O
(	O
one	O
MYO7A	B-GENE
and	O
two	O
USH2A	B-GENE
variants	O
)	O
while	O
in	O
five	O
patients	O
no	O
variant	O
of	O
both	O
genes	O
was	O
detected	O
.	O

Women	O
were	O
randomly	O
assigned	O
to	O
raloxifene	B-Chemical
60	O
mg	O
/	O
d	O
or	O
120	O
mg	O
/	O
d	O
or	O
placebo	O
.	O

The	O
SLC26A4	B-GENE
mutation	O
data	O
were	O
shown	O
in	O
Table	O
1	O
and	O
Table	O
2	O
.	O

We	O
report	O
the	O
first	O
two	O
cases	O
of	O
topiramate	B-Chemical
-	I-DISEASE
induced	I-DISEASE
nephrolithiasis	I-DISEASE
in	O
the	O
urologic	O
literature	O
.	O

OBJECTIVES	O
:	O
The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
examine	O
the	O
relationship	O
between	O
APOE	O
epsilon4	O
and	O
subjective	O
effects	O
of	O
trihexyphenidyl	B-Chemical
on	O
measures	O
reflecting	O
sedation	O
and	O
confusion	O
and	O
to	O
investigate	O
the	O
relationship	O
between	O
trihexyphenidyl	B-Chemical
-	O
induced	O
subjective	O
effects	O
and	O
objective	O
memory	O
performance	O
.	O

Conversely	O
,	O
brain	O
normetanephrine	B-Chemical
concentration	O
was	O
increased	O
from	O
saline	O
control	O
by	O
amantadine	B-Chemical
in	O
the	O
BALB	B-GENE
/	O
C	O
mice	O
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-DISEASE
or	O
ESRD	B-DISEASE
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

,	O
in	O
a	O
clinically	O
well	O
-	O
phenotyped	O
cohort	O
of	O
109	O
Scandinavian	O
patients	O
,	O
showed	O
that	O
10	O
%	O
had	O
monoallelic	O
mutations	O
.	O

Val	B-Chemical
e	O
ro	I-Chemical
described	O
a	O
French	O
family	O
with	O
the	O
same	O
missense	O
mutation	O
[	O
8	O
]	O
.	O

Mouse	O
inner	O
ear	O
tissues	O
were	O
harvested	O
from	O
3	O
or	O
more	O
C57BL	O
/	O
6J	O
mice	O
at	O
P0	O
,	O
P10	O
,	O
and	O
P30	O
.	O

Because	O
there	O
are	O
a	O
large	O
number	O
of	O
known	O
genes	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
we	O
first	O
genotyped	O
two	O
such	O
markers	O
at	O
each	O
site	O
,	O
then	O
added	O
additional	O
markers	O
as	O
necessary	O
.	O

On	O
the	O
test	O
day	O
(	O
day	O
10	O
)	O
,	O
mice	O
were	O
subjected	O
to	O
the	O
thermal	B-DISEASE
sensitivity	I-DISEASE
test	O
and	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O

(	O
2014b	O
)	O
)	O
,	O
mandating	O
comprehensive	O
TGE	O
+	O
MPS	O
and	O
thorough	O
data	O
analysis	O
.	O

In	O
comparison	O
,	O
the	O
cost	O
of	O
48	O
weeks	O
of	O
combination	O
therapy	O
is	O
16	O
,	O
459	O
.	O

In	O
addition	O
,	O
these	O
chips	O
are	O
designed	O
to	O
separately	O
test	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
autosomal	O
dominant	O
or	O
recessive	O
RP	B-DISEASE
genes	O
,	O
resulting	O
in	O
a	O
diagnostic	O
yield	O
for	O
autosomal	O
recessive	O
RP	B-DISEASE
of	O
only	O
~	O
10	O
%	O
[	O
A	O
vila	O
-	O
Fern	O
a	O
ndez	O
et	O
al	O
.	O
,	O
2010	O
]	O
.	O

Culture	O
medium	O
from	O
CEACAM16	B-GENE
-	O
transfected	O
cells	O
were	O
collected	O
and	O
centrifuged	O
at	O
4000	O
x	O
rpm	O
for	O
10	O
min	O
,	O
4	O
deg	O
C	O
,	O
and	O
filtered	O
through	O
0	O
.	O
22	O
mu	O
m	O
filters	O
,	O
then	O
centrifuged	O
at	O
14000	O
x	O
g	O
for	O
10	O
min	O
,	O
4	O
deg	O
C	O
.	O

Interactions	O
between	O
Sox10	B-GENE
,	O
Edn3	B-GENE
and	O
Ednrb	B-GENE
during	O
enteric	O
nervous	O
system	O
and	O
melanocyte	O
development	O
have	O
also	O
been	O
described	O
[	O
21	O
]	O
in	O
mice	O
.	O

Sanger	O
sequencing	O
was	O
not	O
able	O
to	O
verify	O
the	O
presence	O
of	O
rs11542733	B-VARIANT
in	O
CEPH	O
1341	I-Chemical
-	I-Chemical
13	I-Chemical
.	O

These	O
detection	O
rates	O
were	O
higher	O
among	O
all	O
the	O
studies	O
on	O
the	O
Asian	O
deaf	O
populations	O
to	O
date	O
[	O
6	O
,	O
10	O
,	O
45	O
,	O
46	O
,	O
48	O
]	O
.	O

HHL	B-DISEASE
can	O
be	O
conductive	O
(	O
involving	O
the	O
outer	O
ear	O
,	O
the	O
tympanic	O
membrane	O
or	O
the	O
middle	O
ear	O
)	O
and	O
/	O
or	O
sensorineural	O
which	O
involves	O
the	O
inner	O
ear	O
or	O
the	O
acoustic	O
nerve	O
[	O
2	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
femoral	O
head	O
epiphysis	O
closes	O
at	O
17	O
-	O
19	O
years	O
in	O
boys	O
and	O
at	O
15	O
-	O
17	O
years	O
in	O
girls	O
in	O
the	O
Chinese	O
population	O
.	O

Representative	O
Sanger	O
sequencing	O
trace	O
showing	O
heterozygous	O
missense	O
mutation	O
at	O
G6016T	O
(	O
arrow	O
)	O
from	O
patients	O
and	O
control	O
subjects	O
.	O

As	O
described	O
recently	O
,	O
abnormal	O
myosin	O
IIa	O
is	O
responsible	O
for	O
an	O
abnormal	O
distribution	O
of	O
granules	O
and	O
internal	O
membranes	O
in	O
both	O
platelets	O
and	O
megakaryocytes	O
(	O
Chen	O
et	O
al	O
.	O

For	O
family	O
PKDF406	B-Chemical
whole	O
exome	O
sequencing	O
analysis	O
used	O
a	O
genomic	O
DNA	O
sample	O
from	O
one	O
affected	O
individual	O
(	O
NimbleGen	B-Chemical
SeqCap	O
EZ	O
Exome	O
Library	O
v2	O
.	O
0	O
,	O
Roche	O
)	O
and	O
100bp	O
paired	O
-	O
end	O
sequencing	O
was	O
performed	O
on	O
an	O
Illumina	O
HiSeq2000	B-Chemical
instrument	O
.	O

Seizure	O
after	O
flumazenil	B-Chemical
administration	O
in	O
a	O
pediatric	O
patient	O
.	O

Mutations	O
of	O
USH1C	B-GENE
are	O
a	O
rare	O
cause	O
of	O
USH1	B-DISEASE
,	O
except	O
in	O
the	O
Acadian	O
population	O
,	O
which	O
segregates	O
a	O
founder	O
mutation	O
in	O
this	O
gene	O
[	O
13	O
,	O
19	O
,	O
20	O
]	O
.	O

Both	O
mutations	O
(	O
G25V	B-VARIANT
,	O
G60D	B-VARIANT
)	O
were	O
absent	O
in	O
216	O
matched	O
controls	O
,	O
in	O
publicly	O
available	O
databases	O
and	O
in	O
2276	O
exoms	O
from	O
the	O
Popgen	O
population	O
NHLBI	O
Exome	O
Sequencing	O
Project	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
supporting	O
that	O
these	O
variants	O
are	O
not	O
rare	O
polymorphisms	O
but	O
disease	O
causing	O
mutations	O
[	O
20	O
]	O
.	O

76bp	O
reads	O
were	O
aligned	O
to	O
the	O
genome	O
using	O
MAQ	O
algorithm	O
44	O
within	O
the	O
Picard	O
analysis	O
pipeline	O
,	O
and	O
further	O
processed	O
using	O
the	O
SAMtools	B-Chemical
software	O
45	O
and	O
custom	O
scripts	O
.	O

The	O
effect	O
of	O
sequence	O
variants	O
on	O
pre	O
-	O
mRNA	O
processing	O
was	O
assessed	O
in	O
silico	O
and	O
functionally	O
.	O

Within	O
the	O
linkage	O
region	O
,	O
the	O
only	O
gene	O
already	O
known	O
to	O
be	O
involved	O
in	O
NSHHL	B-DISEASE
,	O
MARVELD2	B-GENE
,	O
was	O
then	O
analysed	O
.	O

However	O
,	O
the	O
genetic	O
diagnosis	O
by	O
high	O
-	O
throughput	O
sequence	O
analysis	O
helps	O
clinicians	O
and	O
patients	O
to	O
delineate	O
the	O
characteristics	O
of	O
disease	O
.	O

At	O
discharge	O
,	O
she	O
had	O
complete	O
recovery	O
of	O
neurological	B-DISEASE
and	O
hepatic	B-DISEASE
functions	I-DISEASE
.	O

Nine	O
individuals	O
were	O
found	O
to	O
be	O
heterozygous	O
carriers	O
of	O
GJB2	B-GENE
pathogenic	O
mutations	O
;	O
three	O
had	O
the	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
three	O
had	O
the	O
c	B-VARIANT
.	I-VARIANT
299_c	I-VARIANT
.	I-VARIANT
300delAT	I-VARIANT
,	O
and	O
the	O
c	B-VARIANT
.	I-VARIANT
512_c	I-VARIANT
.	I-VARIANT
513insAACG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
E47X	I-VARIANT
mutation	O
have	O
been	O
detected	O
in	O
single	O
individuals	O
(	O
see	O
Supplemental	O
Table	O
3	O
)	O
.	O

Genotyping	O
of	O
all	O
26	O
family	O
members	O
with	O
DNA	O
available	O
confirmed	O
that	O
the	O
CD164	B-GENE
mutation	O
was	O
found	O
in	O
all	O
individuals	O
carrying	O
the	O
critical	O
haplotype	O
(	O
Fig	O
1A	O
and	O
1D	O
)	O
.	O

Steroid	B-Chemical
structure	O
and	O
pharmacological	O
properties	O
determine	O
the	O
anti	O
-	O
amnesic	O
effects	O
of	O
pregnenolone	B-Chemical
sulphate	I-Chemical
in	O
the	O
passive	O
avoidance	O
task	O
in	O
rats	O
.	O

Hemodynamic	O
parameters	O
and	O
lead	O
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	O
.	O

His	O
father	O
and	O
brother	O
carried	O
the	O
same	O
mutation	O
.	O

In	O
contrast	O
,	O
recessive	O
TECTA	B-GENE
mutations	O
cause	O
more	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
14	O
]	O
.	O

A	O
case	O
report	O
.	O

Fibrous	B-DISEASE
myopathy	I-DISEASE
is	O
a	O
common	O
,	O
well	O
-	O
known	O
side	O
effect	O
of	O
repeated	O
pentazocine	B-Chemical
injection	O
.	O

2010	O
)	O
.	O

This	O
effect	O
was	O
more	O
relevant	O
in	O
patients	O
treated	O
with	O
higher	O
doses	O
.	O

These	O
results	O
suggest	O
that	O
edaravone	B-Chemical
suppresses	O
streptomycin	B-Chemical
-	O
induced	O
vestibulotoxicity	O
.	O

He	O
complained	O
of	O
having	O
decreased	O
vision	O
for	O
several	O
years	O
.	O

Genetic	O
hearing	B-DISEASE
loss	I-DISEASE
has	O
been	O
estimated	O
to	O
be	O
responsible	O
for	O
more	O
than	O
half	O
of	O
congenital	O
bilateral	O
profound	O
deafness	B-DISEASE
cases	O
[	O
10	O
,	O
11	O
]	O
,	O
however	O
no	O
definitive	O
means	O
of	O
confirming	O
this	O
estimate	O
so	O
far	O
.	O

The	O
only	O
missense	O
mutation	O
of	O
p	B-VARIANT
.	I-VARIANT
T3936P	I-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
11806A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
replaces	O
a	O
polar	O
threonine	B-Chemical
with	O
a	O
nonpolar	O
hydrophobic	O
proline	B-Chemical
(	O
Figure	O
7	O
)	O
.	O

TMC1	B-GENE
mutations	O
seem	O
to	O
be	O
rather	O
common	O
causes	O
of	O
recessive	O
deafness	B-DISEASE
in	O
India	O
,	O
Pakistani	O
,	O
Turkish	O
,	O
and	O
Tunisian	O
families	O
[	O
15	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
25	O
]	O
.	O

Each	O
sample	O
had	O
more	O
than	O
98	O
.	O
0	O
%	O
targeted	O
regions	O
covered	O
.	O

Mutation	O
analysis	O
of	O
WFS1	B-GENE
in	O
families	O
with	O
DFNA6	B-DISEASE
/	I-DISEASE
14	I-DISEASE
revealed	O
that	O
the	O
identified	O
pathogenic	O
mutations	O
in	O
this	O
disorder	O
tend	O
to	O
be	O
non	O
-	O
inactivating	O
and	O
cluster	O
at	O
the	O
C	O
-	O
terminus	O
or	O
N	O
-	O
terminus	O
of	O
the	O
protein	O
domain	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
,	O
whereas	O
most	O
of	O
the	O
pathogenic	O
mutations	O
in	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
patients	O
are	O
distributed	O
over	O
the	O
entire	O
coding	O
region	O
and	O
are	O
often	O
inactivating	O
mutations	O
resulting	O
in	O
loss	O
of	O
function	O
of	O
the	O
encoded	O
protein	O
[	O
36	O
]	O
.	O

PCR	O
products	O
were	O
purified	O
by	O
digestion	O
with	O
Antartic	O
Phosphatase	O
and	O
Exonuclease	O
I	O
(	O
New	O
England	O
BioLabs	O
Inc	O
.	O
)	O
and	O
were	O
sequenced	O
in	O
both	O
directions	O
using	O
the	O
Applied	O
Biosystem	O
Big	O
Dye	O
Terminator	O
v3	O
.	O
1	O
Cycle	O
sequencing	O
kit	O
.	O

Thus	O
,	O
their	O
pathogenicity	O
cannot	O
be	O
determined	O
.	O

(	O
A	O
)	O
European	O
(	O
B	O
)	O
Central	O
Asian	O
(	O
C	O
)	O
East	O
Asian	O
(	O
D	O
)	O
African	O
(	O
E	O
)	O
African	O
-	O
European	O
(	O
F	O
)	O
Hispanic	O
(	O
G	O
)	O
Other	O
.	O

We	O
performed	O
whole	O
-	O
exome	O
sequencing	O
in	O
16	O
individuals	O
from	O
13	O
unrelated	O
small	O
families	O
with	O
ARNSHL	B-DISEASE
.	O

In	O
fact	O
,	O
inspection	O
of	O
the	O
crystal	O
structure	O
(	O
PDB	O
entry	O
name	O
1br2	O
for	O
chicken	O
smooth	O
muscle	O
myosin	O
)	O
shows	O
that	O
the	O
mutation	O
of	O
valine	B-Chemical
34	I-Chemical
to	O
a	I-Chemical
glycine	I-Chemical
affects	O
an	O
N	O
-	O
terminal	O
residue	O
of	O
a	O
small	O
domain	O
formed	O
by	O
two	O
short	O
beta	O
-	O
hairpins	O
that	O
pack	O
against	O
each	O
other	O
after	O
relative	O
rotation	O
of	O
an	O
approximately	O
90	O
deg	O
angle	O
(	O
Fig	O
.	O

Additionally	O
,	O
in	O
models	O
of	O
prolonged	B-DISEASE
status	I-DISEASE
epilepticus	I-DISEASE
the	O
pars	O
reticulata	O
of	O
substantia	O
nigra	I-DISEASE
(	O
SNR	B-DISEASE
)	O
suffers	O
from	O
a	O
massive	O
lesion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metabolic	O
derangement	I-DISEASE
and	O
hyperexcitation	O
developing	O
in	O
the	O
activated	O
SNR	O
.	O

The	O
attenuating	O
effect	O
of	O
carteolol	B-Chemical
hydrochloride	I-Chemical
,	O
a	O
beta	O
-	I-DISEASE
adrenoceptor	I-DISEASE
antagonist	O
,	O
on	O
neuroleptic	B-DISEASE
-	O
induced	O
catalepsy	O
in	O
rats	O
.	O

All	O
next	O
-	O
generation	O
sequencing	O
data	O
were	O
initially	O
processed	O
using	O
the	O
corresponding	O
instrument	O
software	O
.	O

The	O
amount	O
of	O
charge	O
conducted	O
by	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
/	O
KCNE1	B-GENE
-	O
WT	O
(	O
n	O
=	O
10	O
)	O
or	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
/	O
KCNE1	B-GENE
-	O
G60D	B-VARIANT
(	O
n	O
=	O
15	O
)	O
channels	O
in	O
the	O
first	O
130	O
ms	O
after	O
the	O
capacitive	O
spike	O
of	O
the	O
pulse	O
at	O
the	O
7th	O
second	O
was	O
calculated	O
and	O
normalized	O
to	O
the	O
charge	O
carried	O
at	O
60	O
bpm	O
(	O
Figure	O
4	O
)	O
.	O

In	O
the	O
present	O
"	O
two	O
step	O
"	O
screening	O
method	O
Invader	O
assay	O
is	O
first	O
performed	O
followed	O
by	O
direct	O
sequencing	O
.	O

They	O
are	O
forward	O
primer	O
(	O
5	O
'	O
-	O
GTTGAACAACAGGCTGATAG	O
-	O
3	O
'	O
)	O
and	O
reverse	O
primer	O
(	O
5	O
'	O
-	O
GCTTGATATCCACTGTGGTG	O
-	O
3	O
'	O
)	O
.	O

Wrote	O
the	O
paper	O
:	O
QW	O
,	O
LZ	O
and	O
RJHS	O
.	O

These	O
findings	O
suggest	O
that	O
not	O
only	O
missense	O
mutation	O
but	O
also	O
in	O
frame	O
-	O
deletion	O
preserving	O
a	O
terminal	O
abnormal	O
transcript	O
,	O
could	O
lead	O
to	O
the	O
extraneurological	O
features	O
observed	O
in	O
OPA1	B-DISEASE
-	I-DISEASE
plus	I-DISEASE
patients	O
[	O
6	O
,	O
7	O
]	O
.	O

Additionally	O
,	O
we	O
found	O
another	O
patient	O
bearing	O
both	O
sequence	O
and	O
CNV	O
mutations	O
in	O
the	O
same	O
gene	O
,	O
which	O
could	O
unmask	O
the	O
heterozygous	O
effects	O
of	O
a	O
GJB3	B-GENE
point	O
mutation	O
and	O
harm	O
gene	O
function	O
.	O

However	O
,	O
several	O
pathogenic	O
proline	O
substitutions	O
have	O
been	O
reported	O
in	O
COL4A5	B-GENE
(	O
e	O
.	O
g	O
.	O

CT	O
scan	O
results	O
of	O
Patients	O
21	O
and	O
22	O
(	O
heterozygote	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
N392Y	B-VARIANT
respectively	O
)	O
were	O
not	O
available	O
(	O
Table	O
1	O
)	O
.	O

In	O
vitro	O
,	O
the	O
association	O
of	O
ELMOD3	B-GENE
with	O
F	O
-	O
actin	O
was	O
unaffected	O
by	O
the	O
Leu265Ser	B-VARIANT
mutation	O
in	O
the	O
ELMO	O
domain	O
(	O
lanes	O
7	O
and	O
8	O
)	O
.	O

These	O
genes	O
include	O
GJB6	B-GENE
[	O
30	O
]	O
,	O
PCDH15	B-GENE
[	O
31	O
]	O
,	O
USH1C	B-GENE
[	O
4	O
]	O
,	O
MYO3A	B-GENE
[	O
32	O
]	O
,	O
SLC26A4	B-GENE
[	O
33	O
]	O
,	O
POU4F3	B-GENE
[	O
34	O
]	O
,	O
the	O
inverted	O
duplication	O
of	O
TJP2	B-GENE
[	O
35	O
]	O
,	O
and	O
LOXHD1	B-GENE
[	O
36	O
]	O
.	O

Pedigree	O
and	O
haplotype	O
maps	O
were	O
constructed	O
using	O
Cyrillic	O
V	O
.	O

These	O
data	O
,	O
together	O
with	O
the	O
clinical	O
presentation	O
of	O
the	O
four	O
affected	O
siblings	O
and	O
the	O
consistent	O
Mandelian	O
inheritance	O
of	O
the	O
variants	O
in	O
the	O
affected	O
and	O
unaffected	O
members	O
,	O
indicate	O
that	O
the	O
MYO7A	B-GENE
compound	O
mutations	O
c	B-VARIANT
.	I-VARIANT
73G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G25R	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
C154X	I-VARIANT
)	O
are	O
the	O
cause	O
of	O
USH1	B-DISEASE
in	O
this	O
family	O
.	O

(	O
D	O
)	O
Real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
of	O
Elmod3	B-GENE
isoforms	O
a	O
and	O
b	O
-	O
c	O
in	O
C57BL	O
/	O
6J	O
mouse	O
cochlear	O
and	O
vestibular	O
tissues	O
at	O
three	O
different	O
ages	O
(	O
P0	O
,	O
P10	O
and	O
P30	O
)	O
.	O

This	O
is	O
very	O
important	O
to	O
find	O
the	O
first	O
mutation	O
for	O
identifying	O
the	O
responsible	O
gene	O
and	O
the	O
results	O
indicate	O
this	O
screening	O
is	O
technically	O
efficient	O
.	O

MYO15A	B-GENE
,	O
which	O
encodes	O
a	O
myosin	O
expressed	O
in	O
the	O
cochlea	O
,	O
harbors	O
many	O
mutations	O
worldwide	O
responsible	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
15	O
,	O
16	O
]	O
,	O
but	O
neither	O
MYO15A	B-GENE
p	B-VARIANT
.	I-VARIANT
R2728H	I-VARIANT
nor	O
MYO15A	B-GENE
c	B-VARIANT
.	I-VARIANT
373delCG	I-VARIANT
has	O
been	O
described	O
previously	O
.	O

Electric	O
Acoustic	O
Stimulation	O
(	O
EAS	O
)	O
is	O
a	O
hearing	O
implant	O
system	O
combining	O
a	O
cochlear	O
implant	O
and	O
acoustic	O
amplification	O
technology	O
in	O
one	O
device	O
,	O
and	O
has	O
recently	O
become	O
a	O
standard	O
intervention	O
for	O
the	O
patients	O
with	O
partial	O
deafness	B-DISEASE
,	O
defined	O
as	O
a	O
mild	O
to	O
moderate	O
low	O
-	O
frequency	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
sloping	O
to	O
a	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
higher	O
frequencies	O
[	O
1	O
]	O
.	O

In	O
2002	O
,	O
the	O
U	O
.	O
S	O
.	O

In	O
all	O
of	O
these	O
cell	O
types	O
,	O
the	O
apical	O
surface	O
is	O
exposed	O
to	O
endolymph	O
,	O
consistent	O
with	O
pendrin	O
'	O
s	O
role	O
as	O
an	O
anion	O
transporter	O
.	O

A	O
substitution	O
T	O
>	O
A	O
was	O
also	O
found	O
in	O
the	O
donor	O
splice	O
site	O
of	O
intron	O
40	O
(	O
c	B-VARIANT
.	I-VARIANT
5765	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
.	O

cTnT	O
found	O
in	O
rats	O
after	O
12	O
mg	O
/	O
kg	O
were	O
significantly	O
greater	O
than	O
that	O
found	O
after	O
7	O
.	O
5	O
mg	O
/	O
kg	O
DOX	B-Chemical
.	O

The	O
incidence	O
of	O
cardiovascular	B-DISEASE
thrombotic	I-DISEASE
events	O
(	O
cardiac	O
,	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
,	O
or	O
arterial	O
thrombotic	I-DISEASE
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	B-Chemical
(	O
10	O
-	O
80	O
mg	O
daily	O
)	O
,	O
nonselective	O
NSAID	O
(	O
diclofenac	B-Chemical
75	O
mg	O
bid	O
,	O
ibuprofen	B-Chemical
800	O
mg	O
tid	O
,	O
or	O
naproxen	B-Chemical
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	B-DISEASE
and	O
rheumatoid	O
arthritis	B-DISEASE
trials	O
that	O
were	O
6	O
-	O
52	O
weeks	O
in	O
duration	O
.	O

By	O
applying	O
the	O
Berendsen	B-Chemical
algorithm	O
,	O
each	O
production	O
simulation	O
was	O
coupled	O
to	O
a	O
300	O
K	O
thermal	O
bath	O
at	O
1	O
.	O
0	O
atm	O
pressure	O
[	O
18	O
]	O
.	O

The	O
vertebral	O
bodies	O
are	O
flattened	O
,	O
the	O
proximal	O
femoral	O
epiphyses	O
are	O
small	O
,	O
and	O
the	O
femoral	O
necks	O
are	O
short	O
.	O

Also	O
included	O
were	O
11	O
cases	O
with	O
a	O
specific	O
skeletal	B-DISEASE
disorder	I-DISEASE
but	O
for	O
which	O
there	O
was	O
at	O
the	O
time	O
no	O
known	O
associated	O
gene	O
.	O

This	O
mutation	O
is	O
predicted	O
to	O
be	O
deleterious	O
according	O
to	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
and	O
Mutation	O
Taster	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mutationtaster	O
.	O
org	O
/	O
)	O
.	O

This	O
individual	O
may	O
be	O
related	O
to	O
family	O
TB114	B-Chemical
;	O
alternatively	O
,	O
p	B-VARIANT
.	I-VARIANT
Q234X	I-VARIANT
may	O
be	O
a	O
recurrent	O
mutation	O
.	O

Results	O
of	O
renal	O
manifestations	O
were	O
evaluated	O
in	O
4	O
of	O
10	O
patients	O
.	O

These	O
percentages	O
were	O
identical	O
to	O
those	O
in	O
the	O
EVA	B-DISEASE
plus	O
MD	B-DISEASE
group	O
.	O

POLR1C	B-GENE
(	O
the	O
bait	O
)	O
is	O
identified	O
by	O
an	O
asterisk	O
.	O

Goldmann	O
perimetry	O
was	O
performed	O
to	O
evaluate	O
visual	O
field	O
size	O
.	O

Interestingly	O
,	O
glutamate	B-Chemical
release	O
from	O
presynaptic	O
terminals	O
in	O
the	O
hippocampus	O
was	O
shown	O
to	O
depend	O
on	O
GIPC1	B-GENE
/	O
Myo6	B-GENE
interactions	O
19	O
.	O

Diltiazem	B-Chemical
was	O
used	O
as	O
a	O
comparison	O
drug	O
and	O
autonomic	O
blockade	O
with	O
atropine	B-Chemical
and	O
nadolol	B-Chemical
was	O
applied	O
in	O
some	O
experiments	O
.	O

The	O
other	O
rats	O
showed	O
a	O
strong	O
decrease	O
in	O
the	O
rigidity	O
and	O
the	O
occurrence	O
of	O
stereotyped	O
(	O
S	O
)	O
licking	O
and	O
/	O
or	O
gnawing	O
in	O
presence	O
of	O
akinetic	O
or	O
hyperkinetic	O
(	O
K	O
)	O
behaviour	O
(	O
AS	O
/	O
KS	B-DISEASE
group	O
)	O
,	O
suggesting	O
signs	O
of	O
dopaminergic	O
activation	O
.	O

Eight	O
of	O
the	O
13	O
recruited	O
subjects	O
(	O
four	O
affected	O
and	O
four	O
unaffected	O
)	O
were	O
chosen	O
for	O
commercial	O
WES	O
(	O
Otogenetics	O
,	O
Norcross	O
,	O
GA	O
)	O
and	O
analyzed	O
as	O
previously	O
reported	O
[	O
3	O
]	O
.	O

The	O
sequence	O
analysis	O
revealed	O
a	O
heterozygous	O
C	O
-	O
to	O
-	O
A	O
transition	O
at	O
position	O
5945	O
in	O
exon	O
19	O
,	O
leading	O
to	O
a	O
p	B-VARIANT
.	I-VARIANT
A1982D	I-VARIANT
substitution	O
at	O
the	O
zona	O
pellucida	O
domain	O
of	O
TECTA	B-GENE
(	O
Figure	O
2a	O
)	O
.	O

Future	O
studies	O
will	O
explore	O
the	O
mechanistic	O
differences	O
in	O
tissue	O
-	O
specific	O
phenotypic	O
expression	O
of	O
NARS2	B-GENE
mutations	O
causing	O
Leigh	B-DISEASE
syndrome	I-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
epilepsy	B-DISEASE
and	O
intellectual	B-DISEASE
disability	I-DISEASE
.	O

Effect	O
of	O
L	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
glyceryl	I-Chemical
-	I-Chemical
phosphorylcholine	I-Chemical
on	O
amnesia	B-DISEASE
caused	O
by	O
scopolamine	B-Chemical
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
next	O
of	O
kin	O
on	O
the	O
behalf	O
of	O
the	O
minors	O
/	O
children	O
participants	O
involved	O
in	O
this	O
study	O
.	O

It	O
corresponded	O
to	O
a	O
43	O
bp	O
sequence	O
in	O
the	O
large	O
exon	O
2	O
of	O
MYO15A	B-GENE
.	O

This	O
patient	O
may	O
also	O
be	O
a	O
carrier	O
of	O
a	O
variant	O
in	O
PCDH15	B-GENE
,	O
and	O
two	O
causative	O
mutations	O
may	O
be	O
located	O
in	O
some	O
other	O
USH	B-DISEASE
gene	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
six	O
novel	O
and	O
one	O
recurrent	O
mutations	O
in	O
the	O
USH2A	B-GENE
gene	O
as	O
the	O
disease	O
-	O
causing	O
mutations	O
for	O
five	O
families	O
.	O

The	O
carrier	O
rate	O
in	O
the	O
Czech	O
Romanies	O
has	O
been	O
established	O
at	O
2	O
%	O
(	O
1	O
:	O
48	O
)	O
[	O
10	O
]	O
.	O

While	O
more	O
extensive	O
sequencing	O
of	O
the	O
regulatory	O
and	O
deep	O
intronic	O
regions	O
of	O
the	O
genes	O
studied	O
might	O
have	O
yielded	O
additional	O
molecular	O
information	O
,	O
the	O
possibility	O
of	O
DNA	O
sequence	O
variations	O
in	O
additional	O
genes	O
or	O
copy	O
number	O
variations	O
must	O
also	O
be	O
considered	O
.	O

Although	O
ribavirin	B-Chemical
-	I-DISEASE
associated	I-DISEASE
anemia	B-DISEASE
can	O
be	O
reversed	O
by	O
dose	O
reduction	O
or	O
discontinuation	O
,	O
this	O
approach	O
compromises	O
outcomes	O
by	O
significantly	O
decreasing	O
SVR	B-DISEASE
rates	O
.	O

Repeated	O
trimipramine	B-Chemical
induces	O
dopamine	B-Chemical
D2	I-DISEASE
/	I-DISEASE
D3	I-DISEASE
and	O
alpha1	O
-	O
adrenergic	O
up	O
-	O
regulation	O
.	O

The	O
p	B-Chemical
.	O
G169	I-Chemical
is	O
conserved	O
in	O
some	O
species	O
,	O
including	O
elephant	O
and	O
a	O
number	O
of	O
primates	O
(	O
such	O
as	O
Pan	O
troglodytes	O
,	O
Gorilla	O
gorilla	O
,	O
Pongo	O
abelii	O
,	O
Nomascus	O
leucogenys	O
,	O
and	O
Callithrix	O
jacchus	O
)	O
.	O

We	O
confirmed	O
this	O
mutation	O
by	O
Sanger	O
sequencing	O
(	O
Fig	O
.	O

The	O
mutations	O
in	O
the	O
nine	O
loci	O
of	O
prevalent	O
deafness	O
-	O
associated	O
genes	O
were	O
detected	O
in	O
13	O
.	O
06	O
%	O
of	O
Uyghur	O
NSD	B-DISEASE
patients	O
and	O
32	O
.	O
45	O
%	O
of	O
Han	O
Chinese	O
patients	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

In	O
vitro	O
functional	O
studies	O
(	O
Born	O
'	O
s	O
method	O
)	O
showed	O
normal	O
platelet	O
aggregation	O
after	O
stimulation	O
with	O
ADP	O
,	O
collagen	O
,	O
and	O
ristocetin	B-Chemical
.	O

Genotypes	O
of	O
43	O
individuals	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
Biallelic	O
mutations	O
were	O
identified	O
in	O
36	O
individuals	O
in	O
USH2A	B-GENE
(	O
transcript	O
NM_206933	O
.	O
2	O
)	O
,	O
MYO7A	B-GENE
(	O
transcript	O
NM_000260	O
.	O
3	O
)	O
,	O
GRP98	B-GENE
(	O
transcript	O
NM_032119	O
.	O
3	O
)	O
.	O

Her	O
father	O
was	O
60	O
years	O
old	O
and	O
was	O
phenotypic	O
ally	O
normal	O
.	O

CI	O
is	O
the	O
main	O
entry	O
point	O
to	O
the	O
respiratory	O
chain	O
and	O
catalyzes	O
the	O
transfer	O
of	O
electrons	O
from	O
NADH	B-Chemical
to	O
ubiquinone	B-Chemical
while	O
pumping	O
protons	B-Chemical
across	O
the	O
mitochondrial	O
inner	O
membrane	O
.	O

The	O
literature	O
that	O
studied	O
patients	O
with	O
WS1	B-DISEASE
caused	O
by	O
mutations	O
in	O
PAX3	B-GENE
was	O
reviewed	O
in	O
2009	O
by	O
Pingault	B-Chemical
et	O
al	O
.	O
,	O
and	O
no	O
relationship	O
was	O
found	O
between	O
the	O
severity	O
of	O
disease	O
and	O
the	O
type	O
of	O
mutation	O
[	O
17	O
]	O
.	O

In	O
the	O
RDH12	B-GENE
gene	O
,	O
we	O
identified	O
the	O
p	B-VARIANT
.	I-VARIANT
Leu93Pro	I-VARIANT
variation	O
.	O

(	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

The	O
SLC26A4	B-GENE
mutation	O
spectrum	O
in	O
ChiFeng	B-Chemical
City	O
,	O
Inner	O
Mongolia	O
is	O
similar	O
to	O
that	O
reported	O
in	O
Chinese	O
population	O
but	O
different	O
from	O
that	O
of	O
Japanese	O
.	O

Whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
allows	O
for	O
the	O
targeted	O
enrichment	O
and	O
resequencing	O
of	O
nearly	O
all	O
exons	O
of	O
protein	O
-	O
coding	O
genes	O
and	O
identifies	O
genetic	O
variation	O
at	O
a	O
single	O
base	O
-	O
pair	O
resolution	O
.	O

This	O
work	O
was	O
also	O
supported	O
by	O
the	O
Action	O
on	O
Hearing	B-DISEASE
Loss	I-DISEASE
grant	O
and	O
National	O
Institute	O
on	O
Deafness	B-DISEASE
and	O
Other	O
Communication	O
Disorders	O
(	O
NIDCD	O
/	O
NIH	O
)	O
research	O
grants	O
R01	O
DC011803	O
and	O
R01	O
DC011748	O
to	O
S	O
.	O
R	O
.	O

Schematic	O
representation	O
of	O
the	O
LARS2	B-GENE
protein	O
showing	O
the	O
position	O
of	O
the	O
newly	O
-	O
identified	O
mutations	O
as	O
well	O
as	O
the	O
previously	O
-	O
reported	O
ones	O
.	O

Symptoms	O
were	O
assessed	O
by	O
using	O
a	O
visual	O
analogue	O
scale	O
before	O
and	O
after	O
treatment	O
.	O

In	O
this	O
gene	O
the	O
novel	O
mutation	O
c	B-VARIANT
.	I-VARIANT
598G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly200Arg	I-VARIANT
)	O
affects	O
a	O
residue	O
in	O
the	O
cysteine	O
-	O
rich	O
domain	O
that	O
is	O
involved	O
in	O
the	O
formation	O
of	O
intramolecular	O
disulphide	O
bonds	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

To	O
study	O
the	O
genetic	O
variation	O
in	O
cancer	O
-	O
susceptibility	O
genes	O
in	O
a	O
cohort	O
representative	O
of	O
a	O
general	O
,	O
ancestrally	O
diverse	O
population	O
,	O
we	O
analyzed	O
whole	O
genome	O
sequences	O
from	O
participants	O
in	O
a	O
pre	B-DISEASE
-	I-DISEASE
term	I-DISEASE
birth	I-DISEASE
research	O
study	O
.	O

Because	O
Bohring	B-DISEASE
-	I-DISEASE
Opitz	I-DISEASE
syndrome	I-DISEASE
is	O
an	O
early	O
-	O
onset	O
severe	O
malformation	B-DISEASE
syndrome	I-DISEASE
and	O
its	O
causal	O
mutations	O
are	O
presumably	O
highly	O
penetrant	O
,	O
the	O
presence	O
of	O
p	B-VARIANT
.	I-VARIANT
Arg404Ter	I-VARIANT
in	O
two	O
African	O
-	O
American	O
EVS	O
subjects	O
leads	O
us	O
to	O
consider	O
this	O
Sanger	O
-	O
validated	O
de	O
novo	O
nonsense	O
mutation	O
as	O
a	O
very	O
good	O
candidate	O
rather	O
than	O
a	O
"	O
genetic	O
diagnosis	O
determined	O
.	O

Ketanserin	B-Chemical
pretreatment	O
reverses	O
alfentanil	B-Chemical
-	O
induced	O
muscle	O
rigidity	O
.	O

These	O
variants	O
were	O
found	O
to	O
affect	O
highly	O
conserved	O
amino	O
-	O
acid	O
residues	O
(	O
Fig	O
.	O

These	O
data	O
demonstrate	O
that	O
administration	O
of	O
MP	B-Chemical
before	O
and	O
after	O
TDI	O
reduces	O
the	O
frequency	O
and	O
severity	O
of	O
the	O
arthralgia	B-DISEASE
-	I-DISEASE
myalgia	I-DISEASE
syndrome	I-DISEASE
.	O

6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	B-Chemical
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	B-Chemical
content	O
of	O
the	O
renal	O
medulla	O
but	O
not	O
in	O
the	O
other	O
organs	O
studied	O
.	O

The	O
National	O
Research	O
Ethics	O
Service	O
Committee	O
(	O
West	O
Midlands	O
-	O
-	O
Staffordshire	O
,	O
UK	O
)	O
approved	O
this	O
study	O
(	O
REC	O
reference	O
09	O
/	O
H1203	O
/	O
74	O
)	O
.	O

None	O
of	O
the	O
mutations	O
identified	O
in	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
patients	O
were	O
present	O
in	O
this	O
large	O
dataset	O
.	O

Herein	O
,	O
we	O
investigate	O
whether	O
doxorubicin	B-Chemical
-	O
associated	O
chronic	O
cardiac	O
toxicity	O
can	O
be	O
ameliorated	O
with	O
the	O
antioxidant	O
hydroxytyrosol	B-Chemical
in	O
rats	O
with	O
breast	B-DISEASE
cancer	I-DISEASE
.	O

The	O
majority	O
of	O
mutations	O
that	O
result	O
in	O
dominant	O
type	B-DISEASE
2	I-DISEASE
Stickler	I-DISEASE
syndrome	I-DISEASE
have	O
been	O
found	O
to	O
affect	O
consensus	O
splice	O
sites	O
in	O
the	O
COL11A1	B-GENE
gene	O
and	O
result	O
in	O
exon	O
skipping	O
.	O

This	O
assay	O
is	O
based	O
on	O
a	O
reaction	O
in	O
which	O
the	O
regeneration	O
of	O
hydrolyzed	O
ATP	B-Chemical
is	O
coupled	O
to	O
the	O
oxidation	O
of	O
NADH	B-Chemical
.	O

Among	O
the	O
genotype	O
-	O
positive	O
cases	O
there	O
were	O
33	O
individuals	O
with	O
a	O
QTc	O
>	O
=	O
480	O
ms	O
,	O
and	O
among	O
the	O
genotype	O
-	O
negative	O
cases	O
,	O
12	O
had	O
QTc	O
>	O
=	O
480	O
ms	O
.	O

Cover	O
glasses	O
were	O
mounted	O
in	O
ProLong	O
anti	O
-	O
fade	O
media	O
(	O
Life	O
Technologies	O
)	O
and	O
visualized	O
with	O
100x	O
oil	O
objective	O
on	O
inverted	O
microscope	O
(	O
Zeiss	O
)	O
fitted	O
with	O
spinning	O
disc	O
confocal	O
scanner	O
(	O
Perkin	O
-	O
Elmer	O
)	O
.	O

METHODS	O
:	O
Data	O
were	O
extracted	O
from	O
2021	O
paired	O
mother	O
-	O
infant	O
records	O
for	O
the	O
year	O
2000	O
birth	O
cohort	O
in	O
New	O
Hampshire	O
'	O
s	O
25	O
delivery	O
hospitals	O
.	O

These	O
data	O
tend	O
to	O
imply	O
that	O
this	O
GJB2	B-GENE
sequence	O
variation	O
is	O
a	O
severe	O
recessive	O
mutation	O
although	O
de	O
novo	O
appearance	O
of	O
the	O
W172C	B-VARIANT
mutation	O
cannot	O
be	O
excluded	O
in	O
this	O
case	O
.	O

In	O
our	O
study	O
,	O
many	O
patients	O
with	O
causative	O
biallelic	O
mutations	O
carried	O
singular	O
heterozygous	O
missense	O
variants	O
in	O
other	O
RD	O
genes	O
(	O
Table	O
1	O
)	O
.	O

of	O
100	O
unrelated	O
patients	O
with	O
EVA	B-DISEASE
in	O
European	O
Caucasian	O
subjects	O
revealed	O
a	O
diverse	O
mutation	O
spectrum	O
without	O
prevalent	O
mutations	O
,	O
and	O
only	O
40	O
patients	O
carried	O
SLC26A4	B-GENE
mutations	O
[	O
24	O
]	O
.	O

+	O
+	O
Insulin	O
<	O
0	O
.	O
5	O
IE	O
/	O
kg	O
/	O
day	O
,	O
HbA	O
1c	O
<	O
7	O
.	O
5	O
%	O
.	O

There	O
were	O
no	O
fibrillation	O
,	O
positive	O
or	O
fasciculation	O
potentials	O
and	O
myotonic	O
discharges	O
were	O
not	O
observed	O
.	O

We	O
appreciate	O
Dr	O
.	O

528	O
of	O
these	O
3	O
516	O
spots	O
were	O
also	O
analyzed	O
in	O
the	O
R2	O
fragment	O
(	O
position	O
190	O
to	O
500	O
of	O
the	O
CDS	O
)	O
.	O

Moreover	O
,	O
the	O
rate	O
-	O
induced	O
latency	O
shifts	O
of	O
ABR	O
wave	O
I	O
recorded	O
from	O
newborns	O
show	O
no	O
,	O
or	O
only	O
very	O
slight	O
,	O
differences	O
compared	O
to	O
adult	O
values	O
(	O
Salamy	B-Chemical
et	O
al	O
.	O

Factura	O
and	O
Sequence	O
Navigator	O
software	O
Packages	O
(	O
Applied	O
Biosystems	O
)	O
were	O
used	O
for	O
mutation	O
detection	O
.	O

Three	O
of	O
the	O
five	O
mutations	O
identified	O
by	O
direct	O
sequencing	O
of	O
known	O
deafness	B-DISEASE
genes	O
in	O
the	O
candidate	O
regions	O
identified	O
by	O
linkage	O
analysis	O
/	O
homozygosity	O
mapping	O
in	O
5	O
families	O
in	O
which	O
DFNB1	B-GENE
had	O
been	O
excluded	O
have	O
been	O
reported	O
previously	O
(	O
Table	O
1	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
CNVs	O
might	O
be	O
a	O
more	O
frequent	O
cause	O
of	O
LQTS	B-DISEASE
than	O
mutations	O
in	O
all	O
of	O
the	O
less	O
common	O
LQTS	O
-	O
associated	O
genes	O
(	O
ANKB	B-GENE
,	O
KCNE1	B-GENE
,	O
KCNE2	B-GENE
,	O
KCNJ2	B-GENE
,	O
CACNA1C	B-GENE
,	O
CAV3	B-GENE
,	O
SCN4B	B-GENE
,	O
AKAP9	B-GENE
,	O
and	O
SNTA1	B-GENE
)	O
together	O
[	O
38	O
-	O
40	O
]	O
.	O

Pedigree	O
analysis	O
showed	O
maternally	O
inherited	O
traits	O
,	O
and	O
these	O
patients	O
were	O
diagnosed	O
as	O
having	O
aminoglycoside	B-Chemical
-	O
induced	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Based	O
upon	O
the	O
decision	O
reached	O
at	O
Hearing	O
Group	O
Meeting	O
,	O
result	O
letters	O
were	O
generated	O
for	O
all	O
patients	O
,	O
reporting	O
all	O
variants	O
with	O
MAF	O
<	O
1	O
%	O
to	O
the	O
ordering	O
physician	O
.	O

Furthermore	O
,	O
coding	O
mutations	O
in	O
WFS1	B-GENE
give	O
rise	O
to	O
two	O
major	O
clinical	O
phenotypes	O
:	O
WS	B-DISEASE
(	O
or	O
DIDMOAD	O
)	O
and	O
sensorineural	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
SNHI	B-DISEASE
)	O
.	O

PRACTICAL	O
IMPLICATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
lithium	B-Chemical
-	O
treated	O
patients	O
become	O
hypercalcemic	B-DISEASE
.	O

F	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
allele	O
generated	O
by	O
use	O
of	O
the	O
alternative	O
acceptor	O
site	O
1	O
.	O

The	O
patient	O
was	O
a	O
12	O
years	O
old	O
boy	O
at	O
the	O
time	O
of	O
initial	O
admission	O
to	O
SCMC	O
and	O
suffered	O
from	O
PA	B-DISEASE
/	I-DISEASE
VSD	I-DISEASE
and	O
patent	B-DISEASE
ductus	I-DISEASE
arteriosus	I-DISEASE
(	O
PDA	B-DISEASE
)	O
.	O

These	O
variants	O
were	O
rare	O
and	O
carried	O
by	O
one	O
or	O
two	O
individuals	O
only	O
,	O
nine	O
of	O
them	O
were	O
novel	O
variants	O
which	O
have	O
never	O
be	O
reported	O
in	O
public	O
database	O
(	O
Table	O
S7	O
)	O
.	O

[	O
55	O
]	O
)	O
.	O

XC	B-Chemical
and	O
GX	B-Chemical
contributed	O
to	O
revisions	O
of	O
the	O
manuscript	O
.	O

Excepting	O
NSRAN	B-DISEASE
patient	O
,	O
each	O
of	O
the	O
other	O
three	O
patients	O
with	O
pathogenic	O
variants	O
(	O
Table	O
1	O
)	O
carries	O
only	O
one	O
copy	O
of	O
an	O
OTOF	B-GENE
variants	O
,	O
which	O
we	O
assume	O
are	O
causative	O
factor	O
for	O
their	O
disease	O
.	O

In	O
19	O
of	O
these	O
patients	O
rare	O
missense	O
variants	O
were	O
detected	O
,	O
that	O
could	O
potentially	O
contribute	O
to	O
the	O
disease	O
phenotype	O
,	O
but	O
these	O
were	O
not	O
considered	O
to	O
be	O
pathogenic	O
by	O
themselves	O
.	O

While	O
both	O
of	O
these	O
hypotheses	O
are	O
attractive	O
,	O
further	O
functional	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
partner	O
proteins	O
of	O
HOMER2	B-GENE
in	O
inner	O
ear	O
and	O
investigate	O
the	O
effect	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
mutation	O
on	O
these	O
interactions	O
.	O

Although	O
knockdown	O
of	O
homer2	B-GENE
altered	O
neither	O
ear	O
size	O
nor	O
morphology	O
(	O
p	O
>	O
0	O
.	O
5	O
)	O
(	O
S3	O
Fig	O
)	O
,	O
injection	O
of	O
in	O
vitro	O
synthesized	O
mRNA	O
encoding	O
HOMER2	B-GENE
P185	O
-	O
mutant	O
RNA	O
(	O
P185RNA	O
)	O
resulted	O
in	O
significantly	O
smaller	O
ear	O
size	O
in	O
larvae	O
as	O
compared	O
to	O
injections	O
with	O
WT	O
HOMER2	B-GENE
(	O
wtRNA	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
3A	O
i	O
-	O
iii	O
and	O
3B	O
;	O
S4	O
Fig	O
)	O
.	O

Saul	O
Merin	O
who	O
passed	O
away	O
during	O
the	O
preparation	O
of	O
this	O
manuscript	O
.	O

Methimazole	B-Chemical
-	O
induced	O
cholestasis	B-DISEASE
was	O
diagnosed	O
,	O
and	O
propranolol	B-Chemical
therapy	O
was	O
resumed	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
I168N	I-VARIANT
mutation	O
is	O
located	O
in	O
the	O
second	O
extracellular	O
loop	O
.	O

Proteins	O
that	O
are	O
predicted	O
by	O
the	O
online	O
software	O
STRING	O
9	O
.	O
1	O
to	O
interact	O
with	O
TMPRSS3	B-GENE
in	O
humans	O
include	O
multiple	O
known	O
deafness	B-DISEASE
proteins	O
such	O
as	O
MYO7A	B-GENE
(	O
MIM	O
#	O
276903	O
)	O
,	O
GJB2	B-GENE
,	O
DFNB59	B-GENE
(	O
MIM	O
#	O
610219	O
)	O
,	O
and	O
SLC26A4	B-GENE
(	O
Figure	O
5	O
)	O
.	O

CIB2	B-GENE
homodimerizes	O
and	O
also	O
interacts	O
with	O
whirlin	O
and	O
myosin	B-GENE
VIIa	I-GENE
(	O
a	O
)	O
Possible	O
CIB2	B-GENE
interactome	O
.	O

Patients	O
were	O
grouped	O
according	O
to	O
their	O
genotypes	O
into	O
patients	O
with	O
missense	O
mutations	O
(	O
M	B-Chemical
)	O
on	O
both	O
alleles	O
(	O
type	O
1	O
,	O
MM	O
)	O
,	O
with	O
premature	O
termination	O
codons	O
(	O
PTCs	B-Chemical
,	O
P	B-Chemical
)	O
on	O
both	O
alleles	O
(	O
type	O
3	O
,	O
PP	B-Chemical
)	O
,	O
or	O
with	O
a	O
combination	O
of	O
a	O
PTC	O
with	O
a	O
missense	O
mutation	O
(	O
type	O
2	O
,	O
MP	O
)	O
.	O

The	O
39	O
-	O
year	O
-	O
old	O
woman	O
had	O
spread	O
a	O
warfarin	B-Chemical
-	O
type	O
rat	O
poison	O
around	O
her	O
house	O
weekly	O
using	O
her	O
bare	O
hands	O
,	O
with	O
no	O
washing	O
post	O
application	O
.	O

Conservation	O
of	O
amino	B-Chemical
acid	O
residue	O
across	O
species	O
is	O
highlighted	O
.	O

The	O
GRHL	O
family	O
members	O
are	O
involved	O
in	O
otic	O
development	O
and	O
hearing	O
in	O
animals	O
,	O
but	O
an	O
association	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
humans	O
was	O
found	O
only	O
in	O
GRHL2	B-GENE
,	O
the	O
causative	O
gene	O
of	O
the	O
DFNA28	B-GENE
locus	O
[	O
16	O
]	O
.	O

1	O
-	O
3	O
HPE	B-DISEASE
and	O
ectrodactyly	B-DISEASE
can	O
occur	O
,	O
separately	O
,	O
as	O
part	O
of	O
numerous	O
syndromes	O
,	O
but	O
the	O
co	O
-	O
occurrence	O
of	O
these	O
two	O
malformations	O
,	O
known	O
as	O
Harstfield	B-DISEASE
syndrome	I-DISEASE
(	O
OMIM	O
300571	O
)	O
,	O
has	O
only	O
been	O
reported	O
in	O
14	O
males	O
and	O
three	O
females	O
(	O
see	O
online	O
supplementary	O
table	O
S1	O
)	O
.	O

Kidney	B-DISEASE
disease	I-DISEASE
associated	O
with	O
deafness	B-DISEASE
was	O
observed	O
in	O
the	O
majority	O
of	O
cases	O
with	O
exon	O
17	O
mutations	O
(	O
for	O
p	B-VARIANT
.	I-VARIANT
R702C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R702H	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R718W	I-VARIANT
)	O
,	O
and	O
in	O
half	O
of	O
the	O
cases	O
with	O
p	B-VARIANT
.	I-VARIANT
S96L	I-VARIANT
or	O
p	B-VARIANT
.	I-VARIANT
N93K	I-VARIANT
mutations	O
in	O
exon	O
2	O
.	O

EVA	B-DISEASE
:	O
Enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
.	O

A	O
reported	O
nonsense	O
mutation	O
was	O
identified	O
in	O
one	O
family	O
.	O

Patients	O
were	O
followed	O
up	O
at	O
6	O
-	O
monthly	O
intervals	O
for	O
not	O
less	O
than	O
18	O
months	O
(	O
range	O
18	O
-	O
43	O
months	O
)	O
.	O

To	O
find	O
sequences	O
homologous	O
to	O
ACTG1	B-GENE
and	O
MYO7A	B-GENE
that	O
could	O
be	O
used	O
as	O
the	O
structural	O
templates	O
for	O
the	O
modeling	O
exercise	O
,	O
we	O
searched	O
the	O
Protein	O
Data	O
Bank	O
(	O
PDB	O
)	O
using	O
Gapped	O
BLAST	O
[	O
20	O
]	O
and	O
PDBsum	O
[	O
21	O
]	O
.	O

Inner	O
ear	O
and	O
olfactory	O
bulbs	O
tissues	O
were	O
harvested	O
from	O
C57BL	O
/	O
6J	O
mice	O
at	O
P30	O
and	O
followed	O
by	O
western	O
blot	O
analysis	O
,	O
as	O
described	O
elsewhere	O
[	O
39	O
]	O
.	O

Rats	O
treated	O
for	O
11	O
days	O
with	O
morphine	B-Chemical
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differences	O
in	O
the	O
development	O
of	O
tolerance	O
:	O
about	O
half	O
of	O
the	O
animals	O
showed	O
a	O
rigidity	O
after	O
the	O
test	O
dose	O
of	O
morphine	B-Chemical
that	O
was	O
not	O
significantly	O
less	O
than	O
in	O
the	O
controls	O
and	O
were	O
akinetic	O
(	O
A	O
group	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
completely	O
unexpected	O
as	O
heterozygous	O
individuals	O
for	O
the	O
EDN3	B-GENE
mutations	O
have	O
been	O
reported	O
to	O
show	O
a	O
few	O
clinical	O
features	O
of	O
WS	B-DISEASE
[	O
25	O
,	O
29	O
]	O
.	O

A	O
second	O
hypothesis	O
focuses	O
on	O
the	O
role	O
of	O
HOMER2	B-GENE
in	O
cytoplasmic	O
Ca	B-Chemical
2	I-Chemical
+	O
control	O
.	O

Dark	O
-	O
adapted	O
(	O
DA	O
)	O
mixed	O
cone	O
-	O
rod	O
a	O
and	O
b	O
-	O
wave	O
amplitudes	O
(	O
normal	O
a	O
-	O
wave	O
90	O
-	O
350	O
mu	O
V	O
,	O
normal	O
b	O
-	O
wave	O
380	O
-	O
630	O
mu	O
V	O
)	O
;	O
Dark	O
-	O
adapted	O
rod	O
response	O
b	O
-	O
wave	O
amplitude	O
(	O
normal	O
range	O
200	O
-	O
500	O
mu	O
V	O
)	O
.	O

For	O
statistical	O
analysis	O
,	O
Snellen	O
VA	O
was	O
converted	O
to	O
logarithm	O
of	O
the	O
minimum	O
angle	O
of	O
resolution	O
(	O
logMAR	O
)	O
.	O

Phenylephrine	B-Chemical
infusion	O
increased	O
arterial	O
pressure	O
,	O
arteriolar	O
diameter	O
and	O
clearance	O
of	O
fluorescent	O
dextran	B-Chemical
by	O
a	O
similar	O
magnitude	O
in	O
both	O
groups	O
.	O

Our	O
study	O
suggests	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
the	O
detected	O
mutations	O
.	O

This	O
model	O
suggested	O
that	O
mechanical	O
forces	O
brought	O
about	O
by	O
bending	O
of	O
stereocilia	O
and	O
tension	O
on	O
the	O
tip	O
links	O
directly	O
activate	O
ion	O
channels	O
.	O

The	O
complete	O
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	O
temporal	O
delay	O
suggests	O
a	O
possible	O
adverse	O
effect	O
on	O
the	O
proximal	O
eighth	O
nerve	O
.	O

These	O
patients	O
had	O
been	O
screened	O
using	O
a	O
combination	O
of	O
techniques	O
as	O
Sanger	O
sequencing	O
,	O
APEX	O
microarray	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
or	O
MLPA	O
.	O

The	O
apical	B-DISEASE
ballooning	I-DISEASE
syndrome	I-DISEASE
(	O
ABS	B-DISEASE
)	O
is	O
a	O
recently	O
described	O
stress	B-DISEASE
-	I-DISEASE
mediated	I-DISEASE
acute	I-DISEASE
cardiac	I-DISEASE
syndrome	I-DISEASE
characterized	O
by	O
transient	O
wall	O
-	O
motion	O
abnormalities	O
involving	O
the	O
apex	O
and	O
midventricle	O
with	O
hyperkinesis	B-DISEASE
of	O
the	O
basal	O
left	O
ventricular	O
(	O
LV	O
)	O
segments	O
without	O
obstructive	O
epicardial	O
coronary	I-DISEASE
disease	I-DISEASE
.	O

Lindane	B-Chemical
(	O
gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
)	O
is	O
an	O
organochlorine	O
insecticide	O
with	O
known	O
neurotoxic	O
effects	O
.	O

The	O
study	O
was	O
lead	O
in	O
the	O
respect	O
of	O
the	O
French	O
law	O
and	O
regulation	O
"	O
.	O

All	O
patients	O
underwent	O
a	O
rapid	O
rule	O
-	O
in	O
protocol	O
that	O
included	O
serial	O
sampling	O
of	O
creatine	B-Chemical
kinase	O
(	O
CK	O
)	O
,	O
CK	O
-	O
MB	O
,	O
and	O
cardiac	O
troponin	O
I	I-GENE
(	O
cTnI	O
)	O
over	O
eight	O
hours	O
.	O

The	O
final	O
concentration	O
of	O
each	O
captured	O
library	O
was	O
determined	O
by	O
a	O
Qubit	O
fluorometer	O
and	O
multiple	O
aliquots	O
diluted	O
to	O
0	O
.	O
5	O
ng	O
/	O
mu	O
l	O
were	O
analyzed	O
on	O
a	O
high	O
sensitivity	O
chip	O
with	O
a	O
Bioanalyzer	O
2100	O
.	O

These	O
are	O
p	B-VARIANT
.	I-VARIANT
A49A	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT

Provenance	O
and	O
peer	O
review	O
:	O
Not	O
commissioned	O
;	O
externally	O
peer	O
reviewed	O
.	O
Mutations	O
in	O
the	O
GJB2	B-GENE
gene	O
have	O
been	O
established	O
as	O
a	O
major	O
cause	O
of	O
inherited	B-DISEASE
non	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
in	O
different	O
populations	O
.	O

Schizophrenia	B-DISEASE
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	B-Chemical
neurotransmission	O
.	O

For	O
this	O
reason	O
,	O
a	O
positive	O
result	O
is	O
only	O
obtained	O
in	O
less	O
than	O
20	O
%	O
of	O
deaf	O
children	O
for	O
which	O
DNA	O
diagnostics	O
is	O
requested	O
[	O
4	O
]	O
.	O

Considering	O
only	O
the	O
patients	O
clearly	O
diagnosed	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
II	I-DISEASE
,	O
the	O
mutation	O
detection	O
ratio	O
raises	O
to	O
56	O
.	O
9	O
%	O
(	O
33	O
/	O
58	O
)	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
normal	O
vocal	O
cord	O
function	O
preoperatively	O
.	O

Patients	O
with	O
USH3	B-DISEASE
show	O
progressive	O
postlingual	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
later	O
onset	O
of	O
RP	B-DISEASE
,	O
and	O
variable	O
vestibular	B-DISEASE
dysfunctions	I-DISEASE
.	O

[	O
8	O
]	O
Mutation	O
detection	O
rates	O
of	O
OPA1	B-GENE
in	O
ADOA	B-DISEASE
patients	O
rangefrom	O
32	O
%	O
to	O
89	O
%	O
.	O

The	O
two	O
hydrogen	O
bonds	O
,	O
which	O
link	O
an	O
alpha	O
-	O
helix	O
with	O
beta	O
-	O
sheets	O
according	O
to	O
the	O
predicted	O
crystal	O
structure	O
,	O
are	O
generally	O
critical	O
for	O
the	O
tertiary	O
structure	O
of	O
the	O
protein	O
.	O

Glycine	B-Chemical
residue	O
268	O
is	O
shown	O
in	O
red	O
and	O
indicated	O
by	O
an	O
arrow	O
.	O

In	O
both	O
sets	O
(	O
four	O
)	O
of	O
eyes	O
of	O
the	O
subjects	O
with	O
persistent	O
visual	B-DISEASE
deficits	I-DISEASE
(	O
patients	O
B	O
and	O
C	O
)	O
,	O
there	O
was	O
an	O
average	O
loss	O
of	O
79	O
%	O
of	O
nerve	O
fiber	O
thickness	O
in	O
the	O
temporal	O
quadrant	O
.	O

For	O
example	O
,	O
1	O
,	O
314	O
cases	O
of	O
osteogenesis	B-DISEASE
imperfecta	I-DISEASE
were	O
reported	O
in	O
the	O
CBM	O
database	O
but	O
in	O
only	O
5	O
%	O
the	O
exact	O
type	O
has	O
been	O
determined	O
.	O

Glu340	O
also	O
forms	O
two	O
hydrogen	O
bonds	O
with	O
Arg388	O
,	O
the	O
first	O
residue	O
of	O
alpha	O
-	O
helix	O
10	O
.	O

First	O
,	O
the	O
majority	O
of	O
the	O
probands	O
were	O
recruited	O
through	O
genetic	O
testing	O
and	O
counseling	O
of	O
patients	O
with	O
hereditary	O
hearing	O
loss	O
,	O
which	O
may	O
lead	O
to	O
over	O
-	O
representation	O
of	O
the	O
multiplex	O
probands	O
(	O
27	O
.	O
9	O
%	O
in	O
our	O
subjects	O
,	O
estimated	O
22	O
.	O
3	O
%	O
in	O
US	O
in	O
comparison	O
[	O
2	O
]	O
)	O
.	O

The	O
mutation	O
is	O
expected	O
to	O
result	O
either	O
in	O
an	O
abortive	O
protein	O
truncated	O
at	O
amino	O
acid	O
position	O
29	O
or	O
in	O
no	O
protein	O
at	O
all	O
due	O
to	O
nonsense	O
mediated	O
mRNA	O
decay	O
[	O
9	O
]	O
.	O

Found	O
in	O
1	O
/	O
872	O
(	O
0	O
.	O
11	O
%	O
)	O
control	O
chromosomes	O
.	O

CONCLUSION	O
:	O
Olanzapine	B-Chemical
demonstrated	O
greater	O
efficacy	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
acute	O
bipolar	O
mania	B-DISEASE
and	O
was	O
generally	O
well	O
tolerated	O
.	O

Our	O
high	O
,	O
even	O
coverage	O
enabled	O
the	O
detection	O
of	O
two	O
multi	O
-	O
exonic	O
duplications	O
and	O
three	O
single	O
or	O
multi	O
-	O
exon	O
deletions	O
by	O
cross	O
-	O
sample	O
normalisation	O
and	O
comparison	O
.	O

According	O
to	O
our	O
criteria	O
3	O
,	O
208	O
Chinese	O
reports	O
were	O
qualified	O
for	O
inclusion	O
.	O

A	O
large	O
Chinese	O
family	O
with	O
nonsyndromic	B-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
was	O
identified	O
through	O
the	O
Department	O
of	O
Otolaryngology	O
-	O
Head	O
and	O
Neck	O
Surgery	O
,	O
the	O
Second	O
Xiangya	O
Hospital	O
of	O
Central	O
South	O
University	O
,	O
China	O
.	O

Of	O
the	O
thirteen	O
cases	O
with	O
identified	O
variants	O
,	O
two	O
(	O
spondylocarpotarsal	B-DISEASE
synostosis	I-DISEASE
and	O
Wolcott	B-DISEASE
-	I-DISEASE
Rallison	I-DISEASE
syndrome	I-DISEASE
)	O
were	O
autosomal	O
recessive	O
.	O

However	O
,	O
wide	O
acceptance	O
in	O
the	O
clinic	O
has	O
been	O
hampered	O
primarily	O
by	O
limitations	O
in	O
our	O
current	O
knowledge	O
of	O
the	O
clinical	O
relevance	O
of	O
the	O
detected	O
sequence	O
variations	O
.	O

H	O
.	O
K	O
.	O

CPA	B-Chemical
reduced	O
cocaine	B-Chemical
action	O
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
influence	O
motility	O
,	O
while	O
CGS	B-Chemical
21680	I-Chemical
and	O
NECA	B-Chemical
decreased	O
the	O
action	O
of	O
cocaine	B-Chemical
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
decreased	O
locomotor	O
activity	O
in	O
animals	O
.	O

BRCA1	B-GENE
,	O
BRCA2	B-GENE
,	O
and	O
APC	B-GENE
are	O
well	O
-	O
studied	O
because	O
of	O
the	O
presence	O
of	O
frequent	O
,	O
pathogenic	O
mutations	O
.	O

A	O
novel	O
compound	O
,	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
,	O
attenuates	O
cognitive	O
deficits	I-DISEASE
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	O
models	O
.	O

High	O
-	O
dose	O
intravenous	O
melphalan	B-Chemical
followed	O
by	O
peripheral	O
blood	O
stem	O
cell	O
transplant	O
(	O
PBSCT	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
therapy	O
,	O
but	O
treatment	O
mortality	O
can	O
be	O
high	O
.	O

Our	O
analysis	O
of	O
1119	O
patients	O
identified	O
5900	O
variants	O
,	O
which	O
we	O
reported	O
to	O
healthcare	O
providers	O
.	O

Cochlear	B-DISEASE
hypoplasia	I-DISEASE
,	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
,	O
and	O
facial	B-DISEASE
nerve	I-DISEASE
anomaly	I-DISEASE
were	O
seen	O
in	O
all	O
of	O
the	O
patients	O
(	O
Fig	O
.	O

Therefore	O
,	O
we	O
focused	O
on	O
the	O
ELMOD3	B-GENE
isoform	O
B	O
for	O
the	O
subsequent	O
biochemical	O
and	O
cellular	O
studies	O
.	O

In	O
summary	O
,	O
in	O
our	O
work	O
we	O
show	O
that	O
whole	O
-	O
exome	O
sequencing	O
could	O
represent	O
a	O
useful	O
tool	O
for	O
molecular	O
diagnosis	O
of	O
hereditary	O
retinal	O
degeneration	O
,	O
a	O
disease	O
for	O
which	O
standard	O
screening	O
procedures	O
still	O
struggle	O
to	O
produce	O
information	O
in	O
a	O
cost	O
-	O
or	O
time	O
-	O
efficient	O
manner	O
.	O

5	O
The	O
mammalian	O
claudin	O
family	O
of	O
twenty	O
-	O
seven	O
genes	O
encodes	O
tight	O
junction	O
proteins	O
that	O
function	O
to	O
maintain	O
integrity	O
of	O
the	O
apical	O
and	O
basolateral	O
membrane	O
domains	O
and	O
prevent	O
diffusion	O
of	O
solutes	O
and	O
solvent	O
molecules	O
through	O
intercellular	O
spaces	O
within	O
epithelial	O
sheets	O
.	O

To	O
date	O
,	O
25	O
genes	O
underlying	O
human	O
CI	B-DISEASE
deficiency	I-DISEASE
have	O
been	O
identified	O
via	O
candidate	O
gene	O
sequencing	O
,	O
linkage	O
analysis	O
,	O
or	O
homozygosity	O
mapping	O
.	O

A	O
total	O
of	O
284	O
deaf	O
subjects	O
from	O
unrelated	O
families	O
were	O
included	O
in	O
this	O
study	O
;	O
134	O
were	O
from	O
Chifeng	O
Special	O
Education	O
School	O
in	O
Inner	O
Mongolia	O
,	O
and	O
150	O
were	O
from	O
Nantong	O
Special	O
Education	O
School	O
in	O
JiangSu	O
Province	O
,	O
China	O
.	O

The	O
position	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
mutation	O
is	O
shown	O
in	O
red	O
.	O

Although	O
we	O
can	O
'	O
t	O
provide	O
a	O
definitive	O
proof	O
of	O
the	O
pathogenicity	O
for	O
the	O
identified	O
variants	O
,	O
some	O
elements	O
support	O
their	O
causative	O
role	O
in	O
producing	O
PEO	B-DISEASE
:	I-DISEASE
i	O
)	O
they	O
are	O
not	O
found	O
in	O
a	O
wide	O
number	O
of	O
ethnic	O
-	O
matched	O
and	O
pan	O
-	O
ethnics	O
control	O
subjects	O
;	O
ii	O
)	O
healthy	O
siblings	O
of	O
the	O
patients	O
don	O
'	O
t	O
harbour	O
the	O
mutations	O
;	O
iii	O
)	O
the	O
variants	O
affect	O
residues	O
located	O
in	O
regions	O
important	O
for	O
a	O
proper	O
structure	O
and	O
function	O
of	O
Twinkle	O
;	O
iv	O
)	O
the	O
signs	O
of	O
mitochondrial	O
pathology	O
disclosed	O
in	O
our	O
patients	O
are	O
related	O
to	O
an	O
impairment	O
in	O
mtDNA	O
replication	O
and	O
their	O
early	O
age	O
of	O
onset	O
is	O
compatible	O
with	O
PEO1	B-GENE
mutations	O
;	O
v	O
)	O
the	O
screening	O
of	O
other	O
PEO	O
-	O
associated	O
genes	O
was	O
negative	O
.	O

Importantly	O
,	O
no	O
mTP	O
were	O
predicted	O
for	O
EDNRB	B-GENE
isoforms	O
1	O
or	O
2	O
.	O

(	O
A	O
)	O
Fundus	O
photos	O
of	O
patient	O
ARRP01	O
-	O
IV	O
:	O
3	O
demonstrate	O
typical	O
RP	B-DISEASE
presentations	O
,	O
including	O
attenuated	O
vessels	O
,	O
waxy	O
optic	O
disk	O
,	O
and	O
pigment	O
deposits	O
in	O
the	O
mid	O
-	O
peripheral	O
of	O
the	O
retina	O
.	O

A	O
.	O

Stereocilia	O
form	O
crosslinks	O
necessary	O
for	O
longitudinal	O
rigidity	O
and	O
outer	O
hair	O
cell	O
structure	O
,	O
and	O
upon	O
mechanical	O
deflection	O
,	O
stereociliary	O
transduction	O
sensitive	O
channels	O
open	O
for	O
cellulardepolarization	O
(	O
5	O
,	O
6	O
)	O
.	O

Novel	O
COMP	B-GENE
and	O
COL2A1	B-GENE
Mutations	O
Identified	O
in	O
Four	O
Patients	O
with	O
Clinically	O
and	O
Radiographically	O
Confirmed	O
PSACH	B-DISEASE
or	O
MED	B-DISEASE
COMP	B-GENE
EGF	O
-	O
like	O
mutations	O
were	O
identified	O
in	O
MED	B-DISEASE
patient	O
ESDN	O
-	O
00521	O
and	O
PSACH	B-DISEASE
patient	O
ESDN	O
-	O
01040	O
,	O
both	O
of	O
which	O
are	O
novel	O
variants	O
that	O
are	O
not	O
present	O
in	O
the	O
dbSNP	O
database	O
version	O
130	O
(	O
May	O
2009	O
)	O
.	O

Effects	O
of	O
calcitonin	O
on	O
rat	O
extrapyramidal	O
motor	O
system	O
:	O
behavioral	O
and	O
biochemical	O
data	O
.	O

5	O
D	O
)	O
.	O

(	O
I	O
)	O
OCTs	O
display	O
atrophy	B-DISEASE
of	I-DISEASE
photoreceptors	I-DISEASE
layer	I-DISEASE
in	O
the	O
perifoveal	O
region	O
and	O
normal	O
foveal	O
thickness	O
.	O

Before	O
conversion	O
8	O
(	O
32	O
%	O
)	O
patients	O
had	O
no	O
proteinuria	B-DISEASE
,	O
whereas	O
afterwards	O
all	O
patients	O
had	O
proteinuria	B-DISEASE
.	O

All	O
mutations	O
identified	O
in	O
this	O
manuscript	O
were	O
described	O
according	O
to	O
the	O
guidelines	O
summarized	O
on	O
the	O
Mutation	O
Nomenclature	O
Homepage	O
at	O
the	O
HGVS	O
website	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hgvs	O
.	O
org	O
/	O
mutnomen	O
/	O
)	O
.	O

In	O
the	O
auditory	O
apparatus	O
,	O
myosin	B-GENE
VIIA	I-GENE
is	O
synthesized	O
in	O
the	O
hair	O
cells	O
of	O
the	O
inner	O
ear	O
and	O
participates	O
in	O
the	O
formation	O
of	O
hair	O
bundles	O
associated	O
with	O
stereocilia	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

DNA	O
from	O
blood	O
lymphocytes	O
was	O
isolated	O
from	O
all	O
five	O
subjects	O
.	O

Finally	O
,	O
we	O
have	O
compared	O
the	O
prevalence	O
of	O
the	O
variants	O
in	O
the	O
hearing	O
impaired	O
population	O
with	O
the	O
general	O
population	O
.	O

The	O
a	O
-	O
and	O
b	O
-	O
waves	O
of	O
the	O
scotopic	O
and	O
photopic	O
full	O
-	O
field	O
ERGs	O
were	O
of	O
normal	O
amplitudes	O
.	O

Dr	O
.	O

Empty	O
squares	O
had	O
fewer	O
than	O
10	O
individuals	O
.	O

We	O
report	O
syncope	B-DISEASE
and	O
bradycardia	B-DISEASE
in	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
following	O
administration	O
of	O
intranasal	O
dexmedetomidine	B-Chemical
for	O
sedation	O
for	O
a	O
voiding	O
cystourethrogram	O
.	O

Introduction	O
of	O
a	O
proline	B-Chemical
would	O
alter	O
the	O
ability	O
of	O
the	O
cleft	O
to	O
open	O
and	O
close	O
properly	O
upon	O
binding	O
to	O
actin	O
.	O

Analysis	O
of	O
family	O
members	O
from	O
whom	O
DNA	O
was	O
available	O
confirmed	O
three	O
of	O
the	O
putative	O
variants	O
were	O
artefacts	O
and	O
the	O
remaining	O
ones	O
in	O
CC2D2A	B-GENE
and	O
WFS1	B-GENE
did	O
not	O
segregate	O
with	O
disease	O
.	O

Increased	O
mental	O
slowing	O
associated	O
with	O
the	O
APOE	O
epsilon4	B-VARIANT
allele	O
after	O
trihexyphenidyl	B-Chemical
oral	O
anticholinergic	O
challenge	O
in	O
healthy	O
elderly	O
.	O

Our	O
subsequent	O
analysis	O
in	O
15	O
ethnically	O
-	O
matched	O
hearing	O
individuals	O
revealed	O
six	O
similar	O
variants	O
,	O
suggesting	O
that	O
this	O
observation	O
is	O
not	O
limited	O
to	O
families	O
with	O
deafness	B-DISEASE
.	O

A	O
72	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
"	O
flash	O
"	O
pulmonary	B-DISEASE
edema	I-DISEASE
,	O
preceded	O
by	O
chest	O
pain	O
,	O
requiring	O
intubation	O
.	O

sv	O
:	O
stria	O
vascularis	O
.	O

We	O
analyzed	O
a	O
cohort	O
of	O
94	O
NSHL	B-DISEASE
and	O
one	O
syndromic	O
patient	O
and	O
determined	O
three	O
homozygous	O
and	O
six	O
heterozygous	O
STRC	B-GENE
deletions	O
.	O

Our	O
cohort	O
of	O
103	O
patients	O
includes	O
94	O
unrelated	O
individuals	O
;	O
52	O
%	O
of	O
them	O
now	O
have	O
firm	O
genetic	O
diagnoses	O
,	O
including	O
diagnoses	O
due	O
to	O
mtDNA	O
mutations	O
(	O
29	O
%	O
)	O
,	O
recessive	O
-	O
type	O
mutations	O
(	O
22	O
%	O
)	O
,	O
and	O
X	O
-	O
linked	O
mutations	O
(	O
1	O
%	O
)	O
(	O
Figure	O
5	O
)	O
.	O

Identification	O
of	O
the	O
responsible	O
mutation	O
in	O
families	O
with	O
autosomal	B-DISEASE
-	I-DISEASE
dominant	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ADNSHL	B-DISEASE
)	O
is	O
difficult	O
because	O
mutations	O
in	O
27	O
different	O
genes	O
have	O
been	O
identified	O
as	O
causing	O
this	O
common	O
form	O
of	O
deafness	B-DISEASE
(	O
Hereditary	O
Hearing	O
Loss	O
Homepage	O
)	O
.	O

Cognitive	B-DISEASE
deterioration	I-DISEASE
from	O
long	O
-	O
term	O
abuse	O
of	O
dextromethorphan	B-Chemical
:	O
a	O
case	O
report	O
.	O

The	O
proband	O
underwent	O
renal	O
biopsy	O
in	O
1985	O
which	O
showed	O
possible	O
mesangial	O
expansion	O
with	O
no	O
significant	O
immunoperoxidase	O
staining	O
,	O
and	O
was	O
interpreted	O
as	O
'	O
possible	O
MPGN	B-DISEASE
'	O
.	O

Clinical	O
features	O
of	O
patients	O
in	O
8	O
Korean	O
families	O
carrying	O
autosomal	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
*	O
The	O
hearing	O
test	O
for	O
III	O
-	O
1	O
(	O
KNUF21	B-Chemical
)	O
was	O
performed	O
by	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
.	O

Possible	O
pathologic	O
mutations	O
were	O
defined	O
as	O
(	O
1	O
)	O
mutations	O
found	O
to	O
be	O
homozygotes	O
or	O
compound	O
heterozygotes	O
(	O
and	O
determined	O
by	O
segregation	O
study	O
)	O
;	O
(	O
2	O
)	O
variants	O
that	O
were	O
not	O
found	O
,	O
or	O
were	O
very	O
few	O
,	O
in	O
the	O
192	O
control	O
subjects	O
;	O
and	O
(	O
3	O
)	O
amino	O
acids	O
that	O
were	O
well	O
conserved	O
among	O
various	O
species	O
.	O

This	O
study	O
systematically	O
reviewed	O
GSDs	B-DISEASE
as	O
defined	O
in	O
"	O
Nosology	O
and	O
Classification	O
of	O
genetic	B-DISEASE
skeletal	I-DISEASE
disorders	I-DISEASE
(	O
2010	O
version	O
)	O
"	O
using	O
Chinese	O
biomedical	O
literature	O
published	O
over	O
the	O
past	O
34	O
years	O
from	O
1978	O
to	O
2012	O
.	O

S1	O
)	O
.	O

In	O
this	O
family	O
,	O
a	O
4	O
,	O
846	O
-	O
bp	O
genomic	O
deletion	O
was	O
detected	O
that	O
resulted	O
in	O
loss	O
of	O
the	O
eya	O
domain	O
(	O
eyaHR	O
)	O
as	O
well	O
as	O
part	O
of	O
the	O
variable	O
region	O
(	O
eyaVR	O
)	O
(	O
16	O
)	O
.	O

Acoustic	O
reflexes	O
were	O
detected	O
in	O
all	O
OPA1	B-GENE
-	O
H	O
patients	O
,	O
whereas	O
they	O
were	O
absent	O
in	O
all	O
but	O
one	O
(	O
Subject	O
10	O
)	O
of	O
the	O
OPA1	B-GENE
-	O
M	O
group	O
.	O

A	O
large	O
number	O
of	O
TCOF1	B-GENE
polymorphisms	O
were	O
detected	O
.	O

Patients	O
who	O
received	O
enalapril	B-Chemical
experienced	O
clinically	O
and	O
statistically	O
significantly	O
less	O
symptomatic	O
hypotension	B-DISEASE
(	O
5	O
.	O
2	O
%	O
)	O
than	O
the	O
patients	O
who	O
received	O
prazosin	B-Chemical
(	O
12	O
.	O
9	O
%	O
)	O
.	O

7	O
,	O
8	O
Mutations	O
of	O
NDP	B-GENE
encoding	O
norrin	O
,	O
a	O
protein	O
of	O
133	O
residues	O
,	O
were	O
identified	O
in	O
subjects	O
with	O
Norrie	B-DISEASE
disease	I-DISEASE
.	O

Six	O
partial	O
responses	O
were	O
observed	O
for	O
an	O
overall	O
response	O
rate	O
of	O
16	O
%	O
.	O

We	O
aligned	O
the	O
reads	O
to	O
the	O
reference	O
genome	O
by	O
Burrows	O
-	O
Wheeler	O
Aligner	O
(	O
BWA0	O
.	O
5	O
.	O
8	O
)	O
[	O
8	O
]	O
,	O
and	O
passed	O
the	O
alignment	O
result	O
to	O
the	O
Genome	O
Analysis	O
Toolkit	O
(	O
GATK1	O
.	O
0	O
.	O
4705	O
)	O
to	O
identify	O
the	O
breakpoints	O
.	O

The	O
most	O
frequent	O
genetic	O
cause	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
identified	O
so	O
far	O
in	O
the	O
Slovak	O
Roma	O
population	O
is	O
the	O
c	B-VARIANT
.	I-VARIANT
71G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Trp24	I-VARIANT
*	I-VARIANT
)	O
mutation	O
in	O
GJB2	B-GENE
gene	O
[	O
26	O
]	O
.	O

C	O
,	O
D	O
OSBPL2	B-GENE
(	O
green	O
)	O
is	O
also	O
expressed	O
in	O
stereocilia	O
of	O
cochlear	O
inner	O
hair	O
cells	O
(	O
IHC	O
)	O
as	O
demonstrated	O
by	O
co	O
-	O
immunostaining	O
with	O
anti	O
-	O
otoferlin	O
antibody	O
(	O
red	O
)	O
.	O

The	O
following	O
genes	O
were	O
identified	O
as	O
being	O
located	O
at	O
regions	O
of	O
distinct	O
CNVs	O
in	O
the	O
indicated	O
family	O
members	O
:	O
GSTM1	B-GENE
in	O
1p13	O
.	O
3	O
(	O
I	O
-	O
1	O
,	O
II	O
-	O
3	O
,	O
II	O
-	O
7	O
,	O
and	O
II	O
-	O
9	O
)	O
(	O
Figure	O
2	O
C	O
)	O
,	O
UGT2B17	B-GENE
in	O
4q13	O
.	O
2	O
(	O
I	O
-	O
2	O
and	O
II	O
-	O
7	O
)	O
,	O
BNTL3	O
in	O
5q35	O
.	O
3	O
(	O
II	O
-	O
1	O
)	O
,	O
and	O
LILRB2	B-GENE
in	O
19q13	O
.	O
4	O
(	O
I	O
-	O
2	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

A	O
-	O
O	O
Chromatograms	O
of	O
characterized	O
pathogenic	O
mutations	O
in	O
TCS	B-DISEASE
patients	O
.	O

OPA1	B-GENE
is	O
situated	O
on	O
chromosome	O
3q28	O
-	O
29	O
,	O
spans	O
approximately	O
100	O
kb	O
,	O
and	O
is	O
composed	O
of	O
30	O
coding	O
exons	O
.	O

In	O
some	O
ears	O
,	O
however	O
,	O
the	O
cochlear	O
potentials	O
showed	O
no	O
clear	O
separation	O
between	O
summating	O
potential	O
and	O
the	O
prolonged	O
negative	O
component	O
.	O

Subject	O
I	O
:	O
1	O
with	O
normal	O
hearing	O
had	O
a	O
heterozygous	O
mutation	O
in	O
CDH23	B-GENE
(	O
p	B-VARIANT
.	I-VARIANT
P240L	I-VARIANT
)	O
,	O
and	O
subject	O
I	O
:	O
2	O
with	O
normal	O
hearing	O
had	O
a	O
heterozygous	O
mutation	O
in	O
PCDH15	B-GENE
(	O
p	B-VARIANT
.	I-VARIANT
R283H	I-VARIANT
)	O
.	O

However	O
,	O
the	O
father	O
of	O
le1432	O
and	O
the	O
mother	O
of	O
le2062	O
harbored	O
an	O
OPA1	B-GENE
mutation	O
.	O

Early	O
recognition	O
that	O
incorporates	O
the	O
clinical	O
and	O
serologic	O
clues	O
is	O
paramount	O
to	O
timely	O
institution	O
of	O
treatment	O
,	O
as	O
its	O
delay	O
may	O
result	O
in	O
catastrophic	O
outcomes	O
.	O

To	O
investigate	O
the	O
presence	O
of	O
functional	O
interactions	O
among	O
genes	O
,	O
including	O
direct	O
(	O
physical	O
)	O
and	O
indirect	O
(	O
functional	O
)	O
associations	O
,	O
we	O
used	O
STRING	O
,	O
a	O
database	O
of	O
known	O
and	O
predicted	O
protein	O
interactions	O
[	O
61	O
]	O
.	O

Patient	O
feedback	O
has	O
highlighted	O
the	O
need	O
for	O
,	O
and	O
perceived	O
value	O
of	O
,	O
a	O
definitive	O
diagnosis	O
based	O
on	O
genetic	O
testing	O
,	O
and	O
has	O
shown	O
that	O
patients	O
are	O
motivated	O
by	O
a	O
variety	O
of	O
factors	O
to	O
seek	O
genetic	O
testing	O
[	O
32	O
]	O
.	O

Ninety	O
-	O
three	O
that	O
consented	O
to	O
molecular	O
genetic	O
testing	O
and	O
underwent	O
at	O
least	O
one	O
molecular	O
genetic	O
test	O
were	O
included	O
.	O

One	O
explanation	O
for	O
these	O
discrepancies	O
could	O
be	O
the	O
presence	O
of	O
population	O
-	O
specific	O
modifiers	O
,	O
genetic	O
or	O
other	O
,	O
such	O
as	O
the	O
recently	O
described	O
polymorphisms	O
in	O
the	O
3	O
'	O
-	O
UTR	O
of	O
KCNQ1	B-GENE
,	O
mitigating	O
the	O
effect	O
of	O
the	O
mutated	O
allele	O
by	O
reduced	O
expression	O
[	O
30	O
]	O
.	O

NA	O
,	O
gene	O
not	O
analyzed	O
by	O
Sanger	O
sequencing	O
;	O
Undef	O
,	O
data	O
not	O
accurate	O
enough	O
to	O
clearly	O
discriminate	O
a	O
clinical	O
subtype	O
.	O

A	O
)	O
The	O
genomic	O
position	O
corresponding	O
to	O
variation	O
MYO7A	B-GENE
c	B-VARIANT
.	I-VARIANT
3827C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
shows	O
a	O
good	O
score	O
for	O
primate	O
,	O
mammal	O
and	O
vertebrate	O
conservation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
find	O
frequent	O
arRP	B-DISEASE
genes	O
in	O
the	O
Japanese	O
population	O
.	O

This	O
means	O
that	O
the	O
differentiation	O
in	O
survival	O
in	O
the	O
type	O
1	O
group	O
is	O
not	O
due	O
to	O
differences	O
in	O
the	O
known	O
5	O
'	O
polymorphisms	O
,	O
and	O
,	O
more	O
generally	O
,	O
that	O
differences	O
in	O
5	O
'	O
polymorphisms	O
are	O
not	O
the	O
cause	O
for	O
the	O
different	O
survival	O
of	O
patients	O
with	O
the	O
same	O
mutations	O
in	O
PEX1	B-GENE
.	O

Among	O
these	O
41	O
patients	O
,	O
deafness	B-DISEASE
(	O
n	O
=	O
35	O
;	O
34	O
.	O
70	O
%	O
)	O
was	O
the	O
most	O
frequent	O
,	O
followed	O
by	O
nephropathy	B-DISEASE
(	O
n	O
=	O
21	O
;	O
20	O
.	O
79	O
%	O
)	O
.	O

Our	O
study	O
agrees	O
well	O
with	O
other	O
work	O
demonstrating	O
that	O
analysis	O
of	O
WES	O
data	O
also	O
allows	O
for	O
CNV	O
and	O
linkage	O
determination	O
due	O
to	O
its	O
quantitative	O
traits	O
.	O

Values	O
are	O
expressed	O
as	O
means	O
+	O
-	O
standard	O
errors	O
of	O
the	O
mean	O
.	O

Platelet	O
serotonin	B-Chemical
content	O
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
nitroglycerin	B-Chemical
in	O
subjects	O
with	O
no	O
migraine	B-DISEASE
attack	I-DISEASE
but	O
no	O
consistent	O
change	O
was	O
observed	O
in	O
patients	O
with	O
migraine	O
attack	O
.	O

Oxidative	O
stress	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epileptogenesis	O
and	O
cognitive	B-DISEASE
deficits	I-DISEASE
,	O
and	O
antioxidants	O
have	O
a	O
putative	O
antiepileptic	O
potential	O
.	O

D356V	B-VARIANT
is	O
predicted	O
by	O
Tmpred	O
[	O
19	O
]	O
to	O
disrupt	O
the	O
transmembrane	O
domain	O
structure	O
and	O
by	O
the	O
program	O
'	O
Sorting	O
Intolerant	O
From	O
Tolerant	O
'	O
[	O
20	O
]	O
not	O
to	O
be	O
a	O
tolerated	O
substitution	O
.	O

Medial	O
changes	O
in	O
arterial	B-DISEASE
spasm	I-DISEASE
induced	O
by	O
L	B-Chemical
-	I-Chemical
norepinephrine	I-Chemical
.	O

The	O
overlapping	O
audiograms	O
of	O
these	O
subjects	O
revealed	O
no	O
significant	O
differences	O
between	O
the	O
subjects	O
with	O
truncating	O
mutations	O
associated	O
with	O
missense	O
mutations	O
and	O
those	O
with	O
biallelic	O
missense	O
mutations	O
(	O
Figure	O
4	O
)	O
.	O

Our	O
study	O
showed	O
that	O
exome	O
sequencing	O
is	O
a	O
fast	O
,	O
sensitive	O
,	O
and	O
relatively	O
low	O
-	O
cost	O
method	O
to	O
identify	O
gene	O
(	O
s	O
)	O
responsible	O
for	O
AS	B-DISEASE
.	O

Anthropometric	O
measurements	O
and	O
laboratory	O
testing	O
were	O
conducted	O
.	O

Previous	O
studies	O
have	O
found	O
that	O
digenic	O
inheritance	O
of	O
NSHI	B-DISEASE
is	O
caused	O
by	O
mutations	O
in	O
the	O
GJB2	B-GENE
and	O
GJB3	B-GENE
genes	O
[	O
26	O
]	O
.	O

Triangles	O
,	O
reaction	O
buffer	O
with	O
0	O
.	O
1	O
mM	O
CaCl	B-Chemical
2	O
;	O
circles	O
,	O
reaction	O
buffer	O
with	O
1	O
mM	O
EGTA	B-Chemical
;	O
open	O
symbols	O
,	O
ATPase	O
activity	O
of	O
WT	O
;	O
solid	O
symbols	O
,	O
ATPase	O
activity	O
of	O
(	O
a	O
)	O
WT	O
and	O
(	O
b	O
)	O
p	B-VARIANT
.	I-VARIANT
R205Q	I-VARIANT
.	O

Seven	O
families	O
were	O
consanguineous	O
.	O

C	O
.	O

However	O
,	O
in	O
the	O
tubular	O
basement	O
membrane	O
(	O
TBM	O
)	O
,	O
very	O
intense	O
granular	O
deposits	O
of	O
polyclonal	O
IgG	O
and	O
C3	O
were	O
noted	O
.	O

PEX1	B-GENE
upstream	O
polymorphisms	O
bear	O
the	O
potential	O
to	O
modulate	O
the	O
disease	O
phenotype	O
due	O
to	O
their	O
influence	O
on	O
PEX1	B-GENE
expression	O
levels	O
.	O

Protection	O
against	O
amphetamine	B-Chemical
-	O
induced	O
neurotoxicity	B-DISEASE
toward	O
striatal	B-DISEASE
dopamine	B-Chemical
neurons	O
in	O
rodents	O
by	O
LY274614	B-Chemical
,	O
an	O
excitatory	O
amino	B-Chemical
acid	I-Chemical
antagonist	O
.	O

SLC26A4	B-GENE
Site	O
-	O
Directed	O
Mutagenesis	O
Primers	O
.	O

Because	O
inheritance	O
was	O
consistent	O
with	O
an	O
autosomal	O
or	O
X	O
-	O
linked	O
recessive	O
pattern	O
based	O
on	O
family	O
pedigrees	O
,	O
candidate	O
pathogenic	O
variants	O
selected	O
for	O
further	O
analysis	O
were	O
rare	O
homozygous	O
or	O
hemizygous	O
nonsense	O
,	O
missense	O
,	O
splice	O
site	O
and	O
indel	O
variants	O
with	O
allele	O
frequencies	O
of	O
<	O
=	O
0	O
.	O
005	O
in	O
public	O
variant	O
databases	O
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
)	O
and	O
risperidone	B-Chemical
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
.	O

High	O
resolution	O
SDOCT	O
images	O
and	O
manual	O
subanalysis	O
of	O
retinal	O
layers	O
allowed	O
detailed	O
quantitative	O
analysis	O
of	O
various	O
inner	O
and	O
outer	O
retinal	O
layers	O
within	O
the	O
macular	O
region	O
in	O
ADOA	B-DISEASE
patients	O
.	O

Given	O
the	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
the	O
family	O
it	O
is	O
very	O
possible	O
that	O
either	O
X	O
-	O
inactivation	O
is	O
skewed	O
in	O
those	O
target	O
systems	O
or	O
that	O
the	O
expression	O
of	O
PRS	B-GENE
-	I-GENE
II	I-GENE
is	O
compensating	O
PRS	O
enzymatic	O
function	O
as	O
previously	O
suggested	O
,	O
and	O
so	O
phosphoribosyl	O
pyrophosphate	I-Chemical
synthesis	O
would	O
not	O
be	O
critically	O
affected	O
[	O
11	O
]	O
.	O

The	O
encoded	O
protein	O
stimulates	O
adenylyl	O
cyclase	O
(	O
AC	O
)	O
,	O
thereby	O
generating	O
the	O
second	O
messenger	O
cAMP	O
.	O

[	O
22	O
]	O
)	O
.	O

Furthermore	O
,	O
preclinical	O
gene	O
therapy	O
studies	O
in	O
animal	O
models	O
are	O
ongoing	O
for	O
a	O
substantial	O
set	O
of	O
RD	B-DISEASE
genes	O
[	O
den	O
Hollander	O
et	O
al	O
.	O
,	O
2010	O
]	O
and	O
are	O
likely	O
to	O
enter	O
clinical	O
trials	O
in	O
near	O
future	O
.	O

Wrote	O
the	O
paper	O
:	O
JG	O
QW	O
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
identified	O
in	O
the	O
additional	O
exons	O
of	O
MATN1	B-GENE
,	O
MATN3	B-GENE
,	O
and	O
MATN4	B-GENE
that	O
we	O
screened	O
,	O
which	O
is	O
consistent	O
with	O
our	O
previous	O
studies	O
[	O
Jackson	O
et	O
al	O
.	O
,	O
2004	O
]	O
.	O

Importantly	O
,	O
10	O
/	O
87	O
heterozygous	O
patients	O
(	O
6M	O
/	O
4F	O
)	O
(	O
11	O
,	O
5	O
%	O
)	O
reached	O
ESKD	B-DISEASE
at	O
ages	O
ranging	O
from	O
37	O
-	O
69	O
-	O
yo	O
(	O
mean	O
50	O
,	O
1	O
-	O
yo	O
)	O
.	O

Yet	O
,	O
while	O
all	O
individuals	O
carrying	O
both	O
the	O
EDNRB	B-GENE
and	O
the	O
EDN3	B-GENE
heterozygous	O
mutations	O
have	O
virtually	O
the	O
same	O
HSCR	B-DISEASE
phenotype	O
(	O
isolated	O
long	O
segment	O
)	O
,	O
only	O
one	O
(	O
II	O
-	O
5	O
)	O
member	O
of	O
the	O
family	O
has	O
pigmentation	O
problems	O
.	O

In	O
families	O
1	O
and	O
2	O
,	O
the	O
staining	O
pattern	O
was	O
characterized	O
by	O
numerous	O
aggregates	O
of	O
small	O
size	O
(	O
<	O
0	O
.	O
5	O
mu	O
m	O
)	O
(	O
Fig	O
.	O

Plates	O
were	O
spun	O
at	O
2500rpm	O
for	O
90	O
minutes	O
and	O
incubated	O
for	O
24	O
hours	O
at	O
37	O
deg	O
C	O
before	O
replacing	O
media	O
.	O

Succinylcholine	B-Chemical
-	O
induced	O
masseter	O
muscle	O
rigidity	O
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O

She	O
communicates	O
as	O
an	O
adult	O
with	O
sign	O
language	O
.	O

reported	O
the	O
pathogenicity	O
of	O
V659L	B-VARIANT
in	O
Chinese	O
EVA	B-DISEASE
patients	O
[	O
25	O
]	O
.	O

The	O
USH2A	B-GENE
large	O
extracellular	O
domain	O
is	O
projected	O
into	O
the	O
pericilliary	O
matrix	O
and	O
may	O
interact	O
with	O
the	O
connecting	O
cilium	O
to	O
fulfil	O
important	O
structural	O
or	O
signaling	O
roles	O
[	O
15	O
]	O
.	O

To	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
WFS1	B-GENE
,	O
patients	O
were	O
divided	O
into	O
three	O
groups	O
according	O
to	O
the	O
predicted	O
functional	O
consequences	O
of	O
each	O
mutation	O
for	O
WFS1	B-GENE
protein	O
function	O
(	O
Table	O
4	O
,	O
Figure	O
1	O
)	O
.	O

We	O
cannot	O
discard	O
the	O
possibility	O
that	O
additional	O
changes	O
in	O
USH2A	B-GENE
or	O
in	O
other	O
USH	B-DISEASE
genes	O
,	O
present	O
in	O
these	O
patients	O
,	O
have	O
some	O
modifying	O
effect	O
on	O
the	O
phenotype	O
[	O
37	O
,	O
38	O
]	O
.	O

Sequencing	O
of	O
MYO7A	B-GENE
exon	O
11	O
revealed	O
that	O
,	O
as	O
expected	O
,	O
he	O
was	O
heterozygote	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
1135	I-VARIANT
-	I-VARIANT
1147dup	I-VARIANT
mutation	O
.	O

Identifying	O
the	O
genetic	O
basis	O
of	O
deafness	B-DISEASE
provides	O
crucial	O
information	O
for	O
diagnosis	O
,	O
intervention	O
and	O
treatment	O
of	O
the	O
disease	O
.	O

Perl	O
script	O
and	O
Annovar	O
were	O
used	O
to	O
annotate	O
variants	O
and	O
search	O
the	O
known	O
SNPs	O
and	O
indels	O
from	O
dbsnp135	O
and	O
1000	O
genome	O
draft	O
.	O

Eight	O
patients	O
stopped	O
using	O
GTN	B-Chemical
because	O
headache	O
-	O
-	O
attributed	O
to	O
its	O
use	O
-	O
-	O
became	O
intolerable	O
.	O

A	O
second	O
concern	O
about	O
routine	O
clinical	O
application	O
of	O
WGS	O
is	O
the	O
high	O
likelihood	O
of	O
uninterpretable	O
findings	O
,	O
since	O
uncertain	O
results	O
can	O
impact	O
medical	O
decision	O
-	O
making	O
and	O
increase	O
costs	O
[	O
77	O
]	O
.	O

This	O
region	O
of	O
the	O
protein	O
is	O
predicted	O
to	O
be	O
highly	O
hydrophobic	O
,	O
as	O
previously	O
shown	O
in	O
a	O
hydrophobicity	O
plot	O
(	O
Figure	O
3	O
)	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
a	O
novel	O
DFNA10	B-DISEASE
mutation	O
,	O
p	B-VARIANT
.	I-VARIANT
I411K	I-VARIANT
,	O
in	O
a	O
Chinese	O
family	O
.	O

No	O
significant	O
effect	O
of	O
5	O
-	O
HTTLPR	I-GENE
or	O
gender	O
was	O
observed	O
.	O

The	O
GRHL2	B-GENE
gene	O
is	O
responsible	O
for	O
autosomal	B-DISEASE
dominant	I-DISEASE
NSHL	I-DISEASE
,	O
affecting	O
the	O
DFNA28	B-GENE
locus	O
.	O

The	O
four	O
probably	O
or	O
possibly	O
damaging	O
mutations	O
that	O
we	O
found	O
were	O
in	O
SLC26A4	B-GENE
,	O
GJB2	B-GENE
,	O
MYO3A	B-GENE
,	O
OTOF	B-GENE
,	O
and	O
STRC	B-GENE
.	O

This	O
mutation	O
is	O
located	O
in	O
the	O
highly	O
conserved	O
GTPase	O
domain	O
and	O
has	O
been	O
previously	O
reported	O
once	O
in	O
two	O
related	O
patients	O
[	O
20	O
]	O
.	O

Gemfibrozil	B-Chemical
-	O
lovastatin	B-Chemical
therapy	O
for	O
primary	O
hyperlipoproteinemias	I-DISEASE
.	O

In	O
one	O
patient	O
(	O
RP	O
-	O
531	O
)	O
the	O
validation	O
of	O
the	O
enrichment	O
process	O
gave	O
an	O
atypical	O
image	O
in	O
the	O
bioanalyzer	O
(	O
Figure	O
3	O
)	O
.	O

However	O
,	O
the	O
administration	O
of	O
lamivudine	B-Chemical
,	O
a	O
reverse	O
transcriptase	O
inhibitor	O
,	O
for	O
23	O
months	O
dramatically	O
improved	O
her	O
liver	O
severity	O
.	O

As	O
it	O
revealed	O
chloroquine	B-Chemical
-	O
induced	O
myopathy	B-DISEASE
,	O
medication	O
was	O
stopped	O
.	O

Note	O
that	O
the	O
exons	O
in	O
n	O
=	O
0	O
were	O
captured	O
in	O
all	O
20	O
samples	O
and	O
at	O
n	O
=	O
0	O
,	O
the	O
experimental	O
counts	O
are	O
greater	O
than	O
the	O
expected	O
ones	O
due	O
to	O
common	O
uncapured	O
exons	O
.	O

With	O
no	O
other	O
mutations	O
identified	O
in	O
WFS1	B-GENE
in	O
these	O
two	O
individuals	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
p	B-VARIANT
.	I-VARIANT
His313Tyr	I-VARIANT
is	O
capable	O
of	O
causing	O
WS	B-DISEASE
in	O
the	O
heterozygous	O
state	O
.	O

No	O
other	O
factor	O
predisposing	O
to	O
RPN	B-DISEASE
could	O
be	O
discovered	O
.	O

Reads	O
passing	O
the	O
Illumina	O
"	O
chastity	O
filter	O
"	O
were	O
aligned	O
to	O
the	O
UCSC	O
hg19	O
genome	O
assembly	O
(	O
pseudoautosomal	O
region	O
on	O
Y	O
chromosome	O
masked	O
,	O
alternative	O
haplotypes	O
removed	O
)	O
using	O
Novoalign	O
v2	O
.	O
07	O
.	O
18	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
novocraft	O
.	O
com	O
)	O
,	O
and	O
duplicate	O
read	O
pairs	O
were	O
removed	O
.	O

We	O
did	O
not	O
perform	O
a	O
functional	O
analysis	O
of	O
the	O
mutated	O
protein	O
,	O
but	O
a	O
molecular	O
difference	O
between	O
these	O
two	O
residues	O
(	O
glutamic	O
acid	O
is	O
an	O
acidic	O
amino	O
acid	O
,	O
whereas	O
lysine	O
is	O
a	O
basic	O
one	O
)	O
supports	O
the	O
hypothesis	O
that	O
this	O
replacement	O
may	O
affect	O
the	O
structure	O
of	O
the	O
protein	O
subunit	O
,	O
thus	O
the	O
function	O
,	O
folding	O
,	O
or	O
trafficking	O
of	O
that	O
protein	O
.	O

The	O
maximum	O
phoneme	O
recognition	O
score	O
(	O
mean	O
percentage	O
correct	O
for	O
both	O
ears	O
)	O
was	O
retained	O
from	O
the	O
monaural	O
performance	O
versus	O
intensity	O
curves	O
.	O

Thus	O
,	O
novel	O
missense	O
variant	O
in	O
SLC26A4	B-GENE
is	O
possibly	O
pathogenic	O
.	O

Liver	O
toxicity	O
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha	O
-	O
glutathione	B-Chemical
S	O
-	O
transferase	O
(	O
alpha	O
-	O
GST	O
)	O
and	O
by	O
histology	O
.	O

Notably	O
,	O
the	O
P1220	O
residue	O
of	O
myosin	B-GENE
VIIa	I-GENE
,	O
and	O
the	O
G1301	O
and	O
C3307	O
residues	O
of	O
usherin	O
,	O
which	O
are	O
involved	O
in	O
the	O
USH	B-DISEASE
patients	O
'	O
missense	O
mutations	O
,	O
are	O
conserved	O
in	O
C	O
.	O

To	O
simulate	O
the	O
background	O
noise	O
of	O
the	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
of	O
a	O
given	O
sample	O
,	O
spectral	O
counts	O
reported	O
as	O
0	O
by	O
Mascot	B-Chemical
were	O
replaced	O
by	O
randomly	O
generated	O
spectral	O
count	O
values	O
that	O
are	O
normally	O
distributed	O
with	O
a	O
mean	O
and	O
s	O
.	O
d	O
.	O

Thirty	O
-	O
six	O
Italian	O
patients	O
(	O
from	O
33	O
different	O
families	O
)	O
with	O
a	O
clinical	O
diagnosis	O
of	O
USH	B-DISEASE
were	O
recruited	O
through	O
the	O
Hereditary	O
Retinal	O
Degenerations	O
Referring	O
Centre	O
of	O
the	O
Eye	O
Clinic	O
of	O
the	O
University	O
of	O
Florence	O
.	O

CAKUT	B-DISEASE
cover	O
a	O
wide	O
range	O
of	O
structural	O
malformations	O
that	O
result	O
from	O
a	O
defect	O
in	O
the	O
morphogenesis	O
of	O
the	O
kidney	O
and	O
/	O
or	O
the	O
urinary	O
tract	O
3	O
-	O
5	O
.	O

Recent	O
genetic	O
studies	O
have	O
demonstrated	O
that	O
mutations	O
in	O
the	O
type	B-GENE
II	I-GENE
collagen	I-GENE
gene	I-GENE
(	O
COL2A1	B-GENE
)	O
may	O
result	O
in	O
certain	O
human	O
disorders	O
collectively	O
termed	O
type	B-DISEASE
II	I-DISEASE
collagenopathies	I-DISEASE
.	O

Future	O
research	O
should	O
evaluate	O
the	O
longitudinal	O
course	O
of	O
this	O
adverse	O
event	O
to	O
determine	O
its	O
temporal	O
stability	O
and	O
whether	O
a	O
higher	O
fracture	O
rate	O
ensues	O
.	O

Thomas	O
Friedman	O
(	O
National	O
Institute	O
on	O
Deafness	B-DISEASE
and	O
Other	O
Communication	O
Disorders	O
/	O
National	O
Institutes	O
of	O
Health	O
)	O
for	O
critically	O
reading	O
this	O
manuscript	O
.	O

1	O
)	O
.	O

Auditory	B-DISEASE
neuropathy	I-DISEASE
is	O
a	O
hearing	B-DISEASE
disorder	I-DISEASE
characterized	O
by	O
a	O
disrupted	O
temporal	O
coding	O
of	O
acoustic	O
signals	O
in	O
the	O
auditory	O
nerve	O
fibres	O
resulting	O
in	O
impairment	O
of	O
auditory	O
perceptions	O
relying	O
on	O
temporal	O
cues	O
(	O
Starr	O
et	O
al	O
.	O

Yasuhiro	O
Kakazu	O
and	O
Shizuo	O
Komune	O
(	O
Kyushu	O
University	O
)	O
,	O
Drs	O
.	O

MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	I-DISEASE
roots	O
indicative	O
of	O
both	O
myelitis	B-DISEASE
and	O
right	B-DISEASE
brachial	B-DISEASE
plexitis	I-DISEASE
.	O

(	O
+	O
)	O
-	O
Propranolol	B-Chemical
had	O
no	O
effect	O
on	O
fatty	B-Chemical
acid	I-Chemical
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	B-Chemical
and	O
glucose	B-Chemical
.	O
4	O
.	O

SNPs	O
and	O
Indels	O
affecting	O
the	O
coding	O
sequence	O
were	O
annotated	O
using	O
Seattle	O
Seq	O
annotation	O
to	O
predict	O
the	O
protein	O
function	O
effect	O
of	O
the	O
variants	O
.	O

Performed	O
the	O
experiments	O
:	O
BYC	O
JK	O
JC	O
ARK	O
SJM	O
SHL	O
NK	O
.	O

Vinorelbine	B-Chemical
-	I-DISEASE
related	I-DISEASE
cardiac	I-DISEASE
events	O
concern	O
about	O
1	O
%	O
of	O
treated	O
patients	O
in	O
clinical	O
trials	O
.	O

In	O
this	O
study	O
,	O
using	O
whole	O
exome	O
sequencing	O
,	O
we	O
have	O
identified	O
the	O
minichromosome	B-GENE
maintenance	I-GENE
complex	I-GENE
component	I-GENE
2	I-GENE
gene	I-GENE
(	O
MCM2	B-GENE
)	O
as	O
a	O
novel	O
gene	O
causing	O
autosomal	B-DISEASE
dominant	I-DISEASE
progressive	I-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
a	O
large	O
Chinese	O
pedigree	O
[	O
10	O
-	O
13	O
]	O
.	O

After	O
application	O
of	O
these	O
5	O
filtering	O
steps	O
(	O
also	O
listed	O
in	O
table	O
2	O
)	O
,	O
we	O
found	O
3	O
SNPs	O
and	O
1	O
indel	O
inpatients	O
DF7	O
-	O
V	O
.	O
1	O
and	O
V	O
.	O
2	O
,	O
11	O
SNPs	O
and	O
1	O
indel	O
inpatient	O
DF22	O
-	O
VI	O
.	O
1	O
,	O
3	O
SNPs	O
and	O
1	O
indel	O
inpatients	O
DF56	O
-	O
VI	O
.	O
1	O
and	O
VI	O
.	O
2	O
,	O
and	O
6	O
SNPs	O
and	O
0	O
indel	O
inpatient	O
DF137	O
-	O
V	O
.	O
1	O
(	O
Table	O
2	O
and	O
Table	O
S2	O
)	O
.	O

More	O
than	O
400	O
genetic	O
syndromes	O
are	O
associated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Linkage	O
analysis	O
with	O
microsatellite	O
markers	O
surrounding	O
the	O
USH1B	B-GENE
locus	O
on	O
11q13	O
.	O
5	O
and	O
USH2A	B-GENE
on	O
1q41	O
were	O
previously	O
reported	O
on	O
six	O
families	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
mice	O
genetically	O
engineered	O
to	O
have	O
unilateral	O
brain	O
DA	B-Chemical
deficits	O
develop	O
METH	B-Chemical
-	O
induced	O
dopaminergic	O
deficits	O
that	O
are	O
of	O
comparable	O
magnitude	O
on	O
both	O
sides	O
of	O
the	O
brain	O
.	O

CONCLUSION	O
:	O
Pretreatment	O
with	O
remifentanil	B-Chemical
1	O
microg	O
/	O
kg	O
reduced	O
myoclonus	O
after	O
etomidate	B-Chemical
induction	O
without	O
side	O
effects	O
such	O
as	O
sedation	B-DISEASE
,	O
apnea	B-DISEASE
,	O
nausea	O
,	O
or	O
pruritus	B-DISEASE
.	O

AN	O
,	O
YA	O
,	O
SM	O
,	O
NM	O
,	O
HS	O
,	O
and	O
KK	O
contributed	O
to	O
the	O
gathering	O
and	O
interpretation	O
of	O
clinical	O
data	O
.	O

RESULTS	O
:	O
The	O
MTD	O
of	O
cis	B-Chemical
-	I-Chemical
RA	I-Chemical
was	O
160	O
mg	O
/	O
m2	O
/	O
d	O
.	O

-	O
The	O
two	O
variants	O
are	O
:	O
c	B-VARIANT
.	I-VARIANT
1220delG	I-VARIANT
in	O
USH1C	B-GENE
and	O
c	B-VARIANT
.	I-VARIANT
218_219insC	I-VARIANT
in	O
VPS11	B-GENE
.	O

Borosilicate	B-Chemical
pipettes	O
with	O
resistances	O
of	O
1	O
-	O
3	O
M	O
omega	O
were	O
pulled	O
on	O
a	O
Sutter	O
P	O
-	O
97	O
puller	O
(	O
Harvard	O
Apparatus	O
)	O
and	O
fire	O
-	O
polished	O
using	O
a	O
Narishige	O
MF	O
-	O
900	O
microforge	O
.	O

Due	O
to	O
the	O
low	O
number	O
of	O
characterized	O
families	O
,	O
this	O
approach	O
should	O
be	O
used	O
in	O
tandem	O
with	O
other	O
techniques	O
.	O

The	O
median	O
maternal	O
age	O
at	O
diagnosis	O
was	O
31	O
years	O
(	O
range	O
18	O
-	O
39	O
)	O
.	O

Observe	O
the	O
broad	O
thumb	O
in	O
proband	O
2	O
(	O
2E	O
)	O
and	O
broad	O
medially	O
deviated	B-DISEASE
thumb	I-DISEASE
in	O
proband	O
5	O
(	O
5E	O
)	O
;	O
Note	O
partial	O
syndactyly	B-DISEASE
between	O
the	O
fi	O
ngers	O
in	O
proband	O
1	O
(	O
1E	O
)	O
.	O

Amplicons	O
were	O
inserted	O
between	O
the	O
XhoI	O
/	O
NheI	B-Chemical
and	O
XhoI	O
/	O
BamHI	O
restriction	O
sites	O
for	O
the	O
variants	O
p	B-VARIANT
.	I-VARIANT
E2496E	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
V382M	I-VARIANT
,	O
respectively	O
,	O
using	O
T4	O
DNA	O
ligase	O
(	O
Invitrogen	O
Corporation	O
,	O
Carlsbad	O
,	O
CA	O
)	O
.	O

Although	O
these	O
drugs	O
are	O
highly	O
effective	O
and	O
represent	O
the	O
mainstay	O
of	O
transplant	B-DISEASE
immunosuppression	I-DISEASE
,	O
they	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
nephrotoxicity	B-DISEASE
.	O

3B	O
and	O
3C	O
)	O
.	O

In	O
the	O
family	O
of	O
patient	O
110	O
afflicted	O
with	O
LCA	B-DISEASE
,	O
we	O
performed	O
genome	O
-	O
wide	O
homozygosity	O
mapping	O
using	O
the	O
Affymetrix	O
GeneChip	O
Human	O
Mapping	O
10K	O
Array	O
,	O
version	O
2	O
.	O
0	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

The	O
typical	O
characteristics	O
of	O
LCPD	B-DISEASE
are	O
coxa	B-DISEASE
palan	I-DISEASE
(	O
coxa	B-DISEASE
vara	I-DISEASE
and	O
elevation	O
of	O
the	O
greater	O
trochanter	O
of	O
the	O
femur	O
)	O
[	O
10	O
]	O
.	O

The	O
syndrome	O
reversed	O
after	O
discontinuing	O
risperidone	B-Chemical
and	O
starting	O
treatment	O
with	O
dantrolene	B-Chemical
and	O
bromocriptine	B-Chemical
.	O

[	O
29	O
]	O
reported	O
that	O
in	O
murine	O
XLAS	B-DISEASE
,	O
favorable	O
X	O
-	O
inactivation	O
improved	O
survival	O
of	O
female	O
carriers	O
.	O

Anteroposterior	O
(	O
AP	O
)	O
and	O
lateral	O
radiographs	O
(	O
Sugioka	O
)	O
obtained	O
at	O
the	O
time	O
of	O
the	O
onset	O
of	O
pain	O
show	O
the	O
crescent	O
sign	O
,	O
collapse	O
of	O
femoral	O
head	O
,	O
and	O
no	O
joint	O
space	O
narrowing	O
in	O
either	O
femoral	O
head	O
.	O

Huawei	O
Li	O
received	O
grant	O
support	O
from	O
the	O
National	O
Science	O
Foundation	O
of	O
China	O
(	O
#	O
30728029	O
and	O
#	O
81230019	O
)	O
and	O
the	O
973	O
program	O
(	O
2011CB504506	O
)	O
.	O

To	O
date	O
,	O
61	O
genes	O
and	O
more	O
than	O
100	O
genetic	O
loci	O
have	O
been	O
implicated	O
in	O
ARNSHL	B-DISEASE
(	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
/	O
)	O
.	O

CASE	O
:	O
We	O
describe	O
a	O
second	O
case	O
of	O
fluconazole	B-Chemical
associated	O
agranulocytosis	B-DISEASE
with	O
thrombocytopenia	B-DISEASE
and	O
recovery	O
upon	O
discontinuation	O
of	O
therapy	O
.	O

DNA	O
variants	O
were	O
filtered	O
against	O
dbSNP132	O
[	O
14	O
]	O
and	O
phase	O
3	O
of	O
the	O
1000	O
Genomes	O
project	O
.	O

The	O
mechanism	O
of	O
water	O
intoxication	O
is	O
discussed	O
in	O
regard	O
to	O
these	O
cases	O
.	O

Finally	O
,	O
we	O
extended	O
our	O
screening	O
to	O
include	O
exon	O
50	O
of	O
COL2A1	B-GENE
since	O
a	O
recurrent	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
Gly1170Ser	I-VARIANT
)	O
in	O
this	O
exon	O
has	O
been	O
shown	O
to	O
cause	O
Legg	O
-	O
Calve	O
-	O
Perthes	O
(	O
LCP	O
)	O
disease	O
in	O
four	O
families	O
[	O
Miyamoto	O
et	O
al	O
.	O
,	O
2007	O
;	O
Su	O
et	O
al	O
.	O
,	O
2008	O
]	O
,	O
and	O
there	O
is	O
clear	O
clinical	O
overlap	O
between	O
LCP	O
and	O
MED	B-DISEASE
[	O
Herring	O
and	O
Hotchkiss	O
,	O
1987	O
;	O
Ikegawa	O
et	O
al	O
.	O
,	O
1991	O
]	O
.	O

We	O
enrolled	O
six	O
cases	O
of	O
ADNSHL	B-DISEASE
from	O
Family	O
3187	O
,	O
a	O
large	O
ethnic	O
Han	O
Chinese	O
family	O
,	O
through	O
the	O
Otolaryngology	O
Department	O
of	O
the	O
General	O
Hospital	O
of	O
People	O
'	O
s	O
Liberation	O
Army	O
,	O
Beijing	O
,	O
China	O
clinical	O
evaluations	O
,	O
temporal	O
bone	O
imaging	O
results	O
,	O
audiograms	O
,	O
and	O
other	O
relevant	O
clinical	O
information	O
were	O
collected	O
for	O
each	O
member	O
.	O

Sequencing	O
of	O
all	O
known	O
USH	B-DISEASE
exons	O
and	O
not	O
only	O
the	O
screening	O
of	O
known	O
mutations	O
is	O
required	O
for	O
proper	O
molecular	O
diagnosis	O
and	O
an	O
accurate	O
genetic	O
counseling	O
.	O

Pedigree	O
of	O
a	O
large	O
Chinese	O
family	O
(	O
SY	O
-	O
026	O
)	O
with	O
late	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
ADNSHL	I-DISEASE
carrying	O
the	O
missense	O
G169R	B-VARIANT
mutation	O
in	O
CEACAM16	B-GENE
and	O
the	O
audiograms	O
of	O
four	O
affected	O
subjects	O
from	O
the	O
family	O
.	O

The	O
study	O
was	O
supported	O
by	O
the	O
Geers	O
-	O
Stiftung	O
(	O
to	O
HJB	O
)	O
and	O
the	O
Wellcome	O
Trust	O
(	O
grant	O
no	O
.	O

Family	O
4794	O
includes	O
two	O
affected	O
siblings	O
(	O
31	O
and	O
25	O
years	O
old	O
)	O
and	O
two	O
unaffected	O
parents	O
(	O
Figure	O
1	O
A	O
)	O
.	O

Interestingly	O
,	O
among	O
the	O
identified	O
hearing	B-DISEASE
loss	I-DISEASE
-	O
associated	O
genes	O
,	O
nineteen	O
encode	O
proteins	O
that	O
interact	O
with	O
actin	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

Thirty	O
-	O
two	O
primer	O
pairs	O
were	O
designed	O
using	O
online	O
Primer	O
3	O
.	O
0	O
software	O
and	O
synthesized	O
by	O
Invitrogen	O
by	O
life	O
technology	O
(	O
Table	O
S2	O
,	O
Beijing	O
,	O
China	O
)	O
to	O
amplify	O
each	O
exon	O
and	O
exon	O
-	O
intron	O
boundaries	O
.	O

For	O
a	O
high	O
pathogenicity	O
profile	O
,	O
scores	O
recorded	O
in	O
the	O
Alamut	O
-	O
HT	O
report	O
included	O
BLOSUM62	O
(	O
Blo	O
cks	O
Su	O
bstitution	O
M	O
atrix	O
;	O
http	O
:	O
/	O
/	O
www	O
.	O
uky	O
.	O
edu	O
/	O
Classes	O
/	O
BIO	O
/	O
520	O
/	O
BIO520WWW	O
/	O
blosum62	O
.	O
htm	O
)	O
<	O
0	O
,	O
AGVGD	O
(	O
A	O
lign	O
G	O
rantham	O
V	O
ariation	O
and	O
G	B-Chemical
rantham	O
D	O
eviation	O
;	O
http	O
:	O
/	O
/	O
agvgd	O
.	O
iarc	O
.	O
fr	O
/	O
agvgd_input	O
.	O
php	O
)	O
between	O
C15	O
and	O
C65	O
,	O
SIFT	O
(	O
S	O
orts	O
I	O
ntolerant	O
F	O
rom	O
T	O
olerant	O
substitutions	O
,	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
)	O
<	O
0	O
.	O
05	O
or	O
deleterious	O
and	O
MAPP	O
(	O
M	O
ultivariate	O
A	O
nalysis	O
of	O
P	O
rotein	O
P	O
olymorphism	O
;	O
http	O
:	O
/	O
/	O
mendel	O
.	O
stanford	O
.	O
edu	O
/	O
SidowLab	O
/	O
downloads	O
/	O
MAPP	O
)	O
=	O
bad	O
.	O

Their	O
data	O
indicated	O
that	O
failure	O
in	O
recruitment	O
of	O
tricellulin	B-GENE
itself	O
does	O
not	O
account	O
for	O
the	O
early	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
severe	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
DFNB49	B-DISEASE
and	O
in	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
deficient	O
in	O
mice	O
.	O

(	O
b	O
)	O
In	O
cases	O
with	O
bulbous	O
dilatation	O
at	O
the	O
distal	O
end	O
of	O
the	O
IAC	O
and	O
basal	O
turn	O
of	O
the	O
cochlea	O
incompletely	O
separated	O
from	O
the	O
IAC	O
(	O
arrow	O
)	O
were	O
tested	O
for	O
POU3F4	B-GENE
.	O

Our	O
study	O
increases	O
the	O
spectrum	O
of	O
WFS1	B-GENE
mutations	O
with	O
two	O
novel	O
variants	O
.	O

We	O
applied	O
customized	O
targeted	O
next	O
-	O
generation	O
exome	O
sequencing	O
(	O
NGS	O
)	O
to	O
determine	O
if	O
mutations	O
in	O
genes	O
associated	O
with	O
renal	B-DISEASE
malformations	I-DISEASE
,	O
Alport	B-DISEASE
syndrome	I-DISEASE
(	O
AS	B-DISEASE
)	O
or	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
are	O
a	O
potential	O
cause	O
of	O
renal	O
abnormalities	O
in	O
patients	O
with	O
equivocal	O
or	O
atypical	O
presentation	O
.	O

The	O
Snellen	O
ratios	O
were	O
then	O
converted	O
to	O
logarithm	O
of	O
the	O
minimum	O
angle	O
of	O
resolution	O
(	O
logMAR	O
)	O
values	O
for	O
the	O
purpose	O
of	O
the	O
study	O
.	O

All	O
causative	O
mutations	O
were	O
identified	O
on	O
both	O
alleles	O
except	O
in	O
one	O
case	O
in	O
which	O
only	O
one	O
heterozygous	O
mutation	O
was	O
found	O
.	O

For	O
genotype	O
-	O
phenotype	O
correlation	O
purposes	O
,	O
typical	O
XLAS	B-DISEASE
is	O
classified	O
into	O
three	O
types	O
:	O
(	O
1	O
)	O
severe	O
type	O
with	O
ERSD	O
at	O
~	O
20	O
years	O
(	O
juvenile	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
ESRD	I-DISEASE
)	O
,	O
80	O
%	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
40	O
%	O
of	O
ocular	B-DISEASE
lesions	I-DISEASE
,	O
caused	O
by	O
large	O
rearrangements	O
,	O
premature	O
stop	O
,	O
frameshift	O
,	O
donor	O
splice	O
,	O
and	O
mutations	O
in	O
the	O
NC1	O
domain	O
;	O
(	O
2	O
)	O
moderate	O
-	O
severe	O
type	O
with	O
ESRD	B-DISEASE
at	O
~	O
26	O
years	O
,	O
caused	O
by	O
non	O
-	O
Gly	O
-	O
X	O
-	O
Y	O
-	O
missense	O
,	O
Gly	O
-	O
X	O
-	O
Y	O
mutations	O
in	O
21	O
-	O
47	O
exons	O
;	O
(	O
3	O
)	O
moderate	O
type	O
with	O
ESRD	B-DISEASE
at	O
~	O
30	O
years	O
(	O
late	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
ESRD	I-DISEASE
)	O
,	O
70	O
%	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
<	O
30	O
%	O
ocular	B-DISEASE
lesions	I-DISEASE
,	O
caused	O
by	O
Gly	O
-	O
X	O
-	O
Y	O
mutations	O
in	O
1	O
-	O
20	O
exons	O
[	O
21	O
,	O
22	O
]	O
.	O

After	O
linkage	O
analysis	O
,	O
we	O
mapped	O
the	O
disease	O
-	O
causing	O
gene	O
in	O
the	O
USH2A	B-GENE
region	O
.	O

We	O
selected	O
controls	O
,	O
matched	O
on	O
age	O
and	O
facility	O
of	O
usual	O
care	O
,	O
at	O
random	O
from	O
healthy	O
members	O
of	O
the	O
health	O
plan	O
.	O

The	O
OTOF	B-GENE
gene	O
is	O
responsible	O
for	O
DFNB9	B-DISEASE
(	O
MIM	O
#	O
601071	O
)	O
[	O
15	O
]	O
and	O
the	O
non	O
-	O
syndromic	O
recessive	O
ANSD	B-DISEASE
[	O
12	O
]	O
.	O

Presumably	O
,	O
the	O
insertion	O
of	O
a	O
aspartic	B-Chemical
acid	O
reside	O
into	O
the	O
C	O
-	O
type	O
motif	O
of	O
T3	O
6	O
is	O
less	O
deleterious	O
to	O
protein	O
folding	O
and	O
structure	O
than	O
its	O
deletion	O
.	O

The	O
mutation	O
frequencies	O
are	O
significantly	O
higher	O
in	O
NSD	B-DISEASE
patients	O
than	O
in	O
control	O
subjects	O
for	O
either	O
ethnicity	O
,	O
supporting	O
the	O
profound	O
role	O
of	O
prevalent	O
deafness	O
-	O
associated	O
genetic	O
testing	O
in	O
the	O
etiological	O
diagnosis	O
of	O
NSD	B-DISEASE
patients	O
.	O

Then	O
,	O
we	O
compared	O
these	O
variants	O
with	O
reported	O
Nonsyndromic	B-DISEASE
Hereditary	I-DISEASE
Hearing	I-DISEASE
Loss	I-DISEASE
genes	O
(	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O

The	O
two	O
patients	O
from	O
family	O
USH01	O
met	O
the	O
diagnostic	O
criteria	O
for	O
USH	B-DISEASE
type	I-DISEASE
2	I-DISEASE
.	O

Laboratory	O
test	O
findings	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecainide	B-Chemical
plasma	O
concentration	O
of	O
1360	O
microg	O
/	O
L	O
(	O
reference	O
range	O
200	O
-	O
1000	O
)	O
.	O

N	O
-	O
terminal	O
myc	O
-	O
tagged	O
FGFR1c	O
cDNA	O
in	O
pcDNA3	O
.	O
1	O
+	O
was	O
used	O
as	O
a	O
template	O
for	O
site	O
-	O
directed	O
mutagenesis	O
using	O
QuikChange	O
II	O
XL	O
site	O
-	O
directed	O
mutagenesis	O
kit	O
(	O
Stratagene	O
,	O
La	O
Jolla	I-Chemical
,	O
CA	O
)	O
.	O

No	O
association	O
was	O
found	O
for	O
hormone	O
use	O
less	O
than	O
1	O
year	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
a	O
common	O
sensory	O
defect	O
that	O
can	O
significantly	O
impact	O
quality	O
of	O
life	O
,	O
and	O
the	O
majority	O
of	O
congenital	O
cases	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
are	O
attributable	O
to	O
genetic	O
factors	O
[	O
1	O
]	O
.	O

Despite	O
previous	O
intensive	O
linkage	O
analysis	O
and	O
candidate	O
gene	O
screening	O
,	O
a	O
large	O
proportion	O
of	O
ARNSHL	B-DISEASE
remain	O
genetically	O
unexplained	O
.	O

The	O
dbNSFP	O
compiles	O
six	O
prediction	O
algorithms	O
(	O
SIFT	O
Polyphen2	O
,	O
LRT	O
,	O
MutationTaster	O
,	O
MutationAssessor	O
and	O
FATHMM	O
)	O
three	O
conservation	O
algorithms	O
(	O
PhyloP	O
,	O
GERP	O
+	O
+	O
and	O
SiPhy	O
;	O
the	O
greater	O
the	O
score	O
,	O
the	O
more	O
conserved	O
the	O
site	O
)	O
and	O
information	O
including	O
allele	O
frequency	O
observed	O
in	O
the	O
data	O
from	O
the	O
1000	O
Genomes	O
Project	O
phase	O
1	O
and	O
NHLBI	O
Exome	O
Sequencing	O
Project	O
[	O
74	O
,	O
75	O
]	O
.	O

Mutations	O
of	O
clarin	O
1	O
(	O
CLRN1	B-GENE
)	O
cause	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
3	I-DISEASE
(	O
USH3	B-DISEASE
)	O
.	O

OBJECTIVE	O
:	O
We	O
describe	O
the	O
unique	O
CT	O
features	O
of	O
ureteric	O
calculi	O
in	O
six	O
HIV	O
-	O
infected	O
patients	O
receiving	O
indinavir	B-Chemical
,	O
the	O
most	O
commonly	O
used	O
HIV	O
protease	O
inhibitor	O
,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
urolithiasis	B-DISEASE
.	O

The	O
leukocyte	B-DISEASE
inclusions	I-DISEASE
of	O
this	O
patient	O
were	O
of	O
type	O
II	O
and	O
it	O
was	O
suggested	O
that	O
the	O
double	O
mutation	O
might	O
have	O
increased	O
myosin	O
aggregate	O
formation	O
.	O

We	O
studied	O
6	O
patients	O
from	O
4	O
families	O
with	O
ADOA	B-DISEASE
,	O
(	O
Figure	O
1	O
)	O
and	O
the	O
clinical	O
characteristics	O
of	O
these	O
6	O
patients	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

We	O
thank	O
all	O
members	O
of	O
the	O
Northwest	O
Genomics	O
Center	O
and	O
Genomic	O
Disorders	O
Group	O
Nijmegen	O
,	O
as	O
well	O
as	O
personnel	O
from	O
the	O
Microarray	O
Facility	O
and	O
Sequencing	O
Facility	O
Nijmegen	O
for	O
excellent	O
technical	O
assistance	O
.	O

PEX1	B-GENE
mutations	O
of	O
this	O
patient	O
cohort	O
are	O
previously	O
published	O
in	O
part	O
[	O
12	O
]	O
.	O

The	O
diagnostic	O
yield	O
of	O
exome	O
sequencing	O
for	O
patients	O
with	O
Mendelian	O
diseases	O
is	O
25	O
%	O
(	O
5	O
)	O
,	O
suggesting	O
that	O
it	O
might	O
complement	O
conventional	O
prenatal	O
diagnostic	O
techniques	O
.	O

,	O
who	O
found	O
a	O
variant	O
in	O
the	O
promoter	O
of	O
SLC26A4	B-GENE
in	O
a	O
consensus	O
binding	O
motif	O
for	O
FOXI1	B-GENE
,	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
101T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
;	O
they	O
showed	O
using	O
EMSAs	O
that	O
binding	O
affinity	O
of	O
FOXI1	B-GENE
to	O
the	O
promoter	O
was	O
reduced	O
in	O
the	O
presence	O
of	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
101T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
used	O
Luciferase	O
reporter	O
constructs	O
to	O
show	O
that	O
transcription	O
from	O
the	O
promoter	O
was	O
completely	O
abolished	O
in	O
the	O
presence	O
of	O
this	O
variant	O
[	O
19	O
]	O
.	O

We	O
sequenced	O
these	O
positions	O
in	O
our	O
cohort	O
and	O
found	O
described	O
mutations	O
in	O
3	O
subjects	O
(	O
4	O
.	O
7	O
%	O
,	O
Supplementary	O
Table	O
1	O
)	O
.	O

Fatal	O
aplastic	B-DISEASE
anemia	I-DISEASE
in	O
a	O
patient	O
treated	O
with	O
carbamazepine	B-Chemical
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Boards	O
(	O
IRBs	O
)	O
at	O
Seoul	O
National	O
University	O
Bundang	O
Hospital	O
(	O
IRB	O
-	O
B	O
-	O
1007	O
-	O
105	O
-	O
402	O
and	O
IRB	O
-	O
B	O
-	O
1111	O
-	O
139	O
-	O
015	O
)	O
and	O
Seoul	O
National	O
University	O
Hospital	O
(	O
IRBY	O
-	O
H	O
-	O
0905	O
-	O
041	O
-	O
281	O
)	O
.	O

Middle	O
right	O
:	O
3days	O
surface	O
maps	O
:	O
the	O
ILM	O
-	O
RPE	O
,	O
displaying	O
the	O
retinal	O
thickness	O
in	O
three	O
dimensions	O
.	O

SD	O
-	O
OCT	O
showed	O
a	O
severe	O
reduction	O
in	O
the	O
retinal	B-DISEASE
nerve	I-DISEASE
fiber	I-DISEASE
layer	I-DISEASE
(	I-DISEASE
RNFL	I-DISEASE
)	I-DISEASE
thickness	I-DISEASE
in	O
all	O
patients	O
.	O

In	O
contrast	O
,	O
this	O
pathology	O
has	O
not	O
been	O
reported	O
in	O
mutant	O
mice	O
carrying	O
a	O
p	B-VARIANT
.	I-VARIANT
Tyr1870Cys	I-VARIANT
mutation	O
responsible	O
for	O
non	O
-	O
progressive	O
stable	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
41	O
]	O
,	O
[	O
46	O
]	O
.	O

Narrow	O
or	O
even	O
obliterated	O
pulp	O
chamber	O
and	O
root	O
canals	O
were	O
shown	O
under	O
X	O
-	O
ray	O
.	O

Intense	O
vasospasm	I-DISEASE
with	O
threatened	O
gangrene	O
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	O
.	O

An	O
overshooting	O
of	O
peak	O
grip	O
force	O
by	O
51	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
of	O
static	O
grip	O
force	O
by	O
45	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
was	O
observed	O
in	O
the	O
ON	O
-	O
compared	O
with	O
the	O
OFF	O
-	O
drug	O
condition	O
.	O

,	O
2005	O
)	O
;	O
CN	B-Chemical
-	O
2	O
:	O
(	O
Ke	O
et	O
al	O
.	O

Family	O
PKDF1132	B-Chemical
.	O

The	O
other	O
was	O
a	O
nonsense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
88C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gln30	I-VARIANT
*	I-VARIANT
)	O
,	O
in	O
exon	O
3	O
of	O
EPS8	B-GENE
(	O
gene	O
ID	O
:	O
2059	O
,	O
NM_004447	B-VARIANT
.	I-VARIANT
5	I-VARIANT
)	O
.	O

Among	O
various	O
oral	O
antiplatelets	O
,	O
a	O
combination	O
of	O
a	O
novel	O
prostacyclin	B-Chemical
analogue	O
beraprost	B-Chemical
(	O
BPT	B-Chemical
)	O
and	O
a	O
potent	O
phosphodiesterase	O
inhibitor	O
cilostazol	B-Chemical
(	O
CLZ	B-Chemical
)	O
may	O
result	O
in	O
untoward	O
clinical	O
effects	O
due	O
to	O
possible	O
synergistic	O
elevation	O
of	O
intracellular	O
cAMP	B-Chemical
(	O
cyclic	B-Chemical
adenosine	I-Chemical
3	I-Chemical
'	I-Chemical
,	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
monophosphate	I-Chemical
)	O
.	O

Consistent	O
with	O
molecular	O
modeling	O
predictions	O
of	O
Ca	B-Chemical
2	I-Chemical
+	O
binding	O
,	O
CIB2	B-GENE
significantly	O
decreased	O
the	O
ATP	O
-	O
induced	O
Ca	B-Chemical
2	O
+	O
responses	O
in	O
heterologous	O
cells	O
,	O
while	O
DFNB48	B-DISEASE
mutations	O
altered	O
CIB2	B-GENE
effects	O
on	O
Ca	B-Chemical
2	O
+	O
responses	O
.	O

Lamivudine	B-Chemical
is	O
effective	O
in	O
suppressing	O
hepatitis	O
B	O
virus	O
DNA	O
in	O
Chinese	O
hepatitis	B-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
carriers	O
:	O
a	O
placebo	O
-	O
controlled	O
trial	O
.	O

Protocadherin	B-GENE
-	I-GENE
15	I-GENE
was	O
localized	O
in	O
the	O
inner	O
ear	O
hair	O
cell	O
stereocilia	O
and	O
in	O
the	O
retinal	O
photoreceptors	O
[	O
13	O
]	O
.	O

Values	O
are	O
the	O
means	O
+	O
-	O
SD	O
of	O
triplicate	O
experiments	O
,	O
and	O
the	O
data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Comprehensive	O
mutation	O
analysis	O
of	O
all	O
7	O
known	O
KS	B-DISEASE
genes	O
(	O
KAL1	B-GENE
,	O
FGFR1	B-GENE
,	O
FGF8	B-GENE
,	O
PROK2	B-GENE
,	O
PROKR2	B-GENE
,	O
CHD7	B-GENE
,	O
and	O
WDR11	B-GENE
)	O
in	O
these	O
30	O
well	O
-	O
phenotyped	O
probands	O
revealed	O
mutations	O
in	O
KAL1	B-GENE
(	O
3	O
men	O
)	O
and	O
FGFR1	B-GENE
(	O
all	O
5	O
women	O
vs	O
.	O

Kausar	O
for	O
technical	O
assistance	O
and	O
Drs	O
.	O

To	O
date	O
,	O
no	O
major	O
genes	O
have	O
been	O
described	O
that	O
cause	O
a	O
significant	O
proportion	O
of	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
any	O
ethnic	O
population	O
.	O

In	O
addition	O
,	O
Subject	O
7	O
had	O
profound	B-DISEASE
deafness	I-DISEASE
with	O
absence	O
of	O
both	O
otoacoustic	O
emissions	O
and	O
summating	O
potential	O
response	O
in	O
the	O
ECochG	O
waveform	O
consistent	O
with	O
cochlear	O
damage	O
.	O

Despite	O
the	O
advances	O
in	O
understanding	O
the	O
molecular	O
pathogenesis	O
of	O
CHI	B-DISEASE
,	O
specific	O
genetic	O
determinants	O
in	O
about	O
50	O
%	O
of	O
the	O
CHI	B-DISEASE
patients	O
remain	O
unknown	O
,	O
suggesting	O
additional	O
locus	O
heterogeneity	O
.	O

Palmoplantar	B-DISEASE
keratoderma	I-DISEASE
was	O
not	O
observed	O
in	O
the	O
affected	O
members	O
of	O
Family	O
DE2624	B-Chemical
,	O
thus	O
indicating	O
that	O
the	O
phenotype	O
associated	O
with	O
GJB2	B-GENE
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
in	O
this	O
family	O
was	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Four	O
variants	O
were	O
novel	O
but	O
were	O
interpreted	O
as	O
pathogenic	O
by	O
the	O
predictive	O
software	O
Alamut	O
2	O
.	O
2	O
.	O

Pregnenolone	B-Chemical
sulphate	I-Chemical
(	O
PREGS	B-Chemical
)	O
has	O
generated	O
interest	O
as	O
one	O
of	O
the	O
most	O
potent	O
memory	O
-	O
enhancing	O
neurosteroids	O
to	O
be	O
examined	O
in	O
rodent	O
learning	O
studies	O
,	O
with	O
particular	O
importance	O
in	O
the	O
ageing	O
process	O
.	O

If	O
haplotypes	O
are	O
compatible	O
with	O
USH3A	B-GENE
linkage	O
or	O
the	O
USH	B-DISEASE
microarray	O
detects	O
only	O
one	O
mutation	O
,	O
we	O
perform	O
direct	O
sequencing	O
of	O
CLRN1	B-GENE
.	O

This	O
capture	O
panel	O
was	O
applied	O
to	O
88	O
patients	O
with	O
an	O
original	O
diagnosis	O
of	O
STGD	B-DISEASE
,	O
including	O
57	O
patients	O
examined	O
at	O
the	O
Montreal	O
Children	O
'	O
s	O
Hospital	O
in	O
Montreal	O
,	O
Canada	O
and	O
31	O
patients	O
examined	O
at	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
in	O
China	O
.	O

Altogether	O
fifteen	O
affected	O
and	O
unaffected	O
members	O
(	O
II	O
:	O
1	O
,	O
II	O
:	O
2	O
,	O
II	O
:	O
5	O
,	O
II	O
:	O
6	O
,	O
II	O
:	O
7	O
,	O
II	O
:	O
9	O
,	O
II	O
:	O
10	O
,	O
III	O
:	O
2	O
,	O
III	O
:	O
3	O
,	O
III	O
:	O
7	O
,	O
III	O
:	O
9	O
,	O
III	O
:	O
10	O
,	O
III	O
:	O
11	O
,	O
III	O
:	O
12	O
,	O
III	O
:	O
13	O
)	O
from	O
the	O
second	O
and	O
third	O
generations	O
were	O
selected	O
for	O
linkage	O
analysis	O
.	O

As	O
expected	O
the	O
majority	O
of	O
mutations	O
where	O
an	O
electrophysiological	O
assessment	O
was	O
available	O
(	O
p	B-VARIANT
.	I-VARIANT
V254M	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
L273F	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Y315C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R583C	I-VARIANT
in	O
KCNQ1	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
F29L	I-VARIANT
in	O
KCNH2	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
L1785Q	I-VARIANT
in	O
SCN5A	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
D76N	I-VARIANT
in	O
KCNE1	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
I57T	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
V65M	I-VARIANT
in	O
KCNE2	B-GENE
)	O
were	O
found	O
to	O
have	O
an	O
effect	O
on	O
protein	O
function	O
.	O

The	O
pathogenicity	O
of	O
KCNQ4	B-GENE
p	B-VARIANT
.	I-VARIANT
S680F	I-VARIANT
was	O
supported	O
by	O
its	O
high	O
SIFT	O
(	O
0	O
.	O
98	O
)	O
and	O
PolyPhen2	O
(	O
0	O
.	O
99	O
)	O
scores	O
,	O
as	O
well	O
as	O
its	O
absence	O
in	O
the	O
5400	O
NHLBI	O
exomes	O
,	O
1000	O
Genomes	O
,	O
and	O
the	O
100	O
normal	O
hearing	O
controls	O
of	O
the	O
present	O
study	O
(	O
Table	O
2	O
)	O
.	O

S1	O
)	O
.	O

Our	O
data	O
showed	O
that	O
the	O
distribution	O
of	O
SLC26A4	B-GENE
mutation	O
in	O
the	O
isolated	O
MD	B-DISEASE
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
EVA	B-DISEASE
with	O
or	O
without	O
MD	B-DISEASE
patients	O
;	O
the	O
one	O
patient	O
from	O
the	O
MD	B-DISEASE
group	O
who	O
carried	O
a	O
monoallelic	O
mutation	O
of	O
SLC26A4	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
919	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
might	O
have	O
been	O
a	O
coincident	O
carrier	O
of	O
this	O
mutation	O
.	O

Patients	O
33	O
,	O
82	O
and	O
29	O
are	O
therefore	O
either	O
accidental	O
carriers	O
of	O
the	O
TULP1	B-GENE
and	O
SAG	B-GENE
mutations	O
with	O
the	O
causative	O
mutation	O
in	O
another	O
arRP	B-DISEASE
gene	O
not	O
known	O
at	O
the	O
time	O
of	O
study	O
design	O
,	O
or	O
the	O
"	O
missing	O
alleles	O
"	O
escaped	O
detection	O
by	O
exonic	O
sequencing	O
because	O
they	O
are	O
deep	O
intronic	O
(	O
as	O
exemplified	O
by	O
the	O
LCA	B-DISEASE
mutation	O
c	B-VARIANT
.	I-VARIANT
2991	I-VARIANT
+	I-VARIANT
1655A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
CEP290	B-GENE
or	O
the	O
only	O
known	O
RP23	B-GENE
mutation	O
in	O
the	O
OFD1	B-GENE
gene	O
[	O
34	O
]	O
)	O
,	O
or	O
because	O
they	O
localize	O
in	O
regulatory	O
non	O
-	O
coding	O
regions	O
(	O
as	O
shown	O
for	O
EYS	B-GENE
exon	O
1	O
in	O
this	O
study	O
)	O
.	O

Proximal	O
tubular	O
damage	O
caused	O
by	O
HCBD	B-Chemical
and	O
papillary	B-DISEASE
damage	I-DISEASE
caused	O
by	O
BEA	B-Chemical
were	O
distinguished	O
both	O
by	O
conventional	O
urinalysis	O
(	O
volume	O
and	O
specific	O
gravity	O
)	O
and	O
by	O
measurement	O
of	O
the	O
two	O
urinary	O
enzymes	O
.	O

ATPase	O
staining	O
of	O
the	O
diaphragm	O
,	O
scalenus	O
medius	O
,	O
and	O
gastrocnemius	O
showed	O
type	O
IIb	O
fiber	O
atrophy	O
in	O
the	O
steroid	B-Chemical
groups	O
and	O
also	O
diaphragmatic	O
type	O
IIa	O
atrophy	O
with	O
T	B-Chemical
,	O
whereas	O
histologic	O
examinations	O
revealed	O
a	O
normal	O
muscular	O
pattern	O
with	O
absence	O
of	O
necrosis	O
.	O

The	O
percentages	O
refer	O
to	O
reads	O
mapped	O
to	O
the	O
targeted	O
region	O
(	O
on	O
-	O
target	O
)	O
,	O
sequences	O
partially	O
mapped	O
to	O
the	O
targeted	O
region	O
(	O
overlap	O
-	O
target	O
)	O
,	O
or	O
reads	O
completely	O
aligned	O
out	O
of	O
region	O
(	O
off	O
-	O
target	O
)	O
.	O

Tests	O
of	O
basic	O
visual	O
function	O
included	O
high	O
-	O
and	O
low	O
-	O
contrast	O
visual	O
acuity	O
(	O
HCVA	O
and	O
LCVA	O
)	O
,	O
Pelli	O
-	O
Robson	O
contrast	O
threshold	O
(	O
CT	O
)	O
and	O
Goldmann	O
perimetry	O
(	O
FIELDS	O
)	O
.	O

The	O
libraries	O
were	O
cleaned	O
and	O
size	O
-	O
selected	O
using	O
the	O
AMPure	O
DNA	O
Purification	O
kit	O
(	O
Beckman	O
Agencourt	O
;	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
.	O

PolyPhen	B-Chemical
-	I-Chemical
2	I-Chemical
[	O
15	O
]	O
and	O
SIFT	O
[	O
16	O
]	O
were	O
used	O
to	O
predict	O
the	O
effect	O
of	O
reported	O
missense	O
changes	O
on	O
protein	O
function	O
.	O

Pedigree	O
analysis	O
showed	O
a	O
hereditarily	O
autosomal	O
dominant	O
pattern	O
characterized	O
by	O
a	O
full	O
penetrance	O
.	O

The	O
aim	O
of	O
the	O
experiment	O
was	O
to	O
evaluate	O
the	O
developmental	O
toxicity	O
of	O
the	O
non	O
-	O
selective	O
(	O
piroxicam	B-Chemical
)	O
and	O
selective	O
(	O
DFU	B-Chemical
;	O
5	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dimethyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
methylsulphonyl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
5H	I-Chemical
)	I-Chemical
-	I-Chemical
furanon	I-Chemical
)	O
COX	B-GENE
-	I-GENE
2	I-GENE
inhibitors	O
.	O

Next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
is	O
accelerating	O
the	O
qualitative	O
improvement	O
of	O
mutational	O
studies	O
for	O
numerous	O
heterogeneous	O
disorders	O
due	O
to	O
its	O
ability	O
to	O
perform	O
simultaneous	O
and	O
massively	O
parallel	O
sequencing	O
.	O

Prostaglandin	B-Chemical
D2	I-Chemical
(	O
0	O
.	O
5	O
-	O
3	O
ng	O
/	O
mouse	O
)	O
had	O
a	O
hyperalgesic	O
action	O
on	O
the	O
response	O
to	O
a	O
hot	O
plate	O
during	O
a	O
3	O
-	O
60	O
min	O
period	O
after	O
injection	O
.	O

Reference	O
:	O
sequence	O
reference	O
RefSeq	B-Chemical
NM_018429	O
Affected	O
:	O
homozygous	O
G	O
/	O
G	O
patient	O
.	O

Also	O
in	O
agreement	O
with	O
previous	O
reports	O
,	O
p	B-VARIANT
.	I-VARIANT
C948Y	I-VARIANT
is	O
the	O
most	O
prevalent	O
CRB1	B-GENE
mutation	O
in	O
our	O
family	O
panel	O
(	O
3	O
of	O
the	O
5	O
CRB1	B-GENE
families	O
)	O
[	O
39	O
]	O
.	O

17	O
Twelve	O
of	O
the	O
14	O
PAX3	B-GENE
mutations	O
are	O
truncating	O
mutations	O
including	O
large	O
deletions	O
.	O

We	O
determined	O
the	O
average	O
thresholds	O
for	O
a	O
frequency	O
range	O
of	O
250	O
-	O
8000	O
Hz	O
.	O

To	O
extend	O
the	O
epidemiological	O
data	O
on	O
common	O
gene	O
mutations	O
in	O
the	O
Chinese	O
population	O
and	O
to	O
provide	O
appropriate	O
genetic	O
testing	O
and	O
counseling	O
for	O
patients	O
with	O
NSHI	B-DISEASE
in	O
south	O
China	O
,	O
we	O
conducted	O
a	O
genetic	O
analysis	O
in	O
this	O
population	O
.	O

Data	O
collected	O
on	O
patients	O
seen	O
from	O
September	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
and	O
its	O
severity	O
.	O

(	O
A	O
)	O
Pedigree	O
of	O
a	O
large	O
Danish	O
family	O
with	O
moderate	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
with	O
the	O
proband	O
indicated	O
with	O
an	O
arrow	O
.	O

Anaesthesia	O
was	O
induced	O
with	O
thiopentone	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
.	O

The	O
identified	O
mutation	O
was	O
not	O
reported	O
in	O
any	O
public	O
database	O
,	O
such	O
as	O
dbSNP	O
,	O
1000genomes	O
and	O
the	O
NHLBI	O
project	O
.	O

However	O
,	O
asymptomatic	B-DISEASE
CMV	I-DISEASE
cases	O
would	O
have	O
been	O
missed	O
,	O
since	O
we	O
were	O
not	O
able	O
to	O
access	O
blood	O
or	O
saliva	O
samples	O
of	O
the	O
patients	O
taken	O
within	O
3	O
-	O
4	O
weeks	O
after	O
birth	O
.	O

100	O
%	O
of	O
our	O
patients	O
with	O
two	O
mutant	O
alleles	O
(	O
17	O
/	O
17	O
)	O
and	O
only	O
33	O
.	O
3	O
%	O
(	O
3	O
/	O
9	O
)	O
of	O
patients	O
with	O
one	O
mutant	O
allele	O
were	O
confirmed	O
to	O
have	O
EVA	B-DISEASE
manifestation	O
.	O

The	O
12	O
-	O
lead	O
electrocardiogram	O
(	O
ECG	O
)	O
for	O
patients	O
from	O
kindred	O
L151	O
:	O
(	O
a	O
)	O
ECGs	O
for	O
L151	O
-	O
01	O
,	O
now	O
a	O
17	O
-	O
year	O
-	O
old	O
girl	O
:	O
The	O
left	O
ECG	O
was	O
recorded	O
when	O
she	O
was	O
12	O
years	O
old	O
and	O
diagnosed	O
as	O
having	O
Long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
(	O
QTc	O
480	O
ms	O
)	O
;	O
the	O
right	O
one	O
was	O
recorded	O
when	O
she	O
was	O
16	O
years	O
old	O
and	O
taking	O
metoprolol	B-Chemical
0	O
.	O
69	O
mg	O
/	O
Kg	O
(	O
QTc	O
530	O
ms	O
)	O
.	O

34	O
Mouse	O
CEACAM16	B-GENE
and	O
its	O
human	O
counterpart	O
are	O
well	O
conserved	O
.	O

Moreover	O
,	O
Subject	O
1	O
had	O
a	O
positive	O
history	O
of	O
exposure	O
to	O
occupational	O
noise	O
and	O
showed	O
a	O
typical	O
audiometric	O
profile	O
of	O
noise	O
-	O
induced	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

These	O
results	O
suggest	O
that	O
paramethasone	B-Chemical
caused	O
pseudoallergic	O
reactions	O
in	O
our	O
patients	O
.	O

The	O
authors	O
speculate	O
that	O
the	O
increased	O
vagal	O
tone	O
during	O
bladder	O
irrigation	O
,	O
a	O
vagal	O
maneuver	O
,	O
in	O
the	O
context	O
of	O
amiodarone	B-Chemical
therapy	O
resulted	O
in	O
amiodarone	B-Chemical
-	O
induced	O
proarrhythmia	B-DISEASE
.	O

Sequencing	O
analysis	O
shows	O
a	O
G	O
-	O
A	O
transition	O
of	O
COL2A1	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
1744G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly582Ser	I-VARIANT
)	O
)	O
.	O

This	O
could	O
be	O
due	O
to	O
the	O
small	O
sample	O
size	O
screened	O
for	O
mutations	O
or	O
because	O
mutations	O
in	O
these	O
isoforms	O
do	O
not	O
cause	O
Usher	B-DISEASE
syndrome	I-DISEASE
but	O
perhaps	O
other	O
disorders	O
.	O

USH2A	B-GENE
has	O
been	O
described	O
as	O
the	O
most	O
common	O
locus	O
for	O
syndromic	O
RP	B-DISEASE
[	O
10	O
]	O
.	O

After	O
obtaining	O
written	O
informed	O
consent	O
,	O
blood	O
samples	O
were	O
obtained	O
from	O
12	O
family	O
members	O
.	O

The	O
major	O
mutation	O
sites	O
of	O
COL2A1	B-GENE
have	O
been	O
found	O
to	O
be	O
glycine	B-Chemical
substitutions	O
in	O
the	O
triple	O
helical	O
domain	O
of	O
type	O
II	O
collagen	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

,	O
2008	O
)	O
.	O

Coexistence	O
of	O
the	O
cerebral	B-DISEASE
artery	O
and	O
the	O
venous	O
sinus	O
occlusion	O
has	O
been	O
described	O
infrequently	O
.	O

34	O
The	O
patient	O
had	O
overlapping	O
manifestations	O
with	O
SPG49	B-DISEASE
,	O
including	O
severe	O
hypotonia	B-DISEASE
,	O
gastroesophageal	B-DISEASE
reflux	I-DISEASE
disease	I-DISEASE
,	O
areflexia	B-DISEASE
,	O
intellectual	B-DISEASE
disability	I-DISEASE
,	O
and	O
breathing	B-DISEASE
abnormalities	I-DISEASE
;	O
however	O
,	O
this	O
patient	O
did	O
not	O
have	O
any	O
qualifying	O
genotypes	O
.	O

Cell	O
cultures	O
,	O
expression	O
of	O
chimeras	O
and	O
microscopy	O
were	O
carried	O
out	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

5	O
,	O
31	O
Loss	O
of	O
either	O
of	O
these	O
claudins	O
results	O
in	O
increased	O
paracellular	O
permeability	O
of	O
K	O
+	O
in	O
the	O
reticular	O
lamina	O
and	O
an	O
elevation	O
in	O
the	O
K	O
+	O
concentration	O
around	O
the	O
basolateral	O
regions	O
of	O
hair	O
cells	O
,	O
which	O
is	O
toxic	O
.	O

The	O
leading	O
causes	O
of	O
death	O
were	O
pneumonia	B-DISEASE
and	O
bronchitis	B-DISEASE
(	O
44	O
.	O
1	O
%	O
)	O
,	O
malignant	B-DISEASE
neoplasms	I-DISEASE
(	O
11	O
.	O
6	O
%	O
)	O
,	O
heart	B-DISEASE
diseases	I-DISEASE
(	O
4	O
.	O
1	O
%	O
)	O
,	O
cerebral	B-DISEASE
infarction	I-DISEASE
(	O
3	O
.	O
7	O
%	O
)	O
and	O
septicaemia	B-DISEASE
(	O
3	O
.	O
3	O
%	O
)	O
.	O

The	O
response	O
of	O
the	O
animals	O
was	O
evaluated	O
using	O
electroencephalography	O
and	O
by	O
monitoring	O
the	O
clinical	O
behaviour	O
during	O
and	O
after	O
recovery	O
from	O
anaesthesia	O
.	O

USH	B-DISEASE
type	I-DISEASE
1	I-DISEASE
has	O
been	O
associated	O
with	O
nine	O
genetic	O
loci	O
(	O
USH1B	O
-	O
1H	O
,	O
1J	O
and	O
1K	O
)	O
,	O
among	O
which	O
six	O
corresponding	O
genes	O
were	O
identified	O
including	O
MYO7A	B-GENE
(	O
USH1B	B-GENE
)	O
[	O
8	O
]	O
,	O
USH1C	B-GENE
(	O
USH1C	B-GENE
)	O
[	O
10	O
]	O
,	O
CDH23	B-GENE
(	O
USH1D	B-GENE
)	O
[	O
11	O
]	O
,	O
PCDH15	B-GENE
(	O
USH1F	B-GENE
)	O
[	O
12	O
]	O
,	O
USH1G	B-GENE
(	O
USH1G	B-GENE
)	O
[	O
13	O
]	O
,	O
and	O
CIB2	B-GENE
(	O
USH1J	B-GENE
)	O
[	O
14	O
]	O
.	O

See	O
also	O
Figure	O
1a	O
.	O

The	O
variant	O
list	O
derived	O
from	O
analysing	O
patient	O
2093	O
(	O
a	O
male	O
)	O
described	O
a	O
homozygous	O
missense	O
variant	O
in	O
BBS2	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
1895G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R632P	I-VARIANT
)	O
as	O
the	O
most	O
likely	O
candidate	O
.	O

Briefly	O
,	O
37	O
different	O
DNA	O
sequence	O
variations	O
of	O
known	O
or	O
uncertain	O
pathogenicity	O
were	O
identified	O
in	O
the	O
coding	O
and	O
near	O
-	O
coding	O
regions	O
of	O
9	O
genes	O
in	O
25	O
of	O
71	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
whose	O
clinical	O
presentation	O
suggested	O
a	O
genetic	O
syndrome	O
or	O
auditory	B-DISEASE
neuropathy	I-DISEASE
.	O

Mutations	O
affecting	O
some	O
of	O
these	O
factors	O
(	O
POLG1	B-GENE
,	O
PEO1	B-GENE
,	O
and	O
RRM2B	B-GENE
)	O
are	O
associated	O
with	O
paediatric	O
severe	O
presentations	O
when	O
inherited	O
according	O
to	O
a	O
recessive	O
pattern	O
[	O
17	O
]	O
.	O

Three	O
clinical	O
types	O
of	O
USH	B-DISEASE
(	O
types	O
I	O
,	O
II	O
and	O
III	O
;	O
USH1	B-DISEASE
,	O
USH2	B-DISEASE
and	O
USH3	B-DISEASE
)	O
are	O
recognized	O
,	O
mainly	O
on	O
the	O
basis	O
of	O
the	O
severity	O
and	O
progression	O
of	O
hearing	O
loss	O
,	O
the	O
age	O
of	O
onset	O
of	O
RP	B-DISEASE
and	O
the	O
presence	O
of	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
[	O
5	O
]	O
.	O

There	O
are	O
other	O
cases	O
in	O
which	O
postnatal	O
exome	O
sequencing	O
of	O
cohorts	O
with	O
specific	O
diseases	O
first	O
manifesting	O
in	O
the	O
prenatal	O
period	O
have	O
yielded	O
diagnoses	O
(	O
36	O
,	O
37	O
)	O
.	O

Rhabdomyolysis	B-DISEASE
in	O
association	O
with	O
simvastatin	B-Chemical
and	O
dosage	O
increment	O
in	O
clarithromycin	B-Chemical
.	O

10	O
We	O
aligned	O
the	O
reads	O
to	O
the	O
human	O
genome	O
GRCh37	O
/	O
hg19	B-Chemical
for	O
each	O
of	O
the	O
six	O
samples	O
independently	O
with	O
the	O
Burrows	O
-	O
Wheeler	O
Alignment	O
tool	O
,	O
11	O
and	O
removed	O
duplicate	O
reads	O
using	O
Picard	O
MarkDuplicates	O
,	O
and	O
used	O
GATK	O
for	O
local	O
realignment	O
around	O
indels	O
and	O
base	O
quality	O
score	O
recalibration	O
.	O

We	O
found	O
expression	O
of	O
Bdp1	B-GENE
in	O
specific	O
cell	O
types	O
in	O
the	O
cochlea	O
including	O
endothelial	O
cells	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
stria	O
vascularis	O
,	O
further	O
supporting	O
a	O
role	O
for	O
this	O
gene	O
in	O
auditory	O
function	O
.	O

Thus	O
prior	O
dosing	O
with	O
H1	O
-	O
and	O
H2	O
-	O
antagonists	O
provides	O
only	O
partial	O
protection	O
.	O

High	O
-	O
throughput	O
sequencing	O
was	O
performed	O
to	O
meet	O
the	O
desired	O
average	O
sequencing	O
depth	O
.	O

52	O
It	O
must	O
be	O
expected	O
,	O
due	O
to	O
the	O
large	O
genetic	O
diversity	O
of	O
African	O
populations	O
,	O
as	O
is	O
evident	O
from	O
the	O
Exome	O
Sequencing	O
Project	O
(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
)	O
,	O
that	O
comprehensive	O
genetic	O
screening	O
of	O
at	O
least	O
five	O
genes	O
will	O
be	O
necessary	O
to	O
provide	O
an	O
adequate	O
genetic	O
diagnosis	O
in	O
these	O
populations	O
.	O

Resuscitation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spontaneous	O
circulation	O
(	O
ROSC	O
)	O
accompanied	O
by	O
a	O
mean	O
arterial	O
pressure	O
at	O
or	O
superior	O
to	O
the	O
baseline	O
pressure	O
and	O
normal	O
sinus	O
rhythm	O
for	O
a	O
period	O
of	O
30	O
min	O
.	O

We	O
established	O
the	O
frequencies	O
of	O
variants	O
within	O
86	O
whole	O
-	O
exome	O
sequencing	O
samples	O
of	O
patients	O
with	O
unrelated	O
disorders	O
,	O
as	O
well	O
as	O
in	O
the	O
100	O
RP	B-DISEASE
samples	O
.	O

We	O
previously	O
reported	O
that	O
simultaneous	O
detection	O
of	O
common	O
deafness	B-DISEASE
gene	O
mutations	O
has	O
excellent	O
sensitivity	O
and	O
accuracy	O
[	O
2	O
]	O
.	O

RESULTS	O
:	O
Six	O
of	O
30	O
patients	O
(	O
20	O
%	O
)	O
without	O
prior	O
chemotherapy	O
achieved	O
a	O
partial	O
response	O
(	O
PR	B-DISEASE
)	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O

Here	O
,	O
we	O
identify	O
mutations	O
in	O
Gipc3	B-GENE
underlying	O
progressive	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
age	B-DISEASE
-	I-DISEASE
related	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
5	I-DISEASE
,	O
ahl5	B-DISEASE
)	O
and	O
audiogenic	B-DISEASE
seizures	I-DISEASE
(	O
juvenile	B-DISEASE
audiogenic	I-DISEASE
monogenic	I-DISEASE
seizure	I-DISEASE
1	I-DISEASE
,	O
jams1	B-DISEASE
)	O
in	O
mice	O
and	O
autosomal	O
recessive	O
deafness	B-DISEASE
DFNB15	B-GENE
and	O
DFNB95	B-GENE
in	O
humans	O
.	O

Patients	O
receiving	O
the	O
drug	O
should	O
be	O
monitored	O
with	O
liver	O
function	O
tests	O
along	O
with	O
complete	O
blood	O
cell	O
counts	O
.	O

Linkage	O
analysis	O
requires	O
a	O
large	O
number	O
of	O
subjects	O
to	O
help	O
identify	O
putative	O
loci	O
.	O

In	O
our	O
study	O
population	O
,	O
51	O
patients	O
had	O
two	O
confirmed	O
pathogenic	O
mutations	O
,	O
plus	O
the	O
patient	O
carrying	O
the	O
dominant	O
R75W	B-VARIANT
,	O
and	O
deafness	B-DISEASE
in	O
18	O
.	O
31	O
%	O
(	O
52	O
/	O
284	O
)	O
of	O
our	O
patients	O
was	O
due	O
to	O
mutations	O
in	O
GJB2	B-GENE
.	O

Human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
cells	O
were	O
cultured	O
in	O
DMEM	O
solution	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
.	O

A	O
pyridoxine	B-Chemical
-	I-DISEASE
dependent	I-DISEASE
behavioral	I-DISEASE
disorder	I-DISEASE
unmasked	O
by	O
isoniazid	B-Chemical
.	O

It	O
showed	O
that	O
the	O
rod	O
-	O
mediated	O
ERG	O
b	O
-	O
wave	O
was	O
within	O
normal	O
amplitude	O
and	O
peak	O
time	O
limits	O
(	O
OU	O
)	O
(	O
Fig	O
.	O

So	O
far	O
,	O
there	O
is	O
less	O
variation	O
in	O
thresholds	O
in	O
families	O
E	O
and	O
H	O
at	O
matching	O
ages	O
.	O

No	O
significant	O
differences	O
between	O
groups	O
were	O
found	O
at	O
enrollment	O
.	O

CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	O
in	O
warfarin	B-Chemical
users	O
with	O
ICH	B-DISEASE
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	O
increase	O
the	O
risk	O
of	O
warfarin	B-Chemical
-	O
associated	O
ICH	B-DISEASE
.	O

Heparin	B-Chemical
-	I-DISEASE
induced	I-DISEASE
thrombocytopenia	I-DISEASE
(	O
HIT	B-DISEASE
)	O
is	O
an	O
adverse	O
immune	O
-	O
mediated	O
reaction	O
to	O
heparin	B-Chemical
,	O
resulting	O
in	O
platelet	O
count	O
decreases	O
of	O
more	O
than	O
50	O
%	O
.	O

The	O
changes	O
in	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
not	O
significant	O
among	O
the	O
three	O
groups	O
.	O

4	O
)	O
.	O

20	O
Primers	O
for	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
,	O
and	O
CLDN14	B-GENE
sequencing	O
were	O
designed	O
using	O
Primer3	O
(	O
http	O
:	O
/	O
/	O
frodo	O
.	O
wi	O
.	O
mit	O
.	O
edu	O
/	O
)	O
.	O

WS	B-DISEASE
type	I-DISEASE
III	I-DISEASE
patients	O
have	O
limb	B-DISEASE
hypoplasia	I-DISEASE
in	O
addition	O
to	O
dystopia	B-DISEASE
canthorum	I-DISEASE
.	O

2008	O
;	O
Aller	O
et	O
al	O
.	O

Two	O
studies	O
evaluated	O
quetiapine	B-Chemical
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
in	O
combination	O
with	O
a	O
mood	O
stabilizer	O
(	O
lithium	B-Chemical
or	O
divalproex	B-Chemical
,	O
QTP	B-Chemical
+	O
Li	B-Chemical
/	O
DVP	B-Chemical
)	O
(	O
n	O
=	O
196	O
)	O
compared	O
to	O
placebo	O
and	O
mood	O
stabilizer	O
(	O
PBO	O
+	O
Li	B-Chemical
/	O
DVP	B-Chemical
)	O
(	O
n	O
=	O
203	O
)	O
.	O

OCT	O
showed	O
small	O
cystic	O
macular	O
changes	O
at	O
age	O
52	O
(	O
Figure	O
3D	O
)	O
.	O

BACKGROUND	O
:	O
Sirolimus	B-Chemical
is	O
the	O
latest	O
immunosuppressive	O
agent	O
used	O
to	O
prevent	O
rejection	B-DISEASE
,	O
and	O
may	O
have	O
less	O
nephrotoxicity	O
than	O
calcineurin	B-GENE
inhibitor	I-GENE
(	O
CNI	B-GENE
)	O
-	O
based	O
regimens	O
.	O

Family	O
members	O
with	O
the	O
C	B-Chemical
>	O
T	O
symbol	O
denote	O
c	B-VARIANT
.	I-VARIANT
130C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
variant	O
in	O
MCM2	B-GENE
,	O
those	O
with	O
the	O
C	O
/	O
C	O
symbol	O
had	O
no	O
variant	O
in	O
MCM2	B-GENE
,	O
and	O
those	O
without	O
the	O
symbols	O
were	O
not	O
examined	O
.	O

However	O
,	O
METH	B-Chemical
significantly	O
increased	O
the	O
immobility	O
time	O
in	O
the	O
tail	O
suspension	O
test	O
at	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O

A	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
severe	O
ocular	O
phenotype	O
was	O
found	O
to	O
be	O
compound	O
heterozygous	O
for	O
two	O
OPA1	B-GENE
mutations	O
,	O
a	O
p	B-VARIANT
.	I-VARIANT
S64fs	I-VARIANT
frameshift	O
deletion	O
and	O
a	O
p	B-VARIANT
.	I-VARIANT
V377I	I-VARIANT
missense	O
mutation	O
,	O
possibly	O
implying	O
an	O
additive	O
effect	O
.	O

No	O
morphological	O
abnormalities	B-DISEASE
in	I-DISEASE
optic	I-DISEASE
disc	I-DISEASE
cupping	O
or	O
loss	B-DISEASE
of	I-DISEASE
the	I-DISEASE
neuroretinal	I-DISEASE
rim	I-DISEASE
were	O
found	O
in	O
either	O
eye	O
.	O

Molecular	O
testing	O
by	O
DNA	O
linkage	O
analysis	O
,	O
mutation	O
screening	O
and	O
/	O
or	O
direct	O
DNA	O
sequencing	O
was	O
our	O
approach	O
for	O
investigation	O
,	O
performed	O
as	O
previously	O
described	O
[	O
6	O
]	O
.	O

Enhanced	O
heart	O
magnetic	O
resonance	O
imaging	O
also	O
showed	O
subendocardial	B-DISEASE
infarction	O
.	O

These	O
results	O
,	O
in	O
combination	O
with	O
previous	O
work	O
,	O
suggest	O
that	O
muscle	B-DISEASE
rigidity	I-DISEASE
,	O
a	O
clinically	O
relevant	O
side	O
-	O
effect	O
of	O
parenteral	O
narcotic	O
administration	O
,	O
may	O
be	O
partly	O
mediated	O
via	O
serotonergic	O
pathways	O
.	O

Moderate	O
-	O
to	O
-	O
severe	O
atrophies	O
of	O
the	O
lower	O
limb	O
muscles	O
and	O
high	B-DISEASE
-	I-DISEASE
arched	I-DISEASE
feet	I-DISEASE
were	O
evident	O
.	O

We	O
also	O
acknowledge	O
Almudena	B-Chemical
A	I-Chemical
vila	I-Chemical
Fern	I-Chemical
a	O
ndez	O
and	O
Fiona	O
Blanco	O
Kelly	O
for	O
their	O
helpful	O
work	O
.	O

Data	O
were	O
analyzed	O
using	O
a	O
local	O
installation	O
of	O
the	O
open	O
-	O
source	O
Galaxy	O
software	O
(	O
Blankenberg	O
et	O
al	O
.	O

To	O
study	O
CLRN1	B-GENE
glycosylation	O
in	O
vitro	O
,	O
we	O
treated	O
HA	B-Chemical
-	O
tagged	O
WT	O
CLRN1	B-GENE
and	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
mutated	O
CLRN1	B-GENE
polypeptides	O
produced	O
in	O
transiently	O
transfected	O
BHK	O
-	O
21	O
cells	O
with	O
PNGase	B-Chemical
F	I-Chemical
,	O
an	O
enzyme	O
that	O
removes	O
all	O
N	B-Chemical
-	O
linked	O
oligosaccharide	O
side	O
chains	O
from	O
glycoproteins	O
.	O

This	O
domain	O
of	O
the	O
fibrillar	O
collagens	O
has	O
a	O
highly	O
conserved	O
pattern	O
of	O
cysteine	B-Chemical
residues	O
which	O
are	O
important	O
in	O
forming	O
intramolecular	O
and	O
intermolecular	O
disulphide	O
bonds	O
during	O
the	O
trimerisation	O
process	O
of	O
a	O
collagen	O
molecule	O
.	O

(	O
XLSX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
zinc	O
finger	O
domain	O
comprises	O
two	O
beta	O
-	O
strands	O
(	O
blue	O
)	O
and	O
one	O
alpha	O
-	O
helix	O
(	O
red	O
)	O
;	O
the	O
turns	O
(	O
green	O
)	O
and	O
the	O
loops	O
(	O
light	O
gray	O
)	O
are	O
shown	O
.	O

In	O
total	O
,	O
99	O
Japanese	O
patients	O
with	O
non	O
-	O
syndromic	O
and	O
unrelated	O
arRP	B-DISEASE
or	O
sporadic	B-DISEASE
RP	I-DISEASE
(	O
spRP	B-DISEASE
)	O
were	O
recruited	O
in	O
this	O
study	O
and	O
ophthalmic	O
examinations	O
were	O
conducted	O
for	O
the	O
diagnosis	O
of	O
RP	B-DISEASE
.	O

The	O
aorta	O
/	O
serum	O
-	O
ratio	O
and	O
the	O
radioactive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I	O
-	O
HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
for	O
42	O
days	O
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	B-Chemical
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
5	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
sodium	B-Chemical
salicylate	I-Chemical
,	O
phenylbutazone	B-Chemical
,	O
indomethacin	B-Chemical
,	O
ibuprofen	B-Chemical
and	O
mefenamic	B-Chemical
acid	I-Chemical
,	O
on	O
seizures	O
produced	O
by	O
pilocarpine	B-Chemical
.	O

We	O
used	O
the	O
average	O
coverage	O
of	O
targeted	O
exons	O
of	O
deafness	B-DISEASE
genes	O
as	O
the	O
basis	O
to	O
calculate	O
CNVs	O
in	O
the	O
targeted	O
regions	O
.	O

Whole	O
genome	O
sequencing	O
is	O
becoming	O
increasingly	O
available	O
in	O
clinical	O
practice	O
,	O
particularly	O
with	O
application	O
to	O
the	O
diagnosis	O
and	O
prognosis	O
of	O
cancer	B-DISEASE
patients	O
.	O

Targeted	O
exome	O
capture	O
was	O
performed	O
using	O
genomic	O
DNA	O
from	O
each	O
subject	O
using	O
SureSelect	O
Human	O
All	O
Exon	O
Target	O
Enrichment	O
System	O
(	O
Agilent	O
)	O
.	O

For	O
novel	O
mutations	O
,	O
use	O
the	O
following	O
key	O
:	O
Sift	O
=	O
Predicted	O
damaging	O
by	O
SIFT	O
.	O

(	O
a	O
)	O
Twenty	O
-	O
one	O
year	O
old	O
affected	O
individual	O
of	O
family	O
PKDF505	O
has	O
profound	O
,	O
bilateral	O
,	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
while	O
his	O
twenty	O
-	O
three	O
years	O
old	O
sibling	O
has	O
moderate	O
to	O
severe	O
,	O
bilateral	O
sensorineural	O
hearing	O
impairment	O
.	O

In	O
addition	O
,	O
using	O
a	O
large	O
number	O
of	O
patients	O
,	O
the	O
present	O
study	O
clarified	O
the	O
molecular	O
epidemiology	O
of	O
deafness	B-DISEASE
in	O
Japanese	O
.	O

Citrate	B-Chemical
dialysate	O
,	O
a	O
new	O
dialysate	O
with	O
citric	B-Chemical
acid	I-Chemical
can	O
be	O
used	O
for	O
anticoagulation	O
in	O
patients	O
who	O
cannot	O
tolerate	O
heparin	B-Chemical
or	O
regional	O
citrate	B-Chemical
.	O

INTRODUCTION	O
:	O
Diazinon	B-Chemical
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	B-Chemical
insecticides	O
in	O
agriculture	O
.	O

This	O
mutation	O
was	O
found	O
homozygously	O
in	O
individual	O
II	O
:	O
3	O
and	O
was	O
not	O
detected	O
in	O
individual	O
II	O
:	O
1	O
.	O

However	O
,	O
in	O
the	O
current	O
family	O
there	O
were	O
no	O
complaints	O
of	O
any	O
renal	O
problems	O
.	O

Recently	O
,	O
the	O
development	O
of	O
massively	O
parallel	O
sequencing	O
(	O
MPS	O
)	O
,	O
also	O
known	O
as	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
,	O
which	O
generates	O
millions	O
of	O
DNA	O
sequence	O
reads	O
in	O
parallel	O
during	O
a	O
single	O
experimental	O
run	O
,	O
offers	O
a	O
potential	O
solution	O
to	O
approach	O
hereditary	O
disorders	O
with	O
genetic	O
heterogeneity	O
such	O
as	O
retinitis	O
pigmentosa	O
[	O
9	O
]	O
,	O
breast	O
cancer	O
[	O
10	O
]	O
,	O
cardiomyopathy	O
[	O
11	O
]	O
,	O
and	O
hereditary	O
hearing	B-DISEASE
impairment	I-DISEASE
[	O
12	O
]	O
,	O
[	O
13	O
]	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
was	O
late	O
onset	O
and	O
the	O
high	O
frequency	O
was	O
initially	O
decreased	O
(	O
Figure	O
S6	O
)	O
.	O

The	O
development	O
of	O
this	O
method	O
was	O
therefore	O
performed	O
in	O
collaboration	O
with	O
Biomedical	O
Laboratories	O
.	O

B	O
:	O
Direct	O
sequencing	O
analysis	O
shows	O
the	O
heterozygous	O
,	O
one	O
-	O
base	O
-	O
deletion	O
mutation	O
c	B-VARIANT
.	I-VARIANT
6249delT	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
I2084fs	I-VARIANT
)	O
in	O
patients	O
073001	O
and	O
073004	O
and	O
in	O
the	O
carrier	O
073003	O
;	O
sequences	O
in	O
individuals	O
073002	O
and	O
073005	O
are	O
the	O
wild	O
type	O
.	O

Whole	O
exome	O
sequencing	O
followed	O
by	O
expanded	O
familial	O
validation	O
by	O
Sanger	O
sequencing	O
.	O

Sequencing	O
of	O
the	O
coding	O
region	O
of	O
the	O
GJB2	B-GENE
gene	O
reveals	O
that	O
14	O
.	O
9	O
%	O
of	O
the	O
patients	O
carry	O
two	O
pathogenic	O
GJB2	B-GENE
mutation	O
and	O
6	O
.	O
1	O
%	O
carry	O
only	O
one	O
mutant	O
allele	O
.	O

The	O
index	O
patient	O
investigated	O
here	O
had	O
previously	O
undergone	O
selected	O
genotyping	O
(	O
APEX	O
analysis	O
,	O
arRP	B-DISEASE
panel	O
)	O
and	O
custom	O
resequencing	O
microarray	O
[	O
22	O
]	O
,	O
but	O
both	O
mutational	O
screening	O
approaches	O
failed	O
to	O
identify	O
the	O
underlying	O
gene	O
defect	O
in	O
this	O
family	O
.	O

He	O
didn	O
'	O
t	O
show	O
mental	O
retardation	O
.	O

Structural	O
and	O
sequence	O
homology	O
with	O
the	O
synaptic	O
protein	O
stargazin	O
suggest	O
a	O
role	O
for	O
CLRN1	B-GENE
in	O
the	O
plasma	O
membranes	O
surrounding	O
ribbon	O
synapses	O
of	O
the	O
inner	O
ear	O
and	O
retina	O
[	O
23	O
]	O
.	O

The	O
average	O
levodopa	B-Chemical
dose	O
decreased	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O

Wrote	O
the	O
paper	O
:	O
TJJ	O
EMR	O
SaR	O
.	O

Caspase	O
activation	O
by	O
cisplatin	B-Chemical
was	O
inhibited	O
by	O
CAA	B-Chemical
.	O

For	O
example	O
,	O
it	O
does	O
not	O
detect	O
mitochondrial	O
disorders	O
and	O
may	O
not	O
capture	O
each	O
exon	O
in	O
every	O
gene	O
and	O
insufficient	O
depth	O
of	O
coverage	O
in	O
some	O
regions	O
can	O
hinder	O
detection	O
of	O
potential	O
disease	O
-	O
causing	O
genetic	O
variants	O
.	O

The	O
same	O
robotic	O
automation	O
was	O
used	O
across	O
the	O
entire	O
set	O
and	O
in	O
all	O
steps	O
in	O
order	O
to	O
guarantee	O
a	O
uniform	O
pipetting	O
error	O
.	O

All	O
but	O
26	O
CNV	O
regions	O
(	O
37	O
CNVs	O
)	O
and	O
all	O
chromosomal	O
aberrations	O
identified	O
in	O
this	O
family	O
had	O
been	O
also	O
been	O
detected	O
among	O
the	O
DGV	O
controls	O
.	O

The	O
predicting	O
information	O
that	O
genetic	O
analysis	O
can	O
give	O
regards	O
the	O
difference	O
between	O
inactivating	O
and	O
non	O
-	O
inactivating	O
mutations	O
.	O

We	O
identified	O
35	O
de	O
novo	O
single	O
-	O
nucleotide	O
variants	O
(	O
SNVs	O
)	O
,	O
small	O
indels	O
,	O
deletions	O
or	O
duplications	O
,	O
of	O
which	O
three	O
(	O
accounting	O
for	O
10	O
%	O
of	O
the	O
cohort	O
)	O
are	O
highly	O
likely	O
to	O
be	O
causative	O
.	O

This	O
evidence	O
suggests	O
several	O
additional	O
genes	O
may	O
be	O
associated	O
with	O
ovarian	B-DISEASE
cancer	I-DISEASE
susceptibility	O
.	O

Myocardial	B-DISEASE
infarction	I-DISEASE
in	O
pregnancy	O
associated	O
with	O
clomiphene	B-Chemical
citrate	I-Chemical
for	O
ovulation	O
induction	O
:	O
a	O
case	O
report	O
.	O

The	O
mutation	O
was	O
investigated	O
in	O
all	O
available	O
family	O
members	O
and	O
showed	O
full	O
co	O
-	O
segregation	O
with	O
the	O
deafness	B-DISEASE
.	O

These	O
concentrations	O
are	O
lower	O
in	O
men	O
with	O
KAL	O
[	O
30	O
]	O
,	O
[	O
32	O
]	O
and	O
in	O
those	O
patients	O
with	O
the	O
classic	O
form	O
of	O
HH	B-DISEASE
compared	O
to	O
men	O
with	O
the	O
adult	O
-	O
onset	O
form	O
of	O
HH	B-DISEASE
[	O
32	O
]	O
,	O
[	O
33	O
]	O
.	O

Analysis	O
of	O
cDNA	O
from	O
fibroblasts	O
treated	O
with	O
CHX	B-Chemical
to	O
inhibit	O
nonsense	O
mediated	O
decay	O
demonstrated	O
the	O
presence	O
of	O
both	O
mutations	O
.	O

The	O
protein	O
structure	O
of	O
TECTA	B-GENE
is	O
not	O
yet	O
known	O
,	O
but	O
we	O
performed	O
homology	O
modeling	O
using	O
the	O
E	O
.	O

For	O
F33	B-Chemical
,	O
a	O
combination	O
of	O
quantitative	O
fluorescent	O
PCR	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
revealed	O
no	O
aneuploidy	O
,	O
or	O
deletions	O
or	O
duplications	O
in	O
the	O
subtelomeric	O
regions	O
.	O

Concerning	O
pedigree	O
11NCE	O
,	O
the	O
milder	O
affectation	O
of	O
women	O
-	O
suggestive	O
of	O
an	O
X	O
-	O
linked	O
trait	O
-	O
,	O
added	O
to	O
the	O
cosegregation	O
of	O
the	O
RP2	B-GENE
haplotype	O
,	O
both	O
pinpointed	O
this	O
candidate	O
for	O
mutational	O
screening	O
.	O

Mutational	O
screening	O
revealed	O
five	O
novel	O
heterozygous	O
mutations	O
(	O
Table	O
1	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
CNVs	O
are	O
unlikely	O
to	O
be	O
a	O
major	O
cause	O
of	O
STGD	B-DISEASE
.	O

The	O
purified	O
proteins	O
were	O
quick	O
frozen	O
and	O
stored	O
at	O
-	O
80	O
deg	O
C	O
.	O

A	O
more	O
extensive	O
analysis	O
of	O
the	O
phenotypes	O
in	O
the	O
family	O
,	O
where	O
the	O
clinical	O
effect	O
of	O
individual	O
mutations	O
can	O
be	O
assessed	O
as	O
the	O
KCNQ1	B-GENE
mutation	O
is	O
located	O
on	O
chromosome	O
11	O
and	O
the	O
KCNE1	B-GENE
-	O
encoded	O
MinK	O
variant	O
is	O
located	O
on	O
chromosome	O
2	O
,	O
14	O
is	O
necessary	O
to	O
establish	O
the	O
clinical	O
significance	O
of	O
the	O
compound	O
heterozygozity	O
.	O

The	O
patients	O
consisted	O
of	O
1179	O
males	O
and	O
884	O
females	O
ranging	O
in	O
age	O
from	O
2	O
to	O
30	O
years	O
with	O
an	O
average	O
age	O
of	O
13	O
.	O
7	O
+	O
-	O
4	O
.	O
5	O
.	O

There	O
are	O
also	O
documented	O
instances	O
of	O
rare	O
single	O
nucleotide	O
variants	O
(	O
SNVs	O
)	O
that	O
are	O
highly	O
penetrant	O
for	O
ASD	B-DISEASE
6	O
.	O

A	O
patient	O
with	O
transfusion	B-DISEASE
-	O
dependent	O
thalassemia	O
was	O
undergoing	O
home	O
intravenous	O
desferrioxamine	B-Chemical
(	O
DFX	B-Chemical
)	O
treatment	O
by	O
means	O
of	O
a	O
totally	O
implanted	O
system	O
because	O
of	O
his	O
poor	O
compliance	O
with	O
the	O
nightly	O
subcutaneous	O
therapy	O
.	O

Despite	O
these	O
uncertainties	O
,	O
this	O
initial	O
evaluation	O
of	O
the	O
direct	O
cost	O
of	O
treating	O
RIHA	B-DISEASE
provides	O
an	O
estimate	O
of	O
the	O
cost	O
and	O
management	O
implications	O
of	O
this	O
clinically	O
important	O
adverse	O
effect	O
.	O

Hepatitis	O
B	O
immune	O
globulin	O
remained	O
significantly	O
superior	O
to	O
ISG	O
in	O
preventing	O
type	B-DISEASE
B	I-DISEASE
hepatitis	I-DISEASE
even	O
when	O
the	O
analysis	O
was	O
confined	O
to	O
these	O
two	O
high	O
-	O
risk	O
subgroups	O
.	O

From	O
day	O
0	O
to	O
day	O
3	O
,	O
the	O
mean	O
peak	O
increase	O
in	O
creatinine	B-Chemical
was	O
0	O
.	O
13	O
mg	O
per	O
deciliter	O
in	O
the	O
iodixanol	B-Chemical
group	O
and	O
0	O
.	O
55	O
mg	O
per	O
deciliter	O
in	O
the	O
iohexol	B-Chemical
group	O
(	O
P	O
=	O
0	O
.	O
001	O
;	O
the	O
increase	O
with	O
iodixanol	B-Chemical
minus	O
the	O
increase	O
with	O
iohexol	B-Chemical
,	O
-	O
0	O
.	O
42	O
mg	O
per	O
deciliter	O
[	O
95	O
percent	O
confidence	O
interval	O
,	O
-	O
0	O
.	O
73	O
to	O
-	O
0	O
.	O
22	O
]	O
)	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
PSV	O
SDC	O
SM	O
AS	O
MCP	O
CB	I-Chemical
GDB	I-Chemical
.	O

Subjects	O
were	O
classified	O
as	O
having	O
USH	B-DISEASE
based	O
on	O
their	O
clinical	O
history	O
and	O
underwent	O
mutation	O
screening	O
of	O
CLRN1	B-GENE
as	O
part	O
of	O
the	O
algorithm	O
for	O
the	O
molecular	O
diagnosis	O
of	O
USH	B-DISEASE
performed	O
in	O
our	O
laboratory	O
,	O
which	O
includes	O
previous	O
analysis	O
with	O
the	O
Asper	O
Biotech	O
Usher	O
genotyping	O
microarray	O
and	O
linkage	O
analysis	O
and	O
haplotype	O
compatibility	O
when	O
possible	O
.	O

USH1C	B-GENE
haplotypes	O
are	O
represented	O
by	O
vertical	O
colored	O
bars	O
(	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
-	I-VARIANT
associated	I-VARIANT
haplotype	O
in	O
red	O
)	O
.	O

To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long	O
-	O
term	O
,	O
fixed	O
-	O
dose	O
,	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	O
-	O
infected	O
individuals	O
in	O
South	O
India	O
,	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV	O
-	O
infected	O
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiary	O
HIV	O
care	O
referral	O
center	O
in	O
South	O
India	O
.	O

We	O
recommend	O
that	O
all	O
patients	O
with	O
congenital	O
HH	B-DISEASE
should	O
be	O
informed	O
by	O
pediatricians	O
before	O
transition	O
to	O
adult	O
healthcare	O
on	O
the	O
possibility	O
of	O
HH	B-DISEASE
reversal	O
.	O

Glycopyrronium	B-Chemical
requirements	O
for	O
antagonism	O
of	O
the	O
muscarinic	O
side	O
effects	O
of	O
edrophonium	B-Chemical
.	O

Most	O
published	O
methods	O
on	O
CNV	O
detections	O
from	O
NGS	O
data	O
are	O
designed	O
for	O
examining	O
CNVs	O
on	O
the	O
whole	O
genome	O
or	O
whole	O
exome	O
scale	O
,	O
with	O
specific	O
mathematical	O
models	O
applied	O
in	O
the	O
algorithms	O
[	O
9	O
]	O
.	O

Sequences	O
were	O
analysed	O
using	O
GAP4	O
,	O
33	O
and	O
SeqMan	O
softwares	O
(	O
DNASTAR	O
Inc	O
,	O
Madison	O
,	O
Wisconsin	O
,	O
USA	O
)	O
.	O

For	O
patients	O
with	O
loss	O
of	O
vision	O
of	O
unclear	O
origin	O
,	O
SDOCT	B-Chemical
helps	O
to	O
distinguish	O
between	O
disorders	O
of	O
the	O
outer	O
retinal	O
layers	O
and	O
disorders	O
of	O
the	O
inner	O
retinal	O
layers	O
,	O
for	O
example	O
,	O
optic	O
neuropathies	O
.	O

CONCLUSION	O
:	O
When	O
performing	O
intracarotid	O
injection	O
of	O
carboplatin	B-Chemical
,	O
we	O
must	O
be	O
aware	O
of	O
its	O
potentially	O
blinding	O
ocular	I-DISEASE
toxicity	I-DISEASE
.	O

Hearing	B-DISEASE
impairment	I-DISEASE
reported	O
in	O
66	O
%	O
of	O
WS	B-DISEASE
patients	O
,	O
ranging	O
from	O
congenital	O
deafness	B-DISEASE
to	O
mild	O
,	O
progressive	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

In	O
addition	O
,	O
loop	O
structures	O
within	O
the	O
model	O
were	O
refined	O
using	O
Rosetta	O
loop	O
modeling	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
rosettacommons	O
.	O
org	O
/	O
)	O
.	O

Clinical	O
reassessment	O
confirmed	O
the	O
diagnosis	O
of	O
RP	B-DISEASE
in	O
these	O
patients	O
.	O

Full	O
-	O
length	O
open	O
reading	O
frames	O
of	O
human	O
ELMOD3	B-GENE
(	O
Isoform	O
B	O
)	O
and	O
the	O
Leu265Ser	B-VARIANT
mutant	O
were	O
cloned	O
into	O
the	O
pLEXm	O
-	O
GST	O
vector	O
[	O
37	O
]	O
using	O
KpnI	O
and	O
SphI	B-Chemical
sites	O
that	O
were	O
inserted	O
into	O
the	O
PCR	O
primers	O
,	O
with	O
subsequent	O
confirmation	O
of	O
the	O
correct	O
DNA	O
sequence	O
.	O

6	O
)	O
.	O

The	O
patient	O
tested	O
normal	O
for	O
Goldmann	O
visual	O
fields	O
(	O
GVF	O
)	O
.	O

We	O
designed	O
43	O
pairs	O
of	O
primers	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
all	O
exons	O
in	O
the	O
coding	O
regions	O
of	O
the	O
OTOF	B-GENE
gene	O
(	O
ENST00000403946	O
)	O
.	O

This	O
change	O
did	O
not	O
segregate	O
with	O
the	O
phenotype	O
.	O

Presumably	O
,	O
other	O
genetic	O
factors	O
and	O
environmental	O
factors	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
EVA	B-DISEASE
in	O
Caucasian	O
populations	O
.	O

The	O
most	O
important	O
functional	O
part	O
of	O
the	O
protein	O
is	O
the	O
FN	O
-	O
III	O
domains	O
.	O

Thus	O
,	O
in	O
our	O
experiments	O
mutant	O
CD164	B-GENE
was	O
able	O
to	O
co	O
-	O
precipitate	O
wild	O
-	O
type	O
CD164	B-GENE
and	O
vice	O
versa	O
demonstrating	O
that	O
mutant	O
CD164	B-GENE
can	O
form	O
heterodimers	O
with	O
wild	O
-	O
type	O
CD164	B-GENE
in	O
HEK	O
cells	O
.	O

Mantle	B-DISEASE
cell	I-DISEASE
lymphoma	I-DISEASE
(	O
MCL	B-DISEASE
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	B-DISEASE
-	I-DISEASE
cell	I-DISEASE
non	I-DISEASE
-	I-DISEASE
Hodgkin	I-DISEASE
'	I-DISEASE
s	I-DISEASE
lymphoma	I-DISEASE
.	O

*	O
*	O
Combination	O
of	O
uncertain	O
pathogenicity	O
variants	O
were	O
counted	O
as	O
heterozygotes	O
,	O
not	O
as	O
compound	O
heterozygotes	O
.	O

Using	O
direct	O
DNA	O
sequence	O
analysis	O
of	O
exons	O
2	O
-	O
72	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
USH2A	B-GENE
,	O
we	O
found	O
two	O
novel	O
compound	O
heterozygous	O
mutations	O
:	O
one	O
missense	O
mutation	O
and	O
one	O
splicing	O
site	O
mutation	O
.	O

Use	O
of	O
verapamil	B-Chemical
in	O
combination	O
with	O
carbamazepine	B-Chemical
should	O
either	O
be	O
avoided	O
or	O
prescribed	O
only	O
with	O
appropriate	O
adjustment	O
of	O
the	O
carbamazepine	B-Chemical
dose	O
(	O
usually	O
reduction	O
of	O
the	O
carbamazepine	B-Chemical
dose	O
by	O
one	O
half	O
)	O
.	O

The	O
reconstructed	O
RPGRIP1	B-GENE
minigene	O
encompassed	O
exons	O
12	O
to	O
18	O
,	O
plus	O
at	O
least	O
200	O
bp	O
of	O
each	O
intron	O
-	O
exon	O
boundary	O
,	O
after	O
amplification	O
of	O
genomic	O
DNA	O
from	O
patient	O
1	O
of	O
the	O
59RE	O
pedigree	O
(	O
heterozygote	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
2367	I-VARIANT
+	I-VARIANT
23del	I-VARIANT
mutation	O
)	O
.	O

Our	O
results	O
strongly	O
indicate	O
that	O
DFNB1	B-GENE
only	O
accounts	O
for	O
3	O
%	O
of	O
non	O
-	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
Saudi	O
Arabian	O
population	O
of	O
ethnic	O
ancestry	O
.	O

Both	O
DHEA	B-Chemical
50	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
significantly	O
decreased	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	B-Chemical
-	O
induced	O
locomotion	O
group	O
.	O

The	O
minigene	O
assays	O
only	O
revealed	O
a	O
mild	O
increase	O
of	O
the	O
transcript	O
excluding	O
exon	O
7	O
(	O
Figure	O
1	O
,	O
band	O
d	O
)	O
when	O
the	O
variant	O
was	O
present	O
,	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
sequence	O
.	O

Green	O
=	O
A	O
,	O
red	O
=	O
T	O
,	O
blue	O
=	O
C	O
,	O
black	O
=	O
G	O
.	O

Primers	O
were	O
chosen	O
using	O
the	O
web	O
-	O
based	O
program	O
Primer3	O
(	O
PRIMER3	B-Chemical
,	O
primer3_	O
www	O
.	O
cgi	O
v	O
0	O
.	O
2	O
)	O
.	O

Coverage	O
and	O
Strand	O
bias	O
test	O
for	O
USH	O
patients	O
Variants	O
.	O

Within	O
the	O
founder	O
families	O
,	O
represented	O
by	O
23	O
probands	O
,	O
two	O
probands	O
(	O
8	O
.	O
5	O
%	O
)	O
were	O
double	O
heterozygotes	O
.	O

All	O
but	O
one	O
of	O
the	O
patients	O
were	O
over	O
60	O
years	O
old	O
,	O
and	O
the	O
6	O
who	O
died	O
were	O
all	O
older	O
than	O
65	O
.	O

(	O
Fig	O
.	O

Currently	O
mutations	O
in	O
eight	O
genes	O
explain	O
approximatively	O
25	O
-	O
35	O
%	O
of	O
KS	B-DISEASE
cases	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

WFS1	B-GENE
participates	O
in	O
many	O
important	O
cellular	O
processes	O
,	O
including	O
insulin	O
production	O
,	O
processing	O
,	O
and	O
secretion	O
;	O
production	O
of	O
cyclic	O
AMP	O
;	O
and	O
regulation	O
of	O
ER	O
calcium	O
levels	O
(	O
as	O
reviewed	O
in	O
16	O
,	O
17	O
)	O
.	O

Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
were	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred	O
.	O

To	O
date	O
,	O
eight	O
mutations	O
have	O
been	O
reported	O
in	O
the	O
EYA4	B-GENE
gene	O
,	O
and	O
other	O
than	O
one	O
missense	O
mutation	O
,	O
six	O
result	O
in	O
truncated	O
proteins	O
that	O
partially	O
or	O
completely	O
lack	O
the	O
SIX3	B-GENE
-	O
interacting	O
region	O
in	O
the	O
Eya	O
HR	O
domain	O
.	O

To	O
avoid	O
sample	O
evaporation	O
,	O
aqueous	O
mixture	O
in	O
each	O
tube	O
was	O
overlaid	O
with	O
30	O
-	O
40	O
u	O
l	O
of	O
mineral	O
oil	O
that	O
was	O
removed	O
by	O
chloroform	B-Chemical
extraction	O
after	O
the	O
reaction	O
.	O

Primers	O
(	O
Table	O
S1	O
)	O
were	O
designed	O
using	O
P	O
rimer	O
3	O
(	O
version	O
0	O
.	O
4	O
.	O
0	O
)	O
software	O
(	O
12	O
)	O
or	O
obtained	O
from	O
the	O
literature	O
(	O
9	O
)	O
.	O

Since	O
the	O
terminally	O
differentiated	O
hair	O
cells	O
cannot	O
survive	O
in	O
incubation	O
medium	O
,	O
we	O
preliminarily	O
applied	O
transient	O
transfected	O
HEK293	O
cells	O
to	O
detect	O
the	O
effects	O
of	O
variant	O
MCM2	B-GENE
.	O

RT	O
-	O
PCR	O
experiments	O
were	O
performed	O
using	O
PRPS1	B-GENE
exonic	O
primers	O
pairs	O
spanning	O
exons	O
1	O
-	O
2	O
,	O
1	O
-	O
4	O
,	O
and	O
4	O
-	O
7	O
(	O
primers	O
available	O
in	O
the	O
Additional	O
file	O
1	O
)	O
.	O

However	O
,	O
because	O
this	O
change	O
was	O
not	O
present	O
in	O
controls	O
,	O
it	O
might	O
have	O
affected	O
the	O
phenotype	O
of	O
these	O
patients	O
or	O
even	O
acted	O
synergistically	O
with	O
the	O
p	B-VARIANT
.	I-VARIANT
R1890C	I-VARIANT
mutation	O
[	O
15	O
]	O
.	O

Dominant	O
TECTA	B-GENE
mutations	O
can	O
cause	O
mid	O
-	O
frequency	O
,	O
high	O
-	O
frequency	O
progressive	O
HL	B-DISEASE
,	O
and	O
TECTA	B-GENE
is	O
reported	O
to	O
be	O
the	O
commonest	O
causative	O
gene	O
among	O
ADNSHL	B-DISEASE
[	O
13	O
]	O
.	O

In	O
this	O
regard	O
,	O
comparison	O
between	O
group	O
1	O
with	O
hypocalcemia	B-DISEASE
and	O
group	O
2	O
without	O
hypocalcemia	B-DISEASE
revealed	O
a	O
large	O
number	O
of	O
non	O
-	O
synonymous	O
and	O
synonymous	O
variants	O
that	O
exclusively	O
belonged	O
to	O
either	O
group	O
1	O
(	O
Table	O
S4	O
)	O
or	O
group	O
2	O
(	O
Table	O
S5	O
)	O
,	O
although	O
the	O
lists	O
did	O
not	O
contain	O
a	O
c	B-VARIANT
.	I-VARIANT
2968A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R990G	I-VARIANT
)	O
SNP	O
in	O
CASR	B-GENE
(	O
calcium	O
sensing	O
receptor	O
)	O
that	O
has	O
a	O
gain	O
-	O
of	O
-	O
function	O
effect	O
and	O
appears	O
to	O
raise	O
the	O
susceptibility	O
to	O
hypocalcemia	B-DISEASE
(	O
Fig	O
.	O

The	O
ERG	O
(	O
LKC	O
Technologies	O
,	O
Inc	O
.	O
,	O
Gaithersburg	O
,	O
MD	O
)	O
was	O
flat	O
in	O
all	O
three	O
affected	O
individuals	O
.	O

Three	O
-	O
dimensional	O
models	O
were	O
built	O
using	O
MODELER	O
[	O
17	O
]	O
from	O
the	O
Accelrys	O
Discovery	O
Studio	O
package	O
.	O

Thirty	O
-	O
five	O
consecutive	O
chemotherapy	O
-	O
naive	O
patients	O
with	O
Stage	O
IV	O
NSCLC	B-DISEASE
and	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	O
of	O
paclitaxel	B-Chemical
(	O
135	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	O
)	O
on	O
Day	O
1	O
,	O
cisplatin	B-Chemical
(	O
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	O
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	B-Chemical
(	O
800	O
mg	O
/	O
m	O
(	O
2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	O
)	O
on	O
Days	O
1	O
and	O
8	O
,	O
every	O
4	O
weeks	O
.	O

Readministration	O
of	O
amantadine	B-Chemical
,	O
after	O
a	O
drug	O
-	O
free	O
overnight	O
period	O
,	O
increased	O
motility	O
from	O
respective	O
saline	O
control	O
in	O
all	O
strains	O
with	O
exception	O
of	O
the	O
BALB	O
/	O
C	O
mice	O
where	O
suppression	O
of	O
motility	O
occurred	O
.	O

It	O
is	O
thus	O
confirmed	O
that	O
the	O
histological	O
characteristics	O
of	O
myopathic	O
rat	O
muscle	O
induced	O
experimentally	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
human	O
myopathy	B-DISEASE
as	O
confirmed	O
during	O
biopsies	O
performed	O
at	O
the	O
Orthopaedic	O
Traumatological	O
Centre	O
,	O
Florence	O
.	O

To	O
specify	O
thickness	O
values	O
of	O
various	O
retinal	O
layers	O
on	O
macular	O
spectral	O
domain	O
Optical	O
Coherence	O
Tomography	O
(	O
SDOCT	O
)	O
scans	O
in	O
patients	O
with	O
autosomal	B-DISEASE
dominant	I-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
(	O
ADOA	B-DISEASE
)	O
compared	O
to	O
healthy	O
controls	O
.	O

Click	O
here	O
for	O
file	O
Electropherogramms	O
of	O
PRPS1	B-GENE
sequencing	O
.	O

All	O
the	O
coding	O
exons	O
and	O
exon	O
-	O
intron	O
junctions	O
of	O
OPA1	B-GENE
(	O
references	O
from	O
NCBI	O
:	O
NC_000003	O
.	O
11	O
for	O
gDNA	O
,	O
NM_015560	O
.	O
1	O
for	O
mRNA	O
,	O
and	O
NP_056375	O
.	O
2	O
for	O
protein	O
)	O
were	O
amplified	O
with	O
PCR	O
using	O
30	O
primer	O
sets	O
(	O
Table	O
1	O
)	O
.	O

Mutations	O
in	O
USH2A	B-GENE
were	O
the	O
molecular	O
cause	O
of	O
USH2	B-DISEASE
in	O
96	O
out	O
of	O
121	O
(	O
79	O
.	O
3	O
%	O
)	O
of	O
USH2	B-DISEASE
families	O
;	O
two	O
pathogenic	O
/	O
UV4	O
/	O
UV3	O
variants	O
were	O
found	O
in	O
73	O
/	O
121	O
(	O
60	O
.	O
3	O
%	O
)	O
of	O
all	O
USH2	B-DISEASE
families	O
and	O
only	O
one	O
pathogenic	O
/	O
UV4	O
/	O
UV3	O
variant	O
was	O
identified	O
in	O
23	O
/	O
121	O
(	O
19	O
%	O
)	O
of	O
USH2	B-DISEASE
families	O
,	O
in	O
spite	O
of	O
full	O
sequence	O
analysis	O
.	O

For	O
example	O
,	O
the	O
EGF	O
-	O
like	O
repeats	O
of	O
COMP	B-GENE
and	O
MATN3	B-GENE
and	O
the	O
EGF	O
-	O
like	O
and	O
A	O
-	O
domains	O
of	O
matrilin	O
-	O
1	O
and	O
-	O
4	O
are	O
important	O
for	O
protein	O
integrity	O
and	O
interactions	O
in	O
cartilage	O
[	O
Wagener	B-Chemical
et	O
al	O
.	O
,	O
2005	O
]	O
.	O

Severe	O
hematologic	O
toxicity	O
(	O
neutrophil	O
count	O
<	O
1000	O
/	O
mm3	O
and	O
/	O
or	O
hemoglobin	O
<	O
8	O
g	O
/	O
dl	O
)	O
occurred	O
in	O
4	O
patients	O
assigned	O
to	O
group	O
I	O
and	O
7	O
assigned	O
to	O
group	O
II	O
.	O

Patients	O
with	O
two	O
GJB2	B-GENE
mutant	O
alleles	O
(	O
22	O
cases	O
)	O
or	O
one	O
dominant	O
mutant	O
allele	O
(	O
one	O
case	O
)	O
or	O
mtDNA	B-VARIANT
1555	I-VARIANT
A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
(	O
one	O
case	O
)	O
were	O
not	O
further	O
analyzed	O
for	O
SLC26A4	B-GENE
mutations	O
.	O

The	O
reason	O
was	O
thought	O
to	O
be	O
the	O
use	O
of	O
uncurated	O
variant	O
database	O
[	O
12	O
]	O
.	O

(	O
Variant	O
Identification	O
Pipeline	O
)	O
[	O
14	O
]	O
.	O

Initial	O
sequencing	O
of	O
seven	O
known	O
hearing	B-DISEASE
loss	I-DISEASE
genes	O
(	O
WFS1	B-GENE
[	O
OMIM	O
606201	O
]	O
,	O
GRHL2	B-GENE
[	O
OMIM	O
608576	O
]	O
,	O
EYA4	B-GENE
[	O
OMIM	O
603550	O
]	O
,	O
ACTG1	B-GENE
[	O
OMIM	O
102560	O
]	O
,	O
GJB2	B-GENE
[	O
OMIM	O
121011	O
]	O
,	O
MYO6	B-GENE
(	O
exon	O
25	O
)	O
[	O
OMIM	O
600970	O
]	O
,	O
and	O
SLC26A4	B-GENE
[	O
OMIM	O
605646	O
]	O
)	O
failed	O
to	O
identify	O
any	O
mutations	O
,	O
prompting	O
us	O
to	O
perform	O
a	O
genome	O
-	O
wide	O
linkage	O
analysis	O
to	O
identify	O
the	O
responsible	O
locus	O
for	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
family	O
.	O

Some	O
had	O
already	O
been	O
screened	O
for	O
mutations	O
in	O
the	O
other	O
known	O
USH1	B-DISEASE
genes	O
(	O
myosin	B-GENE
VIIA	I-GENE
[	O
MYO7A	B-GENE
]	O
,	O
cadherin	B-GENE
-	I-GENE
related	I-GENE
23	I-GENE
[	O
CDH23	B-GENE
]	O
,	O
protocadherin	B-GENE
-	I-GENE
related	I-GENE
15	I-GENE
[	O
PCDH15	B-GENE
]	O
,	O
and	O
Usher	B-GENE
syndrome	I-GENE
1G	I-GENE
[	O
USH1G	B-GENE
]	O
)	O
,	O
but	O
no	O
mutation	O
was	O
found	O
.	O

SLC26A4	B-GENE
encodes	O
pendrin	O
,	O
an	O
anion	O
transporter	O
protein	O
[	O
10	O
]	O
.	O

(	O
Supplementary	O
Data	O
18	O
)	O
We	O
applied	O
a	O
modified	O
version	O
of	O
the	O
cohort	O
allelic	O
sums	O
test	O
(	O
CAST	O
)	O
11	O
to	O
the	O
final	O
list	O
of	O
germline	O
missense	O
variants	O
in	O
the	O
ovarian	B-DISEASE
cancer	I-DISEASE
dataset	O
to	O
determine	O
the	O
statistical	O
significance	O
of	O
deleterious	O
variants	O
in	O
genes	O
that	O
were	O
over	O
-	O
represented	O
in	O
ovarian	O
cases	O
vs	O
.	O

Variants	O
that	O
are	O
highly	O
likely	O
to	O
be	O
causal	O
were	O
noted	O
in	O
three	O
cases	O
(	O
10	O
%	O
)	O
.	O

In	O
some	O
cases	O
,	O
we	O
could	O
observe	O
that	O
the	O
CNV	O
analysis	O
displayed	O
doubtful	O
results	O
in	O
the	O
targeted	O
regions	O
.	O

One	O
explanation	O
for	O
these	O
discrepancies	O
could	O
be	O
the	O
presence	O
of	O
population	O
-	O
specific	O
modifiers	O
,	O
genetic	O
or	O
other	O
,	O
such	O
as	O
the	O
recently	O
described	O
polymorphisms	O
in	O
the	O
3	O
'	O
-	O
UTR	O
of	O
KCNQ1	B-GENE
,	O
mitigating	O
the	O
effect	O
of	O
the	O
mutated	O
allele	O
by	O
reduced	O
expression	O
[	O
30	O
]	O
.	O

The	O
three	O
DNA	O
samples	O
with	O
monoallelic	O
mutations	O
in	O
TULP1	B-GENE
and	O
SAG	B-GENE
mutations	O
were	O
initially	O
sequenced	O
on	O
the	O
GS	O
FLX	O
system	O
;	O
subsequent	O
analysis	O
on	O
the	O
MiSeq	B-Chemical
platform	O
did	O
not	O
identify	O
additional	O
mutant	O
alleles	O
,	O
in	O
particular	O
no	O
CNVs	O
.	O

While	O
use	O
of	O
high	O
dose	O
dexmedetomidine	B-Chemical
is	O
associated	O
with	O
decreases	O
in	O
heart	O
rate	O
and	O
blood	O
pressure	O
outside	O
the	O
established	O
'	O
awake	O
'	O
norms	O
,	O
this	O
deviation	O
is	O
generally	O
within	O
20	O
%	O
of	O
norms	O
,	O
and	O
is	O
not	O
associated	O
with	O
adverse	O
sequelae	O
.	O

The	O
family	O
medical	O
history	O
stated	O
that	O
the	O
onset	O
of	O
hearing	O
loss	O
was	O
pre	O
-	O
lingual	O
,	O
and	O
we	O
observed	O
no	O
evidence	O
of	O
vestibular	O
dysfunction	O
or	O
other	O
balance	O
issues	O
using	O
the	O
Romberg	B-Chemical
and	O
tandem	O
gait	O
tests	O
.	O

Interestingly	O
,	O
one	O
patient	O
(	O
110	O
)	O
with	O
an	O
USH2	B-DISEASE
phenotype	O
and	O
no	O
mutations	O
in	O
USH2	B-DISEASE
genes	O
had	O
a	O
single	O
MYO7A	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
Gly1942X	I-VARIANT
nonsense	O
mutation	O
.	O

Pure	O
tone	O
audiogram	O
for	O
the	O
left	O
and	O
right	O
ears	O
of	O
the	O
YS	O
-	O
151	O
patient	O
(	O
III	O
-	O
2	O
)	O
(	O
lower	O
panel	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
applied	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
to	O
study	O
small	O
Korean	O
families	O
negative	O
for	O
mutations	O
in	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
,	O
and	O
we	O
identified	O
CDH23	B-GENE
mutations	O
in	O
two	O
families	O
with	O
autosomal	B-DISEASE
recessive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ARNSHL	B-DISEASE
)	O
.	O

2A	O
-	O
B	O
)	O
.	O

(	O
C	O
,	O
D	O
)	O
Amino	O
acid	O
residue	O
Glu1595	O
is	O
located	O
in	O
EC15	O
.	O

Patients	O
began	O
thalidomide	B-Chemical
at	O
400	O
mg	O
/	O
d	O
and	O
escalated	O
as	O
tolerated	O
to	O
1200	O
mg	O
/	O
d	O
by	O
day	O
54	O
.	O

Detailed	O
clinical	O
examination	O
of	O
the	O
diabetic	B-DISEASE
family	O
members	O
did	O
not	O
reveal	O
any	O
of	O
the	O
other	O
clinical	O
features	O
of	O
the	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
(	O
WS	B-DISEASE
)	O
(	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
audiograms	O
,	O
optic	B-DISEASE
atrophy	I-DISEASE
or	I-DISEASE
vision	I-DISEASE
impairment	I-DISEASE
in	O
annual	O
ophthalmoscopy	O
examinations	O
,	O
or	O
diabetes	B-DISEASE
insipidus	I-DISEASE
)	O
.	O

As	O
Figure	O
2A	O
indicates	O
,	O
the	O
vestibular	O
aqueduct	O
is	O
enlarged	O
.	O

Nevertheless	O
,	O
thephenotype	O
variation	O
is	O
conspicuous	O
,	O
even	O
among	O
patients	O
with	O
one	O
and	O
the	O
same	O
mutation	O
.	O

Sex	O
,	O
age	O
,	O
diagnosis	O
(	O
bipolar	B-DISEASE
I	I-DISEASE
vs	O
.	O
bipolar	B-DISEASE
II	I-DISEASE
)	O
,	O
and	O
additional	O
treatment	O
did	O
not	O
affect	O
the	O
risk	O
of	O
switching	O
.	O

According	O
to	O
the	O
present	O
data	O
,	O
screening	O
for	O
OTOF	B-GENE
is	O
necessary	O
not	O
only	O
for	O
the	O
patients	O
diagnosed	O
with	O
ANSD	B-DISEASE
,	O
but	O
also	O
should	O
be	O
extended	O
to	O
ARNSHL	B-DISEASE
cases	O
.	O

It	O
is	O
a	O
viable	O
option	O
for	O
other	O
patients	O
as	O
well	O
.	O

Gentamicin	B-Chemical
nephropathy	I-DISEASE
in	O
a	O
neonate	O
.	O

PCR	O
was	O
performed	O
with	O
PE9700	B-Chemical
thermocyclers	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Due	O
to	O
genetic	O
and	O
phenotypic	O
heterogeneity	O
,	O
single	O
gene	O
testing	O
is	O
often	O
ineffective	O
and	O
targeted	O
exome	O
sequencing	O
is	O
emerging	O
as	O
an	O
efficient	O
alternative	O
[	O
3	O
]	O
.	O

Granulomatous	B-DISEASE
hepatitis	I-DISEASE
due	O
to	O
combination	B-Chemical
of	I-Chemical
amoxicillin	I-Chemical
and	I-Chemical
clavulanic	I-Chemical
acid	I-Chemical
.	O

We	O
suggest	O
that	O
close	O
attention	O
should	O
be	O
paid	O
to	O
this	O
gene	O
when	O
performing	O
genetic	O
testing	O
of	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
East	O
Asia	O
.	O

CNV	O
analysis	O
should	O
routinely	O
be	O
applied	O
in	O
targeted	O
NGS	O
,	O
and	O
mutations	O
in	O
non	O
-	O
coding	O
exons	O
give	O
reason	O
to	O
systematically	O
include	O
5	O
'	O
-	O
UTRs	O
in	O
disease	O
gene	O
or	O
exome	O
panels	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
prevalence	O
of	O
CNGA1	B-GENE
mutations	O
is	O
higher	O
in	O
Asian	O
population	O
than	O
in	O
populations	O
of	O
European	O
descent	O
.	O

GCL	O
and	O
ONL	O
+	O
PR	O
showed	O
no	O
difference	O
between	O
subfields	O
.	O

reported	O
that	O
MME	B-DISEASE
was	O
associated	O
with	O
lower	O
visual	B-DISEASE
acuity	I-DISEASE
and	O
a	O
thinner	O
RNFL	O
in	O
patients	O
with	O
MS	B-DISEASE
[	O
23	O
]	O
.	O

The	O
ophthalmologic	O
exploration	O
included	O
visual	O
acuity	O
measurements	O
,	O
fundus	O
ophthalmoscopy	O
,	O
and	O
visual	O
field	O
examination	O
.	O

The	O
hearing	B-DISEASE
impairment	I-DISEASE
is	O
moderate	O
to	O
severe	O
(	O
Fig	O
1B	O
)	O
.	O

A	O
sterile	O
stainless	O
steel	O
needle	O
electrode	O
was	O
passed	O
through	O
the	O
tympanic	O
membrane	O
and	O
placed	O
on	O
the	O
promontory	O
wall	O
with	O
the	O
aid	O
of	O
an	O
operating	O
microscope	O
.	O

Linkage	O
analysis	O
was	O
performed	O
to	O
narrow	O
down	O
the	O
number	O
of	O
candidates	O
based	O
on	O
WES	O
data	O
.	O

For	O
example	O
,	O
two	O
sisters	O
of	O
patient	O
9	O
with	O
the	O
same	O
genotype	O
(	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
/	O
K77I	B-VARIANT
)	O
and	O
one	O
sister	O
of	O
Patient	O
6	O
with	O
homozygous	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
all	O
have	O
EVA	B-DISEASE
.	O

For	O
TMIE	B-GENE
,	O
all	O
eight	O
mutation	O
positive	O
families	O
were	O
homozygous	O
for	O
the	O
observed	O
mutations	O
.	O

RESULTS	O
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B-DISEASE
in	O
subjects	O
treated	O
with	O
clonidine	B-Chemical
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	B-Chemical
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
%	O
;	O
p	O
=	O
.	O
02	O
)	O
,	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O

However	O
the	O
degree	O
of	O
implication	O
of	O
GJB2	B-GENE
/	O
GJB6	B-GENE
genes	O
in	O
deafness	B-DISEASE
depends	O
on	O
the	O
composition	O
in	O
degree	O
of	O
severity	O
of	O
the	O
patient	O
group	O
.	O

However	O
,	O
further	O
investigations	O
are	O
warranted	O
in	O
a	O
model	O
of	O
chronic	O
heart	B-DISEASE
failure	I-DISEASE
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
frequent	O
disease	O
-	O
causing	O
gene	O
mutations	O
in	O
autosomal	B-DISEASE
recessive	I-DISEASE
retinitis	I-DISEASE
pigmentosa	I-DISEASE
(	O
arRP	B-DISEASE
)	O
in	O
the	O
Japanese	O
population	O
.	O

It	O
is	O
possible	O
that	O
a	O
conformational	O
change	O
or	O
loss	O
of	O
stable	O
interactions	O
may	O
target	O
Gipc3	B-GENE
(	O
115Arg	O
)	O
for	O
early	O
degradation	O
.	O

1A	O
)	O
.	O

Known	O
mutation	O
.	O

In	O
two	O
of	O
the	O
studies	O
,	O
when	O
using	O
more	O
stringent	O
criteria	O
(	O
i	O
.	O
e	O
.	O

Therefore	O
,	O
we	O
focused	O
in	O
this	O
study	O
on	O
the	O
comparative	O
evaluation	O
of	O
the	O
coverage	O
depth	O
,	O
which	O
is	O
the	O
major	O
determinant	O
of	O
the	O
power	O
for	O
variant	O
discovery	O
.	O

The	O
phenotype	O
of	O
the	O
morpholino	O
zebrafish	O
may	O
however	O
still	O
be	O
of	O
some	O
interest	O
,	O
since	O
both	O
the	O
kidney	O
and	O
the	O
inner	O
ear	O
contain	O
polarised	O
epithelial	O
cells	O
important	O
for	O
maintenance	O
of	O
fluid	O
homeostasis	O
.	O

In	O
conclusion	O
,	O
SLC17A9	B-GENE
is	O
not	O
only	O
unrelated	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
;	O
its	O
haploinsufficiency	O
does	O
not	O
seem	O
to	O
cause	O
DSAP	B-DISEASE
either	O
.	O

(	O
A	O
)	O
Wild	O
type	O
NARS2	B-GENE
-	O
GFP	O
(	O
green	O
)	O
was	O
transiently	O
expressed	O
in	O
COS	O
-	O
7	O
cells	O
,	O
and	O
Mito	B-Chemical
Tracker	I-Chemical
Red	O
FM	O
was	O
used	O
to	O
stain	O
mitochondria	O
.	O

Furthermore	O
,	O
this	O
mutation	O
is	O
associated	O
with	O
adult	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
cardiomyopathy	I-DISEASE
,	O
but	O
because	O
he	O
is	O
a	O
child	O
,	O
periodic	O
cardiac	O
monitoring	O
is	O
recommended	O
to	O
detect	O
early	O
signs	O
of	O
dysfunction	O
.	O

In	O
the	O
cells	O
transfected	O
with	O
wild	O
-	O
type	O
MCM2	B-GENE
cDNA	O
plasmid	O
,	O
G1	O
,	O
S	O
,	O
and	O
G2	O
phases	O
were	O
27	O
.	O
08	O
+	O
-	O
4	O
.	O
99	O
,	O
50	O
.	O
69	O
+	O
-	O
2	O
.	O
14	O
,	O
22	O
.	O
21	O
+	O
-	O
6	O
.	O
04	O
,	O
respectively	O
.	O

However	O
,	O
OPA1	B-GENE
(	O
NM_130837	O
)	O
is	O
the	O
major	O
gene	O
responsible	O
for	O
ADOA	B-DISEASE
,	O
which	O
was	O
first	O
localized	O
on	O
3q28	O
in	O
1996	O
,	O
followed	O
by	O
the	O
discovery	O
of	O
the	O
OPA1	B-GENE
gene	O
sequence	O
5	O
6	O
.	O

A	O
similar	O
,	O
but	O
less	O
marked	O
,	O
biochemical	O
phenotype	O
has	O
been	O
previously	O
described	O
in	O
fibroblasts	O
from	O
patients	O
with	O
ADOA	B-DISEASE
carrying	O
OPA1	B-GENE
mutations	O
;	O
in	O
this	O
study	O
the	O
reduced	B-DISEASE
efficiency	I-DISEASE
of	I-DISEASE
oxidative	I-DISEASE
phosphorylation	I-DISEASE
was	O
found	O
to	O
be	O
compensated	O
by	O
a	O
higher	O
rate	O
of	O
mitochondrial	O
respiration	O
to	O
maintain	O
ATP	O
synthesis	O
[	O
22	O
]	O
.	O

The	O
corresponding	O
UCSC	O
map	O
positions	O
are	O
indicated	O
below	O
the	O
scheme	O
of	O
the	O
USH1C	B-GENE
gene	O
.	O

In	O
the	O
present	O
investigation	O
,	O
a	O
large	O
deaf	B-DISEASE
Iranian	O
kindred	O
with	O
9	O
patients	O
was	O
subject	O
to	O
genetic	O
linkage	O
analysis	O
and	O
two	O
novel	O
mutations	O
were	O
identified	O
.	O

prepared	O
figures	O
and	O
tables	O
.	O

All	O
mutations	O
were	O
confirmed	O
by	O
reamplification	O
of	O
the	O
fragment	O
and	O
resequencing	O
of	O
the	O
proband	O
and	O
his	O
or	O
her	O
available	O
relatives	O
.	O

The	O
threshold	O
neurotoxic	O
dosage	O
is	O
lower	O
than	O
previously	O
reported	O
.	O

In	O
particular	O
,	O
morphological	O
abnormalities	O
of	O
the	O
cerebellum	O
and	O
brain	O
stem	O
had	O
been	O
documented	O
by	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
14	O
patients	O
,	O
5	O
of	O
whom	O
had	O
no	O
neuro	B-DISEASE
-	I-DISEASE
psychiatric	I-DISEASE
symptoms	I-DISEASE
at	O
the	O
time	O
of	O
examination	O
.	O

The	O
samples	O
were	O
clarified	O
by	O
centrifugation	O
,	O
and	O
400	O
u	O
L	O
was	O
taken	O
for	O
counting	O
in	O
a	O
liquid	O
scintillation	O
counter	O
.	O

(	O
A	O
)	O
Pedigree	O
of	O
the	O
family	O
shows	O
maternal	O
inheritance	O
of	O
the	O
PRPS1	B-GENE
mutation	O
with	O
variable	O
phenotypic	O
severity	O
of	O
disease	O
,	O
reaching	O
from	O
an	O
unaffected	O
state	O
in	O
the	O
mother	O
(	O
I	O
-	O
1	O
)	O
to	O
a	O
mildly	O
affected	O
DFN2	B-DISEASE
phenotype	O
in	O
the	O
sister	O
of	O
the	O
index	O
patient	O
(	O
II	O
-	O
1	O
)	O
to	O
a	O
severe	O
Arts	B-GENE
/	O
CMTX5	B-DISEASE
overlap	O
syndrome	O
in	O
the	O
index	O
patient	O
(	O
II	O
-	O
2	O
)	O
.	O

Interestingly	O
,	O
the	O
patient	O
of	O
this	O
case	O
had	O
progressive	O
external	O
ophthalmoplegia	B-DISEASE
and	O
central	B-DISEASE
vision	I-DISEASE
loss	I-DISEASE
.	O

This	O
was	O
later	O
updated	O
to	O
49	O
mutations	O
(	O
Balduini	O
et	O
al	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
an	O
early	O
stress	O
,	O
in	O
the	O
form	O
of	O
maternal	B-DISEASE
deprivation	I-DISEASE
,	O
combined	O
with	O
a	O
later	O
stress	O
,	O
simulated	O
by	O
chronic	O
periadolescent	O
corticosterone	B-Chemical
treatment	O
,	O
on	O
behaviour	O
in	O
rats	O
.	O

,	O
2008	O
;	O
Hudson	O
et	O
al	O
.	O

BACKGROUND	O
:	O
In	O
dogs	O
,	O
a	O
large	O
amount	O
of	O
intravenous	O
cocaine	B-Chemical
causes	O
a	O
profound	O
deterioration	O
of	O
left	O
ventricular	O
(	O
LV	O
)	O
systolic	O
function	O
and	O
an	O
increase	O
in	O
LV	O
end	O
-	O
diastolic	O
pressure	O
.	O

The	O
wild	O
-	O
type	O
sequence	O
resulted	O
in	O
predicted	O
scores	O
of	O
0	O
.	O
92	O
and	O
0	O
.	O
90	O
,	O
while	O
the	O
calculated	O
values	O
of	O
the	O
numerical	O
score	O
for	O
the	O
altered	O
sequence	O
were	O
0	O
.	O
62	O
and	O
0	O
.	O
60	O
,	O
respectively	O
.	O

HEK293T	O
,	O
CL4	O
and	O
MDCK	O
cells	O
were	O
grown	O
in	O
DMEM	O
that	O
was	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
2	O
mM	O
L	O
-	I-Chemical
glutamine	I-Chemical
,	O
and	O
penicillin	O
/	O
streptomycin	O
(	O
50	O
U	O
/	O
ml	O
)	O
(	O
Life	O
Technologies	O
)	O
and	O
were	O
maintained	O
at	O
37	O
deg	O
C	O
in	O
5	O
%	O
CO	O
2	O
.	O

Table	O
2	O
shows	O
the	O
four	O
novel	O
homozygous	O
missense	O
,	O
nonsense	O
,	O
splice	O
site	O
and	O
frame	O
shift	O
variants	O
(	O
not	O
reported	O
in	O
dbSNP132	O
)	O
in	O
the	O
five	O
autozygous	O
regions	O
when	O
we	O
used	O
a	O
filter	O
of	O
minimum	O
8	O
x	O
read	O
depth	O
.	O

paniscus	O
,	O
XP_003825527	O
.	O
1	O
;	O
E	O
.	O

Similar	O
results	O
were	O
observed	O
with	O
UT	B-GENE
-	I-GENE
A1	I-GENE
expression	O
.	O

The	O
triple	O
helical	O
domain	O
,	O
containing	O
about	O
300	O
amino	O
acids	O
,	O
exists	O
in	O
the	O
limited	O
space	O
of	O
the	O
procollagen	O
,	O
and	O
is	O
restricted	O
so	O
that	O
every	O
three	O
amino	O
acids	O
is	O
a	O
glycine	B-Chemical
,	O
generating	O
a	O
repeating	O
(	O
Gly	O
-	O
X	O
-	O
Y	O
)	O
n	O
sequence	O
pattern	O
.	O

However	O
,	O
we	O
performed	O
a	O
linkage	O
analysis	O
for	O
all	O
known	O
loci	O
so	O
far	O
implicated	O
in	O
the	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
data	O
not	O
shown	O
)	O
,	O
and	O
we	O
were	O
able	O
to	O
discard	O
linkage	O
to	O
all	O
of	O
them	O
except	O
for	O
USH1B	B-GENE
and	O
USH1C	B-GENE
(	O
Figure	O
3	O
)	O
.	O

The	O
ligated	O
product	O
(	O
20	O
ng	O
)	O
was	O
amplified	O
for	O
14	O
PCR	O
cycles	O
with	O
Illumina	O
PCR	O
primers	O
InPE1	O
.	O
0	O
and	O
indexing	O
primer	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

However	O
,	O
in	O
our	O
patient	O
we	O
found	O
heterozygous	O
SNPs	O
in	O
the	O
gene	O
,	O
with	O
close	O
to	O
50	O
%	O
allele	O
distribution	O
,	O
indicating	O
that	O
the	O
gene	O
is	O
not	O
deleted	O
for	O
this	O
patient	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
(	O
p	O
=	O
0	O
.	O
083	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
)	O
.	O

Complex	O
I	O
activity	O
was	O
assessed	O
by	O
following	O
the	O
decrease	O
of	O
NADH	O
absorbance	O
at	O
340	O
nm	O
,	O
using	O
decylubiquinone	B-Chemical
as	O
an	O
electron	O
acceptor	O
.	O

A	O
single	O
-	O
placebo	O
-	O
controlled	O
oral	O
challenge	O
procedure	O
with	O
nimesulide	B-Chemical
or	O
paracetamol	B-Chemical
was	O
applied	O
to	O
829	O
patients	O
with	O
a	O
history	O
of	O
NSAID	B-Chemical
-	O
induced	O
urticaria	B-DISEASE
/	O
angioedema	B-DISEASE
.	O

Each	O
platform	O
included	O
all	O
known	O
NSHL	B-DISEASE
and	O
NSHL	B-DISEASE
mimic	I-DISEASE
genes	O
at	O
the	O
time	O
of	O
design	O
(	O
May	O
2011	O
and	O
November	O
2012	O
,	O
respectively	O
)	O
.	O

Although	O
thousands	O
of	O
variants	O
were	O
detected	O
in	O
each	O
proband	O
(	O
both	O
SNPs	O
and	O
indels	O
)	O
,	O
this	O
analysis	O
yielded	O
a	O
small	O
number	O
of	O
variants	O
that	O
may	O
affect	O
protein	O
function	O
.	O

Annotations	O
for	O
SNP	O
variants	O
were	O
completed	O
using	O
multiple	O
databases	O
,	O
including	O
Consensus	O
CDS	O
(	O
CCDS	O
)	O
database	O
,	O
human	O
genome	O
builder	O
NCBI	O
36	O
.	O
3	O
,	O
and	O
dbSNP	O
database	O
V130	O
.	O

The	O
MYH9	B-GENE
gene	O
encodes	O
myosin	O
IIA	O
heavy	O
chain	O
,	O
which	O
is	O
involved	O
in	O
actomyosin	O
-	O
microtubule	O
crosstalk	O
,	O
cell	O
motility	O
,	O
and	O
maintenance	O
of	O
cell	O
shape	O
[	O
39	O
]	O
.	O

One	O
was	O
a	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
in	O
exon	O
29	O
,	O
which	O
resulted	O
in	O
a	O
substitution	O
of	O
lysine	O
for	O
glutamic	B-Chemical
acid	O
at	O
codon	O
1248	O
(	O
p	B-VARIANT
.	I-VARIANT
E1248K	I-VARIANT
;	I-VARIANT
Figure	O
4A	O
)	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
subjects	O
or	O
guardians	O
before	O
performing	O
the	O
study	O
.	O

Peripheral	O
blood	O
samples	O
were	O
obtained	O
from	O
the	O
23	O
family	O
members	O
(	O
9	O
affected	O
and	O
14	O
unaffected	O
)	O
.	O

However	O
,	O
besides	O
the	O
lower	O
performance	O
of	O
WES	O
regarding	O
the	O
coverage	O
of	O
the	O
Usher	B-DISEASE
target	O
region	O
that	O
was	O
already	O
discussed	O
by	O
Licastro	B-Chemical
et	O
al	O
.	O
,	O
also	O
the	O
reduced	O
costs	O
of	O
sequencing	O
a	O
targeted	O
gene	O
panel	O
might	O
outweigh	O
the	O
easy	O
in	O
silico	O
updateability	O
of	O
the	O
analysis	O
of	O
WES	O
data	O
in	O
a	O
diagnostic	O
setting	O
.	O

The	O
majority	O
of	O
mutations	O
described	O
in	O
our	O
study	O
were	O
localized	O
to	O
the	O
predicted	O
transmembrane	O
domains	O
(	O
64	O
,	O
3	O
%	O
,	O
n	O
=	O
9	O
/	O
14	O
)	O
.	O

METHODS	O
:	O
A	O
retrospective	O
chart	O
analysis	O
and	O
a	O
review	O
of	O
the	O
organ	O
transplant	O
database	O
identified	O
51	O
patients	O
(	O
43	O
men	O
and	O
8	O
women	O
)	O
transplanted	O
for	O
benign	O
HBV	O
-	O
related	O
cirrhotic	O
diseases	O
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
months	O
.	O

PCR	O
products	O
were	O
directly	O
cloned	O
into	O
pGEM	O
-	O
T	O
-	O
Easy	O
Vectors	O
I	O
(	O
Promega	O
,	O
Mannheim	O
,	O
Germany	O
)	O
and	O
sequenced	O
using	O
the	O
T7	O
and	O
SP6	O
sites	O
of	O
the	O
vector	O
.	O

These	O
results	O
expand	O
the	O
spectrum	O
of	O
AIFM1	B-GENE
-	O
associated	O
diseases	O
to	O
include	O
ANSD	B-DISEASE
.	O

Cosegregation	O
with	O
the	O
novel	O
mutated	O
alleles	O
identified	O
is	O
shown	O
in	O
Figure	O
S1	O
.	O

Such	O
localized	O
CAMs	O
have	O
not	O
been	O
found	O
at	O
the	O
tricellular	O
corner	O
as	O
of	O
yet	O
,	O
and	O
moreover	O
such	O
a	O
mechanism	O
seems	O
inefficient	O
considering	O
that	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
is	O
the	O
key	O
protein	O
that	O
recruits	O
tricellulin	B-GENE
to	O
the	O
TC	O
[	O
8	O
]	O
.	O

S91	O
,	O
with	O
Spanish	O
and	O
Algerian	O
origins	O
,	O
carried	O
a	O
homozygous	O
mutation	O
p	O
.	O
(	O
Arg389	O
*	O
)	O
in	O
TMC1	B-GENE
.	O

We	O
analyzed	O
the	O
structure	O
effect	O
caused	O
by	O
the	O
p	B-VARIANT
.	I-VARIANT
G1734R	I-VARIANT
mutation	O
in	O
USH2A	B-GENE
using	O
online	O
Mutagenesis	O
and	O
visualization	O
,	O
which	O
were	O
performed	O
with	O
Swiss	O
Pdb	O
-	O
Viewer	O
4	O
.	O
0	O
.	O
1	O
[	O
35	O
-	O
37	O
]	O
.	O

The	O
hearing	B-DISEASE
impairment	I-DISEASE
has	O
peculiar	O
features	O
reflecting	O
alteration	O
in	O
temporal	O
coding	O
of	O
acoustic	O
information	O
in	O
auditory	O
nerve	O
fibres	O
,	O
which	O
is	O
typically	O
unaffected	O
in	O
cochlear	O
hearing	B-DISEASE
impairment	I-DISEASE
resulting	O
from	O
hair	O
cell	O
loss	O
and	O
disruption	O
of	O
the	O
cochlear	O
amplifier	O
(	O
for	O
a	O
review	O
see	O
Starr	O
et	O
al	O
.	O

A	O
I	O
,	O
Pedigree	O
of	O
the	O
Qatari	O
family	O
carrying	O
the	O
p	B-VARIANT
.	I-VARIANT
*	I-VARIANT
2625Gluext	I-VARIANT
*	I-VARIANT
11	I-VARIANT
mutation	O
in	O
BDP1	B-GENE
gene	O
.	O

These	O
analyses	O
(	O
Figure	O
1	O
)	O
showed	O
significantly	O
greater	O
connectivity	O
amongst	O
the	O
de	O
novo	O
identified	O
proteins	O
than	O
would	O
be	O
expected	O
by	O
chance	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Supplementary	O
Information	O
)	O
.	O

The	O
emergence	O
of	O
new	O
active	O
drugs	O
might	O
translate	O
into	O
more	O
effective	O
regimens	O
for	O
the	O
treatment	O
of	O
this	O
disease	O
.	O

Current	O
options	O
of	O
treatment	O
include	O
oral	O
anticholinergic	O
drugs	O
,	O
the	O
topical	O
application	O
of	O
anticholinergics	O
or	O
aluminum	B-Chemical
chloride	I-Chemical
,	O
and	O
the	O
injection	O
of	O
botulinum	O
toxin	O
.	O

This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	B-DISEASE
for	O
drugs	O
with	O
TdP	O
potential	O
.	O

Residues	O
involved	O
in	O
missense	O
mutations	O
are	O
underlined	O
.	O

Synonymous	O
variants	O
were	O
excluded	O
and	O
the	O
other	O
were	O
then	O
filtered	O
against	O
several	O
control	O
data	O
sets	O
,	O
including	O
dbSNP135	B-Chemical
,	O
the	O
1000	O
Genomes	O
project	O
,	O
exome	O
data	O
from	O
eight	O
HapMap	O
individuals	O
previously	O
sequenced	O
and	O
YH	O
database	O
(	O
YanHuang	O
Project	O
)	O
.	O

There	O
were	O
marked	O
cystic	O
spaces	O
in	O
the	O
inner	O
nuclear	O
layer	O
.	O

The	O
worst	O
toxicities	O
(	O
%	O
)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1	O
/	O
2	O
/	O
3	O
)	O
:	O
leukopenia	O
45	O
.	O
5	O
/	O
18	O
.	O
2	O
/	O
6	O
.	O
1	O
,	O
thrombocytopenia	O
33	O
.	O
3	O
/	O
9	O
.	O
1	O
/	O
6	O
.	O
1	O
,	O
vomitus	O
24	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
diarrhea	O
36	O
.	O
4	O
/	O
6	O
.	O
1	O
/	O
3	O
.	O
0	O
,	O
stomatitis	O
18	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
hand	O
-	O
foot	O
syndrome	O
12	O
.	O
1	O
/	O
0	O
/	O
0	O
.	O

Given	O
that	O
sympathetic	O
neural	O
dominance	O
exhibits	O
a	O
similar	O
developmental	O
pattern	O
,	O
and	O
given	O
that	O
clonidine	B-Chemical
induces	O
sympathetic	B-DISEASE
withdrawal	I-DISEASE
and	O
bradycardia	B-DISEASE
,	O
we	O
hypothesized	O
that	O
clonidine	B-Chemical
'	O
s	O
developmental	O
effects	O
on	O
cardiac	O
rate	O
and	O
ultrasound	O
production	O
would	O
mirror	O
each	O
other	O
.	O

By	O
direct	O
sequencing	O
,	O
208	O
ethnicity	O
-	O
matched	O
negative	O
controls	O
and	O
50	O
Chinese	O
familial	O
patients	O
with	O
ARNSHL	B-DISEASE
were	O
genotyped	O
to	O
screen	O
for	O
the	O
mutations	O
.	O

Furthermore	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
F1442S	I-VARIANT
change	O
affects	O
long	O
and	O
short	O
isoforms	O
while	O
the	O
p	B-VARIANT
.	I-VARIANT
L5063R	I-VARIANT
variant	O
affects	O
only	O
the	O
long	O
isoform	O
of	O
USH2A	B-GENE
.	O

The	O
c	B-VARIANT
.	I-VARIANT
2708_2711del	I-VARIANT
mutation	O
in	O
exon	O
27	O
was	O
present	O
in	O
three	O
of	O
the	O
12	O
probands	O
(	O
25	O
%	O
)	O
.	O

This	O
technique	O
may	O
further	O
be	O
important	O
for	O
the	O
documentation	O
of	O
possible	O
effects	O
of	O
future	O
therapies	O
like	O
gene	O
therapy	O
,	O
in	O
addition	O
to	O
clinical	O
parameters	O
like	O
measurement	O
of	O
VA	O
and	O
visual	O
fields	O
.	O

We	O
confirmed	O
exon	O
24	O
as	O
hot	O
spot	O
of	O
the	O
TCOF1	B-GENE
gene	O
as	O
we	O
described	O
the	O
major	O
number	O
of	O
mutations	O
in	O
the	O
exon	O
(	O
Table	O
2	O
Figure	O
1	O
)	O
.	O

Weedon	O
is	O
supported	O
by	O
the	O
Wellcome	O
Trust	O
as	O
part	O
of	O
the	O
WT	O
Biomedical	O
Informatics	O
Hub	O
funding	O
.	O

Causative	O
variants	O
in	O
the	O
12	O
families	O
were	O
confirmed	O
through	O
the	O
steps	O
of	O
targeted	O
capture	O
of	O
80	O
known	O
deafness	B-DISEASE
genes	O
;	O
massively	O
parallel	O
sequencing	O
with	O
the	O
Illumina	O
platform	O
;	O
variant	O
calling	O
using	O
the	O
BWA	O
,	O
SAMtools	O
,	O
Picard	O
,	O
GATK	O
,	O
and	O
IGV	O
software	O
packages	O
;	O
and	O
data	O
filtering	O
with	O
various	O
criteria	O
,	O
including	O
allele	O
frequencies	O
<	O
5	O
%	O
in	O
both	O
the	O
1000	O
Genomes	O
Project	O
and	O
NHLBI	O
-	O
ESP	O
5400	O
exome	O
project	O
,	O
both	O
PolyPhen2	O
and	O
SIFT	O
scores	O
>	O
0	O
.	O
95	O
,	O
Sanger	O
sequencing	O
,	O
segregation	O
pattern	O
,	O
evolutionary	O
conservation	O
of	O
amino	O
acid	O
residues	O
,	O
and	O
on	O
-	O
line	O
databases	O
of	O
known	O
deafness	B-DISEASE
mutations	O
.	O

We	O
observed	O
the	O
exencephaly	O
induced	O
by	O
5	B-Chemical
-	I-Chemical
azacytidine	I-Chemical
at	O
embryonic	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
,	O
let	O
the	O
embryos	O
develop	O
exo	B-DISEASE
utero	I-DISEASE
until	O
E18	O
.	O
5	O
,	O
and	O
re	O
-	O
observed	O
the	O
same	O
embryos	O
at	O
E18	O
.	O
5	O
.	O

In	O
particular	O
,	O
II	O
:	O
3	O
is	O
a	O
female	O
patient	O
diagnosed	O
with	O
bilateral	O
moderate	O
to	O
severe	O
NSHHL	B-DISEASE
mainly	O
at	O
High	O
Frequency	O
since	O
she	O
was	O
4	O
y	O
.	O
o	O
.	O

These	O
included	O
whole	O
-	O
exome	O
sequence	O
data	O
from	O
244	O
unrelated	O
healthy	O
individuals	O
of	O
European	O
descent	O
(	O
Online	O
Methods	O
and	O
Supplementary	O
Table	O
2	O
)	O
and	O
genome	O
-	O
wide	O
sequence	O
data	O
from	O
629	O
and	O
~	O
2	O
,	O
500	O
individuals	O
available	O
from	O
the	O
1000	O
Genomes	O
Pilot	O
Project	O
19	O
and	O
NHLBI	O
Exome	O
Sequencing	O
Project	O
(	O
ESP	O
)	O
websites	O
(	O
Supplementary	O
Tables	O
3	O
and	O
4	O
)	O
.	O

NA	O
:	O
Not	O
applicable	O
;	O
ND	O
:	O
Not	O
determined	O
.	O

All	O
but	O
one	O
patient	O
were	O
managed	O
using	O
cardiopulmonary	O
bypass	O
.	O

Although	O
the	O
exact	O
percentage	O
of	O
nonsyndromic	O
ANSD	B-DISEASE
is	O
unclear	O
,	O
responsible	O
genes	O
have	O
been	O
gradually	O
revealed	O
.	O

As	O
indicated	O
by	O
these	O
numbers	O
,	O
USH1C	B-GENE
and	O
USH1G	B-GENE
are	O
the	O
rarest	O
contributors	O
to	O
USH1	B-DISEASE
etiology	O
worldwide	O
.	O

The	O
pathogenicity	O
of	O
splice	O
site	O
alterations	O
larger	O
than	O
+	O
-	O
2	O
was	O
predicted	O
by	O
NNSPLICE	O
0	O
.	O
9	O
version	O
[	O
22	O
]	O
.	O

Nevertheless	O
,	O
bleeding	B-DISEASE
was	O
the	O
first	O
manifestation	O
of	O
the	O
macrothrombocytopenia	B-DISEASE
in	O
about	O
a	O
third	O
of	O
the	O
cases	O
(	O
22	O
/	O
74	O
;	O
29	O
.	O
7	O
%	O
)	O
and	O
was	O
observed	O
mainly	O
during	O
childhood	O
(	O
19	O
/	O
22	O
;	O
86	O
.	O
4	O
%	O
of	O
cases	O
)	O
and	O
before	O
5	O
years	O
for	O
a	O
majority	O
(	O
15	O
/	O
19	O
:	O
78	O
.	O
9	O
%	O
)	O
.	O

The	O
average	O
time	O
of	O
death	O
was	O
delayed	O
.	O

Nine	O
days	O
after	O
her	O
second	O
cycle	O
she	O
presented	O
with	O
lethargy	O
and	O
weakness	O
associated	O
with	O
hyponatremia	B-DISEASE
.	O

This	O
association	O
with	O
uveitis	B-DISEASE
and	O
JRA	B-DISEASE
was	O
not	O
noted	O
previously	O
.	O

A	O
:	O
Results	O
of	O
ERG	O
testing	O
showed	O
severe	O
attenuation	O
of	O
phobic	O
(	O
A	O
and	O
B	O
)	O
and	O
scotopic	O
(	O
C	O
,	O
D	O
,	O
E	O
)	O
waveforms	O
in	O
the	O
proband	O
.	O

Therefore	O
,	O
the	O
data	O
in	O
each	O
group	O
represented	O
a	O
sample	O
size	O
(	O
n	O
)	O
of	O
3	O
x	O
3	O
=	O
9	O
trials	O
for	O
each	O
plasmid	O
and	O
control	O
.	O

In	O
vitro	O
,	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
pentylenetetrazol	B-Chemical
and	O
picrotoxin	B-Chemical
were	O
shown	O
to	O
inhibit	O
3H	B-Chemical
-	I-Chemical
TBOB	I-Chemical
binding	O
in	O
mouse	O
whole	O
brain	O
,	O
with	O
IC50	O
values	O
of	O
4	O
.	O
6	O
,	O
404	O
and	O
9	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

In	O
model	O
group	O
,	O
the	O
expression	O
of	O
P2X3	B-GENE
receptor	O
increased	O
in	O
urothelium	O
and	O
suburothelium	O
,	O
and	O
NK1	B-GENE
receptor	O
increased	O
in	O
suburothelium	O
,	O
while	O
the	O
expression	O
of	O
them	O
in	O
intervention	O
group	O
was	O
lower	O
.	O

1119	O
unrelated	O
patients	O
were	O
sequentially	O
accrued	O
during	O
the	O
study	O
period	O
.	O

For	O
MA9	O
,	O
family	O
history	O
suggested	O
dominant	O
inheritance	O
of	O
a	O
macular	O
dystrophy	O
phenotype	O
.	O

In	O
this	O
research	O
,	O
genome	O
-	O
wide	O
linkage	O
analysis	O
mapped	O
the	O
disease	O
locus	O
to	O
a	O
4	O
.	O
3	O
Mb	O
region	O
on	O
chromosome	O
19q13	O
in	O
SY	O
-	O
026	O
,	O
a	O
five	O
-	O
generation	O
nonconsanguineous	O
Chinese	O
family	O
affected	O
by	O
late	O
-	O
onset	O
and	O
progressive	O
ADNSHL	B-DISEASE
.	O

This	O
study	O
was	O
supported	O
by	O
the	O
National	O
Science	O
Fund	O
for	O
Distinguished	O
Young	O
Scholars	O
(	O
30725044	O
to	O
Q	O
.	O
Z	O
.	O
)	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

In	O
all	O
samples	O
,	O
the	O
enzyme	O
also	O
generated	O
a	O
fragment	O
of	O
1	O
bp	O
,	O
which	O
was	O
too	O
small	O
to	O
be	O
seen	O
in	O
the	O
gel	O
.	O

Among	O
the	O
2	O
,	O
011	O
targeted	O
exons	O
,	O
only	O
15	O
exons	O
(	O
0	O
.	O
7	O
%	O
)	O
were	O
covered	O
poorly	O
(	O
less	O
than	O
five	O
times	O
on	O
average	O
)	O
,	O
either	O
due	O
to	O
high	O
GC	O
contents	O
or	O
the	O
abundant	O
presence	O
of	O
repetitive	O
sequences	O
(	O
Figs	O
.	O

French	O
Canadian	O
subjects	O
from	O
Quebec	O
with	O
USH1	B-DISEASE
were	O
identified	O
through	O
the	O
McGill	O
Ocular	O
Genetics	O
Laboratory	O
,	O
Montreal	O
Children	O
'	O
s	O
Hospital	O
Research	O
Institute	O
,	O
McGill	O
University	O
Health	O
Center	O
,	O
Montreal	O
,	O
Quebec	O
,	O
Canada	O
(	O
see	O
Additional	O
data	O
file	O
4	O
for	O
precise	O
origin	O
of	O
each	O
patient	O
)	O
.	O

(	O
A	O
)	O
Sanger	O
sequencing	O
trace	O
of	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
within	O
ILDR1	B-GENE
from	O
SNUH23	O
.	O

YC	O
,	O
HZ	O
,	O
and	O
JS	O
carried	O
out	O
the	O
molecular	O
genetic	O
studies	O
,	O
participated	O
in	O
the	O
collection	O
of	O
blood	O
samples	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

As	O
a	O
control	O
for	O
pathogeneity	O
of	O
each	O
genomic	O
variation	O
,	O
72	O
Japanese	O
samples	O
were	O
used	O
in	O
this	O
study	O
,	O
because	O
they	O
were	O
1	O
)	O
ethnically	O
similar	O
,	O
2	O
)	O
had	O
normal	O
hearing	O
evaluated	O
by	O
pure	O
-	O
tone	O
audiometry	O
,	O
and	O
3	O
)	O
were	O
collected	O
from	O
throughout	O
the	O
nation	O
,	O
and	O
were	O
able	O
to	O
undergo	O
identical	O
procedures	O
.	O

40	O
Neither	O
family	O
was	O
known	O
to	O
be	O
consanguineous	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
explore	O
the	O
potentiality	O
of	O
a	O
novel	O
animal	O
model	O
to	O
be	O
used	O
for	O
the	O
in	O
vivo	O
evaluation	O
of	O
the	O
ability	O
of	O
a	O
drug	O
delivery	O
system	O
to	O
promote	O
the	O
passage	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
and	O
/	O
or	O
to	O
improve	O
the	O
brain	O
localization	O
of	O
a	O
bioactive	O
compound	O
.	O

The	O
delineation	O
of	O
the	O
underlying	O
cellular	O
mechanisms	O
is	O
subject	O
to	O
intensive	O
investigation	O
for	O
cytoplasmic	O
as	O
well	O
as	O
mitochondrial	O
aaRS	O
[	O
10	O
,	O
11	O
]	O
.	O

An	O
accurate	O
autopsy	O
revealed	O
most	O
organs	O
with	O
diffuse	O
petechial	B-DISEASE
haemorrhages	I-DISEASE
.	O

Despite	O
the	O
clinical	O
utility	O
of	O
genetic	O
diagnosis	O
to	O
address	O
idiopathic	O
sensorineural	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
SNHI	B-DISEASE
)	O
,	O
the	O
current	O
strategy	O
for	O
screening	O
mutations	O
via	O
Sanger	O
sequencing	O
suffers	O
from	O
the	O
limitation	O
that	O
only	O
a	O
limited	O
number	O
of	O
DNA	O
fragments	O
associated	O
with	O
common	O
deafness	B-DISEASE
mutations	O
can	O
be	O
genotyped	O
.	O

Performed	O
the	O
experiments	O
:	O
XG	O
QYZ	O
YSS	I-Chemical
GJW	O
FX	O
DYK	O
.	O

The	O
heredity	O
of	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
has	O
recessive	O
and	O
dominant	O
modes	O
of	O
inheritance	O
.	O

Because	O
of	O
mild	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
USH2	B-DISEASE
is	O
often	O
misdiagnosed	O
as	O
nonsyndromic	O
RP	B-DISEASE
.	O

Adverse	O
effects	O
forced	O
a	O
reduction	O
in	O
the	O
dose	O
of	O
amiodarone	B-Chemical
in	O
41	O
%	O
and	O
discontinuation	O
of	O
amiodarone	B-Chemical
in	O
10	O
%	O
of	O
patients	O
.	O

A	O
SIFT	O
score	O
below	O
0	O
.	O
05	O
is	O
predicted	O
to	O
be	O
pathogenic	O
,	O
while	O
SIFT	O
scores	O
above	O
0	O
.	O
05	O
are	O
considered	O
tolerated	O
.	O

To	O
achieve	O
this	O
work	O
,	O
OP	O
has	O
been	O
supported	O
as	O
a	O
"	O
Directeur	O
de	O
Recherche	O
Associ	O
e	O
"	O
,	O
CNRS	O
,	O
DADR	O
/	O
01	O
-	O
IM657	O
.	O

A	O
:	O
Nonsense	O
or	O
frameshift	O
variants	O
.	O

Rhabdomyolysis	B-DISEASE
in	O
a	O
hepatitis	O
C	O
virus	O
infected	O
patient	O
treated	O
with	O
telaprevir	B-Chemical
and	O
simvastatin	B-Chemical
.	O

The	O
coding	O
regions	O
of	O
111	O
RD	B-DISEASE
genes	O
were	O
enriched	O
by	O
target	O
capture	O
and	O
screened	O
for	O
mutations	O
by	O
NGS	O
in	O
112	O
subjects	O
-	O
-	O
12	O
RD	B-DISEASE
patients	O
carrying	O
two	O
known	O
heterozygous	O
mutations	O
in	O
one	O
of	O
the	O
retinal	B-DISEASE
disease	I-DISEASE
genes	O
and	O
100	O
RP	B-DISEASE
patients	O
without	O
a	O
molecular	O
diagnosis	O
.	O

Furthermore	O
,	O
antibodies	O
were	O
used	O
against	O
the	O
UPR	O
pathway	O
proteins	O
such	O
as	O
anti	O
-	O
BiP	O
,	O
anti	O
-	O
p	O
-	O
Perk	O
,	O
anti	O
-	O
CHOP	O
and	O
anti	O
-	O
beta	O
-	O
tubulin	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
followed	O
by	O
peroxidase	B-Chemical
-	O
labelled	O
secondary	O
antibodies	O
.	O

Three	O
heterozygous	O
deletion	O
carriers	O
exhibited	O
hemizygous	O
mutations	O
predicted	O
as	O
negatively	O
impacting	O
the	O
protein	O
.	O

We	O
then	O
focused	O
on	O
the	O
functionally	O
interpretable	O
variants	O
that	O
included	O
:	O
SNVs	O
that	O
were	O
evolutionarily	O
conserved	O
(	O
GERP	O
>	O
2	O
.	O
0	O
)	O
and	O
caused	O
missense	O
or	O
nonsense	O
changes	O
;	O
or	O
SNVs	O
that	O
were	O
located	O
within	O
2	O
bp	O
of	O
intron	O
-	O
exon	O
boundaries	O
;	O
and	O
indels	O
that	O
caused	O
in	O
-	O
frame	O
or	O
frameshift	O
alternations	O
.	O

On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	B-DISEASE
,	O
diarrhea	B-DISEASE
,	O
tinnitus	B-DISEASE
,	O
loss	B-DISEASE
of	I-DISEASE
hearing	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
find	O
this	O
mutation	O
in	O
110	O
Tunisian	O
healthy	O
subjects	O
.	O

The	O
potassium	O
current	O
I	B-GENE
Ks	I-GENE
is	O
essential	O
for	O
cardiac	O
repolarization	O
.	O

TULP1	B-GENE
did	O
not	O
bear	O
any	O
mutation	O
,	O
whereas	O
two	O
previously	O
unreported	O
variants	O
in	O
RPGRIP1	B-GENE
were	O
identified	O
.	O

Precipitates	O
were	O
immuno	O
-	O
blotted	O
with	O
CIB2	B-GENE
and	O
whirlin	O
antibodies	O
.	O

We	O
used	O
WES	O
to	O
analyze	O
the	O
DNA	O
sequences	O
of	O
the	O
patient	O
and	O
her	O
parents	O
and	O
to	O
search	O
for	O
de	O
novo	O
variants	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
patients	O
were	O
impaired	O
on	O
a	O
processing	O
speed	O
task	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
and	O
on	O
a	O
measure	O
of	O
immediate	O
verbal	O
memory	O
(	O
p	O
=	O
0	O
.	O
026	O
)	O
after	O
controlling	O
for	O
the	O
use	O
of	O
hormone	O
replacement	O
therapy	O
in	O
both	O
groups	O
.	O

RESULTS	O
:	O
24	O
patients	O
were	O
evaluable	O
for	O
response	O
with	O
one	O
partial	O
response	O
of	O
11	O
months	O
duration	O
of	O
a	O
patient	O
with	O
hepatic	B-DISEASE
and	O
pulmonary	O
metastases	I-DISEASE
(	O
4	O
%	O
)	O
,	O
one	O
minor	O
response	O
,	O
and	O
2	O
patients	O
stable	O
for	O
over	O
6	O
months	O
.	O

Two	O
of	O
them	O
were	O
homozygous	O
for	O
the	O
mutation	O
and	O
two	O
compound	O
heterozygote	O
.	O

Mutations	O
involving	O
the	O
genes	O
GnRH1	B-GENE
and	O
KISS1	B-GENE
,	O
are	O
a	O
very	O
rare	O
cause	O
of	O
HH	B-DISEASE
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O

Prior	O
dosing	O
with	O
antagonists	O
partially	O
prevented	O
the	O
fall	O
in	O
systemic	O
vascular	O
resistance	O
.	O

Segregation	O
of	O
the	O
identified	O
mutations	O
in	O
the	O
analyzed	O
USH1	B-DISEASE
families	O
.	O

No	O
contrast	O
medium	O
was	O
used	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
of	O
nuclear	B-GENE
factor	I-GENE
-	I-GENE
kappaB	I-GENE
(	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
)	O
,	O
mitogen	O
-	I-GENE
activated	I-GENE
protein	I-GENE
(	O
MAP	O
)	O
kinases	O
and	O
macrophages	O
in	O
the	O
renal	O
cortex	O
and	O
structural	O
and	O
functional	O
renal	O
changes	O
of	O
rats	O
treated	O
with	O
gentamicin	B-Chemical
or	O
gentamicin	B-Chemical
+	O
pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
(	O
PDTC	B-Chemical
)	O
,	O
an	O
NF	B-GENE
-	I-GENE
kappaB	I-GENE
inhibitor	O
.	O

Furthermore	O
,	O
DCE	B-Chemical
reversed	O
the	O
amnesia	B-DISEASE
induced	O
by	O
scopolamine	B-Chemical
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
and	O
diazepam	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

Of	O
the	O
15	O
different	O
mutations	O
identified	O
,	O
8	O
were	O
never	O
described	O
previously	O
and	O
included	O
7	O
changes	O
that	O
were	O
clearly	O
deleterious	O
alleles	O
(	O
frameshifts	O
or	O
nonsenses	O
,	O
Table	O
1	O
)	O
.	O

Three	O
clinical	O
subtypes	O
are	O
distinguished	O
,	O
with	O
type	O
1	O
(	O
USH1	B-DISEASE
;	I-DISEASE
MIM	O
276900	O
)	O
representing	O
the	O
most	O
severe	O
subtype	O
with	O
profound	O
congenital	O
deafness	B-DISEASE
,	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
prepubertal	O
onset	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

Operations	O
lasting	O
up	O
to	O
2h	O
could	O
be	O
performed	O
in	O
the	O
absence	O
of	O
sophisticated	O
equipment	O
such	O
as	O
pulse	O
oximeters	O
or	O
ventilators	O
in	O
patients	O
on	O
spontaneous	O
ventilation	O
breathing	O
air	O
/	O
oxygen	B-Chemical
only	O
.	O

Hom	O
,	O
homozygote	O
;	O
het	O
,	O
heterozygote	O
;	O
y	O
,	O
years	O
;	O
m	O
,	O
months	O
;	O
R	O
,	O
Right	O
eye	O
;	O
L	O
,	O
Left	O
eye	O
;	O
BE	O
,	O
both	O
eyes	O
;	O
SNHL	B-DISEASE
,	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
|	O
Visual	O
Field	O
:	O
confrontation	O
+	O
Color	O
Vision	O
:	O
Ish	O
=	O
Ishihara	O
PseudoIsochromatic	O
plates	O
color	O
test	O
+	O
+	O
Did	O
not	O
follow	O
color	O
tracks	O
,	O
possibly	O
due	O
to	O
misunderstanding	O
of	O
test	O
instructions	O
P	O
FFERG	O
=	O
Full	O
field	O
electroretinography	O
,	O
including	O
the	O
following	O
details	O
:	O
Light	O
-	O
adapted	O
(	O
LA	B-Chemical
)	O
Cone	O
flicker	O
amplitude	O
(	O
Amp	O
,	O
normal	O
60	O
-	O
144	O
mu	O
V	O
)	O
and	O
implicit	O
time	O
(	O
IT	O
,	O
normal	O
27	O
-	O
33	O
msec	O
)	O
.	O

They	O
suggest	O
that	O
,	O
in	O
normal	O
conscious	O
rats	O
,	O
the	O
central	O
tachycardia	O
of	O
bromocriptine	B-Chemical
appears	O
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	B-DISEASE
of	O
this	O
agonist	O
at	O
peripheral	O
dopamine	B-Chemical
D2	O
receptors	O
.	O

L	O
.	O

All	O
subjects	O
or	O
next	O
of	O
kin	O
,	O
caretakers	O
or	O
guardians	O
on	O
behalf	O
of	O
the	O
minors	O
/	O
children	O
gave	O
prior	O
written	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
project	O
,	O
and	O
the	O
Shinshu	O
University	O
Ethical	O
Committee	O
as	O
well	O
as	O
the	O
respective	O
Ethical	O
Committees	O
of	O
the	O
other	O
participating	O
institutions	O
of	O
the	O
Deafness	O
Gene	O
Study	O
Consortium	O
(	O
Hokkaido	O
University	O
,	O
Hirosaki	O
University	O
,	O
Iwate	O
Medical	O
University	O
,	O
Tohoku	O
University	O
,	O
Yamagata	O
University	O
,	O
Fukushima	O
Medical	O
University	O
,	O
Jichi	O
Medical	O
University	O
,	O
Gunma	O
University	O
,	O
Nihon	O
University	O
,	O
Nippon	O
Medical	O
School	O
,	O
Nippon	O
Medical	O
School	O
Tama	O
Nagayama	O
Hospital	O
,	O
Jikei	O
University	O
,	O
Toranomon	O
Hospital	O
,	O
Kitasato	O
University	O
,	O
Hamamatsu	O
Medical	O
University	O
,	O
Mie	O
University	O
,	O
Shiga	O
Medical	O
Center	O
for	O
Children	O
,	O
Osaka	O
Medical	O
College	O
,	O
Hyogo	O
College	O
of	O
Medicine	O
,	O
Kobe	O
City	O
Medical	O
Center	O
General	O
Hospital	O
,	O
Wakayama	O
Medical	O
University	O
,	O
Okayama	O
University	O
,	O
Yamaguchi	O
University	O
,	O
Ehime	O
University	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
University	O
,	O
Nagasaki	O
University	O
,	O
Kanda	O
ENT	O
Clinic	O
,	O
Miyazaki	O
Medical	O
College	O
,	O
Kagoshima	O
University	O
and	O
Ryukyus	O
University	O
)	O
approved	O
the	O
study	O
.	O

Further	O
long	O
-	O
term	O
analysis	O
of	O
renal	O
allograft	O
studies	O
using	O
sirolimus	B-Chemical
as	O
de	O
novo	O
immunosuppression	O
along	O
with	O
clinical	O
and	O
laboratory	O
studies	O
will	O
refine	O
these	O
issues	O
in	O
the	O
future	O
.	O

We	O
extracted	O
RNA	O
from	O
a	O
blood	O
sample	O
from	O
the	O
index	O
patient	O
(	O
IV	O
-	O
5	O
,	O
Fig	O
1A	O
)	O
and	O
after	O
RT	O
-	O
PCR	O
using	O
intron	O
spanning	O
primers	O
and	O
Sanger	O
sequencing	O
,	O
we	O
aligned	O
the	O
obtained	O
sequence	O
to	O
the	O
human	O
genome	O
using	O
BLAT	O
to	O
validate	O
that	O
it	O
was	O
from	O
cDNA	O
and	O
not	O
from	O
genomic	O
DNA	O
(	O
Fig	O
7A	O
)	O
.	O

In	O
each	O
of	O
the	O
11	O
probands	O
,	O
multiple	O
potentially	O
functional	O
variants	O
of	O
predicted	O
damaging	O
effect	O
were	O
identified	O
by	O
our	O
approach	O
and	O
validated	O
by	O
Sanger	O
sequencing	O
(	O
Table	O
1	O
)	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
between	O
COL4A5	B-GENE
mutations	O
and	O
XLAS	B-DISEASE
have	O
been	O
extensively	O
described	O
.	O

2	O
In	O
2006	O
,	O
we	O
reported	O
a	O
large	O
Chinese	O
family	O
with	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
progressive	I-DISEASE
auditory	I-DISEASE
and	I-DISEASE
peripheral	I-DISEASE
sensory	I-DISEASE
neuropathy	I-DISEASE
,	O
and	O
mapped	O
this	O
ANSD	B-DISEASE
locus	O
(	O
AUNX1	B-GENE
)	O
to	O
chrXq23	O
-	O
27	O
.	O
3	O
.	O

Subsequently	O
,	O
according	O
to	O
the	O
communist	O
regime	O
'	O
s	O
social	O
engineering	O
projects	O
in	O
former	O
Czechoslovakia	O
,	O
Roma	O
were	O
moved	O
from	O
their	O
original	O
rural	O
settlements	O
in	O
Slovakia	O
(	O
particularly	O
from	O
its	O
eastern	O
parts	O
)	O
to	O
tenement	O
blocks	O
in	O
Czech	O
cities	O
[	O
35	O
,	O
36	O
]	O
.	O

Asterisks	O
indicate	O
available	O
samples	O
.	O

We	O
identified	O
the	O
en	O
face	O
MME	B-DISEASE
in	O
patients	O
with	O
ADOA	B-DISEASE
;	O
however	O
,	O
there	O
are	O
several	O
other	O
diseases	O
that	O
have	O
MME	B-DISEASE
in	O
their	O
SD	O
-	O
OCT	O
images	O
,	O
for	O
example	O
,	O
MS	B-DISEASE
,	O
recurrent	O
optic	B-DISEASE
neuritis	I-DISEASE
,	O
neuromyelitis	O
optica	O
,	O
LHON	B-DISEASE
,	O
and	O
chiasmal	O
glioma	B-DISEASE
.	O

B	O
:	O
Overlapping	O
audiograms	O
of	O
the	O
subjects	O
with	O
biallelic	O
missense	O
mutations	O
.	O

Eating	B-DISEASE
disorders	I-DISEASE
and	O
the	O
associated	O
behavioural	O
problems	O
and	O
drug	O
abuse	O
are	O
uncommon	O
in	O
pregnancy	O
.	O

Lysates	O
were	O
incubated	O
16h	O
with	O
protein	O
A	O
-	O
Sepharose	O
CL	I-Chemical
-	O
4B	O
beads	O
and	O
centrifuged	O
at	O
10	O
,	O
000	O
g	O
for	O
3	O
min	O
.	O

BACKGROUND	O
:	O
Cisplatin	B-Chemical
has	O
minimal	O
antitumor	O
activity	O
when	O
used	O
as	O
second	O
-	O
or	O
third	O
-	O
line	O
treatment	O
of	O
metastatic	B-DISEASE
breast	I-DISEASE
carcinoma	I-DISEASE
.	O

PCR	O
amplified	O
products	O
were	O
purified	O
with	O
exonuclease	O
and	O
alkaline	O
phosphatase	O
(	O
Fermentas	O
)	O
treatments	O
.	O

(	O
TIF	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

In	O
(	O
A	O
)	O
an	O
additional	O
sequence	O
was	O
located	O
between	O
exons	O
32	O
and	O
33	O
(	O
in	O
bold	O
type	O
)	O
,	O
which	O
corresponded	O
to	O
a	O
pseudoexon	O
in	O
intron	O
32	O
.	O

Depending	O
upon	O
the	O
proteolytic	O
activity	O
of	O
the	O
mutant	O
TMPRSS3	B-GENE
protein	O
[	O
17	O
,	O
30	O
]	O
,	O
two	O
discrete	O
types	O
of	O
phenotypes	O
can	O
manifest	O
.	O

The	O
CC	O
includes	O
the	O
CDC42	B-GENE
binding	O
domain	O
(	O
CBD	B-Chemical
)	O
,	O
Leucine	B-Chemical
Zipper	I-Chemical
-	O
A	O
(	O
LZA	B-Chemical
)	O
and	O
Leucine	B-Chemical
Zipper	I-Chemical
-	I-Chemical
B	I-Chemical
(	O
LZB	B-Chemical
)	O
.	O

et	O
al	O
.	O
'	O
s	O
2010	O
study	O
,	O
[	O
19	O
]	O
two	O
out	O
of	O
three	O
of	O
their	O
probands	O
with	O
two	O
KCNQ1	B-GENE
mutations	O
presented	O
without	O
deafness	B-DISEASE
but	O
with	O
severe	O
phenotypes	O
of	O
RWS	B-DISEASE
.	O

Mutation	O
screening	O
in	O
a	O
large	O
cohort	O
of	O
3	O
additional	O
unrelated	O
families	O
and	O
93	O
sporadic	O
cases	O
with	O
ANSD	B-DISEASE
identified	O
9	O
more	O
missense	O
mutations	O
in	O
AIFM1	B-GENE
.	O

RESULTS	O
:	O
Salbutamol	B-Chemical
significantly	O
increased	O
tremor	B-DISEASE
severity	I-DISEASE
in	O
patients	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
.	O

This	O
study	O
examined	O
the	O
frequency	O
of	O
atrioventricular	B-DISEASE
(	O
AV	O
)	O
dissociation	O
and	O
accelerated	O
junctional	O
rhythms	O
in	O
59	O
patients	O
receiving	O
oral	O
verapamil	B-Chemical
.	O

Thawing	O
was	O
performed	O
at	O
4	O
deg	O
C	O
and	O
room	O
temperature	O
successively	O
.	O

2001	O
;	O
Guipponi	B-Chemical
et	O
al	O
.	O

Data	O
were	O
analysed	O
using	O
chi	O
-	O
square	O
test	O
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Wilcoxon	O
signed	O
ranks	O
tests	O
and	O
correlation	O
.	O

It	O
is	O
notable	O
that	O
in	O
our	O
strategy	O
revealed	O
genetic	O
mutations	O
in	O
several	O
extraordinary	O
cases	O
in	O
this	O
study	O
.	O

The	O
sequences	O
were	O
mapped	O
and	O
quality	O
-	O
checked	O
using	O
the	O
programs	O
BWA	O
,	O
Novoalign	O
,	O
Picard	O
,	O
and	O
GATK	O
,	O
and	O
analyzed	O
by	O
Avadis	O
NGS	O
.	O

Mutations	O
in	O
approximately	O
30	O
genes	O
have	O
been	O
implicated	O
in	O
ADNSHL	B-DISEASE
(	O
with	O
variable	O
evidence	O
)	O
[	O
2	O
]	O
.	O

Sirolimus	B-Chemical
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	O
antiproliferative	O
actions	O
through	O
its	O
ability	O
to	O
inhibit	O
the	O
raptor	O
-	O
containing	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
protein	O
kinase	O
.	O

All	O
procedures	O
were	O
conducted	O
after	O
written	O
informed	O
consent	O
had	O
been	O
obtained	O
from	O
each	O
subject	O
or	O
their	O
parents	O
.	O

This	O
is	O
an	O
updated	O
version	O
of	O
the	O
original	O
Cochrane	O
review	O
first	O
published	O
in	O
2005	O
.	O

OBJECTIVES	O
:	O
Thrombotic	B-DISEASE
microangiopathy	I-DISEASE
is	O
a	O
well	O
-	O
known	O
problem	O
in	O
patients	O
following	O
renal	O
transplantation	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
deaf	O
patients	O
,	O
and	O
their	O
parents	O
and	O
sibs	O
(	O
when	O
possible	O
)	O
and	O
DNA	O
was	O
extracted	O
with	O
the	O
Nucleon	O
BACC3	O
DNA	O
extraction	O
kit	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Piscataway	O
,	O
NJ	O
)	O
.	O

SETTING	O
:	O
Academic	O
primary	O
care	O
practices	O
.	O

Twenty	O
-	O
nine	O
were	O
considered	O
as	O
non	O
-	O
pathogenic	O
because	O
all	O
of	O
them	O
were	O
already	O
described	O
as	O
non	O
-	O
pathogenic	O
in	O
other	O
studies	O
[	O
https	O
:	O
/	O
/	O
grenada	B-Chemical
.	O
lumc	O
.	O
nl	O
/	O
LOVD2	O
/	O
Usher_montpellier	B-Chemical
,	O
[	O
35	O
]	O
]	O
.	O

evaluated	O
the	O
prevalence	O
of	O
RYR2	B-GENE
mutations	O
in	O
a	O
cohort	O
of	O
patients	O
referred	O
for	O
screening	O
of	O
LQTS	B-DISEASE
genes	O
,	O
identifying	O
mutations	O
in	O
RYR2	B-GENE
among	O
6	O
%	O
of	O
the	O
269	O
genotype	O
-	O
negative	O
patients	O
[	O
9	O
]	O
.	O

SNPs3D	O
prediction	O
is	O
based	O
on	O
two	O
models	O
,	O
the	O
first	O
taking	O
into	O
account	O
that	O
many	O
disease	O
SNPs	O
decrease	O
protein	O
stability	O
and	O
the	O
second	O
based	O
on	O
analysis	O
of	O
homology	O
sequence	O
families	O
related	O
to	O
human	O
proteins	O
.	O

The	O
EDITS	O
scores	O
were	O
67	O
.	O
4	O
(	O
10	O
.	O
2	O
)	O
for	O
the	O
bupropion	B-Chemical
and	O
36	O
.	O
3	O
(	O
11	O
.	O
7	O
)	O
for	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

JDS	O
analyzed	O
the	O
data	O
.	O

The	O
authors	O
confirm	O
that	O
,	O
for	O
approved	O
reasons	O
,	O
some	O
access	O
restrictions	O
apply	O
to	O
the	O
data	O
underlying	O
the	O
findings	O
.	O

*	O
*	O
*	O
DAMAGING	O
by	O
SIFT	O
,	O
PolyPhen2	B-Chemical
result	O
:	O
Unknown	O
WARNING	O
:	O
BLAST	O
search	O
results	O
for	O
PCDH15	B-GENE
truncated	O
due	O
to	O
total	O
number	O
of	O
HSPs	O
>	O
2000	O
.	O

Bioinformatic	O
prediction	O
tools	O
were	O
used	O
to	O
evaluate	O
the	O
effect	O
of	O
mutations	O
.	O

His	O
developmental	O
milestones	O
were	O
normal	O
except	O
for	O
speech	B-DISEASE
delay	I-DISEASE
.	O

In	O
fact	O
,	O
some	O
reports	O
support	O
that	O
as	O
much	O
as	O
35	O
%	O
of	O
the	O
second	O
USH2A	B-GENE
mutant	O
alleles	O
are	O
duplications	O
,	O
deletions	O
and	O
deep	O
intronic	O
variants	O
,	O
which	O
are	O
extremely	O
difficult	O
to	O
detect	O
by	O
DNA	O
sequencing	O
[	O
27	O
]	O
.	O

USH	B-DISEASE
is	O
inherited	O
in	O
an	O
AR	O
mode	O
,	O
and	O
is	O
characterized	O
by	O
the	O
combination	O
of	O
RP	B-DISEASE
and	O
bilateral	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
SNHL	B-DISEASE
)	O
,	O
with	O
or	O
without	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

Interestingly	O
,	O
in	O
unrelated	O
Ashkenazi	O
Jewish	O
and	O
Finnish	O
populations	O
,	O
USH3	B-DISEASE
comprises	O
40	O
%	O
of	O
all	O
the	O
USH	B-DISEASE
cases	O
,	O
suggesting	O
multiple	O
founder	O
effects	O
[	O
9	O
,	O
32	O
]	O
.	O

(	O
d	O
)	O
Densitometric	O
analysis	O
of	O
Gipc3	B-GENE
expression	O
from	O
wild	O
-	O
type	O
Gipc3	B-GENE
(	O
115Gly	O
)	O
and	O
mutant	O
Gipc3	B-GENE
(	O
115Arg	O
)	O
-	O
transfected	O
HEK293T	O
cells	O
.	O

Electromyographic	O
findings	O
are	O
characterized	O
by	O
axonal	B-DISEASE
sensory	I-DISEASE
neuropathy	I-DISEASE
;	I-DISEASE
however	O
,	O
no	O
reports	O
exist	O
describing	O
an	O
IOSCA	B-DISEASE
patient	O
harboring	O
motor	B-DISEASE
neuropathy	I-DISEASE
[	O
5	O
-	O
7	O
]	O
.	O

As	O
shown	O
in	O
figure	O
2A	O
,	O
no	O
region	O
in	O
the	O
genome	O
reached	O
statistical	O
significance	O
in	O
this	O
family	O
,	O
according	O
to	O
the	O
general	O
convention	O
of	O
regarding	O
a	O
LOD	O
score	O
as	O
significant	O
,	O
when	O
it	O
reaches	O
or	O
exceeds	O
3	O
.	O

The	O
striking	O
spot	O
of	O
this	O
study	O
is	O
that	O
a	O
new	O
strategy	O
that	O
detects	O
SLC26A4	B-GENE
mutations	O
prior	O
to	O
the	O
temporal	O
bone	O
CT	O
scan	O
to	O
find	O
EVA	B-DISEASE
patients	O
are	O
established	O
.	O

All	O
of	O
the	O
individuals	O
who	O
participated	O
in	O
this	O
study	O
provided	O
an	O
approved	O
informed	O
consent	O
form	O
,	O
which	O
adhered	O
to	O
institutional	O
(	O
King	O
Faisal	O
Specialist	O
Hospital	O
;	O
RAC	O
#	O
2040039	O
)	O
guidelines	O
and	O
to	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Dehydrated	B-DISEASE
rats	O
regularly	O
develop	O
acute	O
renal	O
failure	O
following	O
single	O
injection	O
of	O
aminoglycoside	B-Chemical
antibiotics	O
combined	O
with	O
dextran	O
or	O
of	O
antibiotics	O
only	O
.	O

It	O
is	O
therefore	O
functionally	O
equivalent	O
to	O
the	O
knock	O
-	O
out	O
of	O
the	O
orthologous	O
gene	O
in	O
Eps8	B-GENE
-	O
/	O
-	O
mice	O
,	O
which	O
are	O
also	O
profoundly	O
deaf	O
[	O
10	O
,	O
11	O
]	O
.	O

48	O
Calcium	O
levels	O
control	O
many	O
aspects	O
of	O
Drosophila	O
phototransduction	O
.	O

Inclusion	O
criteria	O
required	O
that	O
all	O
families	O
had	O
a	O
minimum	O
of	O
three	O
affected	O
subjects	O
with	O
isolated	O
GMH	B-DISEASE
or	O
GMH	B-DISEASE
plus	O
proteinuria	B-DISEASE
and	O
CRF	B-DISEASE
.	O

We	O
thank	O
all	O
patients	O
and	O
family	O
members	O
for	O
their	O
participation	O
.	O

We	O
previously	O
showed	O
that	O
compound	O
heterozygous	O
mutations	O
are	O
detected	O
in	O
less	O
than	O
5	O
%	O
of	O
consanguineous	O
families	O
with	O
deafness	B-DISEASE
[	O
3	O
]	O
.	O

Electrocardiographic	O
changes	O
after	O
dipyridamole	B-Chemical
infusion	O
(	O
0	O
.	O
568	O
mg	O
/	O
kg	O
/	O
4	O
min	O
)	O
were	O
studied	O
in	O
41	O
patients	O
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
and	O
compared	O
with	O
those	O
after	O
submaximal	O
treadmill	O
exercise	O
by	O
use	O
of	O
the	O
body	O
surface	O
mapping	O
technique	O
.	O

Report	O
of	O
a	O
case	O
.	O

Currently	O
,	O
few	O
reports	O
have	O
observed	O
the	O
dynamic	O
evolution	O
of	O
macular	B-DISEASE
holes	I-DISEASE
,	O
except	O
that	O
Shah	O
et	O
al	O
.	O

The	O
largest	O
integer	O
number	O
that	O
is	O
not	O
larger	O
than	O
the	O
value	O
giving	O
the	O
cumulative	O
distribution	O
function	O
of	O
0	O
.	O
025	O
of	O
the	O
binomial	O
distribution	O
was	O
used	O
as	O
the	O
threshold	O
value	O
,	O
and	O
the	O
position	O
was	O
selected	O
when	O
the	O
number	O
of	O
the	O
reads	O
of	O
the	O
variant	O
were	O
not	O
lower	O
than	O
the	O
threshold	O
value	O
indicated	O
in	O
formula	O
(	O
1	O
)	O
.	O

2	O
)	O
.	O

The	O
first	O
two	O
groups	O
were	O
used	O
as	O
controls	O
and	O
we	O
mainly	O
focused	O
on	O
the	O
differences	O
between	O
wild	O
type	O
and	O
variant	O
type	O
MCM2	B-GENE
expressed	O
cells	O
.	O

SIFT	O
and	O
Polyphen2	O
were	O
used	O
as	O
a	O
first	O
-	O
pass	O
filter	O
to	O
predict	O
how	O
the	O
identified	O
amino	O
acid	O
substitutions	O
would	O
affect	O
protein	O
function	O
taking	O
into	O
account	O
sequence	O
homology	O
and	O
the	O
physical	O
properties	O
of	O
amino	O
acids	O
.	O

Among	O
users	O
of	O
aspirin	B-Chemical
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofecoxib	B-Chemical
,	O
22	O
,	O
875	O
to	O
celecoxib	B-Chemical
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NSAIDs	B-DISEASE
and	O
38	O
,	O
048	O
to	O
acetaminophen	B-Chemical
.	O

MO	O
i1e1	O
morpholino	O
was	O
used	O
for	O
all	O
subsequent	O
experiments	O
.	O

A	O
higher	O
degree	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
a	O
flat	O
or	O
slightly	O
downsloping	O
configuration	O
was	O
the	O
main	O
audiological	O
feature	O
of	O
the	O
DFNB42	B-DISEASE
family	O
[	O
13	O
]	O
.	O

Alleles	O
forming	O
the	O
risk	O
haplotype	O
are	O
shown	O
in	O
grey	O
boxes	O
.	O

In	O
1	O
patient	O
with	O
atopic	B-DISEASE
dermatitis	I-DISEASE
,	O
telangiectatic	B-DISEASE
and	O
papular	B-DISEASE
rosacea	I-DISEASE
insidiously	O
appeared	O
after	O
5	O
months	O
of	O
treatment	O
.	O

Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction	O
.	O

(	O
C	O
)	O
Two	O
previously	O
indicated	O
hydrogen	O
bonds	O
are	O
eliminated	O
due	O
to	O
the	O
change	O
of	O
the	O
wide	O
type	O
threonine	B-Chemical
into	O
the	O
mutant	O
methionine	B-Chemical
.	O

For	O
the	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
,	O
a	O
454	O
bp	O
DNA	O
fragment	O
was	O
amplified	O
(	O
forward	O
:	O
5	O
'	O
-	O
CGG	O
CTG	O
CCC	O
TCA	O
AAA	O
TCC	O
ACA	O
T	O
-	O
3	O
'	O
;	O
reverse	O
:	O
5	O
'	O
-	O
TGG	O
CAG	O
GTA	O
AAG	O
GCA	B-Chemical
TTG	O
AGA	O
CA	O
-	O
3	O
'	O
)	O
and	O
cut	O
into	O
172	O
bp	O
and	O
282	O
bp	O
with	O
BstXI	O
(	O
New	O
England	O
BioLabs	O
Inc	O
.	O
,	O
Beverly	O
,	O
MA	O
)	O
at	O
37	O
deg	O
C	O
for	O
4	O
h	O
.	O

In	O
none	O
of	O
the	O
patients	O
was	O
there	O
any	O
evidence	O
for	O
extrarenal	O
manifestations	O
,	O
such	O
as	O
ocular	O
findings	O
or	O
hearing	O
loss	O
,	O
although	O
patients	O
weren	O
'	O
t	O
tested	O
by	O
specialists	O
.	O

Variants	O
did	O
not	O
occur	O
with	O
the	O
86	O
in	O
-	O
house	O
exomes	O
with	O
a	O
frequency	O
greater	O
than	O
5	O
%	O
.	O

Conversely	O
,	O
prostaglandin	B-Chemical
E2	I-Chemical
-	O
induced	O
hyperalgesia	B-DISEASE
was	O
blocked	O
by	O
AH6809	B-Chemical
(	O
greater	O
than	O
or	O
equal	O
to	O
500	O
ng	O
)	O
but	O
not	O
by	O
the	O
substance	O
P	O
antagonist	O
.	O

Scrutiny	O
of	O
the	O
time	O
of	O
onset	O
,	O
evolution	O
and	O
severity	O
of	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
and	O
quality	O
of	O
vestibular	O
responses	O
enabled	O
to	O
assign	O
the	O
patients	O
to	O
one	O
of	O
the	O
three	O
clinical	O
types	O
of	O
the	O
disease	O
[	O
43	O
]	O
.	O

(	O
TIF	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Of	O
all	O
the	O
20	O
homozygous	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
patients	O
,	O
three	O
Yi	O
,	O
two	O
Bai	O
,	O
and	O
one	O
Hui	O
patient	O
were	O
homozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
.	O

If	O
a	O
subject	O
'	O
s	O
fasting	O
glucose	O
exceeded	O
11	O
.	O
1	O
mmol	O
/	O
l	O
,	O
the	O
test	O
was	O
not	O
performed	O
,	O
but	O
fasting	O
glucose	O
and	O
C	O
-	O
peptide	O
were	O
obtained	O
.	O

Disruptions	O
of	O
proteolysis	O
are	O
associated	O
with	O
a	O
wide	O
variety	O
of	O
genetic	O
disorders	O
,	O
[	O
17	O
]	O
but	O
TMPRSS3	B-GENE
was	O
the	O
first	O
protease	O
associated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
demonstrated	O
by	O
mutations	O
that	O
defined	O
DFNB8	O
and	O
DFNB10	O
[	O
5	O
]	O
.	O

The	O
plasma	O
inhibin	O
B	O
concentrations	O
were	O
normal	O
in	O
8	O
boys	O
,	O
including	O
6	O
in	O
the	O
pubertal	O
age	O
,	O
at	O
the	O
lower	O
limit	O
of	O
the	O
normal	O
in	O
6	O
boys	O
and	O
decreased	O
in	O
13	O
boys	O
.	O

A	O
.	O

The	O
animals	O
were	O
mechanically	O
ventilated	O
to	O
achieve	O
normocarbia	O
(	O
PCO2	B-DISEASE
=	O
42	O
+	O
/	O
-	O
1	O
mmHg	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

CONCLUSION	O
:	O
Salbutamol	B-Chemical
is	O
presented	O
here	O
as	O
a	O
possible	O
trigger	O
for	O
SIAT	B-DISEASE
.	O

The	O
incidence	O
of	O
subependymal	O
cysts	I-DISEASE
in	O
the	O
117	O
remaining	O
infants	O
was	O
14	O
%	O
(	O
16	O
of	O
117	O
)	O
.	O

Methyldopa	B-Chemical
causes	O
an	O
autoimmune	B-DISEASE
hemolytic	I-DISEASE
anemia	I-DISEASE
in	O
a	O
small	O
percentage	O
of	O
patients	O
who	O
take	O
the	O
drug	O
.	O

The	O
EYA4	B-GENE
(	O
OMIM	O
601316	O
)	O
and	O
GRHL2	B-GENE
(	O
OMIM	O
608641	O
)	O
genes	O
are	O
transcription	O
factors	O
related	O
constitution	O
of	O
the	O
organ	O
of	O
Corti	O
[	O
4	O
,	O
5	O
]	O
.	O

The	O
available	O
phoneme	O
and	O
word	O
scores	O
of	O
sound	O
presented	O
at	O
70	O
dB	O
SPL	O
1	O
year	O
after	O
activation	O
of	O
the	O
speech	O
processor	O
are	O
presented	O
in	O
Table	O
2	O
.	O

Neurological	O
examination	O
revealed	O
high	O
arched	O
feet	O
,	O
hammer	O
toes	O
,	O
and	O
normal	O
secondary	O
sexual	O
characteristics	O
.	O

MEK1	B-GENE
was	O
significantly	O
decreased	O
also	O
after	O
a	O
single	O
injection	O
of	O
METH	B-Chemical
,	O
but	O
to	O
a	O
much	O
lesser	O
degree	O
than	O
after	O
multiple	O
injections	O
of	O
METH	B-Chemical
.	O

Eiberg	O
[	O
7	O
]	O
and	O
Val	B-Chemical
e	O
ro	I-Chemical
[	O
8	O
]	O
reported	O
two	O
families	O
who	O
had	O
a	O
WFS1	B-GENE
missense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
Gln864Lys	I-VARIANT
)	O
in	O
the	O
same	O
conserved	O
region	O
as	O
the	O
mutation	O
that	O
we	O
found	O
.	O

On	O
the	O
other	O
hand	O
,	O
pretreatment	O
with	O
p	B-Chemical
-	I-Chemical
chlorophenylalamine	I-Chemical
(	O
3	O
X	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
,	O
24	O
hr	O
)	O
,	O
a	O
serotonin	B-Chemical
depletor	O
,	O
caused	O
no	O
significant	O
change	O
in	O
the	O
hyperactivity	O
.	O

In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
,	O
we	O
studied	O
12	O
volunteers	O
in	O
three	O
experiments	O
.	O

The	O
asterisk	O
indicates	O
presence	O
in	O
about	O
1	O
/	O
5	O
cases	O
and	O
the	O
double	O
asterisk	O
indicates	O
presence	O
in	O
about	O
3	O
/	O
4	O
cases	O
.	O

This	O
normalized	O
read	O
count	O
per	O
exon	O
was	O
used	O
to	O
compute	O
the	O
mean	O
and	O
variance	O
for	O
the	O
coverage	O
per	O
exon	O
in	O
all	O
analyzed	O
samples	O
.	O

The	O
effect	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
was	O
studied	O
in	O
male	O
rats	O
.	O

Asterisk	O
indicates	O
BCVA	O
after	O
cataract	O
surgery	O
in	O
the	O
left	O
eye	O
.	O

The	O
glycine	B-Chemical
transporter	O
-	O
1	O
inhibitor	O
SSR103800	B-Chemical
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	O
.	O

In	O
this	O
condition	O
,	O
the	O
buffering	O
capacity	O
of	O
calcium	O
and	O
phosphate	O
in	O
bone	O
is	O
diminished	O
,	O
producing	O
conditions	O
that	O
favor	O
extraosseous	O
calcification	O
.	O

BACKGROUND	O
:	O
Unfractionated	B-Chemical
heparin	I-Chemical
sodium	I-Chemical
(	O
UFH	B-Chemical
)	O
or	O
low	B-Chemical
-	I-Chemical
molecular	I-Chemical
weight	I-Chemical
heparin	I-Chemical
(	O
LMWH	O
)	O
is	O
used	O
in	O
anticoagulant	O
protocols	O
at	O
several	O
institutions	O
to	O
prevent	O
thrombosis	B-DISEASE
after	O
liver	O
transplantation	O
.	O

B	O
:	O
Southern	O
blot	O
analysis	O
of	O
muscle	O
-	O
derived	O
mtDNA	O
of	O
Patient	O
2	O
,	O
two	O
positive	O
controls	O
(	O
POLG1	B-GENE
-	O
mutated	O
patients	O
)	O
and	O
a	O
negative	O
control	O
(	O
adult	O
healthy	O
subject	O
)	O
.	O

[	O
6	O
]	O
(	O
ages	O
13	O
,	O
18	O
,	O
20	O
,	O
22	O
years	O
)	O
had	O
no	O
visual	B-DISEASE
symptoms	I-DISEASE
or	O
night	B-DISEASE
blindness	I-DISEASE
.	O

Audiological	O
examination	O
with	O
solid	O
line	O
was	O
performed	O
ten	O
years	O
later	O
.	O

Severe	O
functional	O
impact	O
of	O
this	O
variant	O
was	O
indicated	O
by	O
all	O
three	O
online	O
prediction	O
software	O
.	O

II	O
-	O
2	O
presented	O
with	O
not	O
only	O
anterior	O
and	O
posterior	B-DISEASE
lenticonus	I-DISEASE
,	O
but	O
also	O
macular	B-DISEASE
holes	I-DISEASE
.	O

All	O
the	O
PCR	O
products	O
of	O
affected	O
and	O
unaffected	O
members	O
were	O
completely	O
sequenced	O
.	O

We	O
report	O
a	O
patient	O
who	O
developed	O
cholestatic	B-DISEASE
jaundice	I-DISEASE
shortly	O
after	O
initiation	O
of	O
treatment	O
with	O
metformin	B-Chemical
hydrochloride	I-Chemical
.	O

Pmut	O
provides	O
prediction	O
by	O
neural	O
networks	O
,	O
which	O
use	O
internal	O
databases	O
,	O
secondary	O
structure	O
prediction	O
,	O
and	O
sequence	O
conservation	O
.	O

Column	O
5	O
indicates	O
the	O
number	O
of	O
families	O
in	O
which	O
the	O
mutation	O
was	O
detected	O
.	O

The	O
knee	O
epiphyses	O
are	O
small	O
and	O
irregularly	O
ossified	O
.	O

No	O
patient	O
was	O
excluded	O
based	O
on	O
phenotype	O
,	O
inheritance	O
or	O
previous	O
testing	O
.	O

We	O
next	O
performed	O
WES	O
on	O
DNA	O
samples	O
from	O
individuals	O
II	O
:	O
1	O
(	O
HL	B-DISEASE
and	O
RP	B-DISEASE
)	O
and	O
II	O
:	O
3	O
(	O
RP	B-DISEASE
only	O
)	O
.	O

Illness	B-DISEASE
occurred	O
within	O
1	O
-	O
-	O
9	O
weeks	O
of	O
commencement	O
of	O
therapy	O
in	O
9	O
patients	O
,	O
the	O
remaining	O
3	O
patients	O
having	O
received	O
the	O
drug	O
for	O
13	O
months	O
,	O
15	O
months	O
and	O
7	O
years	O
before	O
experiencing	O
symptoms	O
.	O

Tang	O
et	O
al	O
.	O

Of	O
93	O
previously	O
found	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
mutations	O
,	O
we	O
confirmed	O
87	O
(	O
93	O
.	O
5	O
%	O
)	O
of	O
them	O
(	O
Table	O
S3	O
)	O
.	O

TMC1	B-GENE
is	O
predicted	O
to	O
contain	O
six	O
transmembrane	O
domains	O
,	O
and	O
both	O
C	O
-	O
and	O
N	O
-	O
termini	O
are	O
located	O
intracellularly	O
;	O
this	O
protein	O
exhibits	O
no	O
apparent	O
amino	O
acid	O
sequence	O
similarity	O
to	O
any	O
other	O
proteins	O
of	O
known	O
function	O
.	O

Marie	O
-	O
Christine	O
Picot	O
for	O
helpful	O
comments	O
,	O
Sabine	O
Low	O
Hong	O
for	O
technical	O
assistance	O
,	O
and	O
Gail	O
Billingsley	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
.	O

Moreover	O
,	O
Foxi1	B-GENE
null	O
mice	O
showed	O
phenotypic	O
features	O
of	O
sensorineural	B-DISEASE
deafness	I-DISEASE
due	O
to	O
the	O
defective	O
pendrin	B-Chemical
-	O
chloride	O
mediated	O
reabsorption	O
in	O
which	O
FOXI1	B-GENE
was	O
most	O
likely	O
a	O
key	O
regulator	O
[	O
29	O
]	O
.	O

The	O
entire	O
design	O
,	O
across	O
246	O
loci	O
,	O
spanned	O
1	O
.	O
59	O
Mb	O
.	O

*	O
Citations	O
[	O
#	O
]	O
for	O
patients	O
included	O
in	O
cohorts	O
exploring	O
independent	O
research	O
questions	O
.	O

Transfection	O
experiments	O
for	O
generating	O
stable	O
HeLa	O
cell	O
lines	O
expressing	O
FLAG	B-Chemical
-	O
tagged	O
versions	O
of	O
POLR1C	B-GENE
variants	O
used	O
lipofectamine	B-Chemical
,	O
as	O
described	O
by	O
the	O
supplier	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
18	O
.	O

"	O
This	O
study	O
has	O
been	O
performed	O
with	O
the	O
approval	O
of	O
the	O
ethics	O
committee	O
of	O
Shandong	O
Academy	O
of	O
Medical	O
Science	O
.	O

(	O
TIF	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Among	O
these	O
,	O
40	O
cases	O
(	O
71	O
.	O
4	O
%	O
)	O
had	O
been	O
enrolled	O
in	O
the	O
current	O
study	O
.	O

SIFT	O
,	O
Polyphen	O
-	O
2	O
,	O
PhyloP	O
,	O
LRT	O
,	O
Mutation	O
Taster	O
,	O
and	O
GERP	O
+	O
+	O
are	O
functional	O
prediction	O
scores	O
in	O
which	O
increasing	O
values	O
indicate	O
a	O
probable	O
mutation	O
.	O

His	O
parents	O
are	O
non	O
-	O
consanguineous	O
marriage	O
.	O

The	O
metabolism	O
of	O
the	O
cardioselective	O
beta	O
-	O
blocker	O
metoprolol	B-Chemical
is	O
under	O
genetic	O
control	O
of	O
the	O
debrisoquine	B-Chemical
/	O
sparteine	B-Chemical
type	O
.	O

This	O
mutation	O
has	O
been	O
previously	O
reported	O
once	O
[	O
20	O
]	O
.	O

The	O
acute	O
cytolytic	O
hepatitis	I-DISEASE
occurred	O
rapidly	O
after	O
meloxicam	B-Chemical
administration	O
and	O
was	O
associated	O
with	O
the	O
development	O
of	O
antinuclear	B-DISEASE
antibodies	I-DISEASE
suggesting	O
a	O
hypersensitivity	O
mechanism	O
.	O

To	O
determine	O
whether	O
the	O
capacity	O
for	O
reactive	O
DNA	O
synthesis	O
was	O
also	O
subject	O
to	O
genetic	O
regulation	O
,	O
cardiac	B-DISEASE
hypertrophy	I-DISEASE
was	O
induced	O
in	O
the	O
strains	O
of	O
mice	O
comprising	O
the	O
extremes	O
of	O
the	O
nuclear	O
number	O
survey	O
.	O

A	O
patient	O
who	O
allegedly	O
consumed	O
100	O
tablets	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgesic	O
containing	O
sodium	B-Chemical
acetylsalicylate	I-Chemical
,	O
caffeine	B-Chemical
,	O
and	O
acetaminophen	B-Chemical
displayed	O
no	O
significant	O
CNS	O
stimulation	O
despite	O
the	O
presence	O
of	O
175	O
micrograms	O
of	O
caffeine	B-Chemical
per	O
mL	O
of	O
serum	O
.	O

The	O
a	O
-	O
CGH	O
technique	O
to	O
confirm	O
the	O
presence	O
of	O
the	O
heterozygous	O
duplication	O
of	O
CDH23	B-GENE
(	O
exon	O
29	O
)	O
in	O
patient	O
RP	O
-	O
1781	O
was	O
not	O
succesful	O
due	O
to	O
technical	O
problems	O
.	O

The	O
mean	O
+	O
-	O
standard	O
deviation	O
(	O
SD	O
)	O
levels	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
at	O
250	O
,	O
500	O
,	O
1000	O
,	O
2000	O
,	O
4000	O
,	O
and	O
8000	O
Hz	O
from	O
three	O
older	O
subjects	O
were	O
described	O
(	O
Table	O
1	O
)	O
.	O

Although	O
a	O
recent	O
report	O
recommended	O
GJB2	B-GENE
screening	O
in	O
cases	O
of	O
progressive	O
and	O
recurrent	O
sudden	O
HL	O
[	O
31	O
]	O
)	O
,	O
no	O
GJB2	B-GENE
and	O
/	O
or	O
GJB6	B-GENE
biallelic	O
mutations	O
were	O
identified	O
in	O
patients	O
with	O
progressive	O
,	O
postlingual	O
,	O
asymmetrical	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
study	O
.	O

The	O
number	O
of	O
GSDs	B-DISEASE
reported	O
each	O
year	O
in	O
the	O
CBM	O
database	O
increased	O
gradually	O
since	O
1978	O
and	O
rapidly	O
increased	O
starting	O
in	O
1994	O
.	O

Furthermore	O
,	O
it	O
is	O
vital	O
to	O
ensure	O
EM	O
and	O
ideally	O
IF	O
for	O
collagen	O
proteins	O
are	O
available	O
and	O
reviewed	O
in	O
patients	O
with	O
unexplained	O
haematuria	B-DISEASE
even	O
in	O
the	O
absence	O
of	O
a	O
family	O
history	O
.	O

The	O
increase	O
in	O
accuracy	O
we	O
obtained	O
over	O
traditional	O
methods	O
is	O
due	O
to	O
three	O
features	O
of	O
our	O
capture	O
sequencing	O
protocol	O
,	O
which	O
allowed	O
for	O
a	O
comprehensive	O
analysis	O
of	O
the	O
ABCA4	B-GENE
locus	O
and	O
,	O
when	O
this	O
failed	O
to	O
identify	O
the	O
cause	O
of	O
disease	O
,	O
other	O
retinal	B-DISEASE
disease	I-DISEASE
genes	O
.	O

We	O
demonstrated	O
that	O
the	O
expression	O
level	O
of	O
TCOF1	B-GENE
is	O
18	O
-	O
31	O
%	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
even	O
if	O
we	O
exclude	O
the	O
patients	O
in	O
whom	O
we	O
did	O
not	O
detect	O
the	O
pathogenic	O
mutation	O
.	O

More	O
than	O
38	O
000	O
and	O
1700	O
high	O
-	O
quality	O
variants	O
were	O
called	O
for	O
III	O
-	O
4	O
and	O
III	O
-	O
13	O
,	O
respectively	O
.	O

The	O
H2	O
-	O
histamine	B-Chemical
receptor	O
antagonists	O
ranitidine	B-Chemical
and	O
cimetidine	B-Chemical
were	O
compared	O
for	O
their	O
abilities	O
to	O
control	O
gastric	O
acid	I-DISEASE
hypersecretion	I-DISEASE
on	O
a	O
short	O
-	O
and	O
long	O
-	O
term	O
basis	O
in	O
22	O
patients	O
with	O
gastric	B-DISEASE
acid	I-DISEASE
hypersecretory	I-DISEASE
states	O
.	O

However	O
,	O
the	O
Rg1	B-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsenosides	I-Chemical
failed	O
to	O
prevent	O
OIH	B-DISEASE
in	O
either	O
test	O
.	O

We	O
also	O
identified	O
novel	O
homozygous	O
mutations	O
in	O
NDUFAF2	B-GENE
in	O
3	O
patients	O
presenting	O
with	O
Leigh	B-DISEASE
Syndrome	I-DISEASE
(	O
Table	O
3	O
and	O
Supplementary	O
Fig	O
.	O

AZT	B-Chemical
has	O
induced	O
a	O
macrocytic	B-DISEASE
anemia	I-DISEASE
in	O
AIDS	B-DISEASE
patients	O
on	O
long	O
term	O
AZT	B-Chemical
therapy	O
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	B-Chemical
on	O
experimentally	O
induced	O
myocardial	O
infarction	O
in	O
rats	O
.	O

In	O
Subject	O
7	O
(	O
bottom	O
)	O
both	O
electrically	O
-	O
evoked	O
compound	O
action	O
potentials	O
(	O
left	O
)	O
and	O
electrically	O
-	O
evoked	O
ABRs	O
(	O
middle	O
and	O
right	O
)	O
were	O
recorded	O
at	O
all	O
electrode	O
locations	O
;	O
wave	O
II	O
was	O
also	O
identified	O
in	O
electrically	O
-	O
evoked	O
ABR	O
recordings	O
in	O
addition	O
to	O
wave	O
V	O
.	O

Atorva	B-Chemical
reversed	O
dex	B-Chemical
-	O
induced	O
hypertension	B-DISEASE
(	O
129	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
,	O
vs	O
.	O
135	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
P	O
'	O
<	O
0	O
.	O
05	O
)	O
and	O
decreased	O
plasma	O
superoxide	B-Chemical
(	O
7931	O
+	O
/	O
-	O
392	O
.	O
8	O
dex	B-Chemical
,	O
1187	O
+	O
/	O
-	O
441	O
.	O
2	O
atorva	B-Chemical
+	O
dex	B-Chemical
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Each	O
mutation	O
was	O
within	O
a	O
homozygous	O
run	O
documented	O
via	O
WES	O
.	O

Detection	O
rates	O
in	O
Gansu	O
,	O
Heibei	O
,	O
Hubei	O
,	O
Shaanxi	O
and	O
Heilongjiang	O
province	O
were	O
26	O
.	O
32	O
,	O
25	O
,	O
18	O
.	O
75	O
,	O
18	O
.	O
37	O
and	O
16	O
.	O
67	O
%	O
,	O
respectively	O
.	O

Exome	O
sequencing	O
was	O
carried	O
out	O
at	O
the	O
McGill	O
University	O
and	O
Genome	O
Quebec	O
Innovation	O
Centre	O
,	O
Montreal	O
,	O
Canada	O
as	O
previously	O
detailed	O
[	O
31	O
]	O
,	O
[	O
32	O
]	O
.	O

Her	O
QTc	O
on	O
serial	O
ECGs	O
ranged	O
from	O
480	O
to	O
530	O
ms	O
[	O
Figure	O
3	O
]	O
.	O

The	O
EYA4	B-GENE
gene	O
was	O
located	O
between	O
the	O
D6S262	O
and	O
D6S1038	O
microsatellite	O
markers	O
.	O

Based	O
on	O
the	O
type	O
of	O
gene	O
product	O
,	O
these	O
genes	O
can	O
be	O
categorized	O
into	O
several	O
groups	O
such	O
as	O
those	O
coding	O
for	O
proteins	O
involved	O
in	O
the	O
structure	O
and	O
function	O
of	O
hair	O
cells	O
,	O
auditory	O
nerve	O
,	O
and	O
virtually	O
every	O
structural	O
element	O
of	O
the	O
inner	O
ear	O
.	O

Any	O
genes	O
on	O
the	O
list	O
that	O
represented	O
common	O
fusion	O
products	O
of	O
translocation	O
or	O
any	O
gene	O
that	O
could	O
not	O
be	O
identified	O
based	O
on	O
Ensembl	O
release	O
58	O
and	O
the	O
corresponding	O
release	O
of	O
NCBI	O
Refseq	O
from	O
the	O
same	O
time	O
point	O
were	O
excluded	O
.	O

Diagnosing	O
AS	B-DISEASE
histologically	O
can	O
be	O
challenging	O
because	O
findings	O
on	O
light	O
microscopy	O
are	O
often	O
non	O
-	O
specific	O
.	O

1	O
.	O
6	O
+	O
-	O
2	O
.	O
1	O
years	O
;	O
P	O
=	O
0	O
.	O
064	O
NS	O
)	O
.	O

R	O
.	O
C	O
.	O

In	O
the	O
current	O
work	O
,	O
none	O
of	O
the	O
patients	O
carried	O
presumably	O
pathogenic	O
mutations	O
in	O
more	O
than	O
one	O
gene	O
(	O
FGFR1	B-GENE
or	O
KAL1	B-GENE
)	O
.	O

To	O
quantify	O
this	O
population	O
,	O
the	O
total	O
number	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
was	O
estimated	O
using	O
unbiased	O
stereology	O
at	O
different	O
times	O
after	O
pilocarpine	B-Chemical
-	I-DISEASE
induced	O
status	I-DISEASE
epilepticus	I-DISEASE
.	O

Wrote	O
the	O
paper	O
:	O
HJY	O
.	O

METHODS	O
:	O
An	O
in	O
-	O
depth	O
chart	O
review	O
was	O
undertaken	O
in	O
all	O
24	O
patients	O
who	O
developed	O
perioperative	O
seizures	B-DISEASE
.	O

20	O
,	O
21	O
Three	O
fluorescently	O
labeled	O
microsatellite	O
markers	O
(	O
D21S2078	O
,	O
D21S1252	O
and	O
D21S2080	O
)	O
linked	O
to	O
CLDN14	B-GENE
were	O
PCR	O
-	O
genotyped	O
as	O
described	O
.	O

The	O
participants	O
of	O
this	O
study	O
were	O
diagnosed	O
and	O
enrolled	O
at	O
Union	O
Hospital	O
.	O

In	O
patients	O
with	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
,	O
high	O
glucose	O
concentrations	O
impair	O
expression	O
and	O
secretion	O
of	O
insulin	O
in	O
beta	O
-	O
cells	O
and	O
accelerate	O
apoptosis	O
of	O
islet	O
cells	O
(	O
22	O
,	O
23	O
)	O
.	O

CT	O
carried	O
out	O
capturing	O
and	O
sequencing	O
the	O
DNA	O
samples	O
.	O

These	O
interactions	O
alter	O
the	O
affinity	O
for	O
ligand	O
and	O
heparin	O
[	O
41	O
,	O
42	O
]	O
.	O

The	O
study	O
included	O
100	O
normal	O
Chinese	O
individuals	O
as	O
normal	O
controls	O
.	O

None	O
of	O
our	O
three	O
probands	O
with	O
CHARGE	B-DISEASE
syndrome	O
-	O
like	O
features	O
carried	O
mutations	O
in	O
CHD7	B-GENE
,	O
analyzed	O
both	O
by	O
direct	O
sequencing	O
and	O
MLPA	O
,	O
expanding	O
the	O
phenotypic	O
overlap	O
between	O
KS	B-DISEASE
and	O
CHARGE	B-DISEASE
also	O
in	O
patients	O
without	O
CHD7	B-GENE
mutations	O
.	O

We	O
selected	O
several	O
hundred	O
genes	O
important	O
in	O
kidney	O
development	O
and	O
glomerular	B-DISEASE
diseases	I-DISEASE
to	O
identify	O
mutations	O
that	O
may	O
provide	O
insights	O
into	O
the	O
presence	O
of	O
a	O
congenital	O
anomaly	O
(	O
VUR	B-DISEASE
,	O
hydronephrosis	B-DISEASE
)	O
and	O
proteinuria	B-DISEASE
in	O
a	O
patient	O
where	O
the	O
etiology	O
of	O
either	O
entity	O
was	O
unclear	O
since	O
FSGS	B-DISEASE
pattern	O
can	O
be	O
observed	O
in	O
obstructive	O
or	O
reflux	O
nephropathy	O
or	O
primary	O
glomerular	B-DISEASE
diseases	I-DISEASE
.	O

The	O
fraction	O
of	O
positions	O
where	O
a	O
certain	O
error	O
occurred	O
with	O
the	O
error	O
rate	O
for	O
insertions	O
,	O
deletions	O
,	O
and	O
mismatches	O
.	O

Fig	O
.	O

One	O
day	O
after	O
experimental	O
myocardial	B-DISEASE
infarction	I-DISEASE
,	O
six	O
additional	O
halothane	B-Chemical
-	O
anesthetized	O
dogs	O
received	O
4	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-Chemical
until	O
VT	B-DISEASE
appeared	O
.	O

In	O
contrast	O
,	O
neither	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
nor	O
p	B-VARIANT
.	I-VARIANT
H723R	I-VARIANT
were	O
found	O
in	O
the	O
Tibetan	B-DISEASE
and	I-DISEASE
Uygur	I-DISEASE
patients	O
.	O

These	O
studies	O
suggest	O
that	O
both	O
phenacetin	B-Chemical
and	O
acetaminophen	B-Chemical
may	O
contribute	O
to	O
the	O
burden	O
of	O
ESRD	B-DISEASE
,	O
with	O
the	O
risk	O
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O

(	O
d	O
)	O
Sequencing	O
chromatograms	O
demonstrating	O
the	O
343G	B-VARIANT
>	I-VARIANT
A	I-VARIANT
transition	O
in	O
wild	O
-	O
type	O
(	O
left	O
)	O
and	O
mutant	O
(	O
right	O
)	O
are	O
shown	O
.	O

Scale	O
bars	O
are	O
5	O
u	O
m	O
for	O
higher	O
magnification	O
panels	O
of	O
IHC	O
and	O
OHC	O
.	O

Genetic	O
analysis	O
demonstrates	O
co	O
-	O
segregation	O
of	O
a	O
mutation	O
of	O
MYO7A	B-GENE
(	O
p	B-VARIANT
.	I-VARIANT
Q234X	I-VARIANT
)	O
with	O
USH1	B-DISEASE
.	O

The	O
oxygen	O
consumption	O
rate	O
(	O
OCR	O
)	O
was	O
significantly	O
higher	O
in	O
the	O
cell	O
line	O
expressing	O
wild	O
type	O
NARS2	B-GENE
although	O
rescue	O
was	O
not	O
complete	O
(	O
Fig	O
.	O

(	O
b	O
)	O
Typical	O
audiograms	O
of	O
selected	O
patients	O
from	O
each	O
branch	O
are	O
shown	O
.	O

5	O
Patients	O
1	O
-	O
7	O
detailed	O
phenotypes	O
are	O
described	O
in	O
table	O
1	O
.	O

However	O
,	O
in	O
vivo	O
studies	O
and	O
computational	O
evidence	O
have	O
suggested	O
that	O
its	O
primary	O
role	O
is	O
likely	O
in	O
fatty	B-Chemical
-	O
acid	O
metabolism	O
,	O
while	O
steroid	B-Chemical
conversion	O
is	O
only	O
a	O
secondary	O
and	O
possibly	O
minor	O
activity	O
in	O
vivo	O
[	O
21	O
]	O
.	O

Thus	O
,	O
SLC26A4	B-GENE
mutant	O
alleles	O
accounted	O
for	O
82	O
.	O
61	O
%	O
(	O
38	O
/	O
46	O
)	O
of	O
the	O
total	O
alleles	O
in	O
235	O
NSHI	B-DISEASE
patients	O
.	O

DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	O
with	O
schizophrenia	B-DISEASE
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O

There	O
was	O
a	O
combined	O
mean	O
loss	O
of	O
46	O
%	O
of	O
fibers	O
from	O
the	O
superior	O
,	O
inferior	O
,	O
and	O
nasal	O
quadrants	O
in	O
the	O
(	O
six	O
)	O
eyes	O
of	O
all	O
three	O
subjects	O
(	O
mean	O
average	O
thickness	O
of	O
55	O
+	O
/	O
-	O
29	O
microm	O
)	O
.	O

5th	O
communication	O
:	O
anticonvulsant	O
effects	O
in	O
mice	O
.	O

We	O
are	O
very	O
grateful	O
to	O
all	O
participating	O
patients	O
and	O
their	O
relatives	O
.	O

Protective	O
effect	O
of	O
Terminalia	B-Chemical
chebula	I-Chemical
against	O
experimental	O
myocardial	O
injury	O
induced	O
by	O
isoproterenol	B-Chemical
.	O

Therefore	O
,	O
EM	O
might	O
be	O
helpful	O
in	O
those	O
cases	O
with	O
very	O
faint	O
or	O
undetectable	O
leukocyte	B-DISEASE
inclusions	I-DISEASE
.	O

The	O
unaffected	O
son	O
(	O
F5	O
-	O
III	O
-	O
3	O
)	O
was	O
proved	O
to	O
be	O
a	O
carrier	O
.	O

Detailed	O
information	O
of	O
the	O
two	O
microarrays	O
has	O
been	O
previously	O
described	O
[	O
1	O
]	O
,	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24	O
.	O
3	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanzapine	B-Chemical
and	O
23	O
.	O
9	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95	O
%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
risperidone	B-Chemical
.	O

These	O
models	O
were	O
visualized	O
and	O
delineated	O
with	O
RasMol	B-Chemical
(	O
v	O
.	O

Image	O
analysis	O
and	O
base	O
calling	O
were	O
performed	O
using	O
the	O
Illumina	O
Real	O
-	O
Time	O
Analysis	O
Pipeline	O
version	O
1	O
.	O
14	O
with	O
default	O
parameters	O
[	O
9	O
]	O
.	O

Five	O
amplicons	O
were	O
sequenced	O
to	O
cover	O
this	O
2	O
.	O
20	O
-	O
kb	O
region	O
,	O
which	O
includes	O
0	O
.	O
973	O
kb	O
upstream	O
of	O
the	O
5	O
'	O
UTR	O
,	O
the	O
5	O
'	O
UTR	O
(	O
exon	O
1	O
,	O
0	O
.	O
165	O
kb	O
)	O
,	O
and	O
1	O
.	O
067	O
kb	O
into	O
intron	O
1	O
.	O

WS	B-DISEASE
is	O
classified	O
into	O
four	O
major	O
types	O
depending	O
on	O
the	O
presence	O
or	O
absence	O
of	O
dystopia	B-DISEASE
canthorum	I-DISEASE
and	O
additional	O
symptoms	O
[	O
1	O
,	O
5	O
-	O
8	O
]	O
.	O

B	O
:	O
Dystopia	B-DISEASE
canthorum	I-DISEASE
(	O
W	O
index	O
:	O
2	O
.	O
08	O
)	O
,	O
brilliant	O
blue	O
iris	O
,	O
and	O
synophyris	O
were	O
present	O
in	O
a	O
32	O
-	O
year	O
old	O
man	O
(	O
III	O
:	O
5	O
)	O
.	O

1b	O
)	O
.	O

Y	O
-	O
axis	O
indicated	O
the	O
percentage	O
of	O
total	O
target	O
region	O
under	O
a	O
given	O
sequencing	O
depth	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
(	O
0	O
-	O
100	O
)	O
is	O
in	O
dB	O
,	O
and	O
frequencies	O
(	O
500	O
-	O
8000	O
)	O
are	O
in	O
Hz	O
.	O

The	O
duration	O
of	O
apnea	B-DISEASE
was	O
compared	O
with	O
published	O
data	O
on	O
normal	O
subjects	O
.	O

This	O
suggests	O
that	O
relatively	O
unbiased	O
approaches	O
to	O
genetic	O
testing	O
,	O
such	O
as	O
WES	O
,	O
would	O
be	O
an	O
efficient	O
and	O
successful	O
approach	O
to	O
reach	O
a	O
molecular	O
diagnosis	O
in	O
at	O
least	O
a	O
subset	O
of	O
patients	O
.	O

In	O
Family	O
BF	O
,	O
the	O
lod	O
score	O
for	O
linkage	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
to	O
the	O
D7S496	O
-	O
D7S2459	B-Chemical
haplotype	O
was	O
1	O
.	O
66	O
,	O
which	O
was	O
not	O
statistically	O
significant	O
but	O
was	O
close	O
to	O
the	O
maximum	O
possible	O
for	O
this	O
family	O
.	O

KCNQ1	B-GENE
(	O
I	B-GENE
Ks	I-GENE
)	O
,	O
KCNH2	B-GENE
(	O
I	B-GENE
Kr	I-GENE
)	O
,	O
KCNJ2	B-GENE
(	O
I	B-GENE
K1	I-GENE
)	O
can	O
lead	O
to	O
increased	O
susceptibility	O
to	O
AF	B-DISEASE
[	O
6	O
]	O
.	O

(	O
f	O
)	O
Montage	O
of	O
AO	O
images	O
of	O
the	O
patient	O
outlined	O
area	O
in	O
(	O
d	O
)	O
is	O
shown	O
.	O

Disease	O
in	O
11	O
patients	O
explained	O
by	O
mutations	O
outside	O
ABCA4	B-GENE
Patients	O
who	O
were	O
clinically	O
examined	O
following	O
the	O
molecular	O
diagnosis	O
are	O
in	O
bold	O
.	O

Sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
is	O
a	O
new	O
,	O
potent	O
immunosuppressive	O
agent	O
.	O

Soon	O
after	O
the	O
introduction	O
of	O
ACE	B-Chemical
inhibitors	I-Chemical
,	O
acute	O
bouts	O
of	O
angio	B-DISEASE
-	I-DISEASE
oedema	I-DISEASE
were	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
these	O
drugs	O
.	O

A	O
case	O
of	O
necrotizing	B-DISEASE
myopathy	I-DISEASE
due	O
to	O
a	O
short	O
epsilon	B-Chemical
-	I-Chemical
aminocaproic	I-Chemical
acid	I-Chemical
(	O
EACA	B-Chemical
)	O
treatment	O
in	O
a	O
72	O
year	O
-	O
old	O
patient	O
with	O
subarachnoid	B-DISEASE
haemorrhage	I-DISEASE
(	O
SAH	B-DISEASE
)	O
is	O
described	O
.	O

Bile	B-DISEASE
duct	I-DISEASE
hamartoma	I-DISEASE
occurring	O
in	O
association	O
with	O
long	O
-	O
term	O
treatment	O
with	O
danazol	B-Chemical
.	O

After	O
obtaining	O
informed	O
consent	O
,	O
peripheral	O
blood	O
samples	O
from	O
all	O
participants	O
were	O
collected	O
and	O
genomic	O
DNA	O
was	O
extracted	O
.	O

The	O
FC	O
population	O
did	O
not	O
show	O
a	O
statistically	O
significant	O
increase	O
in	O
unsolved	O
patients	O
with	O
a	O
single	O
observed	O
mutation	O
in	O
ABCA4	B-GENE
.	O

Thus	O
,	O
MPS	O
enables	O
genetic	O
diagnosis	O
in	O
multiplex	O
families	O
with	O
idiopathic	O
SNHI	B-DISEASE
by	O
detecting	O
mutations	O
in	O
relatively	O
uncommon	O
deafness	B-DISEASE
genes	O
.	O

In	O
essence	O
,	O
when	O
the	O
clinical	O
diagnosis	O
makes	O
it	O
likely	O
that	O
the	O
mutation	O
will	O
be	O
in	O
a	O
gene	O
included	O
on	O
the	O
panel	O
,	O
it	O
is	O
more	O
efficient	O
in	O
financial	O
terms	O
and	O
timewise	O
to	O
use	O
panel	O
sequencing	O
.	O

Thus	O
,	O
GJB2	B-GENE
mutations	O
account	O
for	O
17	O
.	O
9	O
%	O
of	O
the	O
mutant	O
alleles	O
in	O
2063	O
NSHI	B-DISEASE
patients	O
.	O

The	O
generated	O
model	O
structure	O
was	O
further	O
optimized	O
by	O
energy	O
minimization	O
using	O
the	O
YASARA	B-Chemical
server	O
[	O
19	O
]	O
.	O

3	O
)	O
.	O

One	O
patient	O
was	O
heterozygous	O
for	O
mutations	O
in	O
both	O
USH	B-DISEASE
genes	O
having	O
received	O
the	O
USH2A	B-GENE
variant	O
from	O
the	O
unaffected	O
father	O
and	O
the	O
MYO7A	B-GENE
variant	O
from	O
the	O
unaffected	O
mother	O
.	O

The	O
authors	O
report	O
no	O
conflict	O
of	O
interest	O
.	O
Academic	O
Editor	O
:	O
Yi	O
Guo	O
Alport	B-DISEASE
syndrome	I-DISEASE
(	O
AS	B-DISEASE
)	O
is	O
a	O
monogenic	O
disease	O
of	O
the	O
basement	O
membrane	O
(	O
BM	O
)	O
,	O
resulting	O
in	O
progressive	O
renal	O
failure	O
due	O
to	O
glomerulonephropathy	B-DISEASE
,	O
variable	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
and	O
ocular	B-DISEASE
anomalies	I-DISEASE
.	O

The	O
scan	O
lines	O
to	O
obtain	O
these	O
images	O
are	O
shown	O
in	O
(	O
d	O
)	O
.	O

Figure	O
4	O
shows	O
patient	O
fundus	O
photographs	O
,	O
OCT	O
,	O
FAF	O
,	O
GVF	O
,	O
focal	O
electroretinogram	O
(	O
fERG	O
)	O
and	O
multi	O
-	O
focal	O
electroretinogram	O
(	O
mfERG	O
)	O
.	O

This	O
variant	O
,	O
found	O
in	O
a	O
single	O
individual	O
in	O
our	O
cohort	O
,	O
is	O
a	O
splice	O
-	O
site	O
-	O
disrupting	O
mutation	O
shown	O
to	O
affect	O
RNA	O
splicing	O
in	O
vitro	O
[	O
53	O
]	O
and	O
has	O
7	O
reports	O
of	O
pathogenicity	O
in	O
BIC	O
.	O

Although	O
Invader	O
Assay	O
is	O
more	O
efficient	O
,	O
if	O
a	O
method	O
other	O
than	O
Invader	O
Assay	O
had	O
been	O
used	O
,	O
the	O
results	O
would	O
have	O
been	O
identical	O
.	O

Of	O
the	O
188	O
variants	O
,	O
96	O
were	O
non	O
-	O
synonymous	O
,	O
missense	O
,	O
nonsense	O
or	O
splice	O
variants	O
.	O

In	O
conclusion	O
,	O
the	O
simultaneous	O
examination	O
of	O
the	O
multiple	O
deafness	B-DISEASE
mutations	O
by	O
Invader	O
assay	O
followed	O
by	O
direct	O
sequencing	O
if	O
necessary	O
,	O
will	O
enable	O
us	O
to	O
detect	O
deafness	B-DISEASE
mutations	O
in	O
an	O
efficient	O
and	O
practical	O
manner	O
for	O
clinical	O
use	O
.	O

Boxes	O
are	O
showed	O
in	O
red	O
when	O
mean	O
DOC	O
in	O
the	O
region	O
is	O
lower	O
than	O
409	O
.	O

CI	O
and	O
Complex	O
IV	O
(	O
CIV	O
)	O
dipstick	O
activity	O
assays	O
were	O
performed	O
on	O
10	O
mu	O
g	O
and	O
15	O
mu	O
g	O
,	O
respectively	O
,	O
of	O
cleared	O
cell	O
lysates	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Mitosciences	B-Chemical
)	O
.	O

We	O
found	O
a	O
44	O
Mb	O
interval	O
on	O
chromosome	O
11	O
that	O
included	O
the	O
MYO7A	B-GENE
gene	O
,	O
underlying	O
USH1B	B-GENE
[	O
6	O
]	O
.	O

A	O
single	O
-	O
strand	O
,	O
conformation	O
,	O
polymorphism	O
analysis	O
and	O
a	O
16	O
%	O
denaturing	O
polyacrylamide	O
gel	O
electrophorese	O
analysis	O
.	O

The	O
SIFT	O
program	O
predicted	O
that	O
the	O
missense	O
variant	O
p	B-VARIANT
.	I-VARIANT
Thr153Ala	I-VARIANT
in	O
RPE65	B-GENE
would	O
be	O
tolerated	O
(	O
SIFT	O
score	O
>	O
0	O
.	O
05	O
)	O
.	O

This	O
study	O
represents	O
a	O
first	O
step	O
towards	O
the	O
treatment	O
for	O
two	O
thirds	O
of	O
our	O
patients	O
by	O
identifying	O
the	O
genetic	O
cause	O
of	O
their	O
disease	O
,	O
giving	O
them	O
the	O
potential	O
participate	O
in	O
developing	O
genetic	O
therapy	O
techniques	O
.	O

Northern	O
Blotting	O
for	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Asn	I-GENE
levels	O
was	O
performed	O
3x	O
for	O
RNA	O
from	O
I	O
.	O
2	O
.	O

In	O
the	O
hair	O
cells	O
of	O
the	O
inner	O
ear	O
,	O
myosin	B-GENE
VIIA	I-GENE
and	O
the	O
other	O
four	O
USH1	O
-	O
related	O
proteins	O
(	O
harmonin	O
encoded	O
by	O
USH1C	B-GENE
,	O
Sans	O
encoded	O
by	O
USH1G	B-GENE
,	O
CDH23	B-GENE
encoded	O
by	O
USH1D	B-GENE
,	O
PCDH15	B-GENE
encoded	O
by	O
USH1F	B-GENE
)	O
participate	O
in	O
the	O
formation	O
of	O
the	O
mechanotransduction	O
complex	O
[	O
22	O
]	O
,	O
which	O
is	O
critical	O
for	O
detecting	O
sound	O
.	O

Therefore	O
pathogenic	O
germline	O
variants	O
would	O
most	O
likely	O
be	O
under	O
-	O
represented	O
in	O
this	O
cohort	O
,	O
which	O
would	O
increase	O
our	O
ability	O
to	O
identify	O
pathogenic	O
variants	O
in	O
TCGA	O
OV	O
cancer	O
cases	O
.	O

G	O
.	O

Fagang	B-Chemical
Jiang	I-Chemical
and	O
Dr	O
.	O

The	O
MAF	O
of	O
UV1	B-Chemical
in	O
control	O
chromosomes	O
was	O
either	O
<	O
0	O
.	O
236	O
%	O
or	O
was	O
not	O
assessed	O
.	O

It	O
is	O
therefore	O
unlikely	O
that	O
heterozygous	O
SLC11A2	B-GENE
mutations	O
cause	O
ADNSHL	B-DISEASE
.	O

Consistent	O
with	O
its	O
playing	O
a	O
major	O
role	O
in	O
ANSD	B-DISEASE
,	O
we	O
have	O
identified	O
10	O
other	O
mutations	O
in	O
AIFM1	B-GENE
in	O
a	O
cohort	O
of	O
familial	O
and	O
sporadic	O
cases	O
of	O
ANSD	B-DISEASE
of	O
Chinese	O
ethnicity	O
.	O

For	O
these	O
patients	O
,	O
we	O
first	O
applied	O
the	O
Invader	O
assay	O
for	O
screening	O
47	O
known	O
mutations	O
of	O
13	O
known	O
deafness	B-DISEASE
genes	O
,	O
followed	O
by	O
direct	O
sequencing	O
as	O
necessary	O
.	O

However	O
,	O
when	O
incubated	O
with	O
polymerized	O
F	O
-	O
actin	O
(	O
lanes	O
3	O
and	O
4	O
)	O
,	O
TF	O
-	O
ELMOD3	B-GENE
was	O
present	O
both	O
in	O
the	O
supernatant	O
(	O
lane	O
3	O
)	O
and	O
pellet	O
fractions	O
(	O
lane	O
4	O
)	O
,	O
further	O
confirming	O
the	O
association	O
of	O
ELMOD3	B-GENE
with	O
F	O
-	O
actin	O
.	O

The	O
two	O
treatment	O
regimens	O
were	O
equally	O
efficacious	O
.	O

A	O
:	O
G25	O
in	O
the	O
wild	O
-	O
type	O
protein	O
has	O
no	O
side	O
chain	O
to	O
interact	O
with	O
the	O
His9	O
and	O
Met59	O
.	O

On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	O
achieved	O
at	O
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O

Since	O
she	O
had	O
no	O
blood	B-DISEASE
pressure	I-DISEASE
elevation	O
at	O
initial	O
diagnosis	O
and	O
none	O
following	O
discontinuation	O
of	O
the	O
Imipramine	B-Chemical
(	O
when	O
she	O
was	O
in	O
florid	O
relapse	O
)	O
,	O
we	O
believe	O
that	O
this	O
drug	O
rather	O
than	O
her	O
underlying	O
disease	O
alone	O
caused	O
her	O
hypertension	B-DISEASE
.	O

The	O
patients	O
were	O
clinically	O
examined	O
,	O
and	O
reversal	O
of	O
HH	B-DISEASE
was	O
assessed	O
after	O
treatment	O
withdrawal	O
.	O

Two	O
studies	O
evaluated	O
quetiapine	B-Chemical
monotherapy	O
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
(	O
n	O
=	O
209	O
)	O
versus	O
placebo	O
(	O
n	O
=	O
198	O
)	O
,	O
with	O
lithium	B-Chemical
or	O
haloperidol	B-Chemical
monotherapy	O
as	O
respective	O
active	O
controls	O
.	O

Treatments	O
have	O
included	O
discontinuation	O
or	O
reduction	O
of	O
cyclosporine	B-Chemical
dose	O
with	O
or	O
without	O
concurrent	O
plasma	O
exchange	O
,	O
plasma	O
infusion	O
,	O
anticoagulation	O
,	O
and	O
intravenous	O
immunoglobulin	O
G	O
infusion	O
.	O

Side	O
effects	O
were	O
reported	O
in	O
21	O
%	O
of	O
patients	O
and	O
caused	O
withdrawal	O
from	O
the	O
study	O
in	O
3	O
patients	O
.	O

Ninety	O
-	O
two	O
35delG	B-VARIANT
heterozygotes	O
and	O
2	O
35delG	B-VARIANT
homozygotes	O
were	O
identified	O
,	O
resulting	O
in	O
a	O
carrier	O
frequency	O
of	O
1	O
/	O
66	O
(	O
1	O
.	O
53	O
%	O
)	O
for	O
35delG	B-VARIANT
.	O

JZ	O
built	O
up	O
the	O
three	O
-	O
dimensional	O
structural	O
model	O
of	O
TBX1	B-GENE
and	O
provided	O
Figure	O
4	O
.	O

One	O
patient	O
had	O
complete	O
response	O
,	O
seven	O
had	O
stable	O
disease	O
,	O
none	O
had	O
partial	O
response	O
and	O
five	O
had	O
progressive	O
disease	O
.	O

Mazindol	B-Chemical
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	O
in	O
the	O
study	O
.	O

We	O
defined	O
the	O
homozygous	O
mutation	O
of	O
TMPRSS3	B-GENE
:	O
c	B-VARIANT
.	I-VARIANT
535G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
as	O
the	O
genetic	O
etiology	O
for	O
two	O
brothers	O
.	O

A	O
non	O
-	O
consanguineous	O
three	O
-	O
generation	O
white	O
Brazilian	O
family	O
of	O
European	O
ancestry	O
(	O
14	O
individuals	O
)	O
with	O
Hirschsprung	O
phenotype	O
was	O
included	O
in	O
this	O
study	O
.	O

Bladder	O
afferent	O
cells	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
labeled	O
by	O
Fluorogold	O
(	O
40	O
microliters	O
)	O
injected	O
into	O
the	O
bladder	O
wall	O
did	O
not	O
exhibit	O
NOS	O
-	O
IR	O
in	O
control	O
animals	O
;	O
however	O
,	O
following	O
chronic	O
CYP	B-Chemical
administration	O
,	O
a	O
significant	O
percentage	O
of	O
bladder	O
afferent	O
neurons	O
were	O
NOS	O
-	O
IR	O
:	O
L6	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
6	O
%	O
)	O
and	O
S1	O
(	O
25	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
9	O
%	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
in	O
Itoh	B-Chemical
H	O
.	O

A	O
polygonal	O
area	O
outlined	O
in	O
yellow	O
is	O
the	O
area	O
shown	O
in	O
Figure	O
6	O
(	O
a	O
)	O
.	O

It	O
has	O
also	O
been	O
known	O
that	O
prevalent	O
GJB2	B-GENE
mutations	O
are	O
highly	O
ethnic	O
-	O
specific	O
(	O
see	O
The	O
connexin	O
-	O
deafness	B-DISEASE
homepage	O
;	O
http	O
:	O
/	O
/	O
davinci	B-Chemical
.	O
crg	O
.	O
es	O
/	O
deafness	O
/	O
)	O
:	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
is	O
common	O
in	O
the	O
Caucasoid	O
population	O
,	O
c	B-VARIANT
.	I-VARIANT
167delT	I-VARIANT
was	O
reported	O
as	O
prevalent	O
in	O
Ashkenazi	O
Jews	O
,	O
p	B-VARIANT
.	I-VARIANT
R143W	I-VARIANT
in	O
a	O
restricted	O
village	O
in	O
Africa	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
in	O
East	O
Asian	O
populations	O
.	O

STR	O
(	O
Short	O
Tandem	O
Repeats	O
;	O
ABI	O
Prism	O
Linkage	O
Mapping	O
Set	O
v2	O
.	O
5	O
,	O
Applied	O
Biosystems	O
Foster	O
City	O
,	O
CA	O
)	O
markers	O
spaced	O
at	O
approximately	O
10	O
cM	O
and	O
also	O
covering	O
the	O
X	O
-	O
chromosome	O
were	O
used	O
for	O
linkage	O
analysis	O
.	O

Acetazolamide	B-Chemical
-	O
induced	O
Gerstmann	B-DISEASE
syndrome	I-DISEASE
.	O

None	O
of	O
the	O
other	O
patients	O
in	O
Branch	O
B	O
had	O
self	O
-	O
reported	O
goiter	B-DISEASE
either	O
,	O
consistent	O
with	O
the	O
rarity	O
of	O
Pendred	B-DISEASE
syndrome	I-DISEASE
among	O
Chinese	O
patients	O
.	O

Pediatric	O
heart	O
transplantation	O
without	O
chronic	O
maintenance	O
steroids	B-Chemical
.	O

In	O
approximately	O
80	O
%	O
of	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
and	O
PS	B-DISEASE
,	O
the	O
mutation	O
is	O
located	O
in	O
the	O
exon	O
8	O
and	O
10	O
of	O
FGFR2	B-GENE
,	O
which	O
encode	O
the	O
third	O
immunoglobulin	O
-	O
like	O
domain	O
of	O
the	O
protein	O
(	O
IgIII	O
)	O
,	O
but	O
mutations	O
in	O
different	O
exxons	O
have	O
also	O
been	O
identified	O
(	O
13	O
,	O
14	O
,	O
22	O
)	O
.	O

We	O
have	O
used	O
ionizing	O
radiation	O
to	O
develop	O
such	O
a	O
control	O
.	O

Similar	O
experiments	O
were	O
conducted	O
in	O
BALB	O
/	O
c	O
mice	O
treated	O
with	O
PJ34	B-Chemical
or	O
vehicle	O
.	O

Identical	O
findings	O
were	O
obtained	O
when	O
cells	O
were	O
transfected	O
with	O
plasmids	O
encoding	O
the	O
opposite	O
combination	O
of	O
fluorescent	O
marker	O
proteins	O
(	O
colour	O
swap	O
)	O
(	O
Fig	O
3C	O
)	O
.	O

'	O
symbol	O
before	O
the	O
number	O
and	O
uses	O
the	O
A	O
of	O
the	O
ATG	O
translation	O
initiation	O
start	O
site	O
as	O
nucleotide	O
1	O
.	O

The	O
pedigree	O
of	O
family	O
GD	O
-	O
O031	O
,	O
which	O
spanning	O
three	O
generations	O
and	O
comprising	O
21	O
members	O
,	O
is	O
consistent	O
with	O
an	O
autosomal	O
dominant	O
inheritance	O
pattern	O
(	O
DFNA	O
)	O
.	O

His	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
test	O
showed	O
response	O
threshold	O
values	O
more	O
than	O
85	O
dBnHL	O
bilaterally	O
.	O

For	O
PCR	O
-	O
based	O
expression	O
analyses	O
,	O
we	O
used	O
cDNA	O
panels	O
(	O
Clontech	O
)	O
produced	O
from	O
tissues	O
obtained	O
from	O
19	O
to	O
69	O
year	O
old	O
human	O
and	O
from	O
8	O
to	O
12	O
weeks	O
old	O
mice	O
.	O

This	O
variant	O
is	O
not	O
known	O
as	O
a	O
polymorphism	O
.	O

Mice	O
lacking	O
mPGES	B-GENE
-	I-GENE
1	I-GENE
are	O
resistant	O
to	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-DISEASE
.	O

Deaths	O
from	O
local	O
anesthetic	O
-	O
induced	O
convulsions	B-DISEASE
in	O
mice	O
.	O

High	O
dose	O
dexmedetomidine	B-Chemical
as	O
the	O
sole	O
sedative	O
for	O
pediatric	O
MRI	O
.	O

Overall	O
,	O
the	O
results	O
of	O
the	O
percentage	O
of	O
target	O
coverage	O
at	O
10	O
x	O
were	O
fairly	O
homogeneous	O
among	O
samples	O
(	O
ranging	O
from	O
83	O
.	O
5	O
to	O
88	O
.	O
7	O
%	O
)	O
.	O

Compared	O
with	O
matching	O
scores	O
of	O
the	O
other	O
family	O
members	O
,	O
the	O
speech	O
recognition	O
score	O
of	O
individual	O
C4	O
was	O
observed	O
at	O
a	O
younger	O
age	O
and	O
a	O
higher	O
PTA	O
1	O
,	O
2	O
,	O
4	O
kHz	O
level	O
(	O
Fig	O
.	O

The	O
first	O
ophthalmological	O
symptoms	O
were	O
detected	O
at	O
the	O
age	O
of	O
8	O
years	O
old	O
as	O
night	O
blindness	B-DISEASE
and	O
tunnel	O
vision	O
.	O

High	O
doses	O
of	O
atropine	B-Chemical
(	O
up	O
to	O
50	O
mg	O
per	O
24	O
hours	O
)	O
,	O
adrenaline	B-Chemical
and	O
dopamine	B-Chemical
were	O
necessary	O
.	O

The	O
interpeduncular	O
nucleus	O
regulates	O
nicotine	B-Chemical
'	O
s	O
effects	O
on	O
free	O
-	O
field	O
activity	O
.	O

In	O
MYH9	B-GENE
-	O
RD	O
,	O
the	O
actual	O
platelet	O
count	O
can	O
be	O
determined	O
only	O
by	O
microscopic	O
counting	O
because	O
automatic	O
cell	O
counters	O
do	O
not	O
recognize	O
giant	B-DISEASE
platelets	I-DISEASE
and	O
therefore	O
greatly	O
underestimate	O
platelet	O
count	O
(	O
ref	O
.	O

There	O
is	O
no	O
consanguinity	O
in	O
this	O
family	O
.	O

0	O
.	O
1	O
.	O
17	O
)	O
[	O
35	O
]	O
and	O
ANNOVAR	O
[	O
36	O
]	O
,	O
respectively	O
.	O

GBMs	O
are	O
very	O
thick	O
structures	O
(	O
average	O
width	O
:	O
female	O
326	O
nm	O
,	O
male	O
373	O
nm	O
)	O
that	O
play	O
a	O
crucial	O
role	O
in	O
establishing	O
and	O
maintaining	O
an	O
effective	O
and	O
properly	O
functioning	O
glomerular	O
filtration	O
barrier	O
(	O
GFB	O
)	O
[	O
10	O
]	O
.	O

(	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Compression	B-DISEASE
neuropathy	I-DISEASE
of	I-DISEASE
the	O
radial	O
nerve	O
due	O
to	O
pentazocine	B-Chemical
-	O
induced	O
fibrous	B-DISEASE
myopathy	I-DISEASE
.	O

When	O
the	O
family	O
has	O
more	O
than	O
one	O
affected	O
member	O
or	O
there	O
is	O
consanguinity	O
,	O
we	O
haplotype	O
the	O
family	O
to	O
discard	O
or	O
not	O
discard	O
linkage	O
to	O
CLRN1	B-GENE
.	O

Armengot	O
et	O
al	O
.	O

This	O
report	O
is	O
followed	O
by	O
review	O
of	O
the	O
literature	O
.	O

Estradiol	B-Chemical
treatment	O
also	O
increased	O
the	O
arrhythmogenicity	O
of	O
bupivacaine	B-Chemical
in	O
myocyte	O
cultures	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesterone	B-Chemical
.	O

Park	O
)	O
,	O
and	O
by	O
the	O
Seoul	O
National	O
University	O
Bundang	O
Hospital	O
Research	O
Fund	O
04	O
-	O
2010	O
-	O
003	O
(	O
to	O
B	O
.	O
Y	O
.	O

Here	O
,	O
we	O
report	O
two	O
cases	O
of	O
severely	O
immunocompromised	B-DISEASE
HIV	O
-	O
infected	O
patients	O
who	O
developed	O
severe	O
intrahepatic	B-DISEASE
cholestasis	I-DISEASE
,	O
and	O
in	O
one	O
patient	O
lesions	O
mimicking	O
liver	B-DISEASE
abscess	I-DISEASE
formation	O
on	O
radiologic	O
exams	O
,	O
during	O
co	B-Chemical
-	I-Chemical
trimoxazole	I-Chemical
treatment	O
for	O
PCP	B-DISEASE
.	O

The	O
incidence	O
of	O
cardiac	B-DISEASE
abnormalities	I-DISEASE
increased	O
with	O
length	O
of	O
follow	O
-	O
up	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
.	O

(	O
Florence	O
)	O
,	O
Riccardo	O
Lera	O
M	O
.	O
D	O
.	O

Click	O
here	O
for	O
file	O
PRPS1	B-GENE
sequencing	O
by	O
PCR	O
(	O
Sanger	O
sequencing	O
)	O
.	O

A	O
well	O
-	O
rounded	O
approach	O
for	O
STRC	B-GENE
mutation	O
assessment	O
calls	O
for	O
consideration	O
of	O
evolutionary	O
conservation	O
of	O
variants	O
(	O
18	O
)	O
,	O
as	O
well	O
as	O
utilizing	O
audiograms	O
as	O
helpful	O
diagnostic	O
tools	O
,	O
since	O
high	O
-	O
frequency	O
sloping	O
appears	O
a	O
uniting	O
feature	O
of	O
DFNB16	B-DISEASE
.	O

This	O
hypothesis	O
stems	O
from	O
findings	O
that	O
PREGS	B-Chemical
is	O
a	O
potent	O
positive	O
modulator	O
of	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
aspartate	I-Chemical
receptors	O
(	O
NMDARs	O
)	O
and	O
a	O
negative	O
modulator	O
of	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
A	O
)	O
receptors	O
(	O
GABA	B-Chemical
(	O
A	O
)	O
Rs	O
)	O
.	O

A	O
rare	O
case	O
of	O
morbid	B-DISEASE
vasospasm	B-DISEASE
,	O
together	O
with	O
striking	O
angiographic	O
findings	O
,	O
is	O
described	O
secondary	O
to	O
the	O
ingestion	O
of	O
methysergide	B-Chemical
by	O
a	O
48	O
-	O
year	O
-	O
old	O
woman	O
.	O

Exome	O
sequencing	O
was	O
performed	O
in	O
two	O
cases	O
by	O
PerkinElmer	B-Chemical
(	O
Branford	B-Chemical
,	O
Connecticut	O
,	O
USA	O
)	O
and	O
in	O
a	O
third	O
case	O
by	O
the	O
Institute	O
for	O
Molecular	O
Biology	O
at	O
the	O
University	O
of	O
Queensland	O
.	O

The	O
main	O
toxic	O
effect	O
was	O
myelosuppression	B-DISEASE
,	O
with	O
Grade	O
3	O
and	O
4	O
neutropenia	B-DISEASE
in	O
16	O
patients	O
,	O
anemia	B-DISEASE
in	O
12	O
patients	O
,	O
thrombocytopenia	B-DISEASE
in	O
11	O
patients	O
,	O
and	O
neutropenic	B-DISEASE
fever	I-DISEASE
in	O
3	O
patients	O
.	O

Sperm	O
analysis	O
of	O
subject	O
#	O
1	O
showed	O
normal	O
sperm	O
count	O
(	O
35	O
x	O
10	O
6	O
/	O
mL	O
)	O
.	O

Nitroprusside	B-Chemical
caused	O
significant	O
decreases	O
in	O
arterial	O
blood	O
pressure	O
and	O
systemic	O
vascular	O
resistance	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
but	O
did	O
not	O
change	O
cardiac	O
output	O
or	O
QS	O
/	O
QT	O
.	O

Does	O
aspirin	B-Chemical
increase	O
gastrointestinal	O
bleeding	O
or	O
hemorrhagic	B-DISEASE
strokes	O
?	O

In	O
general	O
,	O
it	O
is	O
difficult	O
to	O
demonstrate	O
the	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
early	O
childhood	O
;	O
the	O
observation	O
times	O
for	O
younger	O
patients	O
are	O
shorter	O
and	O
the	O
evaluation	O
is	O
performed	O
using	O
different	O
audiological	O
tests	O
depending	O
on	O
the	O
developmental	O
stages	O
.	O

At	O
the	O
time	O
of	O
evaluation	O
all	O
but	O
one	O
patient	O
(	O
Subject	O
10	O
)	O
complained	O
of	O
difficulty	O
in	O
understanding	O
speech	O
.	O

The	O
antiinfective	O
group	O
of	O
drugs	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amoxicillin	B-Chemical
-	I-Chemical
clavulanate	I-Chemical
accounting	O
for	O
the	O
12	O
.	O
8	O
%	O
of	O
the	O
whole	O
series	O
.	O

AL	O
,	O
alobar	O
;	O
CCA	O
,	O
corpus	B-DISEASE
callosum	I-DISEASE
agenesis	I-DISEASE
;	O
CDI	O
,	O
central	B-DISEASE
diabetes	I-DISEASE
insipidus	I-DISEASE
;	O
CLP	O
,	O
cleft	B-DISEASE
lip	I-DISEASE
and	I-DISEASE
palate	I-DISEASE
;	O
DD	O
,	O
developmental	O
delay	O
;	O
F	O
,	O
female	O
;	O
GH	O
,	O
growth	O
hormone	O
;	O
HH	O
,	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
;	O
HPE	B-DISEASE
,	O
holoprosencephaly	B-DISEASE
;	O
ID	O
,	O
intellectual	O
disability	O
;	O
L	O
,	O
lobar	O
;	O
M	O
,	O
male	O
;	O
na	O
,	O
not	O
applicable	O
;	O
nr	O
,	O
not	O
reported	O
;	O
SL	O
,	O
semilobar	O
;	O
TOP	O
,	O
termination	O
of	O
pregnancy	O
;	O
TRH	O
,	O
thyrotropin	O
releasing	O
hormone	O
.	O

This	O
finding	O
corroborates	O
and	O
extends	O
the	O
recent	O
observation	O
from	O
one	O
individual	O
with	O
PRS	B-DISEASE
-	I-DISEASE
I	I-DISEASE
superactivity	I-DISEASE
who	O
showed	O
not	O
only	O
signs	O
of	O
PRS	B-DISEASE
-	I-DISEASE
I	I-DISEASE
superactivity	I-DISEASE
syndrome	O
,	O
but	O
also	O
of	O
Arts	B-DISEASE
syndrome	I-DISEASE
[	O
18	O
]	O
.	O

However	O
,	O
our	O
understanding	O
of	O
HDR	B-DISEASE
syndrome	I-DISEASE
to	O
date	O
is	O
not	O
complete	O
,	O
and	O
future	O
research	O
is	O
needed	O
on	O
this	O
disease	O
.	O

The	O
observed	O
effect	O
of	O
NIMO	B-Chemical
may	O
have	O
been	O
attributable	O
to	O
the	O
preservation	O
of	O
calcium	B-Chemical
homeostasis	O
during	O
hypotension	O
,	O
because	O
there	O
were	O
no	O
differences	O
in	O
the	O
PbtO	B-GENE
(	O
2	O
)	O
indices	O
among	O
groups	O
.	O

For	O
this	O
purpose	O
,	O
bile	B-Chemical
salt	I-Chemical
pool	O
composition	O
,	O
synthesis	O
of	O
individual	O
BS	B-Chemical
in	O
vivo	O
,	O
hepatic	O
activities	O
,	O
and	O
expression	O
levels	O
of	O
cholesterol	B-Chemical
7alpha	O
-	O
hydroxylase	O
(	O
CYP7A	B-GENE
)	O
,	O
and	O
sterol	B-Chemical
27	O
-	O
hydroxylase	O
(	O
CYP27	B-GENE
)	O
,	O
as	O
well	O
as	O
of	O
other	O
enzymes	O
involved	O
in	O
BS	B-Chemical
synthesis	O
,	O
were	O
analyzed	O
in	O
rats	O
treated	O
with	O
EE	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
,	O
3	O
days	O
)	O
or	O
its	O
vehicle	O
.	O

(	O
A	O
)	O
Filled	O
symbols	O
in	O
each	O
pedigree	O
represent	O
affected	O
individuals	O
.	O

The	O
OS	O
shows	O
an	O
atrophic	B-DISEASE
maculopathy	I-DISEASE
sparing	O
the	O
inferior	O
half	O
of	O
fovea	O
.	O

10	O
-	O
12	O
However	O
,	O
a	O
well	O
-	O
known	O
caveat	O
of	O
MPS	O
is	O
the	O
high	O
rate	O
of	O
sequencing	O
errors	O
,	O
which	O
cannot	O
be	O
disregarded	O
when	O
identifying	O
low	O
-	O
level	O
somatic	O
mosaicism	O
.	O

D	O
:	O
Visual	O
field	O
test	O
results	O
obtained	O
on	O
the	O
right	O
(	O
RE	O
)	O
and	O
the	O
left	O
(	O
LE	O
)	O
eye	O
of	O
patient	O
MB9	B-Chemical
at	O
the	O
age	O
of	O
40	O
years	O
are	O
shown	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	B-DISEASE
upon	O
Dex	B-Chemical
administration	O
.	O

The	O
average	O
hearing	O
level	O
was	O
90	O
.	O
1	O
+	O
-	O
12	O
.	O
3	O
(	O
SD	O
)	O
dB	O
.	O

Homozygosity	O
for	O
35delG	B-VARIANT
was	O
found	O
in	O
33	O
.	O
3	O
%	O
(	O
10	O
/	O
30	O
)	O
of	O
the	O
genotyped	O
unrelated	O
deaf	O
patients	O
,	O
50	O
%	O
were	O
carrying	O
this	O
deletion	O
in	O
a	O
compound	O
heterozygous	O
state	O
and	O
16	O
.	O
7	O
%	O
had	O
other	O
mutations	O
.	O

2	O
,	O
a	O
diagnosis	O
of	O
LCPD	B-DISEASE
was	O
made	O
in	O
member	O
III	O
-	O
6	O
and	O
III	O
-	O
7	O
,	O
and	O
of	O
ANFH	B-DISEASE
in	O
members	O
IV	O
-	O
7	O
and	O
IV	O
-	O
8	O
(	O
Table	O
1	O
)	O
.	O

Commonly	O
used	O
methods	O
in	O
previous	O
studies	O
are	O
either	O
array	O
-	O
based	O
or	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
based	O
methods	O
.	O

This	O
analysis	O
revealed	O
that	O
p	O
.	O
Thr300	O
and	O
p	O
.	O
Glu638	O
correspond	O
to	O
the	O
consensus	O
amino	O
acid	O
for	O
both	O
the	O
human	O
-	O
based	O
and	O
E	O
.	O

The	O
OPA1	B-GENE
gene	O
encodes	O
a	O
dynamin	O
-	O
related	O
GTPase	O
that	O
plays	O
an	O
important	O
role	O
in	O
mitochondrial	O
fusion	O
processes	O
,	O
stabilization	O
of	O
cristae	O
,	O
and	O
cytochrome	O
c	O
sequestration	O
[	O
3	O
,	O
4	O
]	O
.	O

However	O
,	O
half	O
of	O
the	O
patients	O
included	O
in	O
this	O
study	O
demonstrated	O
various	O
degrees	O
of	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
also	O
sudden	O
aggravation	O
of	O
hearing	O
was	O
demonstrated	O
in	O
one	O
patient	O
.	O

Focal	O
injury	O
in	O
the	O
cortex	O
was	O
produced	O
by	O
infusion	O
of	O
lactate	B-Chemical
at	O
acid	O
pH	O
or	O
by	O
stab	O
caused	O
by	O
needle	O
insertion	O
.	O

All	O
novel	O
pathogenic	O
missense	O
variants	O
and	O
the	O
previously	O
described	O
variant	O
p	B-VARIANT
.	I-VARIANT
Arg4192His	I-VARIANT
in	O
USH2A	B-GENE
were	O
tested	O
in	O
a	O
healthy	O
Spanish	O
control	O
population	O
.	O

Additionally	O
,	O
12	O
QTc	O
measurements	O
of	O
index	O
cases	O
were	O
obtained	O
from	O
referring	O
clinicians	O
.	O

(	O
g	O
-	O
h	O
)	O
CT	O
scans	O
from	O
a	O
normal	O
hearing	O
individual	O
to	O
provide	O
a	O
comparison	O
of	O
the	O
dysmorphic	O
internal	O
auditory	O
canals	O
seen	O
in	O
the	O
affected	O
individual	O
(	O
g	O
)	O
.	O

Recruitment	O
was	O
revealed	O
in	O
the	O
subjects	O
by	O
the	O
lower	O
dynamic	O
range	O
between	O
hearing	O
and	O
stapedial	O
acoustic	O
reflex	O
thresholds	O
,	O
which	O
indicated	O
that	O
the	O
lesions	O
were	O
in	O
cochlea	O
.	O

Detailed	O
genotype	O
and	O
phenotype	O
analyses	O
were	O
performed	O
to	O
provide	O
effective	O
risk	O
assessment	O
and	O
genetic	O
counseling	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
patients	O
and	O
their	O
families	O
in	O
this	O
area	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	B-GENE
plays	O
in	O
chlorpromazine	B-Chemical
-	I-DISEASE
induced	O
EPS	B-DISEASE
in	O
schizophrenic	B-DISEASE
patients	O
.	O

(	O
C	O
)	O
Electropherograms	O
showing	O
the	O
wild	O
type	O
,	O
homozygous	O
and	O
heterozygous	O
forms	O
of	O
the	O
variant	O
p	B-VARIANT
.	I-VARIANT
T443M	I-VARIANT
in	O
ZNF57	B-GENE
.	O

Overall	O
expression	O
levels	O
were	O
visualized	O
from	O
the	O
PNGase	B-Chemical
-	O
treated	O
samples	O
,	O
and	O
receptor	O
maturation	O
patterns	O
from	O
the	O
EndoH	O
f	O
-	O
treated	O
samples	O
.	O

The	O
best	O
example	O
is	O
reversible	B-DISEASE
infantile	I-DISEASE
respiratory	I-DISEASE
chain	I-DISEASE
deficiency	I-DISEASE
(	O
RIRCD	B-DISEASE
)	O
due	O
to	O
a	O
homoplasmic	O
mutation	O
in	O
the	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Glu	I-GENE
.	O

We	O
identified	O
the	O
CERKL	B-GENE
founder	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
13	O
of	O
the	O
YJ	O
families	O
.	O

2	O
)	O
.	O

Ethambutol	B-Chemical
-	O
associated	O
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

The	O
origin	O
of	O
the	O
founder	O
Roma	O
population	O
is	O
considered	O
to	O
be	O
in	O
Northwest	O
India	O
[	O
12	O
]	O
.	O

The	O
SNV	O
was	O
not	O
present	O
in	O
Exome	O
Variant	O
Server	O
nor	O
1000	O
Genomes	O
,	O
altered	O
a	O
residue	O
conserved	O
to	O
bacteria	O
within	O
a	O
predicted	O
NAD	O
-	O
binding	O
domain	O
,	O
and	O
is	O
predicted	O
to	O
be	O
"	O
probably	O
damaging	O
"	O
by	O
PolyPhen2	O
.	O

For	O
example	O
,	O
patients	O
in	O
families	O
B	O
and	O
E	O
have	O
the	O
p	B-VARIANT
.	I-VARIANT
Thr70fs	I-VARIANT
mutation	O
in	O
common	O
(	O
Table	O
1	O
)	O
;	O
therefore	O
,	O
a	O
comparison	O
of	O
the	O
phenotypic	O
effect	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
Ala306Thr	I-VARIANT
mutation	O
in	O
family	O
B	O
and	O
the	O
p	B-VARIANT
.	I-VARIANT
Ala426Thr	I-VARIANT
mutation	O
in	O
family	O
E	O
is	O
possible	O
.	O

(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
(	O
10	O
-	O
40	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
was	O
able	O
to	O
prevent	O
amnesia	O
induced	O
by	O
scopolamine	B-Chemical
(	O
1	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
and	O
dicyclomine	B-Chemical
(	O
2	O
mg	O
kg	O
-	O
1	O
i	O
.	O
p	O
.	O
)	O
in	O
the	O
mouse	O
passive	O
-	O
avoidance	O
test	O
.	O

Etodolac	B-Chemical
contents	O
were	O
evaluated	O
by	O
UV	O
-	O
spectrophotometric	O
analysis	O
.	O

Patients	O
IV	O
-	O
4	O
,	O
IV	O
-	O
5	O
,	O
IV	O
-	O
8	O
,	O
IV	O
-	O
9	O
,	O
V	O
-	O
1	O
,	O
and	O
V	O
-	O
2	O
were	O
homozygous	O
for	O
this	O
variant	O
.	O

2011	O
;	O
Bonnet	O
and	O
El	O
-	O
Amraoui	I-Chemical
2012	O
;	O
Puffenberger	O
et	O
al	O
.	O

Left	O
ventricular	O
filling	O
pressure	O
decreased	O
from	O
19	O
+	O
/	O
-	O
2	O
to	O
11	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

CaCl2	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
aminopyridine	I-Chemical
.	O

Disclosure	O
The	O
authors	O
of	O
this	O
manuscript	O
declare	O
no	O
financial	O
conflicts	O
of	O
interest	O
.	O

Within	O
this	O
context	O
,	O
the	O
RD	B-DISEASE
-	O
chip	O
efficiency	O
ranges	O
from	O
16	O
%	O
in	O
dominant	O
to	O
80	O
%	O
in	O
consanguineous	O
recessive	O
pedigrees	O
,	O
with	O
an	O
average	O
of	O
47	O
%	O
,	O
well	O
within	O
the	O
upper	O
range	O
of	O
the	O
NGS	O
approaches	O
.	O

This	O
model	O
has	O
the	O
unique	O
advantage	O
of	O
identifying	O
patients	O
with	O
EVA	B-DISEASE
in	O
an	O
epidemiologic	O
study	O
in	O
large	O
-	O
scale	O
deaf	B-DISEASE
populations	O
.	O

In	O
contrast	O
to	O
controls	O
,	O
methoctramine	B-Chemical
increased	O
-	O
-	O
instead	O
of	O
decreased	O
-	O
-	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O

WS4	B-DISEASE
is	O
rare	O
,	O
with	O
an	O
incidence	O
of	O
~	O
1	O
/	O
40	O
,	O
000	O
-	O
1	O
/	O
50	O
,	O
000	O
live	O
-	O
births	O
,	O
and	O
occurs	O
in	O
all	O
races	O
.	O

The	O
incidence	O
of	O
postoperative	O
respiratory	B-DISEASE
apnoea	I-DISEASE
was	O
compared	O
between	O
five	O
patients	O
receiving	O
a	O
continuous	O
i	O
.	O
v	O
.	O
infusion	O
of	O
morphine	B-Chemical
(	O
mean	O
73	O
.	O
6	O
mg	O
)	O
and	O
five	O
patients	O
receiving	O
a	O
continuous	O
extradural	O
infusion	O
of	O
0	O
.	O
25	O
%	O
bupivacaine	B-Chemical
(	O
mean	O
192	O
mg	O
)	O
in	O
the	O
24	O
-	O
h	O
period	O
following	O
upper	O
abdominal	O
surgery	O
.	O

After	O
the	O
end	O
of	O
the	O
treatment	O
,	O
the	O
number	O
and	O
the	O
size	O
of	O
induced	O
PAS	O
positive	O
preneoplastic	O
foci	O
was	O
significantly	O
reduced	O
when	O
PB	B-Chemical
was	O
given	O
simultaneously	O
with	O
DEN	B-Chemical
for	O
4	O
and	O
6	O
weeks	O
.	O

And	O
likewise	O
,	O
bone	O
conduction	O
results	O
are	O
displayed	O
on	O
audiogram	O
using	O
blue	O
"	O
greater	O
than	O
"	O
angle	O
brackets	O
"	O
>	O
"	O
for	O
left	O
ear	O
and	O
red	O
"	O
less	O
than	O
"	O
angle	O
brackets	O
"	O
<	O
"	O
for	O
right	O
ear	O
.	O

In	O
cases	O
where	O
mutations	O
were	O
detected	O
,	O
we	O
performed	O
segregation	O
analysis	O
.	O

The	O
mean	O
+	O
-	O
standard	O
deviation	O
(	O
SD	O
)	O
levels	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
at	O
250	O
,	O
500	O
,	O
1000	O
,	O
2000	O
,	O
4000	O
,	O
and	O
8000	O
Hz	O
from	O
three	O
older	O
subjects	O
were	O
described	O
(	O
Table	O
1	O
)	O
.	O

Analyzed	O
the	O
data	O
:	O
XG	O
LPG	O
QYZ	O
JW	O
YYY	I-Chemical
.	O

Progressive	O
bile	O
duct	O
injury	O
after	O
thiabendazole	B-Chemical
administration	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Hiromi	O
Kojima	O
,	O
Yuika	O
Sakurai	O
and	O
Hiroshi	O
Moriyama	O
(	O
Jikei	O
University	O
)	O
,	O
Dr	O
.	O

Our	O
result	O
is	O
consistent	O
with	O
the	O
findings	O
of	O
Seyedahmadi	O
et	O
al	O
.	O

Cross	O
-	O
sectional	O
echocardiography	O
was	O
used	O
to	O
evaluate	O
two	O
neonates	O
whose	O
mothers	O
ingested	O
lithium	B-Chemical
during	O
pregnancy	O
.	O

The	O
DLT	O
correlated	O
with	O
serum	O
levels	O
>	O
or	O
=	O
10	O
mumol	O
/	O
L	O
.	O

All	O
five	O
common	O
LQTS	B-DISEASE
genes	O
were	O
analysed	O
regardless	O
of	O
whether	O
a	O
mutation	O
had	O
been	O
identified	O
in	O
one	O
of	O
the	O
genes	O
.	O

In	O
this	O
respect	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
DA	B-Chemical
receptors	O
in	O
the	O
occurrence	O
of	O
epilepsy	B-DISEASE
-	O
induced	O
neuronal	B-DISEASE
cell	I-DISEASE
death	I-DISEASE
.	O

None	O
of	O
the	O
5	O
probands	O
had	O
white	B-DISEASE
forelock	I-DISEASE
and	O
skin	B-DISEASE
hypopigmentation	I-DISEASE
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
WZ	O
PW	O
.	O

Neuroleptic	B-DISEASE
-	O
induced	O
catalepsy	B-DISEASE
,	O
a	O
model	O
of	O
neuroleptic	O
-	O
induced	O
extrapyramidal	B-DISEASE
side	O
effects	O
,	O
was	O
considered	O
suitable	O
as	O
a	O
model	O
for	O
predicting	O
neuroleptic	B-DISEASE
-	O
induced	O
akathisia	B-DISEASE
in	O
humans	O
,	O
although	O
neuroleptic	B-DISEASE
-	O
induced	O
catalepsy	B-DISEASE
was	O
not	O
considered	O
a	O
specific	O
test	O
for	O
neuroleptic	O
-	O
induced	O
akathisia	O
.	O

Sanger	O
sequencing	O
confirmed	O
that	O
both	O
siblings	O
inherited	O
a	O
missense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
589G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
p	B-VARIANT
.	I-VARIANT
G197R	I-VARIANT
(	O
maternal	O
allele	O
)	O
,	O
and	O
a	O
nonsense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1171C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
p	B-VARIANT
.	I-VARIANT
Q391X	I-VARIANT
(	O
paternal	O
allele	O
)	O
,	O
in	O
TMC1	B-GENE
.	O

WI	O
,	O
USA	O
)	O
software	O
package	O
,	O
then	O
compared	O
to	O
the	O
reference	O
GenBank	O
sequence	O
(	O
accession	O
number	O
:	O
GJB2	B-GENE
;	O
NM_004004	O
and	O
GJB6	O
;	O
NM_001110219	O
)	O
.	O

The	O
shorter	O
isoform	O
,	O
isoform	O
a	O
,	O
contains	O
five	O
domains	O
,	O
including	O
an	O
N	O
-	O
terminal	O
signal	O
peptide	O
,	O
laminin	O
G	O
-	O
like	O
jellyroll	O
fold	O
,	O
laminin	O
N	O
-	O
terminal	O
,	O
laminin	O
-	O
type	O
EGF	O
-	O
like	O
modules	O
,	O
and	O
fibronectin	O
type	O
III	O
repeats	O
.	O

The	O
co	O
-	O
primary	O
endpoint	O
of	O
being	O
pain	O
free	O
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	B-Chemical
.	O

NS	O
,	O
GS	O
and	O
CV	O
wrote	O
the	O
manuscript	O
.	O

Nelarabine	B-Chemical
neurotoxicity	O
with	O
concurrent	O
intrathecal	O
chemotherapy	O
:	O
Case	O
report	O
and	O
review	O
of	O
literature	O
.	O

Of	O
note	O
,	O
c	B-VARIANT
.	I-VARIANT
3157delT	I-VARIANT
RP1	B-GENE
has	O
been	O
reported	O
as	O
a	O
dominant	O
mutation	O
in	O
an	O
RP1	B-GENE
screening	O
study	O
[	O
30	O
]	O
.	O

Warfarin	B-Chemical
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O

The	O
mechanism	O
of	O
its	O
antidepressant	B-Chemical
activity	O
is	O
still	O
unknown	O
.	O

Table	O
2	O
shows	O
the	O
mutations	O
in	O
CLRN1	B-GENE
found	O
in	O
the	O
Spanish	O
USH	B-DISEASE
population	O
detected	O
in	O
this	O
and	O
previous	O
studies	O
.	O

(	O
G	O
,	O
H	O
,	O
I	O
)	O
Horizontal	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
cross	O
-	O
sections	O
through	O
the	O
fovea	O
in	O
the	O
13	O
yo	O
(	O
panel	O
G	O
)	O
,	O
33	O
yo	O
(	O
H	O
)	O
and	O
72	O
yo	O
(	O
I	O
)	O
USH1C	B-GENE
patients	O
showing	O
progressive	O
loss	O
of	O
retinal	O
and	O
particularly	O
photoreceptor	O
layer	O
thickness	O
with	O
age	O
.	O

The	O
actions	O
of	O
fenoterol	B-Chemical
-	I-Chemical
hydrobromide	I-Chemical
,	O
ritodrin	B-Chemical
-	I-Chemical
HCl	I-Chemical
and	O
placebo	O
given	O
to	O
10	O
healthy	O
subjects	O
by	O
intravenous	O
infusion	O
in	O
a	O
double	O
-	O
blind	O
crossover	O
study	O
were	O
tested	O
by	O
this	O
method	O
.	O

Rebound	O
hypertensive	O
after	O
sodium	B-Chemical
nitroprusside	I-Chemical
prevented	O
by	O
saralasin	B-Chemical
in	O
rats	O
.	O

A	O
mitochondrial	O
m	B-VARIANT
.	I-VARIANT
3243A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
was	O
found	O
in	O
two	O
patients	O
in	O
whom	O
HNF1A	B-GENE
testing	O
had	O
been	O
requested	O
and	O
confirmed	O
a	O
diagnosis	O
of	O
MIDD	B-DISEASE
.	O

Residue	O
170	O
is	O
the	O
first	O
residue	O
of	O
alpha	O
-	O
helix	O
2	O
.	O

Fisher	O
'	O
s	O
exact	O
test	O
was	O
utilized	O
to	O
compare	O
categorical	O
variables	O
between	O
two	O
groups	O
,	O
and	O
two	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
was	O
accepted	O
to	O
indicate	O
statistical	O
significance	O
.	O

We	O
then	O
performed	O
whole	O
exome	O
capture	O
sequencing	O
for	O
two	O
affected	O
individuals	O
(	O
family	O
members	O
III	O
-	O
1	O
and	O
III	O
-	O
2	O
)	O
to	O
identify	O
the	O
disease	O
causing	O
gene	O
in	O
this	O
family	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
8375	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
substitution	O
occurs	O
in	O
exon	O
47	O
of	O
MYO15A	B-GENE
and	O
results	O
in	O
a	O
single	O
amino	O
acid	O
substitution	O
,	O
valine	B-Chemical
to	O
alanine	B-Chemical
(	O
p	B-VARIANT
.	I-VARIANT
V2792A	I-VARIANT
)	O
,	O
within	O
the	O
FERMa	O
domain	O
.	O

Rosaceiform	B-DISEASE
dermatitis	I-DISEASE
associated	O
with	O
topical	O
tacrolimus	B-Chemical
treatment	O
.	O

Images	O
from	O
right	O
eyes	O
(	O
(	O
a	O
)	O
and	O
(	O
c	O
)	O
)	O
and	O
left	O
eyes	O
(	O
(	O
b	O
)	O
and	O
(	O
d	O
)	O
)	O
are	O
shown	O
.	O

In	O
the	O
EVS	O
,	O
however	O
,	O
no	O
homozygous	O
occurrence	O
of	O
the	O
mutated	O
allele	O
has	O
been	O
reported	O
to	O
date	O
(	O
Table	O
S1	O
)	O
.	O

The	O
clinical	O
features	O
associated	O
with	O
this	O
novel	O
mutation	O
in	O
the	O
JSNY	O
-	O
027	O
family	O
lends	O
support	O
to	O
the	O
pathogenic	O
nature	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
G38D	I-VARIANT
variant	O
.	O

Eleven	O
probands	O
and	O
both	O
affected	O
and	O
unaffected	O
relatives	O
in	O
their	O
families	O
were	O
ascertained	O
.	O

Comparison	O
between	O
useful	O
data	O
generated	O
by	O
NGS	O
and	O
Sanger	O
sequencing	O
in	O
Usher	B-DISEASE
test	O
sample	O
.	O

"	O
Thereby	O
,	O
the	O
normalized	O
relative	O
coverage	O
of	O
every	O
target	O
ROI	O
(	O
region	O
of	O
interest	O
)	O
of	O
a	O
patient	O
sample	O
(	O
relative	O
product	O
coverage	O
,	O
RPC	O
P	O
.	O
)	O
was	O
calculated	O
against	O
the	O
normalized	O
average	O
relative	O
target	O
coverage	O
of	O
several	O
control	O
samples	O
(	O
RPC	O
C	O
.	O
)	O
to	O
obtain	O
the	O
ratio	O
relative	O
coverage	O
(	O
ratio	O
RPC	O
)	O
.	O

However	O
,	O
the	O
degree	O
of	O
diagnostic	O
relevance	O
in	O
the	O
referred	O
patients	O
of	O
that	O
study	O
could	O
not	O
be	O
evaluated	O
,	O
also	O
due	O
to	O
lack	O
of	O
phenotypic	O
information	O
.	O

All	O
patients	O
had	O
hypertension	B-DISEASE
with	O
elevated	O
aldosterone	B-Chemical
levels	O
despite	O
suppressed	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
and	O
a	O
pathologic	O
diagnosis	O
of	O
APA	B-DISEASE
(	O
Supplementary	O
Table	O
1	O
)	O
.	O

S3	O
)	O
.	O

Validation	O
of	O
rearrangements	O
of	O
USH2A	B-GENE
and	O
PCDH15	B-GENE
was	O
performed	O
by	O
MLPA	O
analysis	O
.	O

The	O
protocol	O
of	O
this	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Third	O
Xiangya	O
Hospital	O
,	O
Central	O
South	O
University	O
,	O
and	O
all	O
participants	O
signed	O
informed	O
consent	O
.	O

ELMOD3	B-GENE
belongs	O
to	O
the	O
engulfment	O
and	O
cell	O
motility	O
(	O
ELMO	O
)	O
family	O
,	O
which	O
consists	O
of	O
six	O
paralogs	O
in	O
mammals	O
.	O

Here	O
,	O
we	O
report	O
the	O
evaluation	O
of	O
a	O
PCR	O
based	O
enrichment	O
strategy	O
followed	O
by	O
a	O
454	O
NGS	O
approach	O
for	O
5	O
patients	O
using	O
NGS	O
implicated	O
in	O
ARNSHL	B-DISEASE
.	O

Neuroplasticity	O
of	O
the	O
adult	O
primate	O
auditory	O
cortex	O
following	O
cochlear	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

In	O
addition	O
,	O
the	O
normal	O
sister	O
,	O
III	O
-	O
1	O
,	O
has	O
two	O
wild	O
type	O
alleles	O
at	O
this	O
locus	O
(	O
Figure	O
3	O
)	O
.	O

The	O
clinical	O
information	O
of	O
199	O
patients	O
was	O
examined	O
by	O
trained	O
clinicians	O
and	O
none	O
of	O
them	O
had	O
extracardiac	O
anomalies	O
and	O
features	O
suggestive	O
of	O
22q11	O
.	O
2	O
deletion	O
syndrome	O
.	O

and	O
W	O
.	O
B	O
.	O
D	O
.	O

He	O
died	O
in	O
bed	O
at	O
the	O
age	O
of	O
13	O
years	O
.	O

We	O
propose	O
that	O
remoxipride	B-Chemical
and	O
benzene	B-Chemical
may	O
induce	O
aplastic	B-DISEASE
anemia	I-DISEASE
via	O
production	O
of	O
similar	O
reactive	O
metabolites	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	B-Chemical
and	O
NCQ344	B-Chemical
to	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
may	O
contribute	O
to	O
the	O
mechanism	O
underlying	O
acquired	O
aplastic	B-DISEASE
anemia	I-DISEASE
that	O
has	O
been	O
associated	O
with	O
remoxipride	B-Chemical
.	O

[	O
30	O
]	O
suggested	O
that	O
it	O
is	O
unlikely	O
that	O
this	O
variant	O
plays	O
a	O
pathogenic	O
role	O
in	O
deafness	B-DISEASE
.	O

Twenty	O
-	O
eight	O
patients	O
had	O
EVA	B-DISEASE
and	O
two	O
pathogenic	O
mutant	O
alleles	O
,	O
consistent	O
with	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
biallelic	O
loss	O
of	O
function	O
of	O
pendrin	O
protein	O
.	O

WES	O
was	O
performed	O
on	O
one	O
affected	O
member	O
from	O
each	O
of	O
11	O
unrelated	O
families	O
.	O

Because	O
of	O
these	O
characteristics	O
,	O
it	O
is	O
difficult	O
to	O
diagnose	O
and	O
establish	O
the	O
exact	O
causes	O
of	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
although	O
it	O
accounts	O
for	O
approximately	O
50	O
%	O
of	O
all	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
51	O
]	O
.	O

Tranexamic	B-Chemical
acid	I-Chemical
(	O
TNA	B-Chemical
)	O
1	O
g	O
8	O
-	O
hourly	O
was	O
administered	O
to	O
her	O
to	O
control	O
bleeding	O
per	O
vaginum	O
.	O

Their	O
targeted	O
deletion	O
in	O
mice	O
causes	O
significant	O
dysregulation	O
of	O
Ca	B-Chemical
2	I-Chemical
+	O
re	O
-	O
entry	O
that	O
leads	O
to	O
hearing	O
impairment	O
and	O
vestibular	O
deficits	O
[	O
37	O
]	O
.	O

Hemolysis	O
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	B-Chemical
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

In	O
the	O
subsequent	O
cycle	O
the	O
other	O
treatment	O
was	O
used	O
.	O

Two	O
mutations	O
in	O
LRTOMT	B-GENE
had	O
previously	O
been	O
reported	O
in	O
Tunisian	O
patients	O
,	O
c	B-VARIANT
.	I-VARIANT
242G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R81Q	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
313T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
W105R	I-VARIANT
)	O
.	O

The	O
etiology	O
is	O
located	O
within	O
the	O
cochlea	O
,	O
therefore	O
comparatively	O
better	O
outcomes	O
can	O
be	O
predicted	O
.	O

Campbell	O
et	O
al	O
.	O

In	O
addition	O
,	O
Pb867	B-Chemical
is	O
specific	O
for	O
Gipc3	B-GENE
,	O
showing	O
strong	O
reactivity	O
with	O
human	O
GIPC3	B-GENE
and	O
only	O
faint	O
cross	O
reactivity	O
with	O
mouse	O
Gipc1	B-GENE
and	O
Gipc2	B-GENE
(	O
Supplementary	O
Fig	O
.	O

In	O
some	O
cases	O
,	O
goiter	B-DISEASE
is	O
evident	O
during	O
the	O
teen	O
years	O
[	O
12	O
]	O
.	O

These	O
results	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

Desipramine	B-Chemical
-	O
induced	O
sensitization	O
of	O
lidocaine	B-Chemical
seizures	I-DISEASE
may	O
have	O
a	O
mechanism	O
distinct	O
from	O
kindling	O
resulting	O
from	O
repeated	O
administration	O
of	O
cocaine	B-Chemical
.	O

Probands	O
were	O
characterised	O
as	O
having	O
prelingual	O
,	O
bilateral	O
hearing	B-DISEASE
loss	I-DISEASE
that	O
could	O
not	O
be	O
attributed	O
to	O
infection	O
or	O
trauma	O
.	O

Ethnically	O
,	O
the	O
patients	O
consisted	O
of	O
243	O
Han	O
,	O
31	O
Mongolian	O
,	O
7	O
Man	O
,	O
and	O
3	O
Hui	O
Chinese	O
.	O

Blood	O
pressure	O
and	O
heart	O
rate	O
remained	O
stable	O
.	O

The	O
effects	O
of	O
intracoronary	O
administration	O
of	O
methylergonovine	B-Chemical
were	O
studied	O
in	O
21	O
patients	O
with	O
variant	O
angina	B-DISEASE
and	O
22	O
patients	O
with	O
atypical	O
chest	B-DISEASE
pain	I-DISEASE
and	O
in	O
others	O
without	O
angina	B-DISEASE
pectoris	I-DISEASE
(	O
control	O
group	O
)	O
.	O

Samples	O
from	O
15	O
patients	O
were	O
used	O
(	O
14	O
glomerular	O
disease	O
,	O
1	O
glomerular	O
and	O
renal	O
malformation	O
)	O
.	O

To	O
eliminate	O
alignment	O
artefacts	O
due	O
to	O
insertion	O
/	O
deletion	O
positions	O
,	O
the	O
lower	O
strand	O
reads	O
were	O
converted	O
to	O
the	O
reverse	O
complement	O
sequence	O
,	O
i	O
.	O
e	O
.	O

Commercially	O
available	O
genotyping	O
microarrays	O
are	O
based	O
on	O
arrayed	O
primer	O
extension	O
technology	O
(	O
APEX	O
,	O
Asper	O
Ophthalmics	O
,	O
Tartu	O
,	O
Estonia	O
)	O
,	O
which	O
enable	O
the	O
simultaneous	O
screening	O
of	O
multiple	O
genes	O
,	O
but	O
they	O
can	O
detect	O
only	O
a	O
fixed	O
number	O
of	O
known	O
mutations	O
[	O
21	O
]	O
.	O

However	O
,	O
a	O
4	O
.	O
5	O
times	O
higher	O
difference	O
in	O
opposite	O
direction	O
was	O
detected	O
in	O
the	O
carrier	O
rate	O
of	O
the	O
MARVELD2	B-GENE
mutation	O
between	O
control	O
groups	O
of	O
healthy	O
Slovak	O
4	O
.	O
5	O
%	O
(	O
1	O
:	O
23	O
)	O
and	O
Hungarian	O
1	O
%	O
(	O
1	O
:	O
100	O
)	O
Roma	O
individuals	O
.	O

Heterozygous	O
deletion	O
of	O
exon	O
1	O
in	O
the	O
EYS	B-GENE
gene	O
in	O
patient	O
57	O
and	O
his	O
father	O
.	O

Finally	O
,	O
45	O
%	O
of	O
our	O
unsolved	O
patients	O
had	O
single	O
deleterious	O
mutations	O
in	O
ABCA4	B-GENE
,	O
a	O
recessive	O
disease	O
gene	O
.	O

All	O
other	O
probands	O
had	O
prelingual	O
or	O
early	O
-	O
onset	O
,	O
severe	O
-	O
to	O
-	O
profound	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Twenty	O
healthy	O
male	O
volunteers	O
(	O
mean	O
age	O
24	O
years	O
;	O
range	O
18	O
-	O
38	O
years	O
)	O
received	O
intradermal	O
injections	O
of	O
glutamate	B-Chemical
and	O
capsaicin	B-Chemical
in	O
the	O
volar	O
forearm	O
.	O

Daily	O
predicted	O
pollutant	O
concentrations	O
were	O
used	O
to	O
derive	O
surrogates	O
of	O
long	O
-	O
term	O
exposure	O
and	O
link	O
them	O
to	O
study	O
participants	O
'	O
geocoded	O
addresses	O
.	O

2B	O
)	O
,	O
achieving	O
the	O
same	O
reduction	O
of	O
putative	O
causative	O
variants	O
of	O
99	O
.	O
7	O
%	O
(	O
from	O
128	O
,	O
557	O
to	O
359	O
)	O
.	O

Acute	B-DISEASE
hypersensitivity	I-DISEASE
myocarditis	I-DISEASE
was	O
not	O
suspected	O
clinically	O
,	O
and	O
the	O
diagnosis	O
was	O
made	O
post	O
-	O
mortem	O
.	O

Consequently	O
,	O
this	O
might	O
be	O
considered	O
in	O
future	O
experiments	O
for	O
functional	O
evaluation	O
of	O
COL4	O
mutations	O
that	O
could	O
be	O
extended	O
to	O
the	O
final	O
patient	O
prognosis	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
257	I-VARIANT
-	I-VARIANT
262CCTTTC	I-VARIANT
>	I-VARIANT
GCT	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

He	O
had	O
multiple	O
anomalies	O
such	O
as	O
craniofacial	O
,	O
limbs	O
,	O
and	O
sacral	O
anomalies	O
.	O

However	O
,	O
this	O
does	O
not	O
affect	O
the	O
detection	O
of	O
point	O
mutations	O
.	O

The	O
tectorial	O
membrane	O
is	O
formed	O
during	O
development	O
,	O
and	O
tectorin	O
is	O
not	O
usually	O
replaced	O
,	O
based	O
on	O
the	O
expression	O
profile	O
of	O
tectorin	O
in	O
the	O
developing	O
cochlea	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
45	O
]	O
.	O

The	O
average	O
age	O
of	O
onset	O
of	O
patients	O
with	O
SLC26A4	B-GENE
mutations	O
or	O
variants	O
is	O
1	O
.	O
27	O
+	O
-	O
1	O
.	O
10	O
.	O

In	O
addition	O
95	O
pan	O
-	O
ethnic	O
controls	O
were	O
sequenced	O
for	O
FOXI1	B-GENE
.	O

We	O
nevertheless	O
investigated	O
all	O
the	O
mutation	O
classes	O
described	O
above	O
.	O

Subpopulations	O
were	O
defined	O
by	O
clustering	O
the	O
subjects	O
on	O
the	O
calculated	O
admixture	O
proportions	O
.	O

Infarcts	O
in	O
substantia	O
nigra	O
pars	O
reticulata	O
were	O
evoked	O
by	O
prolonged	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-DISEASE
epilepticus	I-DISEASE
.	O

The	O
antiarrhythmic	B-DISEASE
activity	O
of	O
the	O
compound	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
trans	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
tetrahydro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
naphthyl	I-Chemical
)	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
oxo	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
phenyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
methylpropyl	I-Chemical
)	I-Chemical
-	I-Chemical
piperazine	I-Chemical
hydrochloride	I-Chemical
,	O
referred	O
to	O
as	O
P11	B-Chemical
,	O
is	O
studied	O
on	O
anaesthesized	O
cats	O
and	O
Wistar	O
albino	O
rats	O
,	O
as	O
well	O
as	O
on	O
non	O
-	O
anaesthesized	O
rabbits	O
.	O

WSF1	O
encodes	O
wolframin	O
,	O
a	O
hydrophobic	O
transmembrane	O
protein	O
that	O
is	O
related	O
to	O
LFSNHL	B-DISEASE
associated	O
with	O
DFNA6	O
/	O
14	O
/	O
38	O
[	O
8	O
,	O
9	O
]	O
.	O

(	O
D	O
)	O
Immunoblot	O
analysis	O
of	O
transfected	O
GFP	O
-	O
tagged	O
NARS2	B-GENE
constructs	O
.	O

We	O
thereby	O
provide	O
evidence	O
that	O
whole	O
exome	O
sequencing	O
is	O
a	O
powerful	O
,	O
cost	O
-	O
effective	O
screening	O
tool	O
to	O
identify	O
mutations	O
causing	O
recessive	B-DISEASE
deafness	I-DISEASE
in	O
consanguineous	O
families	O
.	O

After	O
direct	O
sequencing	O
for	O
CDH23	B-GENE
mutations	O
,	O
three	O
subjects	O
were	O
identified	O
with	O
homozygous	O
or	O
compound	O
heterozygous	O
pathogenic	O
CDH23	B-GENE
mutations	O
(	O
20	O
.	O
0	O
%	O
of	O
tested	O
subjects	O
)	O
,	O
and	O
three	O
subjects	O
were	O
shown	O
to	O
have	O
heterozygous	O
mutations	O
(	O
20	O
.	O
0	O
%	O
of	O
tested	O
subjects	O
)	O
.	O

All	O
detected	O
variants	O
were	O
filtered	O
against	O
the	O
following	O
5	O
SNP	O
databases	O
,	O
including	O
dbSNP137	O
(	O
http	O
:	O
/	O
/	O
hgdownload	O
.	O
cse	O
.	O
ucsc	O
.	O
edu	O
/	O
goldenPath	O
/	O
hg19	O
/	O
database	O
/	O
snp137	O
.	O
txt	O
.	O
gz	O
.	O
)	O
,	O
HapMap	O
Project	O
(	O
ftp	O
:	O
/	O
/	O
ftp	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
hapmap	O
)	O
,	O
1000	O
Genome	O
Project	O
(	O
ftp	O
:	O
/	O
/	O
ftp	O
.	O
1000genomes	O
.	O
ebi	O
.	O
ac	O
.	O
uk	O
/	O
vol1	O
/	O
ftp	O
)	O
,	O
YH	O
database	O
(	O
http	O
:	O
/	O
/	O
yh	O
.	O
genomics	O
.	O
org	O
.	O
cn	O
/	O
)	O
,	O
and	O
Exome	O
Variant	O
Server	O
(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
)	O
.	O

The	O
jams1	B-DISEASE
locus	O
delimited	O
by	O
the	O
gene	O
Basigin	O
(	O
Bsg	O
)	O
and	O
marker	O
D10Mit140	O
on	O
MMU10	O
is	O
shown	O
(	O
orange	O
box	O
)	O
12	O
.	O

Color	O
vision	O
was	O
defective	O
and	O
fundus	O
examination	O
revealed	O
optic	B-DISEASE
disc	I-DISEASE
edema	I-DISEASE
in	O
both	O
eyes	O
.	O

Both	O
variants	O
co	O
-	O
segregated	O
with	O
the	O
clinical	O
phenotype	O
and	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
were	O
absent	O
in	O
219	O
ethnicity	O
-	O
matched	O
controls	O
.	O

18	O
Variants	O
were	O
filtered	O
against	O
1000	O
Genomes	O
data	O
,	O
and	O
all	O
variants	O
with	O
a	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
>	O
1	O
%	O
were	O
removed	O
from	O
the	O
analysis	O
.	O

No	O
other	O
mutations	O
in	O
either	O
KCNJ10	B-GENE
or	O
FOXI1	B-GENE
were	O
found	O
.	O

RESULTS	O
:	O
A	O
significant	O
increase	O
in	O
intraocular	O
pressure	O
developed	O
in	O
13	O
of	O
the	O
44	O
pairs	O
of	O
eyes	O
perfused	O
with	O
dexamethasone	B-Chemical
with	O
an	O
average	O
pressure	O
rise	O
of	O
17	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
8	O
mm	O
Hg	O
after	O
12	O
days	O
of	O
dexamethasone	B-Chemical
exposure	O
.	O

Mutation	O
screening	O
was	O
performed	O
with	O
direct	O
sequencing	O
.	O

GJB3	B-GENE
or	O
GJB6	B-GENE
coding	O
region	O
mutations	O
were	O
further	O
examined	O
in	O
some	O
of	O
these	O
patients	O
and	O
no	O
pathogenic	O
mutation	O
was	O
detected	O
[	O
15	O
]	O
.	O

Potential	O
mosaic	O
mutations	O
detected	O
in	O
patients	O
with	O
unknown	O
mutations	O
Potential	O
mosaic	O
mutations	O
detected	O
in	O
patients	O
with	O
unknown	O
mutations	O
Because	O
the	O
NLRP3	B-GENE
p	B-VARIANT
.	I-VARIANT
Phe302Leu	I-VARIANT
mutation	O
was	O
novel	O
and	O
not	O
detected	O
in	O
the	O
50	O
healthy	O
controls	O
,	O
we	O
performed	O
an	O
in	O
vitro	O
functional	O
analysis	O
to	O
see	O
the	O
effect	O
of	O
p	B-VARIANT
.	I-VARIANT
Phe302Leu	I-VARIANT
on	O
the	O
protein	O
function	O
.	O

In	O
addition	O
,	O
visually	O
evoked	O
potentials	O
(	O
VEP	O
;	O
Roland	O
Consult	O
,	O
Brandenburg	O
,	O
Germany	O
)	O
were	O
evaluated	O
.	O

Mice	O
carrying	O
a	O
mutation	O
of	O
the	O
orthologous	O
gene	O
(	O
COMT2	B-GENE
)	O
suffer	O
from	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
profound	B-DISEASE
deafness	I-DISEASE
and	O
progressive	O
degeneration	B-DISEASE
of	I-DISEASE
the	I-DISEASE
organ	I-DISEASE
of	I-DISEASE
Corti	I-DISEASE
[	O
19	O
]	O
.	O

Four	O
constellations	O
of	O
the	O
5	O
'	O
polymorphisms	O
were	O
identified	O
in	O
the	O
patient	O
collective	O
of	O
30	O
patients	O
.	O

Red	O
arrows	O
in	O
upper	O
panel	O
indicate	O
reduced	O
coverage	O
of	O
USH2A	B-GENE
exons	O
in	O
patient	O
1598	O
.	O

Furthermore	O
,	O
the	O
high	O
coverage	O
obtained	O
in	O
our	O
study	O
allowed	O
us	O
to	O
detect	O
large	O
rearrangements	O
.	O

The	O
FGFR	B-DISEASE
-	I-DISEASE
related	I-DISEASE
craniosynostosis	I-DISEASE
spectrum	O
includes	O
PS	B-DISEASE
,	O
Apert	B-DISEASE
syndrome	I-DISEASE
,	O
Jackson	B-DISEASE
-	I-DISEASE
Weiss	I-DISEASE
syndrome	I-DISEASE
,	O
Beare	B-DISEASE
-	I-DISEASE
Stevenson	I-DISEASE
syndrome	I-DISEASE
,	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
,	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
with	I-DISEASE
acanthosis	I-DISEASE
nigricans	I-DISEASE
,	O
Muenke	B-DISEASE
syndrome	I-DISEASE
,	O
and	O
FGFR2	B-DISEASE
-	I-DISEASE
related	I-DISEASE
isolated	I-DISEASE
coronal	I-DISEASE
synostosis	I-DISEASE
(	O
11	O
,	O
13	O
,	O
22	O
)	O
.	O

The	O
ischemia	B-DISEASE
probably	O
induced	O
by	O
coronary	O
artery	O
spasm	O
was	O
reversed	O
by	O
nitroglycerin	B-Chemical
and	O
calcium	B-Chemical
blocking	O
agents	O
.	O

However	O
,	O
no	O
study	O
in	O
the	O
literature	O
has	O
reported	O
the	O
use	O
of	O
a	O
statistical	O
model	O
to	O
analyze	O
the	O
variables	O
that	O
influence	O
outcome	O
.	O

We	O
were	O
able	O
to	O
measure	O
the	O
GCL	O
separately	O
and	O
show	O
that	O
not	O
only	O
the	O
RNFL	O
but	O
also	O
the	O
GCL	O
is	O
significantly	O
reduced	O
in	O
ADOA	B-DISEASE
patients	O
compared	O
to	O
healthy	O
controls	O
,	O
but	O
IPL	O
+	O
INL	O
+	O
OPL	O
thickness	O
is	O
not	O
different	O
to	O
healthy	O
subjects	O
.	O

Gentamicin	B-Chemical
at	O
toxic	O
doses	O
,	O
however	O
,	O
increased	O
CSA	B-Chemical
nephrotoxicity	O
.	O

The	O
mutant	O
expression	O
vectors	O
were	O
generated	O
by	O
use	O
of	O
site	O
-	O
directed	O
mutagenesis	O
performed	O
according	O
to	O
the	O
protocol	O
provided	O
by	O
the	O
Quickchange	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Stratagene	B-Chemical
,	O
La	O
Jolla	I-Chemical
,	O
California	O
,	O
USA	O
)	O
,	O
and	O
the	O
wild	O
-	O
type	O
pcDNA3	O
.	O
1	O
-	O
TBX1	B-Chemical
was	O
used	O
as	O
the	O
template	O
.	O

Patient	O
consent	O
:	O
Obtained	O
.	O

It	O
may	O
serve	O
as	O
an	O
alternative	O
to	O
cisplatin	B-Chemical
-	O
containing	O
regimens	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	B-DISEASE
may	O
occur	O
.	O

Approval	O
for	O
the	O
study	O
was	O
obtained	O
by	O
the	O
Second	O
University	O
of	O
Naples	O
and	O
by	O
IRCCS	O
-	O
Burlo	O
Garofolo	O
of	O
Trieste	O
Ethics	O
Committees	O
.	O

Considering	O
individual	O
scores	O
,	O
all	O
the	O
OPA1	B-GENE
-	O
M	O
patients	O
improved	O
performances	O
when	O
using	O
the	O
cochlear	O
implant	O
.	O

Both	O
groups	O
underwent	O
audiometric	O
assessment	O
with	O
pure	O
tone	O
and	O
speech	O
perception	O
evaluation	O
,	O
and	O
otoacoustic	O
emissions	O
and	O
auditory	O
brainstem	O
response	O
recording	O
.	O

A	O
prospective	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	B-Chemical
in	O
autistic	B-DISEASE
disorder	I-DISEASE
.	O

Our	O
40	O
-	O
year	O
-	O
old	O
patient	O
did	O
not	O
have	O
rapid	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
only	O
24	O
dB	O
(	O
125	O
+	O
250	O
+	O
500	O
Hz	O
/	O
3	O
)	O
during	O
the	O
7	O
-	O
year	O
follow	O
-	O
up	O
period	O
)	O
,	O
supporting	O
that	O
this	O
patient	O
was	O
a	O
good	O
candidate	O
for	O
EAS	O
.	O

Five	O
grafts	O
were	O
lost	O
and	O
the	O
patients	O
returned	O
to	O
dialysis	O
.	O

del	O
Castillo	O
,	O
personal	O
communication	O
]	O
.	O

Our	O
result	O
highlights	O
the	O
current	O
limitations	O
in	O
the	O
diagnostic	O
use	O
of	O
NGS	O
for	O
USH	B-DISEASE
patients	O
.	O

In	O
many	O
families	O
carrying	O
such	O
mutations	O
,	O
some	O
members	O
continue	O
to	O
exhibit	O
pure	O
and	O
isolated	O
MH	B-DISEASE
for	O
the	O
rest	O
of	O
their	O
lives	O
,	O
while	O
others	O
develop	O
proteinuria	B-DISEASE
later	O
on	O
in	O
life	O
,	O
usually	O
with	O
hypertension	B-DISEASE
and	O
a	O
variable	O
gradual	O
progression	O
to	O
CRF	B-DISEASE
,	O
up	O
to	O
ESKD	B-DISEASE
[	O
6	O
]	O
-	O
[	O
8	O
]	O
.	O

Impaired	B-DISEASE
vestibular	I-DISEASE
function	I-DISEASE
has	O
previously	O
been	O
reported	O
in	O
other	O
patients	O
with	O
auditory	B-DISEASE
neuropathy	I-DISEASE
,	O
particularly	O
in	O
those	O
with	O
a	O
concomitant	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
,	O
and	O
attributed	O
to	O
degeneration	B-DISEASE
of	I-DISEASE
vestibular	I-DISEASE
nerves	I-DISEASE
(	O
Starr	O
et	O
al	O
.	O

An	O
attempt	O
is	O
made	O
to	O
draw	O
practical	O
conclusions	O
from	O
the	O
preliminary	O
findings	O
.	O

Family	O
PKDF740	O
has	O
four	O
affected	O
individuals	O
in	O
two	O
non	O
-	O
consanguineous	O
sibships	O
(	O
Figure	O
4a	O
)	O
.	O

05	O
)	O
.	O

However	O
,	O
the	O
maximal	O
reduction	O
in	O
body	O
weight	O
seen	O
in	O
animals	O
that	O
received	O
polymer	O
-	O
bound	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
parent	O
HPMA	B-Chemical
copolymer	O
and	O
free	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
672	O
-	O
bp	O
PCR	O
product	O
obtained	O
using	O
the	O
forward	O
primer	O
(	O
5	O
'	O
-	O
TTC	O
CCA	O
CGT	O
ACC	O
ATC	O
TTT	O
CC	O
-	O
3	O
'	O
)	O
and	O
the	O
reverse	O
primer	O
(	O
5	O
'	O
-	O
CAC	O
ATC	O
CAG	O
GTT	O
GGG	O
CTC	O
-	O
3	O
'	O
)	O
contains	O
a	O
polymorphic	O
restriction	O
site	O
at	O
position	O
1235	O
.	O

We	O
performed	O
parallel	O
sequencing	O
of	O
the	O
whole	O
exomes	O
of	O
13	O
small	O
families	O
and	O
rapidly	O
and	O
successfully	O
identified	O
the	O
CDH23	B-GENE
mutation	O
in	O
two	O
families	O
.	O

In	O
the	O
very	O
young	O
child	O
,	O
electrophysiological	O
testing	O
may	O
indicate	O
that	O
OTOF	B-GENE
-	O
related	O
deafness	B-DISEASE
is	O
ANSD	B-DISEASE
,	O
but	O
by	O
age	O
two	O
OAEs	O
have	O
generally	O
disappeared	O
and	O
the	O
test	O
results	O
are	O
more	O
in	O
accord	O
with	O
the	O
findings	O
of	O
cochlear	O
lesions	O
[	O
14	O
]	O
.	O

USH	B-DISEASE
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
and	O
to	O
date	O
,	O
15	O
USH	B-DISEASE
loci	O
have	O
been	O
characterized	O
and	O
12	O
causative	O
genes	O
identified	O
(	O
A	O
-	O
genes	O
,	O
last	O
update	O
May	O
31	O
,	O
2014	O
)	O
.	O

Among	O
72	O
probands	O
presenting	O
with	O
our	O
defined	O
set	O
of	O
clinical	O
features	O
,	O
13	O
subjects	O
(	O
18	O
.	O
1	O
%	O
)	O
exhibited	O
homozygous	O
or	O
compound	O
heterozygous	O
CDH23	B-GENE
mutations	O
.	O

We	O
therefore	O
speculate	O
that	O
the	O
coding	O
region	O
mutation	O
of	O
CRKL	B-GENE
gene	O
may	O
not	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
CTDs	B-DISEASE
.	O

There	O
was	O
a	O
difference	O
in	O
metoprolol	B-Chemical
potency	O
with	O
higher	O
racemic	O
metoprolol	B-Chemical
IC50	O
values	O
in	O
PMs	O
(	O
72	O
+	O
/	O
-	O
7	O
ng	O
.	O
ml	O
-	O
1	O
)	O
than	O
EMs	O
(	O
42	O
+	O
/	O
-	O
8	O
ng	O
.	O
ml	O
-	O
1	O
,	O
P	O
less	O
than	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

(	O
XLSX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

We	O
hypothesized	O
that	O
founder	O
mutations	O
in	O
USH1	B-DISEASE
genes	O
exist	O
in	O
this	O
population	O
.	O

In	O
multivariate	O
analysis	O
,	O
a	O
significant	O
correlation	O
between	O
DBP	B-DISEASE
reduction	O
and	O
worsening	O
of	O
the	O
neurological	O
score	O
was	O
found	O
for	O
the	O
high	O
-	O
dose	O
group	O
(	O
beta	O
=	O
0	O
.	O
49	O
,	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Among	O
the	O
100	O
normal	O
hearing	O
controls	O
,	O
we	O
also	O
identified	O
6	O
carriers	O
with	O
GJB4	B-GENE
p	B-VARIANT
.	I-VARIANT
C169W	I-VARIANT
,	O
revealing	O
an	O
allele	O
frequency	O
of	O
3	O
.	O
0	O
%	O
(	O
6	O
/	O
200	O
chromosomes	O
)	O
.	O

A	O
Chinese	O
family	O
classified	O
as	O
JSNY	O
-	O
023	O
of	O
Han	O
origin	O
(	O
Fig	O
.	O

Transfection	O
with	O
lipofectamine	B-Chemical
only	O
(	O
lipo	B-Chemical
)	O
served	O
as	O
a	O
negative	O
control	O
.	O

Eighteen	O
(	O
39	O
%	O
)	O
had	O
an	O
associated	O
malformation	O
or	O
syndromes	O
.	O

(	O
DOCX	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

H	O
.	O
V	O
.	O

M	O
.	O

C	O
:	O
Normal	O
sequence	O
.	O

In	O
all	O
probands	O
,	O
SNHL	B-DISEASE
was	O
evident	O
since	O
childhood	O
,	O
as	O
classically	O
described	O
[	O
7	O
]	O
.	O

Cochlear	O
microphonic	O
potentials	O
.	O

Thus	O
,	O
GJB2	B-GENE
mutant	O
alleles	O
account	O
for	O
17	O
.	O
9	O
%	O
(	O
739	O
/	O
4126	O
)	O
of	O
the	O
total	O
alleles	O
in	O
2063	O
NSHI	B-DISEASE
patients	O
.	O

Genomic	O
DNA	O
(	O
gDNA	O
)	O
was	O
isolated	O
from	O
3	O
-	O
5	O
ml	O
of	O
blood	O
,	O
according	O
to	O
the	O
standard	O
protocol	O
provided	O
by	O
the	O
manufacturer	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
.	O

Multiple	O
-	O
alignment	O
of	O
the	O
corresponding	O
stretches	O
of	O
protein	O
sequences	O
across	O
different	O
species	O
.	O

Systemic	O
cocaine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
of	O
rats	O
.	O

None	O
of	O
the	O
CNVs	O
co	O
-	O
segregated	O
with	O
affected	O
or	O
unaffected	O
family	O
members	O
.	O

On	O
admission	O
,	O
clinical	O
symptoms	O
(	O
i	O
.	O
e	O
.	O
arthralgia	B-DISEASE
and	O
fever	B-DISEASE
)	O
and	O
laboratory	O
findings	O
(	O
i	O
.	O
e	O
.	O
eosinophilia	B-DISEASE
and	O
renal	B-DISEASE
failure	I-DISEASE
)	O
suggested	O
AIN	B-DISEASE
,	O
and	O
which	O
was	O
confirmed	O
by	O
pathologic	O
findings	O
on	O
renal	O
biopsy	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
myocardial	O
contrast	O
echocardiography	O
is	O
a	O
valuable	O
technique	O
for	O
delineating	O
regions	O
of	O
myocardial	B-DISEASE
underperfusion	I-DISEASE
secondary	O
to	O
coronary	B-DISEASE
occlusion	I-DISEASE
and	O
to	O
critical	O
coronary	B-DISEASE
stenoses	I-DISEASE
in	O
the	O
presence	O
of	O
hyperemic	O
stimulation	O
.	O

Sivachenko	O
for	O
advice	O
on	O
sequence	O
data	O
analysis	O
,	O
M	O
.	O

As	O
USH1C	B-GENE
mutations	O
have	O
so	O
far	O
only	O
been	O
reported	O
in	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
5	O
and	O
6	O
,	O
these	O
exons	O
were	O
sequenced	O
first	O
.	O

Large	O
rearrangements	O
in	O
USH2A	B-GENE
and	O
PCDH15	B-GENE
were	O
subsequently	O
confirmed	O
by	O
MLPA	O
,	O
whereas	O
patients	O
that	O
carried	O
duplications	O
affecting	O
CDH23	B-GENE
and	O
GPR98	B-GENE
were	O
analyzed	O
by	O
a	O
-	O
CGH	O
(	O
data	O
not	O
shown	O
)	O
.	O

62	O
We	O
verified	O
photoreceptor	O
morphology	O
using	O
2	O
mu	O
m	O
plastic	O
sections	O
of	O
dissected	O
retinas	O
,	O
counterstained	O
with	O
toluidine	B-Chemical
blue	I-Chemical
(	O
Sigma	O
)	O
,	O
as	O
previously	O
described	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Subsequently	O
we	O
investigated	O
the	O
efficacy	O
of	O
oxprenolol	B-Chemical
in	O
antagonizing	O
such	O
hypokalemia	B-DISEASE
,	O
together	O
with	O
the	O
pharmacokinetic	O
interaction	O
between	O
both	O
drugs	O
.	O

The	O
SOAPsnp	O
software	O
was	O
used	O
for	O
SNP	O
genotyping	O
(	O
BGI	O
,	O
China	O
)	O
.	O

Choreoathetoid	O
movements	O
associated	O
with	O
rapid	O
adjustment	O
to	O
methadone	B-Chemical
.	O

Three	O
different	O
combinations	O
of	O
heterozygous	O
mutations	O
were	O
observed	O
in	O
the	O
three	O
families	O
.	O

From	O
day	O
2	O
of	O
hospitalization	O
,	O
the	O
patient	O
was	O
started	O
on	O
oral	O
calcium	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
vitD	O
0	O
.	O
5	O
u	O
g	O
/	O
day	O
and	O
was	O
subsequently	O
discharged	O
with	O
outpatient	O
follow	O
-	O
up	O
.	O

The	O
heptad	O
repeat	O
pattern	O
of	O
the	O
residues	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
function	O
of	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
(	O
Franke	O
et	O
al	O
.	O

Pure	O
tone	O
audiometry	O
tests	O
for	O
air	O
and	O
bone	O
conduction	O
were	O
performed	O
on	O
all	O
affected	O
individuals	O
.	O

The	O
possible	O
mechanism	O
is	O
depression	O
of	O
rapidly	O
activating	O
delayed	O
rectifier	O
potassium	B-Chemical
currents	O
.	O

Our	O
study	O
increases	O
the	O
spectrum	O
of	O
WFS1	B-GENE
mutations	O
with	O
two	O
novel	O
variants	O
.	O

Acute	O
renal	I-DISEASE
failure	I-DISEASE
due	O
to	O
rifampicin	B-Chemical
.	O

A	O
.	O

More	O
recently	O
,	O
we	O
performed	O
additional	O
phylogenetic	O
and	O
functional	O
analyses	O
of	O
the	O
ELMO	O
domain	O
that	O
led	O
us	O
to	O
re	O
-	O
examine	O
whether	O
ELMOD3	B-GENE
shares	O
the	O
Arl2	O
GAP	O
activity	O
of	O
ELMOD1	B-GENE
and	O
ELMOD2	B-GENE
.	O

Neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
complicated	O
by	O
massive	B-DISEASE
intestinal	I-DISEASE
bleeding	I-DISEASE
in	O
a	O
patient	O
with	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O

Residue	O
p	O
.	O
Glu638	I-Chemical
is	O
salt	O
bridging	O
p	O
.	O
Lys644	O
at	O
the	O
edge	O
of	O
the	O
KMSKS	O
loop	O
,	O
stabilizing	O
its	O
closed	O
state	O
.	O

In	O
each	O
recording	O
the	O
horizontal	O
dashed	O
line	O
refers	O
to	O
baseline	O
.	O

S4	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
COL2A1	B-GENE
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
1744G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly582Ser	I-VARIANT
)	O
)	O
from	O
the	O
chromosome	O
12q13	O
region	O
within	O
one	O
Japanese	O
family	O
.	O

The	O
present	O
study	O
describes	O
the	O
delayed	O
development	O
of	O
a	O
severe	O
bladder	O
pathology	O
in	O
a	O
susceptible	O
strain	O
of	O
mice	O
(	O
DBA	O
/	O
2	O
)	O
but	O
not	O
in	O
a	O
resistant	O
strain	O
(	O
C57BL	O
/	O
6	O
)	O
when	O
both	O
were	O
treated	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
dose	O
of	O
cyclophosphamide	B-Chemical
(	O
CY	B-Chemical
)	O
.	O

Analysis	O
of	O
data	O
revealed	O
a	O
significant	O
correlation	O
between	O
maximal	O
cTnT	O
and	O
ED	O
and	O
ES	O
LV	O
diameters	O
/	O
BW	O
(	O
r	O
=	O
0	O
.	O
81	O
and	O
0	O
.	O
65	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

In	O
186	O
of	O
the	O
remaining	O
probands	O
,	O
genome	O
-	O
wide	O
homozygosity	O
mapping	O
had	O
been	O
performed	O
,	O
which	O
had	O
resulted	O
in	O
the	O
identification	O
of	O
mutations	O
in	O
three	O
novel	O
autosomal	O
recessive	O
RP	B-DISEASE
genes	O
,	O
EYS	B-GENE
(	O
MIM	O
#	O
612	O
,	O
424	O
)	O
,	O
C2ORF71	B-GENE
(	O
MIM	O
#	O
613	O
,	O
425	O
)	O
,	O
and	O
IMPG2	B-GENE
(	O
MIM	O
#	O
607	O
,	O
056	O
)	O
[	O
Collin	O
et	O
al	O
.	O
,	O
2008	O
;	O
Bandah	O
-	O
Rozenfeld	O
et	O
al	O
.	O
,	O
2010	O
;	O
Collin	O
et	O
al	O
.	O
,	O
2010	O
]	O
in	O
13	O
patients	O
,	O
together	O
with	O
24	O
homozygous	O
mutations	O
in	O
previously	O
known	O
RD	B-DISEASE
genes	O
[	O
Collin	O
et	O
al	O
.	O
,	O
2011	O
]	O
.	O

Long	O
-	O
term	O
efficacy	O
and	O
toxicity	O
of	O
high	O
-	O
dose	O
amiodarone	B-Chemical
therapy	O
for	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
or	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
.	O

This	O
will	O
facilitate	O
genetic	O
testing	O
and	O
counseling	O
in	O
patients	O
with	O
different	O
types	O
of	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
,	O
and	O
may	O
provide	O
motivation	O
to	O
explore	O
the	O
real	O
etiology	O
of	O
isolated	O
MD	B-DISEASE
by	O
new	O
genomic	O
strategies	O
and	O
platforms	O
,	O
such	O
as	O
capturing	O
and	O
sequencing	O
all	O
possible	O
genes	O
related	O
to	O
the	O
development	O
of	O
the	O
inner	O
ear	O
using	O
next	O
-	O
generation	O
sequencing	O
technology	O
.	O

Fig	O
.	O

(	O
C	O
)	O
Sequence	O
chromatograms	O
of	O
COL4A5	B-GENE
(	O
Family	O
1	O
and	O
2	O
)	O
and	O
COL4A3	B-GENE
(	O
Family	O
3	O
)	O
in	O
affected	O
patients	O
with	O
wild	O
-	O
type	O
control	O
.	O

The	O
disease	O
is	O
known	O
as	O
fully	O
penetrant	O
when	O
at	O
least	O
one	O
of	O
its	O
signs	O
is	O
detected	O
,	O
but	O
the	O
penetrance	O
for	O
each	O
one	O
is	O
not	O
complete	O
.	O

WFS1	B-GENE
gene	O
novel	O
point	O
mutation	O
in	O
WS	B-DISEASE
.	O

Members	O
I	O
-	O
1	O
,	O
II	O
-	O
1	O
,	O
3	O
,	O
5	O
(	O
gray	O
)	O
had	O
complained	O
of	O
coxalgia	O
during	O
their	O
lifetimes	O
and	O
are	O
suspected	O
of	O
having	O
had	O
hip	O
joint	O
disease	O
.	O

Regimens	O
commonly	O
used	O
often	O
require	O
inpatient	O
administration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicity	O
.	O

Although	O
the	O
number	O
of	O
mitochondrial	B-DISEASE
disorders	I-DISEASE
caused	O
by	O
genetically	O
defined	O
defects	O
of	O
nuclear	O
genes	O
is	O
still	O
relatively	O
small	O
,	O
great	O
progress	O
in	O
this	O
field	O
has	O
been	O
made	O
in	O
recent	O
years	O
[	O
16	O
]	O
.	O

T	O
.	O
M	O
.	O

C	O
.	O

These	O
include	O
seven	O
mutations	O
in	O
KCNQ1	B-GENE
,	O
nine	O
in	O
KCNH2	B-GENE
and	O
two	O
in	O
SCN5A	B-GENE
(	O
Table	O
2	O
)	O
.	O

The	O
proband	O
22	O
,	O
315	O
and	O
his	O
three	O
siblings	O
all	O
appeared	O
to	O
have	O
inherited	O
the	O
same	O
RHO	B-GENE
allele	O
from	O
the	O
deceased	O
father	O
,	O
strongly	O
suggesting	O
that	O
the	O
RHO	B-GENE
mutation	O
has	O
occurred	O
by	O
a	O
de	O
novo	O
event	O
.	O

(	O
XLS	B-Chemical
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Four	O
types	O
of	O
experimental	O
arrhythmia	B-DISEASE
are	O
used	O
-	O
-	O
with	O
BaCl2	B-Chemical
,	O
with	O
chloroform	B-Chemical
-	O
adrenaline	B-Chemical
,	O
with	O
strophantine	B-Chemical
G	I-Chemical
and	O
with	O
aconitine	B-Chemical
.	O

Current	O
diagnostic	O
strategies	O
make	O
use	O
of	O
a	O
genotyping	O
microarray	O
that	O
is	O
based	O
on	O
the	O
previously	O
reported	O
mutations	O
.	O

Clinicians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
fatal	O
interaction	O
between	O
two	O
commonly	O
used	O
antihypertensive	O
drugs	O
.	O

Colonic	O
biopsy	O
showed	O
aganglionosis	O
.	O

The	O
development	O
of	O
severe	B-DISEASE
anemia	B-DISEASE
at	O
6	O
months	O
post	O
-	O
CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	O
value	O
of	O
more	O
than	O
2	O
.	O
5	O
g	O
/	O
dl	O
after	O
3	O
months	O
of	O
CAB	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

(	O
Physical	O
Therapy	O
)	O
Tamara	O
Hershey	O
(	O
Psychiatry	O
,	O
Neurology	O
,	O
Radiology	O
)	O
James	O
Hoekel	O
,	O
O	O
.	O
D	O
.	O

Ethics	O
approval	O
:	O
The	O
Ethics	O
Reviewing	O
Committee	O
of	O
the	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

Mutations	O
in	O
these	O
categories	O
can	O
be	O
defined	O
as	O
disease	O
-	O
causing	O
,	O
highly	O
likely	O
to	O
be	O
disease	O
-	O
causing	O
,	O
predicted	O
but	O
unconfirmed	O
to	O
be	O
disease	O
-	O
causing	O
,	O
carrier	O
of	O
mutations	O
,	O
and	O
novel	O
mutations	O
with	O
low	O
population	O
allele	O
frequencies	O
(	O
less	O
than	O
0	O
.	O
005	O
)	O
of	O
unknown	O
significance	O
.	O

Mutations	O
in	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
(	O
FGFR1	B-GENE
)	O
gene	O
2	O
)	O
or	O
FGFR2	B-GENE
gene	O
3	O
)	O
cause	O
Pfeiffer	B-DISEASE
syndrome	I-DISEASE
.	O

5B	O
)	O
.	O

enrolled	O
the	O
Turkish	O
families	O
and	O
performed	O
linkage	O
analysis	O
;	O
S	O
.	O
M	O
.	O
L	O
.	O

The	O
current	O
study	O
aimed	O
to	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
LFSNHL	B-DISEASE
in	O
an	O
affected	O
Taiwanese	O
family	O
.	O

[	O
11	O
]	O
,	O
except	O
those	O
for	O
exons	O
6	O
and	O
7	O
.	O

Thermal	O
enhancement	O
of	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
activity	O
and	O
normal	O
tissue	O
toxicities	O
by	O
whole	O
body	O
hyperthermia	O
were	O
compared	O
using	O
a	O
F344	O
rat	O
model	O
.	O

(	O
C	O
)	O
SDS	O
PAGE	O
and	O
Western	O
blot	O
of	O
fibroblast	O
lysates	O
from	O
both	O
affected	O
probands	O
(	O
II	O
.	O
1	O
,	O
II	O
.	O
3	O
)	O
,	O
their	O
parents	O
(	O
I	O
.	O
1	O
,	O
I	O
.	O
2	O
)	O
and	O
controls	O
using	O
anti	O
-	O
NARS2	B-GENE
antibody	O
and	O
anti	O
-	O
GAPDH	B-GENE
antibody	O
as	O
loading	O
control	O
.	O

In	O
inflamed	O
preparations	O
,	O
the	O
muscarinic	B-GENE
receptor	O
antagonism	O
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O

Two	O
deaf	O
individuals	O
from	O
a	O
Tunisian	O
family	O
were	O
enrolled	O
through	O
a	O
deaf	O
school	O
.	O

A	O
Chinese	O
family	O
,	O
GD	O
-	O
O031	O
,	O
with	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
was	O
ascertained	O
from	O
Department	O
of	O
Otolaryngology	O
,	O
Zhongshan	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Guangdong	O
Province	O
in	O
mainland	O
China	O
.	O

Thus	O
,	O
29	O
.	O
23	O
%	O
(	O
83	O
/	O
284	O
)	O
of	O
the	O
unrelated	O
families	O
of	O
deaf	O
patients	O
in	O
typical	O
areas	O
in	O
China	O
had	O
molecular	O
defects	O
in	O
GJB2	B-GENE
,	O
and	O
18	O
.	O
31	O
%	O
(	O
52	O
/	O
284	O
)	O
had	O
confirmed	O
molecular	O
etiology	O
of	O
nonsyndromic	O
hearing	B-DISEASE
impairment	I-DISEASE
(	O
51	O
autosomal	O
recessive	O
and	O
1	O
autosomal	O
dominant	O
)	O
in	O
the	O
GJB2	B-GENE
gene	O
.	O

As	O
expected	O
,	O
the	O
two	O
patients	O
with	O
p	B-VARIANT
.	I-VARIANT
R705H	I-VARIANT
developed	O
early	O
deafness	B-DISEASE
during	O
childhood	O
as	O
described	O
in	O
DFNA17	B-DISEASE
(	O
Lalwani	O
et	O
al	O
.	O

Subject	O
II	O
-	O
4	O
was	O
reluctant	O
to	O
wear	O
a	O
hearing	O
aid	O
;	O
however	O
,	O
subject	O
III	O
-	O
2	O
(	O
F	O
/	O
6yr	O
)	O
had	O
begun	O
wearing	O
a	O
hearing	O
aid	O
.	O

SD	O
-	O
OCT	O
(	O
Carl	O
Zeiss	O
Meditec	O
)	O
images	O
were	O
obtained	O
from	O
all	O
of	O
the	O
patients	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
The	O
State	O
of	O
Minas	O
Gerais	O
Research	O
Foundation	O
-	O
FAPEMIG	B-Chemical
,	O
Minas	O
Gerais	O
,	O
Brazil	O
and	O
the	O
National	O
Council	O
for	O
Scientific	O
and	O
Technological	O
Development	O
-	O
CNPq	O
,	O
Bras	O
i	O
lia	O
,	O
Brazil	O
.	O
HMJ	O
,	O
MJBA	O
and	O
RDC	O
designed	O
the	O
study	O
and	O
drafted	O
the	O
paper	O
.	O

Intermediate	O
proteins	O
(	O
center	O
)	O
are	O
colored	O
in	O
shades	O
of	O
orange	O
based	O
on	O
a	O
p	O
-	O
value	O
computed	O
using	O
a	O
proportion	O
test	O
where	O
darker	O
color	O
represents	O
a	O
lower	O
p	O
-	O
value	O
.	O

We	O
describe	O
four	O
patients	O
with	O
classic	B-DISEASE
APL	B-DISEASE
who	O
developed	O
erythema	O
nodosum	I-DISEASE
during	O
ATRA	B-Chemical
therapy	O
.	O

Numbers	O
designate	O
patients	O
,	O
colors	O
indicate	O
different	O
USH1	B-DISEASE
genes	O
.	O

Co	O
-	O
localization	O
of	O
EGFP	O
expression	O
and	O
the	O
di	B-Chemical
-	I-Chemical
8	I-Chemical
-	I-Chemical
ANEPPS	I-Chemical
dye	O
in	O
the	O
membrane	O
would	O
suggest	O
proper	O
membrane	O
targeting	O
of	O
the	O
proteins	O
[	O
25	O
]	O
.	O

The	O
remaining	O
12	O
novel	O
mutations	O
are	O
well	O
justified	O
,	O
and	O
novel	O
mutations	O
were	O
either	O
completely	O
absent	O
or	O
extremely	O
rare	O
in	O
controls	O
.	O

The	O
striatum	O
as	O
a	O
target	O
for	O
anti	O
-	O
rigor	O
effects	O
of	O
an	O
antagonist	O
of	O
mGluR1	B-GENE
,	O
but	O
not	O
an	O
agonist	O
of	O
group	O
II	O
metabotropic	O
glutamate	B-Chemical
receptors	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
drug	O
-	O
induced	O
hepatocellular	B-DISEASE
jaundice	I-DISEASE
have	O
11	O
.	O
7	O
%	O
chance	O
of	O
progressing	O
to	O
death	O
or	O
transplantation	O
.	O

In	O
our	O
opinion	O
a	O
combined	O
strategy	O
involving	O
different	O
techniques	O
applied	O
to	O
genomic	O
and	O
transcript	O
analysis	O
could	O
offer	O
the	O
most	O
valuable	O
option	O
to	O
investigate	O
the	O
OPA1	B-GENE
defects	O
underlining	O
the	O
several	O
forms	O
of	O
inherited	O
optic	B-DISEASE
neuropathy	I-DISEASE
[	O
17	O
]	O
.	O

(	O
l	O
-	O
o	O
)	O
Inhibition	O
of	O
microphonic	O
potentials	O
in	O
zebrafish	O
lateral	O
line	O
by	O
cib2	B-GENE
morpholino	O
.	O

It	O
tended	O
to	O
reduce	O
VAS	O
scores	O
of	O
spontaneous	O
pain	O
but	O
had	O
no	O
effect	O
on	O
evoked	O
pain	O
.	O

Although	O
D	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
has	O
been	O
used	O
for	O
many	O
rheumatologic	B-DISEASE
diseases	I-DISEASE
,	O
toxicity	O
limits	O
its	O
usefulness	O
in	O
many	O
patients	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
describe	O
the	O
results	O
obtained	O
from	O
the	O
mutation	O
screening	O
of	O
the	O
PCDH15	B-GENE
gene	O
in	O
a	O
series	O
of	O
19	O
Spanish	O
patients	O
with	O
USH	B-DISEASE
in	O
whom	O
MYO7A	B-GENE
and	O
CDH23	B-GENE
had	O
been	O
previously	O
discarded	O
as	O
disease	O
-	O
causative	O
.	O

Heterozygous	O
deletion	O
of	O
exon	O
4	O
in	O
the	O
CRX	B-GENE
gene	O
in	O
patient	O
110	O
and	O
his	O
father	O
.	O

Qualitative	O
comparisons	O
of	O
small	O
artery	O
changes	O
also	O
were	O
made	O
.	O

Studies	O
were	O
also	O
conducted	O
in	O
renal	O
epithelial	O
LLC	O
-	O
PK1	O
cells	O
and	O
in	O
mitochondria	O
isolated	O
from	O
kidneys	O
of	O
all	O
the	O
experimental	O
groups	O
.	O

His	O
cognitive	O
capacities	O
and	O
insight	O
at	O
age	O
36	O
years	O
seemed	O
to	O
be	O
below	O
the	O
stage	O
of	O
an	O
adolescent	O
,	O
but	O
no	O
formal	O
neuropsychological	O
testing	O
was	O
possible	O
given	O
his	O
severe	O
hearing	O
and	O
visual	O
impairments	O
and	O
lack	O
of	O
cooperative	O
behaviour	O
.	O

Methadone	B-Chemical
may	O
aggravate	O
this	O
problem	O
.	O

(	O
J	O
)	O
The	O
arrows	O
indicate	O
that	O
the	O
Thr165	O
and	O
Met946	B-Chemical
residues	O
are	O
evolutionary	O
highly	O
conserved	O
among	O
multiple	O
species	O
.	O

The	O
BALB	O
/	O
C	O
mouse	O
was	O
the	O
most	O
sensitive	O
strain	O
and	O
could	O
serve	O
as	O
the	O
strain	O
of	O
choice	O
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	B-Chemical
.	O

Results	O
are	O
expressed	O
as	O
mean	O
+	O
-	O
SD	O
.	O

Six	O
boys	O
,	O
first	O
seen	O
at	O
the	O
onset	O
of	O
the	O
study	O
,	O
were	O
given	O
i	O
.	O
m	O
.	O

Specifically	O
,	O
a	O
total	O
of	O
22	O
,	O
953	O
missense	O
variants	O
in	O
3	O
,	O
637	O
genes	O
were	O
predicted	O
to	O
be	O
functionally	O
deleterious	O
by	O
Condel	O
10	O
and	O
also	O
had	O
population	O
minor	O
allele	O
frequencies	O
(	O
MAFs	O
)	O
<	O
1	O
%	O
in	O
Caucasian	O
data	O
from	O
the	O
1000	O
Genomes	O
,	O
and	O
the	O
current	O
cohorts	O
(	O
TCGA	O
ovarian	B-DISEASE
cancer	I-DISEASE
cases	O
and	O
WHISP	O
exome	O
controls	O
)	O
(	O
Fig	O
.	O

Spironolactone	B-Chemical
-	O
induced	O
renal	O
insufficiency	I-DISEASE
and	O
hyperkalemia	B-DISEASE
in	O
patients	O
with	O
heart	B-DISEASE
failure	I-DISEASE
.	O

Family	O
93RE	O
whose	O
clinical	O
diagnosis	O
was	O
compatible	O
with	O
either	O
CRD	B-DISEASE
or	O
recessive	B-DISEASE
Stargardt	I-DISEASE
disease	I-DISEASE
showed	O
cosegregation	O
with	O
GNAT2	B-GENE
,	O
ZNF513	B-GENE
,	O
OPA1	B-GENE
,	O
RP1L1	B-GENE
and	O
ABCA4	B-GENE
.	O

The	O
fifth	O
case	O
had	O
features	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
related	O
to	O
an	O
antiphospholipid	B-DISEASE
syndrome	I-DISEASE
in	O
a	O
patient	O
with	O
systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
.	O

Two	O
additional	O
exons	O
have	O
been	O
reported	O
:	O
exon	O
6A	O
,	O
included	O
in	O
the	O
most	O
common	O
isoform	O
,	O
and	O
exon	O
16A	O
,	O
included	O
in	O
a	O
minor	O
isoform	O
[	O
9	O
]	O
.	O

The	O
neutralized	O
DNA	O
was	O
desalted	O
and	O
concentrated	O
on	O
a	O
QIAquick	O
MinElute	O
column	O
and	O
eluted	O
into	O
30	O
u	O
L	O
EB	O
buffer	O
.	O

The	O
MARVELD2	B-GENE
gene	O
(	O
MA	B-GENE
L	I-GENE
and	I-GENE
R	I-GENE
elated	I-GENE
proteins	I-GENE
for	I-GENE
Ve	I-GENE
sicle	I-GENE
trafficking	I-GENE
and	I-GENE
membrane	I-GENE
L	I-GENE
ink	I-GENE
D	I-GENE
omain	I-GENE
containing	I-GENE
2	I-GENE
)	O
,	O
also	O
known	O
as	O
TRIC	B-GENE
and	O
included	O
in	O
the	O
autosomal	O
recessive	O
group	O
,	O
is	O
located	O
on	O
the	O
chromosome	O
5q13	O
.	O
2	O
and	O
linked	O
to	O
the	O
DFNB49	B-GENE
locus	O
[	O
3	O
,	O
4	O
]	O
.	O

Axonal	B-DISEASE
sensory	I-DISEASE
neuropathy	I-DISEASE
is	O
thought	O
to	O
be	O
the	O
most	O
important	O
pathological	O
feature	O
of	O
IOSCA	B-DISEASE
;	I-DISEASE
however	O
,	O
this	O
report	O
represents	O
the	O
first	O
description	O
of	O
an	O
IOSCA	B-DISEASE
patient	O
harboring	O
motor	B-DISEASE
neuropathy	I-DISEASE
.	O

The	O
residual	O
serum	O
concentrations	O
of	O
oxazepam	B-Chemical
,	O
temazepam	B-Chemical
and	O
zopiclone	B-Chemical
were	O
analysed	O
.	O

To	O
date	O
,	O
no	O
mutation	O
has	O
been	O
reported	O
in	O
the	O
additional	O
exons	O
.	O

In	O
humans	O
,	O
myosin	B-GENE
VIIa	I-GENE
is	O
expressed	O
in	O
a	O
variety	O
of	O
cells	O
,	O
including	O
the	O
inner	O
ear	O
hair	O
cells	O
,	O
retinal	O
pigment	O
epithelium	O
,	O
and	O
photoreceptor	O
cells	O
of	O
the	O
retina	O
[	O
20	O
]	O
.	O

Already	O
at	O
this	O
time	O
,	O
the	O
patient	O
showed	O
a	O
severely	O
reduced	O
attention	O
span	O
,	O
mental	O
rigidity	O
,	O
low	O
frustration	O
tolerance	O
and	O
aggression	O
to	O
persons	O
including	O
family	O
members	O
.	O

Hepatotoxicity	O
and	O
malaise	O
are	O
again	O
the	O
most	O
frequent	O
side	O
effects	O
.	O

Mechanisms	O
of	O
myocardial	B-DISEASE
ischemia	I-DISEASE
induced	O
by	O
epinephrine	B-Chemical
:	O
comparison	O
with	O
exercise	O
-	O
induced	O
ischemia	B-DISEASE
.	O

JH	O
and	O
SDK	O
validated	O
the	O
primers	O
.	O

The	O
primary	O
antibodies	O
used	O
were	O
anti	O
-	O
CD164	B-GENE
(	O
SantaCruz	O
,	O
sc	O
-	O
33124	O
,	O
1	O
:	O
75	O
and	O
St	O
.	O
John	O
'	O
s	O
Laboratory	O
,	O
STJ92095	O
,	O
1	O
:	O
500	O
)	O
.	O

Auditory	O
function	O
was	O
assessed	O
with	O
otoscopy	O
,	O
standard	O
pure	O
tone	O
audiometry	O
(	O
250	O
-	O
800	O
Hz	O
)	O
,	O
and	O
tympanometry	O
.	O

Karen	O
Friis	O
Henriksen	O
(	O
ICMM	O
,	O
Copenhagen	O
)	O
is	O
acknowledged	O
for	O
preparing	O
the	O
library	O
and	O
Targeted	O
NimbleGen	O
array	O
capture	O
for	O
NGS	O
.	O

B	O
,	O
Amplified	O
cDNA	O
corresponding	O
to	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutations	O
(	O
same	O
individuals	O
as	O
for	O
genomic	O
analyses	O
)	O
,	O
demonstrates	O
two	O
additional	O
smaller	O
products	O
(	O
indicated	O
with	O
white	O
arrows	O
D	O
and	O
E	O
)	O
,	O
in	O
addition	O
to	O
the	O
normal	O
(	O
C	O
)	O
product	O
.	O

This	O
finding	O
may	O
imply	O
that	O
with	O
increasing	O
age	O
,	O
cardiac	B-DISEASE
event	I-DISEASE
rates	O
may	O
decrease	O
over	O
time	O
in	O
patients	O
with	O
JLNS	B-DISEASE
,	O
a	O
trend	O
generally	O
seen	O
in	O
most	O
patients	O
with	O
RWS	B-DISEASE
.	O

Recent	O
advances	O
in	O
DNA	O
enrichment	O
and	O
next	O
generation	O
sequencing	O
techniques	O
,	O
however	O
,	O
allow	O
rapid	O
and	O
cost	O
-	O
effective	O
analysis	O
to	O
identify	O
the	O
causative	O
mutations	O
in	O
deaf	B-DISEASE
patients	O
[	O
5	O
]	O
.	O

Finally	O
,	O
we	O
identified	O
a	O
HNF1A	B-GENE
gene	O
mutation	O
(	O
proband	O
HI01	O
)	O
that	O
has	O
been	O
previously	O
reported	O
in	O
MODY3	B-DISEASE
patients	O
[	O
21	O
]	O
.	O

Reads	O
coverage	O
versus	O
relative	O
enrichment	O
probe	O
positions	O
.	O

